trial_id	trialacronym	phase	recruitmentstatus	recruitmentstate	approvaldate	actualstartdate	drug_list	drug_classes	combo_list	combo_classes	secondaryid	studytitle	healthcondition	postcode	ext_weblink
ACTRN12613000198729	CARPETS	Phase 1	NOT_RECRUITING	SA	19/02/2013	1/10/2015	Autologous GD2 chimeric antigen receptor-expressing peripheral blood T cells; Dabrafenib; Dabrafenib + GD2-iCAR-PBT + Trametinib; GD2-iCAR-PBT; Trametinib	MEK_inhibitor; BRAF_V600_inhibitor + MEK_inhibitor + autologous_CAR-T-cell_therapy,GD2-targeting; BRAF_V600_inhibitor; autologous_CAR-T-cell_therapy,GD2-targeting	Dabrafenib + GD2-iCAR-PBT + Trametinib; Autologous GD2 chimeric antigen receptor-expressing peripheral blood T cells; Dabrafenib + GD2-iCAR-PBT + Trametinib	BRAF_V600_inhibitor + MEK_inhibitor + autologous_CAR-T-cell_therapy,GD2-targeting; BRAF_V600_inhibitor + MEK_inhibitor + autologous_CAR-T-cell_therapy,GD2-targeting	Nil known	A phase I study of the safety and immune effects of an escalating dose of autologous GD2 chimeric antigen receptor-expressing peripheral blood T cells in patients with GD2-positive metastatic melanoma and refractory solid tumours	Refractory solid tumours; Metastatic melanoma	5000 - Adelaide	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12613000198729
ACTRN12613000279729	HPV-Oropharynx	Phase 3	Recruiting	ACT, WA, NSW, VIC, QLD, NZ, SA	8/03/2013	17/06/2013	Cetuximab; Cetuximab + Radiotherapy; Cisplatin; Radiotherapy	radiotherapy; anti-EGFR_monoclonal_antibody + radiotherapy; platinum-based_antineoplastic_agent; anti-EGFR_monoclonal_antibody	Cetuximab + Radiotherapy; Cetuximab + Radiotherapy; Cisplatin	anti-EGFR_monoclonal_antibody + radiotherapy; anti-EGFR_monoclonal_antibody + radiotherapy; platinum-based_antineoplastic_agent	Nil	TROG 12.01 A Randomised Trial of Weekly Cetuximab and Radiation versus Weekly Cisplatin and Radiation in Good Prognosis Locoregionally Advanced HPV-Associated Oropharyngeal Squamous Cell Carcinoma	HPV positive Oropharyngeal Squamous Cell Carcinoma (OPSCC)	Palmerston North; Auckland	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12613000279729
ACTRN12613000297729	ENG2	Phase 1 / Phase 2	STOPPED_EARLY	NSW, VIC	18/03/2013	8/02/2013	Doxorubicin; Doxorubicin + Panitumumab; Ifosfamide; Panitumumab	anthracycline + anti-EGFR_monoclonal_antibody; anthracycline; alkylating_agent; doxorubicin; anti-EGFR_monoclonal_antibody	Doxorubicin + Panitumumab; Doxorubicin + Panitumumab; Ifosfamide	anthracycline + anti-EGFR_monoclonal_antibody; alkylating_agent; anthracycline + anti-EGFR_monoclonal_antibody; doxorubicin	ENG2	A Phase 1/2 study to determine the effect of EGFR targeted Doxorubicin loaded EnGeneIC Delivery Vehicles (VEDVDox) on progression free survival in Patients with Recurrent Glioblastoma Multiforme (GBM) Expressing Epidermal Growth Factor Receptor (EGFR)	Recurrent Glioblastoma Multiforme		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12613000297729
ACTRN12613000496718	P3BEP	Phase 3	Recruiting	ACT, WA, VIC, NSW, QLD, TAS, NZ, SA	3/05/2013	3/04/2014	Bleomycin; Bleomycin + Cisplatin + Etoposide + Filgrastim; Bleomycin + Cisplatin + Etoposide + Pegfilgrastim; Cisplatin; Etoposide; Filgrastim; Pegfilgrastim	platinum-based_antineoplastic_agent; granulocyte_colony_stimulating_factor; antineoplastic_antibiotic; antineoplastic_antibiotic + granulocyte_colony_stimulating_factor + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; topoisomerase_inhibitor	Bleomycin; Bleomycin + Cisplatin + Etoposide + Filgrastim; Bleomycin + Cisplatin + Etoposide + Pegfilgrastim; Bleomycin + Cisplatin + Etoposide + Filgrastim; Bleomycin + Cisplatin + Etoposide + Pegfilgrastim	antineoplastic_antibiotic; antineoplastic_antibiotic + granulocyte_colony_stimulating_factor + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; antineoplastic_antibiotic + granulocyte_colony_stimulating_factor + platinum-based_antineoplastic_agent + topoisomerase_inhibitor	Nil	In patients with intermediate and poor-risk metastatic germ cell tumours is an accelerated BEP chemotherapy regimen as good as, or better than, the standard BEP chemotherapy regimen for response rate.	Intermediate and poor-risk metastatic germ cell tumours (GCTs)	6150 - Murdoch; 3690 - Wodonga	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12613000496718
ACTRN12613001061729	PMCC-12-79	Phase 1	STATUS_UNKNOWN	VIC	23/09/2013	22/07/2013	Pidnarulex	RNA_polymerase_I_transcription_inhibitor	Pidnarulex	RNA_polymerase_I_transcription_inhibitor	Peter MacCallum Cancer Centre Protocol No. PMCC 12/79	A Phase 1, Open-Label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Intravenously Administered CX-5461 in Patients with Advanced Haematologic Malignancies	Any advanced Haematologic Malignancy	3002 - East Melbourne	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12613001061729
ACTRN12614000365662	ACTRN12614000365662	Phase 1	Recruiting	NZ	7/04/2014	28/04/2014	Oraxol; Oraxol + Paclitaxel; Paclitaxel	taxane	Oraxol + Paclitaxel; Paclitaxel; Oraxol + Paclitaxel	taxane	Nil	Patients with cancer for whom IV paclitaxel (at a dose of 80 mg/m2 IV over 1 hour) is indicated will be treated with intravenous paclitaxel and Oraxol (Paclitaxel + HM30181AK-US) to evaluate bioavailability, safety and tolerability of Oraxol.	Cancer	Dunedin	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12614000365662
ACTRN12614000789662	ACTRN12614000789662	Phase 2	Not yet recruiting	NSW	24/07/2014		Luminespib	HSP90_inhibitor	Luminespib	HSP90_inhibitor	Nil	A Randomised controlled Phase II trial of the pharmacodynamic effects of the heat shock protein 90 (Hsp90) inhibitor AUY922 in high-risk, localised prostate cancer	Prostate Cancer	2050 - Missenden Road	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12614000789662
ACTRN12614001181695	BOSTON-II	Phase 1	Recruiting	VIC	11/11/2014	2/11/2015	Pembrolizumab; Radiotherapy	radiotherapy; anti-PD-1_monoclonal_antibody	Pembrolizumab; Radiotherapy	anti-PD-1_monoclonal_antibody; radiotherapy	Nil	A pilot study to assess the safety and feasibility of stereotactic ablative body radiosurgery combined with MK-3475 in patients with oligometastases from breast cancer.	Metastatic Breast Cancer (1-5 metastases)		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12614001181695
ACTRN12614001248651	MesomiR-1	Phase 1	Recruiting	NSW	28/11/2014	29/09/2014	Dexamethasone; Dexamethasone + TargomiRs; TargomiRs	glucocorticoid + miR-16_miRNA_mimic; glucocorticoid; miR-16_miRNA_mimic	Dexamethasone; Dexamethasone + TargomiRs; TargomiRs; Dexamethasone + TargomiRs	glucocorticoid; glucocorticoid + miR-16_miRNA_mimic; miR-16_miRNA_mimic; glucocorticoid + miR-16_miRNA_mimic	Nil	MesomiR 1: A Phase I study of intravenously administered Epidermal Growth Factor Receptor (EGFR)-targeted, EnGeneIC Delivery Vehicle (EDV)-packaged, miR-16 mimic (TargomiRs) for patients with Malignant Pleural Mesothelioma (MPM) and advanced Non-Small Cell Lung Cancer (NSCLC) failing on standard therapy	Malignant Pleural Mesothelioma; Advanced Non Small Cell Lung Cancer	2139 - Concord Repatriation Hospital; 2065 - St Leonards; 2050 - Camperdown	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12614001248651
ACTRN12615000504516	NAP-CAPABIL	Phase 2	NOT_RECRUITING	NSW	20/05/2015		Capecitabine; Capecitabine + Nab-paclitaxel; Nab-paclitaxel; Paclitaxel	fluoropyrimidine + taxane; taxane; fluoropyrimidine	Capecitabine + Nab-paclitaxel; Capecitabine + Nab-paclitaxel	fluoropyrimidine + taxane; fluoropyrimidine + taxane	Nil	Patients with advanced biliary cancer to be treated with second line combination chemotherapy of NAB Paclitaxel and capecitabine in a single arm pilot study to assess feasibility	advanced biliary cancer		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12615000504516
ACTRN12615001088538	TIDAL-Melanoma	Phase 2	Recruiting	QLD	16/10/2015	6/01/2017	Diphencyprone; Diphencyprone + Imiquimod; Imiquimod	topical_immune_response_modifier	Diphencyprone; Diphencyprone + Imiquimod; Imiquimod; Diphencyprone + Imiquimod	topical_immune_response_modifier	Nil known	The effect of topical imiquimod or diphenylcyclopropenone on complete clinical response in patients with cutaneous in-transit melanoma metastases - A Phase II Single Centre Prospective Randomised Pilot Study.	Cutaneous in-transit melanoma metastases	4102 - Woolloongabba	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12615001088538
ACTRN12615001328561	DESNET2	Phase 2	Not yet recruiting		4/12/2015		Octreotide; Octreotide + Pasireotide; Pasireotide	somatostatin_analog	Octreotide + Pasireotide; Pasireotide; Octreotide + Pasireotide	somatostatin_analog	Novartis Protocol Number: CSOM230FAU04T	Phase II study evaluating the efficacy of Pasireotide LAR (SOM230) dose escalation in patients with refractory non-functional GEP NETs	Gastro-entero-pancreatic neuroendocrine tumours		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12615001328561
ACTRN12616000008426	ACTRN12616000008426		Recruiting	NSW	12/01/2016	3/06/2015	RX108	sodium-potassium_ATPase_inhibitor	RX108	sodium-potassium_ATPase_inhibitor	None	A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of RX108 in Patients with Advanced or Metastatic Solid Tumours.	Advanced or Metastatic Solid Tumours		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12616000008426
ACTRN12616000228482	ACT001-AU-001	Phase 1	Recruiting	SA, VIC, NSW	19/02/2016	19/09/2016	ACT001	NFKB_inhibitor	ACT001	NFKB_inhibitor	ACT001-AU-001 (Sponsor protocol code)	A phase 1 dose-escalation study to evaluate the safety, tolerability and pharmacokinetics of ACT001 in patients with advanced solid tumors	Solid tumors	5042 - Bedford Park; 3004 - Melbourne; 3121 - Richmond; 2031 - Randwick	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12616000228482
ACTRN12616000420448	INTEGRATE-IIa	Phase 3	Recruiting	NT, WA, ACT, SA, NZ, TAS, QLD, VIC, NSW	1/04/2016	10/11/2016	Placebo; Regorafenib	placebo; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor	Regorafenib; Placebo	KIT/PDGFR/RET/VEGFR/FGFR_inhibitor; placebo	AG0315OG  CTC0140	A Randomised Phase III Double-Blind Placebo-Controlled Study to determine if regorafenib improves overall survival in refractory Advanced Gastro-Oesophageal Cancer (AGOC)	Advanced (metastatic or locally recurrent) Gastro-Oesophageal Cancer (AGOC)	2250 - Gosford; 2145 - Westmead; 2305 - New Lambton Heights; 6009 - Nedlands; 5042 - Bedford Park; 2010 - Darlinghurst; 3690 - Wodonga; 6008 - Subiaco; 2065 - St Leonards; 2139 - Concord; 4029 - Herston; 3084 - Heidelberg; 2444 - Port Macquarie; 0810 - Tiwi; 5037 - Kurralta Park; 3355 - Wendouree; 2450 - Coffs Harbour; 3168 - Clayton; 2031 - Randwick; 4814 - Douglas; 2485 - Tweed Heads; 3165 - East Bentleigh; 7000 - Hobart; 5011 - Woodville; 2605 - Garran; 4575 - Birtinya; 2217 - Kogarah	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12616000420448
ACTRN12616000440426	PRIME001	Phase 1 / Phase 2	NOT_RECRUITING; STATUS_UNKNOWN	NSW	6/04/2016	21/02/2017	Carboplatin; Carboplatin + Decitabine; Decitabine	platinum-based_antineoplastic_agent; DNA_methyltransferase_inhibitor; DNA_methyltransferase_inhibitor + platinum-based_antineoplastic_agent	Carboplatin + Decitabine; Carboplatin + Decitabine	DNA_methyltransferase_inhibitor + platinum-based_antineoplastic_agent; DNA_methyltransferase_inhibitor + platinum-based_antineoplastic_agent	None	Pilot Early phase II study of Decitabine and Carboplatin in patients with advanced melanoma	Metastatic melanoma	2298 - Waratah	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12616000440426
ACTRN12616000958482	NABNEC	Phase 2	Recruiting	WA, QLD, NSW, VIC, SA, NZ, TAS	21/07/2016	17/11/2016	Carboplatin; Carboplatin + Nab-paclitaxel; Nab-paclitaxel	platinum-based_antineoplastic_agent; taxane; platinum-based_antineoplastic_agent + taxane	Carboplatin + Nab-paclitaxel; Carboplatin + Nab-paclitaxel	platinum-based_antineoplastic_agent + taxane; platinum-based_antineoplastic_agent + taxane	AG0215NET	A phase II study to establish if carboplatin and nab-paclitaxel combination is an effective and tolerable chemotherapy treatment for grade 3 advanced gastrointestinal Neuroendocrine Carcinomas.	Gastrointestinal Neuroendocrine Carcinomas		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12616000958482
ACTRN12616001019493	MoST-addendum-2	Phase 2	NOT_RECRUITING	NSW, WA	2/08/2016	16/12/2016	Durvalumab; Durvalumab + Tremelimumab; Tremelimumab	anti-PD-L1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody	Durvalumab + Tremelimumab; Durvalumab + Tremelimumab	anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody	CTC0141 Addendum 2	Single arm, open label, signal seeking, phase IIa trial of the activity of Durvalumab (MEDI4736) in combination with Tremelimumab in patients with advanced rare or neglected cancers.	Cancer	2217 - Kogarah; 2010 - Darlinghurst; 6009 - Nedlands; 2050 - Camperdown	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12616001019493
ACTRN12616001187437	MatchMel	Phase 2	NOT_RECRUITING	NSW	29/08/2016		Bortezomib; Cabozantinib; Ceritinib; Crizotinib; Dasatinib; Erlotinib; Everolimus; Gefitinib; Imatinib; Lapatinib; Nilotinib; Olaparib; Palbociclib; Pazopanib; Ramucirumab; Regorafenib; Sorafenib; Sunitinib; Trametinib; Vorinostat	PARP_inhibitor; KIT_inhibitor,first_generation; ERBB2_inhibitor,first_generation; EGFR_inhibitor,first_generation; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor; VEGFR2_inhibitor; MET_inhibitor,type_1; CRAF_inhibitor; FLT3_inhibitor; CDK4/6_inhibitor; AXL_inhibitor; PDGFR_inhibitor; RET_inhibitor; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor; HDAC_inhibitor; PDGFRA_inhibitor; BCR-ABL1_inhibitor,first_generation; ROS1_inhibitor; proteasome_inhibitor; EGFR_inhibitor,type_II; KIT_inhibitor,ATP-competitive; ALK_inhibitor,first_generation; SRC_inhibitor; YES1_inhibitor; MET_inhibitor,type_2; VEGFR_inhibitor; anti-VEGFR2_monoclonal_antibody; MEK_inhibitor; ALK/ROS1/IGF1R_inhibitor; mTORC1_inhibitor; BCR-ABL1_inhibitor,second_generation; KIT_inhibitor; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor	Bortezomib; Cabozantinib; Ceritinib; Crizotinib; Dasatinib; Erlotinib; Everolimus; Gefitinib; Imatinib; Lapatinib; Nilotinib; Olaparib; Palbociclib; Pazopanib; Ramucirumab; Regorafenib; Sorafenib; Sunitinib; Trametinib; Vorinostat	ALK/ROS1/IGF1R_inhibitor; ALK_inhibitor,first_generation; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor; AXL_inhibitor; BCR-ABL1_inhibitor,first_generation; BCR-ABL1_inhibitor,second_generation; CDK4/6_inhibitor; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor; CRAF_inhibitor; EGFR_inhibitor,first_generation; EGFR_inhibitor,type_II; ERBB2_inhibitor,first_generation; FLT3_inhibitor; HDAC_inhibitor; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor; KIT_inhibitor; KIT_inhibitor,ATP-competitive; KIT_inhibitor,first_generation; MEK_inhibitor; MET_inhibitor,type_1; MET_inhibitor,type_2; PARP_inhibitor; PDGFRA_inhibitor; PDGFR_inhibitor; RET_inhibitor; ROS1_inhibitor; SRC_inhibitor; VEGFR2_inhibitor; VEGFR_inhibitor; YES1_inhibitor; anti-VEGFR2_monoclonal_antibody; mTORC1_inhibitor; proteasome_inhibitor	Protocol Number MIA2015/174	Molecular profiling to identify patients with BRAF/NRAS wild type melanoma and the proportion of these patients that undergo matched targeted therapy as a result of extended molecular testing.	Metastatic Melanoma	2145 - Westmead; 2065 - Wollstonecraft; 2050 - Camperdown	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12616001187437
ACTRN12616001637437	ACTRN12616001637437	Phase 1	NOT_RECRUITING	ACT	25/11/2016	7/10/2016	Complete Freund’s Adjuvant; Pembrolizumab	immunopotentiator; anti-PD-1_monoclonal_antibody	Pembrolizumab; Complete Freund’s Adjuvant	anti-PD-1_monoclonal_antibody; immunopotentiator	Nil known	Phase I Study of the safety of Complete Freund’s Adjuvant (CFA) in Patients with Refractory and Relapsed Solid Tumours	Solid Tumours	2605 - Garran	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12616001637437
ACTRN12617000741381	Protocol-CA209-993ISR	Phase 1	Recruiting	NSW, VIC, SA	22/05/2017	31/08/2017	Nivolumab	anti-PD-1_monoclonal_antibody	Nivolumab	anti-PD-1_monoclonal_antibody	Protocol CA209-993ISR	Nivolumab in renal transplant recipients with poor prognosis cancers - a safety study.	Cancer; Renal Transplant	2050 - Camperdown; 3168 - Clayton; 5000 - Adelaide	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12617000741381
ACTRN12617000855325	EMBRACE-study	Phase 2	NOT_RECRUITING	QLD, NSW, VIC, SA, WA	9/06/2017	12/09/2018	Olaparib	PARP_inhibitor	Olaparib	PARP_inhibitor	CTC0160	Phase II clinical trial of the PARP inhibitor, olaparib, in HR-deficient metastatic breast and relapsed ovarian cancer in patients without germline mutations in BRCA1 and BRCA2: The EMBRACE study	Triple negative breast cancer; High grade serous ovarian cancer	2450 - Coffs Harbour; 3355 - Wendouree; 2217 - Kogarah; 5000 - Adelaide; 4066 - Auchenflower; 2640 - Albury; 4217 - Benowa; 4029 - Herston; 6150 - Murdoch; 3000 - Melbourne; 2065 - St Leonards	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12617000855325
ACTRN12617001000392	MoST-Addendum-3	Phase 2	NOT_RECRUITING	SA, NSW	11/07/2017	21/11/2017	Durvalumab; Durvalumab + Olaparib; Olaparib	PARP_inhibitor; anti-PD-L1_monoclonal_antibody; PARP_inhibitor + anti-PD-L1_monoclonal_antibody	Durvalumab; Durvalumab + Olaparib; Durvalumab + Olaparib	PARP_inhibitor + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; PARP_inhibitor + anti-PD-L1_monoclonal_antibody	Nil	Single arm, open label, signal seeking, phase IIa trial of the activity of Olaparib in combination with Durvalumab in patients with tumours with homologous recombination repair defects	Cancer	2010 - Darlinghurst; 2050 - Camperdown; 5000 - Adelaide; 2217 - Kogarah	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12617001000392
ACTRN12617001190392	PIT-Study	Phase 1 / Phase 2	STATUS_UNKNOWN	SA	15/08/2017		Irinotecan; Irinotecan + Panitumumab; Panitumumab; Trifluridine/Tipiracil	Tipiracil Hydrochloride; Trifluridine; antimetabolite; thymidine_phosphorylase_inhibitor; anti-EGFR_monoclonal_antibody + topoisomerase_inhibitor; anti-EGFR_monoclonal_antibody; topoisomerase_inhibitor	Irinotecan + Panitumumab; Trifluridine/Tipiracil; Irinotecan + Panitumumab	Tipiracil Hydrochloride; Trifluridine; anti-EGFR_monoclonal_antibody + topoisomerase_inhibitor; antimetabolite; thymidine_phosphorylase_inhibitor; anti-EGFR_monoclonal_antibody + topoisomerase_inhibitor	None	An open label phase IB/II, non-randomised, dose-finding, safety and tolerability study of Panitumumab, Irinotecan, Trifluridine/Tipiracil in RAS wild-type patients with metastatic colorectal cancer	colorectal cancer	5011 - Woodville; 5000 - Adelaide; 5042 - Bedford Park	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12617001190392
ACTRN12617001325392	DIAmOND	Phase 2	NOT_RECRUITING	VIC, NSW, QLD, SA, TAS, WA	15/09/2017	22/11/2018	Durvalumab; Durvalumab + Trastuzumab; Durvalumab + Trastuzumab + Tremelimumab; Durvalumab + Tremelimumab; Trastuzumab; Tremelimumab	anti-CTLA-4_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-ERBB2_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-ERBB2_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; anti-ERBB2_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody	Durvalumab; Durvalumab + Trastuzumab; Durvalumab + Trastuzumab + Tremelimumab; Durvalumab + Tremelimumab; Trastuzumab; Tremelimumab; Durvalumab + Trastuzumab; Durvalumab + Trastuzumab + Tremelimumab; Durvalumab + Tremelimumab	anti-CTLA-4_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-ERBB2_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-ERBB2_monoclonal_antibody; anti-ERBB2_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-ERBB2_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-ERBB2_monoclonal_antibody + anti-PD-L1_monoclonal_antibody	BCT 1703	BCT 1703 (DIAmOND): An investigator-initiated, non-randomised, phase II study of combination CTLA-4 and PD-L1 blockade in advanced HER2-positive breast cancers who have progressed on prior trastuzumab-based therapy.	Advanced HER2-positive breast cancer	4101 - South Brisbane; 7000 - Hobart; 3550 - Bendigo; 4575 - Birtinya; 2217 - Kogarah; 2145 - Westmead; 5042 - Bedford Park; 3000 - Melbourne; 3084 - Heidelberg; 6150 - Murdoch	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12617001325392
ACTRN12617001573347	ZU545102--CA209-9KJ	Phase 1	NOT_RECRUITING	SA, VIC, NSW, QLD	22/11/2017	24/10/2017	Nivolumab; Nivolumab + Pixatimod; Pixatimod	angiogenesis_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; angiogenesis_inhibitor	Nivolumab + Pixatimod; Nivolumab + Pixatimod	angiogenesis_inhibitor + anti-PD-1_monoclonal_antibody; angiogenesis_inhibitor + anti-PD-1_monoclonal_antibody	ZU545102  CA209-9KJ	An open-label, multi-centre Phase Ib study of the safety and tolerability of IV infused PG545 in combination with nivolumab in patients with advanced solid tumours with an expansion cohort in patients with metastatic pancreatic cancer	Advanced solid tumours; Colorectal cancer; Pancreatic Cancer	2065 - St Leonards; 4029 - Herston; 5000 - Adelaide; 3004 - Prahran	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12617001573347
ACTRN12618000053224	PRIME002	Phase 2	NOT_RECRUITING	NSW, QLD	16/01/2018	22/03/2018	Avelumab; Azacitidine; Azacitidine + Carboplatin; Carboplatin	platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; DNA_methyltransferase_inhibitor; antimetabolite; DNA_methyltransferase_inhibitor + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody	Avelumab; Azacitidine + Carboplatin; Azacitidine + Carboplatin	DNA_methyltransferase_inhibitor + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody; antimetabolite + platinum-based_antineoplastic_agent; DNA_methyltransferase_inhibitor + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent	Nil known	PRIME002: Early phase II study of Azacitidine and Carboplatin priming for Avelumab in patients with advanced melanoma who are resistant to immunotherapy.	Immunotherapy resistant; Metastatic melanoma	4870 - Cairns; 2298 - Waratah	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618000053224
ACTRN12618000233224	MONARCC	Phase 2	NOT_RECRUITING	SA, TAS, QLD, VIC, NSW, WA	14/02/2018	16/07/2018	Fluorouracil; Panitumumab	anti-EGFR_monoclonal_antibody; fluoropyrimidine	Panitumumab; Fluorouracil	anti-EGFR_monoclonal_antibody; fluoropyrimidine	AG0116CR / CTC 0151	MONARCC: A randomised phase II study of Panitumumab monotherapy and panitumumab plus 5 fluorouracil as first line therapy for RAS and BRAF wild type metastatic colorectal cancer.	metastatic colorectal cancer	4032 - Chermside; 4215 - Southport; 5042 - Bedford Park; 2010 - Darlinghurst; 4029 - Herston; 3084 - Heidelberg; 3021 - St Albans; 3690 - Wodonga; 2065 - St Leonards; 2485 - Tweed Heads; 2747 - Kingswood; 7000 - Hobart; 2541 - Nowra; 2450 - Coffs Harbour; 3168 - Clayton; 5011 - Woodville; 4575 - Birtinya; 4102 - Woolloongabba	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618000233224
ACTRN12618000281291	MoST-Addendum-4	Phase 2	Recruiting	NSW, VIC, QLD, TAS, SA, ACT, WA, NT	22/02/2018	7/12/2018	Vismodegib	SMO_inhibitor,first_generation	Vismodegib	SMO_inhibitor,first_generation	CTC0141-addendum 4	Single arm, open label, signal seeking, phase IIa trial of the activity of vismodegib in patients with tumours harbouring PTCH1 or SMO mutations	Cancer	6009 - Nedlands; 2050 - Camperdown; 2010 - Darlinghurst; 0810 - Tiwi; 3000 - Melbourne; 7000 - Hobart; 2605 - Garran; 4102 - Woolloongabba; 5000 - Adelaide; 2217 - Kogarah	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618000281291
ACTRN12618000357257	MoST-Addendum-5	Phase 2	*NOT_RECRUITING	QLD, VIC, NSW, SA, TAS, ACT, NT, WA	9/03/2018	11/04/2019	Eribulin	macrocyclic_ketone_analogue	Eribulin	macrocyclic_ketone_analogue	CTC0141-addendum 5	Single arm, open label, signal seeking, phase IIa trial of the activity of eribulin in patients with advanced CD31 positive angiosarcoma and selected CD31 positive sarcomas.	Cancer 306453 0; Sarcoma; Angiosarcoma	2605 - Garran; 4102 - Woolloongabba; 5000 - Adelaide; 2217 - Kogarah; 7000 - Hobart; 0810 - Tiwi; 3000 - Melbourne; 2010 - Darlinghurst; 2050 - Camperdown; 6009 - Nedlands	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618000357257
ACTRN12618000686202	SOLACE-2	Phase 2	NOT_RECRUITING	NSW, VIC, QLD, TAS, SA	27/04/2018	8/05/2019	Cyclophosphamide; Cyclophosphamide + Durvalumab + Olaparib; Cyclophosphamide + Olaparib; Durvalumab; Durvalumab + Olaparib; Olaparib	PARP_inhibitor; PARP_inhibitor + anti-PD-L1_monoclonal_antibody; alkylating_agent; PARP_inhibitor + alkylating_agent + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; PARP_inhibitor + alkylating_agent	Cyclophosphamide; Cyclophosphamide + Durvalumab + Olaparib; Cyclophosphamide + Olaparib; Durvalumab; Durvalumab + Olaparib; Olaparib; Cyclophosphamide + Durvalumab + Olaparib; Cyclophosphamide + Olaparib; Durvalumab + Olaparib	PARP_inhibitor; PARP_inhibitor + alkylating_agent; PARP_inhibitor + alkylating_agent + anti-PD-L1_monoclonal_antibody; PARP_inhibitor + anti-PD-L1_monoclonal_antibody; alkylating_agent; anti-PD-L1_monoclonal_antibody; PARP_inhibitor + alkylating_agent; PARP_inhibitor + alkylating_agent + anti-PD-L1_monoclonal_antibody; PARP_inhibitor + anti-PD-L1_monoclonal_antibody	CTC 0178 / ANZGOG 1723/2018	A Phase II randomised trial comparing immune priming by low dose oral cyclophosphamide plus olaparib versus priming by olaparib alone, prior to combination therapy with olaparib plus durvalumab, versus single agent olaparib alone, in asymptomatic platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancers with homologous recombination repair defects.	Fallopian tube cancer; Peritoneal cancer; Ovarian cancer	2305 - New Lambton Heights; 2250 - Gosford; 2050 - Camperdown; 5042 - Bedford Park; 2065 - St Leonards; 3000 - Melbourne; 3199 - Frankston; 2450 - Coffs Harbour; 4101 - South Brisbane; 2031 - Randwick; 3050 - Parkville; 2485 - Tweed Heads; 7000 - Hobart; 2217 - Kogarah; 2650 - Wagga Wagga; 5000 - Adelaide	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618000686202
ACTRN12618000941268	PLA001	Phase 0	Recruiting	NSW	4/06/2018	21/02/2018	PLA2 inhibitor	PLA2_inhibitor	PLA2 inhibitor	PLA2_inhibitor	None	Safety, tolerability, and pharmacokinetics of single and multiple doses of a PLA2 inhibitor (c2) in men with prostate cancer: A Phase 0 and limited dose-escalation trial	Prostate Cancer	2170 - Liverpool	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618000941268
ACTRN12618000954224	ICE-PAC	Phase 2	Recruiting	VIC	6/06/2018	1/12/2017	Avelumab; Avelumab + Radiotherapy; Radiotherapy	anti-PD-L1_monoclonal_antibody; radiotherapy; anti-PD-L1_monoclonal_antibody + radiotherapy	Avelumab + Radiotherapy; Avelumab + Radiotherapy	anti-PD-L1_monoclonal_antibody + radiotherapy; anti-PD-L1_monoclonal_antibody + radiotherapy	MS100070-0082	A phase II study of Avelumab + stereotactic ablative body radiosurgery (SABR) for metastatic castration-resistant prostate cancer (mCRPC). To assess radiographic progression-free survival (rPFS).	Metastatic castration-resistant prostate cancer (mCRPC).	3128 - Box Hill; 3168 - Clayton	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618000954224
ACTRN12618001070224	AM-ATX101-01	Phase 1	Recruiting	SA, NSW, WA	27/06/2018	15/10/2018	ATX-101; Dexamethasone	glucocorticoid; cell_penetrating_peptide,PCNA-targeting	ATX-101; Dexamethasone	cell_penetrating_peptide,PCNA-targeting; glucocorticoid	AM ATX101-01	A phase 1 dose escalating study to determine incidence of dose limiting toxicities of single agent ATX-101 given by intravenous infusion every week in patients with advanced solid tumours	Advanced Solid Tumors	2031 - Randwick; 5000 - Adelaide; 6009 - Nedlands; 5042 - Bedford Park	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618001070224
ACTRN12618001073291	LuPin	Phase 1	Recruiting	NSW	27/06/2018	4/12/2017	Idronoxil; Lu-177 vipivotide tetraxetan	radioligand,PSMA-targeting; idronoxil_suppository	Idronoxil; Lu-177 vipivotide tetraxetan	idronoxil_suppository; radioligand,PSMA-targeting	Nil Known	Radionuclide therapy using 177Lu-PSMA: extension of a pilot study in men with castrate-resistant prostate cancer to determine the clinical benefit of combination therapy with idronoxil	Castrate-resistant prostate cancer	2010 - Darlinghurst	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618001073291
ACTRN12618001112257	AM-ATX101-02	Phase 1	Recruiting	SA, NSW, WA	5/07/2018	11/12/2018	ATX-101; Dexamethasone	glucocorticoid; cell_penetrating_peptide,PCNA-targeting	ATX-101; Dexamethasone	cell_penetrating_peptide,PCNA-targeting; glucocorticoid	AM ATX101-02	A long term follow up study, to evaluate the long term safety and efficacy, of single agent ATX-101 given by intravenous infusion once every week in patients with advanced solid tumours	Advanced Solid Tumors	2031 - Randwick; 5000 - Adelaide; 6009 - Nedlands	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618001112257
ACTRN12618001121257	POPCORN	Phase 1 / Phase 2	Recruiting	QLD	6/07/2018	22/05/2019	Denosumab; Denosumab + Nivolumab; Nivolumab	anti-PD-1_monoclonal_antibody; anti-RANK_L_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-RANK_L_monoclonal_antibody	Denosumab + Nivolumab; Nivolumab; Denosumab + Nivolumab	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-RANK_L_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-RANK_L_monoclonal_antibody	20177440 Amgen ISS	Pharmacodynamics of Pre-Operative PD1 Checkpoint Blockade and Receptor Activator of NFkB Ligand (RANKL) Inhibition in Non-Small Cell Lung Cancer (NSCLC) - a phase 1B/2 trial	Non-small cell lung cancer (NSCLC)	4102 - Woolloongabba; 4029 - Herston; 4032 - Chermside	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618001121257
ACTRN12618001337268	ACTRN12618001337268	Not Applicable	Not yet recruiting		8/08/2018						None	The safety and efficacy of immunotherapy with the activited T cells from from umbilical cord blood mononuclear cells ex vivo for small cell lung cancer,Kidney cancer and Primary liver cancer treatment	Histopathologically confirmed Kidney cancer; Histopathologically confirmed small cell lung cancer (SCLC); Histopathologically confirmed Liver cancer		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618001337268
ACTRN12618001480279	ALT-TRACC	Phase 2	Recruiting	VIC	4/09/2018	6/09/2018	Bevacizumab; Capecitabine; Fluorouracil; Irinotecan; Irinotecan + Oxaliplatin; Leucovorin; Oxaliplatin	platinum-based_antineoplastic_agent; Fluorouracil; platinum-based_antineoplastic_agent + topoisomerase_inhibitor; folinic_acid; anti-VEGF_monoclonal_antibody; topoisomerase_inhibitor; fluoropyrimidine	Bevacizumab; Capecitabine; Fluorouracil; Irinotecan; Irinotecan + Oxaliplatin; Leucovorin; Oxaliplatin; Irinotecan + Oxaliplatin	anti-VEGF_monoclonal_antibody; fluoropyrimidine; folinic_acid; platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent + topoisomerase_inhibitor; topoisomerase_inhibitor; Fluorouracil; platinum-based_antineoplastic_agent + topoisomerase_inhibitor	Nil known	Alternating oxaliplatin and irinotecan doublet schedules versus continuous doublet chemotherapy in previously untreated metastatic colorectal cancer: A Treatment of Recurrent and Advanced Colorectal Cancer registry-based prospective randomised trial	Metastatic Colorectal Cancer	3000 - Melbourne; 3021 - St Albans; 3084 - Heidelberg; 3065 - Fitzroy; 3844 - Traralgon; 3076 - Epping; 3011 - Footscray; 3280 - Warrnambool; 3128 - Box Hill	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618001480279
ACTRN12618001573246	CRIO	Phase 2	Not yet recruiting	QLD	20/09/2018		Carboplatin; Carboplatin + Durvalumab + Radiotherapy; Durvalumab; Radiotherapy	anti-PD-L1_monoclonal_antibody; radiotherapy; platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent + radiotherapy	Carboplatin + Durvalumab + Radiotherapy; Carboplatin + Durvalumab + Radiotherapy	anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent + radiotherapy; anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent + radiotherapy	Nil known	A prospective study investigating the efficacy and toxicity of definitive chemoradiation and immunotherapy (CRIO) in locally and/or regionally advanced cutaneous squamous cell carcinoma	squamous cell carcinoma; skin cancer	4029 - Herston	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618001573246
ACTRN12618001742268	ILLUMINATE	Phase 2	Recruiting	QLD, VIC, NSW, TAS, SA, WA	23/10/2018	4/04/2019	Carboplatin; Carboplatin + Cisplatin + Durvalumab + Pemetrexed + Tremelimumab; Cisplatin; Durvalumab; Durvalumab + Pemetrexed; Pemetrexed; Tremelimumab	anti-CTLA-4_monoclonal_antibody; platinum-based_antineoplastic_agent; anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite; anti-PD-L1_monoclonal_antibody + antimetabolite; anti-PD-L1_monoclonal_antibody	Carboplatin + Cisplatin + Durvalumab + Pemetrexed + Tremelimumab; Durvalumab + Pemetrexed; Carboplatin + Cisplatin + Durvalumab + Pemetrexed + Tremelimumab; Durvalumab + Pemetrexed	anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + antimetabolite; anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + antimetabolite	CTC 0209  ALTG 16/009	A Phase 2 trial of durvalumab (MEDI4736) and tremelimumab with chemotherapy in metastatic EGFR mutant non-squamous non-small cell lung cancer (NSCLC) following progression on EGFR Tyrosine Kinase Inhibitors (TKIs) (ILLUMINATE).	EGFR mutant advanced non small cell lung cancer.	6009 - Nedlands; 4032 - Chermside; 5042 - Bedford Park; 2250 - Gosford; 3000 - Melbourne; 3065 - Fitzroy; 7000 - Hobart; 2200 - Bankstown; 3168 - Clayton; 2217 - Kogarah; 2170 - Liverpool; 4102 - Woolloongabba	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618001742268
ACTRN12618001825246	2014-000259-99	Phase 2 / Phase 3	Recruiting	WA, QLD, VIC, NSW, SA, NZ	9/11/2018	25/11/2014	Carboplatin; Carboplatin + Etoposide; Cyclophosphamide; Cyclophosphamide + Topotecan; Docetaxel; Docetaxel + Gemcitabine + Irinotecan + Temozolomide; Etoposide; Gemcitabine; Ifosfamide; Irinotecan; Temozolomide; Topotecan	alkylating_agent + antimetabolite + taxane + topoisomerase_inhibitor; alkylating_agent; gemcitabine; taxane; platinum-based_antineoplastic_agent; alkylating_agent + topoisomerase_inhibitor; platinum-based_antineoplastic_agent + topoisomerase_inhibitor; topoisomerase_inhibitor	Carboplatin + Etoposide; Cyclophosphamide + Topotecan; Docetaxel + Gemcitabine + Irinotecan + Temozolomide; Ifosfamide; Carboplatin + Etoposide; Cyclophosphamide + Topotecan; Docetaxel + Gemcitabine + Irinotecan + Temozolomide	alkylating_agent; alkylating_agent + antimetabolite + taxane + topoisomerase_inhibitor; alkylating_agent + topoisomerase_inhibitor; platinum-based_antineoplastic_agent + topoisomerase_inhibitor; alkylating_agent + antimetabolite + taxane + topoisomerase_inhibitor; alkylating_agent + topoisomerase_inhibitor; gemcitabine; platinum-based_antineoplastic_agent + topoisomerase_inhibitor	RG_13-277  ISRCTN36453794  EudraCT Number: 2014-000259-99	International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma	Ewing Sarcoma	3052 - Parkville; 2031 - Randwick; 3168 - Clayton; 5000 - Adelaide; 4102 - Woolloongabba; 6009 - Nedlands; 2050 - Camperdown; 5006 - North Adelaide; 2145 - Westmead; 2305 - New Lambton; 3000 - Melbourne	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618001825246
ACTRN12619000385145	ENG9	Phase 1 / Phase 2	STOPPED_EARLY	NSW, VIC	12/03/2019	4/03/2019	PNU-159682	EnGeneIC_Dream_Vector-nanocells-delivered,EGFR-targeting	PNU-159682	EnGeneIC_Dream_Vector-nanocells-delivered,EGFR-targeting	Nil known	A Phase I/IIa Study of EGFR-Targeted EDVTMs Carrying the Cytotoxic Drug PNU-159682 (E-EDV-D682) with Concurrent Immunomodulatory Adjuvant Non-Targeted EDVs carrying an immunomodulator (EDV-GC) in (i) Cohort 1, Subjects with Advanced Pancreatic Cancer and (ii) Cohort 2, Subjects with other EGFR Expressing Solid Tumours, who have Failed First or Second-line Therapy or where other Standard Therapies are not Appropriate.	Pancreatic Cancer; Advanced Cancer (Solid Tumours)	3199 - Frankston; 2076 - Wahroonga	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619000385145
ACTRN12619000566134	OXTOX	Phase 2	Recruiting	NSW	10/04/2019	28/01/2021	Ibudilast; Ibudilast + Oxaliplatin; Oxaliplatin	PDE4_inhibitor + platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent; PDE4_inhibitor	Ibudilast + Oxaliplatin; Ibudilast + Oxaliplatin	PDE4_inhibitor + platinum-based_antineoplastic_agent; PDE4_inhibitor + platinum-based_antineoplastic_agent	None	OXTOX: Can Oxaliplatin neurotoxicity be reduced with ibudilast in people with metastatic colorectal cancer – a phase II randomised study	Neurotoxicity caused by oxaliplatin in patients with metastatic colorectal cancer	2500 - Wollongong; 2800 - Orange; 2747 - Kingswood; 2139 - Concord; 2065 - St Leonards	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619000566134
ACTRN12619000567123	EnzAdapt	Phase 1 / Phase 2	Recruiting	NSW	11/04/2019	29/08/2019	Enzalutamide	antiandrogen,nonsteroidal,second_generation	Enzalutamide	antiandrogen,nonsteroidal,second_generation	EnzAdapt	EnzAdapt: Feasibility, acceptability and safety of adaptive dosing of enzalutamide in men with metastatic castrate-resistant prostate cancer	castrate resistant prostate cancer; Prostate cancer	2298 - Waratah; 2340 - Tamworth; 2430 - Taree	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619000567123
ACTRN12619000640101	ACTRN12619000640101	Phase 2	STATUS_UNKNOWN	ACT, QLD, NSW, VIC	30/04/2019	10/02/2020	PAX-1	sodium_arsenite	PAX-1	sodium_arsenite	None	A Phase 2, open label study of orally administered PAX-1 monotherapy in patients with recurrent glioblastoma.	Glioblastoma	4120 - Greenslopes; 3168 - Clayton; 2605 - Garran	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619000640101
ACTRN12619000769189	ATTAC	Phase 1	Recruiting	WA	23/05/2019						None	A pilot study to evaluate the safety and immunogenicity of a personalised tumour neo-antigen peptide vaccine strategy in patients with completely resected non-small cell lung cancer.	Lung Cancer		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619000769189
ACTRN12619000844145	ALKternate	Phase 1 / Phase 2	Recruiting	NSW, VIC	13/06/2019	14/06/2019	Crizotinib; Crizotinib + Lorlatinib; Lorlatinib	MET_inhibitor,type_1 + ROS1_inhibitor; ALK_inhibitor,first_generation; ALK_inhibitor,third_generation; ALK_inhibitor,first_generation + ROS1_inhibitor; ALK_inhibitor,first_generation + ALK_inhibitor,third_generation; ALK_inhibitor,third_generation + MET_inhibitor,type_1; ALK_inhibitor,third_generation + ROS1_inhibitor; MET_inhibitor,type_1; ROS1_inhibitor	Crizotinib + Lorlatinib; Lorlatinib; Crizotinib + Lorlatinib	ALK_inhibitor,first_generation + ALK_inhibitor,third_generation; ALK_inhibitor,first_generation + ROS1_inhibitor; ALK_inhibitor,third_generation; ALK_inhibitor,third_generation + MET_inhibitor,type_1; ALK_inhibitor,third_generation + ROS1_inhibitor; MET_inhibitor,type_1 + ROS1_inhibitor; ROS1_inhibitor; ALK_inhibitor,first_generation + ALK_inhibitor,third_generation; ALK_inhibitor,first_generation + ROS1_inhibitor; ALK_inhibitor,third_generation + MET_inhibitor,type_1; ALK_inhibitor,third_generation + ROS1_inhibitor; MET_inhibitor,type_1 + ROS1_inhibitor	None	A single arm multi-centre translational proof of concept study investigating the safety and efficacy of alternating lorlatinib with crizotinib in a pre-treated advanced ALK-rearranged non-small cell lung cancer population with disease progression on a 2nd generation ALK tyrosine kinase inhibitor	ALK-rearranged advanced non-small cell lung cancer	3000 - Melbourne; 2065 - St Leonards	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619000844145
ACTRN12619000900112	AtTEnd	Phase 3	Not yet recruiting	QLD, NSW, VIC, SA, NZ, TAS, WA	27/06/2019		Atezolizumab; Atezolizumab + Carboplatin + Paclitaxel; Carboplatin; Carboplatin + Paclitaxel; Paclitaxel; Placebo	anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent + taxane; placebo; anti-PD-L1_monoclonal_antibody; taxane	Atezolizumab + Carboplatin + Paclitaxel; Carboplatin; Carboplatin + Paclitaxel; Atezolizumab + Carboplatin + Paclitaxel; Carboplatin + Paclitaxel; Placebo	anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent + taxane; anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; placebo; platinum-based_antineoplastic_agent + taxane	IRFMN-EN-7556  CTC 0246  ANZGOG 1807/2019	Phase III Double-Blind Randomized Placebo Controlled Trial of Atezolizumab in Combination with Paclitaxel and Carboplatin in Women with Advanced/Recurrent Endometrial Cancer.	Endometrial Cancer	3199 - Frankston; 3000 - Melbourne; 4029 - Herston; 3083 - Bundoora; 6008 - Subiaco; 2298 - Waratah; 5006 - North Adelaide; 2640 - Albury; 4217 - Benowa; Auckland; 5000 - Adelaide; 2217 - Kogarah; 2170 - Liverpool; 7000 - Hobart; 4350 - Toowoomba; 3128 - Box Hill; 4101 - South Brisbane	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619000900112
ACTRN12619001117101	CAPTURE	Phase 2	Recruiting	QLD, NSW, VIC, SA, NT, WA	12/08/2019	3/08/2020	Alpelisib; Alpelisib + Fulvestrant; Capecitabine; Fulvestrant; Goserelin	PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; GnRH_analogue; selective_estrogen_receptor_degrader; GnRH_agonist; fluoropyrimidine; PI3K_alpha_inhibitor	Alpelisib; Alpelisib + Fulvestrant; Goserelin; Alpelisib + Fulvestrant; Capecitabine	GnRH_agonist; GnRH_analogue; PI3K_alpha_inhibitor; PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; fluoropyrimidine	BCT 1901	BCT 1901 (CAPTURE): A phase II randomised study to evaluate alpelisib plus fulvestrant versus capecitabine in oestrogen receptor positive, HER2-negative advanced breast cancer patients with PIK3CA mutant circulating DNA.	Advanced Breast Cancer	2145 - Westmead; 5112 - Elizabeth Vale; 2298 - Waratah; 2010 - Darlinghurst; 3844 - Traralgon; 2640 - Albury; 6008 - Subiaco; 3199 - Frankston; 2444 - Port Macquarie; 0810 - Tiwi; 3000 - Melbourne; 3168 - Clayton; 3121 - Richmond; 2747 - Kingswood; 3350 - Ballarat Central; 3135 - Ringwood East; 2060 - North Sydney; 4102 - Woolloongabba; 5011 - Woodville; 3280 - Warrnambool; 2170 - Liverpool	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619001117101
ACTRN12619001147178	MoST-Addendum-6	Phase 2	NOT_RECRUITING	NT, WA, ACT, SA, TAS, QLD, VIC, NSW	16/08/2019	2/11/2020	Larotrectinib	TRK_inhibitor,first_generation	Larotrectinib	TRK_inhibitor,first_generation	CTC0141-Addendum 6	Single arm, open label, signal seeking, phase IIa trial of the activity of Larotrectinib in patients with advanced NTRK1-3 positive tumours.	Cancer	7000 - Hobart; 5000 - Adelaide; 2217 - Kogarah; 2605 - Garran; 4102 - Woolloongabba; 2010 - Darlinghurst; 2050 - Camperdown; 6009 - Nedlands; 0810 - Tiwi; 3000 - Melbourne	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619001147178
ACTRN12619001185156	IGNITE	Phase 2	Recruiting	VIC, NSW, QLD, TAS, SA, WA	22/08/2019	26/03/2020	Adavosertib	WEE1_inhibitor	Adavosertib	WEE1_inhibitor	Nil known	A Phase II signal-seeking trial of Adavosertib (AZD1775) targeting recurrent high grade serous ovarian cancer (HGSC) with Cyclin E1 (CCNE1) over-expression with and without gene amplification to determine the clinical benefit rate.	Primary peritoneal cancer; Ovarian Cancer; Cancer of the falllopian tube	4101 - South Brisbane; 2031 - Randwick; 2800 - Orange; 7000 - Hobart; 2145 - Westmead; 2050 - Camperdown; 6009 - Nedlands; 5042 - Bedford Park; 2065 - St Leonards; 3000 - Melbourne; 3021 - St Albans	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619001185156
ACTRN12619001265167	MoST-Addendum-8	Phase 2	Recruiting	WA, NT, ACT, SA, TAS, VIC, NSW, QLD	12/09/2019	25/06/2020	Trastuzumab Emtansine	anti-ERBB2_antibody-drug_conjugate	Trastuzumab Emtansine	anti-ERBB2_antibody-drug_conjugate	CTC0141-addendum 8	Single arm, open label, signal seeking, phase IIa trial of the activity of Trastuzumab emtansine (T-DM1) in patients with tumours harbouring HER2 amplifications or mutations	Cancer	5000 - Adelaide; 2217 - Kogarah; 2605 - Garran; 4102 - Woolloongabba; 7000 - Hobart; 0810 - Tiwi; 3000 - Melbourne; 6009 - Nedlands; 2050 - Camperdown; 2010 - Darlinghurst	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619001265167
ACTRN12619001298101	ASN-002-IL	Phase 2	Not yet recruiting	QLD	20/09/2019		Fluorouracil; Fluorouracil + Gusacitinib; Gusacitinib	Fluorouracil; SYK/JAK_inhibitor + fluoropyrimidine; SYK/JAK_inhibitor	Fluorouracil + Gusacitinib; Gusacitinib; Fluorouracil + Gusacitinib	SYK/JAK_inhibitor; SYK/JAK_inhibitor + fluoropyrimidine; Fluorouracil; SYK/JAK_inhibitor + fluoropyrimidine	SP-002	A Phase IIa Study to assess the Efficacy and Safety of ASN-002 alone and in combination with chemotherapy in adult participants with Low-Risk Basal Cell Carcinomas	Basal Cell Carcinoma; Basal Cell Nevus Syndrome (BCNS)	4000 - Brisbane	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619001298101
ACTRN12619001324101	ANTHEM	Phase 2	Recruiting	WA	27/09/2019	25/02/2020	Anamorelin; Placebo	Growth_hormone_secretagogue_receptor_agonist; placebo	Anamorelin; Placebo	Growth_hormone_secretagogue_receptor_agonist; placebo	Nil known	A single centre phase II, randomised placebo controlled cross over study to examine the effect of anamorelin on cancer cachexia in patients with mesothelioma	Mesothelioma	6009 - Nedlands	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619001324101
ACTRN12619001407189	QB46C-H03--CTRI-2019-11-022032	Phase 1 / Phase 2	Recruiting	QLD, NSW	14/10/2019	29/11/2019	Tigilanol Tiglate	protein_kinase_C_regulator	Tigilanol Tiglate	protein_kinase_C_regulator	QB46C-H03  CTRI/2019/11/022032	Exploratory Phase Ib/IIa Study of Intratumourally Administered Tigilanol Tiglate to Assess Safety, Tolerability and Tumour Response in Patients with Head and Neck Squamous Cell Carcinoma	Head and neck squamous cell carcinoma.	2010 - Darlinghurst; 4102 - Woolloongabba	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619001407189
ACTRN12619001527156	CESTEM-1	Phase 1	Recruiting	QLD	5/11/2019	1/06/2017	Cetuximab; Cetuximab + Prochlorperazine; Prochlorperazine	anti-EGFR_monoclonal_antibody + antihistamine; antihistamine; anti-EGFR_monoclonal_antibody	Cetuximab + Prochlorperazine; Cetuximab + Prochlorperazine	anti-EGFR_monoclonal_antibody + antihistamine; anti-EGFR_monoclonal_antibody + antihistamine	None	Open-label Phase I study investigating the safety and efficacy of Cetuximab and prochlorperazine (STEMetil) combination therapy in patients with metastatic Head and Neck Squamous Cell Carcinoma and Triple Negative Breast Cancer (CESTEM study)	Cancer	4102 - Woolloongabba	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619001527156
ACTRN12619001533189	FP101A	Phase 1	Recruiting	NSW	6/11/2019	9/03/2020	Deflexifol; Deflexifol + Fluorouracil + Leucovorin; Fluorouracil; Leucovorin	Fluorouracil; folinic_acid; Fluorouracil + fluoropyrimidine + folinic_acid	Deflexifol; Deflexifol + Fluorouracil + Leucovorin; Deflexifol + Fluorouracil + Leucovorin	Fluorouracil; Fluorouracil + fluoropyrimidine + folinic_acid; Fluorouracil + fluoropyrimidine + folinic_acid	TGA CT-2019-CTN-02849-1	A Phase 1 Study of Deflexifol: To determine pharmacokinetic (PK) in patients administered a combined dose of bolus and continuous 46hr infusion of Deflexifol in patients with advanced malignancy after failure of standard treatment	Advanced Malignant Cancer	2500 - Wollongong	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619001533189
ACTRN12620000008921	CTIV1708	Phase 1	Recruiting	SA, VIC	8/01/2020	17/09/2020	MVR-T3011	oncolytic_HSV_virus	MVR-T3011	oncolytic_HSV_virus	Theravir Protocol Number: CTIV1708	A Phase I, Open-Label, Multiple Ascending Dose Study of the Safety and Tolerability of T3011 in advanced Cutaneous or Subcutaneous Malignancies	Any malignancy with cutaneous and/or subcutaneous tumours	3004 - St Kilda Road Melbourne; 3199 - Frankston; 5042 - Bedford Park	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12620000008921
ACTRN12620000244909	VG161-A101	Phase 1	Recruiting	SA, NSW, QLD	26/02/2020	27/04/2020	VG-161	oncolytic_virus	VG-161	oncolytic_virus	VG161-A101	A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG161 in Subjects with Advanced Malignant Solid Tumors that are Refractory to Conventional Therapies	Advanced malignant solid tumors	4029 - Herston; 2010 - Darlinghurst; 5042 - Bedford Park	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12620000244909
ACTRN12620000440921	ALMB-0168-AU-101	Phase 1	Recruiting	VIC, NSW, SA	6/04/2020	23/10/2020	ALMB-0168	anti-Cx43_agonistic_antibody	ALMB-0168	anti-Cx43_agonistic_antibody	ALMB-0168-AU-101	Phase 1, Multicenter, First-in-Human Dose Escalation Study of ALMB-0168 Administered IV as a Single Agent to Patients with Malignant Bone Disease	Osteosarcoma or any other solid tumor cancer with bone metastases	2031 - Randwick; 3199 - Frankston; 5042 - Bedford Park	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12620000440921
ACTRN12620000568910	MoST-Addendum-10	Phase 2	Recruiting	SA, TAS, QLD, NSW, VIC, NT, WA, ACT	15/05/2020	3/05/2021	Avelumab; Avelumab + Palbociclib; Palbociclib	anti-PD-L1_monoclonal_antibody; CDK4/6_inhibitor + anti-PD-L1_monoclonal_antibody; CDK4/6_inhibitor	Avelumab; Avelumab + Palbociclib; Palbociclib; Avelumab + Palbociclib	CDK4/6_inhibitor; CDK4/6_inhibitor + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; CDK4/6_inhibitor + anti-PD-L1_monoclonal_antibody	CTC0141-addendum 10	Single arm, open label, signal seeking, phase II trial of the activity of Palbociclib in combination with Avelumab in patients with tumours with amplified D-type cyclins or CDK4/6 or inactivation of CDKN2A.	Cancer	0810 - Tiwi; 3000 - Melbourne; 2050 - Camperdown; 6009 - Nedlands; 2605 - Garran; 4102 - Woolloongabba; 5000 - Adelaide; 7000 - Hobart	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12620000568910
ACTRN12620000583943	EOHC-1001-01	Phase 1 / Phase 2	Not yet recruiting	VIC	20/05/2020		EO1001	ERBB2_inhibitor,second_generation; EGFR_inhibitor,second_generation	EO1001	EGFR_inhibitor,second_generation; ERBB2_inhibitor,second_generation	EOHC-1001-01	An ascending single and multiple dose study of the safety, tolerability, pharmacokinetics and anti-tumour activity of once-daily oral treatment with EO1001 in patients with advanced cancer.	ERbB-4 (HER4) positive cancer; ErbB-2(HER2) positive cancer; ErbB-1(EGFR) positive cancer	3144 - Malvern; 3168 - Clayton	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12620000583943
ACTRN12620000592943	GQCT001--GQ1001X2101	Phase 1	NOT_RECRUITING	NSW	21/05/2020	25/06/2020	GQ1001	anti-ERBB2_antibody-drug_conjugate	GQ1001	anti-ERBB2_antibody-drug_conjugate	GQCT001  GQ1001X2101	A Phase I, First-In-Human, Multicenter, Open-Label, Study of GQ1001, a HER2 Targeted Antibody-Drug Conjugate, Administered Intravenously in Adult Patients with HER2-Positive Advanced Solid Tumors	HER2-Positive Advanced Solid Tumors	2031 - Randwick	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12620000592943
ACTRN12620000767909	MoST-Addendum-9	Phase 2	Recruiting	WA, NT, ACT, SA, TAS, VIC, NSW, QLD	27/07/2020		Trastuzumab; Trastuzumab + Tucatinib; Tucatinib	anti-ERBB2_monoclonal_antibody; ERBB2_inhibitor,third_generation; ERBB2_inhibitor,third_generation + anti-ERBB2_monoclonal_antibody	Trastuzumab; Trastuzumab + Tucatinib; Tucatinib; Trastuzumab + Tucatinib	ERBB2_inhibitor,third_generation; ERBB2_inhibitor,third_generation + anti-ERBB2_monoclonal_antibody; anti-ERBB2_monoclonal_antibody; ERBB2_inhibitor,third_generation + anti-ERBB2_monoclonal_antibody	CTC0141- addendum 9	Single arm, open label, signal seeking, phase II trial of the activity of tucatinib plus trastuzumab in patients with tumours harbouring HER2 amplifications or mutations	Cancer	3000 - Melbourne; 0810 - Tiwi; 2050 - Camperdown; 6009 - Nedlands; 2010 - Darlinghurst; 4102 - Woolloongabba; 2605 - Garran; 2217 - Kogarah; 5000 - Adelaide; 7000 - Hobart	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12620000767909
ACTRN12620000849998	ACTRN12620000849998	Phase 1 / Phase 2	OLD_TRIAL	NSW, QLD	27/08/2020	12/05/2020	MG010; MG010 + Sorafenib; Sorafenib	CRAF_inhibitor + VEGFR_inhibitor; CRAF_inhibitor + FLT3_inhibitor; CRAF_inhibitor; CRAF_inhibitor + KIT_inhibitor; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor + CRAF_inhibitor; FLT3_inhibitor; CRAF_inhibitor + PDGFR_inhibitor; VEGFR_inhibitor; PDGFR_inhibitor; KIT_inhibitor; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor	MG010 + Sorafenib; MG010 + Sorafenib	CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor + CRAF_inhibitor; CRAF_inhibitor; CRAF_inhibitor + FLT3_inhibitor; CRAF_inhibitor + KIT_inhibitor; CRAF_inhibitor + PDGFR_inhibitor; CRAF_inhibitor + VEGFR_inhibitor; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor + CRAF_inhibitor; CRAF_inhibitor + FLT3_inhibitor; CRAF_inhibitor + KIT_inhibitor; CRAF_inhibitor + PDGFR_inhibitor; CRAF_inhibitor + VEGFR_inhibitor	Nil	A phase I/II, open label, multi-centre study to assess the safety, tolerability, and efficacy of MG010 in combination with sorafenib in subjects with solid tumours who have failed existing treatments.	Metastatic solid tumours having failed existing treatments.	2139 - Concord; 2050 - Camperdown; 2031 - Randwick; 4101 - South Brisbane	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12620000849998
ACTRN12620000861954	MoST-Addendum-12	Phase 2	Recruiting	NSW	28/08/2020		Cobimetinib; Cobimetinib + Vemurafenib; Vemurafenib	MEK_inhibitor; BRAF_V600_inhibitor + MEK_inhibitor; BRAF_V600_inhibitor	Cobimetinib + Vemurafenib; Cobimetinib + Vemurafenib	BRAF_V600_inhibitor + MEK_inhibitor; BRAF_V600_inhibitor + MEK_inhibitor	CTC 0141 / ALTG 20/002 – addendum 12	Single arm, open label, phase II trial of vemurafenib and cobimetinib in patients with metastatic non-squamous non-small cell lung cancer and other tumours harbouring BRAF V600 mutations detected by comprehensive genomic profiling	non-small cell lung cancer; Cancer	2010 - Darlinghurst; 2217 - Kogarah	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12620000861954
ACTRN12620000918921	MoST-addendum-7	Phase 2	Recruiting	ACT, NT, WA, QLD, VIC, NSW, TAS, SA	17/09/2020	30/11/2020	Tremelimumab	anti-CTLA-4_monoclonal_antibody	Tremelimumab	anti-CTLA-4_monoclonal_antibody	CTC0141 Addendum 7	Single arm, open label, signal seeking, phase IIa trial of the activity of Tremelimumab in patients with advanced rare or neglected cancers	cancer	0810 - Tiwi; 3000 - Melbourne; 2065 - St Leonards; 2010 - Darlinghurst; 6009 - Nedlands; 5000 - Adelaide; 2605 - Garran; 4102 - Woolloongabba; 7000 - Hobart	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12620000918921
ACTRN12620000984998	MoST-Addendum-11	Phase 2	Recruiting	NT, WA, ACT, SA, TAS, QLD, NSW, VIC	30/09/2020	9/03/2021	Tildrakizumab	anti-IL-23_monoclonal_antibody	Tildrakizumab	anti-IL-23_monoclonal_antibody	CTC0141-addendum 11	Single arm, open label signal seeking, phase II trial to study the clinical activity of Tildrakizumab in patients with advanced osteosarcoma and soft tissue sarcomas	Cancer; Advanced Osteosarcoma; Soft Tissue Sarcoma	7000 - Hobart; 5000 - Adelaide; 4102 - Woolloongabba; 2605 - Garran; 2050 - Camperdown; 6009 - Nedlands; 3000 - Melbourne; 0810 - Tiwi	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12620000984998
ACTRN12620001146987	ACTRN12620001146987	Phase 1	Recruiting	WA, NSW, VIC	2/11/2020		PMR-116	RNA_polymerase_I_transcription_inhibitor	PMR-116	RNA_polymerase_I_transcription_inhibitor	Nil known	Investigating the safety and tolerability of PMR-116 in Patients with Advanced Malignancies	Advanced solid tumours	3000 - Melbourne; 6009 - Nedlands; 3004 - Melbourne; 2031 - Randwick	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12620001146987
ACTRN12620001198910	MODERN-LUNG	Phase 2	Recruiting	NSW	10/11/2020	15/04/2021	Carboplatin; Carboplatin + Paclitaxel; Durvalumab; Paclitaxel; Radiotherapy	anti-PD-L1_monoclonal_antibody; radiotherapy; platinum-based_antineoplastic_agent; taxane; platinum-based_antineoplastic_agent + taxane	Carboplatin + Paclitaxel; Durvalumab; Radiotherapy; Carboplatin + Paclitaxel	anti-PD-L1_monoclonal_antibody; platinum-based_antineoplastic_agent + taxane; radiotherapy; platinum-based_antineoplastic_agent + taxane	CMNDRO-2005	Phase 2 Study of a Moderately Hypofractionated Schedule of Chemoradiation followed by Immunotherapy for Unresectable Locally Advanced Non-Small Cell Lung Cancer	lung cancer	2148 - Blacktown; 2170 - Liverpool; 2298 - Waratah; 2560 - Campbelltown; 2145 - Westmead	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12620001198910
ACTRN12621000093886	ACT001-AU-004	Phase 2	Not yet recruiting	VIC	1/02/2021		ACT001; ACT001 + Radiotherapy; Radiotherapy	NFKB_inhibitor + radiotherapy; radiotherapy; NFKB_inhibitor	ACT001 + Radiotherapy; ACT001 + Radiotherapy	NFKB_inhibitor + radiotherapy; NFKB_inhibitor + radiotherapy	ACT001-AU-004	A Phase 2, open label, multicentre study assessing the safety and efficacy of ACT001 in combination with whole brain radiation therapy (WBRT) for brain metastases from solid tumours.	Metastatic Brain Cancer; Solid Tumours	3121 - Richmond	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000093886
ACTRN12621000156886	ACE-IT001	Phase 1 / Phase 2	Not yet recruiting	NSW	15/02/2021		Ipilimumab; Ipilimumab + Nivolumab; Nivolumab; Perindopril	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; ACE_inhibitor	Ipilimumab + Nivolumab; Perindopril; Ipilimumab + Nivolumab	ACE_inhibitor; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	NONE	A pilot study of Perindopril in combination with first line Ipilimumab and Nivolumab for patients with unresectable or metastatic melanoma- ACE-IT 001	Melanoma - Metastatic; Melanoma - Unresectable		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000156886
ACTRN12621000269831	HYNOVA	Not Applicable	Not yet recruiting	QLD, NSW, VIC	11/03/2021		Cisplatin	platinum-based_antineoplastic_agent	Cisplatin	platinum-based_antineoplastic_agent	CTC 0302  ANZGOG 1901 /2020	The safety of hyperthermic and normothermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III epithelial ovarian, fallopian tube and primary peritoneal cancer (HYNOVA).	Primary peritoneal cancer; Fallopian tube cancer; Ovarian cancer		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000269831
ACTRN12621000273886	ADELE	Phase 2	Not yet recruiting	VIC, NSW	11/03/2021		Carboplatin; Carboplatin + Paclitaxel + Tislelizumab; Paclitaxel; Tislelizumab	anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; taxane; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane	Carboplatin + Paclitaxel + Tislelizumab; Carboplatin + Paclitaxel + Tislelizumab	anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane	ANZGOG 1910/2020  CTC0299	The effect of adjuvant tislelizumab plus chemotherapy on failure free survival after post-operative pelvic chemoradiation in high risk endometrial cancer - ADELE: a randomised phase 2 trial	Endometrial Cancer	3000 - Melbourne; 3052 - Parkville; 2031 - Randwick	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000273886
ACTRN12621000312842	MoST-Addendum-14	Phase 2	Recruiting	ACT, WA, VIC, NSW, QLD, TAS, SA	22/03/2021	3/09/2021	Alectinib	ALK/RET_inhibitor; ALK_inhibitor,second_generation	Alectinib	ALK/RET_inhibitor; ALK_inhibitor,second_generation	CTC 0141 – addendum 14	A Single arm, open label, phase II trial of tumour response to alectinib in patients with advanced tumours harbouring ALK gene alterations detected by comprehensive genomic profiling	Non-small cell lung cancer; Cancer; ALK gene alterations	5000 - Adelaide; 2217 - Kogarah; 4102 - Woolloongabba; 7000 - Hobart; 3000 - Melbourne; 2065 - St Leonards; 6009 - Nedlands; 2145 - Westmead	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000312842
ACTRN12621000479808	ATTACK-1-trial	Phase 1	*NOT_RECRUITING	SA, NSW, VIC	22/04/2021	16/06/2021	Auceliciclib; Auceliciclib + Temozolomide; Ifosfamide; Temozolomide	CDK4/6_inhibitor + alkylating_agent; alkylating_agent; CDK4/6_inhibitor	Auceliciclib; Auceliciclib + Temozolomide; Auceliciclib + Temozolomide; Ifosfamide	CDK4/6_inhibitor; CDK4/6_inhibitor + alkylating_agent; CDK4/6_inhibitor + alkylating_agent	Nil known	A Phase 1a/b, open-label, dose-exploration, combination/ expansion study to evaluate the safety, tolerability and pharmacokinetics of Auceliciclib in advanced solid tumours and in combination with temozolomide in recurrent or newly diagnosed Glioblastoma multiforme (GBM).	Glioblastoma multiforme (GBM); Ovarian cancer; Cancer; Colorectal cancer; Solid tumors	3084 - Heidelberg; 5042 - Bedford Park; 2170 - Liverpool	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000479808
ACTRN12621000507886	MoST-Addendum-15	Phase 2	Recruiting	SA, QLD	30/04/2021	7/09/2021	Acalabrutinib; Acalabrutinib + Durvalumab; Durvalumab	anti-PD-L1_monoclonal_antibody; BTK_inhibitor; BTK_inhibitor + anti-PD-L1_monoclonal_antibody	Acalabrutinib; Acalabrutinib + Durvalumab; Durvalumab; Acalabrutinib + Durvalumab	BTK_inhibitor; BTK_inhibitor + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; BTK_inhibitor + anti-PD-L1_monoclonal_antibody	CTC0141- addendum 15	A single arm, open label, signal seeking, phase II trial of the activity of Durvalumab in combination with Acalabrutinib in patients with high-grade B cell lymphoma	Cancer; High grade B cell lymphoma	4029 - Herston; 5000 - Adelaide	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000507886
ACTRN12621000611820	PICAASO	Phase 2	Not yet recruiting	VIC, NSW	21/05/2021		Dasatinib	PDGFRA_inhibitor; SRC_inhibitor; BCR-ABL1_inhibitor,second_generation; YES1_inhibitor; KIT_inhibitor	Dasatinib	BCR-ABL1_inhibitor,second_generation; KIT_inhibitor; PDGFRA_inhibitor; SRC_inhibitor; YES1_inhibitor	Nil Known	Prostate-Specific Membrane Antigen (PSMA) Intensity Can be Altered by Androgen and phospho-SrC Obstruction	metastatic castration-resistant prostate cancer	3000 - Melbourne; 2010 - Darlinghurst	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000611820
ACTRN12621000639820	PARAGON-II	Phase 2	Not yet recruiting	WA, TAS, VIC, NSW, QLD	28/05/2021		Alpelisib; Alpelisib + Letrozole; Letrozole; Letrozole + Ribociclib; Ribociclib	PI3K_alpha_inhibitor + aromatase_inhibitor; aromatase_inhibitor; CDK4/6_inhibitor + aromatase_inhibitor; CDK4/6_inhibitor; PI3K_alpha_inhibitor	Alpelisib + Letrozole; Letrozole; Letrozole + Ribociclib; Alpelisib + Letrozole; Letrozole + Ribociclib	CDK4/6_inhibitor + aromatase_inhibitor; PI3K_alpha_inhibitor + aromatase_inhibitor; aromatase_inhibitor; CDK4/6_inhibitor + aromatase_inhibitor; PI3K_alpha_inhibitor + aromatase_inhibitor	None	The activity and tolerability of Aromatase inhibitor plus PI3KCA inhibitor or CDK4/6 inhibitor in women with hormone receptor positive recurrent/metastatic gynaecological neoplasms (PARAGON-II) .	Endometrial stromal sarcomas; Other gynaecological cancers (excluding endometrial cancers); Platinum resistant high-grade epithelial cancers of fallopian tube; Leiomyosarcomas; Platinum resistant high-grade epithelial cancers of primary peritoneum; Low grade epithelial cancers of ovary; Endometrial cancer; Platinum resistant high-grade epithelial cancers of ovary; Granulosa cell tumours	7000 - Hobart; 2031 - Randwick; 3168 - Clayton; 4101 - South Brisbane; 3052 - Parkville; 2217 - Kogarah; 6009 - Nedlands; 2640 - Albury; 2050 - Camperdown; 2305 - New Lambton Heights; 2145 - Westmead; 3000 - Melbourne; 4029 - Herston; 2065 - St Leonards	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000639820
ACTRN12621000747820	TaxAdapt	Phase 1 / Phase 2	Not yet recruiting	NSW	11/06/2021		Docetaxel	taxane	Docetaxel	taxane	Nil known	TaxAdapt: Feasibility, acceptability and safety of adaptive dosing of docetaxel in men with metastatic castrate-resistant prostate cancer	Castration-resistant prostate cancer	2298 - Waratah	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000747820
ACTRN12621000762853	ACTRN12621000762853	Phase 1	Recruiting	QLD	18/06/2021	21/07/2021	Cyclophosphamide; Cyclophosphamide + Fludarabine + Tisagenlecleucel; Fludarabine; Tisagenlecleucel	alkylating_agent; autologous_CAR-T-cell_therapy,CD19-targeting; antimetabolite; alkylating_agent + antimetabolite + autologous_CAR-T-cell_therapy,CD19-targeting	Cyclophosphamide + Fludarabine + Tisagenlecleucel; Tisagenlecleucel; Cyclophosphamide + Fludarabine + Tisagenlecleucel	alkylating_agent + antimetabolite + autologous_CAR-T-cell_therapy,CD19-targeting; autologous_CAR-T-cell_therapy,CD19-targeting; alkylating_agent + antimetabolite + autologous_CAR-T-cell_therapy,CD19-targeting	None	Phase I Clinical Trial of MB.CART19.1 CD19 Chimeric Antigen Receptor (CAR) T Cells in Relapsed or Refractory CD19-Positive Haematological Malignancy	B cell blood cancers, including non-Hodgkin's lymphoma and leukaemia.	4029 - Herston; 4029 - Royal Brisbane Hospital	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000762853
ACTRN12621000802808	LU-TEMP	Phase 2	Not yet recruiting	NSW	25/06/2021		Temozolomide	alkylating_agent	Temozolomide	alkylating_agent	Nil	A pilot open label study of [177Lu]Lu-octretotate and temozolomide in the treatment of succinate dehydrogenase-associated locally advanced or metastatic pheochromocytoma and paraganglioma in adults.	Cancer	2065 - St Leonards	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000802808
ACTRN12621000811808	MoST-Addendum-17	Phase 2	Recruiting	QLD, NSW, VIC, TAS, SA, ACT, NT, WA	28/06/2021	9/11/2021	Tepotinib	MET_inhibitor,type_1	Tepotinib	MET_inhibitor,type_1	CTC0141- addendum 17	A single arm, open label, signal-seeking, phase II trial of tepotinib in patients with advanced non-small cell lung cancer harbouring MET exon 14 skipping mutations detected by comprehensive genomic profiling	Advanced non-small cell lung cancer harbouring MET exon 14 skipping mutations	3065 - Fitzroy; 2065 - St Leonards; 3084 - Heidelberg; 0810 - Tiwi; 3000 - Melbourne; 2145 - Westmead; 4032 - Chermside; 6009 - Nedlands; 2605 - Garran; 4102 - Woolloongabba; 5000 - Adelaide; 2217 - Kogarah; 7000 - Hobart	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000811808
ACTRN12621000991819	PDCCiHNC	Not Applicable	Not yet recruiting	NSW	28/07/2021		Carboplatin; Ceralasertib; Cisplatin; Crizotinib; Dactolisib; Dasatinib; Docetaxel; Doxorubicin; Erlotinib; Etoposide; Fluorouracil; Gemcitabine; Itraconazole; Methotrexate; Paclitaxel; Palbociclib; Pemetrexed; Ruxolitinib; Sorafenib; Vinorelbine; Vistusertib	EGFR_inhibitor,first_generation; PI3K/mTOR_inhibitor; MET_inhibitor,type_1; CRAF_inhibitor; taxane; FLT3_inhibitor; CDK4/6_inhibitor; antifolate; JAK1/JAK2_inhibitor; Fluorouracil; vinca_alkaloid; PDGFR_inhibitor; ATR_inhibitor; mTORC1/mTORC2_inhibitor; topoisomerase_inhibitor; PDGFRA_inhibitor; doxorubicin; SMO_inhibitor; ROS1_inhibitor; gemcitabine; fluoropyrimidine; anthracycline; ALK_inhibitor,first_generation; platinum-based_antineoplastic_agent; SRC_inhibitor; YES1_inhibitor; antimetabolite; VEGFR_inhibitor; BCR-ABL1_inhibitor,second_generation; KIT_inhibitor; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor	Carboplatin; Ceralasertib; Cisplatin; Crizotinib; Dactolisib; Dasatinib; Docetaxel; Doxorubicin; Erlotinib; Etoposide; Fluorouracil; Gemcitabine; Itraconazole; Methotrexate; Paclitaxel; Palbociclib; Pemetrexed; Ruxolitinib; Sorafenib; Vinorelbine; Vistusertib	ALK_inhibitor,first_generation; ATR_inhibitor; BCR-ABL1_inhibitor,second_generation; CDK4/6_inhibitor; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor; CRAF_inhibitor; EGFR_inhibitor,first_generation; FLT3_inhibitor; JAK1/JAK2_inhibitor; KIT_inhibitor; MET_inhibitor,type_1; PDGFRA_inhibitor; PDGFR_inhibitor; PI3K/mTOR_inhibitor; ROS1_inhibitor; SMO_inhibitor; SRC_inhibitor; VEGFR_inhibitor; YES1_inhibitor; anthracycline; antifolate; antimetabolite; fluoropyrimidine; mTORC1/mTORC2_inhibitor; platinum-based_antineoplastic_agent; taxane; topoisomerase_inhibitor; vinca_alkaloid; Fluorouracil; doxorubicin; gemcitabine	Nil known	A Feasibility Trial of Patient Derived Cell Culture (PDCC) Chemosensitivity in Head and Neck Carcinoma (HNC)	Head and Neck Carcinoma	2050 - Camperdown	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000991819
ACTRN12621001155886	PRIME005	Phase 1 / Phase 2	Recruiting	NSW, QLD	27/08/2021	13/09/2021	Azacitidine; Azacitidine + Carboplatin; Azacitidine + Carboplatin + Ipilimumab + Nivolumab; Carboplatin; Ipilimumab; Ipilimumab + Nivolumab; Nivolumab	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; DNA_methyltransferase_inhibitor; antimetabolite; DNA_methyltransferase_inhibitor + platinum-based_antineoplastic_agent; DNA_methyltransferase_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent	Azacitidine + Carboplatin; Azacitidine + Carboplatin + Ipilimumab + Nivolumab; Ipilimumab + Nivolumab; Azacitidine + Carboplatin; Azacitidine + Carboplatin + Ipilimumab + Nivolumab; Ipilimumab + Nivolumab	DNA_methyltransferase_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent; DNA_methyltransferase_inhibitor + platinum-based_antineoplastic_agent; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; DNA_methyltransferase_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent; DNA_methyltransferase_inhibitor + platinum-based_antineoplastic_agent; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent	CA184-602	Phase Ib/II study of safety and clinical response to Azacitidine and Carboplatin priming for Ipilimumab and Nivolumab re-challenge in patients with advanced melanoma who are resistant to immunotherapy.	Advanced Melanoma	4870 - Cairns; 2298 - Waratah; 2298 - Waratah West	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621001155886
ACTRN12621001172897	ACT001-AU-001	Phase 1	Recruiting	SA, NSW, VIC	31/08/2021	15/04/2021	ACT001; ACT001 + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; NFKB_inhibitor; NFKB_inhibitor + anti-PD-1_monoclonal_antibody	ACT001 + Pembrolizumab; ACT001 + Pembrolizumab	NFKB_inhibitor + anti-PD-1_monoclonal_antibody; NFKB_inhibitor + anti-PD-1_monoclonal_antibody	ACT001-AU-001 (Sponsor protocol code) - PART B	A phase 1 dose-escalation study to evaluate the safety, tolerability and pharmacokinetics of ACT001 in patients with advanced solid tumors (PART B).	Glioblastoma Multiforme	3121 - Richmond; 2031 - Randwick; 5042 - Bedford Park	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621001172897
ACTRN12621001225808	MoST-Addendum-18	Phase 2	Recruiting	NSW	13/09/2021		Carboplatin; Carboplatin + Cisplatin + Etoposide; Cisplatin; Durvalumab; Etoposide	platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-PD-L1_monoclonal_antibody; platinum-based_antineoplastic_agent; topoisomerase_inhibitor	Carboplatin + Cisplatin + Etoposide; Durvalumab; Carboplatin + Cisplatin + Etoposide	anti-PD-L1_monoclonal_antibody; platinum-based_antineoplastic_agent + topoisomerase_inhibitor; platinum-based_antineoplastic_agent + topoisomerase_inhibitor	CTC0141- addendum 18	A single-arm, open-label, signal-seeking, phase II trial of durvalumab and chemotherapy in patients with extra-pulmonary small cell carcinoma	Extra-pulmonary small cell carcinoma	2050 - Camperdown; 2170 - Liverpool	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621001225808
ACTRN12621001342808	CL001-559	Phase 1	Recruiting	NSW, VIC, SA, WA	7/10/2021	2/08/2021	CCX559	PD-L1_inhibitor,oral	CCX559	PD-L1_inhibitor,oral	CL001_559	A Phase 1 First In Human, Multicenter, Open label Study To Determine The Safety, Tolerability, Pharmacokinetics And Recommended Phase 2 Dose Of CCX559 In Subjects With Solid Tumors	Neoplastic Disorder - Solid Tumors	3144 - Malvern	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621001342808
ACTRN12621001347853	SPEAR	Phase 2	Recruiting	NSW, VIC, QLD, SA, WA	7/10/2021		Sulfasalazine	SLC7A11_inhibitor	Sulfasalazine	SLC7A11_inhibitor	None	A phase 2, open-label, single-arm sulfasalazine monotherapy trial of progression-free survival in patients with pancreatic adenocarcinoma	Pancreatic cancer		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621001347853
ACTRN12621001403820	IMBO-Pilot-study	Phase 2	Not yet recruiting	NSW, VIC	18/10/2021		Dexamethasone; Placebo	glucocorticoid; placebo	Dexamethasone; Placebo	glucocorticoid; placebo	054/20	A phase II, multi-site, double blind, randomised placebo-controlled feasibility trial of crushed oral famotidine for management of Inoperable Malignant Bowel Obstruction (IMBO)	Bowel Obstruction; Malignant Bowel Obstruction; Bowel cancer	3084 - Heidelberg; 2010 - Darlinghurst; 2170 - Liverpool; 2217 - Kogarah; 2176 - Prairiewood	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621001403820
ACTRN12621001436864	CTB-02-01	Phase 1 / Phase 2	Not yet recruiting	NSW	25/10/2021		Cetuximab; Cetuximab + Cobimetinib + Palbociclib; Cobimetinib; Palbociclib	CDK4/6_inhibitor + MEK_inhibitor + anti-EGFR_monoclonal_antibody; MEK_inhibitor; anti-EGFR_monoclonal_antibody; CDK4/6_inhibitor	Cetuximab; Cetuximab + Cobimetinib + Palbociclib; Cobimetinib; Palbociclib; Cetuximab + Cobimetinib + Palbociclib	CDK4/6_inhibitor; CDK4/6_inhibitor + MEK_inhibitor + anti-EGFR_monoclonal_antibody; MEK_inhibitor; anti-EGFR_monoclonal_antibody; CDK4/6_inhibitor + MEK_inhibitor + anti-EGFR_monoclonal_antibody	CTB-02-01	A two-part open label Phase 1/2 study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of the combination of cetuximab, cobimetinib and palbociclib in subjects with K-RAS wild-type BRAF V600E mutated, or K-RAS mutated, advanced or metastatic colorectal cancer who have failed all available standard therapies	Colorectal Cancer	2050 - Camperdown; 2298 - Waratah	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621001436864
ACTRN12621001458820	CHARMM	Phase 1	Not yet recruiting	NSW	26/10/2021		Carfilzomib; Carfilzomib + Dexamethasone; Carfilzomib + Dexamethasone + Hydroxychloroquine; Dexamethasone; Hydroxychloroquine	anti-malarial_agent; glucocorticoid; proteasome_inhibitor; glucocorticoid + proteasome_inhibitor; anti-malarial_agent + glucocorticoid + proteasome_inhibitor	Carfilzomib; Carfilzomib + Dexamethasone; Carfilzomib + Dexamethasone + Hydroxychloroquine; Hydroxychloroquine; Carfilzomib + Dexamethasone; Carfilzomib + Dexamethasone + Hydroxychloroquine	anti-malarial_agent; anti-malarial_agent + glucocorticoid + proteasome_inhibitor; glucocorticoid + proteasome_inhibitor; proteasome_inhibitor; anti-malarial_agent + glucocorticoid + proteasome_inhibitor; glucocorticoid + proteasome_inhibitor	none	Phase I Clinical Trial to Determine Dosing Schedule of Hydroxychloroquine in Participants with Multiple Myeloma and Partial Response or Less to Carfilzomib	Cancer; Myeloma	2170 - Liverpool	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621001458820
ACTRN12621001537842	NOX66-IS-002--CA209-66P,	Phase 1 / Phase 2	Recruiting	NSW	10/11/2021	25/10/2021	Idronoxil; Idronoxil + Nivolumab; Nivolumab	anti-PD-1_monoclonal_antibody + idronoxil_suppository; anti-PD-1_monoclonal_antibody; idronoxil_suppository	Idronoxil; Idronoxil + Nivolumab; Nivolumab; Idronoxil + Nivolumab	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + idronoxil_suppository; idronoxil_suppository; anti-PD-1_monoclonal_antibody + idronoxil_suppository	NOX66-IS-002  CA209-66P,	Safety and Efficacy of NOX66 in combination with Nivolumab for patients with solid tumours – a pilot study (IONIC-1).	Patients with solid tumours	2076 - Wahroonga; 2228 - Miranda; 2217 - Kogarah; 2148 - Blacktown	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621001537842
ACTRN12621001690842	MoST-addendum-19	Phase 2	Recruiting	TAS, SA, VIC, NSW, WA	10/12/2021		Sotorasib	KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor	Sotorasib	KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor	CTC 0141 – addendum 19	Single arm, open label, signal-seeking phase II study of Sotorasib (AMG-510) in patients with solid tumours harbouring KRAS G12C mutation.	Cancer	2145 - Westmead; 2010 - Darlinghurst; 6009 - Nedlands; 3000 - Melbourne; 7000 - Hobart; 5000 - Adelaide	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621001690842
ACTRN12622000016730	HER2Pro-1B	Phase 1	Not yet recruiting	QLD, NSW	11/01/2022		Dexamethasone; Dexamethasone + Paclitaxel + Pertuzumab + Prochlorperazine + Trastuzumab; Paclitaxel; Paclitaxel + Pertuzumab + Prochlorperazine + Trastuzumab; Paclitaxel + Pertuzumab + Trastuzumab; Pertuzumab; Prochlorperazine; Trastuzumab	glucocorticoid; anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor + antihistamine + glucocorticoid + taxane; anti-ERBB2_monoclonal_antibody; antihistamine; anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor + taxane; taxane; anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor + antihistamine + taxane	Dexamethasone + Paclitaxel + Pertuzumab + Prochlorperazine + Trastuzumab; Paclitaxel + Pertuzumab + Prochlorperazine + Trastuzumab; Paclitaxel + Pertuzumab + Trastuzumab; Prochlorperazine; Dexamethasone + Paclitaxel + Pertuzumab + Prochlorperazine + Trastuzumab; Paclitaxel + Pertuzumab + Prochlorperazine + Trastuzumab; Paclitaxel + Pertuzumab + Trastuzumab	anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor + antihistamine + glucocorticoid + taxane; anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor + antihistamine + taxane; anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor + taxane; antihistamine; anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor + antihistamine + glucocorticoid + taxane; anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor + antihistamine + taxane; anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor + taxane	None	Addition of prochlorperazine to paclitaxel, trastuzumab, and pertuzumab for previously untreated HER2-positive metastatic breast cancer: a phase 1 dose de-escalation study	Metastatic HER2-positive breast cancer	2010 - Darlinghurst; 4102 - Woolloongabba	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12622000016730
ACTRN12622000405718	ONC201-104	Phase 1	Not yet recruiting	NZ	9/03/2022		ONC201	ERK_inhibitor; DRD2_antagonist; AKT_inhibitor	ONC201	AKT_inhibitor; DRD2_antagonist; ERK_inhibitor	ONC201-104	A Phase 1 study to evaluate the effect of renal impairment on the pharmacokinetics of ONC201	Renal Impairment; Solid Tumours; Cancer	Christchurch	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12622000405718
ACTRN12622000513718	GQ1007-101	Phase 1	Not yet recruiting	NSW, VIC, QLD	31/03/2022		Envafolimab; Envafolimab + GQ1007; GQ1007	anti-PD-L1_monoclonal_antibody; anti-ERBB2_antibody-immune-agonist-conjugate + anti-PD-L1_monoclonal_antibody; anti-ERBB2_antibody-immune-agonist-conjugate	Envafolimab; Envafolimab + GQ1007; GQ1007; Envafolimab + GQ1007	anti-ERBB2_antibody-immune-agonist-conjugate; anti-ERBB2_antibody-immune-agonist-conjugate + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; anti-ERBB2_antibody-immune-agonist-conjugate + anti-PD-L1_monoclonal_antibody	GQ1007-101	A Phase I, First-In-Human, Multicenter, Open-Label, Dose Escalation and Expansion Study of GQ1007 Alone and in Combination with Envafolimab in Subjects with HER2-expressing Advanced Solid Tumors	Solid Tumors	3168 - Clayton; 2010 - Darlinghurst; 4217 - Benowa	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12622000513718
ACTRN12622000973718	SHERLOCK	Phase 2	Not yet recruiting	TAS, QLD, NSW, VIC	11/07/2022		Bevacizumab; Carboplatin; Pemetrexed; Sotorasib	KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor; platinum-based_antineoplastic_agent; anti-VEGF_monoclonal_antibody; antimetabolite	Carboplatin; Pemetrexed; Sotorasib; Bevacizumab	KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor; antimetabolite; platinum-based_antineoplastic_agent; anti-VEGF_monoclonal_antibody	TOGA 21/011  CTC 0377	SHERLOCK: Phase 2 trial of sotorasib in combination with carboplatin-pemetrexed and bevacizumab-biosimilar as first line treatment for advanced non-squamous non-small cell lung cancer with KRAS G12C mutation	advanced non-squamous non-small cell lung cancer with KRAS G12C mutation 326412 0		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12622000973718
ACTRN12622000993796	ACTRN12622000993796	Phase 1	Not yet recruiting	NSW, VIC, WA	14/07/2022		AXA-042	TLR2/6_agonist	AXA-042	TLR2/6_agonist	None	A Phase 1, first-in-human, open-label, non-randomized, multicenter, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of AXA-042 as monotherapy in subjects with advanced solid tumors.	Advanced solid tumors	6009 - Nedlands; 3000 - Melbourne; 3175 - Dandenong; 2031 - Randwick	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12622000993796
ACTRN12622001003763	X22-0072	Phase 2	Not yet recruiting	NSW	18/07/2022		Evolocumab	anti-PCSK9_monoclonal_antibody	Evolocumab	anti-PCSK9_monoclonal_antibody	Protocol Number: X22-0072	A multi-centre, open label phase 2 trial investigating the effect of evolocumab in addition to chemotherapy or androgen receptor signalling inhibitor therapy on the circulating lipid profile of men with metastatic castration-resistant prostate cancer	Metastatic Castrate Resistant Prostate Cancer	2139 - Concord; 2010 - Darlinghurst; 2050 - Camperdown	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12622001003763
ACTRN12622001339741	HH3806-A101	Phase 1	Not yet recruiting	VIC	18/10/2022		HH3806	BET_inhibitor	HH3806	BET_inhibitor	HH3806-A101	A Phase I, Open-label, Multicenter, First in Human Study to Evaluate the Safety and Tolerability of HH3806 in Patients with Advanced Malignancies	relapsed/refractory Non-Hodgkin’s lymphomas (NHL); Solid Tumors	3199 - Frankston	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12622001339741
ACTRN12622001514796	KARPOS	Not Applicable	Not yet recruiting	SA	6/12/2022		Bevacizumab; Bevacizumab + GD2-iCAR-PBT; Cyclophosphamide; Cyclophosphamide + Fludarabine; Fludarabine; GD2-iCAR-PBT; Ifosfamide	alkylating_agent + antimetabolite; alkylating_agent; antimetabolite; anti-VEGF_monoclonal_antibody + autologous_CAR-T-cell_therapy,GD2-targeting; anti-VEGF_monoclonal_antibody; autologous_CAR-T-cell_therapy,GD2-targeting	Bevacizumab + GD2-iCAR-PBT; Cyclophosphamide + Fludarabine; GD2-iCAR-PBT; Bevacizumab + GD2-iCAR-PBT; Cyclophosphamide + Fludarabine; Ifosfamide	alkylating_agent + antimetabolite; anti-VEGF_monoclonal_antibody + autologous_CAR-T-cell_therapy,GD2-targeting; autologous_CAR-T-cell_therapy,GD2-targeting; alkylating_agent + antimetabolite; anti-VEGF_monoclonal_antibody + autologous_CAR-T-cell_therapy,GD2-targeting	Nil Known	KARPOS - A Phase 1, Single-Centre, Non-randomised, Open-labelled, Escalating Dose Study of Autologous GD2-Specific Chimeric Antigen Receptor-expressing Peripheral Blood T cells in Patients with Recurrent GD2-positive Glioblastoma Multiforme	Glioblastoma Multiforme	5000 - Adelaide	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12622001514796
ACTRN12622001542785	Lewis-Y-Nivo-CAR-T	Phase 1	Not yet recruiting	VIC	13/12/2022		Cyclophosphamide; Cyclophosphamide + Fludarabine; Fludarabine; LeY-CAR-T; LeY-CAR-T + Nivolumab; Nivolumab	alkylating_agent + antimetabolite; anti-PD-1_monoclonal_antibody; alkylating_agent; anti-PD-1_monoclonal_antibody + autologous_CAR-T-cell_therapy,LeY-targeting; antimetabolite; autologous_CAR-T-cell_therapy,LeY-targeting	Cyclophosphamide + Fludarabine; LeY-CAR-T; LeY-CAR-T + Nivolumab; Nivolumab; Cyclophosphamide + Fludarabine; LeY-CAR-T + Nivolumab	alkylating_agent + antimetabolite; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + autologous_CAR-T-cell_therapy,LeY-targeting; autologous_CAR-T-cell_therapy,LeY-targeting; alkylating_agent + antimetabolite; anti-PD-1_monoclonal_antibody + autologous_CAR-T-cell_therapy,LeY-targeting	Nil known	A Pilot Study Assessing Safety and Tolerability of Lewis Y (LeY) targeting Chimeric Antigen Receptor (CAR) T cells in combination with Nivolumab in Patients With LeY Expressing Solid Tumours	LeY Expressing Advanced Solid Tumours	3000 - Melbourne	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12622001542785
ACTRN12623000073606	SLAP-trial	Phase 0	Not yet recruiting	NSW	23/01/2023		Lu-177 vipivotide tetraxetan	radioligand,PSMA-targeting	Lu-177 vipivotide tetraxetan	radioligand,PSMA-targeting	None	A Single-Arm, Open-Label, Prospective, Phase 0 Trial Evaluating the Safety and Efficacy of Salvage 177Lu-PSMA-I&T in Prostate Specific Antigen (PSA) Biochemical Failure After Radical Prostatectomy for High-Risk Prostate Cancer	Prostate cancer 328693 0	2076 - Wahroonga	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623000073606
ACTRN12623000096651	LUMOS2	Phase 2	Not yet recruiting	TAS, VIC, NSW, QLD	27/01/2023		AK104; Paxalisib; Selinexor	dual_PI3K/mTOR_inhibitor; selective_inhibitor_of_nuclear_export; bispecific_PD-1/CTLA-4_antibody	AK104; Paxalisib; Selinexor	bispecific_PD-1/CTLA-4_antibody; dual_PI3K/mTOR_inhibitor; selective_inhibitor_of_nuclear_export	CTC0837  COGNO2201	LUMOS2: Low & Anaplastic Grade Glioma Umbrella Study of Molecular Guided TherapieS	Grade 3 Glioma; Grade 2 Glioma	2010 - Darlinghurst; 3065 - Fitzroy; 2065 - St Leonards; 4029 - Herston; 3084 - Heidelberg; 3000 - Melbourne; 3168 - Clayton; 7000 - Hobart	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623000096651
ACTRN12623000108617	EMITT-1	Phase 1	Not yet recruiting	SA, VIC, NSW	31/01/2023		GRWD5769	ERAP1_inhibitor	GRWD5769	ERAP1_inhibitor	GRWD5769-ST-01	A modular, multi-part, multi-arm, open-label, Phase I/II Study to evaluate the safety and tolerability of GRWD5769 in patients with solid malignancies - Module 1.	Advanced solid malignancies		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623000108617
ACTRN12623000174684	APG2449OG101	Phase 1	Not yet recruiting	NSW	21/02/2023		Doxorubicin	anthracycline; doxorubicin	Doxorubicin	anthracycline; doxorubicin	APG2449OG101	Safety, tolerability, and efficacy of APG-2449 in Combination with Doxorubicin Hydrochloride Liposome in treating Patients with Platinum-resistant Ovarian Cancer	Ovarian Cancer	2148 - Blacktown	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623000174684
ACTRN12623000185662	SSO110-01	Phase 1	Not yet recruiting	VIC, NSW, QLD, WA	22/02/2023		Atezolizumab; Atezolizumab + Satoreotide Tetraxetan; Satoreotide Tetraxetan	177Lu-DOTA-radioconjugate + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; 177Lu-DOTA-radioconjugate	Atezolizumab; Atezolizumab + Satoreotide Tetraxetan; Atezolizumab + Satoreotide Tetraxetan	177Lu-DOTA-radioconjugate + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; 177Lu-DOTA-radioconjugate + anti-PD-L1_monoclonal_antibody	SSO110-01	A multicentre, open-label, Phase I study investigating the safety, tolerability, and efficacy of 177Lu-SSO110 with 68Ga-SSO120 companion imaging in participants with extensive stage small cell lung cancer (ES-SCLC) who are on maintenance treatment with atezolizumab	Extensive Stage Small Cell Lung Cancer		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623000185662
ACTRN12623000202662	SON-DP-A002-ST	Phase 1	Not yet recruiting	SA	24/02/2023		Radiotherapy	radiotherapy	Radiotherapy	radiotherapy	SON-DP-A002-ST	A First-in-Human (FIH), Open-Label, Phase Ia Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SON-DP in Subjects with Advanced/Metastatic Solid Tumours that have relapsed or are refractory/intolerant to standard of care therapies	Solid tumor malignancies	5042 - Bedford Park	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623000202662
ACTRN12623000216617	RESCUE	Phase 1	Not yet recruiting	NZ	28/02/2023		177Lu-DOTA-rosopatamab; Lu-177 vipivotide tetraxetan; Radiotherapy	radiotherapy; radioligand,PSMA-targeting	177Lu-DOTA-rosopatamab; Lu-177 vipivotide tetraxetan; Radiotherapy	radioligand,PSMA-targeting; radiotherapy	Nil Known	A pilot, feasibility study of 177Lu-DOTA-Rosopatamab (TLX591) therapy in castrate resistant prostate adenocarcinoma patients showing progression on radioligand therapy using PSMA small molecule ligands	Metastatic Prostate Cancer	Auckland	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623000216617
ACTRN12623000223639	iLSTA	Phase 1	Not yet recruiting	WA	2/03/2023		Durvalumab; Durvalumab + Gemcitabine + Nab-paclitaxel; Gemcitabine; Nab-paclitaxel	anti-PD-L1_monoclonal_antibody; gemcitabine; taxane; antimetabolite; anti-PD-L1_monoclonal_antibody + antimetabolite + taxane	Durvalumab; Durvalumab + Gemcitabine + Nab-paclitaxel; Durvalumab + Gemcitabine + Nab-paclitaxel	anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + antimetabolite + taxane; anti-PD-L1_monoclonal_antibody + antimetabolite + taxane; gemcitabine	Nil known	A Phase 1 single-blind study evaluating LSTA1 in combination with durvalumab, gemcitabine and nab-paclitaxel as a first-line treatment in locally advanced pancreatic ductal adenocarcinoma (PDAC)	Cancer	6008 - Subiaco	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623000223639
ACTRN12623000307606	NP-105	Phase 1	Not yet recruiting	NSW	21/03/2023		RX108	sodium-potassium_ATPase_inhibitor	RX108	sodium-potassium_ATPase_inhibitor	NP-105	A Phase I, Open-Label Study of the Safety, Tolerability and Pharmacokinetics of RX108-A Tablet in Patients with Locally Advanced or Metastatic Solid Tumors	Locally Advanced or Metastatic Solid Tumors		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623000307606
ACTRN12623000686606	IMRARP	Not Applicable	Not yet recruiting	VIC	26/06/2023						None	The effect of intrathecal morphine compared to standard care with oral and IV opioids on the quality of recovery after robotic-assisted radical prostatectomy	Bladder Spasms; Post-operative Pain; Prostate Cancer 329956 0	3000 - Melbourne; 3121 - Richmond	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623000686606
ACTRN12623000739617	ACTRN12623000739617	Not Applicable	Not yet recruiting	ACT, WA, NT, NSW, VIC, QLD, TAS, SA	7/07/2023						Nil known	Comparing the effectiveness of two body image writing interventions against a neutral writing control in targeting positive body image in female cancer populations: A Randomised Controlled Trial	cancer		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623000739617
ACTRN12623000798662	HCC	Phase 1 / Phase 2	Not yet recruiting	SA, NSW	26/07/2023		BOS-342	bispecific_4-1BB/GPC3_antibody	BOS-342	bispecific_4-1BB/GPC3_antibody	Nil Known	A Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of BOS-342 in Patients with Hepatocellular Carcinoma (HCC) and other GPC3-expressing Tumors	Other GPC3-expressing Tumors; Hepatocellular Carcinoma (HCC)	2010 - Darlinghurst; 5042 - Bedford Park; 2050 - Camperdown	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623000798662
ACTRN12623000874617	Biomarcer-2	Phase 2	Not yet recruiting	TAS, QLD, VIC, NSW, WA	15/08/2023		Cetuximab; Cetuximab + Fluorouracil + Irinotecan + Leucovorin; Cetuximab + Irinotecan; Fluorouracil; Irinotecan; Leucovorin	anti-EGFR_monoclonal_antibody + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor; Fluorouracil; folinic_acid; anti-EGFR_monoclonal_antibody + topoisomerase_inhibitor; anti-EGFR_monoclonal_antibody; topoisomerase_inhibitor	Cetuximab + Fluorouracil + Irinotecan + Leucovorin; Cetuximab + Irinotecan; Cetuximab + Fluorouracil + Irinotecan + Leucovorin; Cetuximab + Irinotecan	anti-EGFR_monoclonal_antibody + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor; anti-EGFR_monoclonal_antibody + topoisomerase_inhibitor; Fluorouracil; anti-EGFR_monoclonal_antibody + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor; anti-EGFR_monoclonal_antibody + topoisomerase_inhibitor	None	Phase II single arm study to explore the efficacy of cetuximab (in combination with irinotecan based treatment) in advanced stage RAS/BRAF wild-type right-sided colorectal cancer with high AREG/EREG expression	Advanced RAS Wild type right sided Colorectal cancer	3844 - Traralgon; 2298 - Waratah; 3076 - Epping; 2305 - New Lambton Heights; 3000 - Melbourne; 6150 - Murdoch; 3084 - Heidelberg; 7000 - Hobart; 3011 - Footscray; 3280 - Warrnambool	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623000874617
ACTRN12623000956606	Australia	Unknown	Not yet recruiting	NSW, VIC, QLD, SA	4/09/2023		AT-0174	dual_IDO/TDO_inhibitor	AT-0174	dual_IDO/TDO_inhibitor	Antido Therapeutics (Australia) Protocol No. AT-0174-001	A Phase I Study to Evaluate the Safety, Tolerability, Pharmacology, and Preliminary Efficacy of AT-0174 in Subjects with Advanced Solid Malignancies	Locally Advanced Solid Tumours	3065 - Fitzroy; 2228 - Miranda; 5000 - Adelaide; 4575 - Birtinya; 3350 - Ballarat Central	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623000956606
ACTRN12623001072606	LuCape	Unknown	Not yet recruiting	WA	6/10/2023		Capecitabine	fluoropyrimidine	Capecitabine	fluoropyrimidine	Nil known	A phase 1a/b dose-escalation and dose-expansion study to evaluate Lutetium-177-PSMA I&T (Lu-PSMA) with radiosensitising Capecitabine in patients with metastatic castration-resistant prostate cancer (mCRPC)	metastatic castration-resistant prostate cancer 331258 0	6150 - Murdoch	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623001072606
ACTRN12623001077651	EMITT-1	Unknown	Not yet recruiting	VIC, NSW, SA	10/10/2023		Cemiplimab; Cemiplimab + GRWD5769; GRWD5769	ERAP1_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; ERAP1_inhibitor	Cemiplimab; Cemiplimab + GRWD5769; GRWD5769; Cemiplimab + GRWD5769	ERAP1_inhibitor; ERAP1_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; ERAP1_inhibitor + anti-PD-1_monoclonal_antibody	GRWD5769-ST-01 Module 2	A Modular, Multi-part, Multi-arm, Open-label, Phase I/II Study to Evaluate the Safety and Tolerability of GRWD5769 Alone and in Combination with Anticancer Treatments in Patients with Solid Malignancies - Module 2.	Advanced solid malignancies	5042 - Bedford Park; 2010 - Darlinghurst; 3084 - Heidelberg; 3004 - Melbourne	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623001077651
ACTRN12623001126606	TCaP	Unknown	Not yet recruiting	VIC, QLD	1/11/2023		Cytarabine; Cytarabine + Pembrolizumab; Ifosfamide; Pembrolizumab	anti-PD-1_monoclonal_antibody; alkylating_agent; antimetabolite; anti-PD-1_monoclonal_antibody + antimetabolite	Cytarabine + Pembrolizumab; Pembrolizumab; Cytarabine + Pembrolizumab; Ifosfamide	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + antimetabolite; alkylating_agent; anti-PD-1_monoclonal_antibody + antimetabolite	Nil known	Phase I/II clinical trial evaluating the safety and efficacy of allogeneic cytomegalovirus-specific T cells in combination with pembrolizumab for recurrent and newly diagnosed glioblastoma multiforme	Glioblastoma multiforme/astrocytoma grade 4	4006 - Bowen Hills; 4029 - Royal Brisbane Hospital; 3084 - Heidelberg; 4102 - Woolloongabba	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623001126606
ACTRN12623001164684	ACTRN12623001164684	Unknown	Not yet recruiting	QLD	9/11/2023		Atorvastatin; Hydroxychloroquine; Melatonin; Metformin	melatonin; anti-malarial_agent; HMG-CoA_reductase_inhibitor; biguanide_antihyperglycaemic_agent	Atorvastatin; Hydroxychloroquine; Melatonin; Metformin	HMG-CoA_reductase_inhibitor; anti-malarial_agent; biguanide_antihyperglycaemic_agent; melatonin	Nil	Assessing treatment effectiveness of the 'Repurposing-Drugs-in-Oncology' (ReDO) protocol for adult cancer by Circulating Tumour Cell (CTC) analysis: A case-series	Cancer	4209 - Willow Vale	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623001164684
ACTRN12623001216606	MEHDSAM	Unknown	Not yet recruiting	NSW	27/11/2023		Sonidegib	SMO_inhibitor,first_generation	Sonidegib	SMO_inhibitor,first_generation	CT-2023-CTN-04330-1	Single-institution, single-arm, open-label phase II basket study investigating the effect of mutation and/or elevated hedgehog (Hh) expression-directed smoothened inhibitor sonidegib in patients with advanced solid malignancies	Cancer	2065 - St Leonards	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623001216606
ACTRN12623001217695	ACTRN12623001217695	Unknown	Not yet recruiting	NSW	27/11/2023		IMD-101	IL2_conjugate	IMD-101	IL2_conjugate	AFB-105	An Open-Label Dose-Escalation Phase Ia Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of IMD-101 Injectable in Participants with Advanced Malignant Solid Tumours.	Advanced malignant solid tumours		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623001217695
ACTRN12623001219673	EN002-CN-001	Unknown	Recruiting	NSW, QLD	27/11/2023	22/08/2022					EN002-CN-001	A phase I-II clinical trial to evaluate the tolerability, safety, pharmacokinetics and preliminary efficacy of EN002-gel in patients with non-melanoma skin cancer and precancerous lesions	Basal cell carcinoma; Actinic keratosis; Squamous cell carcinoma of the skin; Bowen’s disease	4102 - Woolloongabba; 2289 - Kotara	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623001219673
ACTRN12623001333606	CCaLM	Unknown	Not yet recruiting	NSW	19/12/2023		Placebo	placebo	Placebo	placebo	Nil known	The Novel use of Labetuzumab as Adjuvant Immunotherapy in Patients with Primary Colon Adenocarcinoma with Intact PELPK Binding Motif in their CEACAM5 gene in a Phase II clinical trial regarding the Development of Metachronous Liver Metastases (i.e., those at ‘high-risk’ of metachronous CRCLMs)	Colon cancer	2217 - Kogarah	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12623001333606
ACTRN12624000110583	SOCRATES-PILOT	Unknown	Not yet recruiting	NSW	8/02/2024		Abiraterone; Anastrozole; Apalutamide; Atorvastatin; Bevacizumab; Darolutamide; Enzalutamide; Letrozole; Lomustine; Nab-paclitaxel; Niraparib; Olaparib; Paclitaxel	PARP_inhibitor; alkylating_agent; taxane; HMG-CoA_reductase_inhibitor; CYP17A1_inhibitor; antiandrogen,nonsteroidal,second_generation; aromatase_inhibitor; anti-VEGF_monoclonal_antibody	Abiraterone; Anastrozole; Apalutamide; Atorvastatin; Bevacizumab; Darolutamide; Enzalutamide; Letrozole; Lomustine; Nab-paclitaxel; Niraparib; Olaparib; Paclitaxel	CYP17A1_inhibitor; HMG-CoA_reductase_inhibitor; PARP_inhibitor; alkylating_agent; anti-VEGF_monoclonal_antibody; antiandrogen,nonsteroidal,second_generation; aromatase_inhibitor; taxane	CTC 0393	SOCRATES PILOT: Standard of Care Randomised Treatment Evaluation Studies	Cancer; Cardio Vascular Disease	2050 - Missenden Road; 2050 - Camperdown; 2139 - Concord; 2031 - Randwick	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12624000110583
ACTRN12624000268549	LEPO	Unknown	Not yet recruiting	NSW	15/03/2024						ADRI002	LEPO: A phase 1 study of Leptospermum petersonii extract for patients with mesothelioma	Mesothelioma		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12624000268549
ACTRN12624000288527	REZOLV3R	Unknown	Not yet recruiting	NSW, VIC, QLD	20/03/2024		Bevacizumab	anti-VEGF_monoclonal_antibody	Bevacizumab	anti-VEGF_monoclonal_antibody	CTC 0398	Efficacy of intraperitoneal bevacizumab for decreasing or delaying re-accumulation of recurrent malignant ascites in chemotherapy resistant solid tumours: a randomised trial (REZOLV3R)	Chemotherapy resistant solid tumours; Recurrent malignant ascites		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12624000288527
ACTRN12624000478516	JBI-802-102	Unknown	Not yet recruiting	SA, WA	18/04/2024		JBI802	LSD1/HDAC6_inhibitor	JBI802	LSD1/HDAC6_inhibitor	JBI-802-102	Study to Assess Safety and Preliminary Efficacy of Orally Administered JBI-802 in Subjects with Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) with Thrombocytosis	Essential Thrombocythemia (ET); Myeloproliferative Neoplasms (MPN); Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN)	6009 - Nedlands; 6005 - West Perth; 5000 - Adelaide	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12624000478516
ACTRN12624000532505	INTER-EWING-1	Unknown	Not yet recruiting	NZ, SA, TAS, NSW, VIC, QLD, WA	29/04/2024		Cyclophosphamide; Cyclophosphamide + Doxorubicin + Etoposide + Ifosfamide + Regorafenib + Vincristine; Cyclophosphamide + Vinorelbine; Doxorubicin; Etoposide; Ifosfamide; Radiotherapy; Regorafenib; Vincristine; Vinorelbine	radiotherapy; alkylating_agent; doxorubicin; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + alkylating_agent + anthracycline + topoisomerase_inhibitor + vinca_alkaloid; vinca_alkaloid; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor; topoisomerase_inhibitor; alkylating_agent + vinca_alkaloid	Cyclophosphamide + Doxorubicin + Etoposide + Ifosfamide + Regorafenib + Vincristine; Cyclophosphamide + Vinorelbine; Radiotherapy; Cyclophosphamide + Doxorubicin + Etoposide + Ifosfamide + Regorafenib + Vincristine; Cyclophosphamide + Vinorelbine	KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + alkylating_agent + anthracycline + topoisomerase_inhibitor + vinca_alkaloid; alkylating_agent + vinca_alkaloid; radiotherapy; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + alkylating_agent + anthracycline + topoisomerase_inhibitor + vinca_alkaloid; alkylating_agent + vinca_alkaloid; doxorubicin	ISRCTN17938906  RG_21-151	International clinical research programme to improve outcomes in newly diagnosed Ewing sarcoma – Trial 1 (INTER-EWING-1)	Ewing Sarcoma		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12624000532505
ACTRN12624000574549	ACTRN12624000574549	Unknown	Not yet recruiting	NZ	7/05/2024						Nil known	Using Digital Humans to Deliver Stress Management: Feasibility and Acceptability to Women with Breast Cancer and Healthcare Professionals.	Distress following breast cancer active-treatment		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12624000574549
ACTRN12624000588594	PORCUPINE2-Australian-Extension	Unknown	Not yet recruiting	NSW	8/05/2024		Denosumab; Denosumab + RXC004; RXC004	PORCN_inhibitor + anti-RANK_L_monoclonal_antibody; anti-RANK_L_monoclonal_antibody; PORCN_inhibitor	Denosumab + RXC004; RXC004; Denosumab + RXC004	PORCN_inhibitor; PORCN_inhibitor + anti-RANK_L_monoclonal_antibody; PORCN_inhibitor + anti-RANK_L_monoclonal_antibody	None	A Phase 2, Open-Label, Multicentre Study to Assess the Preliminary Efficacy and Safety of RXC004, in Patients with Advanced Pancreatic Cancer that have Progressed following Therapy with Current Standard of Care	Pancreatic Cancer		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12624000588594
NCT01728155	LINES	Phase 3			13/11/2012	1/12/2011	Isotretinoin; Isotretinoin + Radiotherapy; Radiotherapy	13-cis-retinoic_acid + radiotherapy; radiotherapy; 13-cis-retinoic_acid	Isotretinoin + Radiotherapy; Isotretinoin + Radiotherapy	13-cis-retinoic_acid + radiotherapy; 13-cis-retinoic_acid + radiotherapy	LINES	European Low and Intermediate Risk Neuroblastoma Protocol	LOW AND INTERMEDIATE PAEDIATRIC NEUROBLASTOMA AND NEONATAL SUPRARENAL MASSES		https://clinicaltrials.gov/ct2/show/NCT01728155
NCT01761266	2012-002992-33--E7080-G000-304	Phase 3		WA, QLD, NSW, VIC	4/01/2013	1/03/2013	Lenvatinib; Sorafenib	FLT3_inhibitor; VEGF_inhibitor; VEGFR_inhibitor; CRAF_inhibitor; PDGFR_inhibitor; KIT_inhibitor; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor	Lenvatinib; Sorafenib	CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor; CRAF_inhibitor; FLT3_inhibitor; KIT_inhibitor; PDGFR_inhibitor; VEGFR_inhibitor; VEGF_inhibitor	2012-002992-33  E7080-G000-304	A Multicenter, Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma	Hepatocellular Carcinoma (HCC)	- Nedlands; - Woolloongabba; - Melbourne; - Fitzroy; - Camperdown; - Wentworthville	https://clinicaltrials.gov/ct2/show/NCT01761266
NCT01763164	C4211002--CMEK162A2301	Phase 3		SA, NSW, QLD	8/01/2013	12/07/2013	Binimetinib; Dacarbazine	alkylating_agent; MEK_inhibitor	Binimetinib; Dacarbazine	MEK_inhibitor; alkylating_agent	C4211002  CMEK162A2301	The NEMO Trial (NRAS Melanoma and MEK Inhibitor):A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma	Metastatic or Unresectable Cutaneous Melanoma	2060 - North Sydney; 4102 - Woolloongabba; 05000 - Adelaide; 02290 - Gateshead; 2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT01763164
NCT01765543	2012-003142-33--GO28052	Unknown			10/01/2013	1/07/2013	Vemurafenib	BRAF_V600_inhibitor	Vemurafenib	BRAF_V600_inhibitor	2012-003142-33  GO28052	A Phase I, Open-Label, Multicenter, Three-Period, One-Sequence Study to Investigate the Effect of Rifampin on the Pharmacokinetics of a Single Oral Dose of 960 mg of Vemurafenib	Malignant Melanoma, Neoplasms		https://clinicaltrials.gov/ct2/show/NCT01765543
NCT01765556	2012-003143-29--GO28054	Unknown			10/01/2013		Vemurafenib	BRAF_V600_inhibitor	Vemurafenib	BRAF_V600_inhibitor	2012-003143-29  GO28054	A Phase I, Open-Label, Multicenter, Three-Period, One-Sequence Study To Investigate The Effect Of Ketoconazole On The Pharmacokinetics Of A Single Oral Dose Of 960 Mg Of Vemurafenib	Malignant Melanoma, Neoplasms		https://clinicaltrials.gov/ct2/show/NCT01765556
NCT01765569	2012-003459-13--GO28394	Unknown			10/01/2013	1/07/2013	Vemurafenib	BRAF_V600_inhibitor	Vemurafenib	BRAF_V600_inhibitor	2012-003459-13  GO28394	A Phase I, Open-Label, Multicenter, 3-Period, Fixed-Sequence Study To Investigate The Effect Of Vemurafenib On The Pharmacokinetics Of A Single Dose Of Digoxin In Patients With BRAFV600 Mutation-Positive Metastatic Malignancy	Malignant Melanoma, Neoplasms		https://clinicaltrials.gov/ct2/show/NCT01765569
NCT01767623	2012-003820-18--GO28053	Phase 1		VIC	14/01/2013	20/08/2013	Vemurafenib	BRAF_V600_inhibitor	Vemurafenib	BRAF_V600_inhibitor	2012-003820-18  GO28053	An Open Label, Phase I Study to Evaluate the Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation Positive Cancer Patients	Neoplasms	3199 - Frankston	https://clinicaltrials.gov/ct2/show/NCT01767623
NCT01767857	XCITE	Phase 3		TAS, SA, QLD, NSW, VIC	14/01/2013	31/03/2013	Bermekimab; Placebo	placebo; anti-IL1A_monoclonal_antibody	Bermekimab; Placebo	anti-IL1A_monoclonal_antibody; placebo	2012-PT023	Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer	Metastatic Colorectal Cancer	5112 - Elizabeth Vale; 4029 - Herston; 2065 - St Leonards; 3021 - Saint Albans; 7000 - Hobart	https://clinicaltrials.gov/ct2/show/NCT01767857
NCT01772797	2012-004632-29--CLDK378X2102	Phase 1		VIC	21/01/2013	1/06/2013	Ceritinib; Ceritinib + Luminespib; Luminespib	ALK/ROS1/IGF1R_inhibitor + HSP90_inhibitor; HSP90_inhibitor; ALK/ROS1/IGF1R_inhibitor	Ceritinib + Luminespib; Ceritinib + Luminespib	ALK/ROS1/IGF1R_inhibitor + HSP90_inhibitor; ALK/ROS1/IGF1R_inhibitor + HSP90_inhibitor	2012-004632-29  CLDK378X2102	A Phase Ib, Open-label, Dose Escalation Study of LDK378 and AUY922 in Patients With ALK-rearranged Non-small Cell Lung Cancer	Non-small Cell Lung Cancer; Anaplastic Lymphoma Kinase (ALK)	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT01772797
NCT01773018	HMPL-504	Phase 1		WA, VIC	21/01/2013	1/02/2012	Savolitinib	MET_inhibitor,type_1	Savolitinib	MET_inhibitor,type_1	2011-504-00AU1	A Phase I, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of HMPL-504 in Patients With Advanced Solid Tumors	Tumor	3084 - Melbourne; 6009 - Nedlands; 3168 - Clayton	https://clinicaltrials.gov/ct2/show/NCT01773018
NCT01774344	RESORCE	Phase 3		QLD, NSW, VIC	24/01/2013	14/05/2013	Placebo; Regorafenib; Sorafenib	FLT3_inhibitor; placebo; VEGFR_inhibitor; CRAF_inhibitor; PDGFR_inhibitor; KIT_inhibitor; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor	Regorafenib; Placebo; Sorafenib	KIT/PDGFR/RET/VEGFR/FGFR_inhibitor; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor; CRAF_inhibitor; FLT3_inhibitor; KIT_inhibitor; PDGFR_inhibitor; placebo	2012-003649-14  15982	A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib	Carcinoma, Hepatocellular	3168 - Clayton; 3128 - Box Hill; 2170 - Liverpool; 2050 - Camperdown; 4029 - Herston	https://clinicaltrials.gov/ct2/show/NCT01774344
NCT01774786	JACOB	Phase 3		WA, QLD, VIC	24/01/2013	10/06/2013	Capecitabine; Capecitabine + Cisplatin + Fluorouracil + Pertuzumab + Trastuzumab; Capecitabine + Cisplatin + Fluorouracil + Trastuzumab; Cisplatin; Fluorouracil; Pertuzumab; Placebo; Trastuzumab	anti-ERBB2_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent; placebo; anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor + fluoropyrimidine + platinum-based_antineoplastic_agent; Fluorouracil; anti-ERBB2_monoclonal_antibody; anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; fluoropyrimidine	Capecitabine + Cisplatin + Fluorouracil + Pertuzumab + Trastuzumab; Capecitabine + Cisplatin + Fluorouracil + Trastuzumab; Capecitabine + Cisplatin + Fluorouracil + Pertuzumab + Trastuzumab; Capecitabine + Cisplatin + Fluorouracil + Trastuzumab; Placebo	anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor + fluoropyrimidine + platinum-based_antineoplastic_agent; anti-ERBB2_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; Fluorouracil; anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor + fluoropyrimidine + platinum-based_antineoplastic_agent; anti-ERBB2_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; placebo	2012-003554-83  BO25114	A Double-Blind, Placebo-Controlled, Randomized, Multicenter Phase III Study Evaluating the Efficacy and Safety of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients With HER2-Positive Metastatic Gastroesophageal Junction and Gastric Cancer	Gastric Cancer	6009 - Perth; 4029 - Herston; 3084 - Heidelberg; 3168 - Clayton	https://clinicaltrials.gov/ct2/show/NCT01774786
NCT01777776	CLEE011X2105	Phase 1/Phase 2		SA, NSW	29/01/2013	1/07/2013	Encorafenib; Encorafenib + Ribociclib; Ribociclib	BRAF_V600_inhibitor + CDK4/6_inhibitor; CDK4/6_inhibitor; BRAF_V600_inhibitor	Encorafenib + Ribociclib; Encorafenib + Ribociclib	BRAF_V600_inhibitor + CDK4/6_inhibitor; BRAF_V600_inhibitor + CDK4/6_inhibitor	CLEE011X2105	A Phase Ib/II, Multicenter, Study of LEE011 in Combination With LGX818 in Adult Patients With BRAF Mutant Melanoma.	Locally Advanced Metastatic BRAF Mutant Melanoma	2145 - Westmead; 5011 - Woodville	https://clinicaltrials.gov/ct2/show/NCT01777776
NCT01781572	C4211005--CMEK162X2114	Phase 1/Phase 2		VIC, NSW	1/02/2013	1/06/2013	Binimetinib; Binimetinib + Ribociclib; Ribociclib	MEK_inhibitor; CDK4/6_inhibitor + MEK_inhibitor; CDK4/6_inhibitor	Binimetinib + Ribociclib; Binimetinib + Ribociclib	CDK4/6_inhibitor + MEK_inhibitor; CDK4/6_inhibitor + MEK_inhibitor	C4211005  CMEK162X2114	A Phase Ib/II, Multicenter, Open Label, Study of LEE011 in Combination With MEK162 in Adult Patients With NRAS Mutant Melanoma	Locally Advanced or Metastatic NRAS Mutant Melanoma	2145 - Westmead; - East Melbourne; 2060 - North Sydney	https://clinicaltrials.gov/ct2/show/NCT01781572
NCT01783444	BOLERO-6	Phase 2		NSW, VIC	5/02/2013	26/02/2013	Anastrozole; Capecitabine; Everolimus; Everolimus + Exemestane; Exemestane; Letrozole	aromatase_inhibitor; mTORC1_inhibitor; aromatase_inhibitor + mTORC1_inhibitor; fluoropyrimidine	Capecitabine; Everolimus; Everolimus + Exemestane; Anastrozole; Everolimus + Exemestane; Letrozole	aromatase_inhibitor + mTORC1_inhibitor; fluoropyrimidine; mTORC1_inhibitor; aromatase_inhibitor + mTORC1_inhibitor	2012-003757-28  CRAD001Y2201	A Three-arm, Randomized, Open Label, Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in the Treatment of Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Prior Letrozole or Anastrozole.	Breast Cancer	2076 - Wahroonga; 3050 - Parkville; 3144 - Malvern; 2031 - Randwick	https://clinicaltrials.gov/ct2/show/NCT01783444
NCT01791387	DILIGENCE-1	Phase 2		NZ	15/02/2013	1/03/2012	Dovitinib	VEGFR_inhibitor; PDGFRB_inhibitor; FGFR1/2/3_inhibitor	Dovitinib	FGFR1/2/3_inhibitor; PDGFRB_inhibitor; VEGFR_inhibitor	ACTRN12612000140853  CTKI258AAU02T	Dovitinib In 1st-Line Renal Cell Carcinoma, an Investigation Into Tumour GENe Status and Correlation With Efficacy - 1st Exploratory Study	Clear Cell Renal Cell Carcinoma	Auckland	https://clinicaltrials.gov/ct2/show/NCT01791387
NCT01798004	NCI-2012-02211--ANBL12P1	Not Applicable		NZ, WA	25/02/2013	8/04/2013	Busulfan; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Filgrastim; Melphalan; Mesna; Radiotherapy; Topotecan; Vincristine	alkylating_agent; doxorubicin; granulocyte_colony_stimulating_factor; sodium_mercaptoethanesulfonate; anthracycline; radiotherapy; platinum-based_antineoplastic_agent; vinca_alkaloid; topoisomerase_inhibitor	Busulfan; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Filgrastim; Melphalan; Mesna; Radiotherapy; Topotecan; Vincristine	alkylating_agent; anthracycline; doxorubicin; granulocyte_colony_stimulating_factor; platinum-based_antineoplastic_agent; radiotherapy; sodium_mercaptoethanesulfonate; topoisomerase_inhibitor; vinca_alkaloid	NCI-2012-02211  ANBL12P1	Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients With Newly Diagnosed High-Risk Neuroblastoma	Localized Unresectable Neuroblastoma; Disseminated Neuroblastoma; Stage 4S Neuroblastoma; Regional Neuroblastoma; Localized Resectable Neuroblastoma	Auckland; 6008 - Perth	https://clinicaltrials.gov/ct2/show/NCT01798004
NCT01801111	2012-004455-36--NP28673	Phase 1/Phase 2		QLD, NSW	28/02/2013	20/06/2013	Alectinib; Alectinib + Erlotinib; Crizotinib; Erlotinib	ALK_inhibitor,first_generation; ALK_inhibitor,second_generation + EGFR_inhibitor,first_generation; EGFR_inhibitor,first_generation; ALK/RET_inhibitor; MET_inhibitor,type_1; ALK/RET_inhibitor + EGFR_inhibitor,first_generation; ROS1_inhibitor; ALK_inhibitor,second_generation	Alectinib + Erlotinib; Alectinib + Erlotinib; Crizotinib	ALK/RET_inhibitor + EGFR_inhibitor,first_generation; ALK_inhibitor,second_generation + EGFR_inhibitor,first_generation; ALK/RET_inhibitor + EGFR_inhibitor,first_generation; ALK_inhibitor,first_generation; ALK_inhibitor,second_generation + EGFR_inhibitor,first_generation; MET_inhibitor,type_1; ROS1_inhibitor	2012-004455-36  NP28673	An Open-Label, Non-Randomized, Multicenter Phase I/II Trial of RO5424802 Given Orally to Non-Small Cell Lung Cancer Patients Who Have ALK Mutation and Who Have Failed Crizotinib Treatment	Non-Small-Cell Lung Carcinoma	2065 - St. Leonards; 4032 - Chermside; 4184 - Douglas	https://clinicaltrials.gov/ct2/show/NCT01801111
NCT01802632	AURA	Phase 1/Phase 2		NSW, VIC, WA	1/03/2013	4/03/2013	Osimertinib	EGFR_inhibitor,third_generation	Osimertinib	EGFR_inhibitor,third_generation	D5160C00001	Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of AZD9291 in Patients With Advanced Non Small Cell Lung Cancer Who Progressed on Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Agent	Advanced Non Small Cell Lung Cancer; Advanced (Inoperable) Non Small Cell Lung Cancer	3084 - Heidelberg; 2217 - Kogarah; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT01802632
NCT01808573	NALA	Phase 3		VIC, NSW, QLD	11/03/2013	29/03/2013	Capecitabine; Capecitabine + Lapatinib; Capecitabine + Neratinib; Lapatinib; Neratinib	ERBB2_inhibitor + fluoropyrimidine; ERBB3_inhibitor + fluoropyrimidine; ERBB2_inhibitor,first_generation; ERBB2_inhibitor,first_generation + fluoropyrimidine; EGFR_inhibitor,type_II + fluoropyrimidine; EGFR_inhibitor,second_generation; EGFR_inhibitor,second_generation + fluoropyrimidine; EGFR_inhibitor,type_II; fluoropyrimidine; ERBB2_inhibitor; ERBB3_inhibitor	Capecitabine + Lapatinib; Capecitabine + Neratinib; Capecitabine + Lapatinib; Capecitabine + Neratinib	EGFR_inhibitor,second_generation + fluoropyrimidine; EGFR_inhibitor,type_II + fluoropyrimidine; ERBB2_inhibitor + fluoropyrimidine; ERBB2_inhibitor,first_generation + fluoropyrimidine; ERBB3_inhibitor + fluoropyrimidine; EGFR_inhibitor,second_generation + fluoropyrimidine; EGFR_inhibitor,type_II + fluoropyrimidine; ERBB2_inhibitor + fluoropyrimidine; ERBB2_inhibitor,first_generation + fluoropyrimidine; ERBB3_inhibitor + fluoropyrimidine	2012-004492-38  PUMA-NER-1301	A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUS CAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)	HER2+ Metastatic Breast Cancer (MBC)	4575 - Birtinya; NSW 2200 - Bankstown; 3135 - Melbourne; 3128 - Melbourne; 8833 - Wahroonga; 2485 - Tweed Heads; NSW 2217 - Kogarah	https://clinicaltrials.gov/ct2/show/NCT01808573
NCT01810016	LUD2012-004	Phase 1		VIC	13/03/2013	24/01/2014	Ipilimumab	anti-CTLA-4_monoclonal_antibody	Ipilimumab	anti-CTLA-4_monoclonal_antibody	LUD2012-004	Phase I Study of NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma, for Whom Treatment With Ipilimumab is Indicated	Unresectable or Metastatic Melanoma	- Melbourne	https://clinicaltrials.gov/ct2/show/NCT01810016
NCT01820364	LOGIC	Phase 2		VIC	28/03/2013	1/11/2013	Binimetinib; Buparlisib; Capmatinib; Encorafenib; Infigratinib; Ribociclib	pan-PI3K_inhibitor; MET_inhibitor,type_1; MEK_inhibitor; CDK4/6_inhibitor; FGFR1/2/3_inhibitor; BRAF_V600_inhibitor; PI3K_alpha_inhibitor	Encorafenib; Binimetinib; Buparlisib; Capmatinib; Infigratinib; Ribociclib	BRAF_V600_inhibitor; CDK4/6_inhibitor; FGFR1/2/3_inhibitor; MEK_inhibitor; MET_inhibitor,type_1; PI3K_alpha_inhibitor; pan-PI3K_inhibitor	2012-004798-17  CLGX818X2102	Phase II, Multi-center, Open-label Study of Single-agent LGX818 Followed by a Rational Combination With Agents After Progression on LGX818, in Adult Patients With Locally Advanced or Metastatic BRAF V600 Melanoma	Melanoma	3002 - East Melbourne	https://clinicaltrials.gov/ct2/show/NCT01820364
NCT01828099	2013-000319-26--CLDK378A2301	Phase 3		VIC, QLD, NZ	10/04/2013	9/07/2013	Carboplatin; Carboplatin + Cisplatin + Pemetrexed; Ceritinib; Cisplatin; Pemetrexed	ALK/ROS1/IGF1R_inhibitor; platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; antimetabolite	Carboplatin + Cisplatin + Pemetrexed; Ceritinib; Carboplatin + Cisplatin + Pemetrexed	ALK/ROS1/IGF1R_inhibitor; antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent	2013-000319-26  CLDK378A2301	A Phase III Multicenter, Randomized Study of Oral LDK378 Versus Standard Chemotherapy in Previously Untreated Adult Patients With ALK Rearranged (ALK-positive), Stage IIIB or IV, Non-squamous Non-small Cell Lung Cancer	Non-Small Cell Lung Cancer	3084 - Heidelberg; 4102 - Woolloongabba; 92024 - Auckland	https://clinicaltrials.gov/ct2/show/NCT01828099
NCT01830621	CO23	Phase 3		SA, TAS, QLD, VIC, NSW, WA	12/04/2013	15/04/2013	Napabucasin; Placebo	cancer_stemness_inhibitor; placebo	Napabucasin; Placebo	cancer_stemness_inhibitor; placebo	CO23	A Phase III Randomized Study of BBI608 and Best Supportive Care Versus Placebo and Best Supportive Care in Patients With Pretreated Advanced Colorectal Carcinoma	Colorectal Carcinoma	6008 - Subiaco; 6230 - Bunbury; 7000 - Hobart; 5042 - Bedford Park; 5011 - Woodville South; 4814 - Douglas; 2200 - Bankstown; 3002 - East Melbourne; 5112 - Elizabeth Vale	https://clinicaltrials.gov/ct2/show/NCT01830621
NCT01837251	ENGOT-ov-18	Phase 3		QLD, NSW, VIC, TAS, WA	23/04/2013	1/05/2013	Bevacizumab; Bevacizumab + Carboplatin; Carboplatin; Gemcitabine; Pegylated liposomal doxorubicin	anti-VEGF_monoclonal_antibody + platinum-based_antineoplastic_agent; anthracycline; platinum-based_antineoplastic_agent; anti-VEGF_monoclonal_antibody; antimetabolite	Bevacizumab + Carboplatin; Bevacizumab + Carboplatin; Gemcitabine; Pegylated liposomal doxorubicin	anti-VEGF_monoclonal_antibody + platinum-based_antineoplastic_agent; anthracycline; anti-VEGF_monoclonal_antibody + platinum-based_antineoplastic_agent; antimetabolite	AGO-OVAR 2.21 / ENGOT ov-18	A Prospective Randomized Phase III Trial of Carboplatin/Gemcitabine/Bevacizumab vs. Carboplatin/Pegylated Liposomal Doxorubicin/Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer	Recurrent Platinum-sensitive Ovarian Cancer	- Wodonga; - South Brisbane; - Douglas; - Milton; - St. Leonards; - Bankstown; - Southport; - Herston; - Coffs Harbour; - Nambour; - Subiaco; - Camperdown; - Frankston; - Geelong; - Randwick; - Kogarah; - Hobart; - Port Macquarie; - Nedlands	https://clinicaltrials.gov/ct2/show/NCT01837251
NCT01843374	Tremelimumab	Phase 2		QLD, VIC, NSW, SA, WA	30/04/2013	17/05/2013	Placebo; Tremelimumab	anti-CTLA-4_monoclonal_antibody; placebo	Tremelimumab; Placebo	anti-CTLA-4_monoclonal_antibody; placebo	D4880C00003	A Phase 2b, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects With Unresectable Pleural or Peritoneal Malignant Mesothelioma	Unresectable Pleural or Peritoneal Malignant Mesothelioma	5000 - Adelaide; 3084 - Heidelberg; 4066 - Auchenflower; 3128 - Box Hill; 2298 - Waratah; 3165 - East Bentleigh; 2065 - Saint Leonards; 4032 - Chermside; 6009 - Nedlands; 2250 - Gosford	https://clinicaltrials.gov/ct2/show/NCT01843374
NCT01844505	2012-005371-13--CA209-067	Phase 3		QLD, NSW, VIC, SA, NZ, WA	1/05/2013	11/06/2013	Ipilimumab; Ipilimumab + Nivolumab; Nivolumab; Placebo	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; placebo	Ipilimumab + Nivolumab; Ipilimumab + Nivolumab; Placebo	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; placebo	2012-005371-13  CA209-067	A Phase 3, Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab Versus Ipilimumab Monotherapy in Subjects With Previously Untreated Unresectable or Metastatic Melanoma	Unresectable or Metastatic Melanoma	2290 - Gateshead; 2060 - North Sydney; 4102 - Woolloongabba; 2109 - Macquarie University; 5037 - Kurralta Park; 3000 - Melbourne; 5000 - Adelaide; 3084 - Heidelberg; 4102 - Greenslopes; 2450 - Coffs Harbour; Auckland; 3128 - Box Hill; 4215 - Southport; 2050 - Camperdown; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT01844505
NCT01844674	2012-003705-94--GO28396	Unknown			1/05/2013	2/09/2013	Vemurafenib	BRAF_V600_inhibitor	Vemurafenib	BRAF_V600_inhibitor	2012-003705-94  GO28396	A Phase I, Open-Label, Multicenter, 3- Period, Fixed-Sequence Study to Investigate the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine (a CYP1A2 Substrate) in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy	Malignant Melanoma, Neoplasms		https://clinicaltrials.gov/ct2/show/NCT01844674
NCT01844986	SOLO-1	Phase 3		VIC, NSW	3/05/2013	26/08/2013	Olaparib; Placebo	PARP_inhibitor; placebo	Olaparib; Placebo	PARP_inhibitor; placebo	D0818C00001	A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer Following First Line Platinum Based Chemotherapy.	Advanced Ovarian Cancer; First Line Platinum Chemotherapy; FIGO Stage III-IV; BRCA Mutation; Complete Response; Partial Response; Newly Diagnosed	- Parkville; - Randwick; - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT01844986
NCT01846611	ET743OVC3006--CR100983	Phase 3		WA, NSW, VIC, QLD, NZ, SA	3/05/2013	16/10/2013	Dexamethasone; Dexamethasone + Trabectedin; Pegylated liposomal doxorubicin; Trabectedin	DNA_minor_groove-binding_agent; anthracycline; DNA_minor_groove-binding_agent + glucocorticoid; glucocorticoid	Dexamethasone + Trabectedin; Dexamethasone + Trabectedin; Pegylated liposomal doxorubicin	DNA_minor_groove-binding_agent + glucocorticoid; DNA_minor_groove-binding_agent + glucocorticoid; anthracycline	ET743OVC3006  CR100983	A Randomized, Open-Label Study Comparing the Combination of YONDELIS and DOXIL/CAELYX With DOXIL/CAELYX Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms	- Adelaide; - Townsville; - Ballarat; Wellington; - Parkville; - Subiaco; Auckland; - Woodville; - Brisbane; - Wodonga; - Gosford; - Toorak Gardens	https://clinicaltrials.gov/ct2/show/NCT01846611
NCT01849666	2012-003707-35--GO28398	Unknown			8/05/2013	1/09/2013	Vemurafenib	BRAF_V600_inhibitor	Vemurafenib	BRAF_V600_inhibitor	2012-003707-35  GO28398	A PHASE I, OPEN-LABEL, MULTICENTER, RANDOMINZED, PARALELL STUDY TO INVESTIGATE THE EFFECT OF VEMURAFENIB ON THE PHARMACOKINETICS OF A SINGLE ORAL DOSE OF PHENPROCOUMON IN PATIENTS WITH BRAFV600 MUTATION-POSITIVE METASTATIC MALIGNANCY	Malignant Melanoma, Neoplasms		https://clinicaltrials.gov/ct2/show/NCT01849666
NCT01849874	C4211003--ARRAY-162-311	Phase 3		WA, QLD, NSW, VIC, SA	9/05/2013	28/06/2013	Binimetinib	MEK_inhibitor	Binimetinib	MEK_inhibitor	C4211003  ARRAY-162-311	The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary Peritoneum	Low-grade Serous Fallopian Tube Cancer; Low-grade Serous Ovarian Cancer; Low-grade Serous Peritoneal Cancer	6009 - Nedlands; 4101 - South Brisbane; 2145 - Westmead; 3021 - St Albans; 5000 - Adelaide; 5065 - Toorak Gardens; 5067 - Norwood; 2076 - Wahroonga	https://clinicaltrials.gov/ct2/show/NCT01849874
NCT01851824	2012-003706-27--GO28397	Phase 1		VIC, NSW, NZ	13/05/2013	1/08/2013	Vemurafenib	BRAF_V600_inhibitor	Vemurafenib	BRAF_V600_inhibitor	2012-003706-27  GO28397	A PHASE I, OPEN-LABEL, MULTICENTER, 3-PERIOD, FIXED-SEQUENCE STUDY TO INVESTIGATE THE EFFECT OF VEMURAFENIB ON THE PHARMACOKINETICS OF A SINGLE ORAL DOSE OF ACENOCOUMAROL IN PATIENTS WITH BRAFV600 MUTATION-POSITIVE METASTATIC MALIGNANCY	Malignant Melanoma, Neoplasms	Auckland; 3690 - Wodonga; Christchurch	https://clinicaltrials.gov/ct2/show/NCT01851824
NCT01852292	2013-000744-26--CBKM120H2201	Phase 2		NSW	13/05/2013	1/10/2013	Buparlisib; Buparlisib + Paclitaxel; Paclitaxel; Placebo	pan-PI3K_inhibitor; pan-PI3K_inhibitor + taxane; placebo; PI3K_alpha_inhibitor; PI3K_alpha_inhibitor + taxane; taxane	Buparlisib + Paclitaxel; Buparlisib + Paclitaxel; Placebo	PI3K_alpha_inhibitor + taxane; pan-PI3K_inhibitor + taxane; PI3K_alpha_inhibitor + taxane; pan-PI3K_inhibitor + taxane; placebo	2013-000744-26  CBKM120H2201	Double Blind, Placebo Controlled Study Assessing the Efficacy of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Patients With Platinum Pre-treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)	Head and Neck Squamous Cell Carcinoma	2065 - St Leonards	https://clinicaltrials.gov/ct2/show/NCT01852292
NCT01853826	2009-017661-34--1200.55	Phase 3		NSW, VIC, WA	15/05/2013	17/07/2013	Afatinib	EGFR_inhibitor,second_generation	Afatinib	EGFR_inhibitor,second_generation	2009-017661-34  1200.55	An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)	Carcinoma, Non-Small-Cell Lung	6150 - Murdoch; 3021 - AT Albans; 2031 - Randwick	https://clinicaltrials.gov/ct2/show/NCT01853826
NCT01855451	HPVOropharynx	Phase 3		NSW, VIC, QLD, NZ, SA, ACT, WA	16/05/2013	3/06/2013	Cetuximab; Cetuximab + Radiotherapy; Cisplatin; Cisplatin + Radiotherapy; Radiotherapy	radiotherapy; platinum-based_antineoplastic_agent + radiotherapy; anti-EGFR_monoclonal_antibody + radiotherapy; platinum-based_antineoplastic_agent; anti-EGFR_monoclonal_antibody	Cetuximab + Radiotherapy; Cisplatin + Radiotherapy; Cetuximab + Radiotherapy; Cisplatin + Radiotherapy	anti-EGFR_monoclonal_antibody + radiotherapy; platinum-based_antineoplastic_agent + radiotherapy; anti-EGFR_monoclonal_antibody + radiotherapy; platinum-based_antineoplastic_agent + radiotherapy	ACTRN12613000279729  TROG 12.01	TROG12.01 A Randomised Trial of Weekly Cetuximab and Radiation Versus Weekly Cisplatin and Radiation in Good Prognosis Locoregionally Advanced HPV-Associated Oropharyngeal Squamous Cell Carcinoma	HPV Positive Oropharyngeal Squamous Cell Carcinoma	Auckland; 3002 - East Melbourne; - Wagga Wagga; 2217 - St George; 2145 - Westmead; 4810 - Townsville; - Waratah; 6009 - Nedlands; 2050 - Camperdown; 4006 - Herston; 5042 - Bedford Park; 2170 - Liverpool; 4102 - Woolloongabba; - Canberra; 3084 - Melbourne N.	https://clinicaltrials.gov/ct2/show/NCT01855451
NCT01865747	METEOR	Phase 3		SA, TAS, QLD, NSW, VIC	31/05/2013	1/06/2013	Cabozantinib; Everolimus	AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor; MET_inhibitor,type_2; VEGFR2_inhibitor; AXL_inhibitor; ROS1_inhibitor; mTORC1_inhibitor; RET_inhibitor; KIT_inhibitor	Cabozantinib; Everolimus	AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor; AXL_inhibitor; KIT_inhibitor; MET_inhibitor,type_2; RET_inhibitor; ROS1_inhibitor; VEGFR2_inhibitor; mTORC1_inhibitor	XL184-308	A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma That Has Progressed After Prior VEGFR Tyrosine Kinase Inhibitor Therapy	Renal Cell Carcinoma	5000 - Adelaide; 2217 - Kogarah; 2139 - Concord; 2076 - Wahroonga; 4102 - Wooloongabba; 3690 - Wodonga; - Port Macquarie; 3165 - Bentleight East; 7000 - Hobart; 3128 - Box Hill; 2010 - Darlinghurst; 2031 - Randwick; 2145 - Westmead; 4064 - Milton	https://clinicaltrials.gov/ct2/show/NCT01865747
NCT01870609	COMMAND	Phase 2		QLD, NSW, VIC, NZ, WA	6/06/2013	1/09/2013	Defactinib; Placebo	FAK_inhibitor; placebo	Defactinib; Placebo	FAK_inhibitor; placebo	VS-6063-202	A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma	Malignant Pleural Mesothelioma	- Perth; - Camperdown; Auckland; - Waratah; Christchurch; QLD 4102 - Woolloongabba; - Sydney; 3165 - East Bentlrigh; - Melbourne; - Frankston	https://clinicaltrials.gov/ct2/show/NCT01870609
NCT01872260	2013-001219-57--CLEE011X2107	Phase 1/Phase 2		WA, VIC, NSW	7/06/2013	22/10/2013	Alpelisib; Alpelisib + Letrozole; Alpelisib + Letrozole + Ribociclib; Letrozole; Letrozole + Ribociclib; Ribociclib	CDK4/6_inhibitor + aromatase_inhibitor; CDK4/6_inhibitor + PI3K_alpha_inhibitor + aromatase_inhibitor; CDK4/6_inhibitor; PI3K_alpha_inhibitor; PI3K_alpha_inhibitor + aromatase_inhibitor; aromatase_inhibitor	Alpelisib + Letrozole; Alpelisib + Letrozole + Ribociclib; Letrozole + Ribociclib; Alpelisib + Letrozole; Alpelisib + Letrozole + Ribociclib; Letrozole + Ribociclib	CDK4/6_inhibitor + PI3K_alpha_inhibitor + aromatase_inhibitor; CDK4/6_inhibitor + aromatase_inhibitor; PI3K_alpha_inhibitor + aromatase_inhibitor; CDK4/6_inhibitor + PI3K_alpha_inhibitor + aromatase_inhibitor; CDK4/6_inhibitor + aromatase_inhibitor; PI3K_alpha_inhibitor + aromatase_inhibitor	2013-001219-57  CLEE011X2107	A Phase Ib/II, Multicenter Study of the Combination of LEE011 and BYL719 With Letrozole in Adult Patients With Advanced ER+ Breast Cancer	Breast Cancer	2145 - Westmead; 6009 - Nedlands; 3050 - Parkville	https://clinicaltrials.gov/ct2/show/NCT01872260
NCT01874353	D0816C00002	Phase 3		VIC, NSW	11/06/2013	3/09/2013	Olaparib; Placebo	PARP_inhibitor; placebo	Olaparib; Placebo	PARP_inhibitor; placebo	D0816C00002	Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy	Relapsed Ovarian Cancer; Platinum Sensitive; Following Complete or Partial Response to Platinum Based Chemotherapy; BRCA Mutated	- Heidelberg; - Parkville; - Randwick	https://clinicaltrials.gov/ct2/show/NCT01874353
NCT01878617	NCI-2013-01125--SJMB12	Phase 2		QLD, VIC, NSW, NZ, WA	17/06/2013	23/06/2013	Cisplatin; Cisplatin + Cyclophosphamide + Gemcitabine + Pemetrexed + Radiotherapy + Vincristine; Cisplatin + Cyclophosphamide + Radiotherapy + Vincristine; Cisplatin + Cyclophosphamide + Radiotherapy + Vincristine + Vismodegib; Cyclophosphamide; Gemcitabine; Pemetrexed; Radiotherapy; Vincristine; Vismodegib	alkylating_agent + platinum-based_antineoplastic_agent + radiotherapy + vinca_alkaloid; SMO_inhibitor,first_generation + alkylating_agent + platinum-based_antineoplastic_agent + radiotherapy + vinca_alkaloid; radiotherapy; alkylating_agent; platinum-based_antineoplastic_agent; antimetabolite; vinca_alkaloid; alkylating_agent + antimetabolite + platinum-based_antineoplastic_agent + radiotherapy + vinca_alkaloid; gemcitabine; SMO_inhibitor,first_generation	Cisplatin + Cyclophosphamide + Gemcitabine + Pemetrexed + Radiotherapy + Vincristine; Cisplatin + Cyclophosphamide + Radiotherapy + Vincristine; Cisplatin + Cyclophosphamide + Radiotherapy + Vincristine + Vismodegib; Cisplatin + Cyclophosphamide + Gemcitabine + Pemetrexed + Radiotherapy + Vincristine; Cisplatin + Cyclophosphamide + Radiotherapy + Vincristine; Cisplatin + Cyclophosphamide + Radiotherapy + Vincristine + Vismodegib	SMO_inhibitor,first_generation + alkylating_agent + platinum-based_antineoplastic_agent + radiotherapy + vinca_alkaloid; alkylating_agent + antimetabolite + platinum-based_antineoplastic_agent + radiotherapy + vinca_alkaloid; alkylating_agent + platinum-based_antineoplastic_agent + radiotherapy + vinca_alkaloid; SMO_inhibitor,first_generation + alkylating_agent + platinum-based_antineoplastic_agent + radiotherapy + vinca_alkaloid; alkylating_agent + antimetabolite + platinum-based_antineoplastic_agent + radiotherapy + vinca_alkaloid; alkylating_agent + platinum-based_antineoplastic_agent + radiotherapy + vinca_alkaloid; gemcitabine	NCI-2013-01125  SJMB12	A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma	Medulloblastoma	3052 - Melbourne; 2145 - Westmead; 6008 - Perth; 2031 - Randwick; Auckland; 4029 - Brisbane	https://clinicaltrials.gov/ct2/show/NCT01878617
NCT01881230	tnAcity	Phase 2/Phase 3		WA, ACT, VIC	19/06/2013	26/09/2013	Carboplatin; Carboplatin + Gemcitabine; Carboplatin + Nab-paclitaxel; Gemcitabine; Gemcitabine + Nab-paclitaxel; Nab-paclitaxel; Paclitaxel	platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent + taxane; antimetabolite; gemcitabine; taxane; antimetabolite + taxane	Carboplatin + Gemcitabine; Carboplatin + Nab-paclitaxel; Gemcitabine + Nab-paclitaxel; Carboplatin + Gemcitabine; Carboplatin + Nab-paclitaxel; Gemcitabine + Nab-paclitaxel	antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + taxane; platinum-based_antineoplastic_agent + taxane; antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + taxane; gemcitabine; platinum-based_antineoplastic_agent + taxane	2013-000113-20  ABI-007-MBC-001	A Phase 2/3, Multi-Center, Open-Label, Randomized Study of Weekly Nab®-Paclitaxel in Combination With Gemcitabine or Carboplatin, Compared to Gemcitabine/Carboplatin, as First Line Treatment in Subjects With ER, PgR, and HER2 Negative (Triple Negative) Metastatic Breast Cancer	Stage IV Breast Cancer; Breast Tumor; HER2- Negative Breast Cancer; Triple-negative Metastatic Breast Cancer; Estrogen Receptor- Negative Breast Cancer; Triple-negative Breast Cancer; Breast Cancer; Cancer of the Breast; Progesterone Receptor- Negative Breast Cancer; Metastatic Breast Cancer; Recurrent Breast Cancer	6009 - Nedlands; 3199 - Frankston; 2605 - Garran; 3690 - Wodonga	https://clinicaltrials.gov/ct2/show/NCT01881230
NCT01889186	2012-004027-20--M13-982	Phase 2		NSW, VIC	28/06/2013	27/06/2013	Venetoclax	Bcl2_inhibitor	Venetoclax	Bcl2_inhibitor	2012-004027-20  M13-982	A Phase 2 Open-Label Study of the Efficacy of ABT-199 (GDC-0199) in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia Harboring the 17p Deletion	17p Deletion 0 0; Chronic Lymphocytic Leukemia; Cancer of the Blood and Bone Marrow	3050 - Parkville; 3000 - Melbourne; 3058 - Coburg; 2065 - St Leonards	https://clinicaltrials.gov/ct2/show/NCT01889186
NCT01891344	ARIEL2	Phase 2		QLD, VIC, NSW, SA, WentworthvilleWA, WA	3/07/2013	30/10/2013	Rucaparib	PARP_inhibitor	Rucaparib	PARP_inhibitor	CO-338-017	A Phase 2, Open-Label Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)	Epithelial Ovarian Cancer; Peritoneal Cancer; Fallopian Tube Cancer; Ovarian Cancer	3084 - Heidelberg; 4029 - Herston; NSW 2145 - Westmead; 3052 - Parkville; 2031 - Sydney; 2065 - Saint Leonards; 6009 - Nedlands; 5042 - Bedford Park	https://clinicaltrials.gov/ct2/show/NCT01891344
NCT01905657	2012-004391-19--3475-010	Unknown			23/07/2013	9/08/2013	Docetaxel; Pembrolizumab	anti-PD-1_monoclonal_antibody; taxane	Docetaxel; Pembrolizumab	anti-PD-1_monoclonal_antibody; taxane	2012-004391-19  3475-010	A Phase II/III Randomized Trial of Two Doses of MK-3475 (SCH900475) Versus Docetaxel in Previously Treated Subjects With Non-Small Cell Lung Cancer	Non Small Cell Lung Cancer (NSCLC)		https://clinicaltrials.gov/ct2/show/NCT01905657
NCT01907100	2012-005201-48--1199.93	Phase 2/Phase 3		QLD, VIC, NSW, WA	24/07/2013	19/09/2013	Cisplatin; Cisplatin + Nintedanib + Pemetrexed; Cisplatin + Pemetrexed; Nintedanib; Pemetrexed; Placebo	platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; PDGFRA/VEGFR/FGFR_inhibitor + antimetabolite + platinum-based_antineoplastic_agent; placebo; antimetabolite; PDGFRA/VEGFR/FGFR_inhibitor	Cisplatin + Nintedanib + Pemetrexed; Cisplatin + Pemetrexed; Cisplatin + Nintedanib + Pemetrexed; Cisplatin + Pemetrexed; Placebo	PDGFRA/VEGFR/FGFR_inhibitor + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; PDGFRA/VEGFR/FGFR_inhibitor + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; placebo	2012-005201-48  1199.93	LUME-Meso: Double Blind, Randomised, Multicentre, Phase II/III Study of Nintedanib in Combination With Pemetrexed / Cisplatin Followed by Continuing Nintedanib Monotherapy Versus Placebo in Combination With Pemetrexed / Cisplatin Followed by Continuing Placebo Monotherapy for the Treatment of Patients With Unresectable Malignant Pleural Mesothelioma	Mesothelioma	2065 - St Leonards; 3690 - Wodonga; 3199 - Frankston; 3084 - Heidelberg; 4101 - South Brisbane; 3128 - Box Hill; 2298 - Waratah; 6000 - Perth; 4032 - Chermside; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT01907100
NCT01908426	CELESTIAL	Phase 3		NZ, SA, VIC, NSW, WA	25/07/2013	26/09/2013	Cabozantinib; Placebo; Sorafenib	placebo; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor; VEGFR2_inhibitor; CRAF_inhibitor; ROS1_inhibitor; FLT3_inhibitor; MET_inhibitor,type_2; VEGFR_inhibitor; AXL_inhibitor; PDGFR_inhibitor; RET_inhibitor; KIT_inhibitor; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor	Cabozantinib; Placebo; Sorafenib	AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor; AXL_inhibitor; KIT_inhibitor; MET_inhibitor,type_2; RET_inhibitor; ROS1_inhibitor; VEGFR2_inhibitor; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor; CRAF_inhibitor; FLT3_inhibitor; PDGFR_inhibitor; placebo	XL184-309	A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib	Hepatocellular Carcinoma	3050 - Melbourne; 2145 - Westmead; 2050 - Camperdown; 2010 - Darlinghurst; 6000 - Perth; 2139 - Concord; 5037 - Kurralta Park; 2217 - Kogarah	https://clinicaltrials.gov/ct2/show/NCT01908426
NCT01909453	COLUMBUS	Phase 3		VIC, NSW, QLD, WA	26/07/2013	13/12/2013	Binimetinib; Binimetinib + Encorafenib; Encorafenib; Vemurafenib	MEK_inhibitor; BRAF_V600_inhibitor + MEK_inhibitor; BRAF_V600_inhibitor	Binimetinib + Encorafenib; Encorafenib; Vemurafenib; Binimetinib + Encorafenib	BRAF_V600_inhibitor; BRAF_V600_inhibitor + MEK_inhibitor; BRAF_V600_inhibitor + MEK_inhibitor	C4221004  CMEK162B2301	A 2-part Phase III Randomized, Open Label, Multicenter Study of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma	Melanoma	6009 - Nedlands; 4215 - Southport; 3004 - Prahran; 3004 - Melbourne; 4102 - Woolloongabba; 02290 - Gateshead	https://clinicaltrials.gov/ct2/show/NCT01909453
NCT01915589	2013-000311-25--16553	Phase 2		NZ	5/08/2013	16/09/2013	Refametinib	MEK_inhibitor	Refametinib	MEK_inhibitor	2013-000311-25  16553	A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)	Carcinoma, Hepatocellular	Auckland	https://clinicaltrials.gov/ct2/show/NCT01915589
NCT01915602	2013-000241-39--16728	Phase 2		NZ	5/08/2013	27/09/2013	Refametinib; Refametinib + Sorafenib; Sorafenib	CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor + MEK_inhibitor; CRAF_inhibitor + MEK_inhibitor; CRAF_inhibitor; MEK_inhibitor + VEGFR_inhibitor; FLT3_inhibitor; VEGFR_inhibitor; PDGFR_inhibitor; MEK_inhibitor; KIT_inhibitor; FLT3_inhibitor + MEK_inhibitor; MEK_inhibitor + PDGFR_inhibitor; KIT_inhibitor + MEK_inhibitor; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor	Refametinib + Sorafenib; Refametinib + Sorafenib	CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor + MEK_inhibitor; CRAF_inhibitor + MEK_inhibitor; FLT3_inhibitor + MEK_inhibitor; KIT_inhibitor + MEK_inhibitor; MEK_inhibitor + PDGFR_inhibitor; MEK_inhibitor + VEGFR_inhibitor; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor + MEK_inhibitor; CRAF_inhibitor + MEK_inhibitor; FLT3_inhibitor + MEK_inhibitor; KIT_inhibitor + MEK_inhibitor; MEK_inhibitor + PDGFR_inhibitor; MEK_inhibitor + VEGFR_inhibitor	2013-000241-39  16728	A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Combination With Sorafenib as First Line Treatment in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)	Carcinoma, Hepatocellular	Auckland	https://clinicaltrials.gov/ct2/show/NCT01915602
NCT01928459	CBGJ398X2102	Phase 1		VIC	26/08/2013	1/10/2013	Alpelisib; Alpelisib + Infigratinib; Infigratinib	FGFR1/2/3_inhibitor + PI3K_alpha_inhibitor; FGFR1/2/3_inhibitor; PI3K_alpha_inhibitor	Alpelisib + Infigratinib; Alpelisib + Infigratinib	FGFR1/2/3_inhibitor + PI3K_alpha_inhibitor; FGFR1/2/3_inhibitor + PI3K_alpha_inhibitor	CBGJ398X2102	A Phase Ib, Open-label Study of Oral BGJ398 in Combination With Oral BYL719 in Adult Patients With Select Advanced Solid Tumors	Advanced Solid Tumors; Metastatic Solid Tumors	3050 - Parkville	https://clinicaltrials.gov/ct2/show/NCT01928459
NCT01933932	SELECT-1	Phase 3		QLD, NSW, VIC, SA	2/09/2013	25/09/2013	Docetaxel; Docetaxel + Selumetinib; Pegfilgrastim; Placebo; Selumetinib	MEK_inhibitor; taxane; placebo; granulocyte_colony_stimulating_factor; MEK_inhibitor + taxane	Docetaxel; Docetaxel + Selumetinib; Docetaxel + Selumetinib; Pegfilgrastim; Placebo	MEK_inhibitor + taxane; taxane; MEK_inhibitor + taxane; granulocyte_colony_stimulating_factor; placebo	2013-001676-38  D1532C00079	A Phase III, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Combination With Docetaxel, in Patients Receiving Second Line Treatment for KRAS Mutation-Positive Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB - IV) (SELECT 1)	Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV	3144 - Malvern; 2010 - Darlinghurst; 4032 - Chermside; 5011 - Woodville South; 2050 - Camperdown; 3065 - Fitzroy; 2217 - Kogarah; 5037 - Kurralta Park	https://clinicaltrials.gov/ct2/show/NCT01933932
NCT01934361	2013-003129-27--CBKM120E2102	Phase 1		VIC	4/09/2013	28/02/2014	Buparlisib; Buparlisib + Carboplatin; Buparlisib + Lomustine; Carboplatin; Ifosfamide; Lomustine; Placebo	pan-PI3K_inhibitor; alkylating_agent; platinum-based_antineoplastic_agent; alkylating_agent + pan-PI3K_inhibitor; placebo; PI3K_alpha_inhibitor + platinum-based_antineoplastic_agent; PI3K_alpha_inhibitor; pan-PI3K_inhibitor + platinum-based_antineoplastic_agent; PI3K_alpha_inhibitor + alkylating_agent	Buparlisib + Carboplatin; Buparlisib + Lomustine; Buparlisib + Carboplatin; Buparlisib + Lomustine; Ifosfamide; Placebo	PI3K_alpha_inhibitor + alkylating_agent; PI3K_alpha_inhibitor + platinum-based_antineoplastic_agent; alkylating_agent + pan-PI3K_inhibitor; pan-PI3K_inhibitor + platinum-based_antineoplastic_agent; PI3K_alpha_inhibitor + alkylating_agent; PI3K_alpha_inhibitor + platinum-based_antineoplastic_agent; alkylating_agent + pan-PI3K_inhibitor; pan-PI3K_inhibitor + platinum-based_antineoplastic_agent; placebo	2013-003129-27  CBKM120E2102	Phase Ib/II Multicenter Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme	Recurrent Glioblastoma Multiforme	3084 - Heidelberg; 3050 - Parkville	https://clinicaltrials.gov/ct2/show/NCT01934361
NCT01936363	2013-000902-40--EMR-200066-012	Phase 2		WA, QLD, NSW	6/09/2013	30/09/2013	Pimasertib; Pimasertib + XL765; Placebo; XL765	MEK_inhibitor; placebo; PI3K/mTOR_inhibitor; MEK_inhibitor + PI3K/mTOR_inhibitor	Pimasertib + XL765; Pimasertib + XL765; Placebo	MEK_inhibitor + PI3K/mTOR_inhibitor; MEK_inhibitor + PI3K/mTOR_inhibitor; placebo	2013-000902-40  EMR 200066_012	Phase II Randomized Double Blind Placebo Controlled Trial of Combination of Pimasertib With SAR245409 or of Pimasertib With SAR245409 Placebo in Subjects With Previously Treated Unresectable Low Grade Ovarian Cancer	Ovarian Cancer	4120 - Greenslopes; 2152 - Northmead; 6008 - Subiaco	https://clinicaltrials.gov/ct2/show/NCT01936363
NCT01942135	2013-002580-26--A5481023	Phase 3		WA, QLD, VIC, NSW	13/09/2013	26/09/2013	Fulvestrant; Goserelin; Palbociclib; Placebo	GnRH_analogue; selective_estrogen_receptor_degrader; placebo; CDK4/6_inhibitor; GnRH_agonist	Fulvestrant; Goserelin; Palbociclib; Placebo	CDK4/6_inhibitor; GnRH_agonist; GnRH_analogue; placebo; selective_estrogen_receptor_degrader	2013-002580-26  A5481023	MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 TRIAL OF FULVESTRANT (FASLODEX (REGISTERED)). WITH OR WITHOUT PD-0332991 (PALBOCICLIB) +/- GOSERELIN IN WOMEN WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE THERAPY	Metastatic Breast Cancer	3021 - St Albans; 4560 - Nambour; 3000 - Melbourne; 3199 - Frankston; 6150 - Murdoch; 3220 - Geelong; 4066 - Auchenflower; 2298 - Waratah; 4215 - Southport; 3168 - Clayton; 2200 - Bankstown; 3144 - Malvern; 3002 - East Melbourne; 3186 - Brighton	https://clinicaltrials.gov/ct2/show/NCT01942135
NCT01943851	2013-000445-39--116183	Phase 2		VIC	17/09/2013	14/05/2014	Molibresib	BET_inhibitor	Molibresib	BET_inhibitor	2013-000445-39  116183	A Phase I/II Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies	Neoplasms	3002 - East Melbourne	https://clinicaltrials.gov/ct2/show/NCT01943851
NCT01945775	EMBRACA	Phase 3		WA, QLD, NSW, VIC, SA	19/09/2013	14/10/2013	Capecitabine; Capecitabine + Eribulin + Gemcitabine + Vinorelbine; Eribulin; Gemcitabine; Talazoparib; Vinorelbine	PARP_inhibitor; antimetabolite + fluoropyrimidine + macrocyclic_ketone_analogue + vinca_alkaloid; macrocyclic_ketone_analogue; vinca_alkaloid; gemcitabine; fluoropyrimidine	Capecitabine + Eribulin + Gemcitabine + Vinorelbine; Talazoparib; Capecitabine + Eribulin + Gemcitabine + Vinorelbine	PARP_inhibitor; antimetabolite + fluoropyrimidine + macrocyclic_ketone_analogue + vinca_alkaloid; antimetabolite + fluoropyrimidine + macrocyclic_ketone_analogue + vinca_alkaloid; gemcitabine	C3441009  673-301	A PHASE 3, OPEN-LABEL, RANDOMIZED PARALLEL,2-ARM,MULTI-CENTER STUDY OF TALAZOPARIB(BMN 673) VERSUS PHYSICIAN'S CHOICE IN GERMLINE BRCA MUTATION SUBJECTS WITH LOCALLY ADVANCED AND/OR METASTATIC BREAST CANCER, WHO HAVE RECEIVED PRIOR CHEMOTHERAPY REGIMENS FOR METASTATIC DISEASE	BRCA 2 Gene Mutation; BRCA 1 Gene Mutation; Breast Neoplasms	5042 - Bedford Park; 3149 - Mount Waverley; 6009 - Nedlands; 3353 - Wendouree; 3355 - Wendouree; 4064 - Milton; 4101 - South Brisbane; 3002 - East Melbourne; 3084 - Melbourne; 4104 - South Brisbane; 5037 - Kurralta Park; 3199 - Frankston; 6150 - Murdoch; 3081 - Heidelberg West; 3220 - Geelong; 4102 - Woolloongabba; 2139 - Concord; 4066 - Auchenflower; 4066 - Milton	https://clinicaltrials.gov/ct2/show/NCT01945775
NCT01951586	2013-001662-42--20120249	Phase 2		NSW, VIC, SA	26/09/2013	31/12/2013	Denosumab; Denosumab + Zoledronic Acid; Placebo; Zoledronic Acid	anti-RANK_L_monoclonal_antibody + bisphosphonate; bisphosphonate; anti-RANK_L_monoclonal_antibody; placebo	Denosumab + Zoledronic Acid; Denosumab + Zoledronic Acid; Placebo	anti-RANK_L_monoclonal_antibody + bisphosphonate; anti-RANK_L_monoclonal_antibody + bisphosphonate; placebo	2013-001662-42  20120249	A Randomized, Double-blind, Multi-center Phase 2 Trial of Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer	Non-Small Cell Lung Cancer	3050 - Parkville; 3690 - Wodonga; 2076 - Wahroonga; 3011 - Footscray; 2217 - Kogarah; 5000 - Adelaide	https://clinicaltrials.gov/ct2/show/NCT01951586
NCT01953926	SUMMIT	Phase 2		VIC	1/10/2013	30/09/2013	Fulvestrant; Fulvestrant + Neratinib + Trastuzumab; Neratinib; Neratinib + Trastuzumab; Trastuzumab	ERBB3_inhibitor + anti-ERBB2_monoclonal_antibody + selective_estrogen_receptor_degrader; ERBB2_inhibitor + anti-ERBB2_monoclonal_antibody; EGFR_inhibitor,second_generation; anti-ERBB2_monoclonal_antibody; ERBB2_inhibitor + anti-ERBB2_monoclonal_antibody + selective_estrogen_receptor_degrader; ERBB3_inhibitor + anti-ERBB2_monoclonal_antibody; selective_estrogen_receptor_degrader; EGFR_inhibitor,second_generation + anti-ERBB2_monoclonal_antibody + selective_estrogen_receptor_degrader; ERBB2_inhibitor; ERBB3_inhibitor; EGFR_inhibitor,second_generation + anti-ERBB2_monoclonal_antibody	Fulvestrant + Neratinib + Trastuzumab; Neratinib; Neratinib + Trastuzumab; Fulvestrant + Neratinib + Trastuzumab; Neratinib + Trastuzumab	EGFR_inhibitor,second_generation; EGFR_inhibitor,second_generation + anti-ERBB2_monoclonal_antibody; EGFR_inhibitor,second_generation + anti-ERBB2_monoclonal_antibody + selective_estrogen_receptor_degrader; ERBB2_inhibitor; ERBB2_inhibitor + anti-ERBB2_monoclonal_antibody; ERBB2_inhibitor + anti-ERBB2_monoclonal_antibody + selective_estrogen_receptor_degrader; ERBB3_inhibitor; ERBB3_inhibitor + anti-ERBB2_monoclonal_antibody; ERBB3_inhibitor + anti-ERBB2_monoclonal_antibody + selective_estrogen_receptor_degrader; EGFR_inhibitor,second_generation + anti-ERBB2_monoclonal_antibody; EGFR_inhibitor,second_generation + anti-ERBB2_monoclonal_antibody + selective_estrogen_receptor_degrader; ERBB2_inhibitor + anti-ERBB2_monoclonal_antibody; ERBB2_inhibitor + anti-ERBB2_monoclonal_antibody + selective_estrogen_receptor_degrader; ERBB3_inhibitor + anti-ERBB2_monoclonal_antibody; ERBB3_inhibitor + anti-ERBB2_monoclonal_antibody + selective_estrogen_receptor_degrader	2013-002872-42  PUMA-NER-5201	An Open-Label, Phase 2 Basket Study of Neratinib in Patients With Solid Tumors With Somatic Activating HER Mutations	Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations	8006 - East Melbourne	https://clinicaltrials.gov/ct2/show/NCT01953926
NCT01954043	GSK2118436-200072	Phase 1		VIC	1/10/2013	20/12/2013	Dabrafenib	BRAF_V600_inhibitor	Dabrafenib	BRAF_V600_inhibitor	200072	An Open-label Study to Evaluate the Effects of a Potent CYP3A4 Inducer and the Effects of a pH Elevating Agent on the Repeat Dose Pharmacokinetics of Dabrafenib (GSK2118436) in Subjects With BRAF V600 Mutation Positive Tumors	Cancer	3004 - Melbourne; 3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT01954043
NCT01958021	MONALEESA-2	Phase 3		WA, VIC, SA	8/10/2013	17/12/2013	Letrozole; Letrozole + Ribociclib; Placebo; Ribociclib	aromatase_inhibitor; placebo; CDK4/6_inhibitor + aromatase_inhibitor; CDK4/6_inhibitor	Letrozole + Ribociclib; Letrozole + Ribociclib; Placebo	CDK4/6_inhibitor + aromatase_inhibitor; CDK4/6_inhibitor + aromatase_inhibitor; placebo	2013-003084-61  CLEE011A2301	A Randomized Double-blind, Placebo-controlled Study of LEE011 in Combination With Letrozole for the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative, Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease	Advanced, Metastatic Breast Cancer	3002 - East Melbourne; 6009 - Nedlands; 5037 - Kurralta Park	https://clinicaltrials.gov/ct2/show/NCT01958021
NCT01964235	CINC280X2203	Phase 2		NSW, VIC	17/10/2013		Capmatinib; Placebo; Sorafenib	FLT3_inhibitor; placebo; VEGFR_inhibitor; MET_inhibitor,type_1; CRAF_inhibitor; PDGFR_inhibitor; KIT_inhibitor; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor	Capmatinib; Placebo; Sorafenib	MET_inhibitor,type_1; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor; CRAF_inhibitor; FLT3_inhibitor; KIT_inhibitor; PDGFR_inhibitor; placebo	CINC280X2203	A Randomized Phase II, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of INC280 in Adult Patients With Advanced Hepatocellular Carcinoma After Progression or Intolerance to Sorafenib Treatment	Advanced Hepatocellular Carcinoma	3084 - Heidelberg; 2217 - Kogarah	https://clinicaltrials.gov/ct2/show/NCT01964235
NCT01966003	2013-000738-36--20120265	Phase 3		WA	21/10/2013	11/11/2013	Bevacizumab; Bevacizumab + Carboplatin + Paclitaxel; Carboplatin; Carboplatin + Paclitaxel; Paclitaxel	platinum-based_antineoplastic_agent; anti-VEGF_monoclonal_antibody; taxane; platinum-based_antineoplastic_agent + taxane; anti-VEGF_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane	Bevacizumab + Carboplatin + Paclitaxel; Carboplatin + Paclitaxel; Bevacizumab + Carboplatin + Paclitaxel; Carboplatin + Paclitaxel	anti-VEGF_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; platinum-based_antineoplastic_agent + taxane; anti-VEGF_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; platinum-based_antineoplastic_agent + taxane	2013-000738-36  20120265	A Randomized, Double-blind, Phase 3 Study Evaluating the Efficacy and Safety of ABP 215 Compared With Bevacizumab in Subjects With Advanced Non-Small Cell Lung Cancer	Non-small Cell Lung Cancer Metastatic	6160 - Fremantle	https://clinicaltrials.gov/ct2/show/NCT01966003
NCT01966445	2013-001699-39--117158	Phase 1		WA, VIC	21/10/2013	26/11/2013	GSK2849330	anti-ERBB3_monoclonal_antibody	GSK2849330	anti-ERBB3_monoclonal_antibody	2013-001699-39  117158	A Phase I, First Time in Human, Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Anti-Her3 Monoclonal Antibody GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors	Cancer; Neoplasms	6009 - Nedlands; 3084 - Heidelberg; 3004 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT01966445
NCT01968109	2014-002605-38--CA224-020	Phase 1/Phase 2		WA, VIC, NSW, QLD	23/10/2013	5/11/2013	BMS-986213; BMS-986213 + Nivolumab + Relatlimab; Nivolumab; Nivolumab + Relatlimab; Relatlimab	anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	BMS-986213 + Nivolumab + Relatlimab; Nivolumab + Relatlimab; Relatlimab; BMS-986213 + Nivolumab + Relatlimab; Nivolumab + Relatlimab	anti-LAG3_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	2014-002605-38  CA224-020	A Phase I/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors	Neoplasms by Site	4120 - Greenslopes; 4215 - Southport; 6009 - Nedlands; 3000 - Melbourne; 2060 - North Sydney	https://clinicaltrials.gov/ct2/show/NCT01968109
NCT01968213	ARIEL3	Phase 3		WA, NZ, SA, NSW, VIC, QLD	23/10/2013	7/04/2014	Placebo; Rucaparib	PARP_inhibitor; placebo	Rucaparib; Placebo	PARP_inhibitor; placebo	CO-338-014	Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous and Endometrioid Ovarian Cancer (ARIEL3)	Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cancer	Manawatu; Wellington; 4029 - Herston; 608 - Subiaco; 2031 - Sydney; 2145 - Westmead; 3052 - Parkville; 5042 - Bedford Park; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT01968213
NCT01970865	2013-002620-17--B7461001	Phase 1/Phase 2		VIC, NSW	28/10/2013	8/01/2014	Crizotinib; Lorlatinib	MET_inhibitor,type_1; ALK_inhibitor,first_generation; ROS1_inhibitor; ALK_inhibitor,third_generation	Lorlatinib; Crizotinib	ALK_inhibitor,third_generation; ROS1_inhibitor; ALK_inhibitor,first_generation; MET_inhibitor,type_1	2013-002620-17  B7461001	PHASE 1/2 STUDY OF PF-06463922 (AN ALK/ROS1 TYROSINE KINASE INHIBITOR) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER HARBORING SPECIFIC MOLECULAR ALTERATIONS	ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC	3050 - Parkville; 2050 - Sydney Local Health District [rpa]; 3000 - Melbourne; 2050 - Sydney	https://clinicaltrials.gov/ct2/show/NCT01970865
NCT01975701	CBGJ398X2201	Phase 2		VIC	5/11/2013	9/12/2013	Infigratinib	FGFR1/2/3_inhibitor	Infigratinib	FGFR1/2/3_inhibitor	CBGJ398X2201	A Phase 2, Multicenter, Open-label Study of BGJ398 in Patients With Recurrent Resectable or Unresectable Glioblastoma	Recurrent Glioblastoma or Other Glioma Subtypes	3050 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT01975701
NCT01978236	NCT01978236	Phase 2		NSW	7/11/2013	8/04/2014	Dabrafenib; Dabrafenib + Trametinib; Trametinib	MEK_inhibitor; BRAF_V600_inhibitor + MEK_inhibitor; BRAF_V600_inhibitor	Dabrafenib + Trametinib; Dabrafenib + Trametinib	BRAF_V600_inhibitor + MEK_inhibitor; BRAF_V600_inhibitor + MEK_inhibitor	116521	An Open-Label, Multicentre, Corollary Study of Pre-Operative Therapy With Dabrafenib and the Combination of Dabrafenib With Trametinib in Subjects With BRAF Mutation-Positive Metastatic Melanoma to the Brain	Melanoma and Brain Metastases	2060 - North Sydney	https://clinicaltrials.gov/ct2/show/NCT01978236
NCT01986218	CA002-001	Phase 1		VIC	18/11/2013	1/11/2013	AL102	gamma_secretase_inhibitor	AL102	gamma_secretase_inhibitor	CA002-001	Phase I Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-986115 in Subjects With Advanced Solid Tumors	Various Advanced Cancer	3050 - Parkville	https://clinicaltrials.gov/ct2/show/NCT01986218
NCT01988896	2013-003329-27--GP28363	Phase 1		VIC	20/11/2013	27/12/2013	Atezolizumab; Atezolizumab + Cobimetinib; Cobimetinib	anti-PD-L1_monoclonal_antibody; MEK_inhibitor; MEK_inhibitor + anti-PD-L1_monoclonal_antibody	Atezolizumab + Cobimetinib; Atezolizumab + Cobimetinib	MEK_inhibitor + anti-PD-L1_monoclonal_antibody; MEK_inhibitor + anti-PD-L1_monoclonal_antibody	2013-003329-27  GP28363	A Phase Ib Study of the Safety and Pharmacology of Atezolizumab Administered With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors	Solid Tumors	3050 - Parkville; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT01988896
NCT01997333	METRIC	Phase 2		QLD, NSW, VIC	28/11/2013	1/11/2013	Capecitabine; Glembatumumab Vedotin	anti-GPNMB_antibody-drug_conjugate; fluoropyrimidine	Capecitabine; Glembatumumab Vedotin	anti-GPNMB_antibody-drug_conjugate; fluoropyrimidine	CDX011-04	A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)	Metastatic gpNMB Over-expressing Triple Negative Breast Cancer	2076 - Wahroonga; 3011 - Footscray; 2109 - Macquarie Park; 3084 - Heidelberg; 4814 - Douglas; 3121 - Richmond; 2010 - Darlinghurst; 3128 - Box Hill; 2485 - Tweed Heads	https://clinicaltrials.gov/ct2/show/NCT01997333
NCT01998919	MO18633	Phase 2		NSW	2/12/2013	1/08/2006	Carboplatin; Cisplatin; Erlotinib; Erlotinib + Gemcitabine; Gemcitabine; Placebo	EGFR_inhibitor,first_generation + antimetabolite; platinum-based_antineoplastic_agent; gemcitabine; EGFR_inhibitor,first_generation; placebo; antimetabolite	Erlotinib + Gemcitabine; Gemcitabine; Carboplatin; Cisplatin; Erlotinib + Gemcitabine; Placebo	EGFR_inhibitor,first_generation + antimetabolite; antimetabolite; EGFR_inhibitor,first_generation + antimetabolite; gemcitabine; placebo; platinum-based_antineoplastic_agent	MO18633	A Randomised, Placebo-controlled, Double-blind Phase II of Sequential Administration of Tarceva (Erlotinib) or Placebo in Combination With Gemcitabine/Platinum as First-line Treatment in Patients With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC).	Non-Small Cell Lung Cancer	2050 - Camperdown; 2560 - Campbelltown; 2170 - Liverpool	https://clinicaltrials.gov/ct2/show/NCT01998919
NCT01999673	SUNRISE	Phase 3		QLD, NSW, VIC, SA	3/12/2013	1/12/2013	Bavituximab; Bavituximab + Docetaxel; Docetaxel; Placebo	anti-phosphatidylserine_monoclonal_antibody; taxane; placebo; anti-phosphatidylserine_monoclonal_antibody + taxane	Bavituximab + Docetaxel; Docetaxel; Bavituximab + Docetaxel; Placebo	anti-phosphatidylserine_monoclonal_antibody + taxane; taxane; anti-phosphatidylserine_monoclonal_antibody + taxane; placebo	2013-003953-13  PPHM 1202	SUNRISE: A Phase III, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Previously Treated Stage IIIb/IV Non-Squamous Non Small-Cell Lung Cancer	Non-Small-Cell Lung Carcinoma; Non-Small-Cell Lung Cancer Stage IV; Non-Small-Cell Lung Cancer Stage IIIB; Carcinoma, Non-Small-Cell Lung; Nonsmall Cell Lung Cancer; Non-Small-Cell Lung Cancer Metastatic; Non-Small Cell Lung Cancer	2560 - Campbelltown; 2485 - Tweed Heads; 2050 - Camperdown; 4064 - Milton; 5112 - Elizabeth Vale; 5065 - Toorak Gardens; 4020 - Redcliffe; 3690 - Wodonga; 3220 - Geelong	https://clinicaltrials.gov/ct2/show/NCT01999673
NCT02000947	D4190C00006	Phase 1		NSW	4/12/2013	25/10/2013	Durvalumab; Durvalumab + Tremelimumab; Tremelimumab	anti-PD-L1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody	Durvalumab + Tremelimumab; Durvalumab + Tremelimumab	anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody	2015-003715-38  D4190C00006	A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer	Lung Cancer; Non-small Cell Lung Cancer; NSCLC	2010 - Darlinghurst; 2250 - Gosford; 2217 - Kogarah	https://clinicaltrials.gov/ct2/show/NCT02000947
NCT02008227	OAK	Phase 3		NZ	11/12/2013	11/03/2014	Atezolizumab; Docetaxel	anti-PD-L1_monoclonal_antibody; taxane	Atezolizumab; Docetaxel	anti-PD-L1_monoclonal_antibody; taxane	2013-003331-30  GO28915	A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer After Failure With Platinum Containing Chemotherapy	Non-Squamous Non-Small Cell Lung Cancer	Dunedin; Hamilton; Auckland	https://clinicaltrials.gov/ct2/show/NCT02008227
NCT02013830	ML18469	Phase 2		VIC	17/12/2013	1/05/2005	Bevacizumab; Bevacizumab + Capecitabine; Capecitabine	anti-VEGF_monoclonal_antibody + fluoropyrimidine; anti-VEGF_monoclonal_antibody; fluoropyrimidine	Bevacizumab + Capecitabine; Bevacizumab + Capecitabine	anti-VEGF_monoclonal_antibody + fluoropyrimidine; anti-VEGF_monoclonal_antibody + fluoropyrimidine	ML18469	A Single-arm, Open-label Study of Avastin Plus Xeloda on Objective Treatment Response in Patients With Advanced or Metastatic Liver Cancer Who Have Had no Previous Cytotoxic Chemotherapy	Liver Cancer	3181 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT02013830
NCT02014116	I6X-MC-JBDA--13873	Phase 1		WA	18/12/2013	26/11/2013	LY3009120	RAF_inhibitor,type_2	LY3009120	RAF_inhibitor,type_2	I6X-MC-JBDA  13873	A Phase 1 Study of LY3009120 in Patients With Advanced or Metastatic Cancer	Melanoma; Colorectal Neoplasms; Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung	6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT02014116
NCT02016534	2013-001277-24--20130111	Phase 2		SA, NSW, VIC	20/12/2013	1/02/2014	AMG 337	MET_inhibitor	AMG 337	MET_inhibitor	2013-001277-24  20130111	A Multicenter, Phase 2, Single Arm, Two Cohort Study Evaluating the Efficacy, Safety, and Pharmacokinetics of AMG337 in Subjects With MET Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma or Other MET Amplified Solid Tumors	Stomach Neoplasms	2050 - Camperdown; 3165 - Bentleigh East; 5037 - Kurralta Park; 3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT02016534
NCT02017717	CheckMate-143	Phase 3		NSW, VIC, WA	23/12/2013	7/02/2014	Bevacizumab; Ipilimumab; Ipilimumab + Nivolumab; Nivolumab	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-VEGF_monoclonal_antibody	Bevacizumab; Ipilimumab + Nivolumab; Nivolumab; Ipilimumab + Nivolumab	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-VEGF_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	2013-003738-34  CA209-143	A Randomized Phase 3 Open Label Study of Nivolumab Versus Bevacizumab and Multiple Phase 1 Safety Cohorts of Nivolumab or Nivolumab in Combination With Ipilimumab Across Different Lines of Glioblastoma	Recurrent Glioblastoma	6009 - Nedlands; 3165 - East Bentleigh; 3084 - Heidelberg; 2170 - Liverpool	https://clinicaltrials.gov/ct2/show/NCT02017717
NCT02019277	SAPPHIRE	Phase 3		SA, TAS, QLD, NSW, VIC, WA	24/12/2013	5/12/2013	Docetaxel; Docetaxel + Nab-paclitaxel + Paclitaxel + Pertuzumab + Trastuzumab; Nab-paclitaxel; Paclitaxel; Pertuzumab; Trastuzumab	anti-ERBB2_monoclonal_antibody; anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor + taxane; taxane; anti-ERBB2_monoclonal_antibody,dimerization_inhibitor	Docetaxel + Nab-paclitaxel + Paclitaxel + Pertuzumab + Trastuzumab; Docetaxel + Nab-paclitaxel + Paclitaxel + Pertuzumab + Trastuzumab	anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor + taxane; anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor + taxane	ML28784	An Open-label, Multicentre, Phase IIIb Study With Intravenous Administration of Pertuzumab, Subcutaneous Trastuzumab, and a Taxane in Patients With HER2-positive Metastatic Breast Cancer	Breast Cancer	2444 - Port Macquarie; 2217 - Kogarah; 6150 - Murdoch; 3220 - Geelong; 4102 - Woolloongabba; 3550 - Bendigo; 2298 - Waratah; 7250 - Launceston; 3168 - Clayton; 3052 - Parkville; 5112 - Adelaide; 4101 - South Brisbane	https://clinicaltrials.gov/ct2/show/NCT02019277
NCT02023697	2013-003118-42--16507	Phase 2		NSW, VIC, SA	30/12/2013	10/03/2014	Radium-223	radium_223_radionuclide	Radium-223	radium_223_radionuclide	2013-003118-42  16507	A Three Arm Randomized, Open-label Phase II Study of Radium-223 Dichloride 50 kBq/kg (55 kBq/kg After Implementation of NIST Update) Versus 80 kBq/kg (88 kBq/kg After Implementation of NIST Update), and Versus 50 kBq/kg (55 kBq/kg After Implementation of NIST Update) in an Extended Dosing Schedule in Subjects With Castration-resistant Prostate Cancer Metastatic to the Bone	Prostatic Neoplasms	3052 - Melbourne; 2010 - Darlinghurst; 3128 - Box Hill; 2145 - Westmead; 5000 - Adelaide	https://clinicaltrials.gov/ct2/show/NCT02023697
NCT02030964	DFMO	Phase 1		NSW	9/01/2014	1/12/2013	Celecoxib; Celecoxib + Cyclophosphamide + Topotecan; Cyclophosphamide; Topotecan	alkylating_agent; COX2_inhibitor; COX2_inhibitor + alkylating_agent + topoisomerase_inhibitor; topoisomerase_inhibitor	Celecoxib + Cyclophosphamide + Topotecan; Celecoxib + Cyclophosphamide + Topotecan	COX2_inhibitor + alkylating_agent + topoisomerase_inhibitor; COX2_inhibitor + alkylating_agent + topoisomerase_inhibitor	P01CA081403  N2012-01	N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan for Patients With Relapsed or Refractory Neuroblastoma	Neuroblastoma	2031 - Randwick	https://clinicaltrials.gov/ct2/show/NCT02030964
NCT02031458	BIRCH	Phase 2		NSW, VIC, QLD, WA	9/01/2014	22/01/2014	Atezolizumab	anti-PD-L1_monoclonal_antibody	Atezolizumab	anti-PD-L1_monoclonal_antibody	2013-003330-32  GO28754	A Phase II, Multicenter, Single-Arm Study OF Atezolizumab In Patients With PD-L1-Positive Locally Advanced Or Metastatic Non-Small Cell Lung Cancer	Non-Small Cell Lung Cancer	4102 - Woolloongabba; 3084 - Heidelberg; 2065 - St. Leonards; 3000 - Melbourne; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT02031458
NCT02033993	BL12	Phase 2		WA, SA, TAS, NSW, VIC, QLD	13/01/2014	27/01/2014	Nab-paclitaxel; Paclitaxel	taxane	Nab-paclitaxel; Paclitaxel	taxane	BL12	A Multicentre Randomized Phase II Trial Comparing Nab-Paclitaxel to Paclitaxel in Patients With Advanced Urothelial Cancer Progressing on or After a Platinum Containing Regimen.	Urothelial Cancer	7000 - Hobart; 5042 - Bedford Park; 3128 - Box Hill; 3121 - Richmond; 4814 - Douglas; 2031 - Sydney; 6150 - Perth; 3320 - Geelong; 4560 - Nambour; 3021 - St Albans; 5037 - Kurralta Park; 2444 - Port Macquarie; 3199 - Frankston; 3065 - Fitzroy; 2170 - Sydney; 3690 - Wodonga; 2139 - Sydney	https://clinicaltrials.gov/ct2/show/NCT02033993
NCT02039947	NCT02039947	Phase 2		QLD, NSW, VIC	20/01/2014	21/02/2014	Dabrafenib; Dabrafenib + Trametinib; Trametinib	MEK_inhibitor; BRAF_V600_inhibitor + MEK_inhibitor; BRAF_V600_inhibitor	Dabrafenib + Trametinib; Dabrafenib + Trametinib	BRAF_V600_inhibitor + MEK_inhibitor; BRAF_V600_inhibitor + MEK_inhibitor	117277	BRF117277: A Phase II, Open-Label, Multicentre Study of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain	Melanoma and Brain Metastases	4120 - Greenslopes; 2060 - North Sydney; 3004 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT02039947
NCT02041533	2012-004502-93--CA209-026	Phase 3		SA, NSW, VIC, QLD	22/01/2014	27/03/2014	Carboplatin; Cisplatin; Gemcitabine; Nivolumab; Paclitaxel; Pemetrexed	anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; antimetabolite; gemcitabine; taxane	Nivolumab; Carboplatin; Cisplatin; Gemcitabine; Paclitaxel; Pemetrexed	anti-PD-1_monoclonal_antibody; antimetabolite; gemcitabine; platinum-based_antineoplastic_agent; taxane	2012-004502-93  CA209-026	An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer	Stage IV or Recurrent Non-Small Cell Lung Cancer	2050 - Camperdown; 5112 - Elizabeth Vale; 3084 - Heidelberg; 3065 - Fitzroy; 4102 - Brisbane	https://clinicaltrials.gov/ct2/show/NCT02041533
NCT02042781	PG545102	Phase 1		VIC, WA	23/01/2014	1/01/2014	Pixatimod	angiogenesis_inhibitor	Pixatimod	angiogenesis_inhibitor	PG545102	An Open-label, Multi-centre Phase I Study of the Safety and Tolerability of IV Infused PG545 in Patients With Advanced Solid Tumours	Advanced Solid Tumours	6009 - Nedlands; 3004 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT02042781
NCT02043665	STORM	Phase 1		QLD, VIC, WA	23/01/2014	18/12/2013	CAVATAK; Coxsackievirus A21; Coxsackievirus A21 + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; virus-based_therapy; oncolytic_Coxsackie_virus,ICAM_overexpressing; anti-PD-1_monoclonal_antibody + oncolytic_Coxsackie_virus,ICAM_overexpressing	Coxsackievirus A21 + Pembrolizumab; CAVATAK; Coxsackievirus A21 + Pembrolizumab	anti-PD-1_monoclonal_antibody + oncolytic_Coxsackie_virus,ICAM_overexpressing; anti-PD-1_monoclonal_antibody + oncolytic_Coxsackie_virus,ICAM_overexpressing; virus-based_therapy	2012-005256-42  3475-200	A Phase 1, Dose-finding and Signal-seeking Study of the Safety & Efficacy of Intravenous CAVATAK® Alone and in Combination With Pembrolizumab in Patients With Late Stage Solid Tumours (VLA-009 STORM / KEYNOTE-200)	Bladder Cancer; Non-small Cell Lung Cancer	4216 - Southport; 3168 - Clayton; 3121 - Richmond; 3065 - Fitzroy; 6008 - Subiaco; 3220 - Geelong	https://clinicaltrials.gov/ct2/show/NCT02043665
NCT02043678	ERA-223	Phase 3		SA, VIC, NSW	23/01/2014	30/03/2014	Abiraterone; Abiraterone + Prednisolone + Prednisone + Radium-223; Dexamethasone; Placebo; Prednisolone; Prednisone; Radium-223	CYP17A1_inhibitor + glucocorticoid + radium_223_radionuclide; glucocorticoid; placebo; CYP17A1_inhibitor; radium_223_radionuclide	Abiraterone + Prednisolone + Prednisone + Radium-223; Radium-223; Abiraterone + Prednisolone + Prednisone + Radium-223; Dexamethasone; Placebo	CYP17A1_inhibitor + glucocorticoid + radium_223_radionuclide; radium_223_radionuclide; CYP17A1_inhibitor + glucocorticoid + radium_223_radionuclide; placebo	2013-003438-33  15396	A Phase III Randomized, Double-blind, Placebo-controlled Trial of Radium-223 Dichloride in Combination With Abiraterone Acetate and Prednisone/Prednisolone in the Treatment of Asymptomatic or Mildly Symptomatic Chemotherapy-naïve Subjects With Bone Predominant Metastatic Castration-resistant Prostate Cancer(CRPC)	Prostatic Neoplasms	2031 - Randwick; 3002 - East Melbourne; 2010 - Darlinghurst; 3165 - East Bentleigh; 2065 - St Leonards; 3065 - Melbourne; 5000 - Adelaide; 3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT02043678
NCT02049905	ALDOXORUBICIN-P3-STS-01	Phase 3		NSW	30/01/2014	1/01/2014	Aldoxorubicin; Aldoxorubicin + Doxorubicin; Docetaxel; Doxorubicin; Gemcitabine; Ifosfamide; Pazopanib	anthracycline; KIT_inhibitor,ATP-competitive; alkylating_agent; doxorubicin; antimetabolite; anthracycline + doxorubicin_conjugate; VEGFR_inhibitor; PDGFR_inhibitor; taxane; doxorubicin_conjugate	Aldoxorubicin + Doxorubicin; Aldoxorubicin + Doxorubicin; Docetaxel; Gemcitabine; Ifosfamide; Pazopanib	anthracycline + doxorubicin_conjugate; KIT_inhibitor,ATP-competitive; PDGFR_inhibitor; VEGFR_inhibitor; alkylating_agent; anthracycline + doxorubicin_conjugate; antimetabolite; doxorubicin; taxane	ALDOXORUBICIN-P3-STS-01	A Multicenter, Randomized, Open-Label Phase 3 Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Investigator's Choice in Subjects With Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcomas Who Either Relapsed or Were Refractory to Prior Non-Adjuvant Chemotherapy	Metastatic, Locally Advanced or Unresectable Soft Tissue Sarcoma	- Saint Leonards; - Westmead	https://clinicaltrials.gov/ct2/show/NCT02049905
NCT02051868	InterAACT	Phase 2		NSW	31/01/2014	1/12/2013	Carboplatin; Carboplatin + Paclitaxel; Cisplatin; Cisplatin + Fluorouracil; Fluorouracil; Paclitaxel	platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent + taxane; fluoropyrimidine + platinum-based_antineoplastic_agent; Fluorouracil; taxane; fluoropyrimidine	Carboplatin + Paclitaxel; Cisplatin + Fluorouracil; Carboplatin + Paclitaxel; Cisplatin + Fluorouracil	fluoropyrimidine + platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent + taxane; Fluorouracil; fluoropyrimidine + platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent + taxane	2013-001949-13  CCR 3847 InterAACT	An International Multicentre Open Label Randomised Phase II Advanced Anal Cancer Trial Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel in Patients With Inoperable Locally Recurrent or Metastatic Disease	Squamous Cell Carcinoma of the Anus	NSW 1450 - Sydney	https://clinicaltrials.gov/ct2/show/NCT02051868
NCT02052778	2013-004810-16--TPU-TAS-120-101	Phase 1/Phase 2	NOT_RECRUITING	VIC	3/02/2014	1/07/2014	Futibatinib	pan-FGFR_inhibitor,irreversible	Futibatinib	pan-FGFR_inhibitor,irreversible	2013-004810-16  TPU-TAS-120-101	Phase 1/2 Study of TAS-120 in Patients With Advanced Solid Tumors Harboring FGF/FGFR Aberrations	Breast Cancer; Urothelial Cancer; Primary CNS Tumors; Cholangiocarcinoma; Gastric Cancer; Advanced and Metastatic Cancer Patients With Tumors Harboring FGF/FGFR Tumors	- Melbourne	https://clinicaltrials.gov/ct2/show/NCT02052778
NCT02053636	FINESSE	Phase 2		NSW, VIC	4/02/2014	1/12/2013	Lucitanib	VEGFR/PDGFR/FGFR1/2/3_inhibitor	Lucitanib	VEGFR/PDGFR/FGFR1/2/3_inhibitor	2013-000288-10  CL2-80881-001	An Open, 3-cohort, Phase II Trial Testing Oral Administration of Lucitanib in Patients With FGFR1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer	Breast Cancer	- East Melbourne; 2145 - Westmead	https://clinicaltrials.gov/ct2/show/NCT02053636
NCT02060188	CheckMate142	Phase 2		QLD, VIC, NSW	11/02/2014	12/03/2014	Cobimetinib; Cobimetinib + Ipilimumab + Nivolumab; Daratumumab; Daratumumab + Nivolumab; Ipilimumab; Ipilimumab + Nivolumab; Nivolumab; Nivolumab + Relatlimab; Relatlimab	anti-CTLA-4_monoclonal_antibody; anti-CD38_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; MEK_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; MEK_inhibitor; anti-CD38_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Cobimetinib + Ipilimumab + Nivolumab; Daratumumab + Nivolumab; Ipilimumab + Nivolumab; Nivolumab; Nivolumab + Relatlimab; Cobimetinib + Ipilimumab + Nivolumab; Daratumumab + Nivolumab; Ipilimumab + Nivolumab; Nivolumab + Relatlimab	MEK_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CD38_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; MEK_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CD38_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	2013-003939-30  CA209-142	A Phase 2 Clinical Trial of Nivolumab, or Nivolumab Combinations in Recurrent and Metastatic Microsatellite High (MSI-H) and Non-MSI-H Colon Cancer	Microsatellite Unstable Colorectal Cancer; Mismatch Repair Proficient Colorectal Cancer; Microsatellite Stable Colorectal Cancer; Mismatch Repair Deficient Colorectal Cancer	2145 - Westmead; 3050 - Parkville; 4215 - Southport	https://clinicaltrials.gov/ct2/show/NCT02060188
NCT02075840	ALEX	Phase 3		NZ, SA, NSW, VIC	3/03/2014	19/08/2014	Alectinib; Crizotinib	MET_inhibitor,type_1; ALK_inhibitor,first_generation; ROS1_inhibitor; ALK/RET_inhibitor; ALK_inhibitor,second_generation	Alectinib; Crizotinib	ALK/RET_inhibitor; ALK_inhibitor,first_generation; ALK_inhibitor,second_generation; MET_inhibitor,type_1; ROS1_inhibitor	2013-004133-33  BO28984	Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer	Non-Small Cell Lung Cancer	2065 - St. Leonards; 5011 - Woodville South; 2298 - Waratah; 2010 - Darlinghurst; Auckland; 3168 - Victoria	https://clinicaltrials.gov/ct2/show/NCT02075840
NCT02106546	2013-005020-42--M11-089	Phase 3		NZ, SA, VIC, NSW, QLD	8/04/2014	10/04/2014	Carboplatin; Carboplatin + Paclitaxel; Carboplatin + Paclitaxel + Veliparib; Paclitaxel; Placebo; Veliparib	PARP_inhibitor; platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent + taxane; placebo; PARP_inhibitor + platinum-based_antineoplastic_agent + taxane; taxane	Carboplatin + Paclitaxel; Carboplatin + Paclitaxel + Veliparib; Carboplatin + Paclitaxel; Carboplatin + Paclitaxel + Veliparib; Placebo	PARP_inhibitor + platinum-based_antineoplastic_agent + taxane; platinum-based_antineoplastic_agent + taxane; PARP_inhibitor + platinum-based_antineoplastic_agent + taxane; placebo; platinum-based_antineoplastic_agent + taxane	2013-005020-42  M11-089	Randomized, Double-Blind, Multicenter, Phase 3 Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)	Squamous Non-Small Cell Lung Cancer	4814 - Douglas; 5042 - Bedford Park; Canterbury; 4575 - Birtinya; 3220 - Geelong; 5011 - Woodville; 2500 - Wollongong; Wellington	https://clinicaltrials.gov/ct2/show/NCT02106546
NCT02107703	MONARCH-2	Phase 3	NOT_RECRUITING	WA, SA, VIC, QLD	8/04/2014	22/07/2014	Abemaciclib; Abemaciclib + Fulvestrant; Fulvestrant; Placebo	CDK4/6_inhibitor + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader; placebo; CDK4/6_inhibitor	Abemaciclib + Fulvestrant; Fulvestrant; Abemaciclib + Fulvestrant; Placebo	CDK4/6_inhibitor + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader; CDK4/6_inhibitor + selective_estrogen_receptor_degrader; placebo	I3Y-MC-JPBL  15362	MONARCH 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant With or Without Abemaciclib, a CDK4/6 Inhibitor, for Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer	Breast Neoplasms	6008 - Subiaco; 5037 - Kurralta Park; 4101 - South Brisbane; 4215 - Southport; 3165 - East Bentleigh	https://clinicaltrials.gov/ct2/show/NCT02107703
NCT02110355	NCT02110355	Phase 1		VIC, NSW	10/04/2014	19/12/2014	Dabrafenib; Dabrafenib + Trametinib; Navtemadlin; Navtemadlin + Trametinib; Trametinib	MDM2_inhibitor + MEK_inhibitor; MEK_inhibitor; MDM2_inhibitor; BRAF_V600_inhibitor + MEK_inhibitor; BRAF_V600_inhibitor	Dabrafenib + Trametinib; Navtemadlin + Trametinib; Dabrafenib + Trametinib; Navtemadlin + Trametinib	BRAF_V600_inhibitor + MEK_inhibitor; MDM2_inhibitor + MEK_inhibitor; BRAF_V600_inhibitor + MEK_inhibitor; MDM2_inhibitor + MEK_inhibitor	20120238	A Phase 1b/2a Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 232 Combined With Trametinib and Dabrafenib or Trametinib in Adult Subjects With Metastatic Cutaneous Melanoma	Advanced Malignancy; Tumors; Advanced Solid Tumors; Cancer; Oncology Patients; Oncology; Melanoma	3000 - Melbourne; 2060 - North Sydney	https://clinicaltrials.gov/ct2/show/NCT02110355
NCT02117479	INCB-18424-362	Phase 3		NSW, NZ	21/04/2014	1/03/2014	Capecitabine; Capecitabine + Ruxolitinib; Placebo; Ruxolitinib	JAK1/JAK2_inhibitor; placebo; JAK1/JAK2_inhibitor + fluoropyrimidine; fluoropyrimidine	Capecitabine; Capecitabine + Ruxolitinib; Capecitabine + Ruxolitinib; Placebo	JAK1/JAK2_inhibitor + fluoropyrimidine; fluoropyrimidine; JAK1/JAK2_inhibitor + fluoropyrimidine; placebo	INCB 18424-362	A Randomized, Double-Blind, Phase 3 Study of the JAK1/2 Inhibitor, Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 1 Study)	Pancreatic Cancer	Christchurch; - New South Wales; Hamilton; - Victoria; Auckland; - Australian Capital Territory; - South Australia	https://clinicaltrials.gov/ct2/show/NCT02117479
NCT02118337	D6020C00001	Phase 1/Phase 2		VIC	21/04/2014	19/05/2014	Durvalumab; Durvalumab + MEDI0680; MEDI0680; Nivolumab	anti-PD-L1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	Durvalumab + MEDI0680; MEDI0680; Nivolumab; Durvalumab + MEDI0680	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody	D6020C00001	A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Subjects With Select Advanced Malignancies	Kidney Cancer; Select Advanced Malignancies; Clear Cell Renal Cell Carcinoma	3199 - Frankston; 3165 - East Bentleigh	https://clinicaltrials.gov/ct2/show/NCT02118337
NCT02119676	INCB18424-267	Phase 2		VIC, NSW, QLD, SA	22/04/2014	1/03/2014	Placebo; Regorafenib; Regorafenib + Ruxolitinib; Ruxolitinib	JAK1/JAK2_inhibitor; JAK1/JAK2_inhibitor + KIT/PDGFR/RET/VEGFR/FGFR_inhibitor; placebo; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor	Regorafenib; Regorafenib + Ruxolitinib; Placebo; Regorafenib + Ruxolitinib	JAK1/JAK2_inhibitor + KIT/PDGFR/RET/VEGFR/FGFR_inhibitor; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor; JAK1/JAK2_inhibitor + KIT/PDGFR/RET/VEGFR/FGFR_inhibitor; placebo	INCB18424-267	A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer	CRC (Colorectal Cancer)	- New Lambton Heights; - Herston; - Randwick; - Kurralta Park; - Bentleigh East	https://clinicaltrials.gov/ct2/show/NCT02119676
NCT02125461	PACIFIC	Phase 3		QLD, VIC, NSW, SA, TAS, WA	29/04/2014	7/05/2014	Durvalumab; Placebo; Radiotherapy	anti-PD-L1_monoclonal_antibody; radiotherapy; placebo	Durvalumab; Placebo; Radiotherapy	anti-PD-L1_monoclonal_antibody; placebo; radiotherapy	D4191C00001	A Phase III, Randomised, Double-blind, Placebo-controlled, Multi-centre, International Study of MEDI4736 as Sequential Therapy in Patients With Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed Following Definitive, Platinum-based, Concurrent Chemoradiation Therapy (PACIFIC)	Non-Small Cell Lung Cancer	3128 - Box Hill; 3550 - Bendigo; 5042 - Bedford Park; 6009 - Nedlands; 7250 - Launceston; 2145 - Westmead; 3168 - Clayton; 2031 - Randwick; 2217 - Kogarah; 2444 - Port Macquarie; 3084 - Heidelberg; 4029 - Herston; 4102 - Woolloongabba	https://clinicaltrials.gov/ct2/show/NCT02125461
NCT02129556	PANACEA	Phase 1/Phase 2		VIC, NSW	2/05/2014	1/12/2014	Pembrolizumab; Pembrolizumab + Trastuzumab; Trastuzumab	anti-ERBB2_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-ERBB2_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Pembrolizumab + Trastuzumab; Pembrolizumab + Trastuzumab	anti-ERBB2_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-ERBB2_monoclonal_antibody + anti-PD-1_monoclonal_antibody	2013-004770-10  IBCSG 45-13 / BIG 4-13	A Phase Ib/II Trial Evaluating the Efficacy of MK-3475 and Trastuzumab in Patients With Trastuzumab-resistant, HER2-positive Metastatic Breast Cancers	Metastatic Breast Cancer	- Westmead; - East Melbourne	https://clinicaltrials.gov/ct2/show/NCT02129556
NCT02132754	4166-001	Phase 1	NOT_RECRUITING	NSW	5/05/2014	27/06/2014	MK-4166; MK-4166 + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; anti-GITR_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-GITR_monoclonal_antibody	MK-4166; MK-4166 + Pembrolizumab; MK-4166 + Pembrolizumab	anti-GITR_monoclonal_antibody; anti-GITR_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-GITR_monoclonal_antibody + anti-PD-1_monoclonal_antibody	4166-001	Phase 1 Trial of Single Agent MK-4166 and MK-4166 in Combination With Pembrolizumab in Subjects With Advanced Malignancies	Solid Tumor	- North Ryde	https://clinicaltrials.gov/ct2/show/NCT02132754
NCT02135042	NCI-2014-00635--NRG-HN001	Phase 2/Phase 3		VIC	9/05/2014	1/04/2014	Cisplatin; Cisplatin + Fluorouracil; Fluorouracil; Gemcitabine; Gemcitabine + Paclitaxel; Paclitaxel; Radiotherapy	radiotherapy; platinum-based_antineoplastic_agent; fluoropyrimidine + platinum-based_antineoplastic_agent; antimetabolite; Fluorouracil; gemcitabine; taxane; fluoropyrimidine; antimetabolite + taxane	Cisplatin + Fluorouracil; Gemcitabine + Paclitaxel; Cisplatin + Fluorouracil; Gemcitabine + Paclitaxel; Radiotherapy	antimetabolite + taxane; fluoropyrimidine + platinum-based_antineoplastic_agent; Fluorouracil; antimetabolite + taxane; fluoropyrimidine + platinum-based_antineoplastic_agent; gemcitabine; radiotherapy	NCI-2014-00635  NRG-HN001	Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)	Stage II Nasopharyngeal Carcinoma; Epstein-Barr Virus Infection; Stage IVB Nasopharyngeal Carcinoma; Stage III Nasopharyngeal Carcinoma; Stage IVA Nasopharyngeal Carcinoma	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT02135042
NCT02141295	McCAVE	Phase 2		VIC, NSW, SA	19/05/2014	30/06/2014	Bevacizumab; Bevacizumab + Fluorouracil + Leucovorin; Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin; Fluorouracil; Fluorouracil + Leucovorin; Fluorouracil + Leucovorin + Oxaliplatin; Leucovorin; Oxaliplatin	platinum-based_antineoplastic_agent; anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid; Fluorouracil; folinic_acid; fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; fluoropyrimidine + folinic_acid; anti-VEGF_monoclonal_antibody; fluoropyrimidine	Bevacizumab + Fluorouracil + Leucovorin; Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin; Fluorouracil + Leucovorin; Fluorouracil + Leucovorin + Oxaliplatin; Bevacizumab + Fluorouracil + Leucovorin; Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin; Fluorouracil + Leucovorin; Fluorouracil + Leucovorin + Oxaliplatin	anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid; anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; fluoropyrimidine + folinic_acid; fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; Fluorouracil; anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid; anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; fluoropyrimidine + folinic_acid; fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent	2013-005108-32  BP29262	A Phase II, Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of RO5520985 (Vanucizumab) Plus FOLFOX Versus Bevacizumab Plus FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer	Colorectal Cancer	5011 - Woodville; 2298 - Waratah; 3168 - Clayton	https://clinicaltrials.gov/ct2/show/NCT02141295
NCT02147990	NSCLC	Phase 2		SA, QLD, NSW	28/05/2014	16/06/2014	Rociletinib	EGFR_inhibitor,third_generation	Rociletinib	EGFR_inhibitor,third_generation	CO-1686-019 (TIGER-2)	TIGER-2: A Phase 2, Open-label, Multicenter, Safety and Efficacy Study of Oral CO-1686 as 2nd Line EGFR-directed TKI in Patients With Mutant EGFR Non-small Cell Lung Cancer (NSCLC)	Non-small Cell Lung Cancer	5042 - Bedford Park; 2065 - Sydney; 4101 - South Brisbane; 2145 - Westmead	https://clinicaltrials.gov/ct2/show/NCT02147990
NCT02149108	2012-000095-42--1199.52	Phase 3		VIC, NSW, WA	29/05/2014	25/09/2014	Nintedanib; Placebo	placebo; PDGFRA/VEGFR/FGFR_inhibitor	Nintedanib; Placebo	PDGFRA/VEGFR/FGFR_inhibitor; placebo	2012-000095-42  1199.52	A Double-blind, Randomised, Placebo Controlled Phase III Study of Nintedanib Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Therapies.	Colorectal Neoplasms	- Heidelberg; - Nedlands; - Perth; - St Leonards; - Wollongong; - Concord	https://clinicaltrials.gov/ct2/show/NCT02149108
NCT02151981	AURA3	Phase 3		WA, NSW, VIC, QLD	2/06/2014	4/08/2014	Carboplatin; Carboplatin + Cisplatin + Pemetrexed; Cisplatin; Osimertinib; Pemetrexed	EGFR_inhibitor,third_generation; platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; antimetabolite	Carboplatin + Cisplatin + Pemetrexed; Osimertinib; Carboplatin + Cisplatin + Pemetrexed	EGFR_inhibitor,third_generation; antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent	D5160C00003	A Phase III, Open Label, Randomized Study of AZD9291 Versus Platinum-Based Doublet Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed With Previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Whose Tumours Harbour a T790M Mutation Within the Epidermal Growth Factor Receptor Gene (AURA3).	Anticancer Treatment	2217 - Kogarah; 3084 - Heidelberg; 4102 - Woolloongabba; 2010 - Darlinghurst; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT02151981
NCT02155647	2014-000445-79--100070-003	Phase 2		QLD, VIC, NSW, WA	4/06/2014	3/07/2014	Avelumab	anti-PD-L1_monoclonal_antibody	Avelumab	anti-PD-L1_monoclonal_antibody	2014-000445-79  100070-003	A Phase II, Open-Label, Multicenter Trial to Investigate the Clinical Activity and Safety of Avelumab (MSB0010718C) in Subjects With Merkel Cell Carcinoma	Carcinoma, Merkel Cell	2444 - Port Macquarie; 4102 - Woolloongabba; 2065 - St Leonards; 6000 - Perth; 3128 - East Melbourne; - Southport	https://clinicaltrials.gov/ct2/show/NCT02155647
NCT02159066	LOGIC-2	Phase 2		VIC	9/06/2014	23/07/2014	Binimetinib; Binimetinib + Buparlisib + Encorafenib; Binimetinib + Capmatinib + Encorafenib; Binimetinib + Encorafenib; Binimetinib + Encorafenib + Infigratinib; Binimetinib + Encorafenib + Ribociclib; Buparlisib; Capmatinib; Encorafenib; Infigratinib; Ribociclib	BRAF_V600_inhibitor + FGFR1/2/3_inhibitor + MEK_inhibitor; BRAF_V600_inhibitor + MEK_inhibitor; FGFR1/2/3_inhibitor; BRAF_V600_inhibitor; MET_inhibitor,type_1; BRAF_V600_inhibitor + MEK_inhibitor + PI3K_alpha_inhibitor; BRAF_V600_inhibitor + MEK_inhibitor + MET_inhibitor,type_1; pan-PI3K_inhibitor; BRAF_V600_inhibitor + MEK_inhibitor + pan-PI3K_inhibitor; CDK4/6_inhibitor; PI3K_alpha_inhibitor; MEK_inhibitor; BRAF_V600_inhibitor + CDK4/6_inhibitor + MEK_inhibitor	Binimetinib + Buparlisib + Encorafenib; Binimetinib + Capmatinib + Encorafenib; Binimetinib + Encorafenib; Binimetinib + Encorafenib + Infigratinib; Binimetinib + Encorafenib + Ribociclib; Binimetinib + Buparlisib + Encorafenib; Binimetinib + Capmatinib + Encorafenib; Binimetinib + Encorafenib; Binimetinib + Encorafenib + Infigratinib; Binimetinib + Encorafenib + Ribociclib	BRAF_V600_inhibitor + CDK4/6_inhibitor + MEK_inhibitor; BRAF_V600_inhibitor + FGFR1/2/3_inhibitor + MEK_inhibitor; BRAF_V600_inhibitor + MEK_inhibitor; BRAF_V600_inhibitor + MEK_inhibitor + MET_inhibitor,type_1; BRAF_V600_inhibitor + MEK_inhibitor + PI3K_alpha_inhibitor; BRAF_V600_inhibitor + MEK_inhibitor + pan-PI3K_inhibitor; BRAF_V600_inhibitor + CDK4/6_inhibitor + MEK_inhibitor; BRAF_V600_inhibitor + FGFR1/2/3_inhibitor + MEK_inhibitor; BRAF_V600_inhibitor + MEK_inhibitor; BRAF_V600_inhibitor + MEK_inhibitor + MET_inhibitor,type_1; BRAF_V600_inhibitor + MEK_inhibitor + PI3K_alpha_inhibitor; BRAF_V600_inhibitor + MEK_inhibitor + pan-PI3K_inhibitor	C4221013  CLGX818X2109	The LOGIC 2 Trial A Phase II, Multi-center, Open-label Study of Sequential LGX818/MEK162 Combination Followed by a Rational Combination With Targeted Agents After Progression, to Overcome Resistance in Adult Patients With Locally Advanced or Metastatic BRAF V600 Melanoma	Melanoma	3183 - Melbourne; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT02159066
NCT02163694	2014-000345-70--M12-914	Phase 3		SA, TAS, NSW, VIC, QLD, WA	16/06/2014	5/08/2014	Carboplatin; Carboplatin + Paclitaxel + Veliparib; Paclitaxel; Placebo; Veliparib	PARP_inhibitor; platinum-based_antineoplastic_agent; PARP_inhibitor + platinum-based_antineoplastic_agent + taxane; taxane; placebo	Carboplatin + Paclitaxel + Veliparib; Carboplatin + Paclitaxel + Veliparib; Placebo	PARP_inhibitor + platinum-based_antineoplastic_agent + taxane; PARP_inhibitor + platinum-based_antineoplastic_agent + taxane; placebo	2014-000345-70  M12-914	A Phase 3 Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the PARP Inhibitor Veliparib (ABT-888) in HER2 Negative Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer	Metastatic Breast Cancer	2217 - Kogarah; 2500 - Wollongong; 6009 - Nedlands; 5042 - Bedford Park; 7000 - Hobart; 3052 - Parkville; 4814 - Douglas; 2031 - Randwick	https://clinicaltrials.gov/ct2/show/NCT02163694
NCT02178956	BRIGHTER	Phase 3		NSW, VIC, QLD, SA, WA	1/07/2014	1/10/2014	Napabucasin; Napabucasin + Paclitaxel; Paclitaxel; Placebo	cancer_stemness_inhibitor; taxane; placebo; cancer_stemness_inhibitor + taxane	Napabucasin + Paclitaxel; Paclitaxel; Napabucasin + Paclitaxel; Placebo	cancer_stemness_inhibitor + taxane; taxane; cancer_stemness_inhibitor + taxane; placebo	2014-000774-18  BBI608-336	A Phase III Clinical Trial of BBI608 Plus Weekly Paclitaxel vs. Placebo Plus Weekly Paclitaxel in Adult Patients With Advanced, Previously Treated Gastric and Gastro-Esophageal Junction Adenocarcinoma	Gastric Cancer; Gastroesophageal Junction Cancer	2250 - Gosford; 2200 - Bankstown; 3355 - Wendouree; 4215 - Southport; 5042 - Bedford Park; 3550 - Bendigo; 2010 - Darlinghurst; 4814 - Townsville; 3050 - Parkville; 2050 - Camperdown; 3165 - East Bentleigh; 4102 - Woolloongabba; 5011 - Woodville; 6008 - Subiaco; 3065 - Fitzroy; 2065 - St Leonards; 2444 - Port Macquarie; 2650 - Wagga Wagga; 5037 - Kurralta Park; 4560 - Nambour; 3021 - St Albans; 4029 - Herston; 3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT02178956
NCT02184195	POLO	Phase 3		NSW	9/07/2014	16/12/2014	Olaparib; Placebo	PARP_inhibitor; placebo	Olaparib; Placebo	PARP_inhibitor; placebo	2014-001589-85  D081FC00001	A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients With gBRCA Mutated Metastatic Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy	Germline BRCA1/2 Mutations and; Metastatic Adenocarcinoma of the Pancreas	2031 - Randwick; 2560 - Campbelltown; 2065 - St Leonards	https://clinicaltrials.gov/ct2/show/NCT02184195
NCT02189109	GBM	Phase 1		SA, NSW, VIC	14/07/2014	1/05/2014	Ifosfamide; Perflenapent Emulsion; Temozolomide	perflenapent_emulsion; alkylating_agent	Perflenapent Emulsion; Ifosfamide; Temozolomide	perflenapent_emulsion; alkylating_agent	NVX108-GBM1B	A Phase 1b Dose-finding, Pharmacokinetic and Pharmacodynamic Study of NVX-108 Combined With Radiation and Temozolomide in Patients With Newly-diagnosed Glioblastoma Multiforme	Glioblastoma Multiforme	5042 - Adelaide; 3004 - Melbourne; 3121 - Melbourne; 2010 - Darlinghurst	https://clinicaltrials.gov/ct2/show/NCT02189109
NCT02215447	NABNEC	Phase 2		VIC, NSW	13/08/2014	1/05/2015	Carboplatin; Carboplatin + Nab-paclitaxel + Paclitaxel; Nab-paclitaxel; Paclitaxel	platinum-based_antineoplastic_agent; taxane; platinum-based_antineoplastic_agent + taxane	Carboplatin + Nab-paclitaxel + Paclitaxel; Carboplatin + Nab-paclitaxel + Paclitaxel	platinum-based_antineoplastic_agent + taxane; platinum-based_antineoplastic_agent + taxane	ALCC 14.01	A Feasibility Study Of NAB-Paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas	Gastrointestinal Neuroendocrine Carcinomas	3220 - Geelong; 2065 - St Leonards; 3050 - Parkville	https://clinicaltrials.gov/ct2/show/NCT02215447
NCT02216487	Chime	Phase 2	NOT_RECRUITING	NSW, VIC	15/08/2014	1/06/2014	Cetuximab; Cetuximab + Irinotecan; Irinotecan	anti-EGFR_monoclonal_antibody + topoisomerase_inhibitor; anti-EGFR_monoclonal_antibody; topoisomerase_inhibitor	Cetuximab + Irinotecan; Cetuximab + Irinotecan	anti-EGFR_monoclonal_antibody + topoisomerase_inhibitor; anti-EGFR_monoclonal_antibody + topoisomerase_inhibitor	ACO-004	Phase II Single Arm Trial of FOLF(HA)Iri Plus Cetuximab in Irinotecan-naïve Second Line Patients With KRAS Wild Type Metastatic Colorectal Cancer	Metastatic Colorectal Cancer	3021 - Melbourne; 2500 - Wollongong; 1871 - Sydney	https://clinicaltrials.gov/ct2/show/NCT02216487
NCT02219724	2014-001474-34--GO29313	Phase 1		NSW, VIC, WA	19/08/2014	12/08/2014	Vonlerolizumab	anti-OX40_agonistic_antibody	Vonlerolizumab	anti-OX40_agonistic_antibody	2014-001474-34  GO29313	A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MOXR0916 Administered Intravenously as a Single Agent to Patients With Locally Advanced or Metastatic Solid Tumors	Neoplasms	3084 - Heidelberg; 3000 - Melbourne; 2050 - Camperdown; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT02219724
NCT02221505	CLOP628X2101	Phase 1		VIC	20/08/2014	1/12/2014	LOP628	anti-cKIT_antibody-drug_conjugate	LOP628	anti-cKIT_antibody-drug_conjugate	CLOP628X2101	A Phase I, Multicenter, Open-label Dose Escalation and Expansion Study of LOP628, Administered Intravenously in Adult Patients With cKit-positive Tumors and Acute Myeloid Leukemia	cKIT-positive Solid Tumors 0 0; AML	3050 - Parkville	https://clinicaltrials.gov/ct2/show/NCT02221505
NCT02221960	D6050C00001	Phase 1		VIC	21/08/2014	15/09/2014	Durvalumab; Durvalumab + Efizonerimod; Efizonerimod	anti-PD-L1_monoclonal_antibody; anti-OX40_agonistic_antibody + anti-PD-L1_monoclonal_antibody; anti-OX40_agonistic_antibody	Durvalumab + Efizonerimod; Efizonerimod; Durvalumab + Efizonerimod	anti-OX40_agonistic_antibody; anti-OX40_agonistic_antibody + anti-PD-L1_monoclonal_antibody; anti-OX40_agonistic_antibody + anti-PD-L1_monoclonal_antibody	D6050C00001	A Phase 1 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors	Recurrent or Metastatic Solid Tumors	3052 - Parkville	https://clinicaltrials.gov/ct2/show/NCT02221960
NCT02228369	BLOOM	Phase 1		VIC, NSW	29/08/2014	5/11/2014	Osimertinib; Zorifertinib	EGFR_inhibitor,third_generation	Osimertinib; Zorifertinib	EGFR_inhibitor,third_generation	D6030C00001	A Phase I, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumour Activity of AZD3759 or AZD9291 in Patients With EGFR Mutation Positive Advanced Stage Non Small Cell Lung Cancer (NSCLC)	EGFR Mutation Positive Advanced Non Small Cell Lung Cancer	2050 - Camperdown; 3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT02228369
NCT02231749	2014-001750-42--CA209-214	Phase 3		SA, NSW, VIC, QLD, WA	4/09/2014	16/10/2014	Ipilimumab; Ipilimumab + Nivolumab; Nivolumab; Sunitinib	anti-CTLA-4_monoclonal_antibody; KIT_inhibitor,first_generation; anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; VEGFR_inhibitor; PDGFR_inhibitor	Ipilimumab + Nivolumab; Sunitinib; Ipilimumab + Nivolumab	KIT_inhibitor,first_generation; PDGFR_inhibitor; VEGFR_inhibitor; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	2014-001750-42  CA209-214	A Phase 3, Randomized, Open-Label Study of Nivolumab Combined With Ipilimumab Versus Sunitinib Monotherapy in Subjects With Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma	Advanced Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma	2145 - Westmead; 3168 - Clayton; 5112 - Elizabeth Vale; 3128 - Box Hill; 4215 - Southport; 6009 - Nedlands; 2217 - Kogarah; 6150 - Murdoch; 4029 - Herston	https://clinicaltrials.gov/ct2/show/NCT02231749
NCT02233049	BIOMEDE	Phase 2			5/09/2014	1/10/2014	Dasatinib; Dasatinib + Erlotinib; Dasatinib + Erlotinib + Everolimus; Dasatinib + Everolimus; Erlotinib; Everolimus	KIT_inhibitor + mTORC1_inhibitor; BCR-ABL1_inhibitor,second_generation + mTORC1_inhibitor; BCR-ABL1_inhibitor,second_generation + EGFR_inhibitor,first_generation; EGFR_inhibitor,first_generation; SRC_inhibitor + mTORC1_inhibitor; EGFR_inhibitor,first_generation + SRC_inhibitor; EGFR_inhibitor,first_generation + PDGFRA_inhibitor; BCR-ABL1_inhibitor,second_generation + EGFR_inhibitor,first_generation + mTORC1_inhibitor; EGFR_inhibitor,first_generation + SRC_inhibitor + mTORC1_inhibitor; PDGFRA_inhibitor + mTORC1_inhibitor; PDGFRA_inhibitor; EGFR_inhibitor,first_generation + YES1_inhibitor; EGFR_inhibitor,first_generation + KIT_inhibitor; YES1_inhibitor + mTORC1_inhibitor; EGFR_inhibitor,first_generation + YES1_inhibitor + mTORC1_inhibitor; SRC_inhibitor; YES1_inhibitor; EGFR_inhibitor,first_generation + KIT_inhibitor + mTORC1_inhibitor; EGFR_inhibitor,first_generation + PDGFRA_inhibitor + mTORC1_inhibitor; BCR-ABL1_inhibitor,second_generation; mTORC1_inhibitor; KIT_inhibitor	Dasatinib; Dasatinib + Erlotinib; Dasatinib + Erlotinib + Everolimus; Dasatinib + Everolimus; Dasatinib + Erlotinib; Dasatinib + Erlotinib + Everolimus; Dasatinib + Everolimus	BCR-ABL1_inhibitor,second_generation; BCR-ABL1_inhibitor,second_generation + EGFR_inhibitor,first_generation; BCR-ABL1_inhibitor,second_generation + EGFR_inhibitor,first_generation + mTORC1_inhibitor; BCR-ABL1_inhibitor,second_generation + mTORC1_inhibitor; EGFR_inhibitor,first_generation + KIT_inhibitor; EGFR_inhibitor,first_generation + KIT_inhibitor + mTORC1_inhibitor; EGFR_inhibitor,first_generation + PDGFRA_inhibitor; EGFR_inhibitor,first_generation + PDGFRA_inhibitor + mTORC1_inhibitor; EGFR_inhibitor,first_generation + SRC_inhibitor; EGFR_inhibitor,first_generation + SRC_inhibitor + mTORC1_inhibitor; EGFR_inhibitor,first_generation + YES1_inhibitor; EGFR_inhibitor,first_generation + YES1_inhibitor + mTORC1_inhibitor; KIT_inhibitor; KIT_inhibitor + mTORC1_inhibitor; PDGFRA_inhibitor; PDGFRA_inhibitor + mTORC1_inhibitor; SRC_inhibitor; SRC_inhibitor + mTORC1_inhibitor; YES1_inhibitor; YES1_inhibitor + mTORC1_inhibitor; BCR-ABL1_inhibitor,second_generation + EGFR_inhibitor,first_generation; BCR-ABL1_inhibitor,second_generation + EGFR_inhibitor,first_generation + mTORC1_inhibitor; BCR-ABL1_inhibitor,second_generation + mTORC1_inhibitor; EGFR_inhibitor,first_generation + KIT_inhibitor; EGFR_inhibitor,first_generation + KIT_inhibitor + mTORC1_inhibitor; EGFR_inhibitor,first_generation + PDGFRA_inhibitor; EGFR_inhibitor,first_generation + PDGFRA_inhibitor + mTORC1_inhibitor; EGFR_inhibitor,first_generation + SRC_inhibitor; EGFR_inhibitor,first_generation + SRC_inhibitor + mTORC1_inhibitor; EGFR_inhibitor,first_generation + YES1_inhibitor; EGFR_inhibitor,first_generation + YES1_inhibitor + mTORC1_inhibitor; KIT_inhibitor + mTORC1_inhibitor; PDGFRA_inhibitor + mTORC1_inhibitor; SRC_inhibitor + mTORC1_inhibitor; YES1_inhibitor + mTORC1_inhibitor	2014/2126  2014-001929-32	Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication	Diffuse Intrinsic Pontine Glioma		https://clinicaltrials.gov/ct2/show/NCT02233049
NCT02246621	MONARCH-3	Phase 3		WA, SA, NZ, QLD, VIC, NSW	23/09/2014	6/11/2014	Abemaciclib; Abemaciclib + Anastrozole + Letrozole; Anastrozole; Anastrozole + Letrozole; Letrozole; Placebo	aromatase_inhibitor; placebo; CDK4/6_inhibitor + aromatase_inhibitor; CDK4/6_inhibitor	Abemaciclib + Anastrozole + Letrozole; Anastrozole + Letrozole; Abemaciclib + Anastrozole + Letrozole; Anastrozole + Letrozole; Placebo	CDK4/6_inhibitor + aromatase_inhibitor; aromatase_inhibitor; CDK4/6_inhibitor + aromatase_inhibitor; placebo	I3Y-MC-JPBM  15417	A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) Plus LY2835219, a CDK4/6 Inhibitor, or Placebo in Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Locoregionally Recurrent or Metastatic Breast Cancer With No Prior Systemic Therapy in This Disease Setting	Breast Cancer	Wellington; 6150 - Murdoch; 2500 - Wollongong; 5011 - Woodville; 3065 - Fitzroy; 2076 - Wahroonga; 3220 - Geelong; 4102 - Woolloongabba; 2050 - Camperdown; Auckland; 4101 - South Brisbane	https://clinicaltrials.gov/ct2/show/NCT02246621
NCT02247349	2014-002372-89--CA001-030	Phase 1/Phase 2		QLD, NSW, VIC	25/09/2014	14/11/2014	BMS-986012; BMS-986012 + Nivolumab; Nivolumab	anti-fucosyl-GM1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-fucosyl-GM1_monoclonal_antibody	BMS-986012; BMS-986012 + Nivolumab; BMS-986012 + Nivolumab	anti-PD-1_monoclonal_antibody + anti-fucosyl-GM1_monoclonal_antibody; anti-fucosyl-GM1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-fucosyl-GM1_monoclonal_antibody	2014-002372-89  CA001-030	A Phase 1/2 Multicenter Study of BMS-986012 in Subjects With Relapsed/Refractory Small Cell Lung Cancer	Small Cell Lung Cancer	3168 - Clayton; 4102 - Brisbane; 2065 - St. Leonards	https://clinicaltrials.gov/ct2/show/NCT02247349
NCT02254785	OZM-054	Phase 2		VIC	2/10/2014	1/10/2014	Abiraterone; Abiraterone + Enzalutamide; Cabazitaxel; Enzalutamide	antiandrogen,nonsteroidal,second_generation; taxane; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor	Abiraterone + Enzalutamide; Cabazitaxel; Abiraterone + Enzalutamide	CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation; taxane; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation	OZM-054	A Phase II, Randomized, Multi-center Study of Cabazitaxel Versus Abiraterone or Enzalutamide in Poor Prognosis-metastatic Castration-resistant Prostate Cancer	Metastatic Castration-Resistant Prostatic Cancer	3168 - Clayton; 3128 - Box Hill; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT02254785
NCT02257736	56021927PCR3001--CR105505	Phase 3		NSW, VIC, QLD, SA	6/10/2014	26/11/2014	Abiraterone; Abiraterone + Apalutamide + Prednisone; Apalutamide; Placebo; Prednisone	antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + glucocorticoid; glucocorticoid; placebo; CYP17A1_inhibitor	Abiraterone + Apalutamide + Prednisone; Abiraterone + Apalutamide + Prednisone; Placebo	CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + glucocorticoid; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + glucocorticoid; placebo	56021927PCR3001  CR105505	A Phase 3 Randomized, Placebo-controlled Double-blind Study of JNJ-56021927 in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)	Prostatic Neoplasms	- Liverpool; - Melbourne; - Wahroonga; - Adelaide; - Ashford; - Malvern; - Woolloongabba; - Camperdown; - West Heidelberg; - Herston; - Southport	https://clinicaltrials.gov/ct2/show/NCT02257736
NCT02259582	DENALI	Phase 2		WA, SA, QLD, VIC, NSW	8/10/2014	1/02/2015	Carboplatin; Carboplatin + Demcizumab + Pemetrexed; Carboplatin + Pemetrexed; Demcizumab; Pemetrexed; Placebo	anti-DLL4_monoclonal_antibody; platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; placebo; anti-DLL4_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite	Carboplatin + Demcizumab + Pemetrexed; Carboplatin + Pemetrexed; Carboplatin + Demcizumab + Pemetrexed; Carboplatin + Pemetrexed; Placebo	anti-DLL4_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; anti-DLL4_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; placebo	M18-007	A 2-Arm Phase 2 Double-Blind Randomized Study of Carboplatin, Pemetrexed Plus Placebo Versus Carboplatin, Pemetrexed Plus Truncated Demcizumab as First-Line Treatment in Subjects With Stage IV Non-Squamous Non-Small Cell Lung Cancer	Nonsquamous Nonsmall Cell Neoplasm of Lung	6008 - Subiaco; 4029 - Herston; 2444 - Port Macquarie; 4064 - Milton; 3165 - Bentleigh East; 2050 - Camperdown; 5011 - Woodville South; 2010 - Darlinghurst	https://clinicaltrials.gov/ct2/show/NCT02259582
NCT02262910	NCT02262910	Phase 1	NOT_RECRUITING	VIC, NSW	13/10/2014	1/01/2015	ES414	bispecific_T-cell_engager,PSMA-targeting	ES414	bispecific_T-cell_engager,PSMA-targeting	401	A Phase 1 Study of ES414 in Patients Wtih Metastatic Castration-Resistant Prostate Cancer	Prostate Cancer	3002 - East Melbourne; 3168 - Clayton; 2010 - Darlinghurst	https://clinicaltrials.gov/ct2/show/NCT02262910
NCT02263508	KEYNOTE-034	Phase 3		WA, SA, NSW, VIC, QLD	13/10/2014	8/12/2014	Pembrolizumab; Pembrolizumab + Talimogene Laherparepvec; Placebo; Talimogene Laherparepvec	anti-PD-1_monoclonal_antibody; placebo; oncolytic_HSV_virus; anti-PD-1_monoclonal_antibody + oncolytic_HSV_virus	Pembrolizumab; Pembrolizumab + Talimogene Laherparepvec; Pembrolizumab + Talimogene Laherparepvec; Placebo	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + oncolytic_HSV_virus; anti-PD-1_monoclonal_antibody + oncolytic_HSV_virus; placebo	2014-000185-22  20110265	A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265/KEYNOTE-034)	Melanoma	3084 - Heidelberg; 6150 - Murdoch; 2500 - Wollongong; 3000 - Melbourne; 4102 - Woolloongabba; 3220 - Geelong; 2060 - North Sydney; 5011 - Woodville South; 4215 - Southport; 2298 - Waratah; 3181 - Prahran	https://clinicaltrials.gov/ct2/show/NCT02263508
NCT02264574	PCYC-1130-CA	Phase 3		QLD, VIC, NSW, SA, NZ	15/10/2014	6/10/2014	Chlorambucil; Ibrutinib; Ibrutinib + Obinutuzumab; Obinutuzumab	BTK_inhibitor + anti-CD20_monoclonal_antibody; alkylating_agent; BTK_inhibitor; anti-CD20_monoclonal_antibody	Chlorambucil; Ibrutinib + Obinutuzumab; Ibrutinib + Obinutuzumab	BTK_inhibitor + anti-CD20_monoclonal_antibody; alkylating_agent; BTK_inhibitor + anti-CD20_monoclonal_antibody	PCYC-1130-CA	A Randomized, Multi-center, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Subjects With Treatment-naïve Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Chronic Lymphocytic Leukemia; Small-Cell Lymphoma	- Box Hill; Auckland; - Woolloongabba; - Fitzroy; - Ballarat; - Heidelberg; - Adelaide; Hamilton	https://clinicaltrials.gov/ct2/show/NCT02264574
NCT02264990	2014-002565-30--M14-359	Phase 3		NZ, SA, TAS, NSW	15/10/2014	30/09/2014	Carboplatin; Carboplatin + Paclitaxel + Veliparib; Cisplatin; Paclitaxel; Pemetrexed; Veliparib	PARP_inhibitor; platinum-based_antineoplastic_agent; PARP_inhibitor + platinum-based_antineoplastic_agent + taxane; taxane; antimetabolite	Carboplatin + Paclitaxel + Veliparib; Carboplatin + Paclitaxel + Veliparib; Cisplatin; Pemetrexed	PARP_inhibitor + platinum-based_antineoplastic_agent + taxane; PARP_inhibitor + platinum-based_antineoplastic_agent + taxane; antimetabolite	2014-002565-30  M14-359	A Randomized, Open-Label, Multicenter, Phase 3 Trial Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers	Non-squamous Non-small Cell Lung Cancer	Wellington; 2500 - Wollongong; 2217 - Kogarah; Christchurch; 7000 - Hobart; 5042 - Bedford Park	https://clinicaltrials.gov/ct2/show/NCT02264990
NCT02278120	MONALEESA-7	Phase 3		WA, NSW, VIC	29/10/2014	20/11/2014	Anastrozole; Anastrozole + Goserelin + Letrozole + Ribociclib + Tamoxifen; Goserelin; Letrozole; Placebo; Ribociclib; Tamoxifen	selective_estrogen_receptor_modulator; CDK4/6_inhibitor + GnRH_agonist + aromatase_inhibitor + selective_estrogen_receptor_modulator; GnRH_analogue; placebo; CDK4/6_inhibitor; aromatase_inhibitor; GnRH_agonist; CDK4/6_inhibitor + GnRH_analogue + aromatase_inhibitor + selective_estrogen_receptor_modulator	Anastrozole + Goserelin + Letrozole + Ribociclib + Tamoxifen; Anastrozole + Goserelin + Letrozole + Ribociclib + Tamoxifen; Placebo	CDK4/6_inhibitor + GnRH_agonist + aromatase_inhibitor + selective_estrogen_receptor_modulator; CDK4/6_inhibitor + GnRH_analogue + aromatase_inhibitor + selective_estrogen_receptor_modulator; CDK4/6_inhibitor + GnRH_agonist + aromatase_inhibitor + selective_estrogen_receptor_modulator; CDK4/6_inhibitor + GnRH_analogue + aromatase_inhibitor + selective_estrogen_receptor_modulator; placebo	2014-001931-36  CLEE011E2301	A Phase III Randomized, Double-blind, Placebo-controlled Study of LEE011 or Placebo in Combination With Tamoxifen and Goserelin or a Non-steroidal Aromatase Inhibitor (NSAI) and Goserelin for the Treatment of Premenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer	Advanced Metastatic Breast Cancer	3128 - Box Hill; 2298 - Waratah; 6009 - Nedlands; 3084 - Heidelberg; 6150 - Murdoch	https://clinicaltrials.gov/ct2/show/NCT02278120
NCT02278133	CWNT974X2102C	Phase 1/Phase 2		VIC	29/10/2014	1/12/2014	Cetuximab; Cetuximab + Encorafenib + WNT974; Encorafenib; WNT974	anti-EGFR_monoclonal_antibody; BRAF_V600_inhibitor + PORCN_inhibitor + anti-EGFR_monoclonal_antibody; BRAF_V600_inhibitor; PORCN_inhibitor	Cetuximab + Encorafenib + WNT974; Cetuximab + Encorafenib + WNT974	BRAF_V600_inhibitor + PORCN_inhibitor + anti-EGFR_monoclonal_antibody; BRAF_V600_inhibitor + PORCN_inhibitor + anti-EGFR_monoclonal_antibody	CWNT974X2102C	A Phase Ib/II Multi-center, Open Label, Dose Escalation Study of WNT974, LGX818 and Cetuximab in Patients With BRAFV600-mutant KRAS Wild-type Metastatic Colorectal Cancer Harboring Wnt Pathway Mutations	Metastatic Colorectal Cancer	3050 - Parkville	https://clinicaltrials.gov/ct2/show/NCT02278133
NCT02279862	2014-002987-34--CA184-437	Phase 2		VIC, NSW	31/10/2014	2/12/2014	Ipilimumab	anti-CTLA-4_monoclonal_antibody	Ipilimumab	anti-CTLA-4_monoclonal_antibody	2014-002987-34  CA184-437	A Phase 2, Randomized, Double-Blind Study of Ipilimumab Administered at 3 mg/kg vs 10 mg/kg in Adult Subjects With Metastatic Chemotherapy-Naïve Castration Resistant Prostate Cancer Who Are Asymptomatic or Minimally Symptomatic	Prostate Cancer	3050 - Parkville; 2065 - St Leonards; 2076 - Wahroonga	https://clinicaltrials.gov/ct2/show/NCT02279862
NCT02289690	2014-001764-35--M14-361	Phase 1/Phase 2		QLD, VIC, NSW	13/11/2014	13/10/2014	Carboplatin; Carboplatin + Etoposide; Carboplatin + Etoposide + Veliparib; Etoposide; Placebo; Veliparib	PARP_inhibitor; platinum-based_antineoplastic_agent; PARP_inhibitor + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; placebo; platinum-based_antineoplastic_agent + topoisomerase_inhibitor; topoisomerase_inhibitor	Carboplatin + Etoposide; Carboplatin + Etoposide + Veliparib; Carboplatin + Etoposide; Carboplatin + Etoposide + Veliparib; Placebo	PARP_inhibitor + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; platinum-based_antineoplastic_agent + topoisomerase_inhibitor; PARP_inhibitor + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; placebo; platinum-based_antineoplastic_agent + topoisomerase_inhibitor	2014-001764-35  M14-361	A Phase 1 Dose Escalation and Phase 2 Randomized Double-Blind Study of Veliparib in Combination With Carboplatin and Etoposide as a Therapy of Treatment-Naïve Extensive Stage Disease Small Cell Lung Cancer	Small Cell Lung Cancer	4814 - Douglas; 3199 - Frankston; 2500 - Wollongong; 3690 - Wodonga	https://clinicaltrials.gov/ct2/show/NCT02289690
NCT02289898	YOSEMITE	Phase 2		WA, NSW, VIC	13/11/2014	20/04/2015	Demcizumab; Demcizumab + Gemcitabine + Nab-paclitaxel; Gemcitabine; Gemcitabine + Nab-paclitaxel; Nab-paclitaxel; Placebo	anti-DLL4_monoclonal_antibody; placebo; antimetabolite; anti-DLL4_monoclonal_antibody + antimetabolite + taxane; gemcitabine; taxane; antimetabolite + taxane	Demcizumab + Gemcitabine + Nab-paclitaxel; Gemcitabine + Nab-paclitaxel; Demcizumab + Gemcitabine + Nab-paclitaxel; Gemcitabine + Nab-paclitaxel; Placebo	anti-DLL4_monoclonal_antibody + antimetabolite + taxane; antimetabolite + taxane; anti-DLL4_monoclonal_antibody + antimetabolite + taxane; antimetabolite + taxane; gemcitabine; placebo	M18-006	A 3-Arm Phase 2 Double-Blind Randomized Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma	Pancreatic Cancer	2031 - Randwick; 3165 - Bentleigh East; 3021 - St Albans; 6150 - Murdoch; 6008 - Subiaco	https://clinicaltrials.gov/ct2/show/NCT02289898
NCT02296125	FLAURA	Phase 3		VIC, NSW, QLD, WA	20/11/2014	3/12/2014	Erlotinib; Erlotinib + Gefitinib + Osimertinib; Gefitinib; Osimertinib; Placebo	EGFR_inhibitor,third_generation; EGFR_inhibitor,first_generation + EGFR_inhibitor,third_generation; EGFR_inhibitor,first_generation; placebo	Erlotinib + Gefitinib + Osimertinib; Erlotinib + Gefitinib + Osimertinib; Placebo	EGFR_inhibitor,first_generation + EGFR_inhibitor,third_generation; EGFR_inhibitor,first_generation + EGFR_inhibitor,third_generation; placebo	2014-002694-11  D5160C00007	A Phase III, Double-blind, Randomised Study to Assess the Safety and Efficacy of AZD9291 Versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First Line Treatment in Patients With Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non Small Cell Lung Cancer.	Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer	3168 - Clayton; 6009 - Nedlands; 4032 - Chermside; 2050 - Camperdown; 4102 - Woolloongabba; 3084 - Heidelberg; 2217 - Kogarah	https://clinicaltrials.gov/ct2/show/NCT02296125
NCT02299505	2014-004001-32--CLDK378A2112	Phase 1		Aucklan, NSW, NZ	24/11/2014	9/04/2015	Ceritinib	ALK/ROS1/IGF1R_inhibitor	Ceritinib	ALK/ROS1/IGF1R_inhibitor	2014-004001-32  CLDK378A2112	A Multi-center, Randomized Open Label Study to Assess the Systemic Exposure, Effiacy, and Safety of 450 mg Ceritinib Taken With a Low-fat Meal and 600 mg Ceritinib Taken With a Low-fat Meal as Compared With That of 750 mg Ceritinib Taken in the Fasted State in Adult Patients With ALK Rearranged (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)	Non-Small Cell Lung Cancer	- Grafton; - Auckland	https://clinicaltrials.gov/ct2/show/NCT02299505
NCT02302807	2014-003231-19--GO29294	Phase 3		QLD, VIC, SA	27/11/2014	13/01/2015	Atezolizumab; Docetaxel; Docetaxel + Paclitaxel + Vinflunine; Paclitaxel; Vinflunine	taxane + vinca_alkaloid; anti-PD-L1_monoclonal_antibody; vinca_alkaloid; taxane	Atezolizumab; Docetaxel + Paclitaxel + Vinflunine; Docetaxel + Paclitaxel + Vinflunine	anti-PD-L1_monoclonal_antibody; taxane + vinca_alkaloid; taxane + vinca_alkaloid	2014-003231-19  GO29294	A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer After Failure With Platinum-Containing Chemotherapy	Bladder Cancer	3168 - Clayton; 5000 - Adelaide; 3084 - Melbourne; 4029 - Herston	https://clinicaltrials.gov/ct2/show/NCT02302807
NCT02303366	BOSTON-II	Phase 1		VIC	27/11/2014	1/09/2015	Pembrolizumab	anti-PD-1_monoclonal_antibody	Pembrolizumab	anti-PD-1_monoclonal_antibody	Merck 3475-077	A Pilot Study of Stereotactic Ablation for Oligometastatic Breast Neoplasia in Combination With the Anti-PD-1 Antibody MK-3475.	Breast Neoplasms; Bone Neoplasms	8006 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT02303366
NCT02308020	I3Y-MC-JPBO--15450	Phase 2		WA, QLD, NSW	4/12/2014	20/04/2015	Abemaciclib; Abemaciclib + Gemcitabine + Pemetrexed; Abemaciclib + Gemcitabine + Pemetrexed + Trastuzumab; Abemaciclib + Trastuzumab; Gemcitabine; Pemetrexed; Trastuzumab	CDK4/6_inhibitor + anti-ERBB2_monoclonal_antibody; CDK4/6_inhibitor; antimetabolite; CDK4/6_inhibitor + antimetabolite; CDK4/6_inhibitor + anti-ERBB2_monoclonal_antibody + antimetabolite; anti-ERBB2_monoclonal_antibody; gemcitabine	Abemaciclib; Abemaciclib + Gemcitabine + Pemetrexed; Abemaciclib + Gemcitabine + Pemetrexed + Trastuzumab; Abemaciclib + Trastuzumab; Abemaciclib + Gemcitabine + Pemetrexed; Abemaciclib + Gemcitabine + Pemetrexed + Trastuzumab; Abemaciclib + Trastuzumab	CDK4/6_inhibitor; CDK4/6_inhibitor + anti-ERBB2_monoclonal_antibody; CDK4/6_inhibitor + anti-ERBB2_monoclonal_antibody + antimetabolite; CDK4/6_inhibitor + antimetabolite; CDK4/6_inhibitor + anti-ERBB2_monoclonal_antibody; CDK4/6_inhibitor + anti-ERBB2_monoclonal_antibody + antimetabolite; CDK4/6_inhibitor + antimetabolite; gemcitabine	I3Y-MC-JPBO  15450	A Phase 2 Study of Abemaciclib in Patients With Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer, Non-small Cell Lung Cancer, or Melanoma	Breast Cancer; Melanoma; Non-small Cell Lung Cancer; Brain Metastases	4102 - Woolloongabba; 6009 - Nedlands; 4215 - Southport; 2298 - Newcastle	https://clinicaltrials.gov/ct2/show/NCT02308020
NCT02313012	CC-90003-ST-001	Phase 1		VIC	9/12/2014	5/01/2015	CC-90003	ERK_inhibitor	CC-90003	ERK_inhibitor	CC-90003-ST-001	A Phase 1a Multicenter, Open-label Safety, Tolerability and Pharmacokinetic Study of CC-90003, a Selective Extracellular Signal-Regulated Kinase (ERK) Inhibitor, in Subjects With Locally-Advanced or Metastatic, Relapsed, or Refractory BRAF or RAS-Mutated Malignancies	Neoplasm Metastasis	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT02313012
NCT02318368	FOCAL	Phase 2		SA, QLD, VIC, NSW	17/12/2014	1/11/2014	Erlotinib; Erlotinib + Ficlatuzumab; Ficlatuzumab; Placebo	EGFR_inhibitor,first_generation + anti-HGF_monoclonal_antibody; EGFR_inhibitor,first_generation; placebo; anti-HGF_monoclonal_antibody	Erlotinib; Erlotinib + Ficlatuzumab; Erlotinib + Ficlatuzumab; Placebo	EGFR_inhibitor,first_generation; EGFR_inhibitor,first_generation + anti-HGF_monoclonal_antibody; EGFR_inhibitor,first_generation + anti-HGF_monoclonal_antibody; placebo	AV-299-14-206	A Phase 2, Multicenter, Randomized, Double-blind Study of Ficlatuzumab Plus Erlotinib Versus Placebo Plus Erlotinib in Subjects Who Have Previously Untreated Metastatic, EGFR-mutated Non-small Cell Lung Cancer (NSCLC) and BDX004 Positive Label	Non-small Cell Lung Cancer	5043 - Bedford Park; 2139 - Concord; 3199 - Frankston; 2450 - Coffs Harbour; 3355 - Wendouree; 4102 - Wolloongabba; 4814 - Douglas; 2050 - Camperdown; 4215 - Southport; 3128 - Box Hill	https://clinicaltrials.gov/ct2/show/NCT02318368
NCT02319044	D4193C00003	Phase 2		NSW, SA	18/12/2014	15/04/2015	Durvalumab; Durvalumab + Tremelimumab; Tremelimumab	anti-PD-L1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody	Durvalumab; Durvalumab + Tremelimumab; Tremelimumab; Durvalumab + Tremelimumab	anti-CTLA-4_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody	D4193C00003	A Phase II, Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy, Tremelimumab Monotherapy, and MEDI4736 in Combination With Tremelimumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)	Recurrent/Metastatic Squamous Cell Carcinoma of Head & Neck	5000 - Adelaide; 2485 - Tweed Heads; 2010 - Darlinghurst	https://clinicaltrials.gov/ct2/show/NCT02319044
NCT02322281	TIGER-3	Phase 3		SA, NSW	23/12/2014	1/02/2015	Docetaxel; Docetaxel + Gemcitabine + Paclitaxel + Pemetrexed; Gemcitabine; Paclitaxel; Pemetrexed; Rociletinib	EGFR_inhibitor,third_generation; antimetabolite; gemcitabine; taxane; antimetabolite + taxane	Docetaxel + Gemcitabine + Paclitaxel + Pemetrexed; Rociletinib; Docetaxel + Gemcitabine + Paclitaxel + Pemetrexed	EGFR_inhibitor,third_generation; antimetabolite + taxane; antimetabolite + taxane; gemcitabine	CO-1686-020 (TIGER-3)	TIGER-3: A Phase 3, Open-label, Multicenter, Randomized Study of Oral Rociletinib (CO-1686) Monotherapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR Non-small Cell Lung Cancer (NSCLC) After Failure of at Least 1 Previous EGFR-directed Tyrosine Kinase Inhibitor (TKI) and Platinum-doublet Chemotherapy	Non-small Cell Lung Cancer	2065 - Saint Leonards; 5042 - Bedford Park; 2145 - Westmead	https://clinicaltrials.gov/ct2/show/NCT02322281
NCT02322814	2014-002230-32--WO29479	Phase 2		WA, NSW, VIC, QLD	23/12/2014	25/11/2014	Atezolizumab; Atezolizumab + Cobimetinib + Nab-paclitaxel; Atezolizumab + Cobimetinib + Paclitaxel; Cobimetinib; Cobimetinib + Paclitaxel; Nab-paclitaxel; Paclitaxel; Placebo	placebo; anti-PD-L1_monoclonal_antibody; MEK_inhibitor + anti-PD-L1_monoclonal_antibody + taxane; MEK_inhibitor; taxane; MEK_inhibitor + taxane	Atezolizumab + Cobimetinib + Nab-paclitaxel; Atezolizumab + Cobimetinib + Paclitaxel; Cobimetinib + Paclitaxel; Atezolizumab + Cobimetinib + Nab-paclitaxel; Atezolizumab + Cobimetinib + Paclitaxel; Cobimetinib + Paclitaxel; Placebo	MEK_inhibitor + anti-PD-L1_monoclonal_antibody + taxane; MEK_inhibitor + taxane; MEK_inhibitor + anti-PD-L1_monoclonal_antibody + taxane; MEK_inhibitor + taxane; placebo	2014-002230-32  WO29479	A Multistage, Phase II Study Evaluating the Safety and Efficacy of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as First-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer	Breast Cancer	2298 - Waratah; 4101 - South Brisbane; 3000 - Melbourne; 6150 - Murdoch	https://clinicaltrials.gov/ct2/show/NCT02322814
NCT02323126	EGF816	Phase 2	NOT_RECRUITING	NSW, QLD	23/12/2014	9/02/2015	Capmatinib; Capmatinib + Nivolumab; Nazartinib; Nazartinib + Nivolumab; Nivolumab	EGFR_inhibitor,third_generation; MET_inhibitor,type_1; anti-PD-1_monoclonal_antibody; MET_inhibitor,type_1 + anti-PD-1_monoclonal_antibody; EGFR_inhibitor,third_generation + anti-PD-1_monoclonal_antibody	Capmatinib + Nivolumab; Nazartinib + Nivolumab; Capmatinib + Nivolumab; Nazartinib + Nivolumab	EGFR_inhibitor,third_generation + anti-PD-1_monoclonal_antibody; MET_inhibitor,type_1 + anti-PD-1_monoclonal_antibody; EGFR_inhibitor,third_generation + anti-PD-1_monoclonal_antibody; MET_inhibitor,type_1 + anti-PD-1_monoclonal_antibody	2014-003731-20  CEGF816X2201C	A Phase II, Multicenter, Open-label Study of EGF816 in Combination With Nivolumab in Adult Patients With EGFR Mutated Non-small Cell Lung Cancer and of INC280 in Combination With Nivolumab in Adult Patients With cMet Positive Non-small Cell Lung Cancer	Non Small Cell Lung Cancer	4032 - Chermside; 2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT02323126
NCT02329847	PCI-32765LYM1002--CR106681	Phase 1/Phase 2		NSW, QLD, SA	1/01/2015	11/03/2015	Ibrutinib; Ibrutinib + Nivolumab; Nivolumab	BTK_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; BTK_inhibitor	Ibrutinib + Nivolumab; Ibrutinib + Nivolumab	BTK_inhibitor + anti-PD-1_monoclonal_antibody; BTK_inhibitor + anti-PD-1_monoclonal_antibody	PCI-32765LYM1002  CR106681	A Phase 1/2a Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Subjects With Hematologic Malignancies	Hematologic Neoplasms	- Darlinghurst; - Woolloongabba; - Bedford Park	https://clinicaltrials.gov/ct2/show/NCT02329847
NCT02336165	LUD2013-006	Phase 2		VIC	12/01/2015	26/02/2015	Bevacizumab; Bevacizumab + Durvalumab; Durvalumab; Durvalumab + Radiotherapy; Radiotherapy	anti-PD-L1_monoclonal_antibody; radiotherapy; anti-PD-L1_monoclonal_antibody + radiotherapy; anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody	Bevacizumab + Durvalumab; Durvalumab + Radiotherapy; Bevacizumab + Durvalumab; Durvalumab + Radiotherapy	anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + radiotherapy; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + radiotherapy	LUD2013-006	Phase 2 Study to Evaluate the Clinical Efficacy and Safety of MEDI4736 in Patients With Glioblastoma (GBM)	Glioblastoma	- Melbourne	https://clinicaltrials.gov/ct2/show/NCT02336165
NCT02336451	Ascend-7	Phase 2		NZ	13/01/2015	1/04/2015	Ceritinib; Crizotinib	MET_inhibitor,type_1; ALK_inhibitor,first_generation; ROS1_inhibitor; ALK/ROS1/IGF1R_inhibitor	Crizotinib; Ceritinib	ALK_inhibitor,first_generation; MET_inhibitor,type_1; ROS1_inhibitor; ALK/ROS1/IGF1R_inhibitor	2014-000578-20  CLDK378A2205	A Phase II, Multi-center, Open-label, Five-arm Study to Evaluate the Efficacy and Safety of Oral Ceritinib Treatment for Patients With ALK-positive Non-small Cell Lung Cancer (NSCLC) Metastatic to the Brain and/or to Leptomeninges	ALK-positive Non-small Cell Lung Cancer	- Auckland	https://clinicaltrials.gov/ct2/show/NCT02336451
NCT02338245	ASLAN001-003	Phase 2		WA, NZ	14/01/2015	29/12/2014	Capecitabine; Capecitabine + Lapatinib; Capecitabine + Varlitinib; Lapatinib; Trastuzumab; Varlitinib	ERBB2_inhibitor,first_generation; ERBB2_inhibitor,first_generation + fluoropyrimidine; EGFR_inhibitor,type_II + fluoropyrimidine; anti-ERBB2_monoclonal_antibody; EGFR/ERBB2_inhibitor; EGFR_inhibitor,type_II; EGFR/ERBB2_inhibitor + fluoropyrimidine; fluoropyrimidine	Capecitabine + Lapatinib; Capecitabine + Varlitinib; Capecitabine + Lapatinib; Capecitabine + Varlitinib; Trastuzumab	EGFR/ERBB2_inhibitor + fluoropyrimidine; EGFR_inhibitor,type_II + fluoropyrimidine; ERBB2_inhibitor,first_generation + fluoropyrimidine; EGFR/ERBB2_inhibitor + fluoropyrimidine; EGFR_inhibitor,type_II + fluoropyrimidine; ERBB2_inhibitor,first_generation + fluoropyrimidine; anti-ERBB2_monoclonal_antibody	ASLAN001-003	Randomized Phase 2A/2B Study to Compare the Efficacy and Safety of ASLAN001 + Capecitabine to Lapatinib + Capecitabine in Patients With HER 2-Positive MBC That Has Failed on Prior Trastuzumab Therapy	Metastatic Breast Cancer	6000 - Western Australia; Tauranga; Christchurch	https://clinicaltrials.gov/ct2/show/NCT02338245
NCT02340221	SANDPIPER	Phase 3		WA, NSW, VIC, QLD	16/01/2015	9/04/2015	Fulvestrant; Fulvestrant + Taselisib; Placebo; Taselisib	PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader; placebo; PI3K_alpha_inhibitor	Fulvestrant; Fulvestrant + Taselisib; Fulvestrant + Taselisib; Placebo	PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader; PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; placebo	2014-003185-25  GO29058	A Phase III, Double-Blind, Placebo-Controlled, Randomized Study of Taselisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy	Breast Cancer	- St Albans; 6150 - Murdoch; 2109 - Macquarie Park; 3084 - Heidelberg; 2170 - Liverpool; 2298 - Waratah; 4101 - Brisbane	https://clinicaltrials.gov/ct2/show/NCT02340221
NCT02341456	D6011C00003	Phase 1		VIC, NSW	19/01/2015	16/01/2015	Adavosertib; Adavosertib + Carboplatin + Paclitaxel; Carboplatin; Carboplatin + Paclitaxel; Paclitaxel	WEE1_inhibitor; WEE1_inhibitor + platinum-based_antineoplastic_agent + taxane; platinum-based_antineoplastic_agent; taxane; platinum-based_antineoplastic_agent + taxane	Adavosertib + Carboplatin + Paclitaxel; Carboplatin + Paclitaxel; Paclitaxel; Adavosertib + Carboplatin + Paclitaxel; Carboplatin + Paclitaxel	WEE1_inhibitor + platinum-based_antineoplastic_agent + taxane; platinum-based_antineoplastic_agent + taxane; taxane; WEE1_inhibitor + platinum-based_antineoplastic_agent + taxane; platinum-based_antineoplastic_agent + taxane	D6011C00003	A Phase Ib, Dose Finding Study Evaluating AZD1775 in Monotherapy, in Combination With Carboplatin and Paclitaxel, and in Combination With Only Carboplatin in Adult Asian Patients With Advanced Solid Tumours	Advanced Solid Tumours	2170 - Liverpool; 3004 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT02341456
NCT02341625	2014-002485-70--CA008-002	Phase 1/Phase 2		WA, NSW, VIC, SA	19/01/2015	19/06/2015	BMS-986148; BMS-986148 + Nivolumab; Nivolumab	anti-PD-1_monoclonal_antibody + anti-mesothelin_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody; anti-mesothelin_antibody-drug_conjugate	BMS-986148; BMS-986148 + Nivolumab; BMS-986148 + Nivolumab	anti-PD-1_monoclonal_antibody + anti-mesothelin_antibody-drug_conjugate; anti-mesothelin_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody + anti-mesothelin_antibody-drug_conjugate	2014-002485-70  CA008-002	A Phase I/IIa Study of BMS-986148, a Mesothelin Directed Antibody Drug Conjugate, in Subjects With Select Advanced Solid Tumors	Advanced Cancer	6009 - Nedlands; 3168 - Clayton; 5000 - Adelaide; 2170 - Liverpool	https://clinicaltrials.gov/ct2/show/NCT02341625
NCT02343120	2016-003364-39--BGB-3111-AU-003	Phase 1/Phase 2		NZ, TAS, VIC, NSW, QLD, WA	21/01/2015	26/11/2014	Zanubrutinib	BTK_inhibitor	Zanubrutinib	BTK_inhibitor	2016-003364-39  BGB-3111-AU-003	A Phase I/II, Open-Label, Multiple-Dose, Dose Escalation and Expansion Study to Investigate the Safety and Pharmacokinetics of the BTK Inhibitor BGB-3111 in Subjects With B-Cell Lymphoid Malignancies	B-cell Malignancies	- Heidelberg; - Nedlands; - Hobart; - Sydney; - Melbourne; - Parkville; - Clayton; Auckland; - Brisbane; - Concord; - Westmead; 3050 - Parkville	https://clinicaltrials.gov/ct2/show/NCT02343120
NCT02343406	INTELLANCE-2	Phase 2		SA, TAS, QLD, VIC, NSW	22/01/2015	17/02/2015	Depatuxizumab Mafodotin; Depatuxizumab Mafodotin + Temozolomide; Lomustine; Lomustine + Temozolomide; Temozolomide	alkylating_agent + anti-EGFR/PBD_antibody-drug_conjugate; alkylating_agent; anti-EGFR/PBD_antibody-drug_conjugate	Depatuxizumab Mafodotin; Depatuxizumab Mafodotin + Temozolomide; Lomustine + Temozolomide; Temozolomide; Depatuxizumab Mafodotin + Temozolomide; Lomustine + Temozolomide	alkylating_agent; alkylating_agent + anti-EGFR/PBD_antibody-drug_conjugate; anti-EGFR/PBD_antibody-drug_conjugate; alkylating_agent + anti-EGFR/PBD_antibody-drug_conjugate	2014-004438-24  M14-483	INTELLANCE-2: ABT-414 Alone or ABT-414 Plus Temozolomide Versus Lomustine or Temozolomide for Recurrent Glioblastoma: A Randomized Phase 2 Study of the EORTC Brain Tumor Group	Glioblastoma	2444 - Port Macquarie; 5000 - Adelaide; 2500 - Wollongong; 4029 - Herston; 3220 - Geelong; 2298 - Waratah; 7000 - Hobart; 3052 - Melbourne; 2065 - Saint Leonards; 2031 - Randwick	https://clinicaltrials.gov/ct2/show/NCT02343406
NCT02349633	B7971001	Phase 1/Phase 2		NSW, QLD	29/01/2015	14/05/2015	Avelumab; Avelumab + Mavelertinib; Mavelertinib; Mavelertinib + Palbociclib; Palbociclib	EGFR_inhibitor,third_generation; anti-PD-L1_monoclonal_antibody; EGFR_inhibitor,third_generation + anti-PD-L1_monoclonal_antibody; CDK4/6_inhibitor + EGFR_inhibitor,third_generation; CDK4/6_inhibitor	Avelumab + Mavelertinib; Mavelertinib + Palbociclib; Avelumab + Mavelertinib; Mavelertinib + Palbociclib	CDK4/6_inhibitor + EGFR_inhibitor,third_generation; EGFR_inhibitor,third_generation + anti-PD-L1_monoclonal_antibody; CDK4/6_inhibitor + EGFR_inhibitor,third_generation; EGFR_inhibitor,third_generation + anti-PD-L1_monoclonal_antibody	B7971001	PHASE 1/2 OPEN-LABEL STUDY OF PF-06747775 (EPIDERMAL GROWTH FACTOR RECEPTOR T790M INHIBITOR) IN PATIENTS WITH ADVANCED EPIDERMAL GROWTH FACTOR RECEPTOR MUTANT (DEL 19 OR L858R ± T790M) NON-SMALL CELL LUNG CANCER	Non-Small Cell Lung Cancer	2050 - Camperdown; 4032 - Chermside	https://clinicaltrials.gov/ct2/show/NCT02349633
NCT02352948	ARCTIC	Phase 3		WA, NSW	2/02/2015	13/01/2015	Durvalumab; Durvalumab + Tremelimumab; Erlotinib; Erlotinib + Gemcitabine + Vinorelbine; Gemcitabine; Tremelimumab; Vinorelbine	anti-CTLA-4_monoclonal_antibody; EGFR_inhibitor,first_generation; antimetabolite; EGFR_inhibitor,first_generation + antimetabolite + vinca_alkaloid; anti-PD-L1_monoclonal_antibody; vinca_alkaloid; anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; gemcitabine	Durvalumab; Durvalumab + Tremelimumab; Erlotinib + Gemcitabine + Vinorelbine; Tremelimumab; Durvalumab + Tremelimumab; Erlotinib + Gemcitabine + Vinorelbine	EGFR_inhibitor,first_generation + antimetabolite + vinca_alkaloid; anti-CTLA-4_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; EGFR_inhibitor,first_generation + antimetabolite + vinca_alkaloid; anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; gemcitabine	D4191C00004	A Phase III, Open Label, Randomised, Multi-centre, International Study of MEDI4736, Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV) Who Have Received at Least Two Prior Systemic Treatment Regimens Including One Platinum Based Chemotherapy Regimen and Do Not Have Known EGFR TK Activating Mutations or ALK Rearrangements (ARCTIC).	Non - Small Cell Lung Cancer NSCLC	2444 - Port Macquarie; 6150 - Murdoch	https://clinicaltrials.gov/ct2/show/NCT02352948
NCT02357147	ARTEMIS	Phase 2		WA, QLD, VIC, NSW	6/02/2015	3/11/2015	Amatuximab; Amatuximab + Cisplatin + Pemetrexed; Cisplatin; Cisplatin + Pemetrexed; Pemetrexed; Placebo	platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; placebo; antimetabolite; anti-MSLN_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-MSLN_monoclonal_antibody	Amatuximab + Cisplatin + Pemetrexed; Cisplatin + Pemetrexed; Amatuximab + Cisplatin + Pemetrexed; Cisplatin + Pemetrexed; Placebo	anti-MSLN_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; anti-MSLN_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; placebo	2014-004489-85  MORAb-009-201	A Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma	Mesothelioma, Malignant	- Auchenflower; 3121 - Richmond; - Perth; - Camperdown	https://clinicaltrials.gov/ct2/show/NCT02357147
NCT02358356	CONTROL-NETS	Phase 2		WA, QLD, VIC, NSW	9/02/2015	1/11/2015	Capecitabine; Capecitabine + Octreotate + Temozolomide; Capecitabine + Temozolomide; Octreotate; Temozolomide	alkylating_agent + fluoropyrimidine; alkylating_agent; alkylating_agent + fluoropyrimidine + radionuclide_therapy; radionuclide_therapy; fluoropyrimidine	Capecitabine + Octreotate + Temozolomide; Capecitabine + Temozolomide; Octreotate; Capecitabine + Octreotate + Temozolomide; Capecitabine + Temozolomide	alkylating_agent + fluoropyrimidine; alkylating_agent + fluoropyrimidine + radionuclide_therapy; radionuclide_therapy; alkylating_agent + fluoropyrimidine; alkylating_agent + fluoropyrimidine + radionuclide_therapy	CTC0120 / AG0114NET	Capecitabine ON Temozolomide Radionuclide Therapy Octreotate Lutetium-177 NeuroEndocrine Tumours Study	Midgut Neuroendocrine Tumours; Pancreatic Neuroendocrine Tumours	4029 - Herston; 6150 - Murdoch; 8006 - East Melbourne; 2065 - St Leonards	https://clinicaltrials.gov/ct2/show/NCT02358356
NCT02361723	2017-003646-25--BGB-290-AU-002	Phase 1		SA, VIC, NSW, WA	12/02/2015	3/07/2014	Pamiparib	PARP_inhibitor	Pamiparib	PARP_inhibitor	2017-003646-25  BGB-290-AU-002	A Phase 1A/1B, Open Label, Multiple Dose, Dose Escalation, and Expansion Study to Investigate the Safety, Pharmacokinetics, Food Effect, and Antitumor Activities of BGB-290 in Subjects With Advanced Solid Tumors	For Participants With Advanced Solid Tumors Failed With Previous Lines of Treatment	NSW 2559 - Hamlyn Terrace; VIC 3004 - Melbourne; SA 5042 - Bedford Park; VIC 3084 - Heidelberg; VIC 3000 - Melbourne; WA 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT02361723
NCT02364999	2014-003878-16--B7391003	Phase 3		NSW, VIC, QLD	18/02/2015	1/04/2015	Bevacizumab; Bevacizumab + Carboplatin + Paclitaxel; Carboplatin; Paclitaxel	platinum-based_antineoplastic_agent; anti-VEGF_monoclonal_antibody; taxane; anti-VEGF_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane	Bevacizumab + Carboplatin + Paclitaxel; Bevacizumab + Carboplatin + Paclitaxel	anti-VEGF_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; anti-VEGF_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane	2014-003878-16  B7391003	A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY OF PF- 06439535 PLUS PACLITAXEL-CARBOPLATIN AND BEVACIZUMAB PLUS PACLITAXEL -CARBOPLATIN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER.	Non-Small Cell Lung Cancer	3084 - Heidelberg; 3021 - St Albans; 2485 - Tweed Heads; 2480 - Lismore; 4224 - Tugun	https://clinicaltrials.gov/ct2/show/NCT02364999
NCT02365441	ALT-GIST	Phase 2	NOT_RECRUITING	VIC, NSW, QLD, SA, TAS, ACT, WA	19/02/2015	1/02/2015	Imatinib; Imatinib + Regorafenib; Regorafenib	PDGFRA_inhibitor; BCR-ABL1_inhibitor,first_generation + KIT/PDGFR/RET/VEGFR/FGFR_inhibitor; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + PDGFRA_inhibitor; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + KIT_inhibitor; BCR-ABL1_inhibitor,first_generation; KIT_inhibitor; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor	Imatinib; Imatinib + Regorafenib; Imatinib + Regorafenib	BCR-ABL1_inhibitor,first_generation; BCR-ABL1_inhibitor,first_generation + KIT/PDGFR/RET/VEGFR/FGFR_inhibitor; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + KIT_inhibitor; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + PDGFRA_inhibitor; KIT_inhibitor; PDGFRA_inhibitor; BCR-ABL1_inhibitor,first_generation + KIT/PDGFR/RET/VEGFR/FGFR_inhibitor; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + KIT_inhibitor; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + PDGFRA_inhibitor	ACTRN12614000950662  AG1013GST	A Randomised Phase II Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST)	Gastrointestinal Stromal Tumour	2031 - Sydney; 2606 - Canberra; 6009 - Perth; 5037 - Adelaide; 2310 - Newcastle; 5042 - Adelaide; 3690 - Wodonga; 3199 - Frankston; 7001 - Hobart; 4120 - Brisbane	https://clinicaltrials.gov/ct2/show/NCT02365441
NCT02366143	IMpower150	Phase 3		QLD, VIC, NSW, SA, TAS, WA	19/02/2015	31/03/2015	Atezolizumab; Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel; Atezolizumab + Carboplatin + Paclitaxel; Bevacizumab; Bevacizumab + Carboplatin + Paclitaxel; Carboplatin; Paclitaxel	anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; platinum-based_antineoplastic_agent; anti-VEGF_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; anti-PD-L1_monoclonal_antibody; anti-VEGF_monoclonal_antibody; taxane	Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel; Atezolizumab + Carboplatin + Paclitaxel; Bevacizumab + Carboplatin + Paclitaxel; Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel; Atezolizumab + Carboplatin + Paclitaxel; Bevacizumab + Carboplatin + Paclitaxel	anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; anti-VEGF_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; anti-VEGF_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane	2014-003207-30  GO29436	A Phase III, Open-Label, Randomized Study of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Carboplatin+Paclitaxel With or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer	Carcinoma, Non-Small-Cell Lung	2050 - Camperdown; 6009 - Nedlands; 4032 - Chermside; 7000 - Hobart; 3144 - Malvern; 4810 - Townsville; 7250 - Launceston; 3084 - Heidelberg; 2747 - Sydney; 3181 - Prahan; 5037 - Kurralta Park; 3021 - St Albans; 5000 - Adelaide; 3199 - Frankston; 2139 - Concord; 4102 - Woolloongabba	https://clinicaltrials.gov/ct2/show/NCT02366143
NCT02367794	2014-003208-59--GO29437	Phase 3		WA, VIC, NSW, QLD, SA	20/02/2015	11/06/2015	Atezolizumab; Atezolizumab + Carboplatin + Nab-paclitaxel; Atezolizumab + Carboplatin + Paclitaxel; Carboplatin; Carboplatin + Nab-paclitaxel; Nab-paclitaxel; Paclitaxel	anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent + taxane; anti-PD-L1_monoclonal_antibody; taxane	Atezolizumab + Carboplatin + Nab-paclitaxel; Atezolizumab + Carboplatin + Paclitaxel; Carboplatin + Nab-paclitaxel; Atezolizumab + Carboplatin + Nab-paclitaxel; Atezolizumab + Carboplatin + Paclitaxel; Carboplatin + Nab-paclitaxel	anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; platinum-based_antineoplastic_agent + taxane; anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; platinum-based_antineoplastic_agent + taxane	2014-003208-59  GO29437	A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Carboplatin+Paclitaxel or Atezolizumab in Combination With Carboplatin+Nab-Paclitaxel Versus Carboplatin+Nab-Paclitaxel in Chemotherapy-Naive Patients With Stage IV Squamous Non-Small Cell Lung Cancer	Squamous Non-Small Cell Lung Cancer	4810 - Townsville; 3144 - Malvern; 2298 - Waratah; 4032 - Chermside; 6009 - Nedlands; 2050 - Camperdown; 4102 - Woolloongabba; 5000 - Adelaide; 3021 - St Albans; 3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT02367794
NCT02369198	HREC-13-CRGH-199	Phase 1		NSW	23/02/2015	1/09/2014	TargomiRs	miR-16_miRNA_mimic	TargomiRs	miR-16_miRNA_mimic	HREC/13/CRGH/199	MesomiR 1: A Phase I Study of Intravenously Administered Epidermal Growth Factor Receptor -Targeted, EnGeneIC Delivery Vehicle (EDV)-Packaged, miR-16 Mimic (TargomiRs) for Patients With Malignant Pleural Mesothelioma (MPM) and Advanced Non-Small Cell Lung Cancer (NSCLC) Failing on Std Therapy	Non-Small Cell Lung Cancer; Malignant Pleural Mesothelioma	2050 - Sydney; 2039 - Sydney; 2065 - Sydney	https://clinicaltrials.gov/ct2/show/NCT02369198
NCT02369874	EAGLE	Phase 3		SA, QLD, VIC, NSW	24/02/2015	9/09/2015	Durvalumab; Durvalumab + Tremelimumab; Tremelimumab	anti-PD-L1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody	Durvalumab; Durvalumab + Tremelimumab; Durvalumab + Tremelimumab	anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody	D4193C00002	A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy and MEDI4736 in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)	Recurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck SCCHN	3084 - Heidelberg; 5000 - Adelaide; 3004 - Melbourne; 2065 - St Leonards; 4102 - Woolloongabba	https://clinicaltrials.gov/ct2/show/NCT02369874
NCT02371369	ENLIVEN	Phase 3		QLD, NSW, VIC	25/02/2015	11/05/2015	Pexidartinib; Placebo	FLT3_inhibitor; CSF1R_inhibitor; placebo; KIT_inhibitor	Pexidartinib; Placebo	CSF1R_inhibitor; FLT3_inhibitor; KIT_inhibitor; placebo	2014-000148-14  PLX108-10	A Double-blind, Randomized, Placebo-controlled Phase 3 Study of Orally Administered PLX3397 in Subjects With Pigmented Villonodular Synovitis or Giant Cell Tumor of the Tendon Sheath	Tenosynovial Giant Cell Tumor; Pigmented Villonodular Synovitis; Giant Cell Tumors of the Tendon Sheath	3000 - East Melbourne; 4102 - Woolloongabba; 2050 - Sydney	https://clinicaltrials.gov/ct2/show/NCT02371369
NCT02374242	ABC	Phase 2		QLD, VIC, NSW, SA	27/02/2015	4/11/2014	Ipilimumab; Ipilimumab + Nivolumab; Nivolumab	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Ipilimumab + Nivolumab; Nivolumab; Ipilimumab + Nivolumab	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	ACTRN12614001315606  CA209-170	A Phase II Study of Nivolumab and Nivolumab Combined With Ipilimumab in Patients With Melanoma Brain Metastases	Brain Metastases; Melanoma	5000 - Adelaide; 2060 - North Sydney; 4102 - Woolloongabba; 3002 - East Melbourne	https://clinicaltrials.gov/ct2/show/NCT02374242
NCT02375204	U10CA180821--A031102	Phase 3		NSW, VIC, QLD	2/03/2015	1/03/2015	Carboplatin; Cisplatin; Dexamethasone; Dexamethasone + Paclitaxel; Etoposide; Filgrastim; Filgrastim + Pegfilgrastim; Ifosfamide; Ifosfamide + Mesna; Mesna; Paclitaxel; Pegfilgrastim	glucocorticoid; alkylating_agent; platinum-based_antineoplastic_agent; granulocyte_colony_stimulating_factor; alkylating_agent + sodium_mercaptoethanesulfonate; sodium_mercaptoethanesulfonate; glucocorticoid + taxane; taxane; topoisomerase_inhibitor	Carboplatin; Cisplatin; Dexamethasone + Paclitaxel; Etoposide; Filgrastim; Filgrastim + Pegfilgrastim; Ifosfamide; Ifosfamide + Mesna; Paclitaxel; Pegfilgrastim; Dexamethasone + Paclitaxel; Filgrastim + Pegfilgrastim; Ifosfamide + Mesna	alkylating_agent; alkylating_agent + sodium_mercaptoethanesulfonate; glucocorticoid + taxane; granulocyte_colony_stimulating_factor; platinum-based_antineoplastic_agent; taxane; topoisomerase_inhibitor; alkylating_agent + sodium_mercaptoethanesulfonate; glucocorticoid + taxane	U10CA180821  A031102	A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) With High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors	Extragonadal Seminoma; Yolk Sac Tumor; Germinoma; Non-seminomatous Germ Cell Tumor; Choriocarcinoma; Seminoma; Teratoma; Mixed Germ Cell Tumor; Childhood Teratoma; Germ Cell Tumor; Malignant Germ Cell Neoplasm	4102 - Woolloongabba; 3000 - Melbourne; 2050 - Camperdown; 3128 - Box Hill	https://clinicaltrials.gov/ct2/show/NCT02375204
NCT02381886	CIDH305X2101	Phase 1		VIC	6/03/2015	6/01/2015	IDH305	IDH1_R132_inhibitor	IDH305	IDH1_R132_inhibitor	CIDH305X2101	A Phase I Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations	Advanced Malignancies That Harbor IDHR132 Mutations	3004 - Melbourne; 3050 - Parkville	https://clinicaltrials.gov/ct2/show/NCT02381886
NCT02383212	2015-002132-41--R2810-ONC-1423	Phase 1		VIC	9/03/2015	2/02/2015	Carboplatin; Cemiplimab; Cemiplimab + Cyclophosphamide + Radiotherapy; Cemiplimab + Radiotherapy; Cyclophosphamide; Docetaxel; Paclitaxel; Pemetrexed; Radiotherapy	radiotherapy; anti-PD-1_monoclonal_antibody; alkylating_agent; platinum-based_antineoplastic_agent; alkylating_agent + anti-PD-1_monoclonal_antibody + radiotherapy; anti-PD-1_monoclonal_antibody + radiotherapy; antimetabolite; taxane	Cemiplimab; Cemiplimab + Cyclophosphamide + Radiotherapy; Cemiplimab + Radiotherapy; Carboplatin; Cemiplimab + Cyclophosphamide + Radiotherapy; Cemiplimab + Radiotherapy; Docetaxel; Paclitaxel; Pemetrexed	alkylating_agent + anti-PD-1_monoclonal_antibody + radiotherapy; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + radiotherapy; alkylating_agent + anti-PD-1_monoclonal_antibody + radiotherapy; anti-PD-1_monoclonal_antibody + radiotherapy; antimetabolite; platinum-based_antineoplastic_agent; taxane	2015-002132-41  R2810-ONC-1423	A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies	Advanced Malignancies; Advanced Cancer	- Melbourne	https://clinicaltrials.gov/ct2/show/NCT02383212
NCT02387996	CA209-275	Phase 2		SA, NSW	13/03/2015	4/03/2015	Nivolumab	anti-PD-1_monoclonal_antibody	Nivolumab	anti-PD-1_monoclonal_antibody	CA209-275	A Phase II Single Arm Clinical Trial of Nivolumab (BMS-936558) in Subjects With Metastatic or Unresectable Urothelial Cancer Who Have Progressed or Recurred Following Treatment With a Platinum Agent	Various Advanced Cancer	5112 - Elizabeth Vale; 2298 - Waratah	https://clinicaltrials.gov/ct2/show/NCT02387996
NCT02393625	CLDK378A2120C	Phase 1		VIC	19/03/2015	27/05/2015	Ceritinib; Nivolumab	anti-PD-1_monoclonal_antibody; ALK/ROS1/IGF1R_inhibitor	Ceritinib; Nivolumab	ALK/ROS1/IGF1R_inhibitor; anti-PD-1_monoclonal_antibody	CLDK378A2120C	A Multi-center, Open-label Study to Assess the Safety and Efficacy of Combination Ceritinib (LDK378) and Nivolumab in Adult Patients With Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC)	ALK-positive NSCLC	3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT02393625
NCT02395172	2014-005060-15--100070-004	Phase 3		WA, SA, QLD, VIC, NSW	20/03/2015	24/03/2015	Avelumab; Docetaxel	anti-PD-L1_monoclonal_antibody; taxane	Avelumab; Docetaxel	anti-PD-L1_monoclonal_antibody; taxane	2014-005060-15  100070-004	A Phase III Open-Label, Multicenter Trial of Avelumab (MSB0010718C) Versus Docetaxel in Subjects With Non-Small Cell Lung Cancer That Has Progressed After a Platinum-Containing Doublet	Carcinoma, Non-Small-Cell Lung	4102 - Woolloongabba; 6008 - Subiaco; 3350 - Ballarat; 2480 - Lismore; 2450 - Coffs Harbour; 5112 - Elizabeth Vale; 4120 - Greenslopes; 3128 - Box Hill; 3050 - Parkville	https://clinicaltrials.gov/ct2/show/NCT02395172
NCT02407990	BGB-A317-Study-001	Phase 1		WA, QLD, VIC, NSW, SA, NZ	3/04/2015	2/06/2015	Tislelizumab	anti-PD-1_monoclonal_antibody	Tislelizumab	anti-PD-1_monoclonal_antibody	BGB-A317_Study_001	A Phase 1A/1B, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activities of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Subjects With Advanced Tumors	Advanced Cancer	- East Melbourne; - Clayton; 4216 - Southport; 3144 - Malvern; 2050 - Camperdown; 4102 - Woolloongabba; - Adelaide; Hamilton; - Woodville South; - Nedlands; - Heidelberg; 3004 - Melbourne; - Sydney; - Melbourne; Wellington	https://clinicaltrials.gov/ct2/show/NCT02407990
NCT02408861	NCI-2015-00461--NCI-2015-00461	Phase 1		NSW	6/04/2015	27/08/2015	Ipilimumab; Ipilimumab + Nivolumab; Nivolumab	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Ipilimumab + Nivolumab; Ipilimumab + Nivolumab	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	NCI-2015-00461  NCI-2015-00461	A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV-Associated Solid Tumors With Expansion Cohorts in HIV-Associated Solid Tumors and a Cohort of HIV-Associated Classical Hodgkin Lymphoma	Refractory Classic Hodgkin Lymphoma; Kaposi Sarcoma; Anal Carcinoma; Recurrent Classic Hodgkin Lymphoma; Lung Carcinoma; HIV Infection; Advanced Malignant Solid Neoplasm; Unresectable Solid Neoplasm; Metastatic Malignant Solid Neoplasm	2010 - Darlinghurst; 2052 - Sydney	https://clinicaltrials.gov/ct2/show/NCT02408861
NCT02410512	2015-000516-18--GO29674	Phase 1		VIC, NSW, WA	7/04/2015	24/04/2015	Atezolizumab; Atezolizumab + Vonlerolizumab; Vonlerolizumab	anti-PD-L1_monoclonal_antibody; anti-OX40_agonistic_antibody + anti-PD-L1_monoclonal_antibody; anti-OX40_agonistic_antibody	Atezolizumab + Vonlerolizumab; Atezolizumab + Vonlerolizumab	anti-OX40_agonistic_antibody + anti-PD-L1_monoclonal_antibody; anti-OX40_agonistic_antibody + anti-PD-L1_monoclonal_antibody	2015-000516-18  GO29674	A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors	Neoplasms	2050 - Camperdown; 6009 - Nedlands; 3000 - Melbourne; 3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT02410512
NCT02419417	BET	Phase 1/Phase 2	NOT_RECRUITING	VIC	17/04/2015	19/06/2015	BMS-986158; Nivolumab	anti-PD-1_monoclonal_antibody; BET_inhibitor	BMS-986158; Nivolumab	BET_inhibitor; anti-PD-1_monoclonal_antibody	2015-000324-29  CA011-001	A Phase I/IIa Trial With BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, as Monotherapy or in Combination With Nivolumab in Subjects With Selected Advanced Solid Tumors or Hematologic Malignancies	Advanced Tumors	3004 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT02419417
NCT02420821	IMmotion151	Phase 3		WA, SA, NSW, VIC, QLD	20/04/2015	20/05/2015	Atezolizumab; Atezolizumab + Bevacizumab; Bevacizumab; Sunitinib	VEGFR_inhibitor; anti-PD-L1_monoclonal_antibody; KIT_inhibitor,first_generation; PDGFR_inhibitor; anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody	Atezolizumab + Bevacizumab; Sunitinib; Atezolizumab + Bevacizumab	KIT_inhibitor,first_generation; PDGFR_inhibitor; VEGFR_inhibitor; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody	2014-004684-20  WO29637	A Phase III, Open-Label, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma	Renal Cell Carcinoma	6150 - Murdoch; 2109 - Macquarie Park; 3084 - Heidelberg; 5037 - Kurralta Park; 4101 - South Brisbane; 2050 - Camperdown; 2298 - Waratah	https://clinicaltrials.gov/ct2/show/NCT02420821
NCT02422615	MONALEESA-3	Phase 3		NSW, VIC, QLD, WA	21/04/2015	9/06/2015	Fulvestrant; Fulvestrant + Ribociclib; Placebo; Ribociclib	CDK4/6_inhibitor + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader; placebo; CDK4/6_inhibitor	Fulvestrant + Ribociclib; Fulvestrant + Ribociclib; Placebo	CDK4/6_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + selective_estrogen_receptor_degrader; placebo	2015-000617-43  CLEE011F2301	A Randomized Double-blind, Placebo-controlled Study of Ribociclib in Combination With Fulvestrant for the Treatment of Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer Who Have Received no or Only One Line of Prior Endocrine Treatment	Advanced Breast Cancer	2065 - St Leonards; 4029 - Herston; 3002 - East Melbourne; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT02422615
NCT02425891	2014-005490-37--WO29522	Phase 3		VIC, NSW, QLD, WA	24/04/2015	23/06/2015	Atezolizumab; Atezolizumab + Nab-paclitaxel; Nab-paclitaxel; Placebo	anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + taxane; taxane; placebo	Atezolizumab + Nab-paclitaxel; Nab-paclitaxel; Atezolizumab + Nab-paclitaxel; Placebo	anti-PD-L1_monoclonal_antibody + taxane; taxane; anti-PD-L1_monoclonal_antibody + taxane; placebo	2014-005490-37  WO29522	A Phase III, Multicenter, Randomized, Placebo-Controlled Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Patients With Previously Untreated Metastatic Triple-Negative Breast Cancer	Triple Negative Breast Cancer	2747 - Sydney; 3199 - Frankston; 3000 - Melbourne; 3021 - St Albans; 6008 - Subiaco; 4102 - Woolloongabba; 2050 - Camperdown; 4101 - South Brisbane	https://clinicaltrials.gov/ct2/show/NCT02425891
NCT02426125	RANGE	Phase 3		WA, SA, NSW, VIC	24/04/2015	13/07/2015	Docetaxel; Docetaxel + Ramucirumab; Placebo; Ramucirumab	anti-VEGFR2_monoclonal_antibody; taxane; placebo; anti-VEGFR2_monoclonal_antibody + taxane	Docetaxel; Docetaxel + Ramucirumab; Docetaxel + Ramucirumab; Placebo	anti-VEGFR2_monoclonal_antibody + taxane; taxane; anti-VEGFR2_monoclonal_antibody + taxane; placebo	I4T-MC-JVDC  15679	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ramucirumab Plus Docetaxel Versus Placebo Plus Docetaxel in Patients With Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or After Platinum-Based Therapy	Urothelial Carcinoma	2031 - Randwick; 5000 - Adelaide; 3011 - Footscray; 6008 - Subiaco	https://clinicaltrials.gov/ct2/show/NCT02426125
NCT02435433	REACH-2	Phase 3		SA	6/05/2015	20/07/2015	Placebo; Ramucirumab; Sorafenib	FLT3_inhibitor; placebo; VEGFR_inhibitor; anti-VEGFR2_monoclonal_antibody; CRAF_inhibitor; PDGFR_inhibitor; KIT_inhibitor; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor	Ramucirumab; Placebo; Sorafenib	anti-VEGFR2_monoclonal_antibody; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor; CRAF_inhibitor; FLT3_inhibitor; KIT_inhibitor; PDGFR_inhibitor; placebo	I4T-MC-JVDE  15755	Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (AFP) Following First-Line Therapy With Sorafenib	Hepatocellular Carcinoma	5011 - Woodville; 5037 - Kurralta Park	https://clinicaltrials.gov/ct2/show/NCT02435433
NCT02435680	TNBC	Phase 2		WA	6/05/2015	10/08/2015	Carboplatin; Carboplatin + Gemcitabine; Carboplatin + Gemcitabine + Lacnotuzumab; Gemcitabine; Lacnotuzumab	platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; antimetabolite; anti-CSF1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-CSF1_monoclonal_antibody; gemcitabine	Carboplatin + Gemcitabine; Carboplatin + Gemcitabine + Lacnotuzumab; Carboplatin + Gemcitabine; Carboplatin + Gemcitabine + Lacnotuzumab	anti-CSF1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; anti-CSF1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; gemcitabine	2015-000179-29  CMCS110Z2201	A Randomized Phase II Study of MCS110 Combined With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC)	Advanced Triple Negative Breast Cancer (TNBC) With High TAMs	6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT02435680
NCT02437318	SOLAR-1	Phase 3		SA, QLD, VIC, NSW	7/05/2015	23/07/2015	Alpelisib; Alpelisib + Fulvestrant; Fulvestrant; Placebo	PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader; placebo; PI3K_alpha_inhibitor	Alpelisib + Fulvestrant; Fulvestrant; Alpelisib + Fulvestrant; Placebo	PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader; PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; placebo	2015-000340-42  CBYL719C2301	A Phase III Randomized Double-blind, Placebo Controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment	Breast Cancer	3000 - Melbourne; 2076 - Wahroonga; 4102 - Wooloongabba; 5112 - Elizabeth Vale	https://clinicaltrials.gov/ct2/show/NCT02437318
NCT02437916	NCT02437916	Phase 1		VIC	8/05/2015	1/04/2015	AMG-228	anti-GITR_monoclonal_antibody	AMG-228	anti-GITR_monoclonal_antibody	20140131	A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 228 in Subjects With Selected Advanced Solid Tumors	Advanced Solid Tumors; Cancer; Oncology Patients; Tumors; Advanced Malignancy; Non-small Cell Lung Cancer; Colorectal Cancer; Melanoma; Squamous Cell Carcinoma of the Head and Neck; Transitional Cell Carinoma of Bladder; Oncology	3050 - Parkville	https://clinicaltrials.gov/ct2/show/NCT02437916
NCT02438007	ARMOR3-SV	Phase 3		SA, QLD, NSW, VIC	8/05/2015	1/06/2015	Enzalutamide; Galeterone	antiandrogen,steroidal; antiandrogen,nonsteroidal,second_generation	Enzalutamide; Galeterone	antiandrogen,nonsteroidal,second_generation; antiandrogen,steroidal	ARMOR3-SV	ARMOR3-SV: A Phase 3, Randomized, Open Label, Multi-Center, Controlled Study of Galeterone Compared to Enzalutamide in Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic (M1) Castrate Resistant Prostate Cancer (CRPC)	Prostate Cancer	5037 - Kurralta Park; 2217 - Kogarah; 2444 - Port Macquarie; 4102 - Woolloongabba; 3128 - Box Hill; 4215 - Southport; 3165 - East Bentleigh; 4102 - Kippa-Ring; 2109 - Sydney; 2031 - Randwick; 3002 - East Melbourne; 3144 - Malvern	https://clinicaltrials.gov/ct2/show/NCT02438007
NCT02442349	AURA17	Phase 2		NSW, QLD, WA	13/05/2015	22/06/2015	Osimertinib	EGFR_inhibitor,third_generation	Osimertinib	EGFR_inhibitor,third_generation	D5160C00017	A Phase II, Open Label, Single-arm Study to Assess the Safety and Efficacy of AZD9291 in Asia Pacific Patients With Locally Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed With Previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Whose Tumours Harbour a T790M Mutation Within the Epidermal Growth Factor Receptor Gene.	Non-Small Cell Lung Cancer	6009 - Nedlands; 4102 - Woolloongabba; 2217 - Kogarah	https://clinicaltrials.gov/ct2/show/NCT02442349
NCT02443883	I4T-MC-JVDB--15608	Phase 2		VIC, NSW, NZ, SA, WA	14/05/2015	7/07/2015	Ramucirumab	anti-VEGFR2_monoclonal_antibody	Ramucirumab	anti-VEGFR2_monoclonal_antibody	I4T-MC-JVDB  15608	Randomized Phase 2 Trial Evaluating Pharmacokinetics and Safety of Four Ramucirumab Dosing Regimens in Second-Line Gastric or Gastroesophageal Junction Adenocarcinoma	Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma	Christchurch; 5000 - Adelaide; 3144 - Melbourne; Auckland; 6009 - Nedlands; 2747 - Kingswood	https://clinicaltrials.gov/ct2/show/NCT02443883
NCT02446405	ENZAMET	Phase 3		WA, NT, NSW, VIC, QLD, TAS, NZ, SA	18/05/2015	1/03/2014	Enzalutamide	antiandrogen,nonsteroidal,second_generation	Enzalutamide	antiandrogen,nonsteroidal,second_generation	ACTRN12614000110684  ANZUP 1304	Randomised Phase 3 Trial of Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer: ENZAMET	Prostatic Neoplasms	2217 - Kogarah; 2650 - Wagga Wagga; 2500 - Wollongong; 5000 - Adelaide; 3199 - Frankston; 2444 - Port Macquarie; 5037 - Kurralta Park; 4560 - Nambour; 0810 - Tiwi; - Melbourne; 3084 - Heidelberg; Hamilton; 4102 - Woolloongabba; 2076 - Wahroonga; 3220 - Geelong; 2139 - Concord; 2340 - Tamworth; Christchurch; 3690 - Wodonga; 3065 - Fitzroy; 2065 - St Leonards; 4215 - Southport; 6000 - Perth; 2010 - Darlinghurst; 5042 - Bedford Park; 7000 - Hobart; 2747 - Kingswood; 6009 - Nedlands; 2485 - Tweed Heads; 4006 - Herston; 2800 - Orange; 2050 - Camperdown; 2031 - Randwick; 3165 - Bentleigh East; 3630 - Shepparton; 4814 - Douglas; 3002 - East Melbourne; 3144 - Malvern; Auckland; 2450 - Coffs Harbour; - Bendigo	https://clinicaltrials.gov/ct2/show/NCT02446405
NCT02447003	KEYNOTE-086	Phase 2		NZ, NSW	18/05/2015	11/06/2015	Pembrolizumab	anti-PD-1_monoclonal_antibody	Pembrolizumab	anti-PD-1_monoclonal_antibody	2015-000294-13  3475-086	A Phase II Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy for Metastatic Triple-Negative Breast Cancer (mTNBC) - (KEYNOTE-086)	Breast Cancer	- North Ryde; Wellington	https://clinicaltrials.gov/ct2/show/NCT02447003
NCT02449681	TH-CR-602	Phase 2		NSW, VIC	20/05/2015	1/08/2015	Tarloxotinib	pan_ERBB_inhibitor,hypoxia_activating	Tarloxotinib	pan_ERBB_inhibitor,hypoxia_activating	TH-CR-602	A Phase 2 Study of TH-4000 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Skin	Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Skin	3002 - East Melbourne; 2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT02449681
NCT02450539	I3Y-MC-JPBX--15806	Phase 2		QLD, NSW	21/05/2015	6/08/2015	Abemaciclib; Docetaxel	taxane; CDK4/6_inhibitor	Abemaciclib; Docetaxel	CDK4/6_inhibitor; taxane	I3Y-MC-JPBX  15806	A Randomized Phase 2 Study of Abemaciclib (LY2835219) Versus Docetaxel in Patients With Stage IV Squamous Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy	Non-Small Cell Lung Cancer Stage IV	4102 - Woolloongabba; 2500 - Wollongong; 4101 - South Brisbane; 2050 - Camperdown; 2013 - Randwick	https://clinicaltrials.gov/ct2/show/NCT02450539
NCT02451943	ANNOUNCE	Phase 3		NSW	22/05/2015	14/09/2015	Doxorubicin; Doxorubicin + Olaratumab; Olaratumab; Placebo	anthracycline + anti-PDGFRA_monoclonal_antibody; anthracycline; doxorubicin; placebo; anti-PDGFRA_monoclonal_antibody	Doxorubicin; Doxorubicin + Olaratumab; Doxorubicin + Olaratumab; Placebo	anthracycline; anthracycline + anti-PDGFRA_monoclonal_antibody; anthracycline + anti-PDGFRA_monoclonal_antibody; doxorubicin; placebo	I5B-MC-JGDJ  15677	A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin Plus Olaratumab Versus Doxorubicin Plus Placebo in Patients With Advanced or Metastatic Soft Tissue Sarcoma	Soft Tissue Sarcoma	2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT02451943
NCT02453282	MYSTIC	Phase 3		QLD, NSW, VIC	25/05/2015	21/07/2015	Carboplatin; Cisplatin; Durvalumab; Gemcitabine; Paclitaxel; Pemetrexed; Tremelimumab	anti-CTLA-4_monoclonal_antibody; platinum-based_antineoplastic_agent; antimetabolite; anti-PD-L1_monoclonal_antibody; gemcitabine; taxane	Tremelimumab; Carboplatin; Cisplatin; Durvalumab; Gemcitabine; Paclitaxel; Pemetrexed	anti-CTLA-4_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; antimetabolite; gemcitabine; platinum-based_antineoplastic_agent; taxane	D419AC00001	A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy or MEDI4736 Monotherapy Versus Standard of Care Platinum-Based Chemotherapy in First Line Treatment of Patients With Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC) (MYSTIC)	Non-Small-Cell Lung Carcinoma NSCLC	3128 - Box Hill; 4215 - Southport; 2250 - Gosford; 3000 - Melbourne; 2444 - Port Macquarie; 2217 - Kogarah; 2065 - St Leonards	https://clinicaltrials.gov/ct2/show/NCT02453282
NCT02454842	TH-4000	Phase 2		VIC	27/05/2015	1/06/2015	Tarloxotinib	pan_ERBB_inhibitor,hypoxia_activating	Tarloxotinib	pan_ERBB_inhibitor,hypoxia_activating	TH-CR-601	A Phase 2 Study of TH-4000 (Tarloxotinib) in Patients With EGFR-Mutant, T790M-Negative, Advanced Non-Small Cell Lung Cancer Progressing on an EGFR Tyrosine Kinase Inhibitor	Non-small Cell Lung Cancer; Non-squamous NSCLC; NSCLC	3002 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT02454842
NCT02460224	CLAG525X2101C	Phase 1/Phase 2		NSW, VIC	2/06/2015	17/06/2015	Ieramilimab; Ieramilimab + Spartalizumab; Spartalizumab	anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Ieramilimab; Ieramilimab + Spartalizumab; Ieramilimab + Spartalizumab	anti-LAG3_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	CLAG525X2101C	A Phase I/II, Open Label, Multicenter Study of the Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 Administered to Patients With Advanced Malignancies	Advanced Solid Tumors	3084 - Heidelberg; 2145 - Westmead	https://clinicaltrials.gov/ct2/show/NCT02460224
NCT02470585	VELIA	Phase 3		QLD, NSW, VIC, SA, NZ, WA	12/06/2015	29/06/2015	Carboplatin; Carboplatin + Paclitaxel + Veliparib; Paclitaxel; Placebo; Veliparib	PARP_inhibitor; platinum-based_antineoplastic_agent; PARP_inhibitor + platinum-based_antineoplastic_agent + taxane; taxane; placebo	Carboplatin + Paclitaxel + Veliparib; Carboplatin + Paclitaxel + Veliparib; Placebo	PARP_inhibitor + platinum-based_antineoplastic_agent + taxane; PARP_inhibitor + platinum-based_antineoplastic_agent + taxane; placebo	2014-005070-11  M13-694	A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP Inhibitor) in Subjects With Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Ovarian Cancer; Ovarian Neoplasm	2065 - St Leonards; 6008 - Subiaco; 4029 - Herston; 2500 - Wollongong; 2217 - Kogarah; 5000 - Adelaide; 3052 - Parkville; 2450 - Coffs Harbour; 4101 - South Brisbane; 3144 - Malvern; Auckland; 4814 - Douglas; 2145 - Westmead; 3168 - Clayton; 2305 - Lambton Heights; 2250 - Gosford; 2031 - Randwick; 6009 - Nedlands; 2298 - Waratah	https://clinicaltrials.gov/ct2/show/NCT02470585
NCT02474355	ASTRIS	Phase 3		VIC, NSW, SA	17/06/2015	18/09/2015	Osimertinib	EGFR_inhibitor,third_generation	Osimertinib	EGFR_inhibitor,third_generation	D5160C00022	Open Label, Multinational, Multicenter, Real World Treatment Study of Single Agent AZD9291 for Patients With Advanced/Metastatic Epidermal Growth Factor Receptor (EGFR) T790M Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) Who Have Received Prior Therapy With an EGFR Tyrosine Kinase Inhibitor (EGFR-TKI)	Lung Cancer	2298 - Waratah; 5042 - Bedford Park; 3002 - East Melbourne; 2031 - Randwick; 5037 - Kurralta Park	https://clinicaltrials.gov/ct2/show/NCT02474355
NCT02477826	CheckMate-227	Phase 3	NOT_RECRUITING	SA, QLD, NSW, VIC, WA, ACT	23/06/2015	5/08/2015	Carboplatin; Cisplatin; Gemcitabine; Ipilimumab; Ipilimumab + Nivolumab; Nivolumab; Paclitaxel; Pemetrexed	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; antimetabolite; gemcitabine; taxane	Ipilimumab + Nivolumab; Nivolumab; Carboplatin; Cisplatin; Gemcitabine; Ipilimumab + Nivolumab; Paclitaxel; Pemetrexed	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; antimetabolite; gemcitabine; platinum-based_antineoplastic_agent; taxane	2014-003630-23  CA209-227	An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Subjects With Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)	Non-Small Cell Lung Cancer	2148 - Blacktown; 6150 - Perth; 6150 - Murdoch; - Elizabeth Vale; 2340 - Tamworth; 3065 - Fitzroy; 4102 - Brisbane; 2605 - Garran; 3168 - Clayton; 2250 - Gosford	https://clinicaltrials.gov/ct2/show/NCT02477826
NCT02481830	CheckMate331	Phase 3		WA, SA, QLD, NSW	25/06/2015	14/09/2015	Amrubicin; Nivolumab; Topotecan	anthracycline; anti-PD-1_monoclonal_antibody; topoisomerase_inhibitor	Amrubicin; Nivolumab; Topotecan	anthracycline; anti-PD-1_monoclonal_antibody; topoisomerase_inhibitor	2015-001097-18  CA209-331	An Open-label, Randomized, Phase 3 Study of Nivolumab or Chemotherapy in Subjects With Relapsed Small-cell Lung Cancer After Platinum-based First Line Chemotherapy (CheckMate 331: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 331)	Lung Cancer	2298 - Waratah; 4032 - Brisbane; 5112 - Elizabeth Vale; 5037 - Kurralta Park; 6150 - Murdoch; 6150 - Perth	https://clinicaltrials.gov/ct2/show/NCT02481830
NCT02484443	NCI-2015-01001--NCI-2015-01001	Phase 2		WA, NZ, SA, NSW, VIC, QLD	29/06/2015	30/11/2015	Dinutuximab; Dinutuximab + Sargramostim; Sargramostim	Granulocyte-Macrophage_Colony_Stimulating_Factor + anti-GD2_monoclonal_antibody; anti-GD2_monoclonal_antibody; Granulocyte-Macrophage_Colony_Stimulating_Factor	Dinutuximab + Sargramostim; Dinutuximab + Sargramostim	Granulocyte-Macrophage_Colony_Stimulating_Factor + anti-GD2_monoclonal_antibody; Granulocyte-Macrophage_Colony_Stimulating_Factor + anti-GD2_monoclonal_antibody	NCI-2015-01001  NCI-2015-01001	A Phase 2 Study of Human-Mouse Chimeric Anti-disialoganglioside Monoclonal Antibody ch14.18 (Dinutuximab, NSC# 764038) in Combination With Sargramostim (GM-CSF) in Patients With Recurrent Osteosarcoma	Metastatic Malignant Neoplasm in the Lung; Metastatic Osteosarcoma; Recurrent Osteosarcoma	5006 - North Adelaide; 4101 - South Brisbane; Auckland; 3052 - Parkville; 2145 - Westmead; 2031 - Randwick; 6008 - Perth; 3168 - Clayton; Christchurch; 2310 - Hunter Regional Mail Centre	https://clinicaltrials.gov/ct2/show/NCT02484443
NCT02485652	2015-001435-21--HM-EMSI-202	Phase 2		QLD, NSW, VIC	30/06/2015	31/08/2015	Olmutinib	EGFR_inhibitor,third_generation	Olmutinib	EGFR_inhibitor,third_generation	2015-001435-21  HM-EMSI-202	A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor	Non Small Cell Lung Cancer	- Woolloongabba; - Frankston; - Fitzroy; - St Albans; - Kogarah; - Darlinghurst	https://clinicaltrials.gov/ct2/show/NCT02485652
NCT02489318	TITAN	Phase 3		QLD, NSW, SA	3/07/2015	27/11/2015	Apalutamide; Placebo	antiandrogen,nonsteroidal,second_generation; placebo	Apalutamide; Placebo	antiandrogen,nonsteroidal,second_generation; placebo	2015-000735-32  CR107614	A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)	Prostate Cancer	- Port Macquarie; - Albury; - Kogarah; - Elizabeth Vale; - St Leonards; - South Brisbane	https://clinicaltrials.gov/ct2/show/NCT02489318
NCT02491892	BO16934	Phase 2		NSW, VIC	8/07/2015	1/02/2003	Pertuzumab	anti-ERBB2_monoclonal_antibody,dimerization_inhibitor	Pertuzumab	anti-ERBB2_monoclonal_antibody,dimerization_inhibitor	BO16934	Open-Label, Phase II, Multicenter, Randomized Study of Efficacy and Safety for Two Different Doses of a Recombinant Humanized Antibody to HER2 (rhuMAb 2C4) Administered Every 3 Weeks to Patients With Metastatic Breast Cancer With Low Expression of HER2	Breast Cancer	2050 - Camperdown; 3220 - Geelong; 3065 - Fitzroy	https://clinicaltrials.gov/ct2/show/NCT02491892
NCT02492789	INCSHR1210-101	Phase 1		NSW, VIC, WA	9/07/2015	1/09/2015	Camrelizumab	anti-PD-1_monoclonal_antibody	Camrelizumab	anti-PD-1_monoclonal_antibody	INCSHR1210-101	An Open-Label, Multicenter, Nonrandomized, Dose-Escalation and Tumor-Expansion Phase 1 Study to Evaluate the Safety and Tolerability of INCSHR01210 (Formerly SHR-1210) in Subjects With Advanced Solid Tumors	Solid Tumors and Hematologic Malignancy	- Melbourne; - Heidelberg; - Nedlands; - Camperdown; - Blacktown	https://clinicaltrials.gov/ct2/show/NCT02492789
NCT02503033	2015-523-00AU1	Phase 1		WA, ACT, SA, VIC, NSW, QLD	20/07/2015	1/11/2015	HMPL-523	SYK_inhibitor	HMPL-523	SYK_inhibitor	2015-523-00AU1	A Phase I, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of HMPL-523 in Patients With Relapsed or Refractory Hematologic Malignancies	Hematologic Malignancies	2640 - Albury; 4814 - Townsville; 6000 - Perth; - Heidelberg; 3220 - Geelong; - Adelaide; - Liverpool; 3144 - Melbourne; - Frankston; 3350 - Ballarat; - Canberra; - Fitzroy	https://clinicaltrials.gov/ct2/show/NCT02503033
NCT02503774	D6070C00001	Phase 1	NOT_RECRUITING	NSW, QLD	21/07/2015	24/07/2015	Durvalumab; Durvalumab + Oleclumab; Oleclumab	anti-PD-L1_monoclonal_antibody; anti-CD73_monoclonal_antibody; anti-CD73_monoclonal_antibody + anti-PD-L1_monoclonal_antibody	Durvalumab + Oleclumab; Oleclumab; Durvalumab + Oleclumab	anti-CD73_monoclonal_antibody; anti-CD73_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-CD73_monoclonal_antibody + anti-PD-L1_monoclonal_antibody	D6070C00001	A Phase 1 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI9447 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors	Solid Tumors	4068 - Woolloongabba; 2050 - Camperdown; 3050 - Parkville; 2065 - St Leonards	https://clinicaltrials.gov/ct2/show/NCT02503774
NCT02504489	DUBLIN-3	Phase 3		QLD, VIC, NSW, WA	22/07/2015	1/12/2015	Dexamethasone; Dexamethasone + Docetaxel; Docetaxel; Docetaxel + Plinabulin; Placebo; Plinabulin	glucocorticoid; placebo; taxane + tubulin_polymerization_inhibitor; glucocorticoid + taxane; taxane; tubulin_polymerization_inhibitor	Dexamethasone + Docetaxel; Docetaxel + Plinabulin; Dexamethasone + Docetaxel; Docetaxel + Plinabulin; Placebo	glucocorticoid + taxane; taxane + tubulin_polymerization_inhibitor; glucocorticoid + taxane; placebo; taxane + tubulin_polymerization_inhibitor	BPI-2358-103	Randomized Blinded Phase III Assessment of Second or Third-Line Chemotherapy With Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced Non-Small Cell Lung Cancer and With at Least One Measurable Lung Lesion	Non-Small Cell Lung Cancer	3199 - Melbourne; 6000 - Perth; 3121 - Richmond; 4101 - South Brisbane; 2250 - Gosford; 2640 - East Albury; 6150 - Murdoch; 2148 - Blacktown; 6008 - Subiaco	https://clinicaltrials.gov/ct2/show/NCT02504489
NCT02506556	PIKNIC	Phase 2		VIC	23/07/2015	1/07/2015	Alpelisib	PI3K_alpha_inhibitor	Alpelisib	PI3K_alpha_inhibitor	LL14/02	A Phase II Exploratory, Open-label, Single Arm Study of BYL719 Monotherapy, a Selective Phosphatidylinositol 3-kinase (PI3K) Alpha Inhibitor, in Adult Patients With Advanced Breast Cancer Progressing After First Line Therapy.	Metastatic Breast Cancer	3002 - East Melbourne	https://clinicaltrials.gov/ct2/show/NCT02506556
NCT02512237	ZMC-ARX788-101	Phase 1		QLD, VIC, NZ	30/07/2015	1/03/2016	ARX788	anti-ERBB2_antibody-drug_conjugate	ARX788	anti-ERBB2_antibody-drug_conjugate	  ZMC-ARX788-101	A Phase 1, Multicenter, Open-label, Multiple Dose-escalation Study of ARX788, Intravenously Administered as a Single Agent in Subjects With Advanced Cancers With HER2 Expression	Breast Neoplasms; Stomach Neoplasms	3168 - Clayton; Auckland; 4101 - South Brisbane; 3121 - Richmond; 4102 - Woolloongabba; Christchurch; Wellington	https://clinicaltrials.gov/ct2/show/NCT02512237
NCT02516241	D419BC00001	Phase 3		NSW, VIC, SA	5/08/2015	2/11/2015	Carboplatin; Cisplatin; Durvalumab; Durvalumab + Tremelimumab; Gemcitabine; Tremelimumab	anti-CTLA-4_monoclonal_antibody; platinum-based_antineoplastic_agent; antimetabolite; anti-PD-L1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; gemcitabine	Durvalumab; Durvalumab + Tremelimumab; Carboplatin; Cisplatin; Durvalumab + Tremelimumab; Gemcitabine	anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; antimetabolite; gemcitabine; platinum-based_antineoplastic_agent	D419BC00001	A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line MEDI4736 (Durvalumab) Monotherapy and MEDI4736 (Durvalumab) in Combination With Tremelimumab Versus Standard of Care Chemotherapy in Patients With Unresectable Stage IV Urothelial Cancer	Urothelial Cancer	2065 - St Leonards; 2109 - Macquarie University; 3128 - Box Hill; 2298 - Waratah; 5112 - Elizabeth Vale	https://clinicaltrials.gov/ct2/show/NCT02516241
NCT02516553	2015-001111-12--1367.1	Phase 1	NOT_RECRUITING	NSW	6/08/2015	8/07/2015	BI 894999	BET_inhibitor	BI 894999	BET_inhibitor	2015-001111-12  1367.1	An Open Label, Phase Ia/Ib Dose Finding Study With BI 894999 Orally Administered Once a Day in Patients With Advanced Malignancies, With Repeated Administration in Patients With Clinical Benefit	NUT Carcinoma; Neoplasms	2031 - Randwick	https://clinicaltrials.gov/ct2/show/NCT02516553
NCT02517398	2015-004366-28--EMR-200647-001	Phase 1		WA, SA, QLD, VIC, NSW	7/08/2015	31/08/2015	Bintrafusp Alfa	anti-PD-L1/TGF-beta_fusion_protein	Bintrafusp Alfa	anti-PD-L1/TGF-beta_fusion_protein	2015-004366-28  EMR 200647-001	A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications	Solid Tumors	6150 - Murdoch; 2148 - Blacktown; 2444 - Port Macquarie; 2217 - Kogarah; 3690 - Wodonga; 2170 - Liverpool; 2065 - St Leonards; 6009 - Nedlands; 5011 - Woodville South; 2298 - Waratah; 4120 - Greenslopes; 3144 - Malvern; 3002 - East Melbourne; 4216 - Southport	https://clinicaltrials.gov/ct2/show/NCT02517398
NCT02521493	NCI-2015-00324--AAML1531	Phase 3		WA, VIC, NSW, NZ	13/08/2015	23/11/2015	Asparaginase; Cytarabine; Cytarabine + Daunorubicin + Thioguanine; Cytarabine + Mitoxantrone; Daunorubicin; Etoposide; Mitoxantrone; Thioguanine	anthracycline; asparaginase; antimetabolite; antineoplastic_antibiotic; antimetabolite + antineoplastic_antibiotic; anthracycline + antimetabolite; topoisomerase_inhibitor	Cytarabine + Daunorubicin + Thioguanine; Cytarabine + Mitoxantrone; Asparaginase; Cytarabine + Daunorubicin + Thioguanine; Cytarabine + Mitoxantrone; Etoposide	anthracycline + antimetabolite; antimetabolite + antineoplastic_antibiotic; anthracycline + antimetabolite; antimetabolite + antineoplastic_antibiotic; asparaginase; topoisomerase_inhibitor	NCI-2015-00324  AAML1531	Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome	Down Syndrome; Acute Myeloid Leukemia; Myeloproliferative Neoplasm; Myeloid Leukemia Associated With Down Syndrome; Myelodysplastic Syndrome	2310 - Hunter Regional Mail Centre; Christchurch; 6008 - Perth; 2031 - Randwick; 2145 - Westmead; Auckland; 6009 - Perth; 3052 - Parkville	https://clinicaltrials.gov/ct2/show/NCT02521493
NCT02538666	CheckMate-451	Phase 3		SA, VIC, NSW, QLD	2/09/2015	13/10/2015	Ipilimumab; Ipilimumab + Nivolumab; Nivolumab; Placebo	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; placebo	Ipilimumab + Nivolumab; Nivolumab; Ipilimumab + Nivolumab; Placebo	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; placebo	2015-002441-61  CA209-451	A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination With Ipilimumab, or Placebo as Maintenance Therapy in Subjects With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based First Line Chemotherapy (CheckMate 451: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 451)	Lung Cancer	4575 - Birtinya; 4102 - Brisbane; 5000 - Adelaide; 2500 - Wollongong; - Kogarah; 3165 - East Melbourne	https://clinicaltrials.gov/ct2/show/NCT02538666
NCT02544633	265-109	Phase 2		SA, TAS, QLD, NSW, VIC	9/09/2015	1/10/2015	Glesatinib	MET_inhibitor,type_2	Glesatinib	MET_inhibitor,type_2	265-109	Phase 2, Parallel-Arm Study of MGCD265 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor	Non-Small Cell Lung Cancer	4102 - Woolloongabba; 2139 - Concord; 3165 - Clayton; 2217 - Kogarah; 3084 - Heidelberg; 7000 - Hobart; 5042 - Bedford Park; 2065 - Saint Leonards; 2485 - Tweed Heads	https://clinicaltrials.gov/ct2/show/NCT02544633
NCT02545504	GAMMA-1	Phase 3		NSW, VIC, QLD, SA, TAS, ACT	10/09/2015	13/10/2015	Andecaliximab; Andecaliximab + Fluorouracil; Fluorouracil; Leucovorin; Oxaliplatin; Placebo	anti-MMP9_monoclonal_antibody; platinum-based_antineoplastic_agent; anti-MMP9_monoclonal_antibody + fluoropyrimidine; placebo; Fluorouracil; folinic_acid; fluoropyrimidine	Andecaliximab + Fluorouracil; Fluorouracil; Andecaliximab + Fluorouracil; Leucovorin; Oxaliplatin; Placebo	anti-MMP9_monoclonal_antibody + fluoropyrimidine; fluoropyrimidine; Fluorouracil; anti-MMP9_monoclonal_antibody + fluoropyrimidine; folinic_acid; placebo; platinum-based_antineoplastic_agent	2015-001526-42  GS-US-296-1080	A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5745 Combined With mFOLFOX6 as First Line Treatment in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma	Gastric Adenocarcinoma	- Brisbane; - Garran; - Camperdown; 2485 - Tweed Heads; - Westmead; - Hobart; - Richmond; - Kurralta Park; - Wahroonga; - St Albans	https://clinicaltrials.gov/ct2/show/NCT02545504
NCT02550678	ASN-002-001	Phase 1/Phase 2		NSW, VIC, QLD	15/09/2015	1/09/2015	Fluorouracil; Gusacitinib	Fluorouracil; SYK/JAK_inhibitor; fluoropyrimidine	Fluorouracil; Gusacitinib	SYK/JAK_inhibitor; fluoropyrimidine; Fluorouracil	ASN-002-001	A Phase 1/2a Study of the Efficacy and Safety of ASN-002 Alone or in Combination With 5-FU in Adult Patients With Low-risk Nodular Basal Cell Carcinoma	Basal Cell Nevus Syndrome; Skin Neoplasm; Nodular Basal Cell Carcinoma of Skin	4102 - Brisbane; 4000 - Brisbane; 3002 - Melbourne; 2217 - Kogarah	https://clinicaltrials.gov/ct2/show/NCT02550678
NCT02551991	2015-003086-28--MM-398-07-02-03	Phase 1/Phase 2		WA	16/09/2015	1/09/2015	Fluorouracil; Fluorouracil + Liposomal Irinotecan + Oxaliplatin; Gemcitabine; Leucovorin; Liposomal Irinotecan; Nab-paclitaxel; Oxaliplatin	platinum-based_antineoplastic_agent; antimetabolite; fluoropyrimidine + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; Fluorouracil; folinic_acid; taxane; topoisomerase_inhibitor; fluoropyrimidine	Fluorouracil + Liposomal Irinotecan + Oxaliplatin; Fluorouracil + Liposomal Irinotecan + Oxaliplatin; Gemcitabine; Leucovorin; Nab-paclitaxel	fluoropyrimidine + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; Fluorouracil; antimetabolite; fluoropyrimidine + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; folinic_acid; taxane	2015-003086-28  MM-398-07-02-03	A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-Paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma	Pancreatic Cancer	6008 - Subiaco	https://clinicaltrials.gov/ct2/show/NCT02551991
NCT02554812	2015-002552-27--B9991004	Phase 2	NOT_RECRUITING	VIC, NSW	18/09/2015	9/11/2015	Avelumab; Avelumab + CMP-001; Avelumab + CMP-001 + PF-04518600; Avelumab + CMP-001 + Utomilumab; Avelumab + PD-0360324; Avelumab + PF-04518600; Avelumab + PF-04518600 + Utomilumab; Avelumab + Utomilumab; CMP-001; PD-0360324; PF-04518600; Utomilumab	anti-4-1BB_agonistic_antibody + anti-PD-L1_monoclonal_antibody; TLR9_agonist + anti-OX40_agonistic_antibody + anti-PD-L1_monoclonal_antibody; anti-OX40_agonistic_antibody + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; anti-CSF1_monoclonal_antibody; TLR9_agonist + anti-PD-L1_monoclonal_antibody; TLR9_agonist + anti-4-1BB_agonistic_antibody + anti-PD-L1_monoclonal_antibody; anti-CSF1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-4-1BB_agonistic_antibody + anti-OX40_agonistic_antibody + anti-PD-L1_monoclonal_antibody; anti-OX40_agonistic_antibody; TLR9_agonist; anti-4-1BB_agonistic_antibody	Avelumab + CMP-001; Avelumab + CMP-001 + PF-04518600; Avelumab + CMP-001 + Utomilumab; Avelumab + PD-0360324; Avelumab + PF-04518600; Avelumab + PF-04518600 + Utomilumab; Avelumab + Utomilumab; PD-0360324; Avelumab + CMP-001; Avelumab + CMP-001 + PF-04518600; Avelumab + CMP-001 + Utomilumab; Avelumab + PD-0360324; Avelumab + PF-04518600; Avelumab + PF-04518600 + Utomilumab; Avelumab + Utomilumab	TLR9_agonist + anti-4-1BB_agonistic_antibody + anti-PD-L1_monoclonal_antibody; TLR9_agonist + anti-OX40_agonistic_antibody + anti-PD-L1_monoclonal_antibody; TLR9_agonist + anti-PD-L1_monoclonal_antibody; anti-4-1BB_agonistic_antibody + anti-OX40_agonistic_antibody + anti-PD-L1_monoclonal_antibody; anti-4-1BB_agonistic_antibody + anti-PD-L1_monoclonal_antibody; anti-CSF1_monoclonal_antibody; anti-CSF1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-OX40_agonistic_antibody + anti-PD-L1_monoclonal_antibody; TLR9_agonist + anti-4-1BB_agonistic_antibody + anti-PD-L1_monoclonal_antibody; TLR9_agonist + anti-OX40_agonistic_antibody + anti-PD-L1_monoclonal_antibody; TLR9_agonist + anti-PD-L1_monoclonal_antibody; anti-4-1BB_agonistic_antibody + anti-OX40_agonistic_antibody + anti-PD-L1_monoclonal_antibody; anti-4-1BB_agonistic_antibody + anti-PD-L1_monoclonal_antibody; anti-CSF1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-OX40_agonistic_antibody + anti-PD-L1_monoclonal_antibody	2015-002552-27  B9991004	A PHASE 1B/2 OPEN-LABEL STUDY TO EVALUATE SAFETY, CLINICAL ACTIVITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB (MSB0010718C) IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES	Advanced Cancer	2060 - North Sydney; 2109 - Macquarie University; 3084 - Heidelberg; 2146 - Old Toongabie; 2109 - New South Wales; 3186 - Brighton; 3144 - Malvern; 2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT02554812
NCT02562755	PHOCUS	Phase 3		WA, SA, NZ, QLD, NSW, VIC	29/09/2015	1/10/2015	Pexastimogene Devacirepvec; Pexastimogene Devacirepvec + Sorafenib; Sorafenib	PDGFR_inhibitor + thymidine_kinase-deleted_oncolytic_vaccinia_virus_expressing_human_GM-CSF; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor + thymidine_kinase-deleted_oncolytic_vaccinia_virus_expressing_human_GM-CSF; VEGFR_inhibitor + thymidine_kinase-deleted_oncolytic_vaccinia_virus_expressing_human_GM-CSF; CRAF_inhibitor; KIT_inhibitor + thymidine_kinase-deleted_oncolytic_vaccinia_virus_expressing_human_GM-CSF; thymidine_kinase-deleted_oncolytic_vaccinia_virus_expressing_human_GM-CSF; FLT3_inhibitor; FLT3_inhibitor + thymidine_kinase-deleted_oncolytic_vaccinia_virus_expressing_human_GM-CSF; VEGFR_inhibitor; PDGFR_inhibitor; KIT_inhibitor; CRAF_inhibitor + thymidine_kinase-deleted_oncolytic_vaccinia_virus_expressing_human_GM-CSF; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor	Pexastimogene Devacirepvec + Sorafenib; Sorafenib; Pexastimogene Devacirepvec + Sorafenib	CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor + thymidine_kinase-deleted_oncolytic_vaccinia_virus_expressing_human_GM-CSF; CRAF_inhibitor; CRAF_inhibitor + thymidine_kinase-deleted_oncolytic_vaccinia_virus_expressing_human_GM-CSF; FLT3_inhibitor; FLT3_inhibitor + thymidine_kinase-deleted_oncolytic_vaccinia_virus_expressing_human_GM-CSF; KIT_inhibitor; KIT_inhibitor + thymidine_kinase-deleted_oncolytic_vaccinia_virus_expressing_human_GM-CSF; PDGFR_inhibitor; PDGFR_inhibitor + thymidine_kinase-deleted_oncolytic_vaccinia_virus_expressing_human_GM-CSF; VEGFR_inhibitor; VEGFR_inhibitor + thymidine_kinase-deleted_oncolytic_vaccinia_virus_expressing_human_GM-CSF; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor + thymidine_kinase-deleted_oncolytic_vaccinia_virus_expressing_human_GM-CSF; CRAF_inhibitor + thymidine_kinase-deleted_oncolytic_vaccinia_virus_expressing_human_GM-CSF; FLT3_inhibitor + thymidine_kinase-deleted_oncolytic_vaccinia_virus_expressing_human_GM-CSF; KIT_inhibitor + thymidine_kinase-deleted_oncolytic_vaccinia_virus_expressing_human_GM-CSF; PDGFR_inhibitor + thymidine_kinase-deleted_oncolytic_vaccinia_virus_expressing_human_GM-CSF; VEGFR_inhibitor + thymidine_kinase-deleted_oncolytic_vaccinia_virus_expressing_human_GM-CSF	JX594-HEP024	A Phase 3 Randomized, Open-Label Study Comparing Pexa Vec (Vaccinia GM CSF / Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) Without Prior Systemic Therapy	Hepatocellular Carcinoma (HCC)	- Brisbane; Auckland; - Perth; - Camperdown; - Clayton; - Footscray; - Concord; - Heidelberg; Christchurch; - Adelaide; - Parkville; - Melbourne; - Sydney; - Fitzroy	https://clinicaltrials.gov/ct2/show/NCT02562755
NCT02567435	NCI-2015-01644--NCI-2015-01644	Phase 3		WA, NZ, QLD, NSW	5/10/2015	23/05/2016	Cyclophosphamide; Cyclophosphamide + Dactinomycin + Irinotecan + Temsirolimus + Vincristine + Vinorelbine; Cyclophosphamide + Dactinomycin + Irinotecan + Vincristine + Vinorelbine; Cyclophosphamide + Dactinomycin + Vincristine; Dactinomycin; Irinotecan; Radiotherapy; Temsirolimus; Vincristine; Vinorelbine	alkylating_agent + antineoplastic_antibiotic + topoisomerase_inhibitor + vinca_alkaloid; radiotherapy; alkylating_agent + antineoplastic_antibiotic + mTORC1_inhibitor + topoisomerase_inhibitor + vinca_alkaloid; alkylating_agent; vinca_alkaloid; mTORC1_inhibitor; antineoplastic_antibiotic; topoisomerase_inhibitor; alkylating_agent + antineoplastic_antibiotic + vinca_alkaloid	Cyclophosphamide + Dactinomycin + Irinotecan + Temsirolimus + Vincristine + Vinorelbine; Cyclophosphamide + Dactinomycin + Irinotecan + Vincristine + Vinorelbine; Cyclophosphamide + Dactinomycin + Vincristine; Cyclophosphamide + Dactinomycin + Irinotecan + Temsirolimus + Vincristine + Vinorelbine; Cyclophosphamide + Dactinomycin + Irinotecan + Vincristine + Vinorelbine; Cyclophosphamide + Dactinomycin + Vincristine; Radiotherapy	alkylating_agent + antineoplastic_antibiotic + mTORC1_inhibitor + topoisomerase_inhibitor + vinca_alkaloid; alkylating_agent + antineoplastic_antibiotic + topoisomerase_inhibitor + vinca_alkaloid; alkylating_agent + antineoplastic_antibiotic + vinca_alkaloid; alkylating_agent + antineoplastic_antibiotic + mTORC1_inhibitor + topoisomerase_inhibitor + vinca_alkaloid; alkylating_agent + antineoplastic_antibiotic + topoisomerase_inhibitor + vinca_alkaloid; alkylating_agent + antineoplastic_antibiotic + vinca_alkaloid; radiotherapy	NCI-2015-01644  NCI-2015-01644	A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)	Sclerosing Rhabdomyosarcoma; Botryoid-Type Embryonal Rhabdomyosarcoma; Rhabdomyosarcoma; Embryonal Rhabdomyosarcoma; Spindle Cell Rhabdomyosarcoma; Alveolar Rhabdomyosarcoma	2310 - Hunter Regional Mail Centre; Christchurch; 6008 - Perth; 2031 - Randwick; 2145 - Westmead; Auckland; 6009 - Perth; 4101 - South Brisbane	https://clinicaltrials.gov/ct2/show/NCT02567435
NCT02568267	STARTRK-2	Phase 2	NOT_RECRUITING	VIC, NSW, SA	5/10/2015	19/11/2015	Crizotinib; Entrectinib	MET_inhibitor,type_1; ALK_inhibitor,first_generation; TRK_inhibitor,first_generation; ROS1_inhibitor; ALK_inhibitor,third_generation	Crizotinib; Entrectinib	ALK_inhibitor,first_generation; ALK_inhibitor,third_generation; MET_inhibitor,type_1; ROS1_inhibitor; TRK_inhibitor,first_generation	2015-003385-84  RXDX-101-02	An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements	Ovarian Cancer; Neuroendocrine Tumors; Breast Cancer; Pancreatic Cancer; Adult Solid Tumor; Renal Cell Carcinoma; Cholangiocarcinoma; Sarcomas; Non-Small Cell Lung Cancer; Primary Brain Tumors; Salivary Gland Cancers; Papillary Thyroid Cancer; Colorectal Cancer; Melanoma; Lymphoma, Large-Cell, Anaplastic; Head and Neck Neoplasms	3084 - Heidelberg; 2170 - Liverpool; 5042 - Bedford Park; 2640 - Albury; 2305 - New Lambton Heights	https://clinicaltrials.gov/ct2/show/NCT02568267
NCT02569476	BGB-3111-GA101-Study-001	Phase 1		WA, QLD, NSW, VIC, SA	6/10/2015	13/01/2016	Obinutuzumab; Obinutuzumab + Zanubrutinib; Zanubrutinib	BTK_inhibitor + anti-CD20_monoclonal_antibody; BTK_inhibitor; anti-CD20_monoclonal_antibody	Obinutuzumab + Zanubrutinib; Obinutuzumab + Zanubrutinib	BTK_inhibitor + anti-CD20_monoclonal_antibody; BTK_inhibitor + anti-CD20_monoclonal_antibody	BGB-3111_GA101_Study_001	A Phase 1b Study to Assess Safety, Tolerability and Antitumor Activity of the Combination of BGB 3111 With Obinutuzumab in Subjects With B-Cell Lymphoid Malignancies	B-cell Lymphoid Malignancies	3181 - Melbourne; 2640 - Albury; 4120 - Greenslopes; 6000 - Perth; 3002 - East Melbourne; 3144 - Malvern; 5037 - Kurralta Park; 2217 - Kogarah; 3220 - Geelong	https://clinicaltrials.gov/ct2/show/NCT02569476
NCT02569801	HydranGea	Phase 2		SA, TAS, VIC, NSW	7/10/2015	4/12/2015	Brilanestrant; Brilanestrant + Fulvestrant; Fulvestrant	selective_estrogen_receptor_degrader	Brilanestrant; Brilanestrant + Fulvestrant; Brilanestrant + Fulvestrant	selective_estrogen_receptor_degrader	2015-000106-19  GO29689	A Phase II, Open-Label, Randomized Study of GDC-0810 Versus Fulvestrant in Postmenopausal Women With Advanced or Metastatic ER+ /HER2- Breast Cancer Resistant to Aromatase Inhibitor Therapy	Breast Cancer	3011 - Footscray; 5037 - Kurralta Park; 2444 - Port Macquarie; 3199 - Frankston; 2010 - Darlinghurst; 7000 - Hobart; 3121 - Richmond	https://clinicaltrials.gov/ct2/show/NCT02569801
NCT02573324	Intellance1	Phase 2/Phase 3		QLD, VIC, NSW, SA, NZ, WA	9/10/2015	7/12/2015	Depatuxizumab Mafodotin; Depatuxizumab Mafodotin + Temozolomide; Placebo; Temozolomide	alkylating_agent + anti-EGFR/PBD_antibody-drug_conjugate; alkylating_agent; placebo; anti-EGFR/PBD_antibody-drug_conjugate	Depatuxizumab Mafodotin + Temozolomide; Temozolomide; Depatuxizumab Mafodotin + Temozolomide; Placebo	alkylating_agent; alkylating_agent + anti-EGFR/PBD_antibody-drug_conjugate; alkylating_agent + anti-EGFR/PBD_antibody-drug_conjugate; placebo	2015-001166-26  M13-813	A Randomized, Placebo Controlled Phase 3 Study of ABT-414 With Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1)	Glioblastoma; Gliosarcoma	6008 - Subiaco; Christchurch; 2170 - Liverpool; 3065 - Fitzroy; 2065 - St Leonards; 4102 - Woolloongabba; Wellington; 3084 - Heidelberg; 5000 - Adelaide; 2500 - Wollongong; 5006 - Adelaide; 2031 - Randwick; 2298 - Waratah	https://clinicaltrials.gov/ct2/show/NCT02573324
NCT02576431	NAVIGATE	Phase 2		NSW, WA, NT	15/10/2015	30/09/2015	Larotrectinib	TRK_inhibitor,first_generation	Larotrectinib	TRK_inhibitor,first_generation	LOXO-TRK-15002  20289	A Phase 2 Basket Study of the Oral TRK Inhibitor Larotrectinib in Subjects With NTRK Fusion-positive Tumors	Solid Tumors Harboring NTRK Fusion	6009 - Nedlands; 2109 - Macquarie University; 6008 - Subiaco; 0810 - Tiwi	https://clinicaltrials.gov/ct2/show/NCT02576431
NCT02576509	CheckMate-459	Phase 3		NSW, VIC, SA, WA	15/10/2015	7/12/2015	Nivolumab; Sorafenib	anti-PD-1_monoclonal_antibody; FLT3_inhibitor; VEGFR_inhibitor; CRAF_inhibitor; PDGFR_inhibitor; KIT_inhibitor; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor	Nivolumab; Sorafenib	CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor; CRAF_inhibitor; FLT3_inhibitor; KIT_inhibitor; PDGFR_inhibitor; VEGFR_inhibitor; anti-PD-1_monoclonal_antibody	CA209-459	A Randomized, Multi-center Phase III Study of Nivolumab Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (CheckMate 459: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 459)	Hepatocellular Carcinoma	3084 - Heidelberg; 5000 - Adelaide; 3181 - Prahran; 3168 - Clayton; 2050 - Camperdown; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT02576509
NCT02576574	2015-001537-24--EMR-100070-005	Phase 3		NZ, SA, NSW, VIC, QLD, WA	15/10/2015	29/10/2015	Avelumab; Carboplatin; Cisplatin; Gemcitabine; Paclitaxel; Pemetrexed	platinum-based_antineoplastic_agent; antimetabolite; anti-PD-L1_monoclonal_antibody; gemcitabine; taxane	Avelumab; Carboplatin; Cisplatin; Gemcitabine; Paclitaxel; Pemetrexed	anti-PD-L1_monoclonal_antibody; antimetabolite; gemcitabine; platinum-based_antineoplastic_agent; taxane	2015-001537-24  EMR 100070-005	A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+NSCLC	First Line Non-Small Cell Lung Cancer	Auckland; 2450 - Coffs Harbour; 2480 - Lismore; 2640 - Albury; 2800 - Orange; 5011 - Woodville South; Palmerston North; 4215 - Southport; 2298 - Waratah; 4120 - Greenslopes; 3550 - Bendigo; Tauranga; 2065 - St Leonards; 3280 - Warrnambool; Hamilton; Dunedin; Wellington; 6150 - Murdoch; 2217 - Kogarah; 3350 - Ballarat	https://clinicaltrials.gov/ct2/show/NCT02576574
NCT02580058	2015-003091-77--B9991009	Phase 3		VIC, NSW, QLD	20/10/2015	21/12/2015	Avelumab; Avelumab + Pegylated liposomal doxorubicin; Pegylated liposomal doxorubicin	anthracycline + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; anthracycline	Avelumab; Avelumab + Pegylated liposomal doxorubicin; Avelumab + Pegylated liposomal doxorubicin	anthracycline + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; anthracycline + anti-PD-L1_monoclonal_antibody	2015-003091-77  B9991009	A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF AVELUMAB (MSB0010718C) ALONE OR IN COMBINATION WITH PEGYLATED LIPOSOMAL DOXORUBICIN VERSUS PEGYLATED LIPOSOMAL DOXORUBICIN ALONE IN PATIENTS WITH PLATINUM-RESISTANT/REFRACTORY OVARIAN CANCER	Ovarian Cancer	4066 - Auchenflower; 4029 - Herston; 3000 - Melbourne; 3186 - Brighton; 4101 - South Brisbane; 2305 - Newcastle; 3144 - Malvern; 3052 - Parkville; 2305 - New Lambton Heights; 4032 - Chermside; 4101 - Brisbane; 3050 - Parkville; 4215 - Southport	https://clinicaltrials.gov/ct2/show/NCT02580058
NCT02582697	P3BEP	Phase 3		SA, NZ, TAS, QLD, VIC, NSW, WA	21/10/2015	1/02/2014	Bleomycin; Cisplatin; Etoposide; Filgrastim; Pegfilgrastim	platinum-based_antineoplastic_agent; antineoplastic_antibiotic; topoisomerase_inhibitor; granulocyte_colony_stimulating_factor	Bleomycin; Cisplatin; Etoposide; Filgrastim; Pegfilgrastim	antineoplastic_antibiotic; granulocyte_colony_stimulating_factor; platinum-based_antineoplastic_agent; topoisomerase_inhibitor	ACTRN12613000496718  ANZUP1302	Phase 3 Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours	Germ Cell Tumor	Auckland; 2298 - Newcastle; 4101 - South Brisbane; 3002 - East Melbourne; 2031 - Sydney; 2109 - Sydney; 2485 - Tweed Heads; 7000 - Hobart; 5042 - Bedford Park; 3128 - Box Hill; Palmerston North; 2065 - St Leonards; 3690 - Wodonga; Christchurch; 2139 - Sydney; 2076 - Wahroonga; 4102 - Woolloongabba; 2145 - Sydney; 3084 - Heidelberg; 6847 - Murdoch; Dunedin; 4029 - Brisbane; 3021 - St Albans; 2050 - Sydney; 2751 - Sydney; 5000 - Adelaide	https://clinicaltrials.gov/ct2/show/NCT02582697
NCT02584634	2015-001879-43--B9991005	Phase 2		VIC, NSW, QLD	22/10/2015	18/12/2015	Avelumab; Crizotinib; Lorlatinib	anti-PD-L1_monoclonal_antibody; MET_inhibitor,type_1; ALK_inhibitor,first_generation; ROS1_inhibitor; ALK_inhibitor,third_generation	Avelumab; Crizotinib; Lorlatinib	ALK_inhibitor,first_generation; ALK_inhibitor,third_generation; MET_inhibitor,type_1; ROS1_inhibitor; anti-PD-L1_monoclonal_antibody	2015-001879-43  B9991005	A PHASE 1B/2, OPEN-LABEL, DOSE-FINDING STUDY TO EVALUATE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB (MSB0010718C) IN COMBINATION WITH EITHER CRIZOTINIB OR PF-06463922 IN PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER	Non-Small Cell Lung Cancer	3000 - Melbourne; 4032 - Chermside; 2050 - Camperdown; 3050 - Parkville	https://clinicaltrials.gov/ct2/show/NCT02584634
NCT02588261	SOLAR	Phase 3		SA, NSW, VIC, QLD	27/10/2015	11/02/2016	Erlotinib; Erlotinib + Gefitinib; Gefitinib; Naquotinib	EGFR_inhibitor,third_generation; EGFR_inhibitor,first_generation	Erlotinib + Gefitinib; Naquotinib; Erlotinib + Gefitinib	EGFR_inhibitor,first_generation; EGFR_inhibitor,third_generation	2015-002894-39  8273-CL-0302	An Open-label, Randomized Phase 3 Efficacy Study of ASP8273 vs Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations	Non-small Cell Lung Cancer (NSCLC)	3002 - East Melbourne; 2031 - Randwick; 5000 - Adelaide; 3011 - Footscray; 3065 - Fitzroy; 4102 - Woolloongabba	https://clinicaltrials.gov/ct2/show/NCT02588261
NCT02592707	2015-002867-41--D-FR-01072-001	Phase 1/Phase 2		VIC, WA	30/10/2015	6/03/2017	Satoreotide Tetraxetan	177Lu-DOTA-radioconjugate	Satoreotide Tetraxetan	177Lu-DOTA-radioconjugate	2015-002867-41  D-FR-01072-001	An International, Multicenter, Open-label Study to Evaluate Safety, Tolerability, Biodistribution, Dosimetry and Preliminary Efficacy of 177Lu-OPS201 for the Therapy of Somatostatin Receptor-positive Neuroendocrine Tumors (NETs)	Neuroendocrine Tumors	3002 - East Melbourne; 6009 - Perth	https://clinicaltrials.gov/ct2/show/NCT02592707
NCT02598960	2015-002505-11--CA009-002	Phase 1/Phase 2		WA, QLD, NSW	6/11/2015	9/10/2015	Nivolumab	anti-PD-1_monoclonal_antibody	Nivolumab	anti-PD-1_monoclonal_antibody	2015-002505-11  CA009-002	A Phase 1/2a Dose Escalation and Cohort Expansion Study for Safety, Tolerability, and Efficacy of BMS-986156 Administered Alone and in Combination With Nivolumab (BMS-936558, Anti PD-1 Monoclonal Antibody) in Advanced Solid Tumors	Solid Tumors	4102 - Brisbane; 2170 - Liverpool; 2145 - Westmead; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT02598960
NCT02599402	CheckMate-401	Phase 3		WA, NT, ACT, TAS, SA, NSW, VIC, QLD	6/11/2015	20/12/2015	Ipilimumab; Ipilimumab + Nivolumab; Nivolumab	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Ipilimumab + Nivolumab; Nivolumab; Ipilimumab + Nivolumab	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	2015-001274-17  CA209-401	Clinical Trial of Nivolumab (BMS-936558) Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Therapy of Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma CheckMate 401: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 401	Melanoma	2450 - Coffs Harbour; 4870 - Cairns; 5402 - Bedford Park; 2050 - Camperdown; 6009 - Nedlands; 7000 - Hobart; 4120 - Greenslopes; 4215 - Southport; 4102 - Brisbane; 3004 - Melbourne; 2605 - Garran; 2290 - Gateshead; 2060 - North Sydney; 6150 - Murdoch; 3144 - Melbourne; 0810 - Tiwi; 3128 - Melbourne; 5000 - Adelaide	https://clinicaltrials.gov/ct2/show/NCT02599402
NCT02601378	CLXS196X2101	Phase 1		NSW	10/11/2015	1/02/2016	Darovasertib; Darovasertib + Siremadlin; Siremadlin	HDM2_inhibitor + PKC_inhibitor; HDM2_inhibitor; PKC_inhibitor	Darovasertib; Darovasertib + Siremadlin; Darovasertib + Siremadlin	HDM2_inhibitor + PKC_inhibitor; PKC_inhibitor; HDM2_inhibitor + PKC_inhibitor	CLXS196X2101	A Phase I, Multi-center, Open-label, Study of LXS196, an Oral Protein Kinase C Inhibitor, in Patients With Metastatic Uveal Melanoma	Uveal Melanoma	2145 - Westmead	https://clinicaltrials.gov/ct2/show/NCT02601378
NCT02601950	EZH-202	Phase 2	NOT_RECRUITING	QLD, NSW	11/11/2015	22/12/2015	Tazemetostat	EZH2_inhibitor	Tazemetostat	EZH2_inhibitor	EZH-202	A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma	Malignant Rhabdoid Tumors (MRT); Poorly Differentiated Chordoma (or Other Chordoma With Sponsor Approval); Atypical Teratoid Rhabdoid Tumors (ATRT); Any Solid Tumor With an EZH2 GOF Mutation; Selected Tumors With Rhabdoid Features; Renal Medullary Carcinoma; Synovial Sarcoma; Malignant Rhabdoid Tumor of Ovary; Epithelioid Sarcoma; INI1-negative Tumors; Rhabdoid Tumors of the Kidney (RTK)	2050 - Camperdown; QLD 4102 - Woolloongabba	https://clinicaltrials.gov/ct2/show/NCT02601950
NCT02603432	2015-003262-86--B9991001	Phase 3		QLD, NSW, VIC, SA, NZ, WA	11/11/2015	25/04/2016	Avelumab	anti-PD-L1_monoclonal_antibody	Avelumab	anti-PD-L1_monoclonal_antibody	2015-003262-86  B9991001	A PHASE 3, MULTICENTER, MULTINATIONAL, RANDOMIZED, OPEN-LABEL, PARALLEL-ARM STUDY OF AVELUMAB (MSB0010718C) PLUS BEST SUPPORTIVE CARE VERSUS BEST SUPPORTIVE CARE ALONE AS A MAINTENANCE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER WHOSE DISEASE DID NOT PROGRESS AFTER COMPLETION OF FIRST-LINE PLATINUM-CONTAINING CHEMOTHERAPY	Urothelial Cancer	2217 - Kogarah; 5037 - Kurralta Park; 3350 - Ballarat; 6150 - Murdoch; Hamilton; 4066 - Auchenflower; 4575 - Birtinya; 2139 - Concord; Christchurch; 2109 - Macquarie University; 2484 - Murwillubah; 4215 - Southport; 5037 - Kurralta park; 2830 - Dubbo; 3128 - Box Hill; 5042 - Bedford Park; 3355 - Ballarat; 4032 - Chermside; 2485 - Tweed Heads; 3149 - Mount Waverley; 3165 - East Bentleigh; 5011 - Woodville South; 2050 - Camperdown; 2109 - New South Wales; 3168 - Clayton; 4034 - Geebung; 4814 - Douglas; 2480 - Lismore; 4101 - South Brisbane; Auckland; 3355 - Wendouree	https://clinicaltrials.gov/ct2/show/NCT02603432
NCT02609776	CHRYSALIS	Phase 1		WA, QLD, VIC, NSW	20/11/2015	24/05/2016	Amivantamab; Amivantamab + Lazertinib; Carboplatin; Lazertinib; Pemetrexed	EGFR_inhibitor,third_generation; platinum-based_antineoplastic_agent; bispecific_cMET/EGFR_monoclonal_antibody; antimetabolite; EGFR_inhibitor,third_generation + bispecific_cMET/EGFR_monoclonal_antibody	Amivantamab + Lazertinib; Amivantamab + Lazertinib; Carboplatin; Pemetrexed	EGFR_inhibitor,third_generation + bispecific_cMET/EGFR_monoclonal_antibody; EGFR_inhibitor,third_generation + bispecific_cMET/EGFR_monoclonal_antibody; antimetabolite; platinum-based_antineoplastic_agent	61186372EDI1001  CR108064	A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects With Advanced Non-Small Cell Lung Cancer	Non-Small-Cell Lung Cancer	2050 - Camperdown; 4102 - Woolloongabba; 6150 - Murdoch; 3084 - Heidelberg; 2217 - Kogarah	https://clinicaltrials.gov/ct2/show/NCT02609776
NCT02610140	2012-003650-88--15743	Phase 2		WA, SA, VIC, NSW, QLD	20/11/2015	3/12/2015	Anetumab Ravtansine; Pemetrexed; Vinorelbine	vinca_alkaloid; anti-mesothelin_antibody-drug_conjugate; antimetabolite	Anetumab Ravtansine; Vinorelbine; Pemetrexed	anti-mesothelin_antibody-drug_conjugate; vinca_alkaloid; antimetabolite	2012-003650-88  15743	A Randomized, Open-label, Active-controlled, Phase II Study of Intravenous Anetumab Ravtansine (BAY 94-9343) or Vinorelbine in Patients With Advanced or Metastatic Malignant Pleural Mesothelioma Overexpressing Mesothelin and Progressed on First Line Platinum/Pemetrexed-based Chemotherapy	Mesothelioma	6009 - Nedlands; 5043 - Adelaide; 4102 - Woolloogabba; 2065 - St Leonards; 3122 - Richmond	https://clinicaltrials.gov/ct2/show/NCT02610140
NCT02610361	ACTRN12614001176651--BGB-283-AU-001	Phase 1		QLD, VIC, NSW, SA, NZ, WA	20/11/2015	20/11/2013	Lifirafenib	EGFR/RAF_dimer_inhibitor	Lifirafenib	EGFR/RAF_dimer_inhibitor	ACTRN12614001176651  BGB-283-AU-001	A Phase 1A/1B, Open-Label, Multiple-Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Preliminary Antitumor Activities of the B RAF Inhibitor BGB 283 in Subjects With Solid Tumors	Solid Tumors	5000 - Adelaide; 2444 - Port Macquarie; - Parkville; Wellington; Dunedin; - Melbourne; 4102 - Woolloongabba; Hamilton; - Heidelberg; 3004 - Melbourne; Christchurch; 3128 - Box Hill; 4215 - Southport; 5011 - Woodville South; 2050 - Camperdown; 6009 - Nedlands; 2031 - Randwick; 3168 - Clayton; 2145 - Westmead; 3144 - Malvern	https://clinicaltrials.gov/ct2/show/NCT02610361
NCT02611960	Keynote-122	Phase 3	NOT_RECRUITING	NSW	19/11/2015	18/04/2016	Capecitabine; Capecitabine + Docetaxel + Gemcitabine; Docetaxel; Gemcitabine; Pembrolizumab	anti-PD-1_monoclonal_antibody; antimetabolite + fluoropyrimidine + taxane; antimetabolite; gemcitabine; taxane; fluoropyrimidine	Capecitabine + Docetaxel + Gemcitabine; Pembrolizumab; Capecitabine + Docetaxel + Gemcitabine	anti-PD-1_monoclonal_antibody; antimetabolite + fluoropyrimidine + taxane; antimetabolite + fluoropyrimidine + taxane; gemcitabine	MK-3475-122  3475-122	A Two-arm, Open-label, Randomized Phase III Study of Pembrolizumab (MK-3475) Monotherapy Versus Standard Chemotherapy in Platinum Pre-treated, Recurrent or Metastatic Nasopharyngeal Cancer (NPC) (Keynote-122)	Nasopharyngeal Neoplasms	- North Ryde	https://clinicaltrials.gov/ct2/show/NCT02611960
NCT02614794	HER2CLIMB	Phase 2		QLD, NSW, VIC, WA	25/11/2015	28/01/2016	Capecitabine; Capecitabine + Trastuzumab; Capecitabine + Trastuzumab + Tucatinib; Placebo; Trastuzumab; Tucatinib	ERBB2_inhibitor,third_generation + anti-ERBB2_monoclonal_antibody + fluoropyrimidine; placebo; anti-ERBB2_monoclonal_antibody; ERBB2_inhibitor,third_generation; anti-ERBB2_monoclonal_antibody + fluoropyrimidine; fluoropyrimidine	Capecitabine + Trastuzumab; Capecitabine + Trastuzumab + Tucatinib; Capecitabine + Trastuzumab; Capecitabine + Trastuzumab + Tucatinib; Placebo	ERBB2_inhibitor,third_generation + anti-ERBB2_monoclonal_antibody + fluoropyrimidine; anti-ERBB2_monoclonal_antibody + fluoropyrimidine; ERBB2_inhibitor,third_generation + anti-ERBB2_monoclonal_antibody + fluoropyrimidine; anti-ERBB2_monoclonal_antibody + fluoropyrimidine; placebo	2015-002801-12  ONT-380-206	Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma	HER2 Positive Breast Cancer	2060 - North Sydney; 3000 - Melbourne; 3021 - St Albans; 3084 - Heidelberg; 2145 - Westmead; 4101 - South Brisbane; 3144 - Malvern; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT02614794
NCT02617589	CheckMate-498	Phase 3		NSW, VIC, WA	1/12/2015	1/03/2016	Nivolumab; Nivolumab + Radiotherapy; Radiotherapy; Radiotherapy + Temozolomide; Temozolomide	radiotherapy; anti-PD-1_monoclonal_antibody; alkylating_agent; anti-PD-1_monoclonal_antibody + radiotherapy; alkylating_agent + radiotherapy	Nivolumab + Radiotherapy; Radiotherapy + Temozolomide; Nivolumab + Radiotherapy; Radiotherapy + Temozolomide	alkylating_agent + radiotherapy; anti-PD-1_monoclonal_antibody + radiotherapy; alkylating_agent + radiotherapy; anti-PD-1_monoclonal_antibody + radiotherapy	2015-003739-37  CA209-498	A Randomized Phase 3 Open Label Study of Nivolumab vs Temozolomide Each in Combination With Radiation Therapy in Newly Diagnosed Adult Subjects With Unmethylated MGMT (Tumor O-6-methylguanine DNA Methyltransferase) Glioblastoma (CheckMate 498: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 498)	Brain Cancer	- Liverpool; - Heidelberg; - Nedlands; - Prahran; - St. Leonards	https://clinicaltrials.gov/ct2/show/NCT02617589
NCT02625610	2015-003300-23--EMR-100070-007	Phase 3		WA, QLD, NSW, VIC, TAS, SA	9/12/2015	24/12/2015	Avelumab; Capecitabine; Capecitabine + Fluorouracil + Oxaliplatin; Fluorouracil; Leucovorin; Oxaliplatin	platinum-based_antineoplastic_agent; fluoropyrimidine + platinum-based_antineoplastic_agent; Fluorouracil; folinic_acid; anti-PD-L1_monoclonal_antibody; fluoropyrimidine	Avelumab; Capecitabine + Fluorouracil + Oxaliplatin; Capecitabine + Fluorouracil + Oxaliplatin; Leucovorin	anti-PD-L1_monoclonal_antibody; fluoropyrimidine + platinum-based_antineoplastic_agent; Fluorouracil; fluoropyrimidine + platinum-based_antineoplastic_agent; folinic_acid	2015-003300-23  EMR 100070-007	A Phase III Open-label, Multicenter Trial of Maintenance Therapy With Avelumab (MSB0010718C) Versus Continuation of First-line Chemotherapy in Subjects With Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro-esophageal Junction	Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction	3550 - Bendigo; 5042 - Bedford Park; 7000 - Hobart; 4120 - Greenslopes; 3128 - Box Hill; 3050 - Parkville; 4006 - Herston; 5112 - Elizabeth Vale; 8120 - Bentleigh; 2217 - Kogarah; 3350 - Ballarat; 6150 - Murdoch; 3690 - Wodonga; 2065 - St Leonards	https://clinicaltrials.gov/ct2/show/NCT02625610
NCT02625623	2015-003301-42--EMR-100070-008	Phase 3		WA, TAS, SA, QLD, VIC	9/12/2015	28/12/2015	Avelumab; Irinotecan; Irinotecan + Paclitaxel; Paclitaxel	anti-PD-L1_monoclonal_antibody; taxane; topoisomerase_inhibitor; taxane + topoisomerase_inhibitor	Avelumab; Irinotecan + Paclitaxel; Irinotecan + Paclitaxel	anti-PD-L1_monoclonal_antibody; taxane + topoisomerase_inhibitor; taxane + topoisomerase_inhibitor	2015-003301-42  EMR 100070-008	A Phase III Open-label, Multicenter Trial of Avelumab (MSB0010718C) as a Third-line Treatment of Unresectable, Recurrent, or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma	Gastric Cancer Third Line; Unresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma	3128 - Box Hill; 5042 - Bedford Park; 7000 - Hobart; 5011 - Woodville South; 4102 - Woolloongabba; 3021 - St. Albans; 6008 - Subiaco; 3690 - Wodonga	https://clinicaltrials.gov/ct2/show/NCT02625623
NCT02626000	MASTERKEY232	Phase 1		VIC	10/12/2015	6/04/2016	Pembrolizumab; Pembrolizumab + Talimogene Laherparepvec; Talimogene Laherparepvec	anti-PD-1_monoclonal_antibody; oncolytic_HSV_virus; anti-PD-1_monoclonal_antibody + oncolytic_HSV_virus	Pembrolizumab + Talimogene Laherparepvec; Pembrolizumab + Talimogene Laherparepvec	anti-PD-1_monoclonal_antibody + oncolytic_HSV_virus; anti-PD-1_monoclonal_antibody + oncolytic_HSV_virus	20130232 / KEYNOTE-137  20130232	A Phase 1b/3 Multicenter, Randomized, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab for the Treatment of Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck	Carcinoma of the Head and Neck	3000 - Melbourne; 3220 - Geelong	https://clinicaltrials.gov/ct2/show/NCT02626000
NCT02628067	KEYNOTE-158	Phase 2		NSW	11/12/2015	18/12/2015	Pembrolizumab	anti-PD-1_monoclonal_antibody	Pembrolizumab	anti-PD-1_monoclonal_antibody	2015-002067-41  3475-158	A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)	Biliary Cancer; Cervical Carcinoma; Thyroid Cancer; Bile Duct Cancer; Endometrial Carcinoma; Endometrial Cancer; Small Cell Lung Carcinoma; Advanced Cancer; Salivary Gland Cancer; Cervical Cancer; Small Cell Lung Cancer (SCLC); Cholangiocarcinoma; Vulvar Cancer; Neuroendocrine Tumor; Mesothelioma; Anal Carcinoma; Advanced Solid Tumors; Thyroid Carcinoma; Parotid Gland Cancer; Anal Cancer; Colorectal Carcinoma; Carcinoid Tumor; Vulvar Carcinoma; Salivary Cancer; Salivary Gland Carcinoma	- North Ryde	https://clinicaltrials.gov/ct2/show/NCT02628067
NCT02645149	MatchMel	Phase 2		NSW	1/01/2016	22/11/2021	Dabrafenib; Ribociclib; Ribociclib + Trametinib; Trametinib	MEK_inhibitor; CDK4/6_inhibitor + MEK_inhibitor; CDK4/6_inhibitor; BRAF_V600_inhibitor	Ribociclib + Trametinib; Trametinib; Dabrafenib; Ribociclib + Trametinib	CDK4/6_inhibitor + MEK_inhibitor; MEK_inhibitor; BRAF_V600_inhibitor; CDK4/6_inhibitor + MEK_inhibitor	MIA2015/174	Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma	Melanoma	2145 - Westmead; 2260 - Wollstonecraft	https://clinicaltrials.gov/ct2/show/NCT02645149
NCT02655822	CPI-444-001	Phase 1		QLD, VIC	14/01/2016	1/01/2016	Atezolizumab; Atezolizumab + Ciforadenant; Ciforadenant	anti-PD-L1_monoclonal_antibody; adenosine_A2aR_and_A2bR_antagonist; adenosine_A2aR_and_A2bR_antagonist + anti-PD-L1_monoclonal_antibody	Atezolizumab + Ciforadenant; Ciforadenant; Atezolizumab + Ciforadenant	adenosine_A2aR_and_A2bR_antagonist; adenosine_A2aR_and_A2bR_antagonist + anti-PD-L1_monoclonal_antibody; adenosine_A2aR_and_A2bR_antagonist + anti-PD-L1_monoclonal_antibody	CPI-444-001	A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of Ciforadenant as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers	Renal Cell Cancer; Metastatic Castration Resistant Prostate Cancer	3168 - Clayton; 4029 - Brisbane	https://clinicaltrials.gov/ct2/show/NCT02655822
NCT02657330	CL-SBP-101-01	Phase 1		SA, VIC	15/01/2016	1/01/2016	Ivospemin	polyamine_analogue	Ivospemin	polyamine_analogue	CL-SBP-101-01	A Phase 1A/1B Study of SBP-101 in Previously Treated Subjects With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma	Ductal Adenocarcinoma of the Pancreas; Pancreatic Cancer	5037 - Kurralta Park; 3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT02657330
NCT02657369	2015-001929-17--E7080-M000-213	Phase 2		NSW	15/01/2016	7/07/2016	Lenvatinib	VEGF_inhibitor	Lenvatinib	VEGF_inhibitor	2015-001929-17  E7080-M000-213	An Open-Label, Single-Arm, Multicenter, Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)	Thyroid Carcinoma, Anaplastic	- St Leonards; 2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT02657369
NCT02657434	2015-003605-42--GO29438	Phase 3		TAS, QLD, NSW, VIC	15/01/2016	30/04/2016	Atezolizumab; Atezolizumab + Carboplatin + Cisplatin + Pemetrexed; Carboplatin; Carboplatin + Cisplatin + Pemetrexed; Cisplatin; Pemetrexed	platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; antimetabolite; anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent	Atezolizumab + Carboplatin + Cisplatin + Pemetrexed; Carboplatin + Cisplatin + Pemetrexed; Atezolizumab + Carboplatin + Cisplatin + Pemetrexed; Carboplatin + Cisplatin + Pemetrexed	anti-PD-L1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent	2015-003605-42  GO29438	A Phase III, Open-Label, Randomized Study of Atezolizumab (MPDL3280A, Anti-Pd-L1 Antibody) in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Patients Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer	Non-Small Cell Lung Cancer	7000 - Hobart; 2010 - Darlinghurst; 3353 - Ballarat; 2217 - Sydney; 2076 - Sydney; 4101 - South Brisbane; 3199 - Frankston; 4020 - Redcliffe; 3220 - Geelong	https://clinicaltrials.gov/ct2/show/NCT02657434
NCT02658890	2015-004914-79--CA017-003	Phase 1/Phase 2		NSW, VIC, QLD, WA	20/01/2016	22/02/2016	Ipilimumab; Ipilimumab + Linrodostat + Nivolumab; Linrodostat; Linrodostat + Nivolumab; Nivolumab	IDO1_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; IDO1_inhibitor; IDO1_inhibitor + anti-PD-1_monoclonal_antibody	Ipilimumab + Linrodostat + Nivolumab; Linrodostat + Nivolumab; Ipilimumab + Linrodostat + Nivolumab; Linrodostat + Nivolumab	IDO1_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; IDO1_inhibitor + anti-PD-1_monoclonal_antibody; IDO1_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; IDO1_inhibitor + anti-PD-1_monoclonal_antibody	2015-004914-79  CA017-003	A Phase 1/2a Study of BMS-986205 Administered in Combination With Nivolumab (Anti-PD-1 Monoclonal Antibody) and in Combination With Both Nivolumab and Ipilimumab (Anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors	Melanoma; Advanced Cancer; Non-Small Cell Lung Cancer	2145 - Westmead; 3168 - Clayton; 2010 - Darlinghurst; 6009 - Nedlands; 4102 - Brisbane; 3000 - Melbourne; 2146 - North Sydney	https://clinicaltrials.gov/ct2/show/NCT02658890
NCT02659020	ANNOUNCE-2	Phase 1/Phase 2		VIC, SA	20/01/2016	1/03/2016	Docetaxel; Docetaxel + Gemcitabine + Olaratumab; Gemcitabine; Olaratumab; Placebo	placebo; antimetabolite; anti-PDGFRA_monoclonal_antibody + antimetabolite + taxane; gemcitabine; taxane; anti-PDGFRA_monoclonal_antibody	Docetaxel + Gemcitabine + Olaratumab; Docetaxel + Gemcitabine + Olaratumab; Placebo	anti-PDGFRA_monoclonal_antibody + antimetabolite + taxane; anti-PDGFRA_monoclonal_antibody + antimetabolite + taxane; gemcitabine; placebo	I5B-MC-JGDL  15839	A Phase 1b (Open-Label)/Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma	Soft Tissue Sarcoma	3000 - Melbourne; 5000 - Adelaide	https://clinicaltrials.gov/ct2/show/NCT02659020
NCT02660034	2017-003580-35--BGB-A317-BGB-290-Study-001	Phase 1	NOT_RECRUITING	QLD, VIC, NSW, NZ, ACT, WA	21/01/2016	2/02/2016	Pamiparib; Pamiparib + Tislelizumab; Tislelizumab	PARP_inhibitor; anti-PD-1_monoclonal_antibody; PARP_inhibitor + anti-PD-1_monoclonal_antibody	Pamiparib + Tislelizumab; Pamiparib + Tislelizumab	PARP_inhibitor + anti-PD-1_monoclonal_antibody; PARP_inhibitor + anti-PD-1_monoclonal_antibody	2017-003580-35  BGB-A317/BGB-290_Study_001	A Phase 1/1b, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activity of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Combination With the PARP Inhibitor BGB-290 in Subjects With Advanced Solid Tumors	Solid Tumors	- Melbourne; Wellington; - Parramatta; - Randwick; 2065 - St Leonards; - Nedlands; 2605 - Garran; 4101 - Brisbane; 2450 - Coffs Harbour; 2298 - Newcastle; Auckland; - Clayton	https://clinicaltrials.gov/ct2/show/NCT02660034
NCT02667587	CheckMate548	Phase 3		WA, NSW, VIC	29/01/2016	9/05/2016	Nivolumab; Nivolumab + Radiotherapy + Temozolomide; Placebo; Radiotherapy; Temozolomide	radiotherapy; anti-PD-1_monoclonal_antibody; alkylating_agent; alkylating_agent + anti-PD-1_monoclonal_antibody + radiotherapy; placebo	Nivolumab + Radiotherapy + Temozolomide; Nivolumab + Radiotherapy + Temozolomide; Placebo	alkylating_agent + anti-PD-1_monoclonal_antibody + radiotherapy; alkylating_agent + anti-PD-1_monoclonal_antibody + radiotherapy; placebo	2015-004722-34  CA209-548	A Randomized Phase 3 Single Blind Study of Temozolomide Plus Radiation Therapy Combined With Nivolumab or Placebo in Newly Diagnosed Adult Subjects With MGMT-Methylated (Tumor O6-methylguanine DNA Methyltransferase) Glioblastoma	Brain Neoplasms	3181 - Prahran; 6009 - Nedlands; 2170 - Liverpool; 3084 - Heidelberg; 2065 - St. Leonards	https://clinicaltrials.gov/ct2/show/NCT02667587
NCT02671435	D419NC00001--D419NC00001	Phase 1/Phase 2	NOT_RECRUITING	VIC, NSW, NZ	2/02/2016	22/02/2016	Durvalumab; Durvalumab + Monalizumab; Monalizumab	anti-PD-L1_monoclonal_antibody; anti-NKG2A_monoclonal_antibody; anti-NKG2A_monoclonal_antibody + anti-PD-L1_monoclonal_antibody	Durvalumab + Monalizumab; Durvalumab + Monalizumab	anti-NKG2A_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-NKG2A_monoclonal_antibody + anti-PD-L1_monoclonal_antibody	D419NC00001  D419NC00001	A Phase 1/2 Study of Durvalumab and Monalizumab in Adult Subjects With Select Advanced Solid Tumors	Advanced Solid Tumors	2148 - Blacktown; 2298 - Waratah; 3168 - Clayton	https://clinicaltrials.gov/ct2/show/NCT02671435
NCT02675231	monarcHER	Phase 2		WA, NSW, SA	5/02/2016	23/05/2016	Abemaciclib; Abemaciclib + Fulvestrant + Trastuzumab; Abemaciclib + Trastuzumab; Fulvestrant; Trastuzumab	CDK4/6_inhibitor + anti-ERBB2_monoclonal_antibody + selective_estrogen_receptor_degrader; anti-ERBB2_monoclonal_antibody; CDK4/6_inhibitor + anti-ERBB2_monoclonal_antibody; selective_estrogen_receptor_degrader; CDK4/6_inhibitor	Abemaciclib + Fulvestrant + Trastuzumab; Abemaciclib + Trastuzumab; Trastuzumab; Abemaciclib + Fulvestrant + Trastuzumab; Abemaciclib + Trastuzumab	CDK4/6_inhibitor + anti-ERBB2_monoclonal_antibody; CDK4/6_inhibitor + anti-ERBB2_monoclonal_antibody + selective_estrogen_receptor_degrader; anti-ERBB2_monoclonal_antibody; CDK4/6_inhibitor + anti-ERBB2_monoclonal_antibody; CDK4/6_inhibitor + anti-ERBB2_monoclonal_antibody + selective_estrogen_receptor_degrader	I3Y-MC-JPBZ  15804	monarcHER: A Phase 2, Randomized, Multicenter, 3-Arm, Open-Label Study to Compare the Efficacy of Abemaciclib Plus Trastuzumab With or Without Fulvestrant to Standard-of-Care Chemotherapy of Physician's Choice Plus Trastuzumab in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer	Hormone Receptor Positive Breast Cancer; HER-2 Positive Breast Cancer	2065 - St. Leonards; 5037 - Kurralta Park; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT02675231
NCT02676869	TACTI-mel	Phase 1		SA, VIC, QLD, WA	8/02/2016	1/04/2016	Eftilagimod Alpha; Eftilagimod Alpha + Pembrolizumab; Pembrolizumab	T-cell_immunostimulatory_factor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; T-cell_immunostimulatory_factor	Eftilagimod Alpha + Pembrolizumab; Eftilagimod Alpha + Pembrolizumab	T-cell_immunostimulatory_factor + anti-PD-1_monoclonal_antibody; T-cell_immunostimulatory_factor + anti-PD-1_monoclonal_antibody	IMP321-P012	A Multicentre, Open Label, Dose Escalation, Phase 1 Study in Patients With Unresectable or Metastatic Melanoma Receiving IMP321 (LAG-3Ig Fusion Protein-eftilagimod Alpha) as an Adjunctive Therapy to Anti-PD-1 Therapy With Pembrolizumab	Stage III Melanoma; Stage IV Melanoma	3181 - Melbourne; 3353 - Ballarat; 4029 - Brisbane; 6150 - Perth; 4120 - Brisbane; 5042 - Adelaide; 4102 - Brisbane	https://clinicaltrials.gov/ct2/show/NCT02676869
NCT02677896	ARCHES	Phase 3		NSW, VIC, NZ, SA	9/02/2016	9/03/2016	Enzalutamide; LHRH Agonist; Placebo	antiandrogen,nonsteroidal,second_generation; placebo; LHRH_agonist	Enzalutamide; LHRH Agonist; Placebo	LHRH_agonist; antiandrogen,nonsteroidal,second_generation; placebo	2015-003869-28  9785-CL-0335	A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)	Metastatic Hormone Sensitive Prostate Cancer	2065 - St Leonards; Hamilton; - Parkville; - St. Albans; - Sydney; - Ballarat; - Clayton; 5011 - Woodville South; 2050 - Camperdown; 2485 - Tweed Heads; 2298 - Waratah; Northland	https://clinicaltrials.gov/ct2/show/NCT02677896
NCT02684006	2015-002429-20--B9991003	Phase 3		WA, QLD, NSW, VIC, NZ	17/02/2016	23/03/2016	Avelumab; Avelumab + Axitinib; Axitinib; Sunitinib	KIT_inhibitor,first_generation; KIT_inhibitor,ATP-competitive; VEGFR/PDGFR_inhibitor; KIT_inhibitor,ATP-competitive + anti-PD-L1_monoclonal_antibody; VEGFR_inhibitor; anti-PD-L1_monoclonal_antibody; PDGFR_inhibitor; VEGFR/PDGFR_inhibitor + anti-PD-L1_monoclonal_antibody	Avelumab + Axitinib; Sunitinib; Avelumab + Axitinib	KIT_inhibitor,ATP-competitive + anti-PD-L1_monoclonal_antibody; KIT_inhibitor,first_generation; PDGFR_inhibitor; VEGFR/PDGFR_inhibitor + anti-PD-L1_monoclonal_antibody; VEGFR_inhibitor; KIT_inhibitor,ATP-competitive + anti-PD-L1_monoclonal_antibody; VEGFR/PDGFR_inhibitor + anti-PD-L1_monoclonal_antibody	2015-002429-20  B9991003	A PHASE 3, MULTINATIONAL, RANDOMIZED, OPEN-LABEL, PARALLEL-ARM STUDY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH AXITINIB (INLYTA(REGISTERED)) VERSUS SUNITINIB (SUTENT(REGISTERED)) MONOTHERAPY IN THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA	Renal Cell Cancer	4102 - Woolloongabba; Hamilton; 6050 - Murdoch; Christchurch; Tauranga; 2109 - Macquarie University; 3350 - Ballarat; 6150 - Murdoch; 6150 - Perth; 3168 - Clayton; 2031 - Randwick; 3355 - Wendouree; Auckland; 3128 - Box Hill; Palmerston North; Manawatu-wanganui; 3165 - East Bentleigh; 3149 - Mount Waverley	https://clinicaltrials.gov/ct2/show/NCT02684006
NCT02688101	CMD-2015-001	Phase 1		NSW, VIC	23/02/2016	11/04/2016					CMD-2015-001	A Phase 1 Dose-finding and Pharmacokinetic Study of DpC, Administered Orally to Patients With Advanced Solid Tumors	Neoplasms	- Heidelberg; - Melbourne; - Sydney	https://clinicaltrials.gov/ct2/show/NCT02688101
NCT02693067	PV-10-NET-01	Phase 1		SA	26/02/2016	1/07/2016	PV-10	rose_bengal_disodium	PV-10	rose_bengal_disodium	PV-10-NET-01	A Phase 1 Study to Assess the Safety, Tolerability and Effectiveness of PV-10 Chemoablation of Neuroendocrine Tumours (NET) Metastatic to the Liver in the Reduction of Biochemical Markers and Symptoms Caused by Secretory Products	Neuroendocrine Tumors Metastatic to the Liver	5011 - Woodville	https://clinicaltrials.gov/ct2/show/NCT02693067
NCT02702388	2014-005199-27--E7080-G000-211	Phase 2		WA, VIC, NSW, QLD	8/03/2016	8/06/2017	Lenvatinib; Placebo	placebo; VEGF_inhibitor	Lenvatinib; Placebo	VEGF_inhibitor; placebo	2014-005199-27  E7080-G000-211	A Multicenter, Randomized, Double-Blind Phase 2 Trial of Lenvatinib (E7080) in Subjects With 131I-Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 mg Daily Will Provide Comparable Efficacy to a 24-mg Starting Dose, But Have a Better Safety Profile	Thyroid Cancer	- Darlinghurst; - Nedlands; - Melbourne; - Saint Leonards; - Herston; - Chermside; 4006 - Brisbane	https://clinicaltrials.gov/ct2/show/NCT02702388
NCT02702414	KEYNOTE-224	Phase 2	NOT_RECRUITING	NSW, VIC	3/03/2016	31/05/2016	Pembrolizumab	anti-PD-1_monoclonal_antibody	Pembrolizumab	anti-PD-1_monoclonal_antibody	2015-004566-28  3475-224	A Phase 2 Study of Pembrolizumab (MK-3475) as Monotherapy in Subjects With Advanced Hepatocellular Carcinoma (KEYNOTE-224)	Hepatocellular Carcinoma	3004 - Melbourne; 3168 - Melbourne; 2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT02702414
NCT02703571	2015-005019-34--CTMT212X2106	Phase 1		VIC	9/03/2016	29/06/2016	Ribociclib; Trametinib	MEK_inhibitor; CDK4/6_inhibitor	Ribociclib; Trametinib	CDK4/6_inhibitor; MEK_inhibitor	2015-005019-34  CTMT212X2106	A Phase I/II Study of Safety and Efficacy of Ribociclib (LEE011) in Combination With Trametinib (TMT212) in Patients With Metastatic or Advanced Solid Tumors	Colorectal Cancer for Phase II; Pancreatic Cancer for Phase II; Solid Tumors for Phase Ib	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT02703571
NCT02705482	D6060C00002	Phase 1	NOT_RECRUITING	QLD, VIC, NSW	4/03/2016	30/03/2016	Durvalumab; Durvalumab + Tavolimab; Immune Therapeutic Agent; Tavolimab; Tavolimab + Tremelimumab; Tremelimumab	anti-PD-L1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody; anti-OX40_agonistic_antibody + anti-PD-L1_monoclonal_antibody; anti-OX40_agonistic_antibody; anti-CTLA-4_monoclonal_antibody + anti-OX40_agonistic_antibody; immune_checkpoint_blockade	Durvalumab + Tavolimab; Tavolimab + Tremelimumab; Durvalumab + Tavolimab; Immune Therapeutic Agent; Tavolimab + Tremelimumab	anti-CTLA-4_monoclonal_antibody + anti-OX40_agonistic_antibody; anti-OX40_agonistic_antibody + anti-PD-L1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-OX40_agonistic_antibody; anti-OX40_agonistic_antibody + anti-PD-L1_monoclonal_antibody; immune_checkpoint_blockade	D6060C00002	A Phase 1 Multicenter, Open-label, Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Antitumor Activity of MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors	Select Advanced Solid Tumors	2217 - Kogarah; 2109 - Macquarie University; 2298 - Waratah; 3168 - Clayton; 4068 - Woolloongabba	https://clinicaltrials.gov/ct2/show/NCT02705482
NCT02709512	ATOMIC	Phase 2/Phase 3		QLD, VIC, NSW, SA, WA	16/03/2016	1/08/2017	Cisplatin; Pegargiminase; Pemetrexed; Placebo	platinum-based_antineoplastic_agent; placebo; arginine_deiminase-polyethylene_glycol_conjugate; antimetabolite	Pegargiminase; Cisplatin; Pemetrexed; Placebo	arginine_deiminase-polyethylene_glycol_conjugate; antimetabolite; placebo; platinum-based_antineoplastic_agent	POLARIS2015-003	Randomized, Double-Blind, Phase 2/3 Study in Subjects With Malignant Pleural Mesotheliomato Assess ADI-PEG 20 With Pemetrexed and Cisplatin (ATOMIC-Meso Phase 2/3 Study)	Mesothelioma	3084 - Heidelberg; 4102 - Woolloongabba; 5042 - Bedford Park; 2050 - Camperdown; 2486 - Tweed Heads; 6009 - Perth	https://clinicaltrials.gov/ct2/show/NCT02709512
NCT02711553	I3O-MC-JSBF--16329	Phase 2		NT, VIC, QLD, SA	17/03/2016	19/05/2016	Cisplatin; Cisplatin + Gemcitabine + Merestinib; Cisplatin + Gemcitabine + Ramucirumab; Gemcitabine; Merestinib; Placebo; Ramucirumab	platinum-based_antineoplastic_agent; placebo; antimetabolite; MET_inhibitor,type_2; anti-VEGFR2_monoclonal_antibody; gemcitabine; anti-VEGFR2_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; MET_inhibitor,type_2 + antimetabolite + platinum-based_antineoplastic_agent	Cisplatin + Gemcitabine + Merestinib; Cisplatin + Gemcitabine + Ramucirumab; Cisplatin + Gemcitabine + Merestinib; Cisplatin + Gemcitabine + Ramucirumab; Placebo	MET_inhibitor,type_2 + antimetabolite + platinum-based_antineoplastic_agent; anti-VEGFR2_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; MET_inhibitor,type_2 + antimetabolite + platinum-based_antineoplastic_agent; anti-VEGFR2_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; gemcitabine; placebo	I3O-MC-JSBF  16329	Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer	Advanced Cancer; Biliary Tract Cancer; Metastatic Cancer	Newcastle - Newcastle; 5000 - Adelaide; 3084 - Heidelberg; 4814 - Douglas	https://clinicaltrials.gov/ct2/show/NCT02711553
NCT02713529	MASTERKEY--20150195	Phase 1/Phase 2		VIC, NSW	18/03/2016	14/04/2016	AMG 820; Pembrolizumab	anti-CSF1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	Pembrolizumab; AMG 820	anti-PD-1_monoclonal_antibody; anti-CSF1_monoclonal_antibody	MASTERKEY  20150195	A Phase1b/2 Study Assessing Safety and Anti-tumor Activity of AMG 820 in Combination With Pembrolizumab in Select Advanced Solid Tumors	Non-Small Cell Lung Cancer; Colorectal Cancer; Pancreatic Cancer	3050 - Parkville; 2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT02713529
NCT02713867	CheckMate-384	Phase 3		WA, SA, TAS, QLD, NSW, VIC	21/03/2016	21/04/2016	Nivolumab	anti-PD-1_monoclonal_antibody	Nivolumab	anti-PD-1_monoclonal_antibody	CA209-384	A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks	Lung Cancer	2298 - Waratah; 7000 - Hobart; 5042 - Bedford Park; 5112 - Elizabeth Vale; 6150 - Murdoch; 3084 - Heidelberg; 5037 - Kurralta Park; 2065 - St Leonards; 2145 - Westmead,; 4102 - Woolloongabba	https://clinicaltrials.gov/ct2/show/NCT02713867
NCT02714218	CA209-511	Phase 3		QLD, NSW, VIC	21/03/2016	4/04/2016	Ipilimumab; Ipilimumab + Nivolumab; Nivolumab	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Ipilimumab + Nivolumab; Ipilimumab + Nivolumab	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	CA209-511	Phase IIIb/IV, Randomized, Double Blinded, Study of Nivolumab 3 mg/kg in Combination With Ipilimumab 1 mg/kg vs Nivolumab 1 mg/kg in Combination With Ipilimumab 3 mg/kg in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma	Melanoma	2298 - Waratah; 4120 - Greenslopes; 2060 - North Sydney; 3004 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT02714218
NCT02715531	GO30140	Phase 1		VIC, NZ	22/03/2016	6/04/2016	Atezolizumab; Atezolizumab + Bevacizumab; Atezolizumab + Bevacizumab + Capecitabine + Fluorouracil + Leucovorin + Oxaliplatin; Atezolizumab + Cisplatin + Fluorouracil + Oxaliplatin; Atezolizumab + Gemcitabine + Nab-paclitaxel; Bevacizumab; Capecitabine; Cisplatin; Fluorouracil; Gemcitabine; Leucovorin; Nab-paclitaxel; Oxaliplatin	folinic_acid; anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; gemcitabine; taxane; fluoropyrimidine; platinum-based_antineoplastic_agent; antimetabolite; anti-PD-L1_monoclonal_antibody + antimetabolite + taxane; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; Fluorouracil; anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody	Atezolizumab + Bevacizumab; Atezolizumab + Bevacizumab + Capecitabine + Fluorouracil + Leucovorin + Oxaliplatin; Atezolizumab + Cisplatin + Fluorouracil + Oxaliplatin; Atezolizumab + Gemcitabine + Nab-paclitaxel; Atezolizumab + Bevacizumab; Atezolizumab + Bevacizumab + Capecitabine + Fluorouracil + Leucovorin + Oxaliplatin; Atezolizumab + Cisplatin + Fluorouracil + Oxaliplatin; Atezolizumab + Gemcitabine + Nab-paclitaxel	anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + antimetabolite + taxane; anti-PD-L1_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; Fluorouracil; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + antimetabolite + taxane; anti-PD-L1_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; gemcitabine	GO30140	An Open-Label, Multicenter Phase Ib Study of The Safety and Efficacy of Atezolizumab (Anti-PD-L1 Antibody) Administered in Combination With Bevacizumab and/or Other Treatments in Patients With Solid Tumors	Solid Tumor	3084 - Heidelberg; Auckland; 3168 - Clayton	https://clinicaltrials.gov/ct2/show/NCT02715531
NCT02715804	2015-004068-13--HALO-109-301	Phase 3		VIC, NSW, SA	22/03/2016	14/03/2016	Gemcitabine; Gemcitabine + Nab-paclitaxel; Nab-paclitaxel; Placebo; rHuPH20	placebo; antimetabolite; recombinant_human_hyaluronidase; gemcitabine; taxane; antimetabolite + taxane	Gemcitabine + Nab-paclitaxel; Gemcitabine + Nab-paclitaxel; Placebo; rHuPH20	antimetabolite + taxane; antimetabolite + taxane; gemcitabine; placebo; recombinant_human_hyaluronidase	2015-004068-13  HALO-109-301	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Subjects With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma	Pancreatic Ductal Carcinoma	- Bendigo; - Bankstown; - Camperdown; - St Leonards; - Frankston; - Darlinghurst; - Bedford; - Bentleigh East	https://clinicaltrials.gov/ct2/show/NCT02715804
NCT02721641	2007-000348-28--BO15943	Phase 3		NSW, VIC, QLD, NZ	29/03/2016	1/06/1999	Trastuzumab	anti-ERBB2_monoclonal_antibody	Trastuzumab	anti-ERBB2_monoclonal_antibody	2007-000348-28  BO15943	A Single Arm, Multi-Center, International, Continuation Trial of Recombinant Humanized Antibody Herceptin (Trastuzumab) in Patients With HER2-Overexpressing Tumors	Neoplasms	4006 - Brisbane; 2298 - Waratah; 3052 - Parkville; Auckland; 3220 - Geelong; 3065 - Fitzroy; 2170 - Liverpool; 4066 - Brisbane	https://clinicaltrials.gov/ct2/show/NCT02721641
NCT02723955	2016-000148-32--204691	Phase 1	NOT_RECRUITING	VIC, WA	31/03/2016	23/06/2016	Bintrafusp Alfa; Bintrafusp Alfa + GSK3359609; Carboplatin; Cisplatin; Cobolimab; Cobolimab + Dostarlimab + GSK3359609; Docetaxel; Dostarlimab; Dostarlimab + GSK3359609; Fluorouracil; GSK3174998; GSK3174998 + GSK3359609; GSK3359609; GSK3359609 + Pembrolizumab; Gemcitabine; Paclitaxel; Pembrolizumab; Pemetrexed	anti-PD-1_monoclonal_antibody; anti-PD-L1/TGF-beta_fusion_protein; anti-ICOS_agonistic_antibody + anti-PD-1_monoclonal_antibody + anti-TIM3_monoclonal_antibody; anti-ICOS_agonistic_antibody + anti-PD-1_monoclonal_antibody; anti-TIM3_monoclonal_antibody; gemcitabine; taxane; anti-ICOS_agonistic_antibody + anti-OX40_agonistic_antibody; fluoropyrimidine; platinum-based_antineoplastic_agent; antimetabolite; Fluorouracil; anti-OX40_agonistic_antibody; anti-ICOS_agonistic_antibody + anti-PD-L1/TGF-beta_fusion_protein; anti-ICOS_agonistic_antibody	Bintrafusp Alfa + GSK3359609; Cobolimab + Dostarlimab + GSK3359609; Dostarlimab + GSK3359609; GSK3174998 + GSK3359609; GSK3359609; GSK3359609 + Pembrolizumab; Bintrafusp Alfa + GSK3359609; Carboplatin; Cisplatin; Cobolimab + Dostarlimab + GSK3359609; Docetaxel; Dostarlimab + GSK3359609; Fluorouracil; GSK3174998 + GSK3359609; GSK3359609 + Pembrolizumab; Gemcitabine; Paclitaxel; Pemetrexed	anti-ICOS_agonistic_antibody; anti-ICOS_agonistic_antibody + anti-OX40_agonistic_antibody; anti-ICOS_agonistic_antibody + anti-PD-1_monoclonal_antibody; anti-ICOS_agonistic_antibody + anti-PD-1_monoclonal_antibody + anti-TIM3_monoclonal_antibody; anti-ICOS_agonistic_antibody + anti-PD-L1/TGF-beta_fusion_protein; Fluorouracil; anti-ICOS_agonistic_antibody + anti-OX40_agonistic_antibody; anti-ICOS_agonistic_antibody + anti-PD-1_monoclonal_antibody; anti-ICOS_agonistic_antibody + anti-PD-1_monoclonal_antibody + anti-TIM3_monoclonal_antibody; anti-ICOS_agonistic_antibody + anti-PD-L1/TGF-beta_fusion_protein; antimetabolite; fluoropyrimidine; gemcitabine; platinum-based_antineoplastic_agent; taxane	2016-000148-32  204691	A Phase I Open Label Study of GSK3359609 Administered Alone and in Combination With Anticancer Agents in Subjects With Selected Advanced Solid Tumors	Neoplasms	3000 - Melbourne; 3084 - Heidelberg; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT02723955
NCT02724579	NCI-2016-00150--ACNS1422	Phase 2		SA, NSW, WA	31/03/2016	2/10/2017	Cisplatin; Cyclophosphamide; Lomustine; Radiotherapy; Vincristine	radiotherapy; alkylating_agent; platinum-based_antineoplastic_agent; vinca_alkaloid	Radiotherapy; Cisplatin; Cyclophosphamide; Lomustine; Vincristine	radiotherapy; alkylating_agent; platinum-based_antineoplastic_agent; vinca_alkaloid	NCI-2016-00150  ACNS1422	A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients	Medulloblastoma	6008 - Perth; 6009 - Perth; 5006 - North Adelaide; 2310 - Hunter Regional Mail Centre	https://clinicaltrials.gov/ct2/show/NCT02724579
NCT02725268	U1111-1168-1824--C31004	Phase 2		VIC, NSW, QLD	31/03/2016	1/04/2016	MLN0128; Paclitaxel; Paclitaxel + Sapanisertib; Sapanisertib; Sapanisertib + Serabelisib; Serabelisib	mTORC1/mTORC2_inhibitor + taxane; PI3K_alpha_inhibitor + mTORC1/mTORC2_inhibitor; taxane; mTORC1/mTORC2_inhibitor; PI3K_alpha_inhibitor	Paclitaxel; Paclitaxel + Sapanisertib; Sapanisertib; Sapanisertib + Serabelisib; MLN0128; Paclitaxel + Sapanisertib; Sapanisertib + Serabelisib	PI3K_alpha_inhibitor + mTORC1/mTORC2_inhibitor; mTORC1/mTORC2_inhibitor; mTORC1/mTORC2_inhibitor + taxane; taxane; PI3K_alpha_inhibitor + mTORC1/mTORC2_inhibitor; mTORC1/mTORC2_inhibitor + taxane	U1111-1168-1824  C31004	A Phase 2, Randomized Study of MLN0128 (a Dual TORC1/2 Inhibitor), MLN0128+MLN1117 (a PI3Ka Inhibitor), Weekly Paclitaxel, or the Combination of Weekly Paclitaxel and MLN0128 in Women With Advanced, Recurrent, or Persistent Endometrial Cancer	Endometrial Neoplasms	3144 - Malvern; 3168 - Clayton; 2145 - Westmead; 4029 - Herston; 3011 - Footscray; 3000 - Melbourne; 2217 - Kogarah	https://clinicaltrials.gov/ct2/show/NCT02725268
NCT02726334	BNC101.-001	Phase 1		SA, VIC	1/04/2016	1/03/2016	BNC101	anti-LGR5_monoclonal_antibody	BNC101	anti-LGR5_monoclonal_antibody	BNC101. 001	A Phase I, Dose Escalation Study of BNC101 (Anti-LGR5 Humanized Monoclonal Antibody) in Patients With Metastatic Colorectal Cancer.	Colorectal Cancer	3084 - Heidelberg; 5042 - Bedford Park; 3050 - Melbourne; 3168 - Clayton	https://clinicaltrials.gov/ct2/show/NCT02726334
NCT02737501	ALTA-1L	Phase 3		NSW, VIC	14/04/2016	26/05/2016	Brigatinib; Brigatinib + Crizotinib + Radiotherapy; Crizotinib; Radiotherapy	MET_inhibitor,type_1 + ROS1_inhibitor + radiotherapy; EGFR/FLT3/FER/ROS1/IGF1R_inhibitor; EGFR/FLT3/FER/ROS1/IGF1R_inhibitor + ROS1_inhibitor + radiotherapy; MET_inhibitor,type_1; ROS1_inhibitor; ALK_inhibitor,second_generation + ROS1_inhibitor + radiotherapy; ALK_inhibitor,second_generation; ALK_inhibitor,second_generation + MET_inhibitor,type_1 + radiotherapy; ALK_inhibitor,first_generation + ALK_inhibitor,second_generation + radiotherapy; ROS1_inhibitor + radiotherapy; EGFR/FLT3/FER/ROS1/IGF1R_inhibitor + MET_inhibitor,type_1 + radiotherapy; ALK_inhibitor,first_generation; radiotherapy; ALK_inhibitor,first_generation + EGFR/FLT3/FER/ROS1/IGF1R_inhibitor + radiotherapy; ALK_inhibitor,first_generation + ROS1_inhibitor + radiotherapy	Brigatinib; Brigatinib + Crizotinib + Radiotherapy; Crizotinib; Brigatinib + Crizotinib + Radiotherapy	ALK_inhibitor,first_generation; ALK_inhibitor,first_generation + ALK_inhibitor,second_generation + radiotherapy; ALK_inhibitor,first_generation + EGFR/FLT3/FER/ROS1/IGF1R_inhibitor + radiotherapy; ALK_inhibitor,first_generation + ROS1_inhibitor + radiotherapy; ALK_inhibitor,second_generation; ALK_inhibitor,second_generation + MET_inhibitor,type_1 + radiotherapy; ALK_inhibitor,second_generation + ROS1_inhibitor + radiotherapy; EGFR/FLT3/FER/ROS1/IGF1R_inhibitor; EGFR/FLT3/FER/ROS1/IGF1R_inhibitor + MET_inhibitor,type_1 + radiotherapy; EGFR/FLT3/FER/ROS1/IGF1R_inhibitor + ROS1_inhibitor + radiotherapy; MET_inhibitor,type_1; MET_inhibitor,type_1 + ROS1_inhibitor + radiotherapy; ROS1_inhibitor; ROS1_inhibitor + radiotherapy; ALK_inhibitor,first_generation + ALK_inhibitor,second_generation + radiotherapy; ALK_inhibitor,first_generation + EGFR/FLT3/FER/ROS1/IGF1R_inhibitor + radiotherapy; ALK_inhibitor,first_generation + ROS1_inhibitor + radiotherapy; ALK_inhibitor,second_generation + MET_inhibitor,type_1 + radiotherapy; ALK_inhibitor,second_generation + ROS1_inhibitor + radiotherapy; EGFR/FLT3/FER/ROS1/IGF1R_inhibitor + MET_inhibitor,type_1 + radiotherapy; EGFR/FLT3/FER/ROS1/IGF1R_inhibitor + ROS1_inhibitor + radiotherapy; MET_inhibitor,type_1 + ROS1_inhibitor + radiotherapy; ROS1_inhibitor + radiotherapy	U1111-1210-4363  AP26113-13-301	A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) Versus Crizotinib in Patients With ALK-positive Advanced Lung Cancer	Advanced Malignancies; Lung Cancer; Carcinoma; Non-small Cell Lung Cancer	3165 - Bentleigh East; 2217 - Kogarah; 3065 - Fitzroy; 2065 - St Leonards	https://clinicaltrials.gov/ct2/show/NCT02737501
NCT02741570	CheckMate-651	Phase 3		WA, SA, VIC, NSW, QLD	18/04/2016	5/10/2016	Carboplatin; Cetuximab; Cisplatin; Fluorouracil; Ipilimumab; Ipilimumab + Nivolumab; Nivolumab	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; Fluorouracil; anti-EGFR_monoclonal_antibody; fluoropyrimidine	Ipilimumab + Nivolumab; Carboplatin; Cetuximab; Cisplatin; Fluorouracil; Ipilimumab + Nivolumab	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; Fluorouracil; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-EGFR_monoclonal_antibody; fluoropyrimidine; platinum-based_antineoplastic_agent	2016-000725-39  CA209-651	An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination With Ipilimumab Versus Extreme Study Regimen (Cetuximab + Cisplatin/Carboplatin + Fluorouracil) as First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)	Head and Neck Cancer	5112 - Elizabeth Vale; 4814 - Douglas; 2250 - Gosford; 3168 - Clayton; 6009 - Nedlands; 2010 - Darlinghurst; 4102 - Brisbane; 2148 - Blacktown; 2065 - St. Leonards; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT02741570
NCT02743221	TASCO1	Phase 2		SA, VIC, NSW	19/04/2016	29/04/2016	Bevacizumab; Bevacizumab + Capecitabine; Bevacizumab + Trifluridine/Tipiracil; Capecitabine; Trifluridine/Tipiracil	Tipiracil Hydrochloride; Trifluridine; thymidine_phosphorylase_inhibitor; anti-VEGF_monoclonal_antibody + thymidine_phosphorylase_inhibitor; anti-VEGF_monoclonal_antibody + fluoropyrimidine; fluoropyrimidine; anti-VEGF_monoclonal_antibody + antimetabolite; Tipiracil Hydrochloride + anti-VEGF_monoclonal_antibody; antimetabolite; Trifluridine + anti-VEGF_monoclonal_antibody; anti-VEGF_monoclonal_antibody	Bevacizumab + Capecitabine; Bevacizumab + Trifluridine/Tipiracil; Bevacizumab + Capecitabine; Bevacizumab + Trifluridine/Tipiracil	Tipiracil Hydrochloride + anti-VEGF_monoclonal_antibody; Trifluridine + anti-VEGF_monoclonal_antibody; anti-VEGF_monoclonal_antibody + antimetabolite; anti-VEGF_monoclonal_antibody + fluoropyrimidine; anti-VEGF_monoclonal_antibody + thymidine_phosphorylase_inhibitor; Tipiracil Hydrochloride + anti-VEGF_monoclonal_antibody; Trifluridine + anti-VEGF_monoclonal_antibody; anti-VEGF_monoclonal_antibody + antimetabolite; anti-VEGF_monoclonal_antibody + fluoropyrimidine; anti-VEGF_monoclonal_antibody + thymidine_phosphorylase_inhibitor	2015-004544-18  CL2-95005-002	An Open-label, Randomised, Non-comparative Phase 2 Study Evaluating S 95005 (TAS-102) Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Metastatic COlorectal Cancer Who Are Non-eligible for Intensive Therapy (TASCO1 Study).	Metastatic Colorectal Cancer	VIC 3021 - Saint Albans; NSW 2050 - Camperdown; SA 5011 - Woodville; VIC 3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT02743221
NCT02747342	SHR3680-002	Phase 1	NOT_RECRUITING	QLD, NSW	21/04/2016	1/09/2016	Fuzuloparib; Fuzuloparib + Rezvilutamide; Rezvilutamide	PARP_inhibitor; androgen_receptor_antagonist; PARP_inhibitor + androgen_receptor_antagonist	Fuzuloparib + Rezvilutamide; Fuzuloparib + Rezvilutamide	PARP_inhibitor + androgen_receptor_antagonist; PARP_inhibitor + androgen_receptor_antagonist	SHR3680-002	A Phase 1 Trial of SHR3680 With or Without SHR3162 in Subjects With Metastatic Castration-Resistant Prostate Cancer	Neoplasm; Prostate Cancer	2170 - Liverpool; 2145 - Sydney; 2217 - Kogarah; 4101 - South Brisbane; 2640 - Albury; 2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT02747342
NCT02748213	MO16419	Phase 2		WA, SA, VIC, NSW, QLD	22/04/2016	1/02/2002	Capecitabine; Capecitabine + Docetaxel + Trastuzumab; Docetaxel; Docetaxel + Trastuzumab; Trastuzumab	anti-ERBB2_monoclonal_antibody + taxane; anti-ERBB2_monoclonal_antibody; anti-ERBB2_monoclonal_antibody + fluoropyrimidine + taxane; taxane; fluoropyrimidine	Capecitabine + Docetaxel + Trastuzumab; Docetaxel + Trastuzumab; Capecitabine + Docetaxel + Trastuzumab; Docetaxel + Trastuzumab	anti-ERBB2_monoclonal_antibody + fluoropyrimidine + taxane; anti-ERBB2_monoclonal_antibody + taxane; anti-ERBB2_monoclonal_antibody + fluoropyrimidine + taxane; anti-ERBB2_monoclonal_antibody + taxane	MO16419	An Open-Label, Randomized Phase II Study of Herceptin (Trastuzumab), Taxotere (Docetaxel), and Xeloda (Capecitabine) in Combination, Versus Herceptin (Trastuzumab) Plus Taxotere (Docetaxel), in Patients With Advanced and/or Metastatic Breast Cancers That Overexpress HER2	Breast Cancer	6000 - Perth; 4215 - Southport; 2050 - Camperdown; 3181 - Melbourne; 3002 - Melbourne; 3220 - Geelong; 5011 - Adelaide; 4066 - Brisbane	https://clinicaltrials.gov/ct2/show/NCT02748213
NCT02750514	FRACTION-Lung	Phase 2		VIC	25/04/2016	9/05/2016	Dasatinib; Dasatinib + Nivolumab; Ipilimumab; Ipilimumab + Nivolumab; Linrodostat; Linrodostat + Nivolumab; Nivolumab; Nivolumab + Relatlimab; Relatlimab	PDGFRA_inhibitor; anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; PDGFRA_inhibitor + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; BCR-ABL1_inhibitor,second_generation + anti-PD-1_monoclonal_antibody; SRC_inhibitor + anti-PD-1_monoclonal_antibody; SRC_inhibitor; KIT_inhibitor + anti-PD-1_monoclonal_antibody; IDO1_inhibitor; YES1_inhibitor; IDO1_inhibitor + anti-PD-1_monoclonal_antibody; YES1_inhibitor + anti-PD-1_monoclonal_antibody; BCR-ABL1_inhibitor,second_generation; KIT_inhibitor	Dasatinib + Nivolumab; Ipilimumab + Nivolumab; Linrodostat + Nivolumab; Nivolumab; Nivolumab + Relatlimab; Dasatinib + Nivolumab; Ipilimumab + Nivolumab; Linrodostat + Nivolumab; Nivolumab + Relatlimab	BCR-ABL1_inhibitor,second_generation + anti-PD-1_monoclonal_antibody; IDO1_inhibitor + anti-PD-1_monoclonal_antibody; KIT_inhibitor + anti-PD-1_monoclonal_antibody; PDGFRA_inhibitor + anti-PD-1_monoclonal_antibody; SRC_inhibitor + anti-PD-1_monoclonal_antibody; YES1_inhibitor + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; BCR-ABL1_inhibitor,second_generation + anti-PD-1_monoclonal_antibody; IDO1_inhibitor + anti-PD-1_monoclonal_antibody; KIT_inhibitor + anti-PD-1_monoclonal_antibody; PDGFRA_inhibitor + anti-PD-1_monoclonal_antibody; SRC_inhibitor + anti-PD-1_monoclonal_antibody; YES1_inhibitor + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	CA018-001	A Phase 2, Fast Real Time Assessment of Combination Therapies in Immuno-Oncology Study in Subjects With Advanced Non-Small Cell Lung Cancer (FRACTION-Lung)	Advanced Cancer	- Clayton	https://clinicaltrials.gov/ct2/show/NCT02750514
NCT02752074	Keynote-252	Phase 3		QLD, NSW, VIC, SA, NZ	26/04/2016	21/06/2016	Epacadostat; Epacadostat + Pembrolizumab; Pembrolizumab; Placebo	anti-PD-1_monoclonal_antibody; IDO1_inhibitor; placebo; IDO1_inhibitor + anti-PD-1_monoclonal_antibody	Epacadostat + Pembrolizumab; Pembrolizumab; Epacadostat + Pembrolizumab; Placebo	IDO1_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; IDO1_inhibitor + anti-PD-1_monoclonal_antibody; placebo	INCB 24360-301 (ECHO-301)	A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Pembrolizumab (MK-3475) in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)	Melanoma	Tauranga; - Kurralta Park; - Cairns; Dunedin; - Melbourne; - Greenslopes; - Camperdown; - Westmead; - Wollstonecraft	https://clinicaltrials.gov/ct2/show/NCT02752074
NCT02753127	CanStem303C	Phase 3		NSW, VIC, QLD, SA	27/04/2016	1/06/2016	Bevacizumab; Bevacizumab + Fluorouracil + Irinotecan + Leucovorin; Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Napabucasin; Fluorouracil; Irinotecan; Leucovorin; Napabucasin	anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor; cancer_stemness_inhibitor; anti-VEGF_monoclonal_antibody + cancer_stemness_inhibitor + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor; Fluorouracil; folinic_acid; anti-VEGF_monoclonal_antibody; topoisomerase_inhibitor; fluoropyrimidine	Bevacizumab + Fluorouracil + Irinotecan + Leucovorin; Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Napabucasin; Bevacizumab + Fluorouracil + Irinotecan + Leucovorin; Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Napabucasin	anti-VEGF_monoclonal_antibody + cancer_stemness_inhibitor + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor; anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor; Fluorouracil; anti-VEGF_monoclonal_antibody + cancer_stemness_inhibitor + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor; anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor	BB608-303CRC  CanStem303C	A Phase 3 Study of BBI-608 in Combination With 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients With Previously Treated Metastatic Colorectal Cancer (CRC).	Colorectal Cancer	4215 - Southport; 3021 - Melbourne; 2010 - Darlinghurst; 3550 - Bendigo; 5042 - Bedford Park; 2200 - Bankstown; 2031 - Randwick; 3630 - Shepparton; 3084 - Heidelberg; 2444 - Port Macquarie; 3199 - Frankston; 4560 - Nambour; 5011 - Woodville; 2065 - St Leonards; 3065 - Fitzroy	https://clinicaltrials.gov/ct2/show/NCT02753127
NCT02754141	2016-000603-91--CA013-004	Phase 1/Phase 2	NOT_RECRUITING	NSW, VIC	28/04/2016	21/06/2016	BMS-986179; BMS-986179 + Nivolumab; BMS-986179 + rHuPH20; Nivolumab; rHuPH20	recombinant_human_hyaluronidase; anti-CD73_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CD73_monoclonal_antibody + recombinant_human_hyaluronidase; anti-CD73_monoclonal_antibody + anti-PD-1_monoclonal_antibody	BMS-986179; BMS-986179 + Nivolumab; BMS-986179 + rHuPH20; BMS-986179 + Nivolumab; BMS-986179 + rHuPH20	anti-CD73_monoclonal_antibody; anti-CD73_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CD73_monoclonal_antibody + recombinant_human_hyaluronidase; anti-CD73_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CD73_monoclonal_antibody + recombinant_human_hyaluronidase	2016-000603-91  CA013-004	A Phase 1/2a Study of BMS-986179 Administered Alone and in Combination With Nivolumab (BMS-936558) in Subjects With Advanced Solid Tumors	Malignant Solid Tumor	3004 - Melbourne; 2010 - Darlinghurst; 2031 - Randwick	https://clinicaltrials.gov/ct2/show/NCT02754141
NCT02759640	HS-10241-001	Phase 1		NSW	3/05/2016	1/09/2016	HS-10241	MET_inhibitor	HS-10241	MET_inhibitor	HS-10241-001	First-in-Human, Dose-Escalation Trial of C-Met Kinase Inhibitor HS-10241 in Subjects With Advanced Solid Tumors	Neoplasm; Solid Tumors	2050 - Camperdown; 2170 - Liverpool	https://clinicaltrials.gov/ct2/show/NCT02759640
NCT02759666	SHR3162-002	Phase 1		NSW, VIC	3/05/2016	1/06/2016	Fuzuloparib	PARP_inhibitor	Fuzuloparib	PARP_inhibitor	SHR3162-002	A Multicenter, Open-Label, Phase 1 Trial of SHR3162 Given Orally to Subjects With Advanced Solid Tumors	Solid Tumors; Neoplasm	2640 - Albury; - Melbourne; 2170 - Liverpool	https://clinicaltrials.gov/ct2/show/NCT02759666
NCT02760498	2016-000105-36--R2810-ONC-1540	Phase 2		QLD, VIC, NSW, TAS, SA, NZ, ACT, WA	3/05/2016	7/04/2016	Cemiplimab	anti-PD-1_monoclonal_antibody	Cemiplimab	anti-PD-1_monoclonal_antibody	2016-000105-36  R2810-ONC-1540	A Phase 2 Study of REGN2810, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients With Advanced Cutaneous Squamous Cell Carcinoma	Advanced Cutaneous Squamous Cell Carcinoma	- Bundaberg; - Liverpool; 4029 - Herston; 5037 - Kurralta Park; 3000 - Melbourne; - Kogarah; - Hobart; 2065 - St Leonards; Hamilton; 6009 - Nedlands; - Waratah; - Gosford; - Lismore; - Wodonga; - Southport; - Urraween; - Garran; - Camperdown; - Woolloongabba	https://clinicaltrials.gov/ct2/show/NCT02760498
NCT02763579	IMpower133	Phase 3		NSW, VIC, QLD	5/05/2016	7/06/2016	Atezolizumab; Atezolizumab + Carboplatin + Etoposide; Carboplatin; Carboplatin + Etoposide; Etoposide; Placebo	platinum-based_antineoplastic_agent; placebo; anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-PD-L1_monoclonal_antibody; topoisomerase_inhibitor	Atezolizumab + Carboplatin + Etoposide; Carboplatin + Etoposide; Atezolizumab + Carboplatin + Etoposide; Carboplatin + Etoposide; Placebo	anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; placebo; platinum-based_antineoplastic_agent + topoisomerase_inhibitor	2015-004861-97  GO30081	A Phase I/III, Randomized, Double-Blind, Placebo-Controlled Study of Carboplatin Plus Etoposide With or Without Atezolizumab (Anti-PD-L1 Antibody) in Patients With Untreated Extensive-Stage Small Cell Lung Cancer	Small Cell Lung Carcinoma	4032 - Chermside; 2050 - Camperdown; 3052 - Parkville	https://clinicaltrials.gov/ct2/show/NCT02763579
NCT02767804	X396-CLI-301	Phase 3		NSW, QLD	10/05/2016	1/06/2016	Crizotinib; Ensartinib	MET_inhibitor,type_1; ALK_inhibitor,first_generation; ROS1_inhibitor; ALK_inhibitor,third_generation	Crizotinib; Ensartinib	ALK_inhibitor,first_generation; ALK_inhibitor,third_generation; MET_inhibitor,type_1; ROS1_inhibitor	X396-CLI-301	Phase 3 Randomized Study Comparing X-396 (Ensartinib) to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients	Non-small Cell Lung Cancer	- Woolloongabba; - Camperdown; 2640 - Albury	https://clinicaltrials.gov/ct2/show/NCT02767804
NCT02773524	INTEGRATEIIa	Phase 3		ACT, NT, WA, QLD, VIC, NSW, TAS, SA, NZ	16/05/2016	1/11/2016	Placebo; Regorafenib	placebo; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor	Regorafenib; Placebo	KIT/PDGFR/RET/VEGFR/FGFR_inhibitor; placebo	AG0315OG	A Randomised Phase III Double-Blind Placebo-Controlled Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (AGOC)	Gastro-Oesophageal Cancer	6008 - Subiaco; 2139 - Concord; 2035 - New Lambton Heights; 4029 - Herston; 3084 - Heidelberg; - Saint Leonards; 2217 - Kogarah; 5035 - Ashford; 2444 - Port Macquarie; - Canberra; 0810 - Tiwi; Auckland; 2450 - Coffs Harbour; 3355 - Wendouree; 4560 - Sunshine Coast; 2145 - Westmead; 2031 - Randwick; 2250 - Gosford; 3168 - Clayton; 700 - Hobart; 4814 - Douglas; 6009 - Nedlands; 2485 - Tweed Heads; 2640 - Albury; 5011 - Woodville South; 2010 - Darlinghurst; 5042 - Bedford Park	https://clinicaltrials.gov/ct2/show/NCT02773524
NCT02775435	KEYNOTE-407	Phase 3	NOT_RECRUITING	NSW	15/05/2016	9/06/2016	Carboplatin; Carboplatin + Nab-paclitaxel + Paclitaxel; Carboplatin + Nab-paclitaxel + Paclitaxel + Pembrolizumab; Dexamethasone; Nab-paclitaxel; Paclitaxel; Pembrolizumab; Placebo	glucocorticoid; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent + taxane; placebo; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; taxane	Carboplatin + Nab-paclitaxel + Paclitaxel; Carboplatin + Nab-paclitaxel + Paclitaxel + Pembrolizumab; Carboplatin + Nab-paclitaxel + Paclitaxel; Carboplatin + Nab-paclitaxel + Paclitaxel + Pembrolizumab; Dexamethasone; Placebo	anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; platinum-based_antineoplastic_agent + taxane; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; glucocorticoid; placebo; platinum-based_antineoplastic_agent + taxane	2016-000229-38  3475-407	A Randomized, Double-Blind, Phase III Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in First Line Metastatic Squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-407)	Non-small Cell Lung Cancer	- North Ryde	https://clinicaltrials.gov/ct2/show/NCT02775435
NCT02787005	KEYNOTE-199	Phase 2	NOT_RECRUITING	NSW	26/05/2016	1/07/2016	Enzalutamide; Enzalutamide + Pembrolizumab; Pembrolizumab	antiandrogen,nonsteroidal,second_generation; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation	Enzalutamide + Pembrolizumab; Pembrolizumab; Enzalutamide + Pembrolizumab	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation; anti-PD-1_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation	2015-003644-40  3475-199	Phase II Trial of Pembrolizumab (MK-3475) in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-199)	Metastatic Castration-resistant Prostate Cancer	- North Ryde	https://clinicaltrials.gov/ct2/show/NCT02787005
NCT02788279	2016-000202-11--GO30182	Phase 3		NSW, VIC	2/06/2016	5/07/2016	Atezolizumab; Atezolizumab + Cobimetinib; Cobimetinib; Regorafenib	anti-PD-L1_monoclonal_antibody; MEK_inhibitor; MEK_inhibitor + anti-PD-L1_monoclonal_antibody; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor	Atezolizumab; Atezolizumab + Cobimetinib; Regorafenib; Atezolizumab + Cobimetinib	KIT/PDGFR/RET/VEGFR/FGFR_inhibitor; MEK_inhibitor + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; MEK_inhibitor + anti-PD-L1_monoclonal_antibody	2016-000202-11  GO30182	A Phase III, Open-Label, Multicenter, Three-Arm, Randomized Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy vs. Regorafenib in Patients With Previously Treated Unresectable Locally Advanced or Metastatic Colorectal Adenocarcinoma	Colorectal Cancer	2076 - Sydney; 3168 - Clayton; 2444 - Port Macquarie; 3199 - Frankston; 3084 - Heidelberg; 2065 - St Leonards	https://clinicaltrials.gov/ct2/show/NCT02788279
NCT02794571	2016-000944-33--GO30103	Phase 1		NSW, VIC	9/06/2016	23/05/2016	Atezolizumab; Atezolizumab + Bevacizumab + Tiragolumab; Atezolizumab + Capecitabine + Tiragolumab; Atezolizumab + Carboplatin + Cisplatin + Etoposide + Tiragolumab; Atezolizumab + Carboplatin + Cisplatin + Pemetrexed + Tiragolumab; Atezolizumab + Carboplatin + Paclitaxel + Tiragolumab; Atezolizumab + Tiragolumab; Bevacizumab; Capecitabine; Carboplatin; Cisplatin; Etoposide; Paclitaxel; Pembrolizumab; Pembrolizumab + Tiragolumab; Pemetrexed; Tiragolumab	anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-PD-1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; taxane; fluoropyrimidine; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite; anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + fluoropyrimidine; anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; topoisomerase_inhibitor	Atezolizumab + Bevacizumab + Tiragolumab; Atezolizumab + Capecitabine + Tiragolumab; Atezolizumab + Carboplatin + Cisplatin + Etoposide + Tiragolumab; Atezolizumab + Carboplatin + Cisplatin + Pemetrexed + Tiragolumab; Atezolizumab + Carboplatin + Paclitaxel + Tiragolumab; Atezolizumab + Tiragolumab; Pembrolizumab + Tiragolumab; Tiragolumab; Atezolizumab + Bevacizumab + Tiragolumab; Atezolizumab + Capecitabine + Tiragolumab; Atezolizumab + Carboplatin + Cisplatin + Etoposide + Tiragolumab; Atezolizumab + Carboplatin + Cisplatin + Pemetrexed + Tiragolumab; Atezolizumab + Carboplatin + Paclitaxel + Tiragolumab; Atezolizumab + Tiragolumab; Pembrolizumab + Tiragolumab	anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + fluoropyrimidine; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + fluoropyrimidine; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor	2016-000944-33  GO30103	A Phase Ia/Ib Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Patients With Locally Advanced or Metastatic Tumors	Advanced/Metastatic Tumors	3002 - East Melbourne; 2010 - Darlinghurst	https://clinicaltrials.gov/ct2/show/NCT02794571
NCT02799095	ALK4230-A101	Phase 1/Phase 2		NSW	14/06/2016	1/07/2016	Nemvaleukin alfa; Nemvaleukin alfa + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; IL-2_fusion_protein + anti-PD-1_monoclonal_antibody; IL-2_fusion_protein	Nemvaleukin alfa; Nemvaleukin alfa + Pembrolizumab; Nemvaleukin alfa + Pembrolizumab	IL-2_fusion_protein; IL-2_fusion_protein + anti-PD-1_monoclonal_antibody; IL-2_fusion_protein + anti-PD-1_monoclonal_antibody	ALK4230-A101	A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors - ARTISTRY-1	Advanced Solid Tumors	2640 - Albury; 2298 - Waratah	https://clinicaltrials.gov/ct2/show/NCT02799095
NCT02799602	ARASENS	Phase 3		VIC, NSW, SA	15/06/2016	30/11/2016	Darolutamide; Darolutamide + Docetaxel; Docetaxel; Placebo	antiandrogen,nonsteroidal,second_generation + taxane; antiandrogen,nonsteroidal,second_generation; taxane; placebo	Darolutamide + Docetaxel; Darolutamide + Docetaxel; Placebo	antiandrogen,nonsteroidal,second_generation + taxane; antiandrogen,nonsteroidal,second_generation + taxane; placebo	2015-002590-38  17777	A Randomized, Double-blind, Placebo Controlled Phase III Study of Darolutamide (ODM-201) Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients With Metastatic Hormone Sensitive Prostate Cancer	Prostatic Neoplasms	2031 - Randwick; 3065 - Melbourne; 5037 - Kurralta Park; 5000 - Adelaide; 2010 - Sydney	https://clinicaltrials.gov/ct2/show/NCT02799602
NCT02807181	SIRCCA	Phase 2/Phase 3		NSW, VIC	21/06/2016	1/01/2017	Cisplatin; Cisplatin + Gemcitabine; Gemcitabine	platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; gemcitabine; antimetabolite	Cisplatin + Gemcitabine; Cisplatin + Gemcitabine	antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; gemcitabine	STX0115	Prospective, Multicenter, Randomized, Controlled Study Evaluating SIR-Spheres Y-90 Resin Microspheres Preceding Cisplatin-gemcitabine (CIS-GEM) Chemotherapy Versus CIS-GEM Chemotherapy Alone as First-line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma	Intrahepatic Cholangiocarcinoma	3000 - Melbourne; 2109 - North Ryde	https://clinicaltrials.gov/ct2/show/NCT02807181
NCT02807636	IMvigor130	Phase 3		SA, QLD, NSW, VIC	21/06/2016	30/06/2016	Atezolizumab; Atezolizumab + Carboplatin + Cisplatin + Gemcitabine; Carboplatin; Cisplatin; Gemcitabine; Placebo	anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent; gemcitabine; placebo; antimetabolite	Atezolizumab; Atezolizumab + Carboplatin + Cisplatin + Gemcitabine; Atezolizumab + Carboplatin + Cisplatin + Gemcitabine; Placebo	anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; gemcitabine; placebo	2016-000250-35  WO30070	A Phase III, Multicenter, Randomized, Placebo-Controlled Study of Atezolizumab (Anti-PD-L1 Antibody) as Monotherapy and in Combination With Platinum-Based Chemotherapy in Patients With Untreated Locally Advanced or Metastatic Urothelial Carcinoma	Urothelial Carcinoma	4029 - Herston; 2109 - Macquarie Park; - St Albans; 5037 - Kurralta Park; 3144 - Malvern; 5112 - Adelaide; 3128 - Box Hill	https://clinicaltrials.gov/ct2/show/NCT02807636
NCT02811861	CLEAR	Phase 3		NSW, VIC, QLD, TAS	23/06/2016	13/10/2016	Everolimus; Everolimus + Lenvatinib; Lenvatinib; Lenvatinib + Pembrolizumab; Pembrolizumab; Sunitinib	KIT_inhibitor,first_generation; anti-PD-1_monoclonal_antibody; VEGF_inhibitor; VEGFR_inhibitor; PDGFR_inhibitor; mTORC1_inhibitor; VEGF_inhibitor + mTORC1_inhibitor; VEGF_inhibitor + anti-PD-1_monoclonal_antibody	Everolimus + Lenvatinib; Lenvatinib + Pembrolizumab; Sunitinib; Everolimus + Lenvatinib; Lenvatinib + Pembrolizumab	KIT_inhibitor,first_generation; PDGFR_inhibitor; VEGFR_inhibitor; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + mTORC1_inhibitor; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + mTORC1_inhibitor	KEYNOTE-581  E7080-G000-307	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR)	Renal Cell Carcinoma	- Hobart; - St Albans; 3084 - Heidelberg; - Macquarie park; 3128 - Box Hill; - South Brisbane	https://clinicaltrials.gov/ct2/show/NCT02811861
NCT02821013	STOP-GAP	Phase 3		QLD, NSW, VIC, SA, South A.VIC	1/07/2016	4/07/2016					UQ-QMP-0001  ME13	A Randomized Phase III Trial of the Duration of Anti-PD-1 Therapy in Metastatic Melanoma	Unresectable/Metastatic Melanoma	3128 - Box Hill; 2298 - Waratah; 4215 - Southport; 3168 - Clayton; 2145 - Westmead; 2450 - Coffs Harbour; 4870 - Cairns; 2650 - Wagga Wagga; 4029 - Herston; 4102 - Brisbane; 3004 - Melbourne; 5011 - Woodville	https://clinicaltrials.gov/ct2/show/NCT02821013
NCT02824965	ONJ2015-001	Phase 1		VIC	7/07/2016	9/08/2017	CAVATAK; Coxsackievirus A21; Coxsackievirus A21 + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; virus-based_therapy; oncolytic_Coxsackie_virus,ICAM_overexpressing; anti-PD-1_monoclonal_antibody + oncolytic_Coxsackie_virus,ICAM_overexpressing	Coxsackievirus A21 + Pembrolizumab; CAVATAK; Coxsackievirus A21 + Pembrolizumab	anti-PD-1_monoclonal_antibody + oncolytic_Coxsackie_virus,ICAM_overexpressing; anti-PD-1_monoclonal_antibody + oncolytic_Coxsackie_virus,ICAM_overexpressing; virus-based_therapy	ONJ2015-001	A Phase I/II Open-label Trial of Intravenous CAVATAK^TM in Combination With Pembrolizumab for the Treatment of Patients With Advanced NSCLC	Non-Small Cell Lung Cancer	3078 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT02824965
NCT02829099	64457107CAN1001--CR108186	Phase 1		QLD, VIC, NSW	7/07/2016	21/09/2016	Mitazalimab	anti-CD40_agonistic_antibody	Mitazalimab	anti-CD40_agonistic_antibody	64457107CAN1001  CR108186	A Phase 1, Open-Label Study of the Safety, Pharmacokinetics and Pharmacodynamics of JNJ-64457107, an Agonistic Human Monoclonal Antibody Targeting CD40 in Patients With Advanced Stage Solid Tumors	Advanced Solid Neoplasms	4120 - Greenslopes; 2050 - Camperdown; 3168 - Clayton; 4102 - Woolloongabba	https://clinicaltrials.gov/ct2/show/NCT02829099
NCT02854436	Galahad	Phase 2	NOT_RECRUITING	WA, NSW, VIC, SA	3/08/2016	31/08/2016	Niraparib	PARP_inhibitor	Niraparib	PARP_inhibitor	64091742PCR2001  CR108208	A Phase 2 Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies	Prostatic Neoplasms	- Melbourne; - Wahroonga; - Randwick; - Murdoch; - East Albury; - Port Macquarie; - Darlinghurst; - Kurralta Park; - NSW; - Camperdown	https://clinicaltrials.gov/ct2/show/NCT02854436
NCT02857270	I8S-MC-JUAB--16419	Phase 1	NOT_RECRUITING	WA, NSW	5/08/2016	29/09/2016	Abemaciclib; Abemaciclib + LY3214996; Cetuximab; Cetuximab + Encorafenib + LY3214996; Encorafenib; Gemcitabine; Gemcitabine + LY3214996 + Nab-paclitaxel; LY3214996; LY3214996 + Midazolam; Midazolam; Nab-paclitaxel	CDK4/6_inhibitor + ERK_inhibitor; ERK_inhibitor + benzodiazepam; BRAF_V600_inhibitor; ERK_inhibitor; ERK_inhibitor + antimetabolite + taxane; gemcitabine; anti-EGFR_monoclonal_antibody; taxane; benzodiazepam; CDK4/6_inhibitor; antimetabolite; BRAF_V600_inhibitor + ERK_inhibitor + anti-EGFR_monoclonal_antibody	Abemaciclib + LY3214996; Cetuximab + Encorafenib + LY3214996; Gemcitabine + LY3214996 + Nab-paclitaxel; LY3214996; LY3214996 + Midazolam; Abemaciclib + LY3214996; Cetuximab + Encorafenib + LY3214996; Gemcitabine + LY3214996 + Nab-paclitaxel; LY3214996 + Midazolam	BRAF_V600_inhibitor + ERK_inhibitor + anti-EGFR_monoclonal_antibody; CDK4/6_inhibitor + ERK_inhibitor; ERK_inhibitor; ERK_inhibitor + antimetabolite + taxane; ERK_inhibitor + benzodiazepam; BRAF_V600_inhibitor + ERK_inhibitor + anti-EGFR_monoclonal_antibody; CDK4/6_inhibitor + ERK_inhibitor; ERK_inhibitor + antimetabolite + taxane; ERK_inhibitor + benzodiazepam; gemcitabine	I8S-MC-JUAB  16419	A Phase 1 Study of an ERK1/2 Inhibitor (LY3214996) Administered Alone or in Combination With Other Agents in Advanced Cancer	Metastatic Melanoma; Colorectal Cancer; Metastatic Non-small Cell Lung Cancer; Advanced Cancer	2010 - Sydney; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT02857270
NCT02861573	KEYNOTE-365	Phase 1		NZ	10/08/2016	17/11/2016	Abiraterone; Abiraterone + Pembrolizumab + Prednisone; Dexamethasone; Docetaxel; Docetaxel + Pembrolizumab + Prednisone; Enzalutamide; Enzalutamide + Pembrolizumab; Olaparib; Olaparib + Pembrolizumab; Pembrolizumab; Prednisone	PARP_inhibitor; anti-PD-1_monoclonal_antibody + glucocorticoid + taxane; glucocorticoid; anti-PD-1_monoclonal_antibody; CYP17A1_inhibitor + anti-PD-1_monoclonal_antibody + glucocorticoid; anti-PD-1_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation; taxane; CYP17A1_inhibitor; antiandrogen,nonsteroidal,second_generation; PARP_inhibitor + anti-PD-1_monoclonal_antibody	Abiraterone + Pembrolizumab + Prednisone; Docetaxel + Pembrolizumab + Prednisone; Enzalutamide + Pembrolizumab; Olaparib + Pembrolizumab; Abiraterone + Pembrolizumab + Prednisone; Dexamethasone; Docetaxel + Pembrolizumab + Prednisone; Enzalutamide + Pembrolizumab; Olaparib + Pembrolizumab	CYP17A1_inhibitor + anti-PD-1_monoclonal_antibody + glucocorticoid; PARP_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation; anti-PD-1_monoclonal_antibody + glucocorticoid + taxane; CYP17A1_inhibitor + anti-PD-1_monoclonal_antibody + glucocorticoid; PARP_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation; anti-PD-1_monoclonal_antibody + glucocorticoid + taxane	2016-002312-41  3475-365	Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)	Metastatic Castration-Resistant Prostate Cancer	Auckland	https://clinicaltrials.gov/ct2/show/NCT02861573
NCT02864381	2016-001402-41--GS-US-296-2013	Phase 2		QLD, NSW, TAS	12/08/2016	1/09/2016	Andecaliximab; Andecaliximab + Nivolumab; Nivolumab	anti-MMP9_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-MMP9_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Andecaliximab + Nivolumab; Nivolumab; Andecaliximab + Nivolumab	anti-MMP9_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-MMP9_monoclonal_antibody + anti-PD-1_monoclonal_antibody	2016-001402-41  GS-US-296-2013	A Phase 2, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of GS-5745 Combined With Nivolumab Versus Nivolumab Alone in Subjects With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma	Gastroesophageal Junction Adenocarcinoma; Gastric Adenocarcinoma	2076 - Wahroonga; 7000 - Hobart; 2640 - Albury; 4818 - Douglas	https://clinicaltrials.gov/ct2/show/NCT02864381
NCT02872116	CheckMate649	Phase 3		WA, SA, NSW, VIC, QLD	19/08/2016	12/10/2016	Capecitabine; Capecitabine + Oxaliplatin; Fluorouracil; Fluorouracil + Leucovorin + Oxaliplatin; Ipilimumab; Ipilimumab + Nivolumab; Leucovorin; Nivolumab; Oxaliplatin	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; fluoropyrimidine + platinum-based_antineoplastic_agent; Fluorouracil; folinic_acid; fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; fluoropyrimidine	Capecitabine + Oxaliplatin; Fluorouracil + Leucovorin + Oxaliplatin; Ipilimumab + Nivolumab; Nivolumab; Capecitabine + Oxaliplatin; Fluorouracil + Leucovorin + Oxaliplatin; Ipilimumab + Nivolumab	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; fluoropyrimidine + platinum-based_antineoplastic_agent; Fluorouracil; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; fluoropyrimidine + platinum-based_antineoplastic_agent	2016-001018-76  CA209-649	A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab Plus Ipilimumab or Nivolumab in Combination With Oxaliplatin Plus Fluoropyrimidine Versus Oxaliplatin Plus Fluoropyrimidine in Subjects With Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer	Gastroesophageal Junction Cancer; Gastric Cancer	4215 - Southport; 3630 - Shepparton; 2250 - Gosford; 3350 - Ballarat; 3021 - St Albans; 5000 - Adelaide; 6150 - Perth; 2148 - Blacktown	https://clinicaltrials.gov/ct2/show/NCT02872116
NCT02875548	TRuST	Phase 2		VIC	23/08/2016	1/08/2016	Tazemetostat	EZH2_inhibitor	Tazemetostat	EZH2_inhibitor	EZH-501	Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study	Synovial Sarcoma; Diffuse Large B-cell Lymphoma (DLBCL); Renal Medullary Carcinoma; Follicular Lymphoma (FL); Epitheliod Sarcoma (ES); Non-Hodgkin Lymphoma (NHL); Mesothelioma; Advanced Solid Tumors	3168 - Clayton; - Geelong; 3002 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT02875548
NCT02877966	HF03-14-37	Not Applicable		QLD	25/08/2016		Placebo	placebo	Placebo	placebo	HF03-14-37	Evaluation of the Effects of a Stoichiometric Mixture of Amino Acids (Amixea) on Lean Body Mass and Muscle Strengh of Patients With Unresectable Advanced Non-small Cell Lung Cancer: a Randomized, Double Blind, Placebo-controlled, Multicenter Study	Cancer Patients With Cachexia	QLD 4215 - Southport; QLD 4226 - Woolloongabba; QLD 4226 - Robina	https://clinicaltrials.gov/ct2/show/NCT02877966
NCT02899299	CheckMate743	Phase 3		WA, QLD, VIC, NSW	14/09/2016	29/11/2016	Carboplatin; Carboplatin + Cisplatin + Pemetrexed; Cisplatin; Ipilimumab; Ipilimumab + Nivolumab; Nivolumab; Pemetrexed	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; antimetabolite	Carboplatin + Cisplatin + Pemetrexed; Ipilimumab + Nivolumab; Carboplatin + Cisplatin + Pemetrexed; Ipilimumab + Nivolumab	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; antimetabolite + platinum-based_antineoplastic_agent; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; antimetabolite + platinum-based_antineoplastic_agent	2016-001859-43  CA209-743	A Phase III, Randomized, Open Label Trial of Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma	Mesothelioma	6009 - Nedlands; 3168 - Clayton; 3144 - Malvern; 4575 - Birtinya; 2139 - Sydney	https://clinicaltrials.gov/ct2/show/NCT02899299
NCT02903771	NVGN-002-101	Phase 1		SA, NSW, QLD	16/09/2016	1/11/2016	Cantrixil	benzopyran	Cantrixil	benzopyran	NVGN-002-101	Phase I Study of Intra-peritoneal Cantrixil in Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer.	Peritoneal Neoplasms; Fallopian Tube Neoplasms; Ovarian Neoplasms	- Adelaide; 2145 - Westmead; 4101 - South Brisbane	https://clinicaltrials.gov/ct2/show/NCT02903771
NCT02905266	2016-001941-26--CA209-742	Phase 3		SA, QLD, NSW, VIC	19/09/2016	27/10/2016	Ipilimumab; Ipilimumab + Nivolumab; Nivolumab	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Ipilimumab + Nivolumab; Ipilimumab + Nivolumab	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	2016-001941-26  CA209-742	Phase IIIb, Randomized, Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Previously Untreated Unresectable or Metastatic Melanoma	Melanoma	- Malvern; - North Sydney; - Greenslopes	https://clinicaltrials.gov/ct2/show/NCT02905266
NCT02908672	2016-002482-54--CO39262	Phase 3		QLD, VIC, SA, NZ, WA	21/09/2016	13/01/2017	Atezolizumab; Atezolizumab + Cobimetinib + Vemurafenib; Cobimetinib; Placebo; Vemurafenib	anti-PD-L1_monoclonal_antibody; MEK_inhibitor; placebo; BRAF_V600_inhibitor + MEK_inhibitor + anti-PD-L1_monoclonal_antibody; BRAF_V600_inhibitor	Atezolizumab + Cobimetinib + Vemurafenib; Atezolizumab + Cobimetinib + Vemurafenib; Placebo	BRAF_V600_inhibitor + MEK_inhibitor + anti-PD-L1_monoclonal_antibody; BRAF_V600_inhibitor + MEK_inhibitor + anti-PD-L1_monoclonal_antibody; placebo	2016-002482-54  CO39262	A Phase III, Double-Blinded, Randomized, Placebo-Controlled Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFV600 Mutation-Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma	Melanoma	5000 - Adelaide; 3000 - Melbourne; 6150 - Murdoch; 4102 - Woolloongabba; Tauranga; Palmerston North; Auckland	https://clinicaltrials.gov/ct2/show/NCT02908672
NCT02913313	2016-002263-34--CA020-002	Phase 1/Phase 2	NOT_RECRUITING	WA	23/09/2016	30/11/2016	BMS-986207; BMS-986207 + Ipilimumab + Nivolumab; BMS-986207 + Nivolumab; Ipilimumab; Nivolumab	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-TIGIT_monoclonal_antibody	BMS-986207; BMS-986207 + Ipilimumab + Nivolumab; BMS-986207 + Nivolumab; BMS-986207 + Ipilimumab + Nivolumab; BMS-986207 + Nivolumab	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-TIGIT_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody	2016-002263-34  CA020-002	Phase 1/2a First-In-Human Study of BMS-986207 Monoclonal Antibody Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors	Broad Solid Tumor	6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT02913313
NCT02915744	ATTAIN	Phase 3		VIC, NSW, WA	27/09/2016	1/11/2016	Capecitabine; Docetaxel; Docetaxel + Eribulin + Gemcitabine + Ixabepilone + Nab-paclitaxel + Paclitaxel + Vinorelbine; Eribulin; Etirinotecan Pegol; Gemcitabine; Ixabepilone; Nab-paclitaxel; Paclitaxel; Vinorelbine	antimetabolite; macrocyclic_ketone_analogue; vinca_alkaloid; antimetabolite + macrocyclic_ketone_analogue + microtubule_stabilizing_agent + taxane + vinca_alkaloid; gemcitabine; taxane; topoisomerase_inhibitor; microtubule_stabilizing_agent; fluoropyrimidine	Docetaxel + Eribulin + Gemcitabine + Ixabepilone + Nab-paclitaxel + Paclitaxel + Vinorelbine; Etirinotecan Pegol; Capecitabine; Docetaxel + Eribulin + Gemcitabine + Ixabepilone + Nab-paclitaxel + Paclitaxel + Vinorelbine	antimetabolite + macrocyclic_ketone_analogue + microtubule_stabilizing_agent + taxane + vinca_alkaloid; topoisomerase_inhibitor; antimetabolite + macrocyclic_ketone_analogue + microtubule_stabilizing_agent + taxane + vinca_alkaloid; fluoropyrimidine; gemcitabine	15-102-14	A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine	Breast Cancer; Metastasis	3128 - Box Hill; 2010 - Darlinghurst; 6009 - Nedlands; 2640 - Albury; 2500 - Wollongong; 6008 - Subiaco	https://clinicaltrials.gov/ct2/show/NCT02915744
NCT02923921	Sequoia	Phase 3		NSW, VIC, WA	5/10/2016	1/03/2017	Fluorouracil; Fluorouracil + Leucovorin + Oxaliplatin + Pegilodecakin; Fluorouracil + Oxaliplatin; Gemcitabine; Leucovorin; Oxaliplatin; Pegilodecakin	platinum-based_antineoplastic_agent; fluoropyrimidine + platinum-based_antineoplastic_agent; antimetabolite; Fluorouracil; folinic_acid; fluoropyrimidine + folinic_acid + pegylated_IL-10 + platinum-based_antineoplastic_agent; pegylated_IL-10	Fluorouracil + Leucovorin + Oxaliplatin + Pegilodecakin; Fluorouracil + Oxaliplatin; Fluorouracil + Leucovorin + Oxaliplatin + Pegilodecakin; Fluorouracil + Oxaliplatin; Gemcitabine	fluoropyrimidine + folinic_acid + pegylated_IL-10 + platinum-based_antineoplastic_agent; fluoropyrimidine + platinum-based_antineoplastic_agent; Fluorouracil; antimetabolite; fluoropyrimidine + folinic_acid + pegylated_IL-10 + platinum-based_antineoplastic_agent; fluoropyrimidine + platinum-based_antineoplastic_agent	J1L-AM-JZGB  17158	Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen	Pancreatic Cancer	3144 - Malvern; 2010 - Sydney; 6150 - Murdoch; 3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT02923921
NCT02923934	ONJ2016-001	Phase 2		VIC, NSW	5/10/2016	22/08/2017	Ipilimumab; Ipilimumab + Nivolumab; Nivolumab	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Ipilimumab + Nivolumab; Ipilimumab + Nivolumab	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	ONJ2016-001	A Phase II Clinical Trial Evaluating Ipilimumab and Nivolumab in Combination for the Treatment of Rare Gastrointestinal, Neuro-Endocrine and Gynaecological Cancers	Gastrointestinal Cancer; Neuroendocrine Tumours; Malignant Female Reproductive System Neoplasm	2145 - Sydney; 3000 - Melbourne; 2640 - Albury; 3078 - Heidelberg; 3168 - Clayton	https://clinicaltrials.gov/ct2/show/NCT02923934
NCT02924883	KATE2	Phase 2		VIC, NSW, QLD, WA	5/10/2016	26/09/2016	Atezolizumab; Atezolizumab + Trastuzumab Emtansine; Placebo; Trastuzumab; Trastuzumab Emtansine	anti-PD-L1_monoclonal_antibody; anti-ERBB2_monoclonal_antibody; anti-ERBB2_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody; placebo; anti-ERBB2_antibody-drug_conjugate	Atezolizumab + Trastuzumab Emtansine; Atezolizumab + Trastuzumab Emtansine; Placebo	anti-ERBB2_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody; anti-ERBB2_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody; anti-ERBB2_monoclonal_antibody; placebo	2015-004189-27  WO30085	A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab and Taxane Based Therapy	Metastatic Breast Cancer	4102 - Woolloongabba; 6008 - Subiaco; 3199 - Frankston; 2217 - Kogarah; 3021 - St Albans; 3002 - East Melbourne; 2298 - Waratah	https://clinicaltrials.gov/ct2/show/NCT02924883
NCT02926768	CK-101-101	Phase 1/Phase 2		NZ, QLD	6/10/2016	1/09/2016	CK-101	EGFR_inhibitor,third_generation	CK-101	EGFR_inhibitor,third_generation	CK-101-101	A Phase I/II, Open-Label, Safety, Pharmacokinetic and Efficacy Study of Ascending Doses of Oral CK-101 in Patients With Advanced Solid Tumors	Carcinoma, Non-Small-Cell Lung; Lung Diseases; Lung Neoplasms; Adenocarcinoma	4120 - Greenslopes; Auckland; Wellington; Christchurch	https://clinicaltrials.gov/ct2/show/NCT02926768
NCT02928224	BEACON-CRC	Phase 3		NSW, VIC, QLD, SA, NEW South Wales (nsw)QLD	10/10/2016	13/10/2016	Binimetinib; Binimetinib + Cetuximab + Encorafenib; Cetuximab; Cetuximab + Encorafenib; Cetuximab + Irinotecan; Encorafenib; Fluorouracil; Irinotecan; Leucovorin	BRAF_V600_inhibitor; BRAF_V600_inhibitor + MEK_inhibitor + anti-EGFR_monoclonal_antibody; Fluorouracil; BRAF_V600_inhibitor + anti-EGFR_monoclonal_antibody; folinic_acid; MEK_inhibitor; anti-EGFR_monoclonal_antibody + topoisomerase_inhibitor; anti-EGFR_monoclonal_antibody; topoisomerase_inhibitor; fluoropyrimidine	Binimetinib + Cetuximab + Encorafenib; Cetuximab + Encorafenib; Cetuximab + Irinotecan; Binimetinib + Cetuximab + Encorafenib; Cetuximab + Encorafenib; Cetuximab + Irinotecan; Fluorouracil; Leucovorin	BRAF_V600_inhibitor + MEK_inhibitor + anti-EGFR_monoclonal_antibody; BRAF_V600_inhibitor + anti-EGFR_monoclonal_antibody; anti-EGFR_monoclonal_antibody + topoisomerase_inhibitor; BRAF_V600_inhibitor + MEK_inhibitor + anti-EGFR_monoclonal_antibody; BRAF_V600_inhibitor + anti-EGFR_monoclonal_antibody; Fluorouracil; anti-EGFR_monoclonal_antibody + topoisomerase_inhibitor; fluoropyrimidine; folinic_acid	BEACON CRC  ARRAY-818-302	A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer	BRAF V600E-mutant Metastatic Colorectal Cancer	2150 - Parramatta; 3084 - Heidelberg; 2300 - Sydney; 3000 - Melbourne; 5000 - Adelaide; 4101 - South Brisbane; 3168 - Clayton; 5011 - Woodville South; 5042 - Bedford Park; 2010 - Darlinghurst	https://clinicaltrials.gov/ct2/show/NCT02928224
NCT02928406	2016-002625-11--MO29983	Phase 3		SA, TAS, QLD, VIC, NSW, ACT	10/10/2016	30/11/2016	Atezolizumab	anti-PD-L1_monoclonal_antibody	Atezolizumab	anti-PD-L1_monoclonal_antibody	2016-002625-11  MO29983	An Open Label, Single Arm, Multicenter, Safety Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract	Urinary Tract Cancer	5000 - Adelaide; 3084 - Heidelberg; 2109 - Macquarie Park; 2065 - St Leonards; 3128 - Box Hill; 7000 - Hobart; 2298 - Waratah; 2031 - Randwick; 4101 - South Brisbane; 2606 - Canberra	https://clinicaltrials.gov/ct2/show/NCT02928406
NCT02933944	CT-TG02-01	Phase 1		NZ, QLD, VIC	14/10/2016	1/09/2016	Pembrolizumab	anti-PD-1_monoclonal_antibody	Pembrolizumab	anti-PD-1_monoclonal_antibody	CT TG02-01	A Non-Randomised Open-Label Phase Ib Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer	Rectal Cancer	- Brisbane; Auckland; - Melbourne; Christchurch	https://clinicaltrials.gov/ct2/show/NCT02933944
NCT02935634	FRACTION-GC	Phase 2		ACT, NSW, VIC	17/10/2016	29/11/2016	Ipilimumab; Ipilimumab + Nivolumab; Linrodostat; Linrodostat + Nivolumab; Nivolumab; Nivolumab + Relatlimab; Nivolumab + Rucaparib; Relatlimab; Rucaparib	PARP_inhibitor; anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; IDO1_inhibitor; IDO1_inhibitor + anti-PD-1_monoclonal_antibody; PARP_inhibitor + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Ipilimumab + Nivolumab; Linrodostat + Nivolumab; Nivolumab + Relatlimab; Nivolumab + Rucaparib; Rucaparib; Ipilimumab + Nivolumab; Linrodostat + Nivolumab; Nivolumab + Relatlimab; Nivolumab + Rucaparib	IDO1_inhibitor + anti-PD-1_monoclonal_antibody; PARP_inhibitor; PARP_inhibitor + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; IDO1_inhibitor + anti-PD-1_monoclonal_antibody; PARP_inhibitor + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	2016-002807-24  CA018-003	A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants With Advanced Gastric Cancer (FRACTION-Gastric Cancer)	Advanced Gastric Cancer	2031 - Randwick; 2145 - Westmead; 3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT02935634
NCT02937272	I8X-MC-JECA--16185	Phase 1	NOT_RECRUITING	QLD, NSW	18/10/2016	21/11/2016	Cisplatin; Cisplatin + LY3200882; Gemcitabine; Gemcitabine + LY3200882 + Nab-paclitaxel; Intensity Modulated Radiotherapy; LY3200882; LY3200882 + Lodapolimab; Lodapolimab; Nab-paclitaxel	radiotherapy; platinum-based_antineoplastic_agent; TGFBR1_inhibitor + anti-PD-L1_monoclonal_antibody; antimetabolite; anti-PD-L1_monoclonal_antibody; TGFBR1_inhibitor + platinum-based_antineoplastic_agent; gemcitabine; taxane; TGFBR1_inhibitor + antimetabolite + taxane; TGFBR1_inhibitor	Cisplatin + LY3200882; Gemcitabine + LY3200882 + Nab-paclitaxel; LY3200882; LY3200882 + Lodapolimab; Cisplatin + LY3200882; Gemcitabine + LY3200882 + Nab-paclitaxel; Intensity Modulated Radiotherapy; LY3200882 + Lodapolimab	TGFBR1_inhibitor; TGFBR1_inhibitor + anti-PD-L1_monoclonal_antibody; TGFBR1_inhibitor + antimetabolite + taxane; TGFBR1_inhibitor + platinum-based_antineoplastic_agent; TGFBR1_inhibitor + anti-PD-L1_monoclonal_antibody; TGFBR1_inhibitor + antimetabolite + taxane; TGFBR1_inhibitor + platinum-based_antineoplastic_agent; gemcitabine; radiotherapy	I8X-MC-JECA  16185	A Phase 1 Study of LY3200882 in Patients With Solid Tumors	Solid Tumor	4120 - Greenslopes; 2298 - Newcastle; 2010 - Sydney	https://clinicaltrials.gov/ct2/show/NCT02937272
NCT02947152	CHKT288X2101	Phase 1		VIC	27/10/2016	1/12/2016	HKT288	anti-CDH6_antibody-drug_conjugate	HKT288	anti-CDH6_antibody-drug_conjugate	CHKT288X2101	A Phase I, Multicenter, Open-label Dose Escalation and Expansion Study of HKT288, Administered Intravenously in Adult Patients With Advanced Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell Carcinoma	Renal Cell Carcinoma; Epithelial Ovarian Cancer	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT02947152
NCT02947685	PATINA	Phase 3		ACT, WA, QLD, NSW, VIC, NZ	28/10/2016	21/06/2017	Anastrozole; Anastrozole + Fulvestrant + Letrozole + Pertuzumab + Trastuzumab; Anastrozole + Letrozole + Palbociclib + Pertuzumab + Trastuzumab; Exemestane; Fulvestrant; Letrozole; Palbociclib; Pertuzumab; Trastuzumab	CDK4/6_inhibitor; anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor + aromatase_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor + aromatase_inhibitor; anti-ERBB2_monoclonal_antibody; aromatase_inhibitor; selective_estrogen_receptor_degrader; anti-ERBB2_monoclonal_antibody,dimerization_inhibitor	Anastrozole + Fulvestrant + Letrozole + Pertuzumab + Trastuzumab; Anastrozole + Letrozole + Palbociclib + Pertuzumab + Trastuzumab; Anastrozole + Fulvestrant + Letrozole + Pertuzumab + Trastuzumab; Anastrozole + Letrozole + Palbociclib + Pertuzumab + Trastuzumab; Exemestane	CDK4/6_inhibitor + anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor + aromatase_inhibitor; anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor + aromatase_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor + aromatase_inhibitor; anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor + aromatase_inhibitor + selective_estrogen_receptor_degrader	AFT-38	A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer	Estrogen Receptor Positive Breast Cancer; HER-2 Positive Breast Cancer	- South Brisbane; - Westmead; - Waratah; - Garran; - Clayton; Auckland; - Melbourne; - Darlinghurst; - Nedlands	https://clinicaltrials.gov/ct2/show/NCT02947685
NCT02952534	TRITON2	Phase 2		TAS, VIC, NSW, WA	2/11/2016	15/02/2017	Rucaparib	PARP_inhibitor	Rucaparib	PARP_inhibitor	CO-338-052	TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer Associated With Homologous Recombination Deficiency	Metastatic Castration Resistant Prostate Cancer	3220 - Geelong; 6008 - Subiaco; 2650 - Wagga Wagga; 3199 - Frankston; 3144 - Malvern; 2228 - Miranda; 7000 - Hobart; 2065 - Saint Leonards; 2800 - Orange	https://clinicaltrials.gov/ct2/show/NCT02952534
NCT02955069	2016-002522-36--CPDR001E2201	Phase 2		NSW	4/11/2016	14/02/2017	Spartalizumab	anti-PD-1_monoclonal_antibody	Spartalizumab	anti-PD-1_monoclonal_antibody	2016-002522-36  CPDR001E2201	An Open Label Phase II Study to Evaluate the Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC), That Have Progressed on Prior Treatment.	Well-differentiated Non-functional NET of Pancreatic Origin; Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma; Well-differentiated Non-functional NET of Thoracic Origin; Well-differentiated Non-functional NET of Gastrointestinal Origin	2065 - St Leonards	https://clinicaltrials.gov/ct2/show/NCT02955069
NCT02955251	2016-001461-88--M15-819	Phase 1		NSW	4/11/2016	18/11/2016	ABBV-428; ABBV-428 + Nivolumab; Nivolumab	anti-PD-1_monoclonal_antibody; anti-CD40_agonistic_antibody + anti-PD-1_monoclonal_antibody; anti-CD40_agonistic_antibody	ABBV-428; ABBV-428 + Nivolumab; ABBV-428 + Nivolumab	anti-CD40_agonistic_antibody; anti-CD40_agonistic_antibody + anti-PD-1_monoclonal_antibody; anti-CD40_agonistic_antibody + anti-PD-1_monoclonal_antibody	2016-001461-88  M15-819	A Multi-Center, Phase 1, Open-Label, Dose-Escalation Study of ABBV-428, an Immunotherapy in Subjects With Advanced Solid Tumors	Advanced Solid Tumors Cancer	2065 - St Leonards; 2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT02955251
NCT02960022	2016-001694-32--9785-CL-0123	Phase 2		NZ, SA, NSW, QLD	9/11/2016	22/12/2016	Abiraterone; Abiraterone + Enzalutamide + Prednisone; Enzalutamide; Prednisone	antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + glucocorticoid; glucocorticoid; CYP17A1_inhibitor	Abiraterone + Enzalutamide + Prednisone; Enzalutamide; Abiraterone + Enzalutamide + Prednisone	CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + glucocorticoid; antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + glucocorticoid	2016-001694-32  9785-CL-0123	A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study	Prostate Cancer	- Malvern; 2485 - Tweed Heads; - South Brisbane; - Ashford; - Westmead; Hamilton	https://clinicaltrials.gov/ct2/show/NCT02960022
NCT02964013	MK-7684-001--7684-001	Phase 1	NOT_RECRUITING	NSW	15/11/2016	13/12/2016	Carboplatin; Carboplatin + Cisplatin + Etoposide + Pembrolizumab + Vibostolimab; Carboplatin + Pembrolizumab + Pemetrexed + Vibostolimab; Cisplatin; Etoposide; Pembrolizumab; Pembrolizumab + Vibostolimab; Pemetrexed; Vibostolimab	anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; antimetabolite; anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; topoisomerase_inhibitor	Carboplatin + Cisplatin + Etoposide + Pembrolizumab + Vibostolimab; Carboplatin + Pembrolizumab + Pemetrexed + Vibostolimab; Pembrolizumab + Vibostolimab; Vibostolimab; Carboplatin + Cisplatin + Etoposide + Pembrolizumab + Vibostolimab; Carboplatin + Pembrolizumab + Pemetrexed + Vibostolimab; Pembrolizumab + Vibostolimab	anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor	MK-7684-001  7684-001	A Phase 1 Trial of MK-7684 as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors	Neoplasms	- North Ryde	https://clinicaltrials.gov/ct2/show/NCT02964013
NCT02964507	2016-003074-40--201973	Phase 1	NOT_RECRUITING	SA, VIC, NSW	16/11/2016	2/02/2017	Fulvestrant; Fulvestrant + Molibresib; Molibresib; Placebo	BET_inhibitor + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader; placebo; BET_inhibitor	Fulvestrant; Fulvestrant + Molibresib; Fulvestrant + Molibresib; Placebo	BET_inhibitor + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader; BET_inhibitor + selective_estrogen_receptor_degrader; placebo	2016-003074-40  201973	A Phase I/II Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Combination With Fulvestrant in Subjects With Hormone Receptor-positive/HER2-negative (HR+/HER2-) Advanced or Metastatic Breast Cancer	Neoplasms	2444 - Port Macquarie; 3084 - Heidelberg; 5042 - Bedford Park	https://clinicaltrials.gov/ct2/show/NCT02964507
NCT02966171	2015-453-00AU1	Phase 1		NSW, VIC	17/11/2016	1/01/2017	HMPL-453	FGFR_inhibitor	HMPL-453	FGFR_inhibitor	2015-453-00AU1	A Phase I, Open-label, Multi-center, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of HMPL-453 in Patients With Advanced Solid Malignancies	Solid Tumor	3168 - Melbourne; 2050 - Sydney; 2010 - Sydney; 3199 - Frankston	https://clinicaltrials.gov/ct2/show/NCT02966171
NCT02967692	COMBI-i	Phase 3		WA, QLD, VIC, NSW	18/11/2016	17/02/2017	Dabrafenib; Dabrafenib + Spartalizumab + Trametinib; Dabrafenib + Trametinib; Placebo; Spartalizumab; Trametinib	anti-PD-1_monoclonal_antibody; BRAF_V600_inhibitor + MEK_inhibitor; placebo; BRAF_V600_inhibitor; MEK_inhibitor; BRAF_V600_inhibitor + MEK_inhibitor + anti-PD-1_monoclonal_antibody	Dabrafenib + Spartalizumab + Trametinib; Dabrafenib + Trametinib; Dabrafenib + Spartalizumab + Trametinib; Dabrafenib + Trametinib; Placebo	BRAF_V600_inhibitor + MEK_inhibitor; BRAF_V600_inhibitor + MEK_inhibitor + anti-PD-1_monoclonal_antibody; BRAF_V600_inhibitor + MEK_inhibitor; BRAF_V600_inhibitor + MEK_inhibitor + anti-PD-1_monoclonal_antibody; placebo	2016-002794-35  CPDR001F2301	A Randomized, Double-blind, Placebo-controlled, Phase III Study Comparing the Combination of PDR001, Dabrafenib and Trametinib Versus Placebo, Dabrafenib and Trametinib in Previously Untreated Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma	Melanoma	2290 - Gateshead; 2060 - North Sydney; 3181 - Prahran; 6009 - Nedlands; 4120 - Greenslopes	https://clinicaltrials.gov/ct2/show/NCT02967692
NCT02974725	2016-004293-18--CLXH254X2102	Phase 1		NSW, VIC	28/11/2016	24/02/2017	LTT462; LTT462 + Naporafenib; Naporafenib; Naporafenib + Ribociclib; Naporafenib + Trametinib; Ribociclib; Trametinib	CDK4/6_inhibitor; MEK_inhibitor + RAF_dimer_inhibitor; ERK_inhibitor; MEK_inhibitor; ERK_inhibitor + RAF_dimer_inhibitor; RAF_dimer_inhibitor; CDK4/6_inhibitor + RAF_dimer_inhibitor	LTT462 + Naporafenib; Naporafenib + Ribociclib; Naporafenib + Trametinib; LTT462 + Naporafenib; Naporafenib + Ribociclib; Naporafenib + Trametinib	CDK4/6_inhibitor + RAF_dimer_inhibitor; ERK_inhibitor + RAF_dimer_inhibitor; MEK_inhibitor + RAF_dimer_inhibitor; CDK4/6_inhibitor + RAF_dimer_inhibitor; ERK_inhibitor + RAF_dimer_inhibitor; MEK_inhibitor + RAF_dimer_inhibitor	2016-004293-18  CLXH254X2102	A Phase Ib, Open-label, Multicenter Study of Oral LXH254-centric Combinations in Adult Patients With Advanced or Metastatic KRAS or BRAF Mutant Non-Small Cell Lung Cancer or NRAS Mutant Melanoma	Melanoma; Non-Small Cell Lung Cancer	3000 - Melbourne; 3181 - Prahran; 2145 - Westmead	https://clinicaltrials.gov/ct2/show/NCT02974725
NCT02975934	TRITON3	Phase 3		WA, TAS, VIC, NSW	29/11/2016	13/06/2017	Abiraterone; Abiraterone + Docetaxel + Enzalutamide + Prednisolone + Prednisone; Docetaxel; Enzalutamide; Prednisolone; Prednisone; Rucaparib	PARP_inhibitor; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + glucocorticoid + taxane; glucocorticoid; CYP17A1_inhibitor; antiandrogen,nonsteroidal,second_generation; taxane	Abiraterone + Docetaxel + Enzalutamide + Prednisolone + Prednisone; Rucaparib; Abiraterone + Docetaxel + Enzalutamide + Prednisolone + Prednisone	CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + glucocorticoid + taxane; PARP_inhibitor; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + glucocorticoid + taxane	CO-338-063	TRITON3: A Multicenter, Randomized, Open Label Phase 3 Study of Rucaparib Versus Physician's Choice of Therapy for Patients With Metastatic Castration Resistant Prostate Cancer Associated With Homologous Recombination Deficiency	Metastatic Castration Resistant Prostate Cancer	2228 - Miranda; 7000 - Hobart; 2065 - Saint Leonards; 2800 - Orange; 3220 - Geelong; 6008 - Subiaco; 2650 - Wagga Wagga; 3199 - Frankston	https://clinicaltrials.gov/ct2/show/NCT02975934
NCT02981342	I3Y-MC-JPCJ--16342	Phase 2		NSW	5/12/2016	12/01/2017	Abemaciclib; Abemaciclib + LY3023414; Capecitabine; Capecitabine + Gemcitabine; Gemcitabine; LY3023414	antimetabolite + fluoropyrimidine; PI3K/mTOR_inhibitor; CDK4/6_inhibitor; antimetabolite; gemcitabine; fluoropyrimidine; CDK4/6_inhibitor + PI3K/mTOR_inhibitor	Abemaciclib; Abemaciclib + LY3023414; Capecitabine + Gemcitabine; Abemaciclib + LY3023414; Capecitabine + Gemcitabine	CDK4/6_inhibitor; CDK4/6_inhibitor + PI3K/mTOR_inhibitor; antimetabolite + fluoropyrimidine; CDK4/6_inhibitor + PI3K/mTOR_inhibitor; antimetabolite + fluoropyrimidine; gemcitabine	I3Y-MC-JPCJ  16342	An Adaptive, Open-Label, Randomized Phase 2 Study of Abemaciclib as a Monotherapy and in Combination With Other Agents Versus Choice of Standard of Care (Gemcitabine or Capecitabine) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma	Pancreatic Ductal Adenocarcinoma	2010 - Sydney; 2148 - Blacktown	https://clinicaltrials.gov/ct2/show/NCT02981342
NCT02985957	CheckMate-650	Phase 2	NOT_RECRUITING	SA, QLD, VIC, NSW	7/12/2016	26/03/2017	Cabazitaxel; Ipilimumab; Nivolumab; Prednisone	anti-CTLA-4_monoclonal_antibody; glucocorticoid; anti-PD-1_monoclonal_antibody; taxane	Cabazitaxel; Ipilimumab; Nivolumab; Prednisone	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; glucocorticoid; taxane	2016-001928-54  CA209-650	A Phase 2 Trial of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer	Prostate Cancer	2076 - Wahroonga; 4012 - Woolloongabba; 5112 - Elizabeth Vale; 2145 - Westmead; 3168 - Clayton; 2250 - Gosford; 4215 - Southport	https://clinicaltrials.gov/ct2/show/NCT02985957
NCT02987543	D081DC00007	Phase 3		WA, SA, QLD, NSW, VIC	9/12/2016	6/02/2017	Abiraterone; Abiraterone + Enzalutamide; Enzalutamide; Olaparib	antiandrogen,nonsteroidal,second_generation; PARP_inhibitor; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor	Abiraterone + Enzalutamide; Olaparib; Abiraterone + Enzalutamide	CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation; PARP_inhibitor; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation	D081DC00007	A Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have Homologous Recombination Repair Gene Mutations (PROfound)	Metastatic Castration-resistant Prostate Cancer	2109 - Macquarie University; 4029 - Herston; 3000 - Melbourne; 5000 - Adelaide; 3168 - Clayton; 2031 - Randwick; 6009 - Nedlands; 4120 - Greenslopes; 3128 - Box Hill; 2298 - Waratah	https://clinicaltrials.gov/ct2/show/NCT02987543
NCT02988960	2016-002219-16--M15-862	Phase 1		VIC	12/12/2016	22/02/2017	ABBV-927; ABBV-927 + Budigalimab; Budigalimab	anti-PD-1_monoclonal_antibody; anti-CD40_agonistic_antibody + anti-PD-1_monoclonal_antibody; anti-CD40_agonistic_antibody	ABBV-927; ABBV-927 + Budigalimab; ABBV-927 + Budigalimab	anti-CD40_agonistic_antibody; anti-CD40_agonistic_antibody + anti-PD-1_monoclonal_antibody; anti-CD40_agonistic_antibody + anti-PD-1_monoclonal_antibody	2016-002219-16  M15-862	A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-927 and ABBV-181, an Immunotherapy, in Subjects With Advanced Solid Tumors	Advanced Solid Tumors Cancer	3199 - Frankston; 3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT02988960
NCT02993731	CanStem111P	Phase 3		VIC, NSW, QLD, SA, WA	15/12/2016	1/12/2016	Gemcitabine; Gemcitabine + Nab-paclitaxel; Gemcitabine + Nab-paclitaxel + Napabucasin; Nab-paclitaxel; Napabucasin	cancer_stemness_inhibitor; gemcitabine; antimetabolite + cancer_stemness_inhibitor + taxane; taxane; antimetabolite; antimetabolite + taxane	Gemcitabine + Nab-paclitaxel; Gemcitabine + Nab-paclitaxel + Napabucasin; Gemcitabine + Nab-paclitaxel; Gemcitabine + Nab-paclitaxel + Napabucasin	antimetabolite + cancer_stemness_inhibitor + taxane; antimetabolite + taxane; antimetabolite + cancer_stemness_inhibitor + taxane; antimetabolite + taxane; gemcitabine	CanStem111P	A Phase III Study of BBI-608 Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma	Carcinoma, Pancreatic Ductal	6009 - Nedlands; 2485 - Tweed Heads; 2109 - East Albury; 2109 - Sydney; 2640 - East Albury; 2031 - Randwick; 4101 - South Brisbane; 3144 - Malvern; 3084 - Heidelberg; 2148 - Blacktown; 2076 - Wahroonga	https://clinicaltrials.gov/ct2/show/NCT02993731
NCT02994576	PRINCEPS	Unknown			16/12/2016	12/12/2016	Atezolizumab	anti-PD-L1_monoclonal_antibody	Atezolizumab	anti-PD-L1_monoclonal_antibody	2016/2362  2016-000270-38	A Single-arm Phase 2 Study of Atezolizumab as Induction Therapy in Stage IB-IIIA Non N2 Resectable and Untreated Non-small Cell Lung Cancer (NSCLC)	Nonsmall Cell Lung Cancer		https://clinicaltrials.gov/ct2/show/NCT02994576
NCT02996110	FRACTION-RCC	Phase 2		NSW, VIC	19/12/2016	17/01/2017	BMS-813160; BMS-813160 + Nivolumab; Ipilimumab; Ipilimumab + Nivolumab; Linrodostat; Linrodostat + Nivolumab; Nivolumab; Nivolumab + Relatlimab; Relatlimab	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; IDO1_inhibitor; IDO1_inhibitor + anti-PD-1_monoclonal_antibody; CCR2/CCR5_antagonist; CCR2/CCR5_antagonist + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	BMS-813160 + Nivolumab; Ipilimumab + Nivolumab; Linrodostat + Nivolumab; Nivolumab + Relatlimab; BMS-813160 + Nivolumab; Ipilimumab + Nivolumab; Linrodostat + Nivolumab; Nivolumab + Relatlimab	CCR2/CCR5_antagonist + anti-PD-1_monoclonal_antibody; IDO1_inhibitor + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; CCR2/CCR5_antagonist + anti-PD-1_monoclonal_antibody; IDO1_inhibitor + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	2016-003082-26  CA018-005	A Phase 2, Real-time Assessment of Combination Therapies in Immuno-Oncology Study in Participants With Advanced Renal Cell Carcinoma (FRACTION-RCC)	Advanced Cancer	3165 - Bentleigh; 2145 - Westmead	https://clinicaltrials.gov/ct2/show/NCT02996110
NCT02999893	APROC	Phase 1/Phase 2		VIC	21/12/2016	11/04/2017	Cisplatin; Cisplatin + Eprenetapopt + Fluorouracil; Eprenetapopt; Fluorouracil	platinum-based_antineoplastic_agent; fluoropyrimidine + mutant_p53_reactivator + platinum-based_antineoplastic_agent; Fluorouracil; PRIMA-1_analog; mutant_p53_reactivator; PRIMA-1_analog + fluoropyrimidine + platinum-based_antineoplastic_agent	Cisplatin + Eprenetapopt + Fluorouracil; Cisplatin + Eprenetapopt + Fluorouracil	PRIMA-1_analog + fluoropyrimidine + platinum-based_antineoplastic_agent; fluoropyrimidine + mutant_p53_reactivator + platinum-based_antineoplastic_agent; Fluorouracil; PRIMA-1_analog + fluoropyrimidine + platinum-based_antineoplastic_agent; fluoropyrimidine + mutant_p53_reactivator + platinum-based_antineoplastic_agent	16/012	A phase1b/2 Study Evaluating the Efficacy of APR-246, a First-in-class Agent Targeting Mutant p53 in the Treatment of Platinum Resistant Advanced and Metastatic Oesophageal or Gastro-oesophageal Junction Cancers	Oesophageal Carcinoma	3000 - Heidelberg; 3000 - Clayton; 3000 - Sunshine; 3000 - Prahran; 3002 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT02999893
NCT03000257	2016-002520-89--M15-891	Phase 1	NOT_RECRUITING	NSW, VIC, WA	22/12/2016	14/12/2016	Budigalimab; Budigalimab + Rovalpituzumab Tesirine; Budigalimab + Rovalpituzumab Tesirine + Venetoclax; Budigalimab + Venetoclax; Rovalpituzumab Tesirine; Venetoclax	anti-DLL3_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; Bcl2_inhibitor + anti-DLL3_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody; Bcl2_inhibitor; anti-DLL3_antibody-drug_conjugate; Bcl2_inhibitor + anti-PD-1_monoclonal_antibody	Budigalimab + Rovalpituzumab Tesirine; Budigalimab + Rovalpituzumab Tesirine + Venetoclax; Budigalimab + Venetoclax; Budigalimab + Rovalpituzumab Tesirine; Budigalimab + Rovalpituzumab Tesirine + Venetoclax; Budigalimab + Venetoclax	Bcl2_inhibitor + anti-DLL3_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody; Bcl2_inhibitor + anti-PD-1_monoclonal_antibody; anti-DLL3_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody; Bcl2_inhibitor + anti-DLL3_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody; Bcl2_inhibitor + anti-PD-1_monoclonal_antibody; anti-DLL3_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody	2016-002520-89  M15-891	A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-181 as Monotherapy and in Combination With Another Anti-Cancer Therapy in Subjects With Advanced Solid Tumors	Advanced Solid Tumors	2148 - Blacktown; 3065 - Fitzroy; 6000 - Perth	https://clinicaltrials.gov/ct2/show/NCT03000257
NCT03003962	D419AC00002	Phase 3		NSW, VIC	28/12/2016	2/01/2017	Carboplatin; Cisplatin; Durvalumab; Gemcitabine; Paclitaxel; Pemetrexed	platinum-based_antineoplastic_agent; antimetabolite; anti-PD-L1_monoclonal_antibody; gemcitabine; taxane	Durvalumab; Carboplatin; Cisplatin; Gemcitabine; Paclitaxel; Pemetrexed	anti-PD-L1_monoclonal_antibody; antimetabolite; gemcitabine; platinum-based_antineoplastic_agent; taxane	D419AC00002	A Phase III Randomized, Open-Label, Multi-Center Study of Durvalumab (MEDI4736) Versus Standard of Care (SoC) Platinum-Based Chemotherapy as First Line Treatment in Patients With PD-L1-High Expression Advanced Non Small-Cell Lung Cancer	Non Small Cell Lung Carcinoma NSCLC	2217 - Kogarah; 2065 - St Leonards; 3128 - Box Hill; 2250 - Gosford	https://clinicaltrials.gov/ct2/show/NCT03003962
NCT03005782	2016-002789-30--R3767-ONC-1613	Phase 1		VIC, WA	29/12/2016	7/11/2016	Cemiplimab; Cemiplimab + Fianlimab; Fianlimab	anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Cemiplimab + Fianlimab; Fianlimab; Cemiplimab + Fianlimab	anti-LAG3_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	2016-002789-30  R3767-ONC-1613	A Phase 1, Open-Label, Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (Anti-LAG-3 mAb) Administered Alone or in Combination With REGN2810 (Anti-PD-1 mAb) in Patients With Advanced Malignancies	Malignancies	06009 - Perth; 4029 - Brisbane; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT03005782
NCT03016312	IMbassador250	Phase 3		SA, NSW, VIC, QLD	10/01/2017	10/01/2017	Atezolizumab; Atezolizumab + Enzalutamide; Enzalutamide	antiandrogen,nonsteroidal,second_generation; anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation	Atezolizumab + Enzalutamide; Enzalutamide; Atezolizumab + Enzalutamide	anti-PD-L1_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation; antiandrogen,nonsteroidal,second_generation; anti-PD-L1_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation	2016-003092-22  CO39385	A Phase III, Multicenter, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide Versus Enzalutamide Alone in Patients With Metastatic Castration-Resistant Prostate Cancer After Failure of an Androgen Synthesis Inhibitor and Failure of, Ineligibility for, or Refusal of a Taxane Regimen	Prostatic Neoplasms, Castration-Resistant	2139 - Concord; 5037 - Kurralta Park; 2109 - Macquarie Park; 4029 - Herston; 3168 - Clayton; 3128 - Box Hill	https://clinicaltrials.gov/ct2/show/NCT03016312
NCT03029780	CheckMate-800	Phase 2		SA, NSW, VIC, QLD	24/01/2017	16/02/2017	Ipilimumab; Ipilimumab + Nivolumab; Nivolumab	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Ipilimumab + Nivolumab; Ipilimumab + Nivolumab	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	CA209-800	Phase II, Randomized, Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma	Renal Cell Carcinoma	4029 - Herston; 2145 - Westmead; 3144 - Malvern; 5112 - Elizabeth Vale; 2298 - Waratah	https://clinicaltrials.gov/ct2/show/NCT03029780
NCT03033511	MERU	Phase 3		WA, SA, NSW, VIC	26/01/2017	7/02/2017	Dexamethasone; Dexamethasone + Rovalpituzumab Tesirine; Placebo; Rovalpituzumab Tesirine	anti-DLL3_antibody-drug_conjugate + glucocorticoid; glucocorticoid; anti-DLL3_antibody-drug_conjugate; placebo	Dexamethasone + Rovalpituzumab Tesirine; Dexamethasone + Rovalpituzumab Tesirine; Placebo	anti-DLL3_antibody-drug_conjugate + glucocorticoid; anti-DLL3_antibody-drug_conjugate + glucocorticoid; placebo	2016-003503-64  M16-298	A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects With Extensive Stage Small Cell Lung Cancer (MERU)	Small Cell Lung Cancer	5006 - Adelaide; 2450 - Coffs Harbour; 2250 - Gosford; 2305 - Lambton Heights; 6009 - Nedlands; 2065 - Saint Leonards; 3021 - St Albans	https://clinicaltrials.gov/ct2/show/NCT03033511
NCT03036098	CheckMate901	Phase 3		QLD, VIC, NSW, WA	30/01/2017	24/03/2017	Carboplatin; Cisplatin; Gemcitabine; Ipilimumab; Nivolumab	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; gemcitabine; antimetabolite	Carboplatin; Cisplatin; Gemcitabine; Ipilimumab; Nivolumab	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; antimetabolite; gemcitabine; platinum-based_antineoplastic_agent	2016-003881-14  CA209-901	A Phase 3, Open-label, Randomized Study of Nivolumab Combined With Ipilimumab, or With Standard of Care Chemotherapy, Versus Standard of Care Chemotherapy in Participants With Previously Untreated Unresectable or Metastatic Urothelial Cancer	Urothelial Cancer	3084 - Heidelberg; 2145 - Westmead; 4224 - Tugun; 4101 - South Brisbane; 2298 - Waratah; 2010 - Darlinghurst; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT03036098
NCT03038100	IMagyn050	Phase 3		NSW, VIC	31/01/2017	8/03/2017	Atezolizumab; Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel; Bevacizumab; Carboplatin; Paclitaxel; Placebo	anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; platinum-based_antineoplastic_agent; placebo; anti-PD-L1_monoclonal_antibody; anti-VEGF_monoclonal_antibody; taxane	Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel; Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel; Placebo	anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; placebo	2016-003472-52  YO39523	A Phase III, Multicenter, Randomized, Study of Atezolizumab Versus Placebo Administered in Combination With Paclitaxel, Carboplatin, and Bevacizumab to Patients With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Neoplasms	3144 - Malvern; 3002 - East Melbourne; 2065 - St Leonards	https://clinicaltrials.gov/ct2/show/NCT03038100
NCT03040999	KEYNOTE-412	Phase 3		VIC, NSW, QLD, NZ, SA, (Australia)NSW	2/02/2017	5/04/2017	Cisplatin; Cisplatin + Pembrolizumab + Radiotherapy; Cisplatin + Radiotherapy; Pembrolizumab; Placebo; Radiotherapy	radiotherapy; platinum-based_antineoplastic_agent + radiotherapy; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; placebo; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + radiotherapy	Cisplatin + Pembrolizumab + Radiotherapy; Cisplatin + Radiotherapy; Cisplatin + Pembrolizumab + Radiotherapy; Cisplatin + Radiotherapy; Placebo	anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + radiotherapy; platinum-based_antineoplastic_agent + radiotherapy; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + radiotherapy; placebo; platinum-based_antineoplastic_agent + radiotherapy	2016-003934-25  3475-412	A Randomized Phase III Study of Pembrolizumab Given Concomitantly With Chemoradiation and as Maintenance Therapy Versus Chemoradiation Alone in Subjects With Locally Advanced Head and Neck Squamous Cell Carcinoma (KEYNOTE-412)	Head and Neck Neoplasms	4102 - Brisbane; 2170 - Liverpool; 5000 - Adelaide; 3000 - Melbourne; 4029 - Herston; 2148 - Blacktown	https://clinicaltrials.gov/ct2/show/NCT03040999
NCT03041285	NOX66-version-1	Phase 1		NSW	2/02/2017	31/08/2017	Idronoxil; Idronoxil + Radiotherapy; Radiotherapy	radiotherapy; idronoxil_suppository + radiotherapy; idronoxil_suppository	Idronoxil + Radiotherapy; Idronoxil + Radiotherapy	idronoxil_suppository + radiotherapy; idronoxil_suppository + radiotherapy	NOX66 version 1	Phase I Study of Idronoxil Combined With Radiation Treatment in Men With Metastatic Prostate Cancer	Metastatic Castrate- Resistant Prostate Cancer	2065 - St Leonards	https://clinicaltrials.gov/ct2/show/NCT03041285
NCT03049189	COMPETE	Phase 3		NSW, VIC, WA	9/02/2017	2/02/2017	177Lu-edotreotide; Everolimus	177Lu-DOTA-radioconjugate; mTORC1_inhibitor	177Lu-edotreotide; Everolimus	177Lu-DOTA-radioconjugate; mTORC1_inhibitor	ITM-LET-01	A Prospective, Randomised, Controlled, Open-label, Multicentre Phase III Study to Evaluate Efficacy and Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-Edotreotide Compared to Targeted Molecular Therapy With Everolimus in Patients With Inoperable, Progressive, Somatostatin Receptor-positive (SSTR+), Neuroendocrine Tumours of Gastroenteric or Pancreatic Origin (GEP-NET)	Neuroendocrine Tumors	2065 - Saint Leonards; 2170 - Liverpool; 2217 - Kogarah; 3000 - Melbourne; 3084 - Heidelberg; 6150 - Murdoch	https://clinicaltrials.gov/ct2/show/NCT03049189
NCT03052608	2016-003315-35--B7461006	Phase 3	NOT_RECRUITING	VIC	14/02/2017	14/04/2017	Crizotinib; Lorlatinib	MET_inhibitor,type_1; ALK_inhibitor,first_generation; ROS1_inhibitor; ALK_inhibitor,third_generation	Crizotinib; Lorlatinib	ALK_inhibitor,first_generation; ALK_inhibitor,third_generation; MET_inhibitor,type_1; ROS1_inhibitor	2016-003315-35  B7461006	A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF LORLATINIB (PF-06463922) MONOTHERAPY VERSUS CRIZOTINIB MONOTHERAPY IN THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER	Carcinoma, Non-Small-Cell Lung	3550 - Bendigo; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT03052608
NCT03053466	APL-501-01	Phase 1		WA, NSW, VIC	15/02/2017	27/03/2017	APL-501	anti-PD-1_monoclonal_antibody	APL-501	anti-PD-1_monoclonal_antibody	APL-501-01	A Phase 1 Multicenter, Dose Escalation, Cohort Extension and Dose and Disease Expansion Study of APL-501 in Subjects With Select Advanced or Relapsed/Recurrent Solid Tumors	Solid Tumor; Mismatch Repair Deficiency; Cancer of Unknown Primary Site; Microsatellite Instability	3004 - Melbourne; 3000 - Melbourne; 3144 - Malvern; 2050 - Camperdown; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT03053466
NCT03057106	BR34	Phase 2		TAS, VIC, NSW, QLD, WA	17/02/2017	15/02/2017	Durvalumab; Durvalumab + Tremelimumab; Tremelimumab	anti-PD-L1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody	Durvalumab + Tremelimumab; Durvalumab + Tremelimumab	anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody	BR34	A Randomized Trial of Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic (Stage IV) Squamous or Non-Squamous Non-Small Cell Lung Cancer (NSCLC)	Lung Cancer Metastatic	6008 - Subiaco; 3690 - Wodonga; 2170 - Liverpool; 4102 - Brisbane; 2139 - Concord; 3065 - Victoria Park; 2217 - Kogarah; 3350 - Ballarat; 4101 - South Brisbane; 2450 - Coffs Harbour; 2031 - Randwick; 2480 - Lismore; 4032 - Chermside; 2560 - Campbelltown; 4215 - Southport; 3121 - Richmond; 2751 - Kingswood; 4350 - Toowoomba; 7000 - Hobart	https://clinicaltrials.gov/ct2/show/NCT03057106
NCT03059823	INCMGA-0012-101	Phase 1		NZ, NSW	23/02/2017	15/11/2016	Retifanlimab	anti-PD-1_monoclonal_antibody	Retifanlimab	anti-PD-1_monoclonal_antibody	INCMGA 0012-101	A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of INCMGA00012 in Patients With Advanced Solid Tumors	Metastatic Solid Tumors; Locally Advanced Solid Tumors	Wellington; 02050 - Camperdown; 02010 - Darlinghurst; Auckland	https://clinicaltrials.gov/ct2/show/NCT03059823
NCT03061812	TAHOE	Phase 3		QLD, NSW, VIC	23/02/2017	11/04/2017	Dexamethasone; Rovalpituzumab Tesirine; Topotecan	glucocorticoid; anti-DLL3_antibody-drug_conjugate; topoisomerase_inhibitor	Rovalpituzumab Tesirine; Topotecan; Dexamethasone	anti-DLL3_antibody-drug_conjugate; topoisomerase_inhibitor; glucocorticoid	2016-003726-17  M16-289	A Randomized, Open-Label, Multicenter, Phase 3 Study of Rovalpituzumab Tesirine Compared With Topotecan for Subjects With Advanced or Metastatic DLL3high Small Cell Lung Cancer (SCLC) Who Have First Disease Progression During or Following Front-Line Platinum-Based Chemotherapy (TAHOE)	Small Cell Lung Cancer	4032 - Chermside; 2148 - Blacktown; 3084 - Heidelberg; 3350 - Ballarat; 2500 - Wollongong; 2217 - Kogarah	https://clinicaltrials.gov/ct2/show/NCT03061812
NCT03066778	KEYNOTE-604	Phase 3		VIC, NSW, NZ, SA, WA	28/02/2017	2/05/2017	Carboplatin; Carboplatin + Cisplatin + Etoposide; Carboplatin + Cisplatin + Etoposide + Pembrolizumab; Cisplatin; Dexamethasone; Etoposide; Pembrolizumab; Placebo	glucocorticoid; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; placebo; platinum-based_antineoplastic_agent + topoisomerase_inhibitor; topoisomerase_inhibitor	Carboplatin + Cisplatin + Etoposide; Carboplatin + Cisplatin + Etoposide + Pembrolizumab; Carboplatin + Cisplatin + Etoposide; Carboplatin + Cisplatin + Etoposide + Pembrolizumab; Dexamethasone; Placebo	anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; glucocorticoid; placebo; platinum-based_antineoplastic_agent + topoisomerase_inhibitor	2016-004309-15  3475-604	A Phase 3 Randomized, Double-Blind, Placebo-controlled Trial of Pembrolizumab (MK-3475/SCH900475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for the First-line Treatment of Subjects With Extensive Stage Small Cell Lung Cancer (KEYNOTE-604)	Small Cell Lung Cancer; SCLC	2500 - Wollongong; 6150 - Murdoch; 2148 - Blacktown; 3065 - Fitzroy; Christchurch; 5112 - Elizabeth Vale	https://clinicaltrials.gov/ct2/show/NCT03066778
NCT03069469	DCC-3014-01-001	Phase 1/Phase 2		VIC	3/03/2017	16/02/2017	Vimseltinib	CSF1R_inhibitor	Vimseltinib	CSF1R_inhibitor	DCC-3014-01-001	A Multicenter Phase 1/2, Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor	Tenosynovial Giant Cell Tumor; Pigmented Villonodular Synovitis; Advanced Malignant Neoplasm; Tenosynovial Giant Cell Tumor, Diffuse; Giant Cell Tumor of Tendon Sheath	- Melbourne	https://clinicaltrials.gov/ct2/show/NCT03069469
NCT03070392	IMCgp100-202	Phase 2		VIC, NSW, SA	3/03/2017	16/10/2017	Dacarbazine; Ipilimumab; Pembrolizumab; Tebentafusp	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; alkylating_agent; anti-CD3/scFv_fusion_protein,gp100-targeting	Dacarbazine; Tebentafusp; Ipilimumab; Pembrolizumab	alkylating_agent; anti-CD3/scFv_fusion_protein,gp100-targeting; anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody	IMCgp100-202	A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma	Uveal Melanoma	2010 - Darlinghurst; 5000 - Adelaide; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT03070392
NCT03072238	IPATential150	Phase 3		SA, NSW, VIC	7/03/2017	30/06/2017	Abiraterone; Abiraterone + Ipatasertib + Prednisolone + Prednisone; Abiraterone + Prednisolone + Prednisone; Ipatasertib; Placebo; Prednisolone; Prednisone	glucocorticoid; CYP17A1_inhibitor + glucocorticoid + pan-AKT_inhibitor; placebo; CYP17A1_inhibitor; pan-AKT_inhibitor; CYP17A1_inhibitor + glucocorticoid	Abiraterone + Ipatasertib + Prednisolone + Prednisone; Abiraterone + Prednisolone + Prednisone; Abiraterone + Ipatasertib + Prednisolone + Prednisone; Abiraterone + Prednisolone + Prednisone; Placebo	CYP17A1_inhibitor + glucocorticoid; CYP17A1_inhibitor + glucocorticoid + pan-AKT_inhibitor; CYP17A1_inhibitor + glucocorticoid; CYP17A1_inhibitor + glucocorticoid + pan-AKT_inhibitor; placebo	2016-004429-17  CO39303	A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer	Metastatic Prostate Cancer	2109 - Macquarie Park; 5037 - Kurralta Park; 3000 - Melbourne; 3128 - Melbourne; 3168 - Clayton	https://clinicaltrials.gov/ct2/show/NCT03072238
NCT03081494	2017-000466-30--CPDR001I2102	Phase 1		NSW, WA	16/03/2017	9/06/2017	Regorafenib; Regorafenib + Spartalizumab; Spartalizumab	anti-PD-1_monoclonal_antibody; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + anti-PD-1_monoclonal_antibody; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor	Regorafenib + Spartalizumab; Regorafenib + Spartalizumab	KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + anti-PD-1_monoclonal_antibody; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + anti-PD-1_monoclonal_antibody	2017-000466-30  CPDR001I2102	Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Microsatellite Stable (MSS) Colorectal Cancer	Metastatic Colorectal Cancer	6150 - Murdoch; 2065 - St Leonards	https://clinicaltrials.gov/ct2/show/NCT03081494
NCT03085095	HERO	Phase 3	NOT_RECRUITING	NSW, QLD, NZ	21/03/2017	18/04/2017	Leuprolide Acetate; Relugolix	GnRH_antagonist; GnRH_analogue; synthetic_gonadotropin-releasing_hormone	Leuprolide Acetate; Relugolix	GnRH_analogue; GnRH_antagonist; synthetic_gonadotropin-releasing_hormone	2017-000160-15  MVT-601-3201	HERO: A Multinational Phase 3 Randomized, Open-label, Parallel Group Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer	Prostate Cancer	2050 - Camperdown; 2485 - Tweed Heads; 4215 - Southport; Dunedin; 4020 - Redcliffe; Christchurch; Tauranga; 2076 - Wahroonga; Hamilton	https://clinicaltrials.gov/ct2/show/NCT03085095
NCT03088540	2016-004407-31--R2810-ONC-1624	Phase 3	NOT_RECRUITING	NSW, SA	23/03/2017	29/05/2017	Carboplatin; Cemiplimab; Cisplatin; Gemcitabine; Paclitaxel; Pemetrexed	anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; antimetabolite; gemcitabine; taxane	Cemiplimab; Carboplatin; Cisplatin; Gemcitabine; Paclitaxel; Pemetrexed	anti-PD-1_monoclonal_antibody; antimetabolite; gemcitabine; platinum-based_antineoplastic_agent; taxane	2016-004407-31  R2810-ONC-1624	A Global, Randomised, Phase 3, Open-label Study of REGN2810 (ANTI-PD 1 Antibody) Versus Platinum Based Chemotherapy in First Line Treatment of Patients With Advanced or Metastatic PD L1+Non-small Cell Lung Cancer	Non-small-cell Lung Carcinoma; Nonsmall Cell Lung Cancer; Carcinoma,Non-Small-Cell Lung; Lung Carcinomas, Non-Small-Cell	- Albury; - Fitzroy; - Wollongong	https://clinicaltrials.gov/ct2/show/NCT03088540
NCT03088813	RESILIENT	Phase 2/Phase 3	NOT_RECRUITING	VIC, NSW, QLD	23/03/2017	25/04/2018	Irinotecan; Liposomal Irinotecan; Topotecan	topoisomerase_inhibitor	Irinotecan; Topotecan; Liposomal Irinotecan	topoisomerase_inhibitor	2017-004261-26  MM-398-01-03-04	RESILIENT: A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE®) Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Progressed on or After Platinum-based First-Line Therapy	Small Cell Lung Cancer	- Wollongong; 2640 - Albury; - Woolloongabba; 3280 - Warrnambool	https://clinicaltrials.gov/ct2/show/NCT03088813
NCT03089645	D6840C00001	Phase 1		NSW, VIC	24/03/2017	21/03/2017	Docetaxel; Docetaxel + Durvalumab + MEDI5083; Durvalumab; Durvalumab + MEDI5083; Durvalumab + MEDI5083 + Tremelimumab; MEDI5083; Tremelimumab	anti-CTLA-4_monoclonal_antibody; anti-CD40_agonistic_antibody + anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; CD40L-Fc_fusion_protein + anti-PD-L1_monoclonal_antibody + taxane; taxane; CD40L-Fc_fusion_protein + anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; CD40L-Fc_fusion_protein; anti-CD40_agonistic_antibody + anti-PD-L1_monoclonal_antibody; anti-CD40_agonistic_antibody; anti-CD40_agonistic_antibody + anti-PD-L1_monoclonal_antibody + taxane; CD40L-Fc_fusion_protein + anti-PD-L1_monoclonal_antibody	Docetaxel + Durvalumab + MEDI5083; Durvalumab + MEDI5083; Durvalumab + MEDI5083 + Tremelimumab; Docetaxel + Durvalumab + MEDI5083; Durvalumab + MEDI5083; Durvalumab + MEDI5083 + Tremelimumab	CD40L-Fc_fusion_protein + anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; CD40L-Fc_fusion_protein + anti-PD-L1_monoclonal_antibody; CD40L-Fc_fusion_protein + anti-PD-L1_monoclonal_antibody + taxane; anti-CD40_agonistic_antibody + anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-CD40_agonistic_antibody + anti-PD-L1_monoclonal_antibody; anti-CD40_agonistic_antibody + anti-PD-L1_monoclonal_antibody + taxane; CD40L-Fc_fusion_protein + anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; CD40L-Fc_fusion_protein + anti-PD-L1_monoclonal_antibody; CD40L-Fc_fusion_protein + anti-PD-L1_monoclonal_antibody + taxane; anti-CD40_agonistic_antibody + anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-CD40_agonistic_antibody + anti-PD-L1_monoclonal_antibody; anti-CD40_agonistic_antibody + anti-PD-L1_monoclonal_antibody + taxane	D6840C00001	A Phase 1 First Time in Human Study to Evaluate the Safety, Pharmacokinetics and Immunogenicity of MEDI5083 Alone or in Combination With Durvalumab, Tremelimumab, and/or Docetaxel in Advanced Solid Tumors	Advanced Solid Tumors	2031 - Randwick; 3168 - Clayton; 3000 - Melbourne; 3004 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT03089645
NCT03093116	TRIDENT-1	Phase 1/Phase 2		VIC, NSW, SA	28/03/2017	27/02/2017	Repotrectinib	ROS1_inhibitor; ALK_inhibitor,third_generation; TRK_inhibitor,second_generation	Repotrectinib	ALK_inhibitor,third_generation; ROS1_inhibitor; TRK_inhibitor,second_generation	TPX-0005-01	A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)	Metastatic Solid Tumors; Locally Advanced Solid Tumors	3501 - Melbourne; 5042 - Bedford Park; 2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT03093116
NCT03093870	TreeTopp	Phase 2/Phase 3		NSW	28/03/2017	4/07/2017	Capecitabine; Capecitabine + Varlitinib; Placebo; Varlitinib	EGFR/ERBB2_inhibitor; EGFR/ERBB2_inhibitor + fluoropyrimidine; placebo; fluoropyrimidine	Capecitabine; Capecitabine + Varlitinib; Capecitabine + Varlitinib; Placebo	EGFR/ERBB2_inhibitor + fluoropyrimidine; fluoropyrimidine; EGFR/ERBB2_inhibitor + fluoropyrimidine; placebo	ASLAN001-009	A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Varlitinib Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract Cancer as Second Line Systemic Therapy	Biliary Tract Cancer	- Camperdown	https://clinicaltrials.gov/ct2/show/NCT03093870
NCT03098030	DIV-SCLC-301	Phase 2/Phase 3		VIC, NSW, QLD, SA	31/03/2017	1/06/2017	Dinutuximab; Dinutuximab + Irinotecan; Irinotecan; Topotecan	anti-GD2_monoclonal_antibody + topoisomerase_inhibitor; anti-GD2_monoclonal_antibody; topoisomerase_inhibitor	Dinutuximab + Irinotecan; Irinotecan; Topotecan; Dinutuximab + Irinotecan	anti-GD2_monoclonal_antibody + topoisomerase_inhibitor; topoisomerase_inhibitor; anti-GD2_monoclonal_antibody + topoisomerase_inhibitor	DIV-SCLC-301	A Two-part, Open-label, Randomized, Phase 2/3 Study of Dinutuximab and Irinotecan Versus Irinotecan for Second Line Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer	Small Cell Lung Cancer	QLD 4101 - South Brisbane; 3350 - Ballarat; 5000 - Adelaide; NSW 2450 - Coffs Harbour	https://clinicaltrials.gov/ct2/show/NCT03098030
NCT03098550	2017-000367-33--CA209-9GW	Phase 1/Phase 2		NSW	31/03/2017	15/06/2017	Daratumumab; Daratumumab + Nivolumab; Nivolumab	anti-CD38_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CD38_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Daratumumab + Nivolumab; Nivolumab; Daratumumab + Nivolumab	anti-CD38_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CD38_monoclonal_antibody + anti-PD-1_monoclonal_antibody	2017-000367-33  CA209-9GW	Phase 1/2 Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab Combined With Daratumumab in Participants With Advanced or Metastatic Solid Tumors	Advanced Cancer	2065 - St Leonards	https://clinicaltrials.gov/ct2/show/NCT03098550
NCT03101280	2016-002610-47--WO39409	Phase 1		VIC	5/04/2017	27/04/2017	Atezolizumab; Atezolizumab + Rucaparib; Rucaparib	PARP_inhibitor; anti-PD-L1_monoclonal_antibody; PARP_inhibitor + anti-PD-L1_monoclonal_antibody	Atezolizumab + Rucaparib; Atezolizumab + Rucaparib	PARP_inhibitor + anti-PD-L1_monoclonal_antibody; PARP_inhibitor + anti-PD-L1_monoclonal_antibody	2016-002610-47  WO39409	A Phase IB Combination Study of Rucaparib (CO-338) and Atezolizumab (MPDL3280A) in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer	Gynecologic Neoplasms	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT03101280
NCT03102320	ARCS-Multi	Phase 1		VIC, NSW, SA, WA	5/04/2017	26/05/2017	Anetumab Ravtansine; Anetumab Ravtansine + Cisplatin; Anetumab Ravtansine + Gemcitabine; Cisplatin; Gemcitabine	platinum-based_antineoplastic_agent; gemcitabine; anti-mesothelin_antibody-drug_conjugate + antimetabolite; anti-mesothelin_antibody-drug_conjugate; antimetabolite; anti-mesothelin_antibody-drug_conjugate + platinum-based_antineoplastic_agent	Anetumab Ravtansine; Anetumab Ravtansine + Cisplatin; Anetumab Ravtansine + Gemcitabine; Anetumab Ravtansine + Cisplatin; Anetumab Ravtansine + Gemcitabine	anti-mesothelin_antibody-drug_conjugate; anti-mesothelin_antibody-drug_conjugate + antimetabolite; anti-mesothelin_antibody-drug_conjugate + platinum-based_antineoplastic_agent; anti-mesothelin_antibody-drug_conjugate + antimetabolite; anti-mesothelin_antibody-drug_conjugate + platinum-based_antineoplastic_agent; gemcitabine	2016-004002-33  15834	Phase 1b Multi-indication Study of Anetumab Ravtansine (BAY94-9343) in Patients With Mesothelin Expressing Advanced or Recurrent Malignancies	Neoplasms	2450 - Coffs Harbour; 6009 - Nedlands; 2010 - Darlinghurst; 6008 - Subiaco; 2065 - St Leonards; 3122 - Richmond; 5042 - Adelaide; 2148 - Blacktown	https://clinicaltrials.gov/ct2/show/NCT03102320
NCT03104699	C-700-01	Phase 1/Phase 2		QLD, SA	7/04/2017	11/04/2017	Balstilimab	anti-PD-1_monoclonal_antibody	Balstilimab	anti-PD-1_monoclonal_antibody	C-700-01	A Phase 1 / 2, Open-Label, Multiple Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN2034 in Subjects With Metastatic or Locally Advanced Solid Tumors, With Expansion to Second Line Cervical Cancer	Cervical Cancer; Advanced Cancer	5006 - North Adelaide; 4217 - Benowa	https://clinicaltrials.gov/ct2/show/NCT03104699
NCT03110107	2017-000597-11--CA022-001	Phase 1/Phase 2		NSW, WA	12/04/2017	4/05/2017	BMS-986218; BMS-986218 + Ipilimumab; BMS-986218 + Nivolumab; Ipilimumab; Nivolumab	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	BMS-986218; BMS-986218 + Ipilimumab; BMS-986218 + Nivolumab; BMS-986218 + Ipilimumab; BMS-986218 + Nivolumab	anti-CTLA-4_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	2017-000597-11  CA022-001	Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination With Nivolumab in Advanced Solid Tumors	Advanced Cancer	6150 - Murdoch; 2145 - Westmead; 2065 - Wollstonecraft	https://clinicaltrials.gov/ct2/show/NCT03110107
NCT03126110	INCAGN-1876-201	Phase 1/Phase 2	NOT_RECRUITING	NSW, VIC, QLD, WA	24/04/2017	25/04/2017	INCAGN01876; INCAGN01876 + Ipilimumab; INCAGN01876 + Ipilimumab + Nivolumab; INCAGN01876 + Nivolumab; Ipilimumab; Nivolumab	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-TIGIT_monoclonal_antibody	INCAGN01876 + Ipilimumab; INCAGN01876 + Ipilimumab + Nivolumab; INCAGN01876 + Nivolumab; INCAGN01876 + Ipilimumab; INCAGN01876 + Ipilimumab + Nivolumab; INCAGN01876 + Nivolumab	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody	INCAGN 1876-201	A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies	Metastatic Cancer; Advanced Malignancies	6009 - Perth; 2148 - Randwick; 2148 - Blacktown; 3084 - Heidelberg; 4120 - Brisbane	https://clinicaltrials.gov/ct2/show/NCT03126110
NCT03133247	SHR1316-002	Phase 1		WA, West Australi	28/04/2017	1/06/2017	SHR-1316	anti-PD-L1_monoclonal_antibody	SHR-1316	anti-PD-L1_monoclonal_antibody	SHR1316-002	A Phase 1, Open-Label, Multicenter, Non-Randomized, Dose Escalation Study to Evaluate the Safety and Tolerability of SHR-1316 in Subjects With Advanced Solid Tumors	Advanced Solid Tumors	- Perth	https://clinicaltrials.gov/ct2/show/NCT03133247
NCT03138889	PROPEL	Phase 1/Phase 2		VIC	3/05/2017	9/06/2017	Bempegaldesleukin; Bempegaldesleukin + Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Bempegaldesleukin + Carboplatin + Nab-paclitaxel + Paclitaxel + Pembrolizumab; Bempegaldesleukin + Pembrolizumab; Carboplatin; Cisplatin; Nab-paclitaxel; Paclitaxel; Pembrolizumab; Pemetrexed	anti-PD-1_monoclonal_antibody; IL-2_variant + anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; platinum-based_antineoplastic_agent; IL-2_variant; antimetabolite; IL-2_variant + anti-PD-1_monoclonal_antibody; IL-2_variant + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; taxane	Bempegaldesleukin + Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Bempegaldesleukin + Carboplatin + Nab-paclitaxel + Paclitaxel + Pembrolizumab; Bempegaldesleukin + Pembrolizumab; Bempegaldesleukin + Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Bempegaldesleukin + Carboplatin + Nab-paclitaxel + Paclitaxel + Pembrolizumab; Bempegaldesleukin + Pembrolizumab	IL-2_variant + anti-PD-1_monoclonal_antibody; IL-2_variant + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; IL-2_variant + anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; IL-2_variant + anti-PD-1_monoclonal_antibody; IL-2_variant + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; IL-2_variant + anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane	16-214-05	A Phase 1/2, Open-Label, Multicenter Study to Investigate the Safety and Preliminary Efficacy of Combined Bempegaldesleukin (NKTR-214) and Pembrolizumab With or Without Chemotherapy in Patients With Locally Advanced or Metastatic Solid Tumors	Non-Small Cell Lung Cancer	3121 - Richmond	https://clinicaltrials.gov/ct2/show/NCT03138889
NCT03141177	CheckMate-9ER	Phase 3		WA, SA, VIC, NSW, QLD	4/05/2017	22/08/2017	Cabozantinib; Cabozantinib + Ipilimumab + Nivolumab; Cabozantinib + Nivolumab; Ipilimumab; Nivolumab; Sunitinib	anti-CTLA-4_monoclonal_antibody; KIT_inhibitor,first_generation; KIT_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor; VEGFR2_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + anti-PD-1_monoclonal_antibody; VEGFR2_inhibitor + anti-PD-1_monoclonal_antibody; MET_inhibitor,type_2 + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; KIT_inhibitor + anti-PD-1_monoclonal_antibody; RET_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; ROS1_inhibitor + anti-PD-1_monoclonal_antibody; AXL_inhibitor; PDGFR_inhibitor; RET_inhibitor; AXL_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; MET_inhibitor,type_2 + anti-PD-1_monoclonal_antibody; VEGFR2_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; AXL_inhibitor + anti-PD-1_monoclonal_antibody; ROS1_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; ROS1_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; MET_inhibitor,type_2; RET_inhibitor + anti-PD-1_monoclonal_antibody; VEGFR_inhibitor; KIT_inhibitor	Cabozantinib + Ipilimumab + Nivolumab; Cabozantinib + Nivolumab; Sunitinib; Cabozantinib + Ipilimumab + Nivolumab; Cabozantinib + Nivolumab	AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + anti-PD-1_monoclonal_antibody; AXL_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; AXL_inhibitor + anti-PD-1_monoclonal_antibody; KIT_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; KIT_inhibitor + anti-PD-1_monoclonal_antibody; KIT_inhibitor,first_generation; MET_inhibitor,type_2 + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; MET_inhibitor,type_2 + anti-PD-1_monoclonal_antibody; PDGFR_inhibitor; RET_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; RET_inhibitor + anti-PD-1_monoclonal_antibody; ROS1_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; ROS1_inhibitor + anti-PD-1_monoclonal_antibody; VEGFR2_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; VEGFR2_inhibitor + anti-PD-1_monoclonal_antibody; VEGFR_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + anti-PD-1_monoclonal_antibody; AXL_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; AXL_inhibitor + anti-PD-1_monoclonal_antibody; KIT_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; KIT_inhibitor + anti-PD-1_monoclonal_antibody; MET_inhibitor,type_2 + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; MET_inhibitor,type_2 + anti-PD-1_monoclonal_antibody; RET_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; RET_inhibitor + anti-PD-1_monoclonal_antibody; ROS1_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; ROS1_inhibitor + anti-PD-1_monoclonal_antibody; VEGFR2_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; VEGFR2_inhibitor + anti-PD-1_monoclonal_antibody	2017-000759-20  CA209-9ER	A Phase 3, Randomized, Open-Label Study of Nivolumab Combined With Cabozantinib Versus Sunitinib in Participants With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma	Renal Cell Carcinoma	4101 - South Brisbane; 3144 - Malvern; 5112 - Elizabeth Vale; 2145 - Westmead; 4006 - Herston; 2010 - Darlinghurst; - North Ryde; 4215 - Southport; 2139 - Sydney; 6018 - Doubleview	https://clinicaltrials.gov/ct2/show/NCT03141177
NCT03143153	CheckMate-648	Phase 3		QLD, NSW, WA	8/05/2017	29/06/2017	Cisplatin; Cisplatin + Fluorouracil; Cisplatin + Nivolumab; Fluorouracil; Ipilimumab; Ipilimumab + Nivolumab; Nivolumab	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; fluoropyrimidine + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent; Fluorouracil; fluoropyrimidine	Cisplatin + Fluorouracil; Cisplatin + Nivolumab; Ipilimumab + Nivolumab; Cisplatin + Fluorouracil; Cisplatin + Nivolumab; Ipilimumab + Nivolumab	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent; fluoropyrimidine + platinum-based_antineoplastic_agent; Fluorouracil; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent; fluoropyrimidine + platinum-based_antineoplastic_agent	2016-001514-20  CA209-648	A Randomized Phase 3 Study of Nivolumab Plus Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin in Subjects With Unresectable Advanced, Recurrent or Metastatic Previously Untreated Esophageal Squamous Cell Carcinoma	Various Advanced Cancer	6150 - Murdoch; 2340 - Tamworth; 4814 - Douglas	https://clinicaltrials.gov/ct2/show/NCT03143153
NCT03145909	2016-004597-18--M15-916	Phase 1		QLD, NSW	9/05/2017	3/07/2017	Rolinsatamab Talirine	anti-PRLR_antibody-drug_conjugate	Rolinsatamab Talirine	anti-PRLR_antibody-drug_conjugate	2016-004597-18  M15-916	A Phase 1 Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)	Advanced Solid Tumors Cancer	4101 - South Brisbane; 2031 - Randwick	https://clinicaltrials.gov/ct2/show/NCT03145909
NCT03146468	NIVALLO	Phase 2		VIC	10/05/2017	8/05/2017	Nivolumab	anti-PD-1_monoclonal_antibody	Nivolumab	anti-PD-1_monoclonal_antibody	RMH 2016.281	Pilot Study of the Tolerability of Nivolumab for Relapsed or Residual Haematological Malignancies After Allogeneic Haematopoietic Stem Cell Transplantation	Haematological Malignancy	3050 - Parkville	https://clinicaltrials.gov/ct2/show/NCT03146468
NCT03148795	C3441006--MDV3800-06	Phase 2	NOT_RECRUITING	QLD, VIC, NSW	11/05/2017	4/07/2017	Abiraterone; Enzalutamide; Prednisone; Talazoparib	antiandrogen,nonsteroidal,second_generation; PARP_inhibitor; glucocorticoid; CYP17A1_inhibitor	Talazoparib; Abiraterone; Enzalutamide; Prednisone	PARP_inhibitor; CYP17A1_inhibitor; antiandrogen,nonsteroidal,second_generation; glucocorticoid	C3441006  MDV3800-06	TALAPRO-1: A PHASE 2, OPEN-LABEL, RESPONSE RATE STUDY OF TALAZOPARIB IN MEN WITH DNA REPAIR DEFECTS AND METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO PREVIOUSLY RECEIVED TAXANE-BASED CHEMOTHERAPY AND PROGRESSED ON AT LEAST 1 NOVEL HORMONAL AGENT (ENZALUTAMIDE AND/OR ABIRATERONE ACETATE/PREDNISONE)	Prostate Cancer	4066 - Auchenflower; 3084 - Heidelberg; 3199 - Frankston; 4101 - South Brisbane; 4870 - Cairns; 3168 - Clayton; 2145 - Westmead; 4032 - Chermside; 4215 - Southport; 2010 - Darlinghurst; 3128 - Box Hill	https://clinicaltrials.gov/ct2/show/NCT03148795
NCT03150056	2016-003416-13--204697	Phase 1	NOT_RECRUITING	NSW, VIC	11/05/2017	18/07/2017	Abiraterone; Abiraterone + Molibresib + Prednisone; Enzalutamide; Enzalutamide + Molibresib; Molibresib; Prednisone	glucocorticoid; CYP17A1_inhibitor; BET_inhibitor; antiandrogen,nonsteroidal,second_generation; BET_inhibitor + CYP17A1_inhibitor + glucocorticoid; BET_inhibitor + antiandrogen,nonsteroidal,second_generation	Abiraterone + Molibresib + Prednisone; Enzalutamide + Molibresib; Abiraterone + Molibresib + Prednisone; Enzalutamide + Molibresib	BET_inhibitor + CYP17A1_inhibitor + glucocorticoid; BET_inhibitor + antiandrogen,nonsteroidal,second_generation; BET_inhibitor + CYP17A1_inhibitor + glucocorticoid; BET_inhibitor + antiandrogen,nonsteroidal,second_generation	2016-003416-13  204697	A Phase IB Open-label, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Combination With Androgen Deprivation Therapy and Other Agents in Subjects With Castrate-resistant Prostate Cancer (CRPC)	Solid Tumours	3000 - Melbourne; 2050 - Sydney; 3168 - Clayton	https://clinicaltrials.gov/ct2/show/NCT03150056
NCT03150810	2017-001553-14--BGB-290-103	Phase 1/Phase 2	NOT_RECRUITING	QLD, VIC, NSW	12/05/2017	28/06/2017	Pamiparib; Pamiparib + Temozolomide; Temozolomide	PARP_inhibitor; alkylating_agent; PARP_inhibitor + alkylating_agent	Pamiparib + Temozolomide; Pamiparib + Temozolomide	PARP_inhibitor + alkylating_agent; PARP_inhibitor + alkylating_agent	2017-001553-14  BGB-290-103	A Phase 1b Study to Assess the Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid Tumors	Locally Advanced or Metastatic Solid Tumors	3000 - Melbourne; 4066 - Auchenflower; 4032 - Chermside; 2010 - Darlinghurst; 4215 - Southport; 4101 - South Brisbane; 4509 - North Lakes	https://clinicaltrials.gov/ct2/show/NCT03150810
NCT03157128	LIBRETTO-001	Phase 1/Phase 2		VIC, NSW	17/05/2017	2/05/2017	Selpercatinib	RET_inhibitor	Selpercatinib	RET_inhibitor	J2G-OX-JZJA  17477	A Study of Oral LOXO-292 in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)	Medullary Thyroid Cancer; Colon Cancer; Any Solid Tumor; Non-Small Cell Lung Cancer	3000 - Melbourne; 2065 - St. Leonards	https://clinicaltrials.gov/ct2/show/NCT03157128
NCT03161756	CHARLI	Phase 1/Phase 2		NSW, VIC, QLD, TAS, WA	22/05/2017	7/12/2017	Denosumab; Denosumab + Ipilimumab + Nivolumab; Denosumab + Nivolumab; Ipilimumab; Nivolumab	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-RANK_L_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-RANK_L_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-RANK_L_monoclonal_antibody	Denosumab + Ipilimumab + Nivolumab; Denosumab + Nivolumab; Denosumab + Ipilimumab + Nivolumab; Denosumab + Nivolumab	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-RANK_L_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-RANK_L_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-RANK_L_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-RANK_L_monoclonal_antibody	01.15	A Phase Ib/II Trial of Ipilimumab-Nivolumab-Denosumab and Nivolumab-Denosumab in Patients With Unresectable Stage III and IV Melanoma	Melanoma Stage Iv; Melanoma; Melanoma Stage Iii	3004 - Melbourne; 3000 - Melbourne; 3084 - Heidelberg; 4029 - Herston; 3128 - Box Hill; 7000 - Hobart; 3550 - Bendigo; 2298 - Waratah; 6009 - Nedlands; 2640 - Albury	https://clinicaltrials.gov/ct2/show/NCT03161756
NCT03170960	XL184-021	Phase 1/Phase 2		NSW, VIC	31/05/2017	5/09/2017	Abiraterone; Abiraterone + Apalutamide + Enzalutamide; Abiraterone + Enzalutamide; Apalutamide; Atezolizumab; Atezolizumab + Cabozantinib; Cabozantinib; Cisplatin; Docetaxel; Enzalutamide; Irinotecan; Irinotecan + Oxaliplatin; Oxaliplatin	VEGFR2_inhibitor + anti-PD-L1_monoclonal_antibody; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor; RET_inhibitor + anti-PD-L1_monoclonal_antibody; VEGFR2_inhibitor; taxane; CYP17A1_inhibitor; antiandrogen,nonsteroidal,second_generation; AXL_inhibitor; platinum-based_antineoplastic_agent + topoisomerase_inhibitor; RET_inhibitor; topoisomerase_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + anti-PD-L1_monoclonal_antibody; AXL_inhibitor + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; ROS1_inhibitor; platinum-based_antineoplastic_agent; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation; MET_inhibitor,type_2; KIT_inhibitor + anti-PD-L1_monoclonal_antibody; ROS1_inhibitor + anti-PD-L1_monoclonal_antibody; MET_inhibitor,type_2 + anti-PD-L1_monoclonal_antibody; KIT_inhibitor	Abiraterone + Apalutamide + Enzalutamide; Abiraterone + Enzalutamide; Atezolizumab + Cabozantinib; Cisplatin; Docetaxel; Irinotecan + Oxaliplatin; Abiraterone + Apalutamide + Enzalutamide; Abiraterone + Enzalutamide; Atezolizumab + Cabozantinib; Irinotecan + Oxaliplatin	AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + anti-PD-L1_monoclonal_antibody; AXL_inhibitor + anti-PD-L1_monoclonal_antibody; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation; KIT_inhibitor + anti-PD-L1_monoclonal_antibody; MET_inhibitor,type_2 + anti-PD-L1_monoclonal_antibody; RET_inhibitor + anti-PD-L1_monoclonal_antibody; ROS1_inhibitor + anti-PD-L1_monoclonal_antibody; VEGFR2_inhibitor + anti-PD-L1_monoclonal_antibody; platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent + topoisomerase_inhibitor; taxane; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + anti-PD-L1_monoclonal_antibody; AXL_inhibitor + anti-PD-L1_monoclonal_antibody; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation; KIT_inhibitor + anti-PD-L1_monoclonal_antibody; MET_inhibitor,type_2 + anti-PD-L1_monoclonal_antibody; RET_inhibitor + anti-PD-L1_monoclonal_antibody; ROS1_inhibitor + anti-PD-L1_monoclonal_antibody; VEGFR2_inhibitor + anti-PD-L1_monoclonal_antibody; platinum-based_antineoplastic_agent + topoisomerase_inhibitor	XL184-021	A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors	Castration-resistant Prostate Cancer; Gastric Cancer; Colorectal Cancer; Non-Small Cell Lung Cancer; Endometrial Cancer; Gastroesophageal Junction Adenocarcinoma; Urothelial Carcinoma; Differentiated Thyroid Cancer; Hepatocellular Carcinoma; Triple Negative Breast Cancer; Renal Cell Carcinoma; Lower Esophageal Cancer; Head and Neck Cancer; Ovarian Cancer	3021 - St Albans; 2031 - Randwick; 2250 - Gosford; 2109 - North Ryde; 2050 - Camperdown; 2640 - Albury	https://clinicaltrials.gov/ct2/show/NCT03170960
NCT03173560	2016-002778-11--E7080-G000-218	Phase 2		SA, VIC, NSW, WA	2/06/2017	17/08/2017	Everolimus; Everolimus + Lenvatinib; Lenvatinib	mTORC1_inhibitor; VEGF_inhibitor + mTORC1_inhibitor; VEGF_inhibitor	Everolimus + Lenvatinib; Everolimus + Lenvatinib	VEGF_inhibitor + mTORC1_inhibitor; VEGF_inhibitor + mTORC1_inhibitor	2016-002778-11  E7080-G000-218	A Randomized, Open-Label (Formerly Double-Blind), Phase 2 Trial to Assess Safety and Efficacy of Lenvatinib at Two Different Starting Doses (18 mg vs. 14 mg QD) in Combination With Everolimus (5 mg QD) in Renal Cell Carcinoma Following One Prior VEGF-Targeted Treatment	Renal Cell Carcinoma	- Saint Leonards; - Murdoch; - Kurralta Park; - Saint Albans; - Macquarie Park	https://clinicaltrials.gov/ct2/show/NCT03173560
NCT03175224	SPARTA	Phase 1/Phase 2		VIC, SA, WA	5/06/2017	27/09/2017	Vebreltinib	MET_inhibitor,type_1	Vebreltinib	MET_inhibitor,type_1	APL-101-01	Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors	Solid Tumor; NSCLC; Renal Cancer; Glioblastoma Multiforme; Lung Cancer; Brain Tumor; Gastric Cancer; Gastroesophageal Junction Adenocarcinoma; Advanced Cancer	- Bedford Park; - North Adelaide; - Nedlands; - Albury; - Melbourne	https://clinicaltrials.gov/ct2/show/NCT03175224
NCT03176238	EVEREXES	Phase 3		NSW, VIC, ACT	5/06/2017	29/03/2013	Everolimus; Everolimus + Exemestane; Exemestane	aromatase_inhibitor; mTORC1_inhibitor; aromatase_inhibitor + mTORC1_inhibitor	Everolimus + Exemestane; Everolimus + Exemestane	aromatase_inhibitor + mTORC1_inhibitor; aromatase_inhibitor + mTORC1_inhibitor	CRAD001JIC06	A Phase IIIb, Multi-center, Open-label Study of RAD001 in Combination With EXemestane in Post-menopausal Women With EStrogen Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Locally Advanced or Metastatic Breast Cancer	Post Menopausal Breast Cancer	3084 - Heidelberg; 3021 - St Albans; 2170 - Liverpool; 3135 - Ringwood East; 2605 - Garran; 3128 - Box Hill; 2229 - Caringbah	https://clinicaltrials.gov/ct2/show/NCT03176238
NCT03176264	2017-000520-96--CPDR001I2101	Phase 1		NSW	5/06/2017	25/09/2017	Bevacizumab; Spartalizumab	anti-PD-1_monoclonal_antibody; anti-VEGF_monoclonal_antibody	Spartalizumab; Bevacizumab	anti-PD-1_monoclonal_antibody; anti-VEGF_monoclonal_antibody	2017-000520-96  CPDR001I2101	ElevatION: CRC-101: A Phase Ib Study of PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer	Metastatic Colorectal Cancer	2065 - St Leonards	https://clinicaltrials.gov/ct2/show/NCT03176264
NCT03177239	UNISoN	Phase 2		WA, VIC, NSW, QLD, SA	6/06/2017	19/10/2017	Ipilimumab; Ipilimumab + Nivolumab; Nivolumab	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Ipilimumab + Nivolumab; Ipilimumab + Nivolumab	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	ANZUP 1602	A Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602).	Papillary Renal Cell Carcinoma Type 1; Papillary Renal Cell Carcinoma Type 2; Renal Cell Carcinoma; Xp11 Translocation Carcinoma; Chromophobe Renal Cell Carcinoma; Sarcomatoid Renal Cell Carcinoma	3128 - Box Hill; 2086 - Frenchs Forest; 2010 - Darlinghurst; 3355 - Ballarat; 2560 - Campbelltown; 2050 - Camperdown; 2145 - Westmead; 3168 - Clayton; 2031 - Randwick; 5037 - Adelaide; 2298 - Newcastle; 2217 - Kogarah; 2444 - Port Macquarie; 5000 - Adelaide; 6150 - Murdoch; 2460 - Albury; 4575 - Birtinya; 2340 - Tamworth; 4000 - Brisbane	https://clinicaltrials.gov/ct2/show/NCT03177239
NCT03178552	B-FAST	Phase 2/Phase 3	NOT_RECRUITING	VIC, NSW, QLD, NZ, SA, WA	7/06/2017	22/09/2017	Alectinib; Atezolizumab; Atezolizumab + Bevacizumab + Carboplatin + Pemetrexed; Atezolizumab + Cobimetinib + Vemurafenib; Bevacizumab; Carboplatin; Carboplatin + Cisplatin + Gemcitabine; Carboplatin + Cisplatin + Pemetrexed; Cisplatin; Cobimetinib; Entrectinib; Gemcitabine; Pemetrexed; Vemurafenib	antimetabolite + platinum-based_antineoplastic_agent; BRAF_V600_inhibitor; anti-PD-L1_monoclonal_antibody; ROS1_inhibitor; gemcitabine; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; ALK_inhibitor,second_generation; TRK_inhibitor,first_generation; platinum-based_antineoplastic_agent; ALK_inhibitor,third_generation; ALK/RET_inhibitor; antimetabolite; BRAF_V600_inhibitor + MEK_inhibitor + anti-PD-L1_monoclonal_antibody; MEK_inhibitor; anti-VEGF_monoclonal_antibody	Alectinib; Atezolizumab; Atezolizumab + Bevacizumab + Carboplatin + Pemetrexed; Atezolizumab + Cobimetinib + Vemurafenib; Carboplatin + Cisplatin + Gemcitabine; Carboplatin + Cisplatin + Pemetrexed; Entrectinib; Atezolizumab + Bevacizumab + Carboplatin + Pemetrexed; Atezolizumab + Cobimetinib + Vemurafenib; Carboplatin + Cisplatin + Gemcitabine; Carboplatin + Cisplatin + Pemetrexed	ALK/RET_inhibitor; ALK_inhibitor,second_generation; ALK_inhibitor,third_generation; BRAF_V600_inhibitor + MEK_inhibitor + anti-PD-L1_monoclonal_antibody; ROS1_inhibitor; TRK_inhibitor,first_generation; anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; BRAF_V600_inhibitor + MEK_inhibitor + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; gemcitabine	2017-000076-28  BO29554	A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: Blood-First Assay Screening Trial)	Non-Small Cell Lung Cancer	3084 - Heidelberg; 5037 - Kurralta Park; 2065 - St Leonards; 4032 - Chermside; 6009 - Nedlands; Auckland	https://clinicaltrials.gov/ct2/show/NCT03178552
NCT03178851	2016-004402-34--CO39721	Phase 1		QLD, NSW, VIC, SA	7/06/2017	20/06/2017	Atezolizumab; Atezolizumab + Cobimetinib; Cobimetinib	anti-PD-L1_monoclonal_antibody; MEK_inhibitor; MEK_inhibitor + anti-PD-L1_monoclonal_antibody	Atezolizumab; Atezolizumab + Cobimetinib; Atezolizumab + Cobimetinib	MEK_inhibitor + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; MEK_inhibitor + anti-PD-L1_monoclonal_antibody	2016-004402-34  CO39721	A Phase Ib Study Evaluating Cobimetinib Plus Atezolizumab in Patients With Advanced BRAF V600 Wild-Type Melanoma Who Have Progressed During or After Treatment With Anti-PD-1 Therapy and Atezolizumab Monotherapy in Patients With Previously Untreated Advanced BRAF V600 Wild-Type Melanoma	Malignant Melanoma	4120 - Greenslopes; 5042 - Bedford Park; 2060 - North Sydney; 3004 - Melbourne; 2444 - Port Macquarie; 3000 - Melbourne; 2148 - Blacktown	https://clinicaltrials.gov/ct2/show/NCT03178851
NCT03179436	MK-1308-001--1308-001	Phase 1/Phase 2	NOT_RECRUITING	SA, NZ, QLD, VIC, NSW	7/06/2017	2/07/2017	Pembrolizumab; Pembrolizumab + Quavonlimab; Quavonlimab	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Pembrolizumab + Quavonlimab; Pembrolizumab + Quavonlimab	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	MK-1308-001  1308-001	A Phase 1 / 2 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors	Advanced Solid Tumors	4870 - Cairns; Auckland; 2298 - Waratah; 2065 - Wollstonecraft; Canterbury; 3004 - Melbourne; 3350 - Ballarat; 5037 - Kurralta Park; 2148 - Blacktown; 4120 - Brisbane	https://clinicaltrials.gov/ct2/show/NCT03179436
NCT03184870	2017-001725-40--CV202-103	Phase 1/Phase 2	NOT_RECRUITING	VIC	14/06/2017	8/08/2017	BMS-813160; BMS-813160 + Fluorouracil + Irinotecan + Leucovorin; BMS-813160 + Gemcitabine + Nab-paclitaxel; BMS-813160 + Gemcitabine + Nab-paclitaxel + Nivolumab; BMS-813160 + Nivolumab; Fluorouracil; Gemcitabine; Gemcitabine + Nab-paclitaxel; Irinotecan; Leucovorin; Nab-paclitaxel; Nivolumab	anti-PD-1_monoclonal_antibody; CCR2/CCR5_antagonist + antimetabolite + taxane; folinic_acid; CCR2/CCR5_antagonist; CCR2/CCR5_antagonist + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor; gemcitabine; taxane; fluoropyrimidine; antimetabolite; Fluorouracil; CCR2/CCR5_antagonist + anti-PD-1_monoclonal_antibody; CCR2/CCR5_antagonist + anti-PD-1_monoclonal_antibody + antimetabolite + taxane; topoisomerase_inhibitor; antimetabolite + taxane	BMS-813160; BMS-813160 + Fluorouracil + Irinotecan + Leucovorin; BMS-813160 + Gemcitabine + Nab-paclitaxel; BMS-813160 + Gemcitabine + Nab-paclitaxel + Nivolumab; BMS-813160 + Nivolumab; Gemcitabine + Nab-paclitaxel; BMS-813160 + Fluorouracil + Irinotecan + Leucovorin; BMS-813160 + Gemcitabine + Nab-paclitaxel; BMS-813160 + Gemcitabine + Nab-paclitaxel + Nivolumab; BMS-813160 + Nivolumab; Gemcitabine + Nab-paclitaxel	CCR2/CCR5_antagonist; CCR2/CCR5_antagonist + anti-PD-1_monoclonal_antibody; CCR2/CCR5_antagonist + anti-PD-1_monoclonal_antibody + antimetabolite + taxane; CCR2/CCR5_antagonist + antimetabolite + taxane; CCR2/CCR5_antagonist + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor; antimetabolite + taxane; CCR2/CCR5_antagonist + anti-PD-1_monoclonal_antibody; CCR2/CCR5_antagonist + anti-PD-1_monoclonal_antibody + antimetabolite + taxane; CCR2/CCR5_antagonist + antimetabolite + taxane; CCR2/CCR5_antagonist + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor; Fluorouracil; antimetabolite + taxane; gemcitabine	2017-001725-40  CV202-103	A Phase 1b/2 Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors	Pancreatic Cancer; Colorectal Cancer	- Clayton	https://clinicaltrials.gov/ct2/show/NCT03184870
NCT03188159	GY01-05-16	Phase 2		VIC	15/06/2017	1/07/2017	Vinorelbine	vinca_alkaloid	Vinorelbine	vinca_alkaloid	GY01/05/16	Phase II Study of Intravenous Vinorelbine in Patients With Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer (VIP)	Ovarian Cancer; Fallopian Tube Cancer	- Melbourne	https://clinicaltrials.gov/ct2/show/NCT03188159
NCT03189719	KEYNOTE-590	Phase 3		VIC, NSW, QLD	16/06/2017	25/07/2017	Cisplatin; Cisplatin + Fluorouracil + Pembrolizumab; Fluorouracil; Pembrolizumab; Placebo	anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; placebo; anti-PD-1_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; Fluorouracil; fluoropyrimidine	Cisplatin + Fluorouracil + Pembrolizumab; Cisplatin + Fluorouracil + Pembrolizumab; Placebo	anti-PD-1_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; Fluorouracil; anti-PD-1_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; placebo	2017-000958-19  3475-590	A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab (MK-3475) in Combination With Cisplatin and 5-Fluorouracil Versus Placebo in Combination With Cisplatin and 5-Fluorouracil as First-Line Treatment in Subjects With Advanced/Metastatic Esophageal Carcinoma (KEYNOTE-590)	Esophageal Neoplasms	3000 - Melbourne; 2148 - Blacktown; 4102 - Woolloongabba; 2170 - Liverpool; 3128 - Box Hill	https://clinicaltrials.gov/ct2/show/NCT03189719
NCT03192345	2018-001113-32--TCD14678	Phase 1	NOT_RECRUITING	VIC	20/06/2017	9/06/2017	Cemiplimab; Cemiplimab + SAR439459; SAR439459	anti-PD-1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody; anti-TGF-beta_monoclonal_antibody; anti-PD-1_monoclonal_antibody	Cemiplimab + SAR439459; SAR439459; Cemiplimab + SAR439459	anti-PD-1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody; anti-TGF-beta_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody	2018-001113-32  TCD14678	A Phase 1/1b First-in-human Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR439459 Administered Intravenously as Monotherapy and in Combination With Cemiplimab in Adult Patients With Advanced Solid Tumors	Malignant Solid Tumor	3081 - Heidelberg West; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT03192345
NCT03207867	2017-000241-49--CNIR178X2201	Phase 2	NOT_RECRUITING	NSW	5/07/2017	28/08/2017	NIR178; NIR178 + Spartalizumab; Spartalizumab	anti-PD-1_monoclonal_antibody; adenosine_A2A_receptor_antagonist + anti-PD-1_monoclonal_antibody; adenosine_A2A_receptor_antagonist	NIR178; NIR178 + Spartalizumab; NIR178 + Spartalizumab	adenosine_A2A_receptor_antagonist; adenosine_A2A_receptor_antagonist + anti-PD-1_monoclonal_antibody; adenosine_A2A_receptor_antagonist + anti-PD-1_monoclonal_antibody	2017-000241-49  CNIR178X2201	A Phase 2, Multi-center, Open Label Study of NIR178 in Combination With PDR001 in Patients With Selected Advanced Solid Tumors and Non-Hodgkin Lymphoma	NSCLC, Non Small Cell Lung Cancer; TNBC, Triple Negative Breast Cancer; DLBCL, Diffused Large B Cell Lymphoma; MSS, Microsatellite Stable Colon Cancer; RCC, Renal Cell Cancer; Melanoma; mCRPC, Metastatic Castration Resistant Prostate Cancer 0 0; Pancreatic Cancer; Head and Neck Cancer; Urothelial Cancer	2148 - Blacktown	https://clinicaltrials.gov/ct2/show/NCT03207867
NCT03208959	HTI-1090-101	Phase 1		NSW, QLD	6/07/2017	30/08/2017	HTI-1090	IDO/TDO_inhibitor	HTI-1090	IDO/TDO_inhibitor	HTI-1090-101	A Phase I, Open-Label, Multicenter, Non-Randomized, Dose-Escalation Study to Evaluate the Safety and Tolerability of HTI-1090 in Patients With Advanced Solid Tumors	Advanced Solid Tumors	4101 - South Brisbane	https://clinicaltrials.gov/ct2/show/NCT03208959
NCT03212404	CK-301-101	Phase 1		QLD, NSW, VIC, NZ	11/07/2017	20/09/2017	Cosibelimab	anti-PD-L1_monoclonal_antibody	Cosibelimab	anti-PD-L1_monoclonal_antibody	CK-301-101	A Phase 1, Open-label, Multicenter, Dose-escalation Study of CK-301 Administered Intravenously as a Single Agent to Subjects With Advanced Cancers	Head and Neck Cancer; Carcinoma, Non-Small-Cell Lung; Malignant Mesothelioma, Advanced; Renal Cell Carcinoma; Lung Neoplasms; Endometrial Cancer; Cutaneous Squamous Cell Carcinoma; Classical Hodgkin Lymphoma; Merkel Cell Carcinoma; Urothelial Carcinoma; Carcinoma, Small Cell; Melanoma; Non Hodgkin Lymphoma	2500 - Wollongong; 4102 - Woolloongabba; Christchurch; 4120 - Greenslopes; 3128 - Box Hill; 4556 - Buderim; 4217 - Benowa; 3144 - Malvern; 4101 - South Brisbane	https://clinicaltrials.gov/ct2/show/NCT03212404
NCT03215706	CheckMate-9LA	Phase 3	NOT_RECRUITING	WA, NSW, VIC, SA	12/07/2017	24/08/2017	Carboplatin; Cisplatin; Ipilimumab; Nivolumab; Paclitaxel; Pemetrexed	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; antimetabolite; taxane	Carboplatin; Cisplatin; Ipilimumab; Nivolumab; Paclitaxel; Pemetrexed	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; antimetabolite; platinum-based_antineoplastic_agent; taxane	2017-001195-35  CA209-9LA	A Phase 3, Randomized Study of Nivolumab Plus Ipilimumab in Combination With Chemotherapy vs Chemotherapy Alone as First Line Therapy in Stage IV Non-Small Cell Lung Cancer	Non-Small Cell Lung Cancer	2250 - Gosford; 3128 - Box Hill; 5042 - Bedford Park; 3084 - Heidelberg; 6150 - Murdoch	https://clinicaltrials.gov/ct2/show/NCT03215706
NCT03219268	CP-MGD013-01	Phase 1	NOT_RECRUITING	VIC, NSW	17/07/2017	18/08/2017	Margetuximab; Margetuximab + Tebotelimab; Tebotelimab	humanized_PD-1xLAG-3_dual-affinity_re-targeting_protein; anti-ERBB2_monoclonal_antibody; anti-ERBB2_monoclonal_antibody + humanized_PD-1xLAG-3_dual-affinity_re-targeting_protein	Margetuximab + Tebotelimab; Tebotelimab; Margetuximab + Tebotelimab	anti-ERBB2_monoclonal_antibody + humanized_PD-1xLAG-3_dual-affinity_re-targeting_protein; humanized_PD-1xLAG-3_dual-affinity_re-targeting_protein; anti-ERBB2_monoclonal_antibody + humanized_PD-1xLAG-3_dual-affinity_re-targeting_protein	CP-MGD013-01	A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein Binding PD-1 and LAG-3 in Patients With Unresectable or Metastatic Neoplasms	Advanced Solid Tumors; Hematologic Neoplasms; Squamous Cell Carcinoma of Head and Neck; Small-cell Lung Cancer; Ovarian Cancer; Non Small Cell Lung Cancer; TNBC - Triple-Negative Breast Cancer; HER2-positive Advanced Solid Tumors; Cholangiocarcinoma; Cervical Cancer	2298 - Waratah; 2010 - Darlinghurst; 2500 - Wollongong; 3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT03219268
NCT03234712	M16-438	Phase 1	NOT_RECRUITING	VIC, NSW	31/07/2017	10/10/2017	Serclutamab Talirine	anti-EGFR/PBD_antibody-drug_conjugate	Serclutamab Talirine	anti-EGFR/PBD_antibody-drug_conjugate	M16-438	A Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR)	Advanced Solid Tumors Cancer	3168 - Clayton; 3084 - Heidelberg; 2065 - St Leonards	https://clinicaltrials.gov/ct2/show/NCT03234712
NCT03255070	ARX788-1711	Phase 1		VIC, NSW, QLD	21/08/2017	20/03/2018	ARX788	anti-ERBB2_antibody-drug_conjugate	ARX788	anti-ERBB2_antibody-drug_conjugate	ARX788-1711	A Phase 1, Multicenter, Open-label, Multiple Dose-escalation and Expansion Study of ARX788, as Monotherapy in Advanced Solid Tumors With HER2 Expression	Solid Tumors; Breast Neoplasms; Gastric Neoplasm; Solid Tumour	3168 - Clayton; 2640 - East Albury; 4101 - South Brisbane; 4102 - Woolloongabba	https://clinicaltrials.gov/ct2/show/NCT03255070
NCT03256344	NCT03256344	Phase 1	NOT_RECRUITING	WA, VIC, NSW	22/08/2017	19/03/2018	Atezolizumab; Atezolizumab + Talimogene Laherparepvec; Talimogene Laherparepvec	anti-PD-L1_monoclonal_antibody; oncolytic_HSV_virus; anti-PD-L1_monoclonal_antibody + oncolytic_HSV_virus	Atezolizumab + Talimogene Laherparepvec; Atezolizumab + Talimogene Laherparepvec	anti-PD-L1_monoclonal_antibody + oncolytic_HSV_virus; anti-PD-L1_monoclonal_antibody + oncolytic_HSV_virus	20140299	A Phase 1b Study of Talimogene Laherparepvec in Combination With Atezolizumab in Subjects With Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases	Metastatic Colorectal Cancer; Metastatic Triple Negative Breast Cancer	3168 - Clayton; 6009 - Nedlands; 2170 - Liverpool; 6150 - Murdoch	https://clinicaltrials.gov/ct2/show/NCT03256344
NCT03257267	2017-000350-19--R2810-ONC-1676	Phase 3		WA, QLD, NSW, VIC	22/08/2017	5/09/2017	Cemiplimab	anti-PD-1_monoclonal_antibody	Cemiplimab	anti-PD-1_monoclonal_antibody	2017-000350-19  R2810-ONC-1676	An Open-Label, Randomized, Phase 3 Clinical Trial of REGN2810 Versus Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Carcinoma	Squamous Cell Carcinoma (SCC); Recurrent or Metastatic, Platinum-refractory Cervical Cancer	2485 - Tweed Heads; 6009 - Nedlands; 03000 - Melbourne; 4011 - Herston; 2217 - Kogarah; 6008 - Subiaco	https://clinicaltrials.gov/ct2/show/NCT03257267
NCT03260894	KEYNOTE-679	Phase 3		ACT, WA, VIC, NSW, NZ	24/08/2017	7/12/2017	Epacadostat; Epacadostat + Pembrolizumab; Pazopanib; Pazopanib + Sunitinib; Pembrolizumab; Sunitinib	KIT_inhibitor,first_generation; anti-PD-1_monoclonal_antibody; KIT_inhibitor,ATP-competitive + VEGFR_inhibitor; KIT_inhibitor,ATP-competitive + PDGFR_inhibitor; KIT_inhibitor,ATP-competitive; IDO1_inhibitor; IDO1_inhibitor + anti-PD-1_monoclonal_antibody; KIT_inhibitor,first_generation + PDGFR_inhibitor; VEGFR_inhibitor; KIT_inhibitor,ATP-competitive + KIT_inhibitor,first_generation; PDGFR_inhibitor; PDGFR_inhibitor + VEGFR_inhibitor; KIT_inhibitor,first_generation + VEGFR_inhibitor	Epacadostat + Pembrolizumab; Pazopanib + Sunitinib; Epacadostat + Pembrolizumab; Pazopanib + Sunitinib	IDO1_inhibitor + anti-PD-1_monoclonal_antibody; KIT_inhibitor,ATP-competitive + KIT_inhibitor,first_generation; KIT_inhibitor,ATP-competitive + PDGFR_inhibitor; KIT_inhibitor,ATP-competitive + VEGFR_inhibitor; KIT_inhibitor,first_generation + PDGFR_inhibitor; KIT_inhibitor,first_generation + VEGFR_inhibitor; PDGFR_inhibitor; PDGFR_inhibitor + VEGFR_inhibitor; VEGFR_inhibitor; IDO1_inhibitor + anti-PD-1_monoclonal_antibody; KIT_inhibitor,ATP-competitive + KIT_inhibitor,first_generation; KIT_inhibitor,ATP-competitive + PDGFR_inhibitor; KIT_inhibitor,ATP-competitive + VEGFR_inhibitor; KIT_inhibitor,first_generation + PDGFR_inhibitor; KIT_inhibitor,first_generation + VEGFR_inhibitor; PDGFR_inhibitor + VEGFR_inhibitor	2017-002259-26  KEYNOTE-679/ECHO-302	A Randomized, Open-Label, Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care (Sunitinib or Pazopanib) as First-Line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-679/ECHO-302)	Renal Cell Carcinoma (RCC)	3144 - Malvern; 2145 - Westmead; 2298 - Waratah; 2605 - Garran; 6150 - Murdoch	https://clinicaltrials.gov/ct2/show/NCT03260894
NCT03261011	AK104-101	Phase 1	STATUS_UNKNOWN	WA, VIC	24/08/2017	3/10/2017	AK104	bispecific_PD-1/CTLA-4_antibody	AK104	bispecific_PD-1/CTLA-4_antibody	AK104-101	A Phase 1A/1B Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK104 in Subjects With Advanced Solid Tumors	Advanced Cancer	3168 - Clayton; 6009 - Nedlands; 3002 - Melbourne; 3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT03261011
NCT03273153	2016-004387-18--CO39722	Phase 3	NOT_RECRUITING	WA, QLD, TAS	6/09/2017	11/12/2017	Atezolizumab; Atezolizumab + Cobimetinib; Cobimetinib; Pembrolizumab	anti-PD-L1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; MEK_inhibitor; MEK_inhibitor + anti-PD-L1_monoclonal_antibody	Atezolizumab + Cobimetinib; Pembrolizumab; Atezolizumab + Cobimetinib	MEK_inhibitor + anti-PD-L1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; MEK_inhibitor + anti-PD-L1_monoclonal_antibody	2016-004387-18  CO39722	A Phase III, Open-Label, Multicenter, Two Arm, Randomized Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Patients With Previously Untreated Advanced BRAF V600 Wild-Type Melanoma	Advanced BRAFV600 Wild-type Melanoma	4184 - Douglas; 4870 - Cairns; 7000 - Hobart; 4102 - Woolloongabba; 6150 - Murdoch	https://clinicaltrials.gov/ct2/show/NCT03273153
NCT03278717	ICON9	Phase 3	NOT_RECRUITING	ACT, QLD, NSW, VIC, SA, NZ, TAS	12/09/2017	15/06/2018	Cediranib; Cediranib + Olaparib; Olaparib	PARP_inhibitor; PARP_inhibitor + VEGF_inhibitor; VEGF_inhibitor	Cediranib + Olaparib; Olaparib; Cediranib + Olaparib	PARP_inhibitor; PARP_inhibitor + VEGF_inhibitor; PARP_inhibitor + VEGF_inhibitor	UCL/14/0795	International Phase III Randomised Study to Evaluate the Efficacy of Maintenance Therapy With Olaparib and Cediranib or Olaparib Alone in Patients With Relapsed Ovarian Cancer Following a Response to Platinum-based Chemotherapy	Ovarian Cancer	- Gosford; Canterbury; - Westmead; - South Brisbane; Auckland; - Clayton; - Camperdown; - Bedford Park; - Melbourne; - Sydney; - Canberra; - Albury; Christchurch; - Townsville; - Benowa; - Hobart	https://clinicaltrials.gov/ct2/show/NCT03278717
NCT03281369	2016-004529-17--YO39609	Phase 1/Phase 2		NSW, VIC	13/09/2017	13/10/2017	Atezolizumab; Atezolizumab + Cisplatin + Fluorouracil; Atezolizumab + Cisplatin + Fluorouracil + Tiragolumab; Atezolizumab + Cobimetinib; Atezolizumab + Cobimetinib + Fluorouracil + Leucovorin + Oxaliplatin; Atezolizumab + Cobimetinib + Linagliptin; Atezolizumab + Cobimetinib + Motixafortide; Atezolizumab + Cobimetinib + Paclitaxel + Ramucirumab; Atezolizumab + Cobimetinib + rHuPH20; Cisplatin; Cisplatin + Fluorouracil; Cobimetinib; Fluorouracil; Leucovorin; Linagliptin; Motixafortide; Oxaliplatin; Paclitaxel; Ramucirumab; Tiragolumab; rHuPH20	dipeptidyl_peptidase-4_inhibitor; MEK_inhibitor + anti-PD-L1_monoclonal_antibody + anti-VEGFR2_monoclonal_antibody + taxane; fluoropyrimidine + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; recombinant_human_hyaluronidase; folinic_acid; anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; MEK_inhibitor + anti-PD-L1_monoclonal_antibody; CXCR4_antagonist; taxane; fluoropyrimidine; platinum-based_antineoplastic_agent; MEK_inhibitor + anti-PD-L1_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; MEK_inhibitor + anti-PD-L1_monoclonal_antibody + recombinant_human_hyaluronidase; anti-TIGIT_monoclonal_antibody; Fluorouracil; anti-VEGFR2_monoclonal_antibody; CXCR4_antagonist + MEK_inhibitor + anti-PD-L1_monoclonal_antibody; MEK_inhibitor; MEK_inhibitor + anti-PD-L1_monoclonal_antibody + dipeptidyl_peptidase-4_inhibitor	Atezolizumab + Cisplatin + Fluorouracil; Atezolizumab + Cisplatin + Fluorouracil + Tiragolumab; Atezolizumab + Cobimetinib; Atezolizumab + Cobimetinib + Fluorouracil + Leucovorin + Oxaliplatin; Atezolizumab + Cobimetinib + Linagliptin; Atezolizumab + Cobimetinib + Motixafortide; Atezolizumab + Cobimetinib + Paclitaxel + Ramucirumab; Atezolizumab + Cobimetinib + rHuPH20; Cisplatin + Fluorouracil; Atezolizumab + Cisplatin + Fluorouracil; Atezolizumab + Cisplatin + Fluorouracil + Tiragolumab; Atezolizumab + Cobimetinib; Atezolizumab + Cobimetinib + Fluorouracil + Leucovorin + Oxaliplatin; Atezolizumab + Cobimetinib + Linagliptin; Atezolizumab + Cobimetinib + Motixafortide; Atezolizumab + Cobimetinib + Paclitaxel + Ramucirumab; Atezolizumab + Cobimetinib + rHuPH20; Cisplatin + Fluorouracil	CXCR4_antagonist + MEK_inhibitor + anti-PD-L1_monoclonal_antibody; MEK_inhibitor + anti-PD-L1_monoclonal_antibody; MEK_inhibitor + anti-PD-L1_monoclonal_antibody + anti-VEGFR2_monoclonal_antibody + taxane; MEK_inhibitor + anti-PD-L1_monoclonal_antibody + dipeptidyl_peptidase-4_inhibitor; MEK_inhibitor + anti-PD-L1_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; MEK_inhibitor + anti-PD-L1_monoclonal_antibody + recombinant_human_hyaluronidase; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; fluoropyrimidine + platinum-based_antineoplastic_agent; CXCR4_antagonist + MEK_inhibitor + anti-PD-L1_monoclonal_antibody; Fluorouracil; MEK_inhibitor + anti-PD-L1_monoclonal_antibody; MEK_inhibitor + anti-PD-L1_monoclonal_antibody + anti-VEGFR2_monoclonal_antibody + taxane; MEK_inhibitor + anti-PD-L1_monoclonal_antibody + dipeptidyl_peptidase-4_inhibitor; MEK_inhibitor + anti-PD-L1_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; MEK_inhibitor + anti-PD-L1_monoclonal_antibody + recombinant_human_hyaluronidase; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; fluoropyrimidine + platinum-based_antineoplastic_agent	2016-004529-17  YO39609	A Phase Ib/II, Open-Label, Multicenter, Randomized, Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)	Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma	3168 - Clayton; 2148 - Blacktown; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT03281369
NCT03284424	2017-000594-37--3475-629	Phase 2		QLD, NSW	15/09/2017	26/10/2017	Pembrolizumab	anti-PD-1_monoclonal_antibody	Pembrolizumab	anti-PD-1_monoclonal_antibody	2017-000594-37  3475-629	A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)	Squamous Cell Carcinoma	2480 - Lismore; 4814 - Douglas; 2800 - Orange; 4102 - Woolloongabba; 4029 - Herston; 2500 - Wollongong	https://clinicaltrials.gov/ct2/show/NCT03284424
NCT03284723	2017-002538-22--C0541001	Phase 1		NSW	15/09/2017	1/11/2017	Letrozole; PF-06804103; Palbociclib	aromatase_inhibitor; CDK4/6_inhibitor; anti-ERBB2_antibody-drug_conjugate	PF-06804103; Letrozole; Palbociclib	anti-ERBB2_antibody-drug_conjugate; CDK4/6_inhibitor; aromatase_inhibitor	2017-002538-22  C0541001	A Phase 1 Dose Escalation Study Evaluating the Safety and Tolerability of PF-06804103 in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive and Negative Solid Tumors	Breast Neoplasms	2050 - Camperdown; 2109 - Macquarie University	https://clinicaltrials.gov/ct2/show/NCT03284723
NCT03286842	D0816C00018	Phase 3	NOT_RECRUITING	NSW	14/09/2017	17/01/2018	Olaparib	PARP_inhibitor	Olaparib	PARP_inhibitor	D0816C00018	A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Monotherapy in the Treatment of HER2-ve Metastatic Breast Cancer Patients With Germline or Somatic BRCA1/2 Mutations.	Somatic BRCA1/2 Mutations; HER2-ve Metastatic Breast Cancer; Germline BRCA1/2 Mutations	NSW 2031 - Randwick	https://clinicaltrials.gov/ct2/show/NCT03286842
NCT03287427	MYPHISMO	Phase 1	NOT_RECRUITING	VIC	19/09/2017		TetMYB; TetMYB + Tislelizumab; Tislelizumab	MYB-targeting_vaccine + anti-PD-1_monoclonal_antibody; MYB-targeting_vaccine; anti-PD-1_monoclonal_antibody	TetMYB + Tislelizumab; TetMYB + Tislelizumab	MYB-targeting_vaccine + anti-PD-1_monoclonal_antibody; MYB-targeting_vaccine + anti-PD-1_monoclonal_antibody	MYPHISMO	First-in-human Phase I Clinical Trial of a Combined Immune Modulatory Approach Using TetMYB Vaccine and Anti-PD1 Antibody in Patients With Advanced Solid Cancer Including Colorectal or Adenoid Cystic Carcinoma.	Colorectal Cancer; Adenoid Cystic Carcinoma	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT03287427
NCT03292172	2017-001147-13--NP39487	Phase 1		VIC, NSW	25/09/2017	8/11/2017	Atezolizumab; Atezolizumab + RO6870810; RO6870810	anti-PD-L1_monoclonal_antibody; BET_inhibitor; BET_inhibitor + anti-PD-L1_monoclonal_antibody	Atezolizumab + RO6870810; Atezolizumab + RO6870810	BET_inhibitor + anti-PD-L1_monoclonal_antibody; BET_inhibitor + anti-PD-L1_monoclonal_antibody	2017-001147-13  NP39487	Open Label, Dose Finding and Expansion Phase IB Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (Pd L1 Antibody) in Pateints With Advanced Ovarian Cancer or Triple Negative Breast Cancer	Advanced Ovarian Cancer; Triple Negative Breast Cancer	2010 - Darlinghurst; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT03292172
NCT03294083	JX594-REN026	Phase 1/Phase 2		SA, NSW	26/09/2017	7/06/2018	Cemiplimab; Cemiplimab + Pexastimogene Devacirepvec; Pexastimogene Devacirepvec	thymidine_kinase-deleted_oncolytic_vaccinia_virus_expressing_human_GM-CSF; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + thymidine_kinase-deleted_oncolytic_vaccinia_virus_expressing_human_GM-CSF	Cemiplimab; Cemiplimab + Pexastimogene Devacirepvec; Pexastimogene Devacirepvec; Cemiplimab + Pexastimogene Devacirepvec	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + thymidine_kinase-deleted_oncolytic_vaccinia_virus_expressing_human_GM-CSF; thymidine_kinase-deleted_oncolytic_vaccinia_virus_expressing_human_GM-CSF; anti-PD-1_monoclonal_antibody + thymidine_kinase-deleted_oncolytic_vaccinia_virus_expressing_human_GM-CSF	JX594-REN026	A Phase 1b/2a Dose-escalation and Safety/Efficacy Evaluation Study of Pexa-Vec (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) in Combination With Cemiplimab (REGN2810; Anti-PD-1) in Patients With Metastatic or Unresectable Renal Cell Carcinoma (RCC)	Renal Cell Carcinoma	- Camperdown; SA5042 - Bedford Park	https://clinicaltrials.gov/ct2/show/NCT03294083
NCT03296696	2017-001658-32--20160132	Phase 1	NOT_RECRUITING	VIC, NSW	28/09/2017	18/04/2018	AMG 404; AMG 404 + AMG 596; AMG 596	anti-PD-1_monoclonal_antibody; bispecific_T-cell_engager,EGFRvIII-targeting; anti-PD-1_monoclonal_antibody + bispecific_T-cell_engager,EGFRvIII-targeting	AMG 404 + AMG 596; AMG 404 + AMG 596	anti-PD-1_monoclonal_antibody + bispecific_T-cell_engager,EGFRvIII-targeting; anti-PD-1_monoclonal_antibody + bispecific_T-cell_engager,EGFRvIII-targeting	2017-001658-32  20160132	Phase 1/1b Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 596 as Monotherapy and in Combination With AMG 404 in Subjects With Glioblastoma or Malignant Glioma Expressing Mutant Epidermal Growth Factor Receptor Variant III (EGFRvIII)	Glioblastoma or Malignant Glioma	2065 - St Leonards; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT03296696
NCT03302234	KEYNOTE-598	Phase 3		WA, NSW, VIC, QLD	5/10/2017	14/12/2017	Ipilimumab; Ipilimumab + Pembrolizumab; Pembrolizumab; Placebo	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; placebo	Ipilimumab + Pembrolizumab; Pembrolizumab; Ipilimumab + Pembrolizumab; Placebo	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; placebo	2016-004364-20  3475-598	A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Plus Ipilimumab vs Pembrolizumab Plus Placebo in Previously Untreated, Stage IV, Metastatic Non-small Cell Lung Cancer Subjects Whose Tumors Are PD-L1 Positive (TPS = 50%) (KEYNOTE-598)	Carcinoma, Non-Small-Cell Lung	3065 - Fitzroy; 6150 - Perth; 4814 - Douglas; 4101 - South Brisbane; 2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT03302234
NCT03306394	PRECONNECT	Phase 3		NSW, VIC, SA, ACT, WA	11/10/2017	18/10/2016	Trifluridine/Tipiracil	thymidine_phosphorylase_inhibitor; Tipiracil Hydrochloride; Trifluridine; antimetabolite	Trifluridine/Tipiracil	Tipiracil Hydrochloride; Trifluridine; antimetabolite; thymidine_phosphorylase_inhibitor	2016-002311-18  CL3-95005-004	An Open-label Early Access Phase IIIb Study of Trifluridine / Tipiracil (S 95005/TAS-102) in Patients With a Pretreated Metastatic Colorectal Cancer (PRECONNECT)	Metastatic Colorectal Cancer	2605 - Garran; 3065 - Fitzroy; 4029 - Herston; 3144 - Malvern; NSW 2050 - Camperdown; SA 5011 - Woodville; 6000 - Perth; 2010 - Darlinghurst	https://clinicaltrials.gov/ct2/show/NCT03306394
NCT03317496	B9991023--B9991023	Phase 1/Phase 2	NOT_RECRUITING	VIC, NSW	23/10/2017	21/12/2017	Avelumab; Avelumab + Carboplatin + Pemetrexed; Avelumab + Cisplatin + Gemcitabine; Carboplatin; Cisplatin; Gemcitabine; Pemetrexed	platinum-based_antineoplastic_agent; antimetabolite; anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; gemcitabine	Avelumab + Carboplatin + Pemetrexed; Avelumab + Cisplatin + Gemcitabine; Avelumab + Carboplatin + Pemetrexed; Avelumab + Cisplatin + Gemcitabine	anti-PD-L1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; gemcitabine	B9991023  B9991023	A MULTICENTER, OPEN-LABEL, PHASE 1B/2 STUDY TO EVALUATE SAFETY AND EFFICACY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH CHEMOTHERAPY WITH OR WITHOUT OTHER ANTI-CANCER IMMUNOTHERAPIES AS FIRST-LINE TREATMENT IN PATIENTS WITH ADVANCED MALIGNANCIES	Urothelial Cancer; Non-small Cell Lung Cancer	2050 - Camperdown; 2010 - Darlinghurst; 3021 - St Albans	https://clinicaltrials.gov/ct2/show/NCT03317496
NCT03319628	XMT-1536-1	Phase 1/Phase 2		NSW, VIC	24/10/2017	12/12/2017	Upifitamab Rilsodotin	anti-NaPi2b_antibody-drug_conjugate	Upifitamab Rilsodotin	anti-NaPi2b_antibody-drug_conjugate	XMT-1536-1	A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b	Non Small Cell Lung Cancer Metastatic; Platinum Resistant Ovarian Cancer	- Melbourne; 2148 - Blacktown; - Heidelberg; - Camperdown	https://clinicaltrials.gov/ct2/show/NCT03319628
NCT03319940	NCT03319940	Phase 1		NSW	24/10/2017	26/12/2017	Pembrolizumab; Pembrolizumab + Tarlatamab; Tarlatamab	anti-PD-1_monoclonal_antibody; bispecific_T-cell_engager,DLL3-targeting; anti-PD-1_monoclonal_antibody + bispecific_T-cell_engager,DLL3-targeting	Pembrolizumab + Tarlatamab; Tarlatamab; Pembrolizumab + Tarlatamab	anti-PD-1_monoclonal_antibody + bispecific_T-cell_engager,DLL3-targeting; bispecific_T-cell_engager,DLL3-targeting; anti-PD-1_monoclonal_antibody + bispecific_T-cell_engager,DLL3-targeting	20160323	A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of AMG 757 in Subjects With Small Cell Lung Cancer	Small Cell Lung Carcinoma	2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT03319940
NCT03322540	KEYNOTE-654-05-ECHO-305-05	Phase 2		VIC, WA	26/10/2017	15/12/2017	Epacadostat; Epacadostat + Pembrolizumab; Pembrolizumab; Placebo	anti-PD-1_monoclonal_antibody; IDO1_inhibitor; placebo; IDO1_inhibitor + anti-PD-1_monoclonal_antibody	Epacadostat + Pembrolizumab; Pembrolizumab; Epacadostat + Pembrolizumab; Placebo	IDO1_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; IDO1_inhibitor + anti-PD-1_monoclonal_antibody; placebo	KEYNOTE-654-05/ECHO-305-05	A Phase 2, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) Plus Epacadostat (INCB024360) Versus Pembrolizumab Plus Placebo as First-Line Treatment in Patients With Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1	Lung Cancer	3084 - Heidelberg; 6150 - Murdoch	https://clinicaltrials.gov/ct2/show/NCT03322540
NCT03322566	2017-001810-27--KEYNOTE-715-06-ECHO-306-06	Phase 2		(Australia)NSW, NSW, QLD	26/10/2017	9/01/2018	Carboplatin; Carboplatin + Cisplatin + Epacadostat + Paclitaxel + Pembrolizumab + Pemetrexed; Cisplatin; Epacadostat; Epacadostat + Pembrolizumab; Paclitaxel; Pembrolizumab; Pemetrexed; Placebo	anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; IDO1_inhibitor; placebo; IDO1_inhibitor + anti-PD-1_monoclonal_antibody; antimetabolite; taxane; IDO1_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane	Carboplatin + Cisplatin + Epacadostat + Paclitaxel + Pembrolizumab + Pemetrexed; Epacadostat + Pembrolizumab; Carboplatin + Cisplatin + Epacadostat + Paclitaxel + Pembrolizumab + Pemetrexed; Epacadostat + Pembrolizumab; Placebo	IDO1_inhibitor + anti-PD-1_monoclonal_antibody; IDO1_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; IDO1_inhibitor + anti-PD-1_monoclonal_antibody; IDO1_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; placebo	2017-001810-27  KEYNOTE-715-06/ECHO-306-06	A Randomized Phase 2 Study of the Combination of Pembrolizumab (MK-3475) Plus Epacadostat (INCB024360) With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo as First-Line Treatment in Patients With Metastatic Non-Small Cell Lung Cancer	Lung Cancer	2148 - Blacktown; 2444 - Port Macquarie; 2500 - Wollongong; 2050 - Camperdown; 4870 - Cairns; 2145 - Westmead	https://clinicaltrials.gov/ct2/show/NCT03322566
NCT03326674	CONTESSA	Phase 3		VIC, NSW, QLD, SA, WA	31/10/2017	21/12/2017	Capecitabine; Capecitabine + Tesetaxel; Tesetaxel	fluoropyrimidine + taxane; taxane; fluoropyrimidine	Capecitabine; Capecitabine + Tesetaxel; Capecitabine + Tesetaxel	fluoropyrimidine; fluoropyrimidine + taxane; fluoropyrimidine + taxane	ODO-TE-B301	A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane	Breast Cancer	- Clayton; - Bedford Park; - Perth; - Woolloongabba; 2640 - Albury; - South Brisbane; - Nedlands; 2076 - Wahroonga; 3199 - Frankston	https://clinicaltrials.gov/ct2/show/NCT03326674
NCT03329846	2017-002499-14--CA017-055	Phase 3		QLD, VIC, NSW, NZ	6/11/2017	30/11/2017	Linrodostat; Linrodostat + Nivolumab; Nivolumab; Placebo	anti-PD-1_monoclonal_antibody; IDO1_inhibitor; placebo; IDO1_inhibitor + anti-PD-1_monoclonal_antibody	Linrodostat + Nivolumab; Nivolumab; Linrodostat + Nivolumab; Placebo	IDO1_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; IDO1_inhibitor + anti-PD-1_monoclonal_antibody; placebo	2017-002499-14  CA017-055	A Phase 3, Randomized, Double-blind Study of BMS-986205 Combined With Nivolumab Versus Nivolumab in Participants With Metastatic or Unresectable Melanoma That is Previously Untreated	Melanoma; Skin Cancer	4120 - Greenslopes; 3128 - Box Hill; Christchurch; 3004 - Melbourne; Wellington; 2148 - Blacktown; 2146 - North Sydney; 4120 - Woolloongabba; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT03329846
NCT03330405	2017-001509-33--B9991025	Phase 2	NOT_RECRUITING	WA, NSW, QLD	6/11/2017	19/10/2017	Avelumab; Talazoparib	PARP_inhibitor; anti-PD-L1_monoclonal_antibody	Avelumab; Talazoparib	anti-PD-L1_monoclonal_antibody; PARP_inhibitor	2017-001509-33  B9991025	A PHASE 1B/2 STUDY TO EVALUATE SAFETY AND ANTI TUMOR ACTIVITY OF AVELUMAB IN COMBINATION WITH THE POLY(ADENOSINE DIPHOSPHATE [ADP]-RIBOSE) POLYMERASE (PARP) INHIBITOR TALAZOPARIB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS	Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors	6150 - Murdoch; 2065 - St. Leonards; 2109 - North Ryde; 4101 - Brisbane	https://clinicaltrials.gov/ct2/show/NCT03330405
NCT03332797	2017-002083-41--GO39932	Phase 1	NOT_RECRUITING	VIC, NSW	6/11/2017	27/11/2017	Brilanestrant; Brilanestrant + Giredestrant; Giredestrant; Giredestrant + LHRH Agonist; Giredestrant + LHRH Agonist + Palbociclib; Giredestrant + Palbociclib; LHRH Agonist; Palbociclib	CDK4/6_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + LHRH_agonist + selective_estrogen_receptor_degrader; CDK4/6_inhibitor; LHRH_agonist + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader; LHRH_agonist	Brilanestrant + Giredestrant; Giredestrant; Giredestrant + LHRH Agonist; Giredestrant + LHRH Agonist + Palbociclib; Giredestrant + Palbociclib; Brilanestrant + Giredestrant; Giredestrant + LHRH Agonist; Giredestrant + LHRH Agonist + Palbociclib; Giredestrant + Palbociclib	CDK4/6_inhibitor + LHRH_agonist + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + selective_estrogen_receptor_degrader; LHRH_agonist + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader; CDK4/6_inhibitor + LHRH_agonist + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + selective_estrogen_receptor_degrader; LHRH_agonist + selective_estrogen_receptor_degrader	2017-002083-41  GO39932	A Phase Ia/Ib, Multicenter, Open-Label, Dose Escalation, Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-9545 Alone or in Combination With Palbociclib and/or LHRH Agonist in Patients With Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer	Breast Cancer	2010 - Darlinghurst; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT03332797
NCT03334487	2017-003173-33--M16-292	Phase 3		NSW, VIC, QLD, WA	7/11/2017	15/03/2018	Dexamethasone; Dexamethasone + Rovalpituzumab Tesirine; Rovalpituzumab Tesirine	anti-DLL3_antibody-drug_conjugate + glucocorticoid; glucocorticoid; anti-DLL3_antibody-drug_conjugate	Dexamethasone + Rovalpituzumab Tesirine; Dexamethasone + Rovalpituzumab Tesirine	anti-DLL3_antibody-drug_conjugate + glucocorticoid; anti-DLL3_antibody-drug_conjugate + glucocorticoid	2017-003173-33  M16-292	Open-Label, Single Arm, Phase 3b Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory DLL3 Expressing Small Cell Lung Cancer	Small Cell Lung Cancer	4814 - Douglas; 2450 - Coffs Harbour; 6009 - Nedlands; 2485 - Tweed Heads; 3690 - Wodonga; 3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT03334487
NCT03337698	Morpheus-Lung	Phase 1/Phase 2		VIC, NSW	9/11/2017	2/01/2018	Atezolizumab; Atezolizumab + Bevacizumab; Atezolizumab + Bevacizumab + Radiotherapy; Atezolizumab + Carboplatin + Gemcitabine; Atezolizumab + Carboplatin + Pemetrexed; Atezolizumab + Cibisatamab; Atezolizumab + Ciforadenant; Atezolizumab + Cobimetinib; Atezolizumab + Docetaxel; Atezolizumab + Evolocumab; Atezolizumab + Ipatasertib; Atezolizumab + Linagliptin; Atezolizumab + Sacituzumab Govitecan; Bevacizumab; Carboplatin; Cibisatamab; Ciforadenant; Cobimetinib; Docetaxel; Evolocumab; Gemcitabine; Ipatasertib; Linagliptin; Pemetrexed; Radiotherapy; Sacituzumab Govitecan; Tocilizumab	taxane; anti-Trop2_antibody-drug_conjugate; anti-PD-L1_monoclonal_antibody + dipeptidyl_peptidase-4_inhibitor; adenosine_A2aR_and_A2bR_antagonist; anti-PD-L1_monoclonal_antibody + taxane; adenosine_A2aR_and_A2bR_antagonist + anti-PD-L1_monoclonal_antibody; anti-IL-6_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + bispecific_T-cell_engager,CEA-targeting; anti-PD-L1_monoclonal_antibody + pan-AKT_inhibitor; anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; dipeptidyl_peptidase-4_inhibitor; anti-PD-L1_monoclonal_antibody; anti-PCSK9_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; MEK_inhibitor + anti-PD-L1_monoclonal_antibody; gemcitabine; radiotherapy; platinum-based_antineoplastic_agent; pan-AKT_inhibitor; antimetabolite; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + radiotherapy; anti-PD-L1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; bispecific_T-cell_engager,CEA-targeting; anti-PD-L1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PCSK9_monoclonal_antibody; MEK_inhibitor	Atezolizumab; Atezolizumab + Bevacizumab; Atezolizumab + Bevacizumab + Radiotherapy; Atezolizumab + Carboplatin + Gemcitabine; Atezolizumab + Carboplatin + Pemetrexed; Atezolizumab + Cibisatamab; Atezolizumab + Ciforadenant; Atezolizumab + Cobimetinib; Atezolizumab + Docetaxel; Atezolizumab + Evolocumab; Atezolizumab + Ipatasertib; Atezolizumab + Linagliptin; Atezolizumab + Sacituzumab Govitecan; Docetaxel; Atezolizumab + Bevacizumab; Atezolizumab + Bevacizumab + Radiotherapy; Atezolizumab + Carboplatin + Gemcitabine; Atezolizumab + Carboplatin + Pemetrexed; Atezolizumab + Cibisatamab; Atezolizumab + Ciforadenant; Atezolizumab + Cobimetinib; Atezolizumab + Docetaxel; Atezolizumab + Evolocumab; Atezolizumab + Ipatasertib; Atezolizumab + Linagliptin; Atezolizumab + Sacituzumab Govitecan; Tocilizumab	MEK_inhibitor + anti-PD-L1_monoclonal_antibody; adenosine_A2aR_and_A2bR_antagonist + anti-PD-L1_monoclonal_antibody; anti-PCSK9_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + radiotherapy; anti-PD-L1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + bispecific_T-cell_engager,CEA-targeting; anti-PD-L1_monoclonal_antibody + dipeptidyl_peptidase-4_inhibitor; anti-PD-L1_monoclonal_antibody + pan-AKT_inhibitor; anti-PD-L1_monoclonal_antibody + taxane; taxane; MEK_inhibitor + anti-PD-L1_monoclonal_antibody; adenosine_A2aR_and_A2bR_antagonist + anti-PD-L1_monoclonal_antibody; anti-IL-6_monoclonal_antibody; anti-PCSK9_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + radiotherapy; anti-PD-L1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + bispecific_T-cell_engager,CEA-targeting; anti-PD-L1_monoclonal_antibody + dipeptidyl_peptidase-4_inhibitor; anti-PD-L1_monoclonal_antibody + pan-AKT_inhibitor; anti-PD-L1_monoclonal_antibody + taxane; gemcitabine	2017-001267-21  BO39610	A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Non-Small Cell Lung Cancer (Morpheus-Lung)	Carcinoma, Non-Small-Cell Lung	2148 - Blacktown; 3002 - East Melbourne	https://clinicaltrials.gov/ct2/show/NCT03337698
NCT03337724	IPATunity130	Phase 3	NOT_RECRUITING	WA, QLD, NSW, VIC	9/11/2017	6/01/2018	Ipatasertib; Ipatasertib + Paclitaxel; Paclitaxel; Placebo	taxane; placebo; pan-AKT_inhibitor + taxane; pan-AKT_inhibitor	Ipatasertib + Paclitaxel; Paclitaxel; Ipatasertib + Paclitaxel; Placebo	pan-AKT_inhibitor + taxane; taxane; pan-AKT_inhibitor + taxane; placebo	2017-001548-36  CO40016	A Double-Blind, Placebo-Controlled, Randomized Phase III Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Patients With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer	Breast Cancer	2145 - Wentworthville; 6149 - Bull Creek; 2050 - Camperdown; 2298 - Waratah; 3144 - Malvern; 4101 - South Brisbane	https://clinicaltrials.gov/ct2/show/NCT03337724
NCT03338790	CheckMate-9KD	Phase 2	NOT_RECRUITING	NSW, VIC, QLD, SA	9/11/2017	19/12/2017	Docetaxel; Docetaxel + Nivolumab + Prednisone; Enzalutamide; Enzalutamide + Nivolumab; Nivolumab; Nivolumab + Rucaparib; Prednisone; Rucaparib	PARP_inhibitor; anti-PD-1_monoclonal_antibody + glucocorticoid + taxane; glucocorticoid; anti-PD-1_monoclonal_antibody; antiandrogen,nonsteroidal,second_generation; PARP_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation; taxane	Docetaxel + Nivolumab + Prednisone; Enzalutamide + Nivolumab; Nivolumab + Rucaparib; Docetaxel + Nivolumab + Prednisone; Enzalutamide + Nivolumab; Nivolumab + Rucaparib	PARP_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation; anti-PD-1_monoclonal_antibody + glucocorticoid + taxane; PARP_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation; anti-PD-1_monoclonal_antibody + glucocorticoid + taxane	CA209-9KD	A Phase 2 Study of Nivolumab in Combination With Either Rucaparib, Docetaxel, or Enzalutamide in Men With Castration-resistant Metastatic Prostate Cancer	Prostate Cancer	3084 - Heidelberg; 2050 - Camperdown; 4101 - South Brisbane; 5112 - Elizabeth Vale; 2145 - Westmead; 3168 - Clayton	https://clinicaltrials.gov/ct2/show/NCT03338790
NCT03352531	AK105-101	Phase 1	*STATUS_UNKNOWN	NSW, QLD, SA	24/11/2017	22/12/2017	Penpulimab	anti-PD-1_monoclonal_antibody	Penpulimab	anti-PD-1_monoclonal_antibody	AK105-101	A Phase 1A/1B Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK105 in Subjects With Advanced Solid Tumors	Advanced Cancer	2170 - Liverpool; 5037 - Kurralta Park; 4101 - South Brisbane; 2010 - Darlinghurst	https://clinicaltrials.gov/ct2/show/NCT03352531
NCT03353753	INVICTUS	Phase 3		VIC	27/11/2017	27/02/2018	Placebo; Ripretinib	PDGFRA_inhibitor; KIT_inhibitor,switch_control_kinase_inhibitor; placebo	Ripretinib; Placebo	KIT_inhibitor,switch_control_kinase_inhibitor; PDGFRA_inhibitor; placebo	DCC-2618-03-001	A Phase 3, INterVentional, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of DCC-2618 In Patients With AdvanCed Gastrointestinal Stromal TUmorS Who Have Received Treatment With Prior Anticancer Therapies	Gastrointestinal Stromal Tumors	- Melbourne	https://clinicaltrials.gov/ct2/show/NCT03353753
NCT03358472	KEYNOTE-669	Phase 3		NSW, QLD	30/11/2017	1/12/2017	Carboplatin; Carboplatin + Cetuximab + Cisplatin + Fluorouracil; Cetuximab; Cisplatin; Epacadostat; Epacadostat + Pembrolizumab; Fluorouracil; Pembrolizumab	anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; IDO1_inhibitor; IDO1_inhibitor + anti-PD-1_monoclonal_antibody; Fluorouracil; anti-EGFR_monoclonal_antibody; fluoropyrimidine; anti-EGFR_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent	Carboplatin + Cetuximab + Cisplatin + Fluorouracil; Epacadostat + Pembrolizumab; Pembrolizumab; Carboplatin + Cetuximab + Cisplatin + Fluorouracil; Epacadostat + Pembrolizumab	IDO1_inhibitor + anti-PD-1_monoclonal_antibody; anti-EGFR_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody; Fluorouracil; IDO1_inhibitor + anti-PD-1_monoclonal_antibody; anti-EGFR_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent	KEYNOTE-669/ECHO 304	A Phase 3 Randomized, Open-Label Clinical Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen as First Line Treatment for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)	Head and Neck Cancer	2050 - Camperdown; 2109 - North Ryde; 4029 - Herston	https://clinicaltrials.gov/ct2/show/NCT03358472
NCT03358875	2018-000245-39--BGB-A317-303	Phase 3	NOT_RECRUITING	NZ	2/12/2017	30/11/2017	Docetaxel; Tislelizumab	anti-PD-1_monoclonal_antibody; taxane	Docetaxel; Tislelizumab	anti-PD-1_monoclonal_antibody; taxane	2018-000245-39  BGB-A317-303	A Phase 3, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of BGB-A317 (Anti-PD1 Antibody) Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer Who Have Progressed on a Prior Platinum-Containing Regimen	Non-small Cell Lung Cancer	Wellington; Hamilton; Tauranga	https://clinicaltrials.gov/ct2/show/NCT03358875
NCT03361865	KEYNOTE-672	Phase 3		NSW, VIC, SA	5/12/2017	4/12/2017	Cisplatin; Epacadostat; Epacadostat + Pembrolizumab; Pembrolizumab; Placebo	anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; IDO1_inhibitor; placebo; IDO1_inhibitor + anti-PD-1_monoclonal_antibody	Epacadostat + Pembrolizumab; Pembrolizumab; Cisplatin; Epacadostat + Pembrolizumab; Placebo	IDO1_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; IDO1_inhibitor + anti-PD-1_monoclonal_antibody; placebo; platinum-based_antineoplastic_agent	KEYNOTE-672/ECHO-307	A Phase 3 Randomized, Double-Blind Trial of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) or Placebo in Participants With Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)	UC (Urothelial Cancer)	2298 - Waratah; 2109 - Macquarie Park; 3084 - Heidelberg; 2500 - Wollongong; 5037 - Kurralta Park	https://clinicaltrials.gov/ct2/show/NCT03361865
NCT03363776	2017-002199-24--CA034-001	Phase 1/Phase 2	NOT_RECRUITING	VIC, NSW, QLD	6/12/2017	24/11/2017	BMS-986277; BMS-986277 + Nivolumab; Nivolumab	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + replication-competent_oncolytic_adenovirus; replication-competent_oncolytic_adenovirus	BMS-986277; BMS-986277 + Nivolumab; BMS-986277 + Nivolumab	anti-PD-1_monoclonal_antibody + replication-competent_oncolytic_adenovirus; replication-competent_oncolytic_adenovirus; anti-PD-1_monoclonal_antibody + replication-competent_oncolytic_adenovirus	2017-002199-24  CA034-001	Phase 1/2a First in Human Study of BMS-986277 Administered Alone and in Combination With Nivolumab in Advanced Epithelial Tumors	Cancer	2050 - Camperdown; 3050 - Parkville; 4029 - Herston	https://clinicaltrials.gov/ct2/show/NCT03363776
NCT03363867	BEACON	Phase 2		VIC	6/12/2017	10/07/2018	Atezolizumab; Atezolizumab + Bevacizumab + Cobimetinib; Bevacizumab; Cobimetinib	anti-PD-L1_monoclonal_antibody; MEK_inhibitor; MEK_inhibitor + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-VEGF_monoclonal_antibody	Atezolizumab + Bevacizumab + Cobimetinib; Atezolizumab + Bevacizumab + Cobimetinib	MEK_inhibitor + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; MEK_inhibitor + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody	BEACON	BEACON - A Phase II Study of Bevacizumab, Atezolizumab and Cobimetinib in Patients With Recurrent Platinum Resistant High Grade Serous Ovarian Cancer	Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT03363867
NCT03369223	2018-000416-21--CA030-001	Phase 1/Phase 2		VIC, NSW, SA	11/12/2017	6/12/2017	BMS-986249; BMS-986249 + Nivolumab; Ipilimumab; Ipilimumab + Nivolumab; Nivolumab	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; CTLA-4-directed_probody; CTLA-4-directed_probody + anti-PD-1_monoclonal_antibody	BMS-986249; BMS-986249 + Nivolumab; Ipilimumab + Nivolumab; Nivolumab; BMS-986249 + Nivolumab; Ipilimumab + Nivolumab	CTLA-4-directed_probody; CTLA-4-directed_probody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; CTLA-4-directed_probody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	2018-000416-21  CA030-001	A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors	Advanced Cancer	2060 - North Sydney; 3199 - Frankston; 5000 - Adelaide; 3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT03369223
NCT03374488	KEYNOTE-698	Phase 3		SA, VIC, NSW	15/12/2017	22/12/2017	Epacadostat; Epacadostat + Pembrolizumab; Pembrolizumab; Placebo	anti-PD-1_monoclonal_antibody; IDO1_inhibitor; placebo; IDO1_inhibitor + anti-PD-1_monoclonal_antibody	Epacadostat + Pembrolizumab; Pembrolizumab; Epacadostat + Pembrolizumab; Placebo	IDO1_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; IDO1_inhibitor + anti-PD-1_monoclonal_antibody; placebo	KEYNOTE-698/ECHO-303	A Phase 3 Randomized, Double-Blind Clinical Study of Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo as a Treatment for Recurrent or Progressive Metastatic Urothelial Carcinoma in Patients Who Have Failed a First-Line Platinum-containing Chemotherapy Regimen for Advanced/Metastatic Disease (KEYNOTE-698/ECHO-303)	UC (Urothelial Cancer)	3084 - Heidelberg; 2109 - Macquarie Park; 5037 - Kurralta Park; 2500 - Wollongong	https://clinicaltrials.gov/ct2/show/NCT03374488
NCT03377361	CheckMate-9N9	Phase 1/Phase 2	NOT_RECRUITING	NSW, VIC, QLD, SA	19/12/2017	1/02/2018	Ipilimumab; Ipilimumab + Nivolumab + Trametinib; Nivolumab; Nivolumab + Trametinib; Regorafenib; Trametinib	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; MEK_inhibitor + anti-PD-1_monoclonal_antibody; MEK_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; MEK_inhibitor; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor	Ipilimumab + Nivolumab + Trametinib; Nivolumab + Trametinib; Regorafenib; Ipilimumab + Nivolumab + Trametinib; Nivolumab + Trametinib	KIT/PDGFR/RET/VEGFR/FGFR_inhibitor; MEK_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; MEK_inhibitor + anti-PD-1_monoclonal_antibody; MEK_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; MEK_inhibitor + anti-PD-1_monoclonal_antibody	2017-001830-24  CA209-9N9	A Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Metastatic Colorectal Cancers	Colorectal Tumors; Colorectal Cancer; Colorectal Neoplasm; Colorectal Carcinoma	2145 - Blacktown; 5112 - Elizabeth Vale; 3168 - Clayton; - Herston; 4215 - Southport; 3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT03377361
NCT03377491	EF-27	Phase 3		QLD, WA	19/12/2017	10/05/2018	Gemcitabine; Gemcitabine + Nab-paclitaxel; Nab-paclitaxel; Paclitaxel	gemcitabine; taxane; antimetabolite; antimetabolite + taxane	Gemcitabine + Nab-paclitaxel; Gemcitabine + Nab-paclitaxel	antimetabolite + taxane; antimetabolite + taxane; gemcitabine	EF-27	Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma	Pancreas Adenocarcinoma	6150 - Murdoch; 4120 - Greenslopes	https://clinicaltrials.gov/ct2/show/NCT03377491
NCT03379259	2018-000265-37--BGB-900-101	Phase 1/Phase 2		WA, NZ, VIC	20/12/2017	27/11/2017	BGB-A333; BGB-A333 + Tislelizumab; Tislelizumab	anti-PD-L1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	BGB-A333; BGB-A333 + Tislelizumab; BGB-A333 + Tislelizumab	anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-PD-L1_monoclonal_antibody	2018-000265-37  BGB-900-101	Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-PD-L1 Monoclonal Antibody BGB-A333 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors	Advanced Solid Tumors	6009 - Perth; 3168 - Clayton; 3004 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT03379259
NCT03382340	IMX-110-001	Phase 1/Phase 2		NSW, QLD	22/12/2017	15/02/2018	IMX-110	nanoparticle_Stat3/NF-kB/poly-TKI; doxorubicin	IMX-110	doxorubicin; nanoparticle_Stat3/NF-kB/poly-TKI	IMX-110-001	A Phase 1/2a Open-Label, Dose-Escalation/Dose-Expansion Safety, Tolerability and Pharmacokinetic Study of IMX-110 in Patients With Advanced Solid Tumors	Pancreatic Cancer; Breast Cancer; Ovarian Cancer; Solid Tumor, Adult; Advanced Solid Tumors	QLD 4487 - Sydney	https://clinicaltrials.gov/ct2/show/NCT03382340
NCT03386721	2017-003182-94--BP40234	Phase 2		NZ	29/12/2017	19/02/2018	Atezolizumab; Atezolizumab + Docetaxel + RO-6874281; Atezolizumab + RO-6874281; Docetaxel; Docetaxel + Gemcitabine + Vinorelbine; Gemcitabine; RO-6874281; Vinorelbine	anti-FAP/interleukin-2_fusion_protein + anti-PD-L1_monoclonal_antibody + taxane; anti-FAP/interleukin-2_fusion_protein; antimetabolite; anti-FAP/interleukin-2_fusion_protein + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; vinca_alkaloid; gemcitabine; taxane; antimetabolite + taxane + vinca_alkaloid	Atezolizumab + Docetaxel + RO-6874281; Atezolizumab + RO-6874281; Docetaxel; Docetaxel + Gemcitabine + Vinorelbine; Atezolizumab + Docetaxel + RO-6874281; Atezolizumab + RO-6874281; Docetaxel + Gemcitabine + Vinorelbine	anti-FAP/interleukin-2_fusion_protein + anti-PD-L1_monoclonal_antibody; anti-FAP/interleukin-2_fusion_protein + anti-PD-L1_monoclonal_antibody + taxane; antimetabolite + taxane + vinca_alkaloid; taxane; anti-FAP/interleukin-2_fusion_protein + anti-PD-L1_monoclonal_antibody; anti-FAP/interleukin-2_fusion_protein + anti-PD-L1_monoclonal_antibody + taxane; antimetabolite + taxane + vinca_alkaloid; gemcitabine	2017-003182-94  BP40234	An Open-Label, Multicenter, Phase II Study to Evaluate the Therapeutic Activity of RO6874281, an Immunocytokine, Consisting of Interleukin-2 Variant (IL-2v) Targeting Fibroblast Activation Protein-? (FAP), in Combination With Atezolizumab (Anti-PD-L1), Administered Intravenously, in Participants With Advanced and/or Metastatic Solid Tumors	Advanced/Metastatic Head and Neck, Oesophageal and Cervical Cancers	Auckland	https://clinicaltrials.gov/ct2/show/NCT03386721
NCT03390504	2017-002932-18--CR108401	Phase 3		WA, VIC, NSW	4/01/2018	23/03/2018	Docetaxel; Docetaxel + Vinflunine; Erdafitinib; Pembrolizumab; Vinflunine	anti-PD-1_monoclonal_antibody; taxane + vinca_alkaloid; vinca_alkaloid; pan-FGFR_inhibitor; taxane	Docetaxel + Vinflunine; Erdafitinib; Pembrolizumab; Docetaxel + Vinflunine	anti-PD-1_monoclonal_antibody; pan-FGFR_inhibitor; taxane + vinca_alkaloid; taxane + vinca_alkaloid	2017-002932-18  CR108401	A Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects With Advanced Urothelial Cancer and Selected FGFR Gene Aberrations	Urothelial Cancer	3199 - Melbourne; 2050 - Camperdown; 2109 - North Ryde; 6150 - Murdoch; 3000 - Melbourne; 2217 - Kogarah; 3199 - Frankston	https://clinicaltrials.gov/ct2/show/NCT03390504
NCT03392428	TheraP	Phase 2		SA, NSW, VIC, QLD, WA	8/01/2018	29/01/2018	Cabazitaxel; Lu-177 vipivotide tetraxetan	radioligand,PSMA-targeting; taxane	Cabazitaxel; Lu-177 vipivotide tetraxetan	radioligand,PSMA-targeting; taxane	ANZUP 1603	TheraP: A Randomised Phase 2 Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer (ANZUP Protocol 1603)	Metastatic Cancer; Cancer of the Prostate	2010 - Sydney; 5000 - Adelaide; 3084 - Melbourne; 4029 - Brisbane; 6450 - Murdoch; 3165 - Moorabbin; 3008 - Melbourne; 2170 - Liverpool; 2065 - Sydney; 2298 - Waratah; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT03392428
NCT03395197	TALAPRO-2	Phase 3		QLD, NSW, VIC, NZ	10/01/2018	18/12/2017	Enzalutamide; Enzalutamide + Talazoparib; Placebo; Talazoparib	antiandrogen,nonsteroidal,second_generation; PARP_inhibitor; PARP_inhibitor + antiandrogen,nonsteroidal,second_generation; placebo	Enzalutamide + Talazoparib; Enzalutamide + Talazoparib; Placebo	PARP_inhibitor + antiandrogen,nonsteroidal,second_generation; PARP_inhibitor + antiandrogen,nonsteroidal,second_generation; placebo	2017-003295-31  C3441021	A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER	mCRPC 0 0	3000 - Melbourne; 2444 - Port Macquarie; 3051 - North Melbourne; 4066 - Auchenflower; 4102 - Brisbane; 2010 - Darlinghurst; 4215 - Southport; Canterbury; Waikato; 2050 - Camperdown; 4032 - Chermside; Auckland; 4101 - South Brisbane	https://clinicaltrials.gov/ct2/show/NCT03395197
NCT03400332	2018-000340-26--CA027-002	Phase 1/Phase 2		WA, VIC, NSW, SA	17/01/2018	12/02/2018	BMS-986253; BMS-986253 + Ipilimumab + Nivolumab; BMS-986253 + Nivolumab; Ipilimumab; Ipilimumab + Nivolumab; Nivolumab; Placebo	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; placebo; anti-IL8_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-IL8_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-IL8_monoclonal_antibody	BMS-986253 + Ipilimumab + Nivolumab; BMS-986253 + Nivolumab; Ipilimumab + Nivolumab; BMS-986253 + Ipilimumab + Nivolumab; BMS-986253 + Nivolumab; Ipilimumab + Nivolumab; Placebo	anti-CTLA-4_monoclonal_antibody + anti-IL8_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-IL8_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-IL8_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-IL8_monoclonal_antibody + anti-PD-1_monoclonal_antibody; placebo	2018-000340-26  CA027-002	A Phase 1/2 Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers	Cancer; Melanoma	5000 - Adelaide; 3004 - Melbourne; 6009 - Nedlands; 2065 - Wollstonecraft; 3350 - Ballarat Central; 3076 - Epping	https://clinicaltrials.gov/ct2/show/NCT03400332
NCT03410693	FORT-1	Phase 2/Phase 3		NSW, VIC, QLD	25/01/2018	31/05/2018	Rogaratinib	pan-FGFR_inhibitor	Rogaratinib	pan-FGFR_inhibitor	2016-004340-11  17403	A Randomized, Open Label, Multicenter Phase 2/3 Study to Evaluate the Efficacy and Safety of Rogaratinib (BAY1163877) Compared to Chemotherapy in Patients With FGFR-positive Locally Advanced or Metastatic Urothelial Carcinoma Who Have Received Prior Platinum-containing Chemotherapy	Carcinoma, Transitional Cell	2650 - Wagga Wagga; 2065 - St Leonards; 2076 - Wahroonga; 4217 - Benowa; 2450 - Coffs Harbour; 3168 - Clayton; 2109 - Sydney	https://clinicaltrials.gov/ct2/show/NCT03410693
NCT03411473	C-500-03	Phase 2		NZ, NSW, QLD	26/01/2018	4/10/2017	Pembrolizumab; Pembrolizumab + Zalifrelimab; Zalifrelimab	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Pembrolizumab + Zalifrelimab; Pembrolizumab + Zalifrelimab	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	C-500-03	A Phase IIa Open-Label Trial of AGEN1884 in Combination With Pembrolizumab in Subjects With Chemotherapy Naïve, PD-L1 High, Metastatic Non-Small Cell Lung Cancer (NSCLC)	NSCLC Stage IV	- Brisbane; Auckland; - Sydney; - Wahroonga; - Tugun	https://clinicaltrials.gov/ct2/show/NCT03411473
NCT03412799	CL-SBP-101-03	Phase 1		SA, QLD, VIC, NSW	26/01/2018	4/06/2018	Gemcitabine; Ivospemin; Nab-paclitaxel	polyamine_analogue; gemcitabine; taxane; antimetabolite	Gemcitabine; Ivospemin; Nab-paclitaxel	antimetabolite; polyamine_analogue; taxane; gemcitabine	CL-SBP-101-03	Phase 1A/1B Dose Escalation and Expansion Study of SBP-101 in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma	Pancreatic Cancer Metastatic; Pancreatic Cancer Stage IV; Stage IV Pancreatic Cancer	2148 - Blacktown; 3084 - Heidelberg; 5037 - Kurralta Park; 4224 - Tugun	https://clinicaltrials.gov/ct2/show/NCT03412799
NCT03414047	I4D-MC-JTJN--16712	Phase 2		QLD, NSW, VIC, SA	29/01/2018	10/04/2018	Prexasertib	CHEK1_inhibitor	Prexasertib	CHEK1_inhibitor	I4D-MC-JTJN  16712	A Phase 2 Study of Prexasertib in Platinum-Resistant or Refractory Recurrent Ovarian Cancer	Ovarian Cancer	4101 - South Brisbane; 2031 - Randwick; 5042 - Bedford Park; 2139 - Concord; 2145 - Wentworthville; 4029 - Herston; 3000 - Melbourne; 5065 - Toorak Gardens	https://clinicaltrials.gov/ct2/show/NCT03414047
NCT03417037	2017-003058-18--CA017-062	Phase 3		WA, VIC, NSW, QLD	31/01/2018		Linrodostat; Linrodostat + Nivolumab; Nivolumab	anti-PD-1_monoclonal_antibody; IDO1_inhibitor; IDO1_inhibitor + anti-PD-1_monoclonal_antibody	Linrodostat + Nivolumab; Linrodostat + Nivolumab	IDO1_inhibitor + anti-PD-1_monoclonal_antibody; IDO1_inhibitor + anti-PD-1_monoclonal_antibody	2017-003058-18  CA017-062	A Phase 3 Open Label, Randomized Study of BMS-986205 Combined With Nivolumab With or Without Chemotherapy Versus Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer	Lung Cancer; Non-Small Cell Lung Cancer	2010 - Darlinghurst; 2340 - North Tamworth; 6150 - Murdoch; 4102 - Brisbane; 3004 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT03417037
NCT03419403	2017-003171-64--M16-534	Phase 3		VIC, NSW, QLD	5/02/2018	30/07/2018	Depatuxizumab Mafodotin; Temozolomide	alkylating_agent; anti-EGFR/PBD_antibody-drug_conjugate	Depatuxizumab Mafodotin; Temozolomide	anti-EGFR/PBD_antibody-drug_conjugate; alkylating_agent	2017-003171-64  M16-534	Phase 3b Study for Management of Ocular Side Effects in Subjects With EGFR-amplified Glioblastoma Receiving Depatuxizumab Mafodotin (ABT-414)	Glioblastoma Multiforme	2065 - Saint Leonards; 2298 - Waratah; 3084 - Heidelberg; 4029 - Herston	https://clinicaltrials.gov/ct2/show/NCT03419403
NCT03424005	Morpheus-TNBC	Phase 1/Phase 2	NOT_RECRUITING	VIC	6/02/2018	2/04/2018	Atezolizumab; Atezolizumab + Bevacizumab + Selicrelumab; Atezolizumab + Carboplatin + Eribulin + Gemcitabine; Atezolizumab + Ipatasertib; Atezolizumab + Ladiratuzumab Vedotin; Atezolizumab + Nab-paclitaxel; Atezolizumab + Nab-paclitaxel + Tocilizumab; Atezolizumab + Sacituzumab Govitecan; Bevacizumab; Capecitabine; Carboplatin; Eribulin; Gemcitabine; Ipatasertib; Ladiratuzumab Vedotin; Nab-paclitaxel; Sacituzumab Govitecan; Selicrelumab; Tocilizumab	macrocyclic_ketone_analogue; anti-PD-L1_monoclonal_antibody; gemcitabine; taxane; anti-Trop2_antibody-drug_conjugate; fluoropyrimidine; anti-IL-6_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + taxane; anti-LIV1_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody; platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + taxane; anti-IL-6_monoclonal_antibody; anti-CD40_agonistic_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; pan-AKT_inhibitor; antimetabolite; anti-PD-L1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-PD-L1_monoclonal_antibody + pan-AKT_inhibitor; anti-PD-L1_monoclonal_antibody + antimetabolite + macrocyclic_ketone_analogue + platinum-based_antineoplastic_agent; anti-CD40_agonistic_antibody; anti-VEGF_monoclonal_antibody; anti-LIV1_antibody-drug_conjugate	Atezolizumab + Bevacizumab + Selicrelumab; Atezolizumab + Carboplatin + Eribulin + Gemcitabine; Atezolizumab + Ipatasertib; Atezolizumab + Ladiratuzumab Vedotin; Atezolizumab + Nab-paclitaxel; Atezolizumab + Nab-paclitaxel + Tocilizumab; Atezolizumab + Sacituzumab Govitecan; Capecitabine; Atezolizumab + Bevacizumab + Selicrelumab; Atezolizumab + Carboplatin + Eribulin + Gemcitabine; Atezolizumab + Ipatasertib; Atezolizumab + Ladiratuzumab Vedotin; Atezolizumab + Nab-paclitaxel; Atezolizumab + Nab-paclitaxel + Tocilizumab; Atezolizumab + Sacituzumab Govitecan	anti-CD40_agonistic_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-IL-6_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + taxane; anti-LIV1_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-PD-L1_monoclonal_antibody + antimetabolite + macrocyclic_ketone_analogue + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + pan-AKT_inhibitor; anti-PD-L1_monoclonal_antibody + taxane; fluoropyrimidine; anti-CD40_agonistic_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-IL-6_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + taxane; anti-LIV1_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-PD-L1_monoclonal_antibody + antimetabolite + macrocyclic_ketone_analogue + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + pan-AKT_inhibitor; anti-PD-L1_monoclonal_antibody + taxane; gemcitabine	2017-002038-21  CO40115	A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Triple-Negative Breast Cancer (Morpheus-TNBC)	Triple Negative Breast Cancer	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT03424005
NCT03427814	2017-003493-13--BGB-290-303	Phase 2	NOT_RECRUITING	QLD, NSW, VIC	9/02/2018	23/07/2018	Pamiparib; Placebo	PARP_inhibitor; placebo	Pamiparib; Placebo	PARP_inhibitor; placebo	2017-003493-13  BGB-290-303	PARALLEL 303: A Phase 2, Double-blind, Randomized Study of BGB-290 Versus Placebo as Maintenance Therapy in Patients With Inoperable Locally Advanced or Metastatic Gastric Cancer That Responded to Platinum-based First-line Chemotherapy	Advanced or Inoperable Gastric Cancer	3355 - Wendouree; 3076 - Epping; 2250 - Gosford; 3168 - Clayton; 4814 - Douglas	https://clinicaltrials.gov/ct2/show/NCT03427814
NCT03428217	CANTATA	Phase 2		WA, VIC, NSW, QLD, NZ	9/02/2018	14/05/2018	Cabozantinib; Cabozantinib + Telaglenastat; Placebo; Telaglenastat	AXL_inhibitor + glutaminase_inhibitor; placebo; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor; KIT_inhibitor + glutaminase_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + glutaminase_inhibitor; VEGFR2_inhibitor; RET_inhibitor + glutaminase_inhibitor; ROS1_inhibitor + glutaminase_inhibitor; ROS1_inhibitor; glutaminase_inhibitor; VEGFR2_inhibitor + glutaminase_inhibitor; MET_inhibitor,type_2; AXL_inhibitor; RET_inhibitor; KIT_inhibitor; MET_inhibitor,type_2 + glutaminase_inhibitor	Cabozantinib; Cabozantinib + Telaglenastat; Cabozantinib + Telaglenastat; Placebo	AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + glutaminase_inhibitor; AXL_inhibitor; AXL_inhibitor + glutaminase_inhibitor; KIT_inhibitor; KIT_inhibitor + glutaminase_inhibitor; MET_inhibitor,type_2; MET_inhibitor,type_2 + glutaminase_inhibitor; RET_inhibitor; RET_inhibitor + glutaminase_inhibitor; ROS1_inhibitor; ROS1_inhibitor + glutaminase_inhibitor; VEGFR2_inhibitor; VEGFR2_inhibitor + glutaminase_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + glutaminase_inhibitor; AXL_inhibitor + glutaminase_inhibitor; KIT_inhibitor + glutaminase_inhibitor; MET_inhibitor,type_2 + glutaminase_inhibitor; RET_inhibitor + glutaminase_inhibitor; ROS1_inhibitor + glutaminase_inhibitor; VEGFR2_inhibitor + glutaminase_inhibitor; placebo	CX-839-008	A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)	Advanced Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma	6009 - Nedlands; 2485 - Tweed Heads; 4217 - Benowa; 2050 - Camperdown; 2109 - North Ryde; 4870 - Cairns; 4101 - South Brisbane; 3144 - Malvern; 2576 - Bowral; 3630 - Shepparton; Wellington; 3199 - Frankston; 3350 - Ballarat; 2170 - Sydney; Hamilton; 4102 - Woolloongabba	https://clinicaltrials.gov/ct2/show/NCT03428217
NCT03430063	2017-003684-35--R2810-ONC-1763	Phase 2	NOT_RECRUITING	NSW	9/02/2018	29/05/2018	Cemiplimab; Ipilimumab	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody	Cemiplimab; Ipilimumab	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody	2017-003684-35  R2810-ONC-1763	A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (Cemiplimab; Anti-PD-1 Antibody) and Ipilimumab (Anti-CTLA-4 Antibody) in the Second-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer	Advanced Non-Small Cell Lung Carcinoma	- Wollongong	https://clinicaltrials.gov/ct2/show/NCT03430063
NCT03434379	IMbrave150	Phase 3		NSW, VIC, SA	15/02/2018	15/03/2018	Atezolizumab; Atezolizumab + Bevacizumab; Bevacizumab; Sorafenib	FLT3_inhibitor; VEGFR_inhibitor; anti-PD-L1_monoclonal_antibody; CRAF_inhibitor; PDGFR_inhibitor; anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; KIT_inhibitor; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor	Atezolizumab + Bevacizumab; Sorafenib; Atezolizumab + Bevacizumab	CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor; CRAF_inhibitor; FLT3_inhibitor; KIT_inhibitor; PDGFR_inhibitor; VEGFR_inhibitor; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody	2017-003691-31  YO40245	A Phase III, Open-Label, Randomized Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma	Carcinoma, Hepatocellular	2200 - Bankstown; 5011 - Woodville; 3021 - St Albans; 2217 - Kogarah	https://clinicaltrials.gov/ct2/show/NCT03434379
NCT03443674	CLO-SCB-313-001	Phase 1		NSW, QLD, SA	23/02/2018	18/06/2018	SCB-313	recombinant_human_TRAIL_trimer_fusion_protein	SCB-313	recombinant_human_TRAIL_trimer_fusion_protein	CLO-SCB-313-001	A Phase I Study Evaluating Safety, Tolerability, and Pharmacokinetics of SCB-313, a Fully-Human TRAIL-Trimer Fusion Protein, for the Treatment of Peritoneal Malignancies	Peritoneal Malignancies	2500 - Wollongong; 2170 - Liverpool; 5042 - Bedford Park; 2800 - Orange; 4224 - Tugun	https://clinicaltrials.gov/ct2/show/NCT03443674
NCT03445533	ILLUMINATE-301	Phase 3		WA, SA, VIC, QLD	26/02/2018	30/05/2018	Ipilimumab; Ipilimumab + Tilsotolimod Sodium; Tilsotolimod Sodium	TLR9_agonist + anti-CTLA-4_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody; TLR9_agonist	Ipilimumab; Ipilimumab + Tilsotolimod Sodium; Ipilimumab + Tilsotolimod Sodium	TLR9_agonist + anti-CTLA-4_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody; TLR9_agonist + anti-CTLA-4_monoclonal_antibody	2125-MEL-301	A Randomized Phase 3 Comparison of IMO-2125 With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301)	Metastatic Melanoma	5011 - Woodville South; 4215 - Southport; 4120 - Greenslopes; 4101 - South Brisbane; 6150 - Murdoch; 3220 - Geelong	https://clinicaltrials.gov/ct2/show/NCT03445533
NCT03446040	2019-000442-35--CA031-002	Phase 1/Phase 2	NOT_RECRUITING	VIC, NSW	26/02/2018	8/03/2018	BMS-986258; BMS-986258 + Nivolumab; BMS-986258 + rHuPH20; Nivolumab; rHuPH20	recombinant_human_hyaluronidase; anti-PD-1_monoclonal_antibody + anti-TIM3_monoclonal_antibody; anti-TIM3_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-TIM3_monoclonal_antibody + recombinant_human_hyaluronidase	BMS-986258; BMS-986258 + Nivolumab; BMS-986258 + rHuPH20; BMS-986258 + Nivolumab; BMS-986258 + rHuPH20	anti-PD-1_monoclonal_antibody + anti-TIM3_monoclonal_antibody; anti-TIM3_monoclonal_antibody; anti-TIM3_monoclonal_antibody + recombinant_human_hyaluronidase; anti-PD-1_monoclonal_antibody + anti-TIM3_monoclonal_antibody; anti-TIM3_monoclonal_antibody + recombinant_human_hyaluronidase	2019-000442-35  CA031-002	A Phase 1/2 First-in-Human Study of BMS-986258 Alone and in Combination With Nivolumab in Advanced Malignant Tumors	Advanced Cancer	2145 - Westmead; 3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT03446040
NCT03448042	GO40311	Phase 1	NOT_RECRUITING	VIC	27/02/2018	6/06/2018	Runimotamab	bispecific_T-cell_engager,ERBB2-targeting	Runimotamab	bispecific_T-cell_engager,ERBB2-targeting	GO40311	A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of BTRC4017A Administered Intravenously in Patients With Locally Advanced or Metastatic HER2-Expressing Cancers	Solid Tumors	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT03448042
NCT03450330	JACKPOT1	Phase 1/Phase 2		VIC, NSW	1/03/2018	16/04/2018	AZD4205; Osimertinib	JAK1-selective_inhibitor; EGFR_inhibitor,third_generation	AZD4205; Osimertinib	JAK1-selective_inhibitor; EGFR_inhibitor,third_generation	DZ2017J0001	A Phase I/II, Open-Label, Multicentre Study to Investigate the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of AZD4205 as Monotherapy or in Combination With Osimertinib in Patients With EGFR Mutant Advanced Stage Non-Small Cell Lung Cancer (NSCLC)	Nonsmall Cell Lung Cancer	2066 - Sydney; 3084 - Heidelberg; - Melbourne; - Sydney	https://clinicaltrials.gov/ct2/show/NCT03450330
NCT03452137	2017-003302-40--WO40242	Phase 3		VIC, NSW, SA, WA	2/03/2018	3/04/2018	Atezolizumab; Placebo	anti-PD-L1_monoclonal_antibody; placebo	Atezolizumab; Placebo	anti-PD-L1_monoclonal_antibody; placebo	2017-003302-40  WO40242	A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab (Anti-Pd-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck	Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)	5037 - Kurralta Park; 2217 - Kogarah; 6009 - Nedlands; 3002 - East Melbourne	https://clinicaltrials.gov/ct2/show/NCT03452137
NCT03454451	CPI-006-001	Phase 1	NOT_RECRUITING	VIC, NSW, QLD	6/03/2018	25/04/2018	CPI-006; CPI-006 + Ciforadenant; CPI-006 + Pembrolizumab; Ciforadenant; Pembrolizumab	anti-CD73_monoclonal_antibody; adenosine_A2aR_and_A2bR_antagonist; anti-PD-1_monoclonal_antibody; adenosine_A2aR_and_A2bR_antagonist + anti-CD73_monoclonal_antibody; anti-CD73_monoclonal_antibody + anti-PD-1_monoclonal_antibody	CPI-006; CPI-006 + Ciforadenant; CPI-006 + Pembrolizumab; CPI-006 + Ciforadenant; CPI-006 + Pembrolizumab	adenosine_A2aR_and_A2bR_antagonist + anti-CD73_monoclonal_antibody; anti-CD73_monoclonal_antibody; anti-CD73_monoclonal_antibody + anti-PD-1_monoclonal_antibody; adenosine_A2aR_and_A2bR_antagonist + anti-CD73_monoclonal_antibody; anti-CD73_monoclonal_antibody + anti-PD-1_monoclonal_antibody	CPI-006-001	A PHASE 1/1b MULTICENTER STUDY TO EVALUATE THE HUMANIZED ANTI-CD73 ANTIBODY, CPI-006, AS A SINGLE AGENT OR IN COMBINATION WITH CIFORADENANT, WITH PEMBROLIZUMAB, AND WITH CIFORADENANT PLUS PEMBROLIZUMAB IN ADULT SUBJECTS WITH ADVANCED CANCERS	Bladder Cancer; Triple Negative Breast Cancer; Sarcoma; Ovarian Cancer; Pancreatic Cancer; Squamous Cell Carcinoma of the Head and Neck; Metastatic Castration Resistant Prostate Cancer; Colorectal Cancer; Endometrial Cancer; Non-hodgkin Lymphoma; Non-Small Cell Lung Cancer; Renal Cell Cancer; Cervical Cancer	3168 - Westmead; 3168 - Clayton; 2010 - Darlinghurst; 2050 - Camperdown; 4029 - Herston	https://clinicaltrials.gov/ct2/show/NCT03454451
NCT03459222	2018-000058-22--CA224-048	Phase 1/Phase 2	NOT_RECRUITING	WA, NSW	8/03/2018	30/05/2018	Ipilimumab; Ipilimumab + Nivolumab + Relatlimab; Linrodostat; Linrodostat + Nivolumab + Relatlimab; Nivolumab; Relatlimab	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody; IDO1_inhibitor; anti-CTLA-4_monoclonal_antibody + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; IDO1_inhibitor + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Ipilimumab + Nivolumab + Relatlimab; Linrodostat + Nivolumab + Relatlimab; Ipilimumab + Nivolumab + Relatlimab; Linrodostat + Nivolumab + Relatlimab	IDO1_inhibitor + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; IDO1_inhibitor + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	2018-000058-22  CA224-048	A Phase 1/2 Study of Relatlimab (Anti-LAG-3 Monoclonal Antibody) Administered in Combination With Both Nivolumab (Anti-PD-1 Monoclonal Antibody) and BMS-986205 (IDO1 Inhibitor) or in Combination With Both Nivolumab and Ipilimumab (Anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors	Advanced Cancer	6009 - Nedlands; 2060 - North Sydney	https://clinicaltrials.gov/ct2/show/NCT03459222
NCT03468426	2017-001378-41--1336-0011	Phase 1		NSW, VIC	16/03/2018	3/05/2018	BI836880; BI836880 + Ezabenlimab; Ezabenlimab	VEGF/Ang2-blocking_nanobody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; VEGF/Ang2-blocking_nanobody	BI836880 + Ezabenlimab; BI836880 + Ezabenlimab	VEGF/Ang2-blocking_nanobody + anti-PD-1_monoclonal_antibody; VEGF/Ang2-blocking_nanobody + anti-PD-1_monoclonal_antibody	2017-001378-41  1336-0011	An Open Label Phase Ib Dose Finding Study of BI 836880 in Combination With Ezabenlimab to Characterize Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy in Patients With Locally Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer and in Other Solid Tumors	Neoplasms; Non-squamous, Non-Small-Cell Lung Cancer	3199 - Frankston; 2145 - Westmead; 2065 - St Leonards; 3004 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT03468426
NCT03470922	RELATIVITY-047	Phase 2/Phase 3		SA, NZ, QLD, NSW, WA	20/03/2018	11/04/2018	Nivolumab; Nivolumab + Relatlimab; Relatlimab	anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Nivolumab; Nivolumab + Relatlimab; Nivolumab + Relatlimab	anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	2017-003583-12  CA224-047	A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined With Nivolumab Versus Nivolumab in Participants With Previously Untreated Metastatic or Unresectable Melanoma	Melanoma	Hamilton; 2060 - North Sydney; Tauranga; 2298 - Waratah; 4215 - Southport; 5042 - Bedford Park; 4120 - Greenslopes; Dunedin; 6150 - Murdoch	https://clinicaltrials.gov/ct2/show/NCT03470922
NCT03473925	MK-7123-034--7123-034	Phase 2	NOT_RECRUITING	NSW, VIC	22/03/2018	10/04/2018	Navarixin; Navarixin + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; CXCR2_antagonist; CXCR2_antagonist + anti-PD-1_monoclonal_antibody	Navarixin + Pembrolizumab; Navarixin + Pembrolizumab	CXCR2_antagonist + anti-PD-1_monoclonal_antibody; CXCR2_antagonist + anti-PD-1_monoclonal_antibody	MK-7123-034  7123-034	A Phase II Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced/Metastatic Solid Tumors	Solid Tumors; Microsatellite Stable Colorectal Cancer; Non-small Cell Lung Cancer; Castration Resistant Prostate Cancer	2148 - Blacktown; 3000 - Melbourne; 2031 - Randwick	https://clinicaltrials.gov/ct2/show/NCT03473925
NCT03474107	2017-003344-21--7465-CL-0301	Phase 3		SA, NSW	22/03/2018	27/06/2018	Docetaxel; Docetaxel + Paclitaxel + Vinflunine; Enfortumab Vedotin; Paclitaxel; Vinflunine	taxane + vinca_alkaloid; vinca_alkaloid; anti-NECTIN4_antibody-drug_conjugate; taxane	Docetaxel + Paclitaxel + Vinflunine; Enfortumab Vedotin; Docetaxel + Paclitaxel + Vinflunine	anti-NECTIN4_antibody-drug_conjugate; taxane + vinca_alkaloid; taxane + vinca_alkaloid	2017-003344-21  7465-CL-0301	An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)	Urothelial Cancer; Ureteral Cancer; Bladder Cancer	- St. Leonards; - Adelaide; - Miranda; - Sydney	https://clinicaltrials.gov/ct2/show/NCT03474107
NCT03475251	ACTRN12618000382279--CS1003-101	Phase 1	NOT_RECRUITING	NSW	23/03/2018	9/05/2018	CS1003; CS1003 + Regorafenib; Regorafenib	anti-PD-1_monoclonal_antibody; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + anti-PD-1_monoclonal_antibody; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor	CS1003; CS1003 + Regorafenib; CS1003 + Regorafenib	KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + anti-PD-1_monoclonal_antibody	ACTRN12618000382279  CS1003-101	A Phase Ia/Ib, Open-Label, Multiple-Dose, Dose-Escalation and Expansion Study of the Anti-PD-1 Monoclonal Antibody CS1003 in Subjects With Advanced Solid Tumors	Advanced Cancer	2031 - Randwick	https://clinicaltrials.gov/ct2/show/NCT03475251
NCT03477175	2017-003668-11--E7080-G000-604	Phase 2	NOT_RECRUITING	VIC	26/03/2018	16/08/2018	Lenvatinib; Sorafenib	VEGFR_inhibitor; CRAF_inhibitor; PDGFR_inhibitor; FLT3_inhibitor; KIT_inhibitor; VEGF_inhibitor; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor	Lenvatinib; Sorafenib	VEGF_inhibitor; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor; CRAF_inhibitor; FLT3_inhibitor; KIT_inhibitor; PDGFR_inhibitor	2017-003668-11  E7080-G000-604	An Open-label, Multi-center, Roll-over Study to Assess Long Term Safety of Lenvatinib Monotherapy or Lenvatinib Combination Regimen or Comparator Treatment Arm to Cancer Patients in Eisai Sponsored Lenvatinib Trials	Solid Tumors	3181 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT03477175
NCT03484520	2017-003213-26--M16-183	Phase 1		TAS, QLD, VIC	30/03/2018	23/07/2018	Dinaciclib; Dinaciclib + Venetoclax; Venetoclax	Bcl2_inhibitor + CDK1/2/5/9_inhibitor; CDK1/2/5/9_inhibitor; Bcl2_inhibitor; Bcl2_inhibitor + CDK12_inhibitor; CDK12_inhibitor	Dinaciclib + Venetoclax; Dinaciclib + Venetoclax	Bcl2_inhibitor + CDK1/2/5/9_inhibitor; Bcl2_inhibitor + CDK12_inhibitor; Bcl2_inhibitor + CDK1/2/5/9_inhibitor; Bcl2_inhibitor + CDK12_inhibitor	2017-003213-26  M16-183	Phase 1b Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid Leukemia	Cancer - Acute Myeloid Leukemia	7000 - Hobart; 4215 - Southport; 3168 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT03484520
NCT03484923	PLATforM	Phase 2		NSW	2/04/2018	10/09/2018	Canakinumab; Canakinumab + Spartalizumab; Capmatinib; Capmatinib + Spartalizumab; Ieramilimab; Ieramilimab + Spartalizumab; Ribociclib; Ribociclib + Spartalizumab; Spartalizumab	anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody; anti-IL-1beta_monoclonal_antibody + anti-PD-1_monoclonal_antibody; CDK4/6_inhibitor; MET_inhibitor,type_1 + anti-PD-1_monoclonal_antibody; MET_inhibitor,type_1; CDK4/6_inhibitor + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-IL-1beta_monoclonal_antibody	Canakinumab + Spartalizumab; Capmatinib + Spartalizumab; Ieramilimab + Spartalizumab; Ribociclib + Spartalizumab; Canakinumab + Spartalizumab; Capmatinib + Spartalizumab; Ieramilimab + Spartalizumab; Ribociclib + Spartalizumab	CDK4/6_inhibitor + anti-PD-1_monoclonal_antibody; MET_inhibitor,type_1 + anti-PD-1_monoclonal_antibody; anti-IL-1beta_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; CDK4/6_inhibitor + anti-PD-1_monoclonal_antibody; MET_inhibitor,type_1 + anti-PD-1_monoclonal_antibody; anti-IL-1beta_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	2018-000610-38  CPDR001J2201	A Randomized, Open-label, Phase II Open Platform Study Evaluating the Efficacy and Safety of Novel Spartalizumab (PDR001) Combinations in Previously Treated Unresectable or Metastatic Melanoma	Melanoma	2145 - Westmead; 2060 - North Sydney	https://clinicaltrials.gov/ct2/show/NCT03484923
NCT03486873	MK-3475-587--3475-587	Unknown		NZ, SA, NSW, VIC, QLD, WA	3/04/2018	21/08/2018	Pembrolizumab	anti-PD-1_monoclonal_antibody	Pembrolizumab	anti-PD-1_monoclonal_antibody	MK-3475-587  3475-587	A Multicenter, Open Label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial	Solid Tumors	4029 - Herston; Wellington; 6009 - Nedlands; 2065 - Wollstonecraft; 2050 - Camperdown; Canterbury; 4120 - Brisbane; Waikato; 3084 - Heidelberg; 2298 - Waratah; 5000 - Adelaide; 4215 - Southport; 3000 - Melbourne; 2109 - Macquarie University; Auckland; 6008 - Subiaco; 3168 - Clayton; 2145 - Westmead; 2060 - North Sydney; 4102 - Woolloongabba	https://clinicaltrials.gov/ct2/show/NCT03486873
NCT03495882	C-550-01	Phase 1/Phase 2		NSW, QLD, WA	12/04/2018	18/12/2017	Balstilimab; Balstilimab + Zalifrelimab; Zalifrelimab	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Balstilimab + Zalifrelimab; Balstilimab + Zalifrelimab	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	C-550-01	A Phase 1 / 2, Open-Label, Multi-Arm Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN1884 in Combination With AGEN2034 in Subjects With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors	Cervical Cancer	6009 - Perth; 4101 - South Brisbane; - South Brisbane; - Sydney	https://clinicaltrials.gov/ct2/show/NCT03495882
NCT03497767	OUTRUN	Phase 2	*NOT_RECRUITING - IN FOLLOW UP	SA, QLD, NSW, VIC, WA	13/04/2018	15/08/2019	Osimertinib	EGFR_inhibitor,third_generation	Osimertinib	EGFR_inhibitor,third_generation	TROG 17.02	A Randomised Phase II Trial of Osimertinib With or Without Stereotactic Radiosurgery for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases	Metastatic Non Small Cell Lung Cancer	2148 - Sydney; 4102 - Brisbane; 2298 - Newcastle; - Adelaide; - Perth; 3002 - Melbourne; 2217 - Sydney; 2145 - Sydney; 4120 - Brisbane; 2002 - Sydney; 3175 - Melbourne; 2010 - Sydney	https://clinicaltrials.gov/ct2/show/NCT03497767
NCT03498521	CUPISCO	Phase 2		QLD, NSW, VIC, SA	13/04/2018	10/07/2018	Alectinib; Atezolizumab; Bevacizumab; Carboplatin; Carboplatin + Cisplatin + Gemcitabine + Paclitaxel; Cisplatin; Cobimetinib; Entrectinib; Erlotinib; Gemcitabine; Ipatasertib; Ivosidenib; Olaparib; Paclitaxel; Pemigatinib; Pertuzumab; Trastuzumab; Vemurafenib; Vismodegib	PARP_inhibitor; EGFR_inhibitor,first_generation; FGFR1/2/3_inhibitor; BRAF_V600_inhibitor; anti-PD-L1_monoclonal_antibody; anti-ERBB2_monoclonal_antibody; ROS1_inhibitor; gemcitabine; taxane; ALK_inhibitor,second_generation; IDH1_R132_inhibitor; TRK_inhibitor,first_generation; platinum-based_antineoplastic_agent; ALK_inhibitor,third_generation; ALK/RET_inhibitor; pan-AKT_inhibitor; antimetabolite; antimetabolite + platinum-based_antineoplastic_agent + taxane; MEK_inhibitor; anti-VEGF_monoclonal_antibody; anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; SMO_inhibitor,first_generation	Carboplatin + Cisplatin + Gemcitabine + Paclitaxel; Alectinib; Atezolizumab; Bevacizumab; Carboplatin + Cisplatin + Gemcitabine + Paclitaxel; Cobimetinib; Entrectinib; Erlotinib; Ipatasertib; Ivosidenib; Olaparib; Pemigatinib; Pertuzumab; Trastuzumab; Vemurafenib; Vismodegib	antimetabolite + platinum-based_antineoplastic_agent + taxane; ALK/RET_inhibitor; ALK_inhibitor,second_generation; ALK_inhibitor,third_generation; BRAF_V600_inhibitor; EGFR_inhibitor,first_generation; FGFR1/2/3_inhibitor; IDH1_R132_inhibitor; MEK_inhibitor; PARP_inhibitor; ROS1_inhibitor; SMO_inhibitor,first_generation; TRK_inhibitor,first_generation; anti-ERBB2_monoclonal_antibody; anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; anti-PD-L1_monoclonal_antibody; anti-VEGF_monoclonal_antibody; antimetabolite + platinum-based_antineoplastic_agent + taxane; gemcitabine; pan-AKT_inhibitor	2017-003040-20  MX39795	A Phase II, Randomized, Active-Controlled, Multi-Center Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Guided by Genomic Profiling Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site Who Have Received Three Cycles of Platinum Doublet Chemotherapy	Cancer of Unknown Primary Site	2065 - St Leonards; 4101 - South Brisbane; 3002 - East Melbourne; 5042 - Bedford Park; 2148 - Blacktown	https://clinicaltrials.gov/ct2/show/NCT03498521
NCT03499899	CLAG525B2101	Phase 2		QLD, VIC, WA	17/04/2018	2/07/2018	Carboplatin; Carboplatin + Ieramilimab; Carboplatin + Ieramilimab + Spartalizumab; Ieramilimab; Ieramilimab + Spartalizumab; Spartalizumab	anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody; platinum-based_antineoplastic_agent; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent; anti-LAG3_monoclonal_antibody + platinum-based_antineoplastic_agent; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Carboplatin + Ieramilimab; Carboplatin + Ieramilimab + Spartalizumab; Ieramilimab + Spartalizumab; Carboplatin + Ieramilimab; Carboplatin + Ieramilimab + Spartalizumab; Ieramilimab + Spartalizumab	anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent; anti-LAG3_monoclonal_antibody + platinum-based_antineoplastic_agent; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent; anti-LAG3_monoclonal_antibody + platinum-based_antineoplastic_agent	CLAG525B2101	A Phase II Open-label, Randomized, Three-arm, Multicenter Study of LAG525 Given in Combination With Spartalizumab (PDR001), or With Spartalizumab and Carboplatin, or With Carboplatin, as First or Second Line Therapy in Patients With Advanced Triple-negative Breast Cancer	Triple-negative Breast Cancer	3000 - Melbourne; 6009 - Nedlands; 4102 - Wooloongabba	https://clinicaltrials.gov/ct2/show/NCT03499899
NCT03504397	Spotlight	Phase 3		SA, NSW, VIC, QLD	20/04/2018	21/06/2018	Fluorouracil; Fluorouracil + Leucovorin; Fluorouracil + Leucovorin + Zolbetuximab; Leucovorin; Oxaliplatin; Placebo; Zolbetuximab	platinum-based_antineoplastic_agent; placebo; anti-CLDN18.2_monoclonal_antibody; Fluorouracil; folinic_acid; anti-CLDN18.2_monoclonal_antibody + fluoropyrimidine + folinic_acid; fluoropyrimidine + folinic_acid; fluoropyrimidine	Fluorouracil + Leucovorin; Fluorouracil + Leucovorin + Zolbetuximab; Fluorouracil + Leucovorin; Fluorouracil + Leucovorin + Zolbetuximab; Oxaliplatin; Placebo	anti-CLDN18.2_monoclonal_antibody + fluoropyrimidine + folinic_acid; fluoropyrimidine + folinic_acid; Fluorouracil; anti-CLDN18.2_monoclonal_antibody + fluoropyrimidine + folinic_acid; fluoropyrimidine + folinic_acid; placebo; platinum-based_antineoplastic_agent	2017-002567-17  8951-CL-0301	A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus mFOLFOX6 Compared With Placebo Plus mFOLFOX6 as First-line Treatment of Subjects With Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma	Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer; Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer; Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma; Metastatic Gastric Adenocarcinoma or Cancer	4224 - Tugun; 4814 - Douglas; 5011 - Adelaide; 2217 - Kogarah; 3165 - East Bentleigh	https://clinicaltrials.gov/ct2/show/NCT03504397
NCT03505528	Epi-PRIMED	Phase 1		ACT, NSW	23/04/2018	17/08/2017	Nab-paclitaxel; Nab-paclitaxel + Phenelzine; Phenelzine	irreversible_monoamine_oxidase_inhibitor; taxane; irreversible_monoamine_oxidase_inhibitor + taxane	Nab-paclitaxel + Phenelzine; Nab-paclitaxel + Phenelzine	irreversible_monoamine_oxidase_inhibitor + taxane; irreversible_monoamine_oxidase_inhibitor + taxane	EpiAxis 001-0716	A Phase Ib Safety and Pharmacokinetics (PK)/ Pharmacodynamics (PD) Study to Determine the Dosage of Abraxane in Combination With Phenelzine Sulfate in Metastatic or Inoperable Locally Advanced Breast Cancer	Metastatic Breast Cancer	260 - Canberra; 2500 - Wollongong; 2170 - Sydney	https://clinicaltrials.gov/ct2/show/NCT03505528
NCT03507543	IMP4297-2016-AU01	Phase 1	NOT_RECRUITING	NSW, VIC	25/04/2018	3/02/2017	Senaparib	PARP_inhibitor	Senaparib	PARP_inhibitor	IMP4297-2016-AU01	A Phase I, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors	Prostate Cancer; Primary Peritoneal Cancer; Advanced Solid Tumours; Breast Cancer; Ovarian Cancer	2148 - Blacktown; - Kogarah; 3004 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT03507543
NCT03515824	MK1697-001--1697-001	Phase 1	NOT_RECRUITING	NSW	4/05/2018	13/08/2018	MK-1697	bispecific_PD-1/LAG3_antibody	MK-1697	bispecific_PD-1/LAG3_antibody	MK1697-001  1697-001	A Phase 1 Study of MK-1697 in Participants With Advanced Solid Tumors	Neoplasms; Colorectal Neoplasms; Head and Neck Neoplasms	2031 - Randwick	https://clinicaltrials.gov/ct2/show/NCT03515824
NCT03515837	KEYNOTE-789	Phase 3	NOT_RECRUITING	VIC, NSW	4/05/2018	29/06/2018	Carboplatin; Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Carboplatin + Cisplatin + Pemetrexed; Cisplatin; Dexamethasone; Pembrolizumab; Pemetrexed	glucocorticoid; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite	Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Carboplatin + Cisplatin + Pemetrexed; Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Carboplatin + Cisplatin + Pemetrexed; Dexamethasone	anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; glucocorticoid	MK-3475-789  3475-789	A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789)	Non-small Cell Lung Cancer	3084 - Heidelberg; 2050 - Camperdown; 3128 - Box Hill; 2145 - Westmead	https://clinicaltrials.gov/ct2/show/NCT03515837
NCT03516123	CS3006-101	Phase 1	NOT_RECRUITING	NSW	4/05/2018	14/06/2018	CS3006	MEK_inhibitor	CS3006	MEK_inhibitor	CS3006-101	A Phase I, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Tolerability, PK and Antitumor Activities of the MEK Inhibitor CS3006 in Subjects With Locally Advanced or Metastatic Solid Tumors	Solid Tumor, Adult	2010 - Sydney	https://clinicaltrials.gov/ct2/show/NCT03516123
NCT03516981	KEYNOTE-495	Phase 2		WA, NSW, QLD	7/05/2018	1/10/2018	Favezelimab; Favezelimab + Pembrolizumab; Lenvatinib; Lenvatinib + Pembrolizumab; Pembrolizumab; Pembrolizumab + Quavonlimab; Quavonlimab	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; VEGF_inhibitor; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Favezelimab + Pembrolizumab; Lenvatinib + Pembrolizumab; Pembrolizumab + Quavonlimab; Favezelimab + Pembrolizumab; Lenvatinib + Pembrolizumab; Pembrolizumab + Quavonlimab	VEGF_inhibitor + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	MK-3475-495  3475-495	A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab-(MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT)	Advanced Non-Small Cell Lung Cancer	6150 - Murdoch; 4120 - Brisbane; 2148 - Blacktown	https://clinicaltrials.gov/ct2/show/NCT03516981
NCT03517176	U1111-1213-3234--CEND1-001	Phase 1		WA, VIC, SA	7/05/2018	31/07/2018	CEND-1; CEND-1 + Gemcitabine + Nab-paclitaxel; Gemcitabine; Nab-paclitaxel; Paclitaxel	gemcitabine; tumor-homing_peptide_iRGD; taxane; antimetabolite; antimetabolite + taxane + tumor-homing_peptide_iRGD	CEND-1 + Gemcitabine + Nab-paclitaxel; CEND-1 + Gemcitabine + Nab-paclitaxel	antimetabolite + taxane + tumor-homing_peptide_iRGD; antimetabolite + taxane + tumor-homing_peptide_iRGD; gemcitabine	U1111-1213-3234  CEND1-001	A Phase 1 Clinical Trial of CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Exocrine Pancreatic Cancer	Pancreatic Ductal Adenocarcinoma; Pancreatic Cancer	3004 - Melbourne; 6008 - Subiaco; 5011 - Woodville South	https://clinicaltrials.gov/ct2/show/NCT03517176
NCT03517449	2017-004387-35--E7080-G000-309	Phase 3		WA, QLD, VIC, NSW, NZ	7/05/2018	11/06/2018	Doxorubicin; Doxorubicin + Paclitaxel; Lenvatinib; Lenvatinib + Pembrolizumab; Paclitaxel; Pembrolizumab	anthracycline; anti-PD-1_monoclonal_antibody; doxorubicin; anthracycline + taxane; VEGF_inhibitor; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; taxane	Doxorubicin + Paclitaxel; Lenvatinib + Pembrolizumab; Doxorubicin + Paclitaxel; Lenvatinib + Pembrolizumab	VEGF_inhibitor + anti-PD-1_monoclonal_antibody; anthracycline + taxane; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; anthracycline + taxane; doxorubicin	2017-004387-35  E7080-G000-309	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer	Endometrial Neoplasms	Auckland; 6008 - Subiaco; 3000 - Melbourne; 2065 - Sydney; 4029 - Herston	https://clinicaltrials.gov/ct2/show/NCT03517449
NCT03522064	HiTeCH	Phase 2		NSW	11/05/2018	30/07/2018	Carboplatin; Testosterone Enanthate	testosterone; platinum-based_antineoplastic_agent	Carboplatin; Testosterone Enanthate	platinum-based_antineoplastic_agent; testosterone	HiTECH	High Dose Testosterone + Carboplatin in Men With Advanced Prostate Cancer	Castration-resistant Prostate Cancer; Homologous Recombination Deficiency	2010 - Sydney	https://clinicaltrials.gov/ct2/show/NCT03522064
NCT03522246	ATHENA	Phase 3	NOT_RECRUITING	NZ, SA, NSW, VIC, QLD, WA	11/05/2018	14/05/2018	Nivolumab; Nivolumab + Rucaparib; Placebo; Rucaparib	PARP_inhibitor; anti-PD-1_monoclonal_antibody; PARP_inhibitor + anti-PD-1_monoclonal_antibody; placebo	Nivolumab; Nivolumab + Rucaparib; Rucaparib; Nivolumab + Rucaparib; Placebo	PARP_inhibitor; PARP_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; PARP_inhibitor + anti-PD-1_monoclonal_antibody; placebo	CO-338-087/GOG-3020/ENGOT-ov45	ATHENA (A Multicenter, Randomized, Double-Blind, Placebo- Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)	Complete Response; Epithelial Ovarian Cancer; Newly Diagnosed; FIGO Stage III-IV; Fallopian Tube Cancer; Partial Response; Primary Peritoneal	2031 - Sydney; Hamilton; 2145 - Westmead; 2145 - New Lambton Heights; Auckland; Tauranga; Christchurch; 4020 - Brisbane; Palmerston North; 5065 - Toorak Gardens; 3000 - Melbourne; 6005 - Subiaco; 2065 - Saint Leonards	https://clinicaltrials.gov/ct2/show/NCT03522246
NCT03523585	2018-000221-31--DS8201-A-U301	Phase 3	NOT_RECRUITING	VIC, NSW, QLD, SA, ACT, WA	14/05/2018	1/08/2018	Capecitabine; Capecitabine + Lapatinib + Trastuzumab Emtansine; Capecitabine + Trastuzumab + Trastuzumab Emtansine; Lapatinib; Trastuzumab; Trastuzumab Deruxtecan; Trastuzumab Deruxtecan + Trastuzumab Emtansine; Trastuzumab Emtansine	ERBB2_inhibitor,first_generation; EGFR_inhibitor,type_II + anti-ERBB2_antibody-drug_conjugate + fluoropyrimidine; anti-ERBB2_antibody-drug_conjugate + anti-ERBB2_monoclonal_antibody + fluoropyrimidine; ERBB2_inhibitor,first_generation + anti-ERBB2_antibody-drug_conjugate + fluoropyrimidine; anti-ERBB2_monoclonal_antibody; EGFR_inhibitor,type_II; fluoropyrimidine; anti-ERBB2_antibody-drug_conjugate	Capecitabine + Lapatinib + Trastuzumab Emtansine; Capecitabine + Trastuzumab + Trastuzumab Emtansine; Trastuzumab Deruxtecan + Trastuzumab Emtansine; Capecitabine + Lapatinib + Trastuzumab Emtansine; Capecitabine + Trastuzumab + Trastuzumab Emtansine; Trastuzumab Deruxtecan + Trastuzumab Emtansine	EGFR_inhibitor,type_II + anti-ERBB2_antibody-drug_conjugate + fluoropyrimidine; ERBB2_inhibitor,first_generation + anti-ERBB2_antibody-drug_conjugate + fluoropyrimidine; anti-ERBB2_antibody-drug_conjugate; anti-ERBB2_antibody-drug_conjugate + anti-ERBB2_monoclonal_antibody + fluoropyrimidine; EGFR_inhibitor,type_II + anti-ERBB2_antibody-drug_conjugate + fluoropyrimidine; ERBB2_inhibitor,first_generation + anti-ERBB2_antibody-drug_conjugate + fluoropyrimidine; anti-ERBB2_antibody-drug_conjugate + anti-ERBB2_monoclonal_antibody + fluoropyrimidine	2018-000221-31  DS8201-A-U301	A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study of Trastuzumab Deruxtecan (DS-8201a), an Anti-HER2-antibody Drug Conjugate, Versus Treatment of Investigator's Choice for HER2-positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1	Breast Cancer	2170 - Liverpool; 3355 - Wendouree; 3280 - Warrnambool; 6008 - Subiaco; 4102 - Woolloongabba; 2109 - Sydney; 3021 - Saint Albans; 3084 - Heidelberg; 2485 - Tweed Heads; 5037 - Kurralta Park; 2010 - Darlinghurst; 3000 - Melbourne; 2614 - Bruce; 3128 - Box Hill; 3199 - Frankston	https://clinicaltrials.gov/ct2/show/NCT03523585
NCT03523819	CS1002-101	Phase 1		SA, NSW, VIC	14/05/2018	1/05/2018	CS1002; CS1003	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody	CS1002; CS1003	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody	CS1002-101	A Phase Ia/Ib, Open-Label, Dose-Escalation, and Dose-Expansion Study of the Anti-CTLA-4 Monoclonal Antibody CS1002 as Monotherapy and in Combination With Anti-PD-1 Monoclonal Antibody CS1003 in Subjects With Advanced Solid Tumors	Solid Tumor, Adult	3128 - Melbourne; 2500 - Wollongong; 3186 - Malvern; 2010 - Sydney; 2800 - Orange; 2640 - Albury; 3004 - Melbourne; 5037 - Adelaide	https://clinicaltrials.gov/ct2/show/NCT03523819
NCT03529110	2018-000222-61--DS8201-A-U302	Phase 3	NOT_RECRUITING	NSW, VIC, QLD, WA	18/05/2018	20/07/2018	Trastuzumab; Trastuzumab + Trastuzumab Deruxtecan; Trastuzumab + Trastuzumab Emtansine; Trastuzumab Deruxtecan; Trastuzumab Emtansine	anti-ERBB2_monoclonal_antibody; anti-ERBB2_antibody-drug_conjugate + anti-ERBB2_monoclonal_antibody; anti-ERBB2_antibody-drug_conjugate	Trastuzumab + Trastuzumab Deruxtecan; Trastuzumab + Trastuzumab Emtansine; Trastuzumab + Trastuzumab Deruxtecan; Trastuzumab + Trastuzumab Emtansine	anti-ERBB2_antibody-drug_conjugate + anti-ERBB2_monoclonal_antibody; anti-ERBB2_antibody-drug_conjugate + anti-ERBB2_monoclonal_antibody	2018-000222-61  DS8201-A-U302	A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of DS-8201a (Trastuzumab Deruxtecan), an Anti-HER2 Antibody Drug Conjugate (ADC), Versus Ado Trastuzumab Emtansine (T-DM1) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane	Breast Cancer	2485 - Tweed Heads; 3199 - Frankston; 3000 - Melbourne; 3128 - Box Hill; 6008 - Subiaco; 4102 - Woolloongabba	https://clinicaltrials.gov/ct2/show/NCT03529110
NCT03529526	KN046-AUS-001	Phase 1	STATUS_UNKNOWN	QLD	18/05/2018		KN046	bispecific_PD-L1/CTLA-4_antibody	KN046	bispecific_PD-L1/CTLA-4_antibody	KN046-AUS-001	An Open-Label, Multi-center, Dose-Escalation Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics and Immunogenicity of KN046 in Subjects With Advanced Solid Tumors	Advanced Solid Tumors	4125 - Southport	https://clinicaltrials.gov/ct2/show/NCT03529526
NCT03530397	D7980C00001	Phase 1		VIC, NSW	21/05/2018	24/04/2018	Carboplatin; Carboplatin + MEDI5752 + Pemetrexed; Carboplatin + Pembrolizumab + Pemetrexed; MEDI5752; Pembrolizumab; Pemetrexed	bispecific_PD-L1/CTLA-4_antibody; antimetabolite + bispecific_PD-L1/CTLA-4_antibody + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite	Carboplatin + MEDI5752 + Pemetrexed; Carboplatin + Pembrolizumab + Pemetrexed; MEDI5752; Carboplatin + MEDI5752 + Pemetrexed; Carboplatin + Pembrolizumab + Pemetrexed	anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + bispecific_PD-L1/CTLA-4_antibody + platinum-based_antineoplastic_agent; bispecific_PD-L1/CTLA-4_antibody; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + bispecific_PD-L1/CTLA-4_antibody + platinum-based_antineoplastic_agent	D7980C00001	A Phase 1, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability Pharmacokinetics Immunogenicity, and Antitumor Activity of MEDI5752 in Subjects With Advanced Solid Tumors.	Selected Advanced Solid Tumors	2031 - Randwick; 3004 - Melbourne; 3000 - Melbourne; 3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT03530397
NCT03535740	ALTA-2	Phase 2		WA, VIC	24/05/2018	31/01/2019	Alectinib; Brigatinib; Ceritinib	EGFR/FLT3/FER/ROS1/IGF1R_inhibitor; ROS1_inhibitor; ALK/ROS1/IGF1R_inhibitor; ALK/RET_inhibitor; ALK_inhibitor,second_generation	Brigatinib; Alectinib; Ceritinib	ALK_inhibitor,second_generation; EGFR/FLT3/FER/ROS1/IGF1R_inhibitor; ROS1_inhibitor; ALK/RET_inhibitor; ALK/ROS1/IGF1R_inhibitor	2018-000635-27  Brigatinib-2002	Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib	ALK-positive Advanced NSCLC	6009 - Nedlands; 3199 - Frankston; 3065 - Fitzroy	https://clinicaltrials.gov/ct2/show/NCT03535740
NCT03537482	APG2575-001	Phase 0		VIC	25/05/2018	7/08/2018	Lisaftoclax	Bcl2_inhibitor	Lisaftoclax	Bcl2_inhibitor	APG2575-001	A Phase I Study of Safety, Tolerability, Pharmacokinetic and Pharmacodynamics Property of Orally Administered APG-2575 in Patients With Hematologic Malignancies	Hematologic Malignancies	- Melbourne	https://clinicaltrials.gov/ct2/show/NCT03537482
NCT03539536	2018-001772-38--M14-239	Phase 2	NOT_RECRUITING	QLD, NSW, WA	29/05/2018	10/10/2018	Telisotuzumab Vedotin	anti-cMET_antibody-drug_conjugate	Telisotuzumab Vedotin	anti-cMET_antibody-drug_conjugate	2018-001772-38  M14-239	Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects With Previously Treated c-Met+ Non-Small Cell Lung Cancer	Non-small Cell Lung Cancer	2305 - Lambton Heights; 4101 - South Brisbane; 6008 - Subiaco; 2010 - Darlinghurst; 2485 - Tweed Heads	https://clinicaltrials.gov/ct2/show/NCT03539536
NCT03549000	2018-000153-51--CNZV930X2101	Phase 1	NOT_RECRUITING	VIC	7/06/2018	18/07/2018	NIR178; NIR178 + NZV930; NIR178 + NZV930 + Spartalizumab; NZV930; NZV930 + Spartalizumab; Spartalizumab	anti-CD73_monoclonal_antibody; anti-PD-1_monoclonal_antibody; adenosine_A2A_receptor_antagonist + anti-CD73_monoclonal_antibody; adenosine_A2A_receptor_antagonist + anti-CD73_monoclonal_antibody + anti-PD-1_monoclonal_antibody; adenosine_A2A_receptor_antagonist; anti-CD73_monoclonal_antibody + anti-PD-1_monoclonal_antibody	NIR178 + NZV930; NIR178 + NZV930 + Spartalizumab; NZV930; NZV930 + Spartalizumab; NIR178 + NZV930; NIR178 + NZV930 + Spartalizumab; NZV930 + Spartalizumab	adenosine_A2A_receptor_antagonist + anti-CD73_monoclonal_antibody; adenosine_A2A_receptor_antagonist + anti-CD73_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CD73_monoclonal_antibody; anti-CD73_monoclonal_antibody + anti-PD-1_monoclonal_antibody; adenosine_A2A_receptor_antagonist + anti-CD73_monoclonal_antibody; adenosine_A2A_receptor_antagonist + anti-CD73_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CD73_monoclonal_antibody + anti-PD-1_monoclonal_antibody	2018-000153-51  CNZV930X2101	A Phase I/Ib, Open-label, Multi-center, Study of NZV930 as a Single Agent and in Combination With PDR001 and/or NIR178 in Patients With Advanced Malignancies.	Metastatic Castration Resistant Prostate Cancer (mCRPC); Triple Negative Breast Cancer (TNBC); Renal Cell Carcinoma (RCC); Pancreatic Ductal Adenocarcinoma (PDAC); Non-small Cell Lung Cancer (NSCLC); Ovarian Cancer; Colorectal Cancer Microsatellite Stable (MSS)	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT03549000
NCT03551626	COMBI-APlus	Phase 3	NOT_RECRUITING	QLD	11/06/2018	29/08/2018	Dabrafenib; Dabrafenib + Trametinib; Trametinib	MEK_inhibitor; BRAF_V600_inhibitor + MEK_inhibitor; BRAF_V600_inhibitor	Dabrafenib + Trametinib; Dabrafenib + Trametinib	BRAF_V600_inhibitor + MEK_inhibitor; BRAF_V600_inhibitor + MEK_inhibitor	2018-000168-27  CDRB436F2410	COMBI-APlus: Open-label, Phase IIIb Study of Dabrafenib in COMBInation With Trametinib in the Adjuvant Treatment of Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes of an Adapted Pyrexia AE-management Algorithm (Plus)	Malignant Melanoma	4102 - Woolloongabba; QLD 4870 - Cairns	https://clinicaltrials.gov/ct2/show/NCT03551626
NCT03555149	2017-004566-99--CO39612	Phase 1/Phase 2	NOT_RECRUITING	VIC	13/06/2018	27/09/2018	Atezolizumab; Atezolizumab + Bevacizumab + PGG Beta-Glucan; Atezolizumab + Bevacizumab + Selicrelumab; Atezolizumab + Etrumadenant + Regorafenib; Atezolizumab + Idasanutlin; Atezolizumab + Isatuximab; Atezolizumab + Regorafenib; Bevacizumab; Etrumadenant; Idasanutlin; Isatuximab; PGG Beta-Glucan; Regorafenib; Selicrelumab	anti-CD38_monoclonal_antibody; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + adenosine_A2aR_and_A2bR_antagonist + anti-PD-L1_monoclonal_antibody; MDM2_inhibitor; anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + dectin_receptor_agonist; adenosine_A2aR_and_A2bR_antagonist; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + anti-PD-L1_monoclonal_antibody; anti-CD40_agonistic_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-CD38_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; MDM2_inhibitor + anti-PD-L1_monoclonal_antibody; dectin_receptor_agonist; anti-CD40_agonistic_antibody; anti-VEGF_monoclonal_antibody; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor	Atezolizumab; Atezolizumab + Bevacizumab + PGG Beta-Glucan; Atezolizumab + Bevacizumab + Selicrelumab; Atezolizumab + Etrumadenant + Regorafenib; Atezolizumab + Idasanutlin; Atezolizumab + Isatuximab; Atezolizumab + Regorafenib; Regorafenib; Atezolizumab + Bevacizumab + PGG Beta-Glucan; Atezolizumab + Bevacizumab + Selicrelumab; Atezolizumab + Etrumadenant + Regorafenib; Atezolizumab + Idasanutlin; Atezolizumab + Isatuximab; Atezolizumab + Regorafenib	KIT/PDGFR/RET/VEGFR/FGFR_inhibitor; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + adenosine_A2aR_and_A2bR_antagonist + anti-PD-L1_monoclonal_antibody; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + anti-PD-L1_monoclonal_antibody; MDM2_inhibitor + anti-PD-L1_monoclonal_antibody; anti-CD38_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-CD40_agonistic_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + dectin_receptor_agonist; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + adenosine_A2aR_and_A2bR_antagonist + anti-PD-L1_monoclonal_antibody; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + anti-PD-L1_monoclonal_antibody; MDM2_inhibitor + anti-PD-L1_monoclonal_antibody; anti-CD38_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-CD40_agonistic_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + dectin_receptor_agonist	2017-004566-99  CO39612	A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)	Colorectal Cancer	3002 - East Melbourne	https://clinicaltrials.gov/ct2/show/NCT03555149
NCT03557619	M16-185	Phase 1		VIC, NSW	15/06/2018	30/07/2019	Venetoclax	Bcl2_inhibitor	Venetoclax	Bcl2_inhibitor	M16-185	A Study to Assess the Effect of Venetoclax on the Pharmacokinetics of Ethinyl Estradiol/Levonorgestrel in Female Subjects With Hematologic Malignancies	Hematologic Malignancies	2010 - Darlinghurst; 3002 - East Melbourne	https://clinicaltrials.gov/ct2/show/NCT03557619
NCT03564340	2019-003298-24--R4018-ONC-1721	Phase 1/Phase 2		VIC	20/06/2018	21/05/2018	Cemiplimab	anti-PD-1_monoclonal_antibody	Cemiplimab	anti-PD-1_monoclonal_antibody	2019-003298-24  R4018-ONC-1721	A Phase 1/2 Study of REGN4018 (A MUC16xCD3 Bispecific Antibody) Administered Alone or in Combination With Cemiplimab in Patients With Recurrent Ovarian Cancer	Recurrent Ovarian Cancer; Recurrent Fallopian Tube Cancer; Recurrent Primary Peritoneal Cancer	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT03564340
NCT03564691	MK-4830-001--4830-001	Phase 1		NSW	21/06/2018	11/07/2018	Carboplatin; Carboplatin + MK-4830 + Pembrolizumab + Pemetrexed; Cisplatin; Cisplatin + MK-4830 + Pembrolizumab + Pemetrexed; Lenvatinib; Lenvatinib + MK-4830 + Pembrolizumab; MK-4830; MK-4830 + Paclitaxel + Pembrolizumab; MK-4830 + Pembrolizumab; Paclitaxel; Pembrolizumab; Pemetrexed	anti-ILT4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + taxane; anti-PD-1_monoclonal_antibody; VEGF_inhibitor; taxane; anti-ILT4_monoclonal_antibody; anti-ILT4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent; antimetabolite; anti-ILT4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-ILT4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Carboplatin + MK-4830 + Pembrolizumab + Pemetrexed; Cisplatin + MK-4830 + Pembrolizumab + Pemetrexed; Lenvatinib + MK-4830 + Pembrolizumab; MK-4830; MK-4830 + Paclitaxel + Pembrolizumab; MK-4830 + Pembrolizumab; Carboplatin + MK-4830 + Pembrolizumab + Pemetrexed; Cisplatin + MK-4830 + Pembrolizumab + Pemetrexed; Lenvatinib + MK-4830 + Pembrolizumab; MK-4830 + Paclitaxel + Pembrolizumab; MK-4830 + Pembrolizumab	VEGF_inhibitor + anti-ILT4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-ILT4_monoclonal_antibody; anti-ILT4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-ILT4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-ILT4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + taxane; VEGF_inhibitor + anti-ILT4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-ILT4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-ILT4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-ILT4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + taxane	MK-4830-001  4830-001	A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab for Participants With Advanced Solid Tumors	Neoplasms	2170 - Liverpool	https://clinicaltrials.gov/ct2/show/NCT03564691
NCT03584009	Veronica	Phase 2	NOT_RECRUITING	NSW, VIC, QLD	12/07/2018	6/09/2018	Fulvestrant; Fulvestrant + Venetoclax; Venetoclax	Bcl2_inhibitor; selective_estrogen_receptor_degrader; Bcl2_inhibitor + selective_estrogen_receptor_degrader	Fulvestrant; Fulvestrant + Venetoclax; Fulvestrant + Venetoclax	Bcl2_inhibitor + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader; Bcl2_inhibitor + selective_estrogen_receptor_degrader	2017-005118-74  WO40181	A Phase II, Multicenter, Randomized Study To Compare The Efficacy Of Venetoclax Plus Fulvestrant Versus Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy	Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer	4101 - South Brisbane; 3002 - East Melbourne; 2059 - North Sydney	https://clinicaltrials.gov/ct2/show/NCT03584009
NCT03588650	HLX20	Phase 1		NSW, VIC, QLD, SA	17/07/2018	7/08/2018	HLX20	anti-PD-1_monoclonal_antibody	HLX20	anti-PD-1_monoclonal_antibody	HLX20-001	A Phase 1 Study of HLX20, a Human Monoclonal Antibody Targeting Programmed Death Ligand 1 (PD-L1) Protein in Patients With Advanced Solid Tumors	Advanced Solid Tumors	3144 - Melbourne; 2010 - Darlinghurst; 4215 - Southport; 5000 - Adelaide; 4000 - Brisbane; 2109 - Darlinghurst	https://clinicaltrials.gov/ct2/show/NCT03588650
NCT03595059	M16-573	Phase 1		VIC, NSW	23/07/2018	13/07/2018	Docetaxel; Docetaxel + Mirzotamab clezutoclax + Paclitaxel; Mirzotamab clezutoclax; Mirzotamab clezutoclax + Paclitaxel; Paclitaxel	anti-B7H3_antibody-drug_conjugate + taxane; taxane; anti-B7H3_antibody-drug_conjugate	Docetaxel + Mirzotamab clezutoclax + Paclitaxel; Mirzotamab clezutoclax; Mirzotamab clezutoclax + Paclitaxel; Docetaxel + Mirzotamab clezutoclax + Paclitaxel; Mirzotamab clezutoclax + Paclitaxel	anti-B7H3_antibody-drug_conjugate; anti-B7H3_antibody-drug_conjugate + taxane; anti-B7H3_antibody-drug_conjugate + taxane	M16-573	A Phase 1 First-in-Human Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors	Advanced Solid Tumors	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT03595059
NCT03599713	INCMGA-0012-201	Phase 2		NSW	26/07/2018	25/02/2019	Retifanlimab	anti-PD-1_monoclonal_antibody	Retifanlimab	anti-PD-1_monoclonal_antibody	INCMGA 0012-201	A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Cell Carcinoma (POD1UM-201)	Metastatic Merkel Cell Carcinoma	02010 - Darlinghurst	https://clinicaltrials.gov/ct2/show/NCT03599713
NCT03600883	NCT03600883	Phase 1/Phase 2		QLD, NSW, VIC, SA	26/07/2018	27/08/2018	Midazolam; Midazolam + Sotorasib; Sotorasib	KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + benzodiazepam; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor; benzodiazepam	Midazolam + Sotorasib; Sotorasib; Midazolam + Sotorasib	KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + benzodiazepam; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + benzodiazepam	20170543	A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreaK 100)	KRAS p.G12C Mutant Advanced Solid Tumors	4102 - Woolloongabba; 2031 - Randwick; 5011 - Woodville South; 3050 - Parkville	https://clinicaltrials.gov/ct2/show/NCT03600883
NCT03603184	AtTEnd	Phase 3		NZ, SA, TAS, NSW, VIC, QLD	27/07/2018	2/10/2018	Atezolizumab; Atezolizumab + Carboplatin + Paclitaxel; Carboplatin; Carboplatin + Paclitaxel; Paclitaxel; Placebo	anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent + taxane; placebo; anti-PD-L1_monoclonal_antibody; taxane	Atezolizumab + Carboplatin + Paclitaxel; Carboplatin + Paclitaxel; Atezolizumab + Carboplatin + Paclitaxel; Carboplatin + Paclitaxel; Placebo	anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; platinum-based_antineoplastic_agent + taxane; anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; placebo; platinum-based_antineoplastic_agent + taxane	IRFMN-EN-7556	Phase III Double-blind Randomized Placebo Controlled Trial of Atezolizumab in Combination With Paclitaxel and Carboplatin in Women With Advanced/Recurrent Endometrial Cancer	Endometrial Cancer	- Waratah; - Gosford; - Frankston; - Wollongong; - Liverpool; - Saint Leonards; - Toowoomba; - Herston; - Adelaide; - Queensland; - Albury; Auckland; - Benowa; - Box Hill; - Hobart	https://clinicaltrials.gov/ct2/show/NCT03603184
NCT03611556	D6070C00005--D6070C00005	Phase 1/Phase 2		NSW, VIC	2/08/2018	21/06/2018	Durvalumab; Durvalumab + Fluorouracil + Leucovorin + Oleclumab + Oxaliplatin; Durvalumab + Gemcitabine + Nab-paclitaxel + Oleclumab; Fluorouracil; Fluorouracil + Leucovorin + Oleclumab + Oxaliplatin; Fluorouracil + Leucovorin + Oxaliplatin; Gemcitabine; Gemcitabine + Nab-paclitaxel; Gemcitabine + Nab-paclitaxel + Oleclumab; Leucovorin; Nab-paclitaxel; Oleclumab; Oxaliplatin	anti-CD73_monoclonal_antibody; anti-CD73_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + antimetabolite + taxane; anti-CD73_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; folinic_acid; anti-PD-L1_monoclonal_antibody; anti-CD73_monoclonal_antibody + antimetabolite + taxane; gemcitabine; taxane; anti-CD73_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent; Fluorouracil; fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; antimetabolite + taxane	Durvalumab + Fluorouracil + Leucovorin + Oleclumab + Oxaliplatin; Durvalumab + Gemcitabine + Nab-paclitaxel + Oleclumab; Fluorouracil + Leucovorin + Oleclumab + Oxaliplatin; Fluorouracil + Leucovorin + Oxaliplatin; Gemcitabine + Nab-paclitaxel; Gemcitabine + Nab-paclitaxel + Oleclumab; Durvalumab + Fluorouracil + Leucovorin + Oleclumab + Oxaliplatin; Durvalumab + Gemcitabine + Nab-paclitaxel + Oleclumab; Fluorouracil + Leucovorin + Oleclumab + Oxaliplatin; Fluorouracil + Leucovorin + Oxaliplatin; Gemcitabine + Nab-paclitaxel; Gemcitabine + Nab-paclitaxel + Oleclumab	anti-CD73_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + antimetabolite + taxane; anti-CD73_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; anti-CD73_monoclonal_antibody + antimetabolite + taxane; anti-CD73_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; antimetabolite + taxane; fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; Fluorouracil; anti-CD73_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + antimetabolite + taxane; anti-CD73_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; anti-CD73_monoclonal_antibody + antimetabolite + taxane; anti-CD73_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; antimetabolite + taxane; fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; gemcitabine	D6070C00005  D6070C00005	A Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of Oleclumab (MEDI9447) With or Without Durvalumab in Combination With Chemotherapy in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma	Metastatic Pancreatic Adenocarcinoma; Carcinoma	3084 - Heidelberg; 2148 - Blacktown; 2065 - St Leonards; 3168 - Clayton	https://clinicaltrials.gov/ct2/show/NCT03611556
NCT03611868	Keynote-MK-3475-B66--APG-115-US-002	Phase 1/Phase 2		QLD, SA	2/08/2018	29/08/2018	Alrizomadlin; Alrizomadlin + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; MDM2_inhibitor; anti-PD-1_monoclonal_antibody + p53-HDM2_interaction_inhibitor; MDM2_inhibitor + anti-PD-1_monoclonal_antibody; p53-HDM2_interaction_inhibitor	Alrizomadlin + Pembrolizumab; Alrizomadlin + Pembrolizumab	MDM2_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + p53-HDM2_interaction_inhibitor; MDM2_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + p53-HDM2_interaction_inhibitor	Keynote MK-3475-B66  APG-115-US-002	A Phase Ib/II Study of APG-115 in Combination With Pembrolizumab in Patients With Unresectable or Metastatic Melanomas or Advanced Solid Tumors	Uveal Melanoma; MDM2 Gene Mutation; Liposarcoma; Melanoma; Cutaneous Melanoma; P53 Mutation; Mucosal Melanoma; Non Small Cell Lung Cancer; STK11 Gene Mutation; ATM Gene Mutation; Urothelial Carcinoma; Malignant Peripheral Nerve Sheath Tumors; MPNST; Unresectable or Metastatic Melanoma or Advanced Solid Tumors	4101 - South Brisbane; - Brisbane; 5042 - Bedford Park	https://clinicaltrials.gov/ct2/show/NCT03611868
NCT03615326	KEYNOTE-811	Phase 3		NZ, VIC, NSW	3/08/2018	5/10/2018	Capecitabine; Cisplatin; Fluorouracil; Oxaliplatin; Pembrolizumab; Pembrolizumab + Trastuzumab; Placebo; Tegafur-gimeracil-oteracil pPotassium; Trastuzumab	anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; placebo; antimetabolite; orotate_phosphoribosyltransferase_inhibitor; Fluorouracil; anti-ERBB2_monoclonal_antibody; anti-ERBB2_monoclonal_antibody + anti-PD-1_monoclonal_antibody; DPD_inhibitor; fluoropyrimidine	Pembrolizumab + Trastuzumab; Capecitabine; Cisplatin; Fluorouracil; Oxaliplatin; Pembrolizumab + Trastuzumab; Placebo; Tegafur-gimeracil-oteracil pPotassium	anti-ERBB2_monoclonal_antibody + anti-PD-1_monoclonal_antibody; DPD_inhibitor; Fluorouracil; anti-ERBB2_monoclonal_antibody + anti-PD-1_monoclonal_antibody; antimetabolite; fluoropyrimidine; orotate_phosphoribosyltransferase_inhibitor; placebo; platinum-based_antineoplastic_agent	2018-000224-34  3475-811	A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab Plus Chemotherapy and Placebo as First-line Treatment in Participants With HER2 Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (KEYNOTE 811)	Gastric Neoplasms; Gastroesophageal Junction Adenocarcinoma	2145 - Westmead; 3168 - Clayton; 2170 - Liverpool; Auckland; 2500 - Wollongong	https://clinicaltrials.gov/ct2/show/NCT03615326
NCT03625323	TACTI-002	Phase 2		WA, QLD	10/08/2018	18/02/2019	Eftilagimod Alpha; Pembrolizumab	anti-PD-1_monoclonal_antibody; T-cell_immunostimulatory_factor	Eftilagimod Alpha; Pembrolizumab	T-cell_immunostimulatory_factor; anti-PD-1_monoclonal_antibody	Keynote-PN798  TACTI-002	TACTI-002 (Two ACTive Immunotherapeutics): A Multicenter, Open Label, Phase II Study in Patients With Previously Untreated Unresectable or Metastatic Non-small Cell Lung Cancer (NSCLC), or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic Squamous Head and Neck Cancer (HNSCC) Receiving the Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) in Combination With Pembrolizumab (PD-1 Antagonist)	NSCLC; HNSCC	WA 6008 - Perth; 4215 - Southport	https://clinicaltrials.gov/ct2/show/NCT03625323
NCT03626545	CANOPY-2	Phase 3		VIC, QLD	13/08/2018	23/01/2019	Canakinumab; Canakinumab + Docetaxel; Docetaxel; Placebo	anti-IL-1beta_monoclonal_antibody + taxane; taxane; placebo; anti-IL-1beta_monoclonal_antibody	Canakinumab + Docetaxel; Docetaxel; Canakinumab + Docetaxel; Placebo	anti-IL-1beta_monoclonal_antibody + taxane; taxane; anti-IL-1beta_monoclonal_antibody + taxane; placebo	2018-002480-26  CACZ885V2301	A Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Canakinumab in Combination With Docetaxel Versus Placebo in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancer (NSCLC) Previously Treated With PD-(L)1 Inhibitors and Platinum-based Chemotherapy (CANOPY 2)	Non-Small-Cell Lung	4120 - Greenslopes; 3630 - Shepparton	https://clinicaltrials.gov/ct2/show/NCT03626545
NCT03628677	AB154CSP0001	Phase 1		VIC, NSW, QLD	14/08/2018	12/09/2018	Domvanalimab; Domvanalimab + Zimberelimab; Zimberelimab	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-TIGIT_monoclonal_antibody	Domvanalimab; Domvanalimab + Zimberelimab; Domvanalimab + Zimberelimab	anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody	AB154CSP0001	A Phase 1 Study to Evaluate the Safety and Tolerability of AB154 Monotherapy and Combination Therapy in Participants With Advanced Malignancies	Solid Tumor, Unspecified, Adult	2010 - Darlinghurst; 2640 - Albury; 2480 - Tweed Heads; 2050 - Camperdown; 3084 - Heidelberg; 2031 - Randwick; 4101 - South Brisbane	https://clinicaltrials.gov/ct2/show/NCT03628677
NCT03629756	AB928CSP0005	Phase 1	NOT_RECRUITING	QLD, NSW, VIC	14/08/2018	24/07/2018	Etrumadenant; Etrumadenant + Zimberelimab; Zimberelimab	adenosine_A2aR_and_A2bR_antagonist + anti-PD-1_monoclonal_antibody; adenosine_A2aR_and_A2bR_antagonist; anti-PD-1_monoclonal_antibody	Etrumadenant + Zimberelimab; Etrumadenant + Zimberelimab	adenosine_A2aR_and_A2bR_antagonist + anti-PD-1_monoclonal_antibody; adenosine_A2aR_and_A2bR_antagonist + anti-PD-1_monoclonal_antibody	AB928CSP0005	A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies	Castration-resistant Prostate Cancer; GastroEsophageal Cancer; Squamous Cell Carcinoma of the Head and Neck; Melanoma; Bladder Cancer; Colorectal Cancer; Non-small Cell Lung Cancer; Renal Cell Carcinoma; Endometrial Cancer; Merkel Cell Carcinoma; Breast Cancer; Ovarian Cancer	3144 - Malvern; 2217 - Kogarah; 4120 - Greenslopes	https://clinicaltrials.gov/ct2/show/NCT03629756
NCT03631199	CANOPY-1	Phase 3	NOT_RECRUITING	WA, VIC, NSW, QLD	15/08/2018	21/12/2018	Canakinumab; Canakinumab + Pembrolizumab; Carboplatin; Cisplatin; Nab-paclitaxel; Paclitaxel; Pembrolizumab; Pemetrexed; Placebo	anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; anti-IL-1beta_monoclonal_antibody + anti-PD-1_monoclonal_antibody; placebo; antimetabolite; taxane; anti-IL-1beta_monoclonal_antibody	Canakinumab + Pembrolizumab; Canakinumab + Pembrolizumab; Carboplatin; Cisplatin; Nab-paclitaxel; Pemetrexed; Placebo	anti-IL-1beta_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-IL-1beta_monoclonal_antibody + anti-PD-1_monoclonal_antibody; antimetabolite; placebo; platinum-based_antineoplastic_agent; taxane	2018-001547-32  CACZ885U2301	A Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab as First Line Therapy for Locally Advanced or Metastatic Non-squamous and Squamous Non-small Cell Lung Cancer Subjects (CANOPY-1)	Non-small Cell Lung Cancer	3000 - Melbourne; 6150 - Murdoch; 2145 - Westmead; 4102 - Wooloongabba	https://clinicaltrials.gov/ct2/show/NCT03631199
NCT03631784	KEYNOTE-799	Phase 2	NOT_RECRUITING	NSW, VIC, NZ	15/08/2018	19/10/2018	Carboplatin; Carboplatin + Paclitaxel + Pembrolizumab + Radiotherapy; Cisplatin; Cisplatin + Pembrolizumab + Pemetrexed + Radiotherapy; Paclitaxel; Pembrolizumab; Pemetrexed; Radiotherapy; Thoracic Radiation Therapy	radiotherapy; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; antimetabolite; taxane; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + radiotherapy + taxane; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + radiotherapy	Carboplatin + Paclitaxel + Pembrolizumab + Radiotherapy; Cisplatin + Pembrolizumab + Pemetrexed + Radiotherapy; Carboplatin + Paclitaxel + Pembrolizumab + Radiotherapy; Cisplatin + Pembrolizumab + Pemetrexed + Radiotherapy; Thoracic Radiation Therapy	anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + radiotherapy; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + radiotherapy + taxane; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + radiotherapy; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + radiotherapy + taxane	MK-3475-799  3475-799	A Phase 2 Trial of Pembrolizumab (MK-3475) in Combination With Platinum Doublet Chemotherapy and Radiotherapy for Participants With Unresectable, Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC) (KEYNOTE-799).	Non-small Cell Lung Cancer	2444 - Port Macquarie; 2500 - Wollongong; 3350 - Ballarat; 2148 - Blacktown; Auckland	https://clinicaltrials.gov/ct2/show/NCT03631784
NCT03635567	KEYNOTE-826	Phase 3		WA, NSW, VIC, QLD, SA	17/08/2018	25/10/2018	Bevacizumab; Bevacizumab + Carboplatin + Cisplatin + Paclitaxel; Bevacizumab + Carboplatin + Cisplatin + Paclitaxel + Pembrolizumab; Carboplatin; Cisplatin; Paclitaxel; Pembrolizumab; Placebo	anti-PD-1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; placebo; anti-VEGF_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; anti-VEGF_monoclonal_antibody; taxane	Bevacizumab + Carboplatin + Cisplatin + Paclitaxel; Bevacizumab + Carboplatin + Cisplatin + Paclitaxel + Pembrolizumab; Bevacizumab + Carboplatin + Cisplatin + Paclitaxel; Bevacizumab + Carboplatin + Cisplatin + Paclitaxel + Pembrolizumab; Placebo	anti-PD-1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; anti-VEGF_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; anti-PD-1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; anti-VEGF_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; placebo	2018-001440-53  3475-826	A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer (KEYNOTE-826)	Cervical Cancer	5042 - Bedford Park; 3168 - Clayton; 6008 - Subiaco; 4101 - South Brisbane; 2065 - St Leonards	https://clinicaltrials.gov/ct2/show/NCT03635567
NCT03635983	2018-001423-40--CA045-001	Phase 3		WA, NZ, SA, VIC, NSW, QLD	17/08/2018	14/09/2018	Bempegaldesleukin; Bempegaldesleukin + Nivolumab; Nivolumab	anti-PD-1_monoclonal_antibody; IL-2_variant; IL-2_variant + anti-PD-1_monoclonal_antibody	Bempegaldesleukin + Nivolumab; Nivolumab; Bempegaldesleukin + Nivolumab	IL-2_variant + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; IL-2_variant + anti-PD-1_monoclonal_antibody	2018-001423-40  CA045-001	A Phase 3, Randomized, Open-label Study of NKTR-214 Combined With Nivolumab Versus Nivolumab in Participants With Previously Untreated Unresectable or Metastatic Melanoma	Melanoma	4120 - Greenslopes; 3000 - Melbourne; 6009 - Nedlands; Wellington; 2060 - North Sydney; Christchurch; 4870 - Cairns; 5112 - Elizabeth Vale; Auckland; 3004 - Melbourne; 2450 - Coffs Harbour; 4012 - Woolloongabba	https://clinicaltrials.gov/ct2/show/NCT03635983
NCT03639714	GO-004	Phase 1/Phase 2	NOT_RECRUITING	VIC	21/08/2018	13/02/2019	Ipilimumab; Nivolumab	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody	Ipilimumab; Nivolumab	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody	GO-004	An International Phase 1/2 Study of GRT-C901/GRT-R902, a Neoantigen Cancer Vaccine, in Combination With Immune Checkpoint Blockade for Patients With Advanced Solid Tumors	Gastroesophageal Adenocarcinoma; Colorectal Cancer; Urothelial Carcinoma; Non Small Cell Lung Cancer	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT03639714
NCT03642132	2017-004456-30--B9991030	Phase 3		VIC	22/08/2018	19/07/2018	Avelumab; Avelumab + Talazoparib; Bevacizumab; Talazoparib	PARP_inhibitor; anti-PD-L1_monoclonal_antibody; PARP_inhibitor + anti-PD-L1_monoclonal_antibody; anti-VEGF_monoclonal_antibody	Avelumab + Talazoparib; Bevacizumab; Talazoparib; Avelumab + Talazoparib	PARP_inhibitor; PARP_inhibitor + anti-PD-L1_monoclonal_antibody; anti-VEGF_monoclonal_antibody; PARP_inhibitor + anti-PD-L1_monoclonal_antibody	2017-004456-30  B9991030	A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AVELUMAB IN COMBINATION WITH CHEMOTHERAPY FOLLOWED BY MAINTENANCE THERAPY OF AVELUMAB IN COMBINATION WITH THE POLY (ADENOSINE DIPHOSPHATE [ADP]-RIBOSE) POLYMERASE (PARP) INHIBITOR TALAZOPARIB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED OVARIAN CANCER (JAVELIN OVARIAN PARP100)	Ovarian Cancer	3002 - East Melbourne; 3121 - Richmond	https://clinicaltrials.gov/ct2/show/NCT03642132
NCT03647839	MODULATE	Phase 2	NOT_RECRUITING	NT, VIC, NSW, QLD, SA	27/08/2018	6/09/2018	BNC-105; BNC-105 + Nivolumab; Napabucasin; Napabucasin + Nivolumab; Nivolumab	tubulin_polymerization_inhibitor_and_vascular_disruption_agents; cancer_stemness_inhibitor; anti-PD-1_monoclonal_antibody + cancer_stemness_inhibitor; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + tubulin_polymerization_inhibitor_and_vascular_disruption_agents	BNC-105 + Nivolumab; Napabucasin + Nivolumab; BNC-105 + Nivolumab; Napabucasin + Nivolumab	anti-PD-1_monoclonal_antibody + cancer_stemness_inhibitor; anti-PD-1_monoclonal_antibody + tubulin_polymerization_inhibitor_and_vascular_disruption_agents; anti-PD-1_monoclonal_antibody + cancer_stemness_inhibitor; anti-PD-1_monoclonal_antibody + tubulin_polymerization_inhibitor_and_vascular_disruption_agents	CA209-99U	Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal Cancer	Colorectal Cancer Metastatic	5037 - Kurralta Park; 5042 - Bedford Park; - Ballarat; 3084 - Heidelberg; 5011 - Woodville South; 4029 - Herston; 2640 - Albury; - Mornington Peninsula; 2145 - Westmead; 3021 - Saint Albans; 3168 - Clayton; 2065 - St Leonards; - Box Hill; - Newcastle	https://clinicaltrials.gov/ct2/show/NCT03647839
NCT03655613	APOLLO	Phase 1/Phase 2		New South WhalesSA, WA, VIC, NSW, SA, NZ	31/08/2018	5/09/2018	APL-501; APL-501 + Vebreltinib; Nivolumab; Nivolumab + Vebreltinib; Vebreltinib	MET_inhibitor,type_1; anti-PD-1_monoclonal_antibody; MET_inhibitor,type_1 + anti-PD-1_monoclonal_antibody	APL-501 + Vebreltinib; Nivolumab + Vebreltinib; APL-501 + Vebreltinib; Nivolumab + Vebreltinib	MET_inhibitor,type_1 + anti-PD-1_monoclonal_antibody; MET_inhibitor,type_1 + anti-PD-1_monoclonal_antibody	APOLLO	A Phase 1/2 Dose Escalation and Expansion Study of Combination APL-501 or Nivolumab With APL-101 in Locally Advanced or Metastatic Hepatocellular and Renal Cell Carcinoma	Renal Cell Carcinoma; Hepatocellular Carcinoma	3050 - Melbourne; 5037 - Adelaide; Auckland; 2109 - Sydney; 3021 - Saint Albans; 2145 - Westmead; 6018 - Perth; 2640 - Albury; 6150 - Murdoch	https://clinicaltrials.gov/ct2/show/NCT03655613
NCT03656718	2018-001585-42--CA209-8KX	Phase 1/Phase 2	NOT_RECRUITING	NZ	4/09/2018	24/09/2018	Nivolumab; Nivolumab + rHuPH20; rHuPH20	recombinant_human_hyaluronidase; anti-PD-1_monoclonal_antibody + recombinant_human_hyaluronidase; anti-PD-1_monoclonal_antibody	Nivolumab; Nivolumab + rHuPH20; Nivolumab + rHuPH20	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + recombinant_human_hyaluronidase; anti-PD-1_monoclonal_antibody + recombinant_human_hyaluronidase	2018-001585-42  CA209-8KX	Phase I/II Pharmacokinetic Multi-Tumor Study of Subcutaneous Formulation of Nivolumab Monotherapy	Neoplasms by Site	Wellington; Dunedin; Tauranga	https://clinicaltrials.gov/ct2/show/NCT03656718
NCT03658447	PRINCE	Phase 1/Phase 2	NOT_RECRUITING	VIC, NSW	5/09/2018	12/07/2019	Lu-177 vipivotide tetraxetan; Lu-177 vipivotide tetraxetan + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody + radioligand,PSMA-targeting; radioligand,PSMA-targeting; anti-PD-1_monoclonal_antibody	Lu-177 vipivotide tetraxetan + Pembrolizumab; Lu-177 vipivotide tetraxetan + Pembrolizumab	anti-PD-1_monoclonal_antibody + radioligand,PSMA-targeting; anti-PD-1_monoclonal_antibody + radioligand,PSMA-targeting	PeterMac project no. 18/114	Phase Ib/II Study of Radionuclide 177Lutetium-PSMA-617 Therapy in Combination With Pembrolizumab for Treatment of Metastatic Castration Resistant Prostate Cancer (mCRPC)	Metastatic Castration Resistant Prostate Cancer	3128 - Melbourne; 3000 - Melbourne; 2050 - Sydney; 2010 - Sydney	https://clinicaltrials.gov/ct2/show/NCT03658447
NCT03659136	2017-003131-11--1280-0022	Phase 2	NOT_RECRUITING	NSW, VIC	6/09/2018	28/11/2018	Everolimus; Everolimus + Exemestane; Everolimus + Exemestane + Xentuzumab; Exemestane; Placebo; Xentuzumab	placebo; aromatase_inhibitor + mTORC1_inhibitor; anti-IGF_ligand_monoclonal_antibody; aromatase_inhibitor; mTORC1_inhibitor; anti-IGF_ligand_monoclonal_antibody + aromatase_inhibitor + mTORC1_inhibitor	Everolimus + Exemestane; Everolimus + Exemestane + Xentuzumab; Everolimus + Exemestane; Everolimus + Exemestane + Xentuzumab; Placebo	anti-IGF_ligand_monoclonal_antibody + aromatase_inhibitor + mTORC1_inhibitor; aromatase_inhibitor + mTORC1_inhibitor; anti-IGF_ligand_monoclonal_antibody + aromatase_inhibitor + mTORC1_inhibitor; aromatase_inhibitor + mTORC1_inhibitor; placebo	2017-003131-11  1280-0022	XENERA™1: A Multi-centre, Double-blind, Placebo-controlled, Randomised Phase II Trial to Compare Efficacy of Xentuzumab in Combination With Everolimus and Exemestane Versus Everolimus and Exemestane in Women With HR+ / HER2- Metastatic Breast Cancer and Non-visceral Disease	Breast Neoplasms	3199 - Frankston; 2485 - Tweed Heads	https://clinicaltrials.gov/ct2/show/NCT03659136
NCT03662659	2018-001069-18--CA224-060	Phase 2		NSW, VIC, QLD, SA, WA	7/09/2018	16/10/2018	BMS-986213; Nivolumab; Relatlimab	anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody	BMS-986213; Nivolumab; Relatlimab	anti-LAG3_monoclonal_antibody; anti-PD-1_monoclonal_antibody	2018-001069-18  CA224-060	A Randomized, Open-label, Phase II Clinical Trial of Relatlimab (Anti-LAG-3) and Nivolumab in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy as First-Line Treatment in Patients With Gastric or Gastroesophageal Junction Adenocarcinoma	Esophagogastric Junction; Cancer of the Stomach; Gastric Cancer	4029 - Herston; 6150 - Murdoch; 3084 - Heidelberg; 5024 - Bedford Park; 3144 - Malvern; 2145 - Westmead	https://clinicaltrials.gov/ct2/show/NCT03662659
NCT03665597	KEYNOTE-555	Phase 1		SA, VIC, NSW, QLD	11/09/2018	19/11/2018	Pembrolizumab	anti-PD-1_monoclonal_antibody	Pembrolizumab	anti-PD-1_monoclonal_antibody	MK-3475-555  3475-555	A Phase 1 Randomized Clinical Study of Pembrolizumab (MK-3475) to Evaluate the Relative Bioavailability of Subcutaneous Injection Versus Intravenous Infusion in Participants With Advanced Melanoma (KEYNOTE-555)	Melanoma	2800 - Orange; 2298 - Waratah; 5000 - Adelaide; 2444 - Port Macquarie; 3350 - Ballarat; 4870 - Cairns	https://clinicaltrials.gov/ct2/show/NCT03665597
NCT03666143	CTR20181404--BGB-900-103	Phase 1	NOT_RECRUITING	NSW, VIC, QLD, WA	11/09/2018	1/11/2018	Sitravatinib; Tislelizumab	anti-PD-1_monoclonal_antibody; VEGFR_inhibitor; PDGFR_inhibitor; RET_inhibitor; KIT/PDGFR/RET/VEGFR_inhibitor; KIT_inhibitor	Sitravatinib; Tislelizumab	KIT/PDGFR/RET/VEGFR_inhibitor; KIT_inhibitor; PDGFR_inhibitor; RET_inhibitor; anti-PD-1_monoclonal_antibody	CTR20181404  BGB-900-103	A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Solid Tumors	Advanced Solid Tumors	- South Brisbane; - Melbourne; - Blacktown; - Perth; - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT03666143
NCT03666988	2018-001629-20--207675	Phase 1	NOT_RECRUITING	VIC	12/09/2018	22/10/2018	GSK3368715	type_1_PRMT_inhibitor	GSK3368715	type_1_PRMT_inhibitor	2018-001629-20  207675	A Phase I, Open-label, Dose-escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3368715 in Participants With Solid Tumors and DLBCL	Neoplasms	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT03666988
NCT03668119	CheckMate-848	Phase 2		NSW, QLD	12/09/2018	31/10/2018	Ipilimumab; Ipilimumab + Nivolumab; Nivolumab	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Ipilimumab + Nivolumab; Nivolumab; Ipilimumab + Nivolumab	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	2016-002898-35  CA209-848	A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination With Ipilimumab or Nivolumab Monotherapy in Participants With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)	Pan Tumor	2010 - Darlinghurst; 2065 - St Leonards; 4012 - Woolloongabba	https://clinicaltrials.gov/ct2/show/NCT03668119
NCT03673501	intrigue	Phase 3	NOT_RECRUITING	SA, VIC, NSW, QLD	17/09/2018	11/02/2019	Imatinib; Ripretinib; Sunitinib	PDGFRA_inhibitor; KIT_inhibitor,first_generation; BCR-ABL1_inhibitor,first_generation; VEGFR_inhibitor; KIT_inhibitor,switch_control_kinase_inhibitor; PDGFR_inhibitor; KIT_inhibitor	Ripretinib; Sunitinib; Imatinib	KIT_inhibitor,first_generation; KIT_inhibitor,switch_control_kinase_inhibitor; PDGFRA_inhibitor; PDGFR_inhibitor; VEGFR_inhibitor; BCR-ABL1_inhibitor,first_generation	DCC-2618-03-002	A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of DCC-2618 vs Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumors After Treatment With Imatinib	Gastrointestinal Stromal Tumors	- Woolloongabba; 2031 - Randwick; - Albury; 3004 - Melbourne; - Kurralta Park; 5037 - Kurralta Park	https://clinicaltrials.gov/ct2/show/NCT03673501
NCT03674567	KEYNOTE-877--FLX475-02	Phase 1/Phase 2	NOT_RECRUITING	WA, VIC	17/09/2018	25/09/2018	FLX475; FLX475 + Pembrolizumab; Pembrolizumab	CCR4_inhibitor; anti-PD-1_monoclonal_antibody; CCR4_inhibitor + anti-PD-1_monoclonal_antibody	FLX475; FLX475 + Pembrolizumab; FLX475 + Pembrolizumab	CCR4_inhibitor; CCR4_inhibitor + anti-PD-1_monoclonal_antibody; CCR4_inhibitor + anti-PD-1_monoclonal_antibody	KEYNOTE-877  FLX475-02	Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination With Pembrolizumab in Advanced Cancer	Advanced Cancer	6009 - Nedlands; 3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT03674567
NCT03675737	KEYNOTE-859	Phase 3		VIC, NSW, NZ	18/09/2018	8/11/2018	Capecitabine; Capecitabine + Cisplatin + Fluorouracil + Oxaliplatin + Pembrolizumab; Cisplatin; Fluorouracil; Oxaliplatin; Pembrolizumab; Placebo	anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; placebo; anti-PD-1_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; Fluorouracil; fluoropyrimidine	Capecitabine + Cisplatin + Fluorouracil + Oxaliplatin + Pembrolizumab; Capecitabine + Cisplatin + Fluorouracil + Oxaliplatin + Pembrolizumab; Placebo	anti-PD-1_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; Fluorouracil; anti-PD-1_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; placebo	2018-001757-27  3475-859	A Phase 3, Randomized, Double-blind Clinical Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy as First-line Treatment in Participants With HER2 Negative, Previously Untreated, Unresectable or Metastatic Gastric Orgastroesophageal Junction Adenocarcinoma (KEYNOTE-859)	Stomach Neoplasms	2170 - Liverpool; 2500 - Wollongong; Northland; 3128 - Box Hill	https://clinicaltrials.gov/ct2/show/NCT03675737
NCT03682068	NILE	Phase 3		QLD, VIC, NSW, SA, WA	24/09/2018	27/09/2018	Carboplatin; Cisplatin; Durvalumab; Durvalumab + Tremelimumab; Gemcitabine; Tremelimumab	anti-PD-L1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody; platinum-based_antineoplastic_agent; anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; antimetabolite	Durvalumab; Durvalumab + Tremelimumab; Carboplatin; Cisplatin; Durvalumab + Tremelimumab; Gemcitabine	anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; antimetabolite; platinum-based_antineoplastic_agent	D933SC00001	A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination With Standard of Care Chemotherapy and Durvalumab in Combination With Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone in Patients With Unresectable Locally Advanced or Metastatic Urothelial Cancer.	Metastatic Urothelial Cancer; Unresectable Locally Advanced Urothelial Cancer	2217 - Kogarah; 3128 - Box Hill; 3021 - St Albans; 6150 - Murdoch; 2800 - Orange; 2109 - Macquarie University; 5112 - Elizabeth Vale; 4101 - South Brisbane	https://clinicaltrials.gov/ct2/show/NCT03682068
NCT03684811	2102-ONC-102	Phase 1/Phase 2	NOT_RECRUITING	VIC	26/09/2018	1/11/2018	Azacitidine; Cisplatin; Gemcitabine; Nivolumab; Olutasidenib	IDH1_R132_inhibitor; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; DNA_methyltransferase_inhibitor; antimetabolite; gemcitabine	Olutasidenib; Azacitidine; Cisplatin; Gemcitabine; Nivolumab	IDH1_R132_inhibitor; DNA_methyltransferase_inhibitor; anti-PD-1_monoclonal_antibody; antimetabolite; gemcitabine; platinum-based_antineoplastic_agent	2102-ONC-102	A Phase 1b/2 Study of FT 2102 in Participants With Advanced Solid Tumors and Gliomas With an IDH1 Mutation	Cohort 1a and 1b: Glioblastoma Multiforme; Cohort 4a and 4b: Intrahepatic Cholangiocarcinoma; Cohort 5a: Other Solid Tumors With IDH1 Mutations; Cohort 3a and 3b: Chondrosarcoma; Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas); Cohort 1a and 1b: Glioma	3084 - Heidelberg; VIC 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT03684811
NCT03685448	UNICAB	Phase 2		NT, SA, QLD, VIC, NSW	26/09/2018	11/04/2019	Cabozantinib	AXL_inhibitor; ROS1_inhibitor; RET_inhibitor; KIT_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor; MET_inhibitor,type_2; VEGFR2_inhibitor	Cabozantinib	AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor; AXL_inhibitor; KIT_inhibitor; MET_inhibitor,type_2; RET_inhibitor; ROS1_inhibitor; VEGFR2_inhibitor	ANZUP1802	A Phase II of Single Agent Cabozantinib in Patients With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma Post Immunotherapy or Who Are Unsuitable for Immunotherapy (ANZUP1802)	Chromophobe Renal Cell Carcinoma; Xp11.2 Translocation-Related Renal Cell Carcinoma; Renal Cell Carcinoma; Papillary Renal Cell Carcinoma Type 2; Papillary Renal Cell Carcinoma Type 1; Sarcomatoid Renal Cell Carcinoma	- Herston; 2460 - Albury; - Clayton; 3630 - Shepparton; - Newcastle; 5037 - Kurralta Park; 3128 - Box Hill; - Kogarah; 5042 - Bedford Park; 2560 - Campbelltown; 2109 - Macquarie Park	https://clinicaltrials.gov/ct2/show/NCT03685448
NCT03690154	FN-1501-UP1	Phase 1	NOT_RECRUITING	VIC	1/10/2018	23/07/2018	FN-1501	CDK2/4/6/FLT3_inhibitor	FN-1501	CDK2/4/6/FLT3_inhibitor	FN-1501-UP1	A Phase 1, Multi-center, Open-label, Single-arm, Dose-escalation, Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of FN-1501 Monotherapy in Patients With Advanced Solid Tumors or Relapsed/Refractory Acute Myeloid Leukemia (AML)	Acute Myeloid Leukemia Refractory; Advanced Cancer; Solid Tumors; Acute Myeloid Leukemia, in Relapse	3144 - Malvern	https://clinicaltrials.gov/ct2/show/NCT03690154
NCT03690388	XL184-311	Phase 3		SA, NSW, VIC	1/10/2018	5/10/2018	Cabozantinib; Placebo	placebo; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor; MET_inhibitor,type_2; VEGFR2_inhibitor; AXL_inhibitor; ROS1_inhibitor; RET_inhibitor; KIT_inhibitor	Cabozantinib; Placebo	AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor; AXL_inhibitor; KIT_inhibitor; MET_inhibitor,type_2; RET_inhibitor; ROS1_inhibitor; VEGFR2_inhibitor; placebo	XL184-311	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects With Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy	Differentiated Thyroid Cancer	3004 - Melbourne; 2298 - Waratah; 5042 - Bedford Park; 4029 - Herston; 2065 - St. Leonards	https://clinicaltrials.gov/ct2/show/NCT03690388
NCT03693612	GSK3359609-207871	Phase 1/Phase 2		VIC	3/10/2018	26/11/2018	Cetuximab; Cetuximab + Docetaxel + Paclitaxel; Docetaxel; GSK3359609; Paclitaxel; Tremelimumab	anti-CTLA-4_monoclonal_antibody; anti-EGFR_monoclonal_antibody; taxane; anti-EGFR_monoclonal_antibody + taxane; anti-ICOS_agonistic_antibody	Cetuximab + Docetaxel + Paclitaxel; Tremelimumab; Cetuximab + Docetaxel + Paclitaxel; GSK3359609	anti-CTLA-4_monoclonal_antibody; anti-EGFR_monoclonal_antibody + taxane; anti-EGFR_monoclonal_antibody + taxane; anti-ICOS_agonistic_antibody	207871	A Phase I/II, Open-label, Two Part Study of GSK3359609 in Combination With Tremelimumab in Participants With Selected, Advanced Solid Tumors	Neoplasms	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT03693612
NCT03694522	FIGHT	Phase 2	NOT_RECRUITING	NSW, QLD	3/10/2018	14/09/2018	Bemarituzumab; Placebo	anti-FGFR2_monoclonal_antibody; placebo	Bemarituzumab; Placebo	anti-FGFR2_monoclonal_antibody; placebo	FPA144-004 Phase 2	FIGHT: A Phase 2 Randomized, Double-Blind, Controlled Study Evaluating Bemarituzumab (FPA144) and Modified FOLFOX6 in Patients With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Preceded by Dose-Finding in Phase 1	Gastric Cancer	- Camperdown; - Douglas; - Wahroonga	https://clinicaltrials.gov/ct2/show/NCT03694522
NCT03703466	I3Y-MC-JPCP--17041	Phase 2		SA, NSW, VIC	12/10/2018	28/11/2018	Abemaciclib	CDK4/6_inhibitor	Abemaciclib	CDK4/6_inhibitor	I3Y-MC-JPCP  17041	An Open-Label, Randomized Phase 2 Study of the Impact of Food on Tolerability When Receiving Abemaciclib for Patients With Previously Treated Hormone Receptor-Positive, HER2-Negative, Metastatic Breast Cancer	Metastatic Breast Cancer	3000 - Melbourne; 5037 - Kurralta Park; 2010 - Sydney; 2291 - North Sydney	https://clinicaltrials.gov/ct2/show/NCT03703466
NCT03704077	2018-001070-20--CA224-061	Phase 2		WA, VIC, NSW, SA	12/10/2018		BMS-986213; Nivolumab; Nivolumab + Paclitaxel; Nivolumab + Paclitaxel + Relatlimab; Nivolumab + Relatlimab; Paclitaxel; Paclitaxel + Ramucirumab; Ramucirumab; Relatlimab	anti-PD-1_monoclonal_antibody + taxane; anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody; anti-VEGFR2_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + taxane; taxane; anti-VEGFR2_monoclonal_antibody + taxane; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Nivolumab; Nivolumab + Paclitaxel; Nivolumab + Paclitaxel + Relatlimab; Nivolumab + Relatlimab; Paclitaxel + Ramucirumab; BMS-986213; Nivolumab + Paclitaxel; Nivolumab + Paclitaxel + Relatlimab; Nivolumab + Relatlimab; Paclitaxel + Ramucirumab	anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + taxane; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + taxane; anti-VEGFR2_monoclonal_antibody + taxane; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + taxane; anti-PD-1_monoclonal_antibody + taxane; anti-VEGFR2_monoclonal_antibody + taxane	2018-001070-20  CA224-061	A Randomized, Active-Controlled, Open-Label, Phase 2 Clinical Trial of BMS-986213, in Combination With Various Standard-of-Care Therapeutic Regimens, in Participants With Recurrent, Locally Advanced, or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction (GEJ) Adenocarcinoma	Stomach Cancer; Cancer of the Stomach; Gastroesophageal Junction; Gastric Cancer	2145 - Westmead; 3144 - Malvern; 3000 - Melbourne; 6150 - Murdoch; 5024 - Bedford Park; 3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT03704077
NCT03706365	CYCLONE-2	Phase 2/Phase 3		NSW, VIC	16/10/2018	26/11/2018	Abemaciclib; Abemaciclib + Abiraterone + Prednisone; Abiraterone; Abiraterone + Prednisone; Placebo; Prednisone	glucocorticoid; placebo; CYP17A1_inhibitor; CDK4/6_inhibitor; CYP17A1_inhibitor + glucocorticoid; CDK4/6_inhibitor + CYP17A1_inhibitor + glucocorticoid	Abemaciclib + Abiraterone + Prednisone; Abiraterone + Prednisone; Abemaciclib + Abiraterone + Prednisone; Abiraterone + Prednisone; Placebo	CDK4/6_inhibitor + CYP17A1_inhibitor + glucocorticoid; CYP17A1_inhibitor + glucocorticoid; CDK4/6_inhibitor + CYP17A1_inhibitor + glucocorticoid; CYP17A1_inhibitor + glucocorticoid; placebo	I3Y-MC-JPCM  16598	A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer	Prostate Cancer	3000 - Melbourne; 2109 - Macquarie Park; 2050 - Camperdown; 2031 - Randwick; 2228 - Kogarah; 3065 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT03706365
NCT03708328	2018-000982-35--NP40435	Phase 1		NZ	17/10/2018	15/10/2018	RO7121661	bispecific_PD-1/TIM-3_antibody	RO7121661	bispecific_PD-1/TIM-3_antibody	2018-000982-35  NP40435	An Open Label, Multicenter, Dose Escalation and Expansion, Phase 1 Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-Tumor Activity of RO7121661, a PD-1/TIM-3 Bispecific Antibody, in Patients With Advanced and/or Metastatic Solid Tumors	Non-small Cell Lung Cancer (NSCLC); Small Cell Lung Cancer (SCLC); Metastatic Melanoma; Solid Tumors	Auckland	https://clinicaltrials.gov/ct2/show/NCT03708328
NCT03710876	INFINITE	Phase 3		VIC, NSW	18/10/2018	21/01/2019	Celecoxib; Celecoxib + Gemcitabine; Celecoxib + Gemcitabine + Nadofaragene Firadenovec; Gemcitabine; Nadofaragene Firadenovec	adenovirus-delivered_interferon_alpha-2b; COX2_inhibitor; gemcitabine; COX2_inhibitor + antimetabolite; antimetabolite; COX2_inhibitor + adenovirus-delivered_interferon_alpha-2b + antimetabolite	Celecoxib + Gemcitabine; Celecoxib + Gemcitabine + Nadofaragene Firadenovec; Celecoxib + Gemcitabine; Celecoxib + Gemcitabine + Nadofaragene Firadenovec	COX2_inhibitor + adenovirus-delivered_interferon_alpha-2b + antimetabolite; COX2_inhibitor + antimetabolite; COX2_inhibitor + adenovirus-delivered_interferon_alpha-2b + antimetabolite; COX2_inhibitor + antimetabolite; gemcitabine	2017-003169-82  rAd-IFN-MM-301	A Phase 3, Open-Label, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intrapleural Administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in Combination With Celecoxib and Gemcitabine in Patients With Malignant Pleural Mesothelioma	Malignant Pleural Mesothelioma	2050 - Camperdown; 3168 - Clayton	https://clinicaltrials.gov/ct2/show/NCT03710876
NCT03713593	LEAP-002	Phase 3		NZ, NSW, VIC, QLD	22/10/2018	31/12/2018	Dexamethasone; Lenvatinib; Lenvatinib + Pembrolizumab; Pembrolizumab; Placebo	glucocorticoid; anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; placebo; VEGF_inhibitor	Lenvatinib; Lenvatinib + Pembrolizumab; Dexamethasone; Lenvatinib + Pembrolizumab; Placebo	VEGF_inhibitor; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; glucocorticoid; placebo	MK-7902-002  7902-002	A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib in First-line Therapy of Participants With Advanced Hepatocellular Carcinoma (LEAP-002)	Carcinoma, Hepatocellular	2050 - Camperdown; 2170 - Liverpool; 3065 - Fitzroy; Auckland; Christchurch; 4102 - Wooloongabba; 3168 - Clayton	https://clinicaltrials.gov/ct2/show/NCT03713593
NCT03719326	AB928CSP0002	Phase 1		VIC, NSW, QLD	25/10/2018	15/10/2018	Etrumadenant; IPI-549; Nab-paclitaxel; Pegylated liposomal doxorubicin	anthracycline; adenosine_A2aR_and_A2bR_antagonist; taxane; PI3K-gamma_inhibitor	Etrumadenant; IPI-549; Nab-paclitaxel; Pegylated liposomal doxorubicin	PI3K-gamma_inhibitor; adenosine_A2aR_and_A2bR_antagonist; anthracycline; taxane	AB928CSP0002	A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Breast or Gynecologic Malignancies	Ovarian Cancer; TNBC - Triple-Negative Breast Cancer	2010 - Darlinghurst; 3199 - Frankston; 2217 - Kogarah; 2050 - Camperdown; 4217 - Benowa; 2109 - Macquarie; 3144 - Malvern	https://clinicaltrials.gov/ct2/show/NCT03719326
NCT03719690	AIM-HN-SEQ-HN	Phase 2		VIC, NSW	25/10/2018	5/11/2018	Tipifarnib	farnesyltransferase_inhibitor	Tipifarnib	farnesyltransferase_inhibitor	KO-TIP-007	A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC) With HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC (SEQ-HN)	HNSCC; HRAS Gene Mutation	2065 - Saint Leonards; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT03719690
NCT03720431	PMC-TTAC-0001-05	Phase 1	NOT_RECRUITING	WA, NSW	25/10/2018	3/01/2019	Olinvacimab; Olinvacimab + Pembrolizumab; Pembrolizumab	anti-VEGFR2_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-VEGFR2_monoclonal_antibody	Olinvacimab + Pembrolizumab; Olinvacimab + Pembrolizumab	anti-PD-1_monoclonal_antibody + anti-VEGFR2_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-VEGFR2_monoclonal_antibody	PMC_TTAC-0001_05	A Phase 1b, Open-Label, Safety and Tolerability Study of TTAC-0001 in Combination With Pembrolizumab in Patients With Metastatic Triple-Negative Breast Cancer	Triple Negative Breast Cancer	2170 - Liverpool; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT03720431
NCT03720678	AB928CSP0003	Phase 1	NOT_RECRUITING	VIC, NSW	25/10/2018	18/11/2018	Etrumadenant	adenosine_A2aR_and_A2bR_antagonist	Etrumadenant	adenosine_A2aR_and_A2bR_antagonist	AB928CSP0003	A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Gastrointestinal Malignancies	GastroEsophageal Cancer; Colorectal Cancer	3144 - Malvern; 2217 - Kogarah; 3199 - Frankston; 2010 - Darlinghurst; 2640 - Albury; 2109 - Macquarie Park; 2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT03720678
NCT03722342	PMC-TTAC-0001-04	Phase 1		VIC, WA	26/10/2018	16/01/2019	Olinvacimab; Olinvacimab + Pembrolizumab; Pembrolizumab	anti-VEGFR2_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-VEGFR2_monoclonal_antibody	Olinvacimab + Pembrolizumab; Olinvacimab + Pembrolizumab	anti-PD-1_monoclonal_antibody + anti-VEGFR2_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-VEGFR2_monoclonal_antibody	PMC_TTAC-0001_04	A Phase 1b, Open-Label, Safety and Tolerability Study of TTAC-0001 in Combination With Pembrolizumab in Patients With Recurrent Glioblastoma	Recurrent Glioblastoma	3084 - Heidelberg; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT03722342
NCT03729245	CA045002--17-214-09	Phase 3	NOT_RECRUITING	NSW, VIC, SA, NZ	2/11/2018	18/12/2018	Bempegaldesleukin; Bempegaldesleukin + Nivolumab; Cabozantinib; Cabozantinib + Sunitinib; Nivolumab; Sunitinib	KIT_inhibitor,first_generation; anti-PD-1_monoclonal_antibody; VEGFR2_inhibitor + VEGFR_inhibitor; PDGFR_inhibitor + ROS1_inhibitor; IL-2_variant; PDGFR_inhibitor + VEGFR2_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor; VEGFR2_inhibitor; KIT_inhibitor + KIT_inhibitor,first_generation; RET_inhibitor + VEGFR_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + VEGFR_inhibitor; KIT_inhibitor,first_generation + ROS1_inhibitor; KIT_inhibitor,first_generation + VEGFR2_inhibitor; AXL_inhibitor; PDGFR_inhibitor; RET_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + PDGFR_inhibitor; MET_inhibitor,type_2 + PDGFR_inhibitor; ROS1_inhibitor + VEGFR_inhibitor; KIT_inhibitor + PDGFR_inhibitor; IL-2_variant + anti-PD-1_monoclonal_antibody; ROS1_inhibitor; AXL_inhibitor + PDGFR_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + KIT_inhibitor,first_generation; MET_inhibitor,type_2 + VEGFR_inhibitor; PDGFR_inhibitor + RET_inhibitor; KIT_inhibitor + VEGFR_inhibitor; AXL_inhibitor + KIT_inhibitor,first_generation; AXL_inhibitor + VEGFR_inhibitor; MET_inhibitor,type_2; KIT_inhibitor,first_generation + RET_inhibitor; VEGFR_inhibitor; KIT_inhibitor; KIT_inhibitor,first_generation + MET_inhibitor,type_2	Bempegaldesleukin + Nivolumab; Cabozantinib + Sunitinib; Bempegaldesleukin + Nivolumab; Cabozantinib + Sunitinib	AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + KIT_inhibitor,first_generation; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + PDGFR_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + VEGFR_inhibitor; AXL_inhibitor + KIT_inhibitor,first_generation; AXL_inhibitor + PDGFR_inhibitor; AXL_inhibitor + VEGFR_inhibitor; IL-2_variant + anti-PD-1_monoclonal_antibody; KIT_inhibitor + KIT_inhibitor,first_generation; KIT_inhibitor + PDGFR_inhibitor; KIT_inhibitor + VEGFR_inhibitor; KIT_inhibitor,first_generation + MET_inhibitor,type_2; KIT_inhibitor,first_generation + RET_inhibitor; KIT_inhibitor,first_generation + ROS1_inhibitor; KIT_inhibitor,first_generation + VEGFR2_inhibitor; MET_inhibitor,type_2 + PDGFR_inhibitor; MET_inhibitor,type_2 + VEGFR_inhibitor; PDGFR_inhibitor + RET_inhibitor; PDGFR_inhibitor + ROS1_inhibitor; PDGFR_inhibitor + VEGFR2_inhibitor; RET_inhibitor + VEGFR_inhibitor; ROS1_inhibitor + VEGFR_inhibitor; VEGFR2_inhibitor + VEGFR_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + KIT_inhibitor,first_generation; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + PDGFR_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + VEGFR_inhibitor; AXL_inhibitor + KIT_inhibitor,first_generation; AXL_inhibitor + PDGFR_inhibitor; AXL_inhibitor + VEGFR_inhibitor; IL-2_variant + anti-PD-1_monoclonal_antibody; KIT_inhibitor + KIT_inhibitor,first_generation; KIT_inhibitor + PDGFR_inhibitor; KIT_inhibitor + VEGFR_inhibitor; KIT_inhibitor,first_generation + MET_inhibitor,type_2; KIT_inhibitor,first_generation + RET_inhibitor; KIT_inhibitor,first_generation + ROS1_inhibitor; KIT_inhibitor,first_generation + VEGFR2_inhibitor; MET_inhibitor,type_2 + PDGFR_inhibitor; MET_inhibitor,type_2 + VEGFR_inhibitor; PDGFR_inhibitor + RET_inhibitor; PDGFR_inhibitor + ROS1_inhibitor; PDGFR_inhibitor + VEGFR2_inhibitor; RET_inhibitor + VEGFR_inhibitor; ROS1_inhibitor + VEGFR_inhibitor; VEGFR2_inhibitor + VEGFR_inhibitor	CA045002  17-214-09	A Phase 3 Randomized Open Label Study to Compare NKTR-214 Combined With Nivolumab to the Investigator's Choice of Sunitinib or Cabozantinib in Patients With Previously Untreated Advanced Renal Cell Carcinoma	Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma	3220 - Geelong; 2109 - Sydney; Auckland; Christchurch; 5037 - Kurralta Park; 2065 - Saint Leonards; 2800 - Orange	https://clinicaltrials.gov/ct2/show/NCT03729245
NCT03729596	CP-MGC018-01	  Phase 1/Phase 2	NOT_RECRUITING	VIC, NSW, QLD	2/11/2018	21/11/2018	Retifanlimab; Retifanlimab + Vobramitamab duocarmazine; Vobramitamab duocarmazine	anti-B7H3_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-B7H3_antibody-drug_conjugate	Retifanlimab + Vobramitamab duocarmazine; Vobramitamab duocarmazine; Retifanlimab + Vobramitamab duocarmazine	anti-B7H3_antibody-drug_conjugate; anti-B7H3_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody; anti-B7H3_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody	CP-MGC018-01	A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of MGC018 (Anti-B7-H3 Antibody Drug Conjugate) Alone and in Combination With MGA012 (Anti-PD-1 Antibody) in Patients With Advanced Solid Tumors	Non Small Cell Lung Cancer; Advanced Solid Tumor, Adult; Metastatic Castrate Resistant Prostate Cancer; Squamous Cell Carcinoma of Head and Neck; Melanoma; Triple Negative Breast Cancer	2010 - Darlinghurst; 4105 - Woolloongabba; 2298 - Waratah; 3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT03729596
NCT03732820	2018-002011-10--D081SC00001	Phase 3		SA, NSW, VIC, QLD	7/11/2018	31/10/2018	Abiraterone; Abiraterone + Olaparib; Olaparib; Placebo	PARP_inhibitor; CYP17A1_inhibitor + PARP_inhibitor; placebo; CYP17A1_inhibitor	Abiraterone + Olaparib; Abiraterone + Olaparib; Placebo	CYP17A1_inhibitor + PARP_inhibitor; CYP17A1_inhibitor + PARP_inhibitor; placebo	2018-002011-10  D081SC00001	A Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study of Olaparib Plus Abiraterone Relative to Placebo Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (PROpel Study)	Metastatic Castration-resistant Prostate Cancer	4029 - Herston; 2747 - Kingswood; 2298 - Waratah; 3021 - St Albans; 4120 - Greenslopes; 3128 - Box Hill; 2010 - Darlinghurst; 5037 - Kurralta Park	https://clinicaltrials.gov/ct2/show/NCT03732820
NCT03735121	BP40657	Phase 1/Phase 2		NZ	8/11/2018	27/12/2018	Atezolizumab; Atezolizumab + Bevacizumab; Atezolizumab + rHuPH20; Bevacizumab; Carboplatin; Paclitaxel; rHuPH20	platinum-based_antineoplastic_agent; recombinant_human_hyaluronidase; anti-PD-L1_monoclonal_antibody + recombinant_human_hyaluronidase; anti-PD-L1_monoclonal_antibody; anti-VEGF_monoclonal_antibody; taxane; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody	Atezolizumab + Bevacizumab; Atezolizumab + rHuPH20; Atezolizumab + Bevacizumab; Atezolizumab + rHuPH20; Carboplatin; Paclitaxel	anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + recombinant_human_hyaluronidase; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + recombinant_human_hyaluronidase; platinum-based_antineoplastic_agent; taxane	BP40657	A Two-Part Phase Ib/II Study to Investigate the Pharmacokinetics, Efficacy, and Safety of Atezolizumab Subcutaneous in Patients With Stage IV Non-Small Cell Lung Cancer	Non-Small Cell Lung Cancer	Christchurch	https://clinicaltrials.gov/ct2/show/NCT03735121
NCT03739710	NCT03739710	Phase 1/Phase 2		NSW, VIC, TAS	9/11/2018	24/01/2019	Docetaxel; Docetaxel + GSK3359609; GSK3359609	anti-ICOS_agonistic_antibody + taxane; taxane; anti-ICOS_agonistic_antibody	Docetaxel; Docetaxel + GSK3359609; Docetaxel + GSK3359609	anti-ICOS_agonistic_antibody + taxane; taxane; anti-ICOS_agonistic_antibody + taxane	205801	A Phase II, Randomized, Open-label Platform Trial Utilizing a Master Protocol to Study Novel Regimens Versus Standard of Care Treatment in NSCLC Participants	Neoplasms	3004 - Melbourne; 3630 - Shepparton; 2250 - Gosford; 3168 - Clayton; 2050 - Camperdown; 3350 - Ballarat; 7000 - Hobart; 2500 - Wollongong; 3199 - Frankston	https://clinicaltrials.gov/ct2/show/NCT03739710
NCT03740165	2018-001973-25--7339-001	Phase 3		NSW, VIC, QLD	14/11/2018	18/12/2018	Bevacizumab; Bevacizumab + Carboplatin + Docetaxel + Olaparib + Paclitaxel + Pembrolizumab; Carboplatin; Docetaxel; Olaparib; Paclitaxel; Pembrolizumab; Placebo	PARP_inhibitor; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; placebo; PARP_inhibitor + anti-PD-1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; anti-VEGF_monoclonal_antibody; taxane	Bevacizumab + Carboplatin + Docetaxel + Olaparib + Paclitaxel + Pembrolizumab; Bevacizumab + Carboplatin + Docetaxel + Olaparib + Paclitaxel + Pembrolizumab; Placebo	PARP_inhibitor + anti-PD-1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; PARP_inhibitor + anti-PD-1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; placebo	2018-001973-25  7339-001	A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (KEYLYNK-001 / ENGOT-ov43 / GOG-3036)	Peritoneal Neoplasms; Ovarian Cancer; Fallopian Tube Cancer	4870 - Cairns; 3168 - Clayton; 2217 - Kogarah; 3021 - St Albans; 3350 - Ballarat	https://clinicaltrials.gov/ct2/show/NCT03740165
NCT03742349	2018-002244-82--CADPT01A12101C	Phase 1		NSW	15/11/2018	31/01/2019	Canakinumab; Canakinumab + Ieramilimab + Spartalizumab; Capmatinib; Capmatinib + Ieramilimab + Spartalizumab; Ieramilimab; Ieramilimab + Lacnotuzumab + Spartalizumab; Ieramilimab + NIR178 + Spartalizumab; Lacnotuzumab; NIR178; Spartalizumab	anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody; adenosine_A2A_receptor_antagonist + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-IL-1beta_monoclonal_antibody + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CSF1_monoclonal_antibody; MET_inhibitor,type_1; anti-CSF1_monoclonal_antibody + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; MET_inhibitor,type_1 + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; adenosine_A2A_receptor_antagonist; anti-IL-1beta_monoclonal_antibody	Canakinumab + Ieramilimab + Spartalizumab; Capmatinib + Ieramilimab + Spartalizumab; Ieramilimab + Lacnotuzumab + Spartalizumab; Ieramilimab + NIR178 + Spartalizumab; Canakinumab + Ieramilimab + Spartalizumab; Capmatinib + Ieramilimab + Spartalizumab; Ieramilimab + Lacnotuzumab + Spartalizumab; Ieramilimab + NIR178 + Spartalizumab	MET_inhibitor,type_1 + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; adenosine_A2A_receptor_antagonist + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CSF1_monoclonal_antibody + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-IL-1beta_monoclonal_antibody + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; MET_inhibitor,type_1 + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; adenosine_A2A_receptor_antagonist + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CSF1_monoclonal_antibody + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-IL-1beta_monoclonal_antibody + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	2018-002244-82  CADPT01A12101C	A Phase Ib, Multicenter, Open-label Dose Escalation and Expansion Platform Study of Select Immunotherapy Combinations in Adult Patients With Triple-negative Breast Cancer	Triple Negative Breast Cancer (TNBC)	2145 - Westmead	https://clinicaltrials.gov/ct2/show/NCT03742349
NCT03742895	MK-7339-002--7339-002	Phase 2		WA, NSW	15/11/2018	12/12/2018	Olaparib	PARP_inhibitor	Olaparib	PARP_inhibitor	MK-7339-002  7339-002	A Phase 2 Study of Olaparib Monotherapy in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer	Advanced Solid Neoplasms	6009 - Nedlands; 2010 - Darlinghurst; 2444 - Port Macquarie	https://clinicaltrials.gov/ct2/show/NCT03742895
NCT03744468	BGB-900-102	Phase 1/Phase 2	NOT_RECRUITING	WA, VIC	16/11/2018	13/11/2018	BGB-A425; BGB-A425 + Tislelizumab; Tislelizumab	anti-PD-1_monoclonal_antibody + anti-TIM3_monoclonal_antibody; anti-TIM3_monoclonal_antibody; anti-PD-1_monoclonal_antibody	BGB-A425 + Tislelizumab; BGB-A425 + Tislelizumab	anti-PD-1_monoclonal_antibody + anti-TIM3_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIM3_monoclonal_antibody	BGB-900-102	Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors	Locally Advanced or Metastatic Solid Tumors for Phase 1 HNSCC, NSCLC and RCC for Phase 2	- Melbourne; - Perth	https://clinicaltrials.gov/ct2/show/NCT03744468
NCT03746431	FPX-01-01	Phase 1		SA, VIC	19/11/2018	17/01/2019	FPI-1175; FPI-1547	IGF1R-radionucleotide_conjugate	FPI-1175; FPI-1547	IGF1R-radionucleotide_conjugate	FPX-01-01	A Phase 1 Study of [225Ac]-FPI-1434 Injection in Patients With Advanced Solid Tumours	Actinium-225; Antineoplastic Agents; Radioimmunoconjugate; Advanced Solid Tumours; Targeted Alpha Therapy	5000 - Adelaide; 3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT03746431
NCT03748134	ORIENT-15	Phase 3		WA, SA, VIC, NSW	20/11/2018	24/12/2018	Cisplatin; Fluorouracil; Paclitaxel; Placebo; Sintilimab	anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; placebo; Fluorouracil; taxane; fluoropyrimidine	Sintilimab; Cisplatin; Fluorouracil; Paclitaxel; Placebo	anti-PD-1_monoclonal_antibody; Fluorouracil; fluoropyrimidine; placebo; platinum-based_antineoplastic_agent; taxane	CIBI308A301	A Multicenter, Double-Blind, Randomized Phase 3 Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo, in Combination With Chemotherapy, for First-Line Treatment of Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)	Esophageal Squamous Cell Carcinoma	3079 - Heidelberg; 5011 - Woodville South; 6009 - Nedlands; 2640 - East Albury; 6008 - Subiaco	https://clinicaltrials.gov/ct2/show/NCT03748134
NCT03748641	MAGNITUDE	Phase 3		QLD, VIC, NSW, SA, TAS, WA	21/11/2018	25/01/2019	Abiraterone; Abiraterone + Niraparib + Prednisone; Niraparib; Niraparib + Prednisone; Placebo; Prednisone	PARP_inhibitor; glucocorticoid; placebo; CYP17A1_inhibitor; CYP17A1_inhibitor + PARP_inhibitor + glucocorticoid; PARP_inhibitor + glucocorticoid	Abiraterone + Niraparib + Prednisone; Niraparib + Prednisone; Abiraterone + Niraparib + Prednisone; Niraparib + Prednisone; Placebo	CYP17A1_inhibitor + PARP_inhibitor + glucocorticoid; PARP_inhibitor + glucocorticoid; CYP17A1_inhibitor + PARP_inhibitor + glucocorticoid; PARP_inhibitor + glucocorticoid; placebo	2017-003364-12  CR108534	A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Metastatic Prostate Cancer	Castration-Resistant Prostatic Cancer	2109 - Macquarie University; 3144 - Malvern; 4102 - Brisbane; 2031 - Randwick; 5116 - Adelaide; 2076 - Wahroonga; 4575 - Birtinya; 6009 - Nedlands; 4217 - Benowa; 6150 - Murdoch; 2500 - Wollongong; 2010 - Darlinghurst; 3000 - Melbourne; 7000 - Hobart	https://clinicaltrials.gov/ct2/show/NCT03748641
NCT03750786	AGENT	Phase 3		NSW, VIC	23/11/2018	18/12/2018	Arfolitixorin; Arfolitixorin + Bevacizumab + Fluorouracil + Oxaliplatin; Bevacizumab; Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin; Fluorouracil; Leucovorin; Oxaliplatin	anti-VEGF_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent + reduced_folate-based_biomodulator; platinum-based_antineoplastic_agent; anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; Fluorouracil; folinic_acid; reduced_folate-based_biomodulator; anti-VEGF_monoclonal_antibody; fluoropyrimidine	Arfolitixorin + Bevacizumab + Fluorouracil + Oxaliplatin; Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin; Arfolitixorin + Bevacizumab + Fluorouracil + Oxaliplatin; Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin	anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; anti-VEGF_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent + reduced_folate-based_biomodulator; Fluorouracil; anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; anti-VEGF_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent + reduced_folate-based_biomodulator	ISO-CC-007	A Randomized, Multicenter, Parallel-group, Phase III Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal Cancer	Colo-rectal Cancer	3168 - Melbourne; 3199 - Frankston; 2500 - Wollongong; 2050 - Sydney; 3021 - Melbourne; 2640 - Albury; 2145 - Sydney; 3076 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT03750786
NCT03755791	COSMIC-312	Phase 3	NOT_RECRUITING	WA, VIC, NSW, QLD, NZ, SA	28/11/2018	10/12/2018	Atezolizumab; Atezolizumab + Cabozantinib; Cabozantinib; Sorafenib	VEGFR2_inhibitor + anti-PD-L1_monoclonal_antibody; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor; RET_inhibitor + anti-PD-L1_monoclonal_antibody; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + anti-PD-L1_monoclonal_antibody; VEGFR2_inhibitor; AXL_inhibitor + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; CRAF_inhibitor; ROS1_inhibitor; FLT3_inhibitor; MET_inhibitor,type_2; VEGFR_inhibitor; AXL_inhibitor; KIT_inhibitor + anti-PD-L1_monoclonal_antibody; PDGFR_inhibitor; RET_inhibitor; ROS1_inhibitor + anti-PD-L1_monoclonal_antibody; MET_inhibitor,type_2 + anti-PD-L1_monoclonal_antibody; KIT_inhibitor; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor	Atezolizumab + Cabozantinib; Sorafenib; Atezolizumab + Cabozantinib	AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + anti-PD-L1_monoclonal_antibody; AXL_inhibitor + anti-PD-L1_monoclonal_antibody; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor; CRAF_inhibitor; FLT3_inhibitor; KIT_inhibitor; KIT_inhibitor + anti-PD-L1_monoclonal_antibody; MET_inhibitor,type_2 + anti-PD-L1_monoclonal_antibody; PDGFR_inhibitor; RET_inhibitor + anti-PD-L1_monoclonal_antibody; ROS1_inhibitor + anti-PD-L1_monoclonal_antibody; VEGFR2_inhibitor + anti-PD-L1_monoclonal_antibody; VEGFR_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + anti-PD-L1_monoclonal_antibody; AXL_inhibitor + anti-PD-L1_monoclonal_antibody; KIT_inhibitor + anti-PD-L1_monoclonal_antibody; MET_inhibitor,type_2 + anti-PD-L1_monoclonal_antibody; RET_inhibitor + anti-PD-L1_monoclonal_antibody; ROS1_inhibitor + anti-PD-L1_monoclonal_antibody; VEGFR2_inhibitor + anti-PD-L1_monoclonal_antibody	XL184-312	A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy	Hepatocellular Carcinoma	6009 - Nedlands; 2747 - Kingswood; Wellington; 3084 - Heidelberg; 3050 - Parkville; 2050 - Camperdown; 2217 - Kogarah; 3128 - Box Hill; 4120 - Greenslopes; 2010 - Darlinghurst; - Kurralta Park; Auckland; 2145 - Westmead	https://clinicaltrials.gov/ct2/show/NCT03755791
NCT03763422	IWOT	Phase 3		NSW, VIC, QLD, TAS, SA, QLDNSW, Brisbane, WA, West-Australi	4/12/2018	16/03/2020	Radiotherapy; Radiotherapy + Temozolomide; Temozolomide	radiotherapy; alkylating_agent; alkylating_agent + radiotherapy	Radiotherapy + Temozolomide; Radiotherapy + Temozolomide	alkylating_agent + radiotherapy; alkylating_agent + radiotherapy	EORTC-BTG-1635	IDH Mutated 1p/19q Intact Lower Grade Glioma Following Resection: Wait Or Treat? IWOT - a Phase III Study	Wait or Treat; Phase III; Low-grade Glioma; Temozolomide	7000 - Hobart; 5000 - Adelaide; 2500 - Wollongong; 3084 - Heidelberg; 2031 - Randwick - Sydney; 3065 - Fitzroy (Melbourne); 6009 - Nedlands; 4102 - Woolloongabba; 3168 - Clayton; 2145 - Westmead	https://clinicaltrials.gov/ct2/show/NCT03763422
NCT03773302	2018-004004-19--QBGJ398-301	Phase 3		WA, NSW, VIC, SA	12/12/2018	27/12/2019	Cisplatin; Cisplatin + Gemcitabine + Infigratinib; Gemcitabine; Infigratinib	platinum-based_antineoplastic_agent; gemcitabine; FGFR1/2/3_inhibitor + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite; FGFR1/2/3_inhibitor	Cisplatin + Gemcitabine + Infigratinib; Infigratinib; Cisplatin + Gemcitabine + Infigratinib	FGFR1/2/3_inhibitor; FGFR1/2/3_inhibitor + antimetabolite + platinum-based_antineoplastic_agent; FGFR1/2/3_inhibitor + antimetabolite + platinum-based_antineoplastic_agent; gemcitabine	2018-004004-19  QBGJ398-301	A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib Versus Gemcitabine With Cisplatin in Subjects With Advanced/Metastatic or Inoperable Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations: The PROOF Trial	FGFR2 Gene Mutation; Advanced Cholangiocarcinoma	- Frankston; - Camperdown; - Adelaide; - Subiaco; - Darlinghurst; - Bentleigh East	https://clinicaltrials.gov/ct2/show/NCT03773302
NCT03776136	LEAP-004	Phase 2		QLD, NSW, VIC, WA	14/12/2018	30/01/2019	Lenvatinib; Lenvatinib + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor	Lenvatinib + Pembrolizumab; Lenvatinib + Pembrolizumab	VEGF_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody	MK-7902-004  7902-004	A Multicenter, Open-label, Phase 2 Trial to Assess the Efficacy and Safety of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Melanoma Previously Exposed to an Anti-PD-1/L1 Agent (LEAP-004)	Advanced Melanoma	3128 - Box Hill; 2065 - Wollstonecraft; 6150 - Perth; 4102 - Woolloongabba; 2480 - Lismore	https://clinicaltrials.gov/ct2/show/NCT03776136
NCT03778931	EMERALD	Phase 3	NOT_RECRUITING	NSW, VIC, QLD	19/12/2018	10/05/2019	Anastrozole; Anastrozole + Exemestane + Fulvestrant + Letrozole; Elacestrant; Exemestane; Fulvestrant; Letrozole	aromatase_inhibitor + selective_estrogen_receptor_degrader; aromatase_inhibitor; selective_estrogen_receptor_degrader	Anastrozole + Exemestane + Fulvestrant + Letrozole; Elacestrant; Anastrozole + Exemestane + Fulvestrant + Letrozole	aromatase_inhibitor + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader; aromatase_inhibitor + selective_estrogen_receptor_degrader	RAD1901-308	Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial	Breast Cancer	3065 - Fitzroy; 4575 - Birtinya; 2560 - Campbelltown	https://clinicaltrials.gov/ct2/show/NCT03778931
NCT03778957	EMERALD-1	Phase 3		VIC, NSW, QLD	19/12/2018	30/11/2018	Bevacizumab; Bevacizumab + Durvalumab; Durvalumab; Placebo	anti-PD-L1_monoclonal_antibody; anti-VEGF_monoclonal_antibody; placebo; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody	Bevacizumab + Durvalumab; Durvalumab; Bevacizumab + Durvalumab; Placebo	anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; placebo	2018-002134-20  D933GC00001	A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination With Either Durvalumab Monotherapy or Durvalumab Plus Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma (EMERALD-1)	Hepatocellular Carcinoma	2145 - Westmead; 3168 - Clayton; 3004 - Melbourne; 3065 - Fitzroy; 2170 - Liverpool; 3128 - Box Hill; 4029 - Herston; 4217 - Benowa; 2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT03778957
NCT03783078	KEYNOTE-913	Phase 3		NZ, NSW	20/12/2018	25/02/2019	Pembrolizumab	anti-PD-1_monoclonal_antibody	Pembrolizumab	anti-PD-1_monoclonal_antibody	MK-3475-913  3475-913	A Phase 3 Open-label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) as First Line Therapy in Participants With Advanced Merkel Cell Carcinoma (KEYNOTE-913)	Merkel Cell Carcinoma	2298 - Waratah; Auckland; 2065 - North Sydney	https://clinicaltrials.gov/ct2/show/NCT03783078
NCT03783403	U1111-1224-8251--CC-95251-ST-001	Phase 1		VIC, NSW	21/12/2018	1/02/2019	CC-95251; CC-95251 + Cetuximab; CC-95251 + Rituximab; Cetuximab; Rituximab	anti-EGFR_monoclonal_antibody; anti-SIRPa_monoclonal_antibody; anti-EGFR_monoclonal_antibody + anti-SIRPa_monoclonal_antibody; anti-CD20_monoclonal_antibody + anti-SIRPa_monoclonal_antibody; anti-CD20_monoclonal_antibody	CC-95251; CC-95251 + Cetuximab; CC-95251 + Rituximab; CC-95251 + Cetuximab; CC-95251 + Rituximab	anti-CD20_monoclonal_antibody + anti-SIRPa_monoclonal_antibody; anti-EGFR_monoclonal_antibody + anti-SIRPa_monoclonal_antibody; anti-SIRPa_monoclonal_antibody; anti-CD20_monoclonal_antibody + anti-SIRPa_monoclonal_antibody; anti-EGFR_monoclonal_antibody + anti-SIRPa_monoclonal_antibody	U1111-1224-8251  CC-95251-ST-001	A Phase 1, Open-Label, Dose Finding Study of CC-95251, A Monoclonal Antibody Directed Against SIRPa, Alone and in Combination With Cetuximab or Rituximab in Subjects With Advanced Solid and Hematologic Cancers	Neoplasms	3000 - Melbourne; 3084 - Heidelberg; 2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT03783403
NCT03783442	2018-000587-28--BGB-A317-306	Phase 3		WA, Pacific HighwayQLD, QLD, NSW, VIC, TAS, SA	21/12/2018	11/12/2018	Capecitabine; Cisplatin; Fluorouracil; Oxaliplatin; Paclitaxel; Placebo; Tislelizumab	anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; placebo; Fluorouracil; taxane; fluoropyrimidine	Tislelizumab; Capecitabine; Cisplatin; Fluorouracil; Oxaliplatin; Paclitaxel; Placebo	anti-PD-1_monoclonal_antibody; Fluorouracil; fluoropyrimidine; placebo; platinum-based_antineoplastic_agent; taxane	2018-000587-28  BGB-A317-306	A Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Efficacy and Safety of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First-Line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma	Esophageal Squamous Cell Carcinoma (ESCC)	4814 - Douglas; 6008 - Kurralta Park; 3065 - Fitzroy; 2450 - Coffs Harbour; 3355 - Wendouree; 7000 - Hobart	https://clinicaltrials.gov/ct2/show/NCT03783442
NCT03785925	PIVOT-10	Phase 2	NOT_RECRUITING	WA, SA, QLD, VIC, NSW	24/12/2018	29/04/2019	Bempegaldesleukin; Bempegaldesleukin + Nivolumab; Cisplatin; Nivolumab	anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; IL-2_variant; IL-2_variant + anti-PD-1_monoclonal_antibody	Bempegaldesleukin + Nivolumab; Bempegaldesleukin + Nivolumab; Cisplatin	IL-2_variant + anti-PD-1_monoclonal_antibody; IL-2_variant + anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent	CA045-012  18-214-10	A Phase 2, Single-Arm Study of Bempegaldesleukin (NKTR-214) in Combination With Nivolumab in Cisplatin Ineligible, Locally Advanced or Metastatic Urothelial Cancer Patients	Neoplasm Metastasis; Urinary Bladder Neoplasm	4215 - Southport; 5037 - Kurralta Park; 2010 - Darlinghurst; 6009 - Nedlands; 3165 - Bentleigh East	https://clinicaltrials.gov/ct2/show/NCT03785925
NCT03786783	NCI-2018-03732--NCI-2018-03732	Phase 2		NSW, VIC, NZ	26/12/2018	14/01/2019	Carboplatin; Cisplatin; Cyclophosphamide; Dexrazoxane; Dinutuximab; Dinutuximab + Sargramostim; Doxorubicin; Etoposide; Isotretinoin; Melphalan; Radiotherapy; Sargramostim; Thiotepa; Topotecan; Vincristine	anti-GD2_monoclonal_antibody; alkylating_agent; doxorubicin; Granulocyte-Macrophage_Colony_Stimulating_Factor; Granulocyte-Macrophage_Colony_Stimulating_Factor + anti-GD2_monoclonal_antibody; 13-cis-retinoic_acid; anthracycline; radiotherapy; platinum-based_antineoplastic_agent; iron_chelator; vinca_alkaloid; topoisomerase_inhibitor	Dinutuximab + Sargramostim; Carboplatin; Cisplatin; Cyclophosphamide; Dexrazoxane; Dinutuximab + Sargramostim; Doxorubicin; Etoposide; Isotretinoin; Melphalan; Radiotherapy; Thiotepa; Topotecan; Vincristine	Granulocyte-Macrophage_Colony_Stimulating_Factor + anti-GD2_monoclonal_antibody; 13-cis-retinoic_acid; Granulocyte-Macrophage_Colony_Stimulating_Factor + anti-GD2_monoclonal_antibody; alkylating_agent; anthracycline; doxorubicin; iron_chelator; platinum-based_antineoplastic_agent; radiotherapy; topoisomerase_inhibitor; vinca_alkaloid	NCI-2018-03732  NCI-2018-03732	A Pilot Induction Regimen Incorporating Chimeric 14.18 Antibody (ch14.18, Dinutuximab) (NSC# 764038) and Sargramostim (GM-CSF) for the Treatment of Newly Diagnosed High-Risk Neuroblastoma	High Risk Neuroblastoma; Ganglioneuroblastoma	3052 - Parkville; Auckland; 2145 - Westmead	https://clinicaltrials.gov/ct2/show/NCT03786783
NCT03787602	KRT-232-103	Phase 1/Phase 2		QLD	26/12/2018	19/03/2019	Avelumab; Avelumab + Navtemadlin; Navtemadlin	anti-PD-L1_monoclonal_antibody; MDM2_inhibitor + anti-PD-L1_monoclonal_antibody; MDM2_inhibitor	Avelumab + Navtemadlin; Navtemadlin; Avelumab + Navtemadlin	MDM2_inhibitor; MDM2_inhibitor + anti-PD-L1_monoclonal_antibody; MDM2_inhibitor + anti-PD-L1_monoclonal_antibody	KRT-232-103	A Phase 1b/2, Open-Label Study Evaluating the Safety and Efficacy of KRT-232 in Patients With p53 Wild-Type (p53WT) Merkel Cell Carcinoma (MCC) Who Have Failed Anti-PD-1 or Anti-PD-L1 Immunotherapy, or in Combination With Avelumab in MCC Patients Who Are Anti-PD-1 or Anti-PD-L1 Treatment Naïve	Merkel Cell Carcinoma	- Woolloongabba	https://clinicaltrials.gov/ct2/show/NCT03787602
NCT03792841	NCT03792841	Phase 1	NOT_RECRUITING	NSW, VIC	3/01/2019	5/02/2019	Pembrolizumab	anti-PD-1_monoclonal_antibody	Pembrolizumab	anti-PD-1_monoclonal_antibody	20180101	A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Prostate Specific Membrane Antigen Half-life Extended Bispecific T-cell Engager Acapatamab in Subjects With Metastatic Castration-resistant Prostate Cancer	Prostate Cancer; Metastatic Castration-resistant Prostate Cancer	3050 - Parkville; 2050 - Camperdown; 2031 - Randwick	https://clinicaltrials.gov/ct2/show/NCT03792841
NCT03797326	LEAP-005	Phase 2	Recruiting	WA, VIC, QLD	9/01/2019	12/02/2019	Lenvatinib; Lenvatinib + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor	Lenvatinib; Lenvatinib + Pembrolizumab; Lenvatinib + Pembrolizumab	VEGF_inhibitor; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody	2018-003747-37  7902-005	A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects With Selected Solid Tumors (LEAP-005)	Advanced Solid Tumors; Colorectal Cancer; Gastric Cancer; Triple Negative Breast Cancer; Glioblastoma; Pancreatic Cancer; Biliary Tract Cancers; Ovarian Cancer	6009 - Nedlands; 4029 - Herston; 3004 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT03797326
NCT03798626	2018-003952-19--CVPM087A2101	Phase 1		SA, South AustrailiaVIC, VIC	10/01/2019	22/05/2019	Bevacizumab; Bevacizumab + Gevokizumab; Cabozantinib; Cabozantinib + Gevokizumab; Gevokizumab; Gevokizumab + Paclitaxel + Ramucirumab; Paclitaxel; Ramucirumab	AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor; AXL_inhibitor + anti-IL-1beta_monoclonal_antibody; VEGFR2_inhibitor; ROS1_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + anti-IL-1beta_monoclonal_antibody; taxane; anti-IL-1beta_monoclonal_antibody + anti-VEGFR2_monoclonal_antibody + taxane; MET_inhibitor,type_2 + anti-IL-1beta_monoclonal_antibody; ROS1_inhibitor + anti-IL-1beta_monoclonal_antibody; MET_inhibitor,type_2; RET_inhibitor + anti-IL-1beta_monoclonal_antibody; AXL_inhibitor; anti-VEGFR2_monoclonal_antibody; RET_inhibitor; KIT_inhibitor + anti-IL-1beta_monoclonal_antibody; anti-VEGF_monoclonal_antibody; VEGFR2_inhibitor + anti-IL-1beta_monoclonal_antibody; KIT_inhibitor; anti-IL-1beta_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-IL-1beta_monoclonal_antibody	Bevacizumab + Gevokizumab; Cabozantinib + Gevokizumab; Gevokizumab + Paclitaxel + Ramucirumab; Bevacizumab + Gevokizumab; Cabozantinib + Gevokizumab; Gevokizumab + Paclitaxel + Ramucirumab	AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + anti-IL-1beta_monoclonal_antibody; AXL_inhibitor + anti-IL-1beta_monoclonal_antibody; KIT_inhibitor + anti-IL-1beta_monoclonal_antibody; MET_inhibitor,type_2 + anti-IL-1beta_monoclonal_antibody; RET_inhibitor + anti-IL-1beta_monoclonal_antibody; ROS1_inhibitor + anti-IL-1beta_monoclonal_antibody; VEGFR2_inhibitor + anti-IL-1beta_monoclonal_antibody; anti-IL-1beta_monoclonal_antibody + anti-VEGFR2_monoclonal_antibody + taxane; anti-IL-1beta_monoclonal_antibody + anti-VEGF_monoclonal_antibody; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + anti-IL-1beta_monoclonal_antibody; AXL_inhibitor + anti-IL-1beta_monoclonal_antibody; KIT_inhibitor + anti-IL-1beta_monoclonal_antibody; MET_inhibitor,type_2 + anti-IL-1beta_monoclonal_antibody; RET_inhibitor + anti-IL-1beta_monoclonal_antibody; ROS1_inhibitor + anti-IL-1beta_monoclonal_antibody; VEGFR2_inhibitor + anti-IL-1beta_monoclonal_antibody; anti-IL-1beta_monoclonal_antibody + anti-VEGFR2_monoclonal_antibody + taxane; anti-IL-1beta_monoclonal_antibody + anti-VEGF_monoclonal_antibody	2018-003952-19  CVPM087A2101	Phase Ib Study of Gevokizumab in Combination With Standard of Care Anti-cancer Therapies in Patients With Metastatic Colorectal Cancer, Gastroesophageal Cancer and Renal Cell Carcinoma	Colorectal Cancer; Renal Cell Carcinoma; Gastroesophageal Cancer	5011 - Woodville; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT03798626
NCT03800836	2017-001957-15--CO40151	Phase 1	NOT_RECRUITING	NSW, VIC	11/01/2019	13/02/2018	Atezolizumab; Atezolizumab + Cyclophosphamide + Doxorubicin + Ipatasertib + Paclitaxel; Atezolizumab + Ipatasertib; Atezolizumab + Ipatasertib + Nab-paclitaxel; Atezolizumab + Ipatasertib + Paclitaxel; Cyclophosphamide; Doxorubicin; Ipatasertib; Nab-paclitaxel; Paclitaxel	alkylating_agent; doxorubicin; anti-PD-L1_monoclonal_antibody + pan-AKT_inhibitor + taxane; pan-AKT_inhibitor; anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + pan-AKT_inhibitor; alkylating_agent + anthracycline + anti-PD-L1_monoclonal_antibody + pan-AKT_inhibitor + taxane; taxane	Atezolizumab + Cyclophosphamide + Doxorubicin + Ipatasertib + Paclitaxel; Atezolizumab + Ipatasertib; Atezolizumab + Ipatasertib + Nab-paclitaxel; Atezolizumab + Ipatasertib + Paclitaxel; Atezolizumab + Cyclophosphamide + Doxorubicin + Ipatasertib + Paclitaxel; Atezolizumab + Ipatasertib; Atezolizumab + Ipatasertib + Nab-paclitaxel; Atezolizumab + Ipatasertib + Paclitaxel	alkylating_agent + anthracycline + anti-PD-L1_monoclonal_antibody + pan-AKT_inhibitor + taxane; anti-PD-L1_monoclonal_antibody + pan-AKT_inhibitor; anti-PD-L1_monoclonal_antibody + pan-AKT_inhibitor + taxane; alkylating_agent + anthracycline + anti-PD-L1_monoclonal_antibody + pan-AKT_inhibitor + taxane; anti-PD-L1_monoclonal_antibody + pan-AKT_inhibitor; anti-PD-L1_monoclonal_antibody + pan-AKT_inhibitor + taxane; doxorubicin	2017-001957-15  CO40151	A Phase Ib, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer	Breast Cancer	3002 - East Melbourne; 3084 - Heidelberg; 2010 - Darlinghurst	https://clinicaltrials.gov/ct2/show/NCT03800836
NCT03811652	D8540C00002	Phase 1	NOT_RECRUITING	VIC	21/01/2019	20/12/2018	Abiraterone; Abiraterone + Enzalutamide; Capecitabine; Capecitabine + Fluorouracil + Irinotecan + Oxaliplatin + Raltitrexed + Tegafur; Enzalutamide; Fluorouracil; Irinotecan; MEDI7247; Oxaliplatin; Raltitrexed; Tegafur	platinum-based_antineoplastic_agent; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor; antimetabolite; antimetabolite + fluoropyrimidine + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-ASCT2_antibody-drug_conjugate; antiandrogen,nonsteroidal,second_generation; Fluorouracil; topoisomerase_inhibitor; fluoropyrimidine	Abiraterone + Enzalutamide; Capecitabine + Fluorouracil + Irinotecan + Oxaliplatin + Raltitrexed + Tegafur; Abiraterone + Enzalutamide; Capecitabine + Fluorouracil + Irinotecan + Oxaliplatin + Raltitrexed + Tegafur; MEDI7247	CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation; antimetabolite + fluoropyrimidine + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation; Fluorouracil; anti-ASCT2_antibody-drug_conjugate; antimetabolite + fluoropyrimidine + platinum-based_antineoplastic_agent + topoisomerase_inhibitor	D8540C00002	A Phase 1/1b Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI7247 in Patients With Advanced or Metastatic Disease in Selected Solid Tumors	Head and Neck Squamous Cell Carcinoma (HNSCC); Colorectal Cancer (CRC); Non Small Cell Lung Cancer Squamous (NSCLC-Sq); Pancreatic Ductal Adenocarcinoma (PDAC); Small Cell Lung Cancer (SCLC); Metastatic Castration-resistant Prostate Cancer (mCRPC)	3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT03811652
NCT03815058	IMCODE001	Phase 2		SA, VIC, NSW, WA	24/01/2019	8/01/2019	Pembrolizumab; Pembrolizumab + RO7198457; RO7198457	anti-PD-1_monoclonal_antibody; personalized_cancer_vaccine; anti-PD-1_monoclonal_antibody + personalized_cancer_vaccine	Pembrolizumab + RO7198457; Pembrolizumab + RO7198457	anti-PD-1_monoclonal_antibody + personalized_cancer_vaccine; anti-PD-1_monoclonal_antibody + personalized_cancer_vaccine	2018-001773-24  GO40558	A Phase II, Open-Label, Multicenter, Randomized Study Of The Efficacy And Safety Of RO7198457 In Combination With Pembrolizumab Versus Pembrolizumab In Patients With Previously Untreated Advanced Melanoma	Advanced Melanoma	2170 - Liverpool; 6008 - Subiaco; 3000 - Melbourne; 5011 - Woodville South; 3181 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT03815058
NCT03815643	2018-003711-21--MS100070-0176	Phase 3		VIC	24/01/2019	22/03/2019	Avelumab	anti-PD-L1_monoclonal_antibody	Avelumab	anti-PD-L1_monoclonal_antibody	2018-003711-21  MS100070_0176	An Open-Label, Multicenter Follow-up Study to Collect Long-term Data on Participants From Multiple Avelumab (MSB0010718C) Clinical Studies	Solid Tumors	- Ballarat; - Clayton	https://clinicaltrials.gov/ct2/show/NCT03815643
NCT03816163	2018-002551-15--8951-CL-5201	Phase 2		NSW, VIC, SA	25/01/2019	15/03/2019	Gemcitabine; Gemcitabine + Nab-paclitaxel; Gemcitabine + Nab-paclitaxel + Zolbetuximab; Nab-paclitaxel; Zolbetuximab	anti-CLDN18.2_monoclonal_antibody; antimetabolite; gemcitabine; taxane; antimetabolite + taxane; anti-CLDN18.2_monoclonal_antibody + antimetabolite + taxane	Gemcitabine + Nab-paclitaxel; Gemcitabine + Nab-paclitaxel + Zolbetuximab; Gemcitabine + Nab-paclitaxel; Gemcitabine + Nab-paclitaxel + Zolbetuximab	anti-CLDN18.2_monoclonal_antibody + antimetabolite + taxane; antimetabolite + taxane; anti-CLDN18.2_monoclonal_antibody + antimetabolite + taxane; antimetabolite + taxane; gemcitabine	2018-002551-15  8951-CL-5201	A Phase 2, Open-Label, Randomized Study to Assess the Efficacy and Safety of Zolbetuximab (IMAB362) in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma	Metastatic Pancreatic Cancer; Metastatic Pancreatic Adenocarcinoma; Pancreatic Cancer	NSW 2250 - Gosford; 5XRF+WX - Fitzroy; HVGM+3C - Wollongong; 5006 - North Adelaide; VIC 3280 - Warrnambool	https://clinicaltrials.gov/ct2/show/NCT03816163
NCT03820986	LEAP-003	Phase 3		QLD, VIC, NSW, WA, ACT	29/01/2019	12/03/2019	Lenvatinib; Lenvatinib + Pembrolizumab; Pembrolizumab; Placebo	anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; placebo; VEGF_inhibitor	Lenvatinib + Pembrolizumab; Lenvatinib + Pembrolizumab; Placebo	VEGF_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; placebo	2018-002520-16  7902-003	A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) and Lenvatinib (E7080/MK-7902) Versus Pembrolizumab Alone as First-line Intervention in Participants With Advanced Melanoma (LEAP-003)	Malignant Melanoma	2145 - Westmead; 4102 - Wooloongabba; 2060 - North Sydney; 2480 - Lismore; 6150 - Murdoch; 3128 - Box Hill	https://clinicaltrials.gov/ct2/show/NCT03820986
NCT03821233	ZWI-ZW49-101	Phase 1		SA	29/01/2019	15/04/2019	ZW49	anti-ERBB2_antibody-drug_conjugate	ZW49	anti-ERBB2_antibody-drug_conjugate	ZWI-ZW49-101	A Phase 1 Study of ZW49 in Patients With Locally Advanced (Unresectable) or Metastatic HER2-Expressing Cancers	HER2-expressing Cancers	5042 - Adelaide	https://clinicaltrials.gov/ct2/show/NCT03821233
NCT03821935	2018-004303-40--M19-345	Phase 1		NSW, QLD	30/01/2019	21/02/2019	ABBV-151; ABBV-151 + Budigalimab; Budigalimab	anti-GARP_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-GARP_monoclonal_antibody + anti-PD-1_monoclonal_antibody	ABBV-151; ABBV-151 + Budigalimab; ABBV-151 + Budigalimab	anti-GARP_monoclonal_antibody; anti-GARP_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-GARP_monoclonal_antibody + anti-PD-1_monoclonal_antibody	2018-004303-40  M19-345	A Phase 1 First-in Human, Multi-Center, Open Label Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Subjects With Locally Advanced or Metastatic Solid Tumors	Advanced Solid Tumors Cancer	4101 - South Brisbane; 2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT03821935
NCT03829319	LEAP-006	Phase 3	NOT_RECRUITING	NZ, QLD, NSW, VIC	4/02/2019	25/03/2019	Carboplatin; Carboplatin + Cisplatin + Lenvatinib + Pembrolizumab + Pemetrexed; Cisplatin; Lenvatinib; Pembrolizumab; Pemetrexed; Placebo	anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; placebo; antimetabolite; VEGF_inhibitor; VEGF_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent	Carboplatin + Cisplatin + Lenvatinib + Pembrolizumab + Pemetrexed; Carboplatin + Cisplatin + Lenvatinib + Pembrolizumab + Pemetrexed; Placebo	VEGF_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; VEGF_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; placebo	2018-003824-35  7902-006	A Phase 3 Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First-line Intervention in Participants With Metastatic Nonsquamous Non-small Cell Lung Cancer (LEAP-006)	Nonsquamous Non-small Cell Lung Cancer	Auckland; 4870 - Cairns; 2050 - Sydney; 3350 - Ballarat; 2444 - Port Macquarie; 2145 - Sydney; 2148 - Blacktown; 4032 - Chermside	https://clinicaltrials.gov/ct2/show/NCT03829319
NCT03829332	LEAP-007	Phase 3	NOT_RECRUITING	WA, QLD, NSW, VIC	4/02/2019	13/03/2019	Lenvatinib; Lenvatinib + Pembrolizumab; Pembrolizumab; Placebo	anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; placebo; VEGF_inhibitor	Lenvatinib + Pembrolizumab; Lenvatinib + Pembrolizumab; Placebo	VEGF_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; placebo	MK-7902-007  7902-007	A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) in Participants With Treatment-naïve, Metastatic Nonsmall Cell Lung Cancer (NSCLC) Whose Tumors Have a Tumor Proportion Score (TPS) Greater Than or Equal to 1% (LEAP-007)	Non-small Cell Lung Cancer	3355 - Wendouree; 2800 - Orange; 6150 - Perth; 4032 - Chermside; 2500 - Wollongong	https://clinicaltrials.gov/ct2/show/NCT03829332
NCT03833154	PACIFIC-4	Phase 3		VIC	6/02/2019	6/03/2019	Durvalumab; Osimertinib; Placebo; Radiotherapy	EGFR_inhibitor,third_generation; anti-PD-L1_monoclonal_antibody; radiotherapy; placebo	Durvalumab; Osimertinib; Placebo; Radiotherapy	EGFR_inhibitor,third_generation; anti-PD-L1_monoclonal_antibody; placebo; radiotherapy	2018-002572-41  D9103C00001	A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab With Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients With Unresected Stage I/II, Lymph-node Negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515) Osimertinib Following SBRT, a Single Arm Cohort for Patients With Unresected Stage I/II, Lymph Node Negative NSCLC Harboring a Sensitizing EGFR Mutation	Carcinoma, Non-Small-Cell Lung	3168 - Clayton	https://clinicaltrials.gov/ct2/show/NCT03833154
NCT03834220	2018-003584-53--Debio-1347-201	Phase 2		QLD, NSW, VIC, WA	7/02/2019	1/03/2019	Debio1347	FGFR1/2/3_inhibitor	Debio1347	FGFR1/2/3_inhibitor	2018-003584-53  Debio 1347-201	A Phase II Basket Study of the Oral Selective Pan-FGFR Inhibitor Debio 1347 in Subjects With Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3	Solid Tumor	6009 - Nedlands; 3199 - Frankston; NSW 2576 - Bowral; 4224 - Tugun	https://clinicaltrials.gov/ct2/show/NCT03834220
NCT03834493	KEYNOTE-641	Phase 3		WA, SA, NZ, QLD, NSW, VIC	8/02/2019	28/07/2019	Enzalutamide; Enzalutamide + Pembrolizumab; Pembrolizumab; Placebo	antiandrogen,nonsteroidal,second_generation; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation; placebo	Enzalutamide; Enzalutamide + Pembrolizumab; Enzalutamide + Pembrolizumab; Placebo	anti-PD-1_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation; antiandrogen,nonsteroidal,second_generation; anti-PD-1_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation; placebo	2018-004117-40  3475-641	A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641)	Prostatic Neoplasms	Auckland; 2109 - Macquarie University; 3168 - Clayton; Canterbury; 6150 - Perth; 4120 - Greenslopes; 2010 - Darlinghurst; 2444 - Port Macquarie; 2298 - Waratah; 5000 - Adelaide; 2217 - Kogarah; 4215 - Southport	https://clinicaltrials.gov/ct2/show/NCT03834493
NCT03834506	KEYNOTE-921	Phase 3		WA, NSW, QLD	8/02/2019	2/05/2019	Dexamethasone; Dexamethasone + Docetaxel + Pembrolizumab + Prednisone; Dexamethasone + Docetaxel + Prednisone; Docetaxel; Pembrolizumab; Placebo; Prednisone	anti-PD-1_monoclonal_antibody + glucocorticoid + taxane; glucocorticoid; anti-PD-1_monoclonal_antibody; placebo; glucocorticoid + taxane; taxane	Dexamethasone + Docetaxel + Pembrolizumab + Prednisone; Dexamethasone + Docetaxel + Prednisone; Dexamethasone + Docetaxel + Pembrolizumab + Prednisone; Dexamethasone + Docetaxel + Prednisone; Placebo	anti-PD-1_monoclonal_antibody + glucocorticoid + taxane; glucocorticoid + taxane; anti-PD-1_monoclonal_antibody + glucocorticoid + taxane; glucocorticoid + taxane; placebo	2018-004116-22  3475-921	A Phase 3, Randomized, Double-blind Study of Pembrolizumab (MK-3475) Plus Docetaxel Plus Prednisone Versus Placebo Plus Docetaxel Plus Prednisone in Participants With Chemotherapy-naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Progressed on a Next Generation Hormonal Agent (NHA) (KEYNOTE-921)	Prostatic Neoplasms	2109 - Macquarie University; 4224 - Tugun; 6009 - Nedlands; 2217 - Kogarah; 2444 - Port Macquarie; 2298 - Waratah; 4020 - Redcliffe	https://clinicaltrials.gov/ct2/show/NCT03834506
NCT03834519	KEYLYNK-010	Phase 3	NOT_RECRUITING	QLD, NSW, VIC, NZ, WA	8/02/2019	2/05/2019	Abiraterone; Abiraterone + Enzalutamide + Prednisone; Enzalutamide; Olaparib; Olaparib + Pembrolizumab; Pembrolizumab; Prednisone	PARP_inhibitor; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + glucocorticoid; glucocorticoid; anti-PD-1_monoclonal_antibody; CYP17A1_inhibitor; antiandrogen,nonsteroidal,second_generation; PARP_inhibitor + anti-PD-1_monoclonal_antibody	Abiraterone + Enzalutamide + Prednisone; Olaparib + Pembrolizumab; Abiraterone + Enzalutamide + Prednisone; Olaparib + Pembrolizumab	CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + glucocorticoid; PARP_inhibitor + anti-PD-1_monoclonal_antibody; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + glucocorticoid; PARP_inhibitor + anti-PD-1_monoclonal_antibody	2018-004118-16  7339-010	A Phase 3, Randomized Open-label Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Who Are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment With One Next-generation Hormonal Agent (NHA) and Chemotherapy (KEYLYNK-010)	Prostatic Neoplasms	4224 - Tugun; 2109 - Macquarie University; Auckland; 2500 - Wollongong; 2298 - Waratah; 2444 - Port Macquarie; 3000 - Melbourne; 2010 - Darlinghurst; 3128 - Box Hill; 4029 - Herston; 6150 - Murdoch	https://clinicaltrials.gov/ct2/show/NCT03834519
NCT03840200	BO40933	Phase 1/Phase 2	NOT_RECRUITING	VIC, NSW	15/02/2019	11/06/2019	Abiraterone; Abiraterone + Apalutamide + Enzalutamide + Ipatasertib + Rucaparib; Apalutamide; Enzalutamide; Ipatasertib; Ipatasertib + Rucaparib; Rucaparib	PARP_inhibitor; CYP17A1_inhibitor + PARP_inhibitor + antiandrogen,nonsteroidal,second_generation + pan-AKT_inhibitor; PARP_inhibitor + pan-AKT_inhibitor; CYP17A1_inhibitor; pan-AKT_inhibitor; antiandrogen,nonsteroidal,second_generation	Abiraterone + Apalutamide + Enzalutamide + Ipatasertib + Rucaparib; Ipatasertib + Rucaparib; Abiraterone + Apalutamide + Enzalutamide + Ipatasertib + Rucaparib; Ipatasertib + Rucaparib	CYP17A1_inhibitor + PARP_inhibitor + antiandrogen,nonsteroidal,second_generation + pan-AKT_inhibitor; PARP_inhibitor + pan-AKT_inhibitor; CYP17A1_inhibitor + PARP_inhibitor + antiandrogen,nonsteroidal,second_generation + pan-AKT_inhibitor; PARP_inhibitor + pan-AKT_inhibitor	BO40933	A Phase Ib, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Ipatasertib in Combination With Rucaparib in Patients With Advanced Breast, Ovarian, or Prostate Cancer	Prostate Cancer; Breast Cancer; Ovarian Cancer	3144 - Malvern; 2010 - Darlinghurst; 2109 - Macquarie Park	https://clinicaltrials.gov/ct2/show/NCT03840200
NCT03840902	2018-003265-34--MS200647-0005	Phase 2		SA, NSW, VIC, QLD	15/02/2019	16/04/2019	Bintrafusp Alfa; Bintrafusp Alfa + Carboplatin + Cisplatin + Durvalumab + Etoposide + Paclitaxel + Pemetrexed + Radiotherapy; Bintrafusp Alfa + Carboplatin + Cisplatin + Etoposide + Paclitaxel + Pemetrexed + Radiotherapy; Carboplatin; Cisplatin; Durvalumab; Etoposide; Paclitaxel; Pemetrexed; Placebo; Radiotherapy	radiotherapy; platinum-based_antineoplastic_agent; anti-PD-L1/TGF-beta_fusion_protein; placebo; antimetabolite; anti-PD-L1_monoclonal_antibody; anti-PD-L1/TGF-beta_fusion_protein + antimetabolite + platinum-based_antineoplastic_agent + radiotherapy + taxane + topoisomerase_inhibitor; taxane; anti-PD-L1/TGF-beta_fusion_protein + anti-PD-L1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + radiotherapy + taxane + topoisomerase_inhibitor; topoisomerase_inhibitor	Bintrafusp Alfa + Carboplatin + Cisplatin + Durvalumab + Etoposide + Paclitaxel + Pemetrexed + Radiotherapy; Bintrafusp Alfa + Carboplatin + Cisplatin + Etoposide + Paclitaxel + Pemetrexed + Radiotherapy; Bintrafusp Alfa + Carboplatin + Cisplatin + Durvalumab + Etoposide + Paclitaxel + Pemetrexed + Radiotherapy; Bintrafusp Alfa + Carboplatin + Cisplatin + Etoposide + Paclitaxel + Pemetrexed + Radiotherapy; Placebo	anti-PD-L1/TGF-beta_fusion_protein + anti-PD-L1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + radiotherapy + taxane + topoisomerase_inhibitor; anti-PD-L1/TGF-beta_fusion_protein + antimetabolite + platinum-based_antineoplastic_agent + radiotherapy + taxane + topoisomerase_inhibitor; anti-PD-L1/TGF-beta_fusion_protein + anti-PD-L1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + radiotherapy + taxane + topoisomerase_inhibitor; anti-PD-L1/TGF-beta_fusion_protein + antimetabolite + platinum-based_antineoplastic_agent + radiotherapy + taxane + topoisomerase_inhibitor; placebo	2018-003265-34  MS200647_0005	A Multicenter, Double Blind, Randomized, Controlled Study of M7824 With Concurrent Chemoradiation Followed by M7824 Versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants With Unresectable Stage III Non-small Cell Lung Cancer	Non-small Cell Lung Cancer	- Bendigo; - Heidelberg Heights; - St Leonards; - Pergamino; - Randwick; - St Albans; - Douglas; - Elizabeth Vale; - Warrnambool; - Fitzroy; - Geelong	https://clinicaltrials.gov/ct2/show/NCT03840902
NCT03843359	GSK3745417-208850	Phase 1		VIC	18/02/2019	12/03/2019	Dostarlimab; Dostarlimab + GSK3745417; GSK3745417	anti-PD-1_monoclonal_antibody; STING_agonist; STING_agonist + anti-PD-1_monoclonal_antibody	Dostarlimab + GSK3745417; GSK3745417; Dostarlimab + GSK3745417	STING_agonist; STING_agonist + anti-PD-1_monoclonal_antibody; STING_agonist + anti-PD-1_monoclonal_antibody	208850	A Phase I First Time in Human Open Label Study of GSK3745417 Administered With and Without Anticancer Agents in Participants With Advanced Solid Tumors	Neoplasms	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT03843359
NCT03844048	2018-004356-38--M19-388	Phase 3		WA, VIC, NSW, NZ	18/02/2019	6/09/2019	Venetoclax	Bcl2_inhibitor	Venetoclax	Bcl2_inhibitor	2018-004356-38  M19-388	An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial	Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Multiple Myeloma; Non-Hodgkin's Lymphoma; Chronic Lymphocytic Leukemia; Cancer	2170 - Liverpool; Auckland; 2050 - Camperdown; 6150 - Murdoch; 6009 - Nedlands; Wellington; 2010 - Darlinghurst; 3000 - Melbourne; 2217 - Kogarah	https://clinicaltrials.gov/ct2/show/NCT03844048
NCT03845166	STELLAR-001	Phase 1		NSW	19/02/2019	20/03/2019	Atezolizumab; Atezolizumab + Zanzalintinib; Avelumab; Avelumab + Zanzalintinib; Zanzalintinib	anti-PD-L1_monoclonal_antibody; MET/VEGFR2/AXL/MER_inhibitor; MET/VEGFR2/AXL/MER_inhibitor + anti-PD-L1_monoclonal_antibody	Atezolizumab + Zanzalintinib; Avelumab + Zanzalintinib; Zanzalintinib; Atezolizumab + Zanzalintinib; Avelumab + Zanzalintinib	MET/VEGFR2/AXL/MER_inhibitor; MET/VEGFR2/AXL/MER_inhibitor + anti-PD-L1_monoclonal_antibody; MET/VEGFR2/AXL/MER_inhibitor + anti-PD-L1_monoclonal_antibody	XL092-001	A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects With Inoperable Locally Advanced or Metastatic Solid Tumors	Metastatic Castration-resistant Prostate Cancer; Neoplasm Malignant; Renal Cell Carcinoma; Colorectal Cancer; Urothelial Carcinoma; Hormone Receptor Positive Breast Carcinoma	2010 - Darlinghurst; 2170 - Liverpool	https://clinicaltrials.gov/ct2/show/NCT03845166
NCT03850795	HC1119-CS-03	Phase 3		SA, WA	22/02/2019	15/03/2021	Enzalutamide	antiandrogen,nonsteroidal,second_generation	Enzalutamide	antiandrogen,nonsteroidal,second_generation	HC1119-CS-03	PROCADE: A Multinational Phase 3, Randomized, Double-Blind, Non-inferiority, Efficacy and Safety Study of Oral HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)	Prostate Cancer Metastatic; Castration-resistant Prostate Cancer	5037 - Kurralta Park; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT03850795
NCT03851146	LeY-CAR-T	Phase 1	NOT_RECRUITING	VIC	22/02/2019	24/11/2016	LeY-CAR-T	autologous_CAR-T-cell_therapy,LeY-targeting	LeY-CAR-T	autologous_CAR-T-cell_therapy,LeY-targeting	ACTRN12616001580460  LeYPh1-02	A Phase I Investigation of the Safety, Tolerability and Immunological Effects of T Lymphocytes Transduced With an Anti-Lewis Y (LeY) Chimeric Antigen Receptor Gene (LeY-CAR-T) in Patients With LeY Antigen Expressing Advanced Solid Tumours	Advanced Cancer	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT03851146
NCT03853109	NCT03853109	Phase 1		SA, NSW	25/02/2019	5/03/2019	AMG 404	anti-PD-1_monoclonal_antibody	AMG 404	anti-PD-1_monoclonal_antibody	20180143	A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 404, a Programmed Death-1 (PD-1) Antibody, in Patients With Advanced Solid Tumors	Advanced Solid Tumors	5011 - Woodville South; 2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT03853109
NCT03856099	PMC-TTAC-0001-03	Phase 2		VIC	27/02/2019	13/11/2019	Bevacizumab; Olinvacimab	anti-VEGFR2_monoclonal_antibody; anti-VEGF_monoclonal_antibody	Olinvacimab; Bevacizumab	anti-VEGFR2_monoclonal_antibody; anti-VEGF_monoclonal_antibody	PMC_TTAC-0001_03	A Multicenter, Open-Label, Phase ? Clinical Trial to Evaluate the Safety and Efficacy of TTAC-0001, a Fully Human Monoclonal Antibody in Patients With Recurrent Glioblastoma Progressed on Bevacizumab Including Therapy	Recurrent Glioblastoma	3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT03856099
NCT03858972	CONTESSA-2	Phase 2	NOT_RECRUITING	NSW	1/03/2019	5/02/2019	Capecitabine; Capecitabine + Tesetaxel; Tesetaxel	fluoropyrimidine + taxane; taxane; fluoropyrimidine	Capecitabine + Tesetaxel; Capecitabine + Tesetaxel	fluoropyrimidine + taxane; fluoropyrimidine + taxane	ODO-TE-B201	Multinational, Multicenter, Phase 2 Study of Tesetaxel Plus a Reduced Dose of Capecitabine in Patients With HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Received a Taxane	Breast Cancer	2640 - Albury	https://clinicaltrials.gov/ct2/show/NCT03858972
NCT03869892	SOLSTICE	Phase 3	NOT_RECRUITING	VIC, NSW	11/03/2019	21/03/2019	Bevacizumab; Bevacizumab + Capecitabine; Capecitabine; Trifluridine/Tipiracil	Tipiracil Hydrochloride; Trifluridine; antimetabolite; thymidine_phosphorylase_inhibitor; anti-VEGF_monoclonal_antibody + fluoropyrimidine; anti-VEGF_monoclonal_antibody; fluoropyrimidine	Bevacizumab; Bevacizumab + Capecitabine; Bevacizumab + Capecitabine; Trifluridine/Tipiracil	anti-VEGF_monoclonal_antibody; anti-VEGF_monoclonal_antibody + fluoropyrimidine; Tipiracil Hydrochloride; Trifluridine; anti-VEGF_monoclonal_antibody + fluoropyrimidine; antimetabolite; thymidine_phosphorylase_inhibitor	2017-004059-22  CL3-95005-006	An Open-label, Randomised, Phase III Study cOmparing trifLuridine/Tipiracil (S 95005) in Combination With Bevacizumab to Capecitabine in Combination With Bevacizumab in firST-line Treatment of Patients With metastatIC Colorectal Cancer Who Are Not candidatE for Intensive Therapy (SOLSTICE Study)	Metastatic Colorectal Cancer	2148 - Blacktown; 2217 - Kogarah; 2500 - Wollongong; 3199 - Frankston; 2290 - Gateshead; 2076 - Wahroonga	https://clinicaltrials.gov/ct2/show/NCT03869892
NCT03873493	2018-002179-17--M18-803	Phase 2		VIC	13/03/2019	14/01/2020	Ibrutinib; Ibrutinib + Venetoclax; Venetoclax	BTK_inhibitor + Bcl2_inhibitor; BTK_inhibitor; Bcl2_inhibitor	Ibrutinib + Venetoclax; Ibrutinib + Venetoclax	BTK_inhibitor + Bcl2_inhibitor; BTK_inhibitor + Bcl2_inhibitor	2018-002179-17  M18-803	A Prospective, Open-Label, Single-Arm, Phase 2, Multicenter Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Subjects With T-Cell Prolymphocytic Leukemia	T-cell Prolymphocytic Leukemia (T-PLL); Cancer; Leukemia	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT03873493
NCT03874884	LuPARP	Phase 1		NSW, VIC	14/03/2019	9/07/2019	Lu-177 vipivotide tetraxetan; Lu-177 vipivotide tetraxetan + Olaparib; Olaparib	PARP_inhibitor; radioligand,PSMA-targeting; PARP_inhibitor + radioligand,PSMA-targeting	Lu-177 vipivotide tetraxetan + Olaparib; Lu-177 vipivotide tetraxetan + Olaparib	PARP_inhibitor + radioligand,PSMA-targeting; PARP_inhibitor + radioligand,PSMA-targeting	Peter Mac project no.18/216	177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer	Metastatic Castration Resistant Prostate Cancer (mCRPC)	3000 - Melbourne; 2010 - Sydney	https://clinicaltrials.gov/ct2/show/NCT03874884
NCT03875079	2018-003872-11--BP41054	Phase 1	NOT_RECRUITING	NSW, VIC	14/03/2019	24/06/2019	Pembrolizumab; Pembrolizumab + RO-6874281; RO-6874281	anti-PD-1_monoclonal_antibody; anti-FAP/interleukin-2_fusion_protein; anti-FAP/interleukin-2_fusion_protein + anti-PD-1_monoclonal_antibody	Pembrolizumab + RO-6874281; Pembrolizumab + RO-6874281	anti-FAP/interleukin-2_fusion_protein + anti-PD-1_monoclonal_antibody; anti-FAP/interleukin-2_fusion_protein + anti-PD-1_monoclonal_antibody	2018-003872-11  BP41054	An Open-Label, Multicenter, Phase Ib Study To Evaluate Safety And Therapeutic Activity Of RO6874281, An Immunocytokine, Consisting Of Interleukin-2 Variant (IL-2v) Targeting Fibroblast Activation Protein-? (FAP), In Combination With Pembrolizumab (Anti-PD-1), In Participants With Advanced Or Metastatic Melanoma	Metastatic Melanoma	3000 - Melbourne; 2060 - North Sydney	https://clinicaltrials.gov/ct2/show/NCT03875079
NCT03878719	C4221011--ARRAY-162-115	Phase 1	NOT_RECRUITING	NZ, VIC, NSW	18/03/2019	13/08/2020	Binimetinib; Binimetinib + Encorafenib; Encorafenib	MEK_inhibitor; BRAF_V600_inhibitor + MEK_inhibitor; BRAF_V600_inhibitor	Binimetinib + Encorafenib; Binimetinib + Encorafenib	BRAF_V600_inhibitor + MEK_inhibitor; BRAF_V600_inhibitor + MEK_inhibitor	C4221011  ARRAY-162-115	A Multicenter, Open-label Phase 1b Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma	Melanoma	2031 - Sydney; 3168 - Clayton; 2145 - Westmead; Wellington	https://clinicaltrials.gov/ct2/show/NCT03878719
NCT03884101	LEAP-001	Phase 3		WA, NSW, VIC, QLD	21/03/2019	11/04/2019	Carboplatin; Carboplatin + Paclitaxel; Lenvatinib; Lenvatinib + Pembrolizumab; Paclitaxel; Pembrolizumab	anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent + taxane; VEGF_inhibitor; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; taxane	Carboplatin + Paclitaxel; Lenvatinib + Pembrolizumab; Carboplatin + Paclitaxel; Lenvatinib + Pembrolizumab	VEGF_inhibitor + anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent + taxane; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent + taxane	2018-003009-24  7902-001	A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma (LEAP-001)	Endometrial Neoplasms	3002 - Melbourne; 2031 - Randwick; 3168 - Clayton; 2145 - Westmead; 2065 - St Leonards; 4101 - South Brisbane; 2050 - Camperdown; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT03884101
NCT03893955	2019-000478-45--M19-037	Phase 1		QLD	28/03/2019	21/05/2019	ABBV-927; ABBV-927 + Budigalimab; ABBV-927 + Budigalimab + Carboplatin; ABBV-927 + Carboplatin; ABBV-927 + Nab-paclitaxel; Budigalimab; Carboplatin; Nab-paclitaxel	anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; anti-CD40_agonistic_antibody + platinum-based_antineoplastic_agent; anti-CD40_agonistic_antibody + anti-PD-1_monoclonal_antibody; anti-CD40_agonistic_antibody; taxane; anti-CD40_agonistic_antibody + taxane; anti-CD40_agonistic_antibody + anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent	ABBV-927; ABBV-927 + Budigalimab; ABBV-927 + Budigalimab + Carboplatin; ABBV-927 + Carboplatin; ABBV-927 + Nab-paclitaxel; ABBV-927 + Budigalimab; ABBV-927 + Budigalimab + Carboplatin; ABBV-927 + Carboplatin; ABBV-927 + Nab-paclitaxel	anti-CD40_agonistic_antibody; anti-CD40_agonistic_antibody + anti-PD-1_monoclonal_antibody; anti-CD40_agonistic_antibody + anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent; anti-CD40_agonistic_antibody + platinum-based_antineoplastic_agent; anti-CD40_agonistic_antibody + taxane; anti-CD40_agonistic_antibody + anti-PD-1_monoclonal_antibody; anti-CD40_agonistic_antibody + anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent; anti-CD40_agonistic_antibody + platinum-based_antineoplastic_agent; anti-CD40_agonistic_antibody + taxane	2019-000478-45  M19-037	A Phase 1, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Combinations of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Subjects With Locally Advanced or Metastatic Solid Tumors	Advanced Solid Tumors; Cancer; Metastatic Solid Tumors; Non-small-cell-lung-cancer (NSCLC); Triple-Negative Breast Cancer (TNBC)	4101 - South Brisbane	https://clinicaltrials.gov/ct2/show/NCT03893955
NCT03898180	LEAP-011	Phase 3		QLD, NSW, VIC	1/04/2019	6/05/2019	Cisplatin; Lenvatinib; Lenvatinib + Pembrolizumab; Pembrolizumab; Placebo	anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; placebo; VEGF_inhibitor	Lenvatinib + Pembrolizumab; Pembrolizumab; Cisplatin; Lenvatinib + Pembrolizumab; Placebo	VEGF_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; placebo; platinum-based_antineoplastic_agent	2018-003752-21  7902-011	A Phase 3, Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Lenvatinib (E7080/MK-7902) Versus Pembrolizumab and Placebo as First Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma in Cisplatin-ineligible Participants Whose Tumors Express PD-L1, and in Participants Ineligible for Any Platinum-containing Chemotherapy Regardless of PD-L1 Expression (LEAP-011)	Urothelial Carcinoma	3168 - Clayton; 4101 - South Brisbane; 2109 - North Ryde; 3199 - Frankston; 3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT03898180
NCT03900442	PTX-100-PD-012017	Phase 1	UNKNOWN_STATUS	VIC	3/04/2019	1/09/2019	PTX-100	geranylgeranyl_transferase_inhibitor	PTX-100	geranylgeranyl_transferase_inhibitor	PTX-100-PD-012017	Phase 1 Pharmacodynamic and Pharmacokinetic Study of the Geranylgeranyltransferase I Inhibitor PTX-100 (GGTI-2418) in Patients With Advanced Malignancies	Advanced Cancer	3121 - Melbourne; 3199 - Frankston	https://clinicaltrials.gov/ct2/show/NCT03900442
NCT03900884	PALVEN	Phase 1		VIC	3/04/2019	25/09/2019	Letrozole; Letrozole + Palbociclib + Venetoclax; Palbociclib; Venetoclax	aromatase_inhibitor; Bcl2_inhibitor; CDK4/6_inhibitor; Bcl2_inhibitor + CDK4/6_inhibitor + aromatase_inhibitor	Letrozole + Palbociclib + Venetoclax; Letrozole + Palbociclib + Venetoclax	Bcl2_inhibitor + CDK4/6_inhibitor + aromatase_inhibitor; Bcl2_inhibitor + CDK4/6_inhibitor + aromatase_inhibitor	18/028	A Phase 1b Study of Palbociclib, Letrozole and Venetoclax in ER and BCL-2 Positive Locally Advanced or Metastatic Breast Cancer	Breast Neoplasm Female	3084 - Melbourne; 3000 - Melbourne; 3052 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT03900884
NCT03901950	XNW7201-1-02	Phase 1		QLD	3/04/2019	1/07/2019	XNW7201	PORCN_inhibitor	XNW7201	PORCN_inhibitor	XNW7201-1-02	A Phrase I, Open-label, Multi-center, Non-randomized, Does Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of XNW7201 in Subjects With Advanced Solid Tumors	Advanced Solid Tumors	4101 - South Brisbane	https://clinicaltrials.gov/ct2/show/NCT03901950
NCT03905148	BGB-283-PD-0325901-AU-001	Phase 1/Phase 2		WA, VIC, NSW	5/04/2019	1/05/2019	Lifirafenib; Lifirafenib + Mirdametinib; Mirdametinib	EGFR/RAF_dimer_inhibitor; MEK_inhibitor; EGFR/RAF_dimer_inhibitor + MEK_inhibitor	Lifirafenib + Mirdametinib; Lifirafenib + Mirdametinib	EGFR/RAF_dimer_inhibitor + MEK_inhibitor; EGFR/RAF_dimer_inhibitor + MEK_inhibitor	BGB-283/PD-0325901-AU-001	A Phase 1b, Open-Label, Dose-escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activities of a RAF Dimer Inhibitor BGB-283 in Combination With MEK Inhibitor PD-0325901 in Patients With Advanced or Refractory Solid Tumors	Solid Tumor, Adult	2031 - Randwick; 3000 - Melbourne; 2148 - Blacktown; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT03905148
NCT03906331	Selpercatinib-EAP--17494			WA, QLD, VIC, NSW, NZ	8/04/2019		Selpercatinib	RET_inhibitor	Selpercatinib	RET_inhibitor	Selpercatinib EAP  17494	Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation	Non Small Cell Lung Cancer; Pancreatic Cancer; Breast Cancer; Medullary Thyroid Cancer; Colon Cancer; Other Solid Tumors With Evidence of Activating RET Alteration; Papillary Thyroid Cancer	Auckland; 3000 - Melbourne; 4032 - Chermside; 6009 - Nedlands; 2065 - St. Leonards; 2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT03906331
NCT03918278	MK-0482-001--0482-001	Phase 1		NSW, VIC	17/04/2019	19/06/2019	Carboplatin; Carboplatin + MK-0482 + Pembrolizumab + Pemetrexed; Gemcitabine; Gemcitabine + MK-0482 + Nab-paclitaxel + Pembrolizumab; MK-0482; MK-0482 + Paclitaxel + Pembrolizumab; MK-0482 + Pembrolizumab; Nab-paclitaxel; Paclitaxel; Pembrolizumab; Pemetrexed	anti-ILT3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + taxane; anti-ILT3_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-ILT3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; anti-ILT3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + taxane; antimetabolite; gemcitabine; taxane; anti-ILT3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent	Carboplatin + MK-0482 + Pembrolizumab + Pemetrexed; Gemcitabine + MK-0482 + Nab-paclitaxel + Pembrolizumab; MK-0482; MK-0482 + Paclitaxel + Pembrolizumab; MK-0482 + Pembrolizumab; Carboplatin + MK-0482 + Pembrolizumab + Pemetrexed; Gemcitabine + MK-0482 + Nab-paclitaxel + Pembrolizumab; MK-0482 + Paclitaxel + Pembrolizumab; MK-0482 + Pembrolizumab	anti-ILT3_monoclonal_antibody; anti-ILT3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-ILT3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-ILT3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + taxane; anti-ILT3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + taxane; anti-ILT3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-ILT3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-ILT3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + taxane; anti-ILT3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + taxane; gemcitabine	MK-0482-001  0482-001	A Phase 1b, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-0482 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors.	Neoplasms	3004 - Melbourne; 2109 - Macquarie University	https://clinicaltrials.gov/ct2/show/NCT03918278
NCT03933761	PRECISE	Phase 2		QLD, VIC, NSW, WA	1/05/2019	29/07/2019	Pamiparib	PARP_inhibitor	Pamiparib	PARP_inhibitor	ANZGOG 1721/2018	A Phase II, Signal-Seeking Trial of the Clinical Benefit Rate Associated With Pamiparib in Subjects With Germline or Somatic BRCA1/2 High Grade Serous Ovarian Cancer or Carcinosarcoma Who Have Progressed on P-gp Substrate Chemotherapy or PARPi With the Presence of an ABCB1 Fusion and the Absence of a BRCA1/2 Reversion	Ovarian Cancer; Carcinosarcoma	2031 - Randwick; 3168 - Clayton; - Brisbane; 2298 - Waratah; 3000 - Melbourne; 2560 - Campbelltown; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT03933761
NCT03936959	J1E-MC-JZEA--17101	Phase 1	NOT_RECRUITING	NSW	3/05/2019	24/05/2019	LY3434172	bispecific_PD-1/PD-L1_antibody	LY3434172	bispecific_PD-1/PD-L1_antibody	J1E-MC-JZEA  17101	A Phase 1 Study of LY3434172, a Bispecific Antibody Monotherapy in Advanced Solid Tumors	Advanced Cancer	2010 - Sydney	https://clinicaltrials.gov/ct2/show/NCT03936959
NCT03937219	COSMIC-313	Phase 3		WA, SA, NZ, QLD, NSW, VIC	3/05/2019	25/06/2019	Cabozantinib; Cabozantinib + Ipilimumab + Nivolumab; Ipilimumab; Nivolumab; Placebo	anti-CTLA-4_monoclonal_antibody; KIT_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; placebo; VEGFR2_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor; VEGFR2_inhibitor; ROS1_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; ROS1_inhibitor; MET_inhibitor,type_2 + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; RET_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; MET_inhibitor,type_2; AXL_inhibitor; RET_inhibitor; KIT_inhibitor; AXL_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Cabozantinib + Ipilimumab + Nivolumab; Cabozantinib + Ipilimumab + Nivolumab; Placebo	AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; AXL_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; KIT_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; MET_inhibitor,type_2 + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; RET_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; ROS1_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; VEGFR2_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; AXL_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; KIT_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; MET_inhibitor,type_2 + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; RET_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; ROS1_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; VEGFR2_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; placebo	XL184-313	A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination With Nivolumab and Ipilimumab Versus Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk	Renal Cell Carcinoma	4102 - Woolloongabba; 2031 - Randwick; 6008 - Subiaco; 4101 - South Brisbane; 3350 - Ballarat; 3128 - Box Hill; 2109 - North Ryde; 2217 - Kogarah; 2065 - Sydney; 5006 - North Adelaide; 5000 - Adelaide; Waikato; 2640 - Albury; Wellington	https://clinicaltrials.gov/ct2/show/NCT03937219
NCT03947385	IDE196-001	Phase 1/Phase 2		NSW	13/05/2019	28/06/2019	Binimetinib; Binimetinib + Darovasertib; Crizotinib; Crizotinib + Darovasertib; Darovasertib	ALK_inhibitor,first_generation; PKC_inhibitor + ROS1_inhibitor; PKC_inhibitor; MET_inhibitor,type_1; ROS1_inhibitor; MEK_inhibitor; ALK_inhibitor,first_generation + PKC_inhibitor; MET_inhibitor,type_1 + PKC_inhibitor; MEK_inhibitor + PKC_inhibitor	Binimetinib; Binimetinib + Darovasertib; Crizotinib; Crizotinib + Darovasertib; Darovasertib; Binimetinib + Darovasertib; Crizotinib + Darovasertib	ALK_inhibitor,first_generation; ALK_inhibitor,first_generation + PKC_inhibitor; MEK_inhibitor; MEK_inhibitor + PKC_inhibitor; MET_inhibitor,type_1; MET_inhibitor,type_1 + PKC_inhibitor; PKC_inhibitor; PKC_inhibitor + ROS1_inhibitor; ROS1_inhibitor; ALK_inhibitor,first_generation + PKC_inhibitor; MEK_inhibitor + PKC_inhibitor; MET_inhibitor,type_1 + PKC_inhibitor; PKC_inhibitor + ROS1_inhibitor	IDE196-001	A Phase 1/2 Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions	Other Solid Tumors; Cutaneous Melanoma; Metastatic Uveal Melanoma; Colorectal Cancer	- Sydney	https://clinicaltrials.gov/ct2/show/NCT03947385
NCT03948763	V941-001--V941-001	Phase 1	NOT_RECRUITING	NSW, VIC, SA, NZ	14/05/2019	26/06/2019	Pembrolizumab; Pembrolizumab + mRNA-5671; mRNA-5671	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + mRNA_personalised_cancer_vaccine,KRAS-targeting; mRNA_personalised_cancer_vaccine,KRAS-targeting	Pembrolizumab + mRNA-5671; mRNA-5671; Pembrolizumab + mRNA-5671	anti-PD-1_monoclonal_antibody + mRNA_personalised_cancer_vaccine,KRAS-targeting; mRNA_personalised_cancer_vaccine,KRAS-targeting; anti-PD-1_monoclonal_antibody + mRNA_personalised_cancer_vaccine,KRAS-targeting	V941-001  V941-001	A Phase 1, Open-Label, Multicenter Study to Assess the Safety and Tolerability of mRNA-5671/V941 as a Monotherapy and in Combination With Pembrolizumab in Participants With KRAS Mutant Advanced or Metastatic Non-Small Cell Lung Cancer, Colorectal Cancer or Pancreatic Adenocarcinoma	Neoplasms; Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms	Canterbury; 5042 - Bedford Park; 2010 - Darlinghurst; Auckland; 3168 - Clayton	https://clinicaltrials.gov/ct2/show/NCT03948763
NCT03964233	2019-001173-84--1403-0002	Phase 1		WA	28/05/2019	11/06/2019	BI 754111; BI 754111 + Brigimadlin + Ezabenlimab; Brigimadlin; Brigimadlin + Ezabenlimab; Ezabenlimab	anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody; MDM2_inhibitor; MDM2_inhibitor + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; MDM2_inhibitor + anti-PD-1_monoclonal_antibody	BI 754111 + Brigimadlin + Ezabenlimab; Brigimadlin + Ezabenlimab; BI 754111 + Brigimadlin + Ezabenlimab; Brigimadlin + Ezabenlimab	MDM2_inhibitor + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; MDM2_inhibitor + anti-PD-1_monoclonal_antibody; MDM2_inhibitor + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; MDM2_inhibitor + anti-PD-1_monoclonal_antibody	2019-001173-84  1403-0002	A Phase Ia/Ib, Open Label, Dose-escalation Study of the Combination of BI 907828 With BI 754091 (Ezabenlimab) and BI 754111 and the Combination of BI 907828 With BI 754091(Ezabenlimab) Followed by Expansion Cohorts, in Patients With Advanced Solid Tumors	Neoplasms	6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT03964233
NCT03964727	TROPiCS-03	Phase 2	NOT_RECRUITING	NSW, QLD	28/05/2019	15/10/2019	Sacituzumab Govitecan	anti-Trop2_antibody-drug_conjugate	Sacituzumab Govitecan	anti-Trop2_antibody-drug_conjugate	IMMU-132-11	A Phase 2 Open-Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects With Metastatic Solid Tumors	Metastatic Solid Tumor	2298 - Waratah; 4217 - Benowa; 2145 - Westmead	https://clinicaltrials.gov/ct2/show/NCT03964727
NCT03974022	DZ2019E0001	Phase 1/Phase 2		WA, VIC, NSW	4/06/2019	9/07/2019	Sunvozertinib	EGFR_inhibitor,exon_20_selective; ERBB2_inhibitor,exon_20_selective	Sunvozertinib	EGFR_inhibitor,exon_20_selective; ERBB2_inhibitor,exon_20_selective	DZ2019E0001	A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of DZD9008 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With EGFR or HER2 Mutation	NonSmall Cell Lung Cancer	- Heidelberg; - Blacktown; - Perth; - Wollongong; - North Melbourne; - Kogarah	https://clinicaltrials.gov/ct2/show/NCT03974022
NCT03975647	SGNTUC-016	Phase 3		WA, Othe, NSW, VIC	5/06/2019	2/10/2019	Placebo; Trastuzumab Emtansine; Trastuzumab Emtansine + Tucatinib; Tucatinib	ERBB2_inhibitor,third_generation + anti-ERBB2_antibody-drug_conjugate; ERBB2_inhibitor,third_generation; placebo; anti-ERBB2_antibody-drug_conjugate	Trastuzumab Emtansine; Trastuzumab Emtansine + Tucatinib; Placebo; Trastuzumab Emtansine + Tucatinib	ERBB2_inhibitor,third_generation + anti-ERBB2_antibody-drug_conjugate; anti-ERBB2_antibody-drug_conjugate; ERBB2_inhibitor,third_generation + anti-ERBB2_antibody-drug_conjugate; placebo	SGNTUC-016	Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)	HER2-positive Breast Cancer	2145 - Westmead; 6009 - Nedlands; 2060 - Sydney; 3084 - Melbourne; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT03975647
NCT03976323	MK-7339-006--7339-006	Phase 3	NOT_RECRUITING	NZ, VIC, NSW, QLD	6/06/2019	28/06/2019	Carboplatin; Cisplatin; Olaparib; Olaparib + Pembrolizumab + Pemetrexed; Pembrolizumab; Pembrolizumab + Pemetrexed; Pemetrexed	PARP_inhibitor; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; PARP_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite; antimetabolite; anti-PD-1_monoclonal_antibody + antimetabolite	Olaparib + Pembrolizumab + Pemetrexed; Pembrolizumab + Pemetrexed; Carboplatin; Cisplatin; Olaparib + Pembrolizumab + Pemetrexed; Pembrolizumab + Pemetrexed	PARP_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite; anti-PD-1_monoclonal_antibody + antimetabolite; PARP_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite; anti-PD-1_monoclonal_antibody + antimetabolite; platinum-based_antineoplastic_agent	MK-7339-006  7339-006	A Phase 3 Study of Pembrolizumab in Combination With Pemetrexed/Platinum (Carboplatin or Cisplatin) Followed by Pembrolizumab and Maintenance Olaparib vs Maintenance Pemetrexed in the First-Line Treatment of Participants With Metastatic Nonsquamous Non-Small-Cell Lung Cancer	Carcinoma, Non-squamous Non-small-cell Lung	Manawatu-Wanganui; 2500 - Wollongong; 4814 - Townsville; Wellington; 3168 - Clayton; 2170 - Liverpool	https://clinicaltrials.gov/ct2/show/NCT03976323
NCT03976362	2018-004721-88--7339-008	Phase 3		QLD, NSW, VIC, NZ	6/06/2019	28/06/2019	Carboplatin; Carboplatin + Olaparib + Pembrolizumab; Nab-paclitaxel; Olaparib; Paclitaxel; Pembrolizumab; Placebo	PARP_inhibitor; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; PARP_inhibitor + anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent; placebo; taxane	Carboplatin + Olaparib + Pembrolizumab; Carboplatin + Olaparib + Pembrolizumab; Nab-paclitaxel; Placebo	PARP_inhibitor + anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent; PARP_inhibitor + anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent; placebo; taxane	2018-004721-88  7339-008	A Phase 3 Study of Pembrolizumab in Combination With Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab With or Without Maintenance Olaparib in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)	Carcinoma, Squamous Cell, Non-small-cell Lung	2500 - Wollongong; Manawatu-Wanganui; Wellington; 4814 - Townsville; 3168 - Clayton; 2170 - Liverpool	https://clinicaltrials.gov/ct2/show/NCT03976362
NCT03976375	LEAP-008	Phase 3		QLD, NSW, VIC, SA	6/06/2019	26/06/2019	Docetaxel; Lenvatinib; Lenvatinib + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; taxane; VEGF_inhibitor	Docetaxel; Lenvatinib; Lenvatinib + Pembrolizumab; Lenvatinib + Pembrolizumab	VEGF_inhibitor; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; taxane; VEGF_inhibitor + anti-PD-1_monoclonal_antibody	MK-7902-008  7902-008	A Phase 3, Multicenter, Randomized, Open-label Trial to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Lenvatinib (E7080/MK-7902) Versus Docetaxel in Previously Treated Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (LEAP-008)	Metastatic Non-Small Cell Lung Cancer	2148 - Blacktown; 2444 - Port Macquarie; 2500 - Wollongong; 5112 - Elizabeth Vale; 2145 - Westmead; 3552 - Bendigo; 4102 - Woolloongabba	https://clinicaltrials.gov/ct2/show/NCT03976375
NCT03980314	2018-002993-38--CA209-8FC	Phase 1/Phase 2		NSW, NZ	10/06/2019	24/06/2019	Nivolumab	anti-PD-1_monoclonal_antibody	Nivolumab	anti-PD-1_monoclonal_antibody	2018-002993-38  CA209-8FC	A Randomized, Double-Blind, Parallel, Phase 1 Study to Compare the Pharmacokinetics of BMSCHO1-Nivolumab Process D to Nivolumab Process C After Complete Resection of Stage IIIa/b/c/d or Stage IV Melanoma	Melanoma	Christchurch; Auckland; Wellington; 2065 - Wollstonecraft	https://clinicaltrials.gov/ct2/show/NCT03980314
NCT03994393	ILLUMINATE	Phase 2		NSW, VIC, QLD, SA, TAS	21/06/2019	23/10/2018	Durvalumab; Tremelimumab	anti-PD-L1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody	Durvalumab; Tremelimumab	anti-CTLA-4_monoclonal_antibody; anti-PD-L1_monoclonal_antibody	ALTG 16/009  CTC 0209	A Phase 2 Trial of Durvalumab (MEDI4736) and Tremelimumab With Chemotherapy in Metastatic EGFR Mutant Non-squamous Non-small Cell Lung Cancer (NSCLC) Following Progression on EGFR Tyrosine Kinase Inhibitors (TKIs)	EGFR Mutant Advanced Non Small Cell Lung Cancer	- Melbourne; - Gosford; - Chermside; - Liverpool; - Kogarah; - Hobart; - Bankstown; - Clayton; - Bedford Park; - Woolloongabba	https://clinicaltrials.gov/ct2/show/NCT03994393
NCT03995472	SHR-1501-I-101	Phase 1		QLD, NSW	24/06/2019	14/02/2020	SHR-1316; SHR-1316 + SHR-1501; SHR-1501	anti-IL-15_agonistic_antibody + anti-PD-L1_monoclonal_antibody; anti-IL-15_agonistic_antibody; anti-PD-L1_monoclonal_antibody	SHR-1316 + SHR-1501; SHR-1316 + SHR-1501	anti-IL-15_agonistic_antibody + anti-PD-L1_monoclonal_antibody; anti-IL-15_agonistic_antibody + anti-PD-L1_monoclonal_antibody	SHR-1501-I-101	A Phase I Clinical Study to Evaluate the Tolerability, Safety, Pharmacokinetics and Efficacy of SHR-1501 in Combination With SHR-1316 in Patients With Advanced Malignancies	Advanced Malignancies	2170 - Liverpool; 4101 - South Brisbane; 2031 - Randwick; 4224 - Tugun	https://clinicaltrials.gov/ct2/show/NCT03995472
NCT04000529	CTNO155B12101	Phase 1		NSW	27/06/2019	30/07/2019	Ribociclib; Ribociclib + TNO155; Spartalizumab; Spartalizumab + TNO155; TNO155	SHP2_inhibitor + anti-PD-1_monoclonal_antibody; SHP2_inhibitor; anti-PD-1_monoclonal_antibody; CDK4/6_inhibitor + SHP2_inhibitor; CDK4/6_inhibitor	Ribociclib + TNO155; Spartalizumab + TNO155; Ribociclib + TNO155; Spartalizumab + TNO155	CDK4/6_inhibitor + SHP2_inhibitor; SHP2_inhibitor + anti-PD-1_monoclonal_antibody; CDK4/6_inhibitor + SHP2_inhibitor; SHP2_inhibitor + anti-PD-1_monoclonal_antibody	CTNO155B12101	A Phase Ib, Open-label, Multi-center Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies	Non-small Cell Lung Carcinoma; Esophageal SCC; Gastrointestinal Stromal Tumors; Head and Neck Squamous Cell Carcinoma; Colorectal Cancer	2145 - Westmead	https://clinicaltrials.gov/ct2/show/NCT04000529
NCT04003636	KEYNOTE-966	Phase 3		NZ, NSW, VIC, QLD	1/07/2019	24/09/2019	Cisplatin; Cisplatin + Gemcitabine + Pembrolizumab; Gemcitabine; Pembrolizumab; Placebo	anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; placebo; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite; gemcitabine	Cisplatin + Gemcitabine + Pembrolizumab; Cisplatin + Gemcitabine + Pembrolizumab; Placebo	anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; gemcitabine; placebo	2019-000944-82  3475-966	A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants With Advanced and/or Unresectable Biliary Tract Carcinoma	Biliary Tract Carcinoma	2170 - Liverpool; Auckland; 3128 - Box Hill; 3021 - St Albans; 2444 - Port Macquarie; 4120 - Brisbane	https://clinicaltrials.gov/ct2/show/NCT04003636
NCT04008030	CheckMate-8HW	Phase 3		SA, VIC, NSW, QLD	5/07/2019	29/07/2019	Bevacizumab; Cetuximab; Fluorouracil; Ipilimumab; Ipilimumab + Nivolumab; Irinotecan; Leucovorin; Nivolumab; Oxaliplatin	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; Fluorouracil; folinic_acid; anti-VEGF_monoclonal_antibody; anti-EGFR_monoclonal_antibody; topoisomerase_inhibitor; fluoropyrimidine	Ipilimumab + Nivolumab; Nivolumab; Bevacizumab; Cetuximab; Fluorouracil; Ipilimumab + Nivolumab; Irinotecan; Leucovorin; Oxaliplatin	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; Fluorouracil; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-EGFR_monoclonal_antibody; anti-VEGF_monoclonal_antibody; fluoropyrimidine; folinic_acid; platinum-based_antineoplastic_agent; topoisomerase_inhibitor	2018-000040-26  CA209-8HW	A Phase 3 Randomized Clinical Trial of Nivolumab Alone, Nivolumab in Combination With Ipilimumab, or an Investigator's Choice Chemotherapy in Participants With Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic Colorectal Cancer	Metastatic Colorectal Cancer	5112 - Elizabeth Vale; 2145 - Westmead; 3168 - Clayton; 4102 - Woolloongabba; 3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT04008030
NCT04025307	bacTRL-IL-12-001	Phase 1		VIC	18/07/2019	5/08/2019	bacTRL-IL-12	bifidobacterium-delivered_IL-12	bacTRL-IL-12	bifidobacterium-delivered_IL-12	bacTRL-IL-12-001	A Multi-centre, Open-label, Phase I Trial of bacTRL-IL-12 in Adult Subjects With Advanced, Treatment-refractory Solid Tumours	Cancer - Solid Tumours	- Melbourne	https://clinicaltrials.gov/ct2/show/NCT04025307
NCT04026412	CheckMate73L	Phase 3		WA, VIC, NSW, QLD, SA	19/07/2019	8/10/2019	Durvalumab; Ipilimumab; Ipilimumab + Nivolumab; Nivolumab; Radiotherapy	anti-PD-L1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody; radiotherapy; anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Durvalumab; Ipilimumab + Nivolumab; Nivolumab; Ipilimumab + Nivolumab; Radiotherapy	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; radiotherapy	2019-001222-98  CA209-73L	A Phase 3, Randomized, Open Label Study to Compare Nivolumab Plus Concurrent Chemoradiotherapy (CCRT) Followed by Nivolumab Plus Ipilimumab or Nivolumab Plus CCRT Followed by Nivolumab vs CCRT Followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC)	Non-Small Cell Lung Cancer (NSCLC)	3004 - Melbourne; 2250 - Gosford; 2747 - Kingswood; 3199 - Melbourne; 6150 - Murdoch; 5000 - Adelaide; 2444 - Port Macquarie; 2010 - Darlinghurst; 4120 - Greenslopes; 3350 - Ballarat	https://clinicaltrials.gov/ct2/show/NCT04026412
NCT04029922	MT-5111	Phase 1/Phase 2		VIC, NSW, SA, NZ	23/07/2019	12/11/2019	MT-5111	anti-ERBB2_engineered_toxin_body	MT-5111	anti-ERBB2_engineered_toxin_body	MT-5111_001	A Phase 1 Open-label, Multicenter Dose Escalation and Expansion Study of MT-5111 in Subjects With Previously Treated Advanced HER2-positive Solid Tumors	HER2-positive Solid Cancers	5000 - Adelaide; 2109 - Macquarie; 3630 - Shepparton; 3021 - Saint Albans; 2576 - Bowral; Christchurch	https://clinicaltrials.gov/ct2/show/NCT04029922
NCT04032704	SGNLVA-005	Phase 2		QLD, VIC, NSW, SA, Othe, TAS	25/07/2019	9/10/2019	Ladiratuzumab Vedotin	anti-LIV1_antibody-drug_conjugate	Ladiratuzumab Vedotin	anti-LIV1_antibody-drug_conjugate	SGNLVA-005	Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors	Gastroesophageal Junction Adenocarcinoma; Gastric Adenocarcinoma; Non-small Cell Lung Cancer, Non-squamous; Melanoma; Head and Neck Squamous Cell Carcinoma; Esophageal Squamous Cell Carcinoma; Prostate Cancer; Small Cell Lung Cancer; Non-small Cell Lung Cancer, Squamous	7000 - Hobart; 5042 - Bedford Park; 3199 - Frankston; 2010 - Sydney; 3144 - Malvern; 4814 - Douglas; 2250 - Gosford	https://clinicaltrials.gov/ct2/show/NCT04032704
NCT04035434	CRSP-ONC-001	Phase 1		NSW, VIC	29/07/2019	22/07/2019	CTX110	allogeneic_CAR-T-cell_therapy,CD19-targeting	CTX110	allogeneic_CAR-T-cell_therapy,CD19-targeting	CRSP-ONC-001	A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Allogeneic CRISPR-Cas9-Engineered T Cells (CTX110) in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)	Adult B Cell ALL; B-cell Lymphoma; B-cell Malignancy; Non-Hodgkin Lymphoma	3000 - Melbourne; 2050 - Sydney	https://clinicaltrials.gov/ct2/show/NCT04035434
NCT04035473	KX-ORAX-002	Phase 1		VIC, NZ	29/07/2019	1/08/2015	Oraxol; Oraxol + Paclitaxel; Paclitaxel	taxane	Oraxol + Paclitaxel; Oraxol + Paclitaxel	taxane	KX-ORAX-002	A Randomized Crossover Study to Determine the Bioequivalence of Three Consecutive Daily Doses of Oraxol in Cancer Patients Treated With Intravenous Paclitaxel	Solid Tumor	Auckland; Wellington; Dunedin; - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04035473
NCT04035486	FLAURA2	Phase 3		SA, QLD, VIC, NSW	29/07/2019	2/07/2019	Carboplatin; Carboplatin + Cisplatin + Osimertinib + Pemetrexed; Cisplatin; Osimertinib; Pemetrexed	EGFR_inhibitor,third_generation; platinum-based_antineoplastic_agent; antimetabolite; EGFR_inhibitor,third_generation + antimetabolite + platinum-based_antineoplastic_agent	Carboplatin + Cisplatin + Osimertinib + Pemetrexed; Osimertinib; Carboplatin + Cisplatin + Osimertinib + Pemetrexed	EGFR_inhibitor,third_generation; EGFR_inhibitor,third_generation + antimetabolite + platinum-based_antineoplastic_agent; EGFR_inhibitor,third_generation + antimetabolite + platinum-based_antineoplastic_agent	D5169C00001	A Phase III, Open-label, Randomized Study of Osimertinib With or Without Platinum Plus Pemetrexed Chemo, as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAURA2).	Non-Small Cell Lung Cancer	5112 - Elizabeth Vale; 2050 - Camperdown; 3084 - Heidelberg; 4032 - Chermside; 3000 - Melbourne; 2217 - Kogarah	https://clinicaltrials.gov/ct2/show/NCT04035486
NCT04039607	CheckMate-9DW	Phase 3		VIC, NSW, QLD, NZ, SA	31/07/2019	30/09/2019	Ipilimumab; Ipilimumab + Nivolumab; Lenvatinib; Lenvatinib + Sorafenib; Nivolumab; Sorafenib	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor + VEGF_inhibitor; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; PDGFR_inhibitor + VEGF_inhibitor; VEGF_inhibitor; CRAF_inhibitor; CRAF_inhibitor + VEGF_inhibitor; VEGFR_inhibitor + VEGF_inhibitor; KIT_inhibitor + VEGF_inhibitor; FLT3_inhibitor; FLT3_inhibitor + VEGF_inhibitor; VEGFR_inhibitor; PDGFR_inhibitor; KIT_inhibitor; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor	Ipilimumab + Nivolumab; Lenvatinib + Sorafenib; Ipilimumab + Nivolumab; Lenvatinib + Sorafenib	CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor + VEGF_inhibitor; CRAF_inhibitor + VEGF_inhibitor; FLT3_inhibitor + VEGF_inhibitor; KIT_inhibitor + VEGF_inhibitor; PDGFR_inhibitor + VEGF_inhibitor; VEGFR_inhibitor + VEGF_inhibitor; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor + VEGF_inhibitor; CRAF_inhibitor + VEGF_inhibitor; FLT3_inhibitor + VEGF_inhibitor; KIT_inhibitor + VEGF_inhibitor; PDGFR_inhibitor + VEGF_inhibitor; VEGFR_inhibitor + VEGF_inhibitor; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	CA209-9DW	A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination With Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants With Advanced Hepatocellular Carcinoma	Hepatocellular Carcinoma	3021 - St Albans; 2217 - Kogarah; 5000 - Adelaide; 4029 - Herston; 2152 - Northmead; 3168 - Clayton; 2170 - Liverpool; 3065 - Fitzroy; Christchurch; 4560 - Birtinya; Auckland; 3004 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04039607
NCT04045613	FIDES-02	Phase 1/Phase 2		NZ, QLD, VIC, NSW	5/08/2019	25/07/2019	Atezolizumab; Atezolizumab + Derazantinib; Derazantinib	anti-PD-L1_monoclonal_antibody; FGFR1/2/3_inhibitor + anti-PD-L1_monoclonal_antibody; FGFR1/2/3_inhibitor	Atezolizumab + Derazantinib; Derazantinib; Atezolizumab + Derazantinib	FGFR1/2/3_inhibitor; FGFR1/2/3_inhibitor + anti-PD-L1_monoclonal_antibody; FGFR1/2/3_inhibitor + anti-PD-L1_monoclonal_antibody	2019-000359-15  DZB-CS-201	An Open-label Multi-cohort Phase 1b/2 Study of Derazantinib and Atezolizumab in Patients With Urothelial Cancer Expressing Activating Molecular FGFR Aberrations	Urothelial Carcinoma	3355 - Wendouree; 4575 - Birtinya; 2145 - Westmead; 4224 - Tugun; Hamilton; 2065 - Canberra	https://clinicaltrials.gov/ct2/show/NCT04045613
NCT04047290	AK112-101	Phase 1		SA, NSW, VIC, QLD	6/08/2019		Ivonescimab	bispecific_PD-1/VEGF_monoclonal_antibody	Ivonescimab	bispecific_PD-1/VEGF_monoclonal_antibody	AK112-101	A Phase 1a/1b, Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK112 in Subjects With Advanced Solid Tumors	Neoplasms Malignant	2031 - Randwick; 3168 - Clayton; 4101 - South Brisbane; 5037 - Kurralta Park	https://clinicaltrials.gov/ct2/show/NCT04047290
NCT04047862	BGB-900-105	Phase 1		WA, QLD, VIC, NSW, SA, NZ, TAS	7/08/2019	26/08/2019	Capecitabine; Capecitabine + Cisplatin + Fluorouracil + Ociperlimab + Tislelizumab; Carboplatin; Cisplatin; Cisplatin + Fluorouracil + Ociperlimab + Paclitaxel + Tislelizumab; Etoposide; Etoposide + Ociperlimab + Tislelizumab; Fluorouracil; Nab-paclitaxel; Nab-paclitaxel + Ociperlimab + Paclitaxel + Tislelizumab; Ociperlimab; Ociperlimab + Pemetrexed + Tislelizumab; Ociperlimab + Tislelizumab; Oxaliplatin; Paclitaxel; Pemetrexed; Tislelizumab	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + taxane; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + topoisomerase_inhibitor; taxane; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + antimetabolite; fluoropyrimidine; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent + taxane; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent; antimetabolite; anti-TIGIT_monoclonal_antibody; Fluorouracil; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; topoisomerase_inhibitor	Capecitabine + Cisplatin + Fluorouracil + Ociperlimab + Tislelizumab; Cisplatin + Fluorouracil + Ociperlimab + Paclitaxel + Tislelizumab; Etoposide + Ociperlimab + Tislelizumab; Nab-paclitaxel + Ociperlimab + Paclitaxel + Tislelizumab; Ociperlimab + Pemetrexed + Tislelizumab; Ociperlimab + Tislelizumab; Capecitabine + Cisplatin + Fluorouracil + Ociperlimab + Tislelizumab; Carboplatin; Cisplatin + Fluorouracil + Ociperlimab + Paclitaxel + Tislelizumab; Etoposide + Ociperlimab + Tislelizumab; Nab-paclitaxel + Ociperlimab + Paclitaxel + Tislelizumab; Ociperlimab + Pemetrexed + Tislelizumab; Ociperlimab + Tislelizumab; Oxaliplatin	anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + antimetabolite; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent + taxane; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + taxane; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + topoisomerase_inhibitor; Fluorouracil; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + antimetabolite; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent + taxane; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + taxane; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + topoisomerase_inhibitor	BGB-900-105	Phase 1/1b Study Investigating Safety, Tolerability, PK and Antitumor Activity of Anti-TIGIT Monoclonal Antibody BGB-A1217 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors	Locally Advanced and Metastatic Solid Tumors	5087 - Adelaide; 2050 - Camperdown; 2146 - Blacktown; 5042 - Bedford Park; 7000 - Hobart; 4101 - South Brisbane; 6008 - Subiaco; Christchurch; 6009 - Perth; 5037 - Adelaide; Auckland; 3168 - Clayton; 4102 - Woolloongabba	https://clinicaltrials.gov/ct2/show/NCT04047862
NCT04049617	GS-US-494-5484	Phase 1/Phase 2	NOT_RECRUITING	NZ	8/08/2019	26/08/2019	GS-4224	anti-PD-L1_monoclonal_antibody	GS-4224	anti-PD-L1_monoclonal_antibody	GS-US-494-5484	A Phase 1b/2 Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of GS-4224 in Subjects With Advanced Solid Tumors	Advanced Solid Tumors	Auckland	https://clinicaltrials.gov/ct2/show/NCT04049617
NCT04050436	CERPASS	Phase 2		WA, VIC, NSW, QLD	8/08/2019	8/10/2019	Cemiplimab	anti-PD-1_monoclonal_antibody	Cemiplimab	anti-PD-1_monoclonal_antibody	RPL-002-18	A Randomized, Controlled, Open-Label, Phase 2 Study of Cemiplimab as a Single Agent and in Combination With RP1 in Patients With Advanced Cutaneous Squamous Cell Carcinoma	Metastatic Cutaneous Squamous Cell Carcinoma; Cutaneous Squamous Cell Carcinoma; Advanced Cutaneous Squamous Cell Carcinoma	- Camperdown; - Clayton; - Southport; - Nedlands; - Wollongong; - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04050436
NCT04051827	2019-000725-44--TAK-788-1004	Phase 1	NOT_RECRUITING	VIC, NSW, SA	9/08/2019	23/12/2019	Midazolam; Midazolam + Mobocertinib; Mobocertinib	EGFR_inhibitor,exon_20_selective + benzodiazepam; EGFR_inhibitor,exon_20_selective; benzodiazepam; ERBB2_inhibitor,exon_20_selective + benzodiazepam; ERBB2_inhibitor,exon_20_selective	Midazolam + Mobocertinib; Mobocertinib; Midazolam + Mobocertinib	EGFR_inhibitor,exon_20_selective; EGFR_inhibitor,exon_20_selective + benzodiazepam; ERBB2_inhibitor,exon_20_selective; ERBB2_inhibitor,exon_20_selective + benzodiazepam; EGFR_inhibitor,exon_20_selective + benzodiazepam; ERBB2_inhibitor,exon_20_selective + benzodiazepam	2019-000725-44  TAK-788-1004	A Phase 1, Open-Label, Multicenter, Drug-Drug Interaction Study of TAK-788 and Midazolam, a Sensitive CYP3A Substrate, in Patients With Advanced Non-Small Cell Lung Cancer	Carcinoma, Non-Small-Cell Lung; Lung Neoplasms	2065 - St Leonards; 3004 - Melbourne; 5042 - Bedford Park; 3199 - Frankston	https://clinicaltrials.gov/ct2/show/NCT04051827
NCT04052971	ABN401-001	Phase 1/Phase 2		WA, NSW	12/08/2019	1/08/2019	ABN401	MET_inhibitor,type_1	ABN401	MET_inhibitor,type_1	ABN401-001	A Phase 1-2 Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of ABN401 in Patients With Advanced Solid Tumors	Advanced Solid Tumors	2217 - Kogarah; 2031 - Randwick; 2170 - Liverpool; 6009 - Perth	https://clinicaltrials.gov/ct2/show/NCT04052971
NCT04059484	AMEERA-3	Phase 2		WA, QLD	16/08/2019	22/10/2019	Amcenestrant; Anastrozole; Exemestane; Fulvestrant; Letrozole; Tamoxifen	selective_estrogen_receptor_modulator; aromatase_inhibitor; selective_estrogen_receptor_degrader	Amcenestrant; Fulvestrant; Anastrozole; Exemestane; Letrozole; Tamoxifen	selective_estrogen_receptor_degrader; aromatase_inhibitor; selective_estrogen_receptor_modulator	2018-004593-98  ACT16105	An Open Label Randomized Phase 2 Trial of Amcenestrant (SAR439859), Versus Endocrine Monotherapy as Per Physician's Choice in Patients With Estrogen Receptor-positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer With Prior Exposure to Hormonal Therapies	Breast Cancer Metastatic	4101 - South Brisbane; 4102 - Woolloongabba; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT04059484
NCT04060862	IPATunity150	Phase 3	NOT_RECRUITING	VIC	19/08/2019	15/11/2019	Fulvestrant; Fulvestrant + Ipatasertib + Palbociclib; Fulvestrant + Palbociclib; Ipatasertib; Palbociclib; Placebo	CDK4/6_inhibitor + selective_estrogen_receptor_degrader; placebo; CDK4/6_inhibitor + pan-AKT_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor; pan-AKT_inhibitor; selective_estrogen_receptor_degrader	Fulvestrant + Ipatasertib + Palbociclib; Fulvestrant + Palbociclib; Fulvestrant + Ipatasertib + Palbociclib; Fulvestrant + Palbociclib; Placebo	CDK4/6_inhibitor + pan-AKT_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + pan-AKT_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + selective_estrogen_receptor_degrader; placebo	2019-001072-11  CO41012	A Phase Ib/III Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer	Breast Cancer	3021 - St Albans; 3144 - Malvern	https://clinicaltrials.gov/ct2/show/NCT04060862
NCT04064060	U1111-1235-8123--ACE-536-LTFU-001	Phase 3		NSW, VIC, QLD, SA	21/08/2019	12/08/2019	Luspatercept	recombinant_human_ActRIIb_fusion_protein	Luspatercept	recombinant_human_ActRIIb_fusion_protein	U1111-1235-8123  ACE-536-LTFU-001	A Phase 3b, Open Label, Single-arm Rollover Study to Evaluate Long Term Safety in Subjects Who Have Participated in Other Luspatercept (Ace-536) Clinical Trials.	Myelodysplastic Syndromes (MDS); Beta-thalassemia; Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis	2031 - Randwick; 3168 - Clayton; 4101 - South Brisbane; 5000 - Adelaide; 2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT04064060
NCT04066491	2019-001992-35--MS200647-0055	Phase 2/Phase 3		QLD, NSW, VIC	26/08/2019	20/09/2019	Bintrafusp Alfa; Bintrafusp Alfa + Cisplatin + Gemcitabine; Cisplatin; Cisplatin + Gemcitabine; Gemcitabine; Placebo	platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; anti-PD-L1/TGF-beta_fusion_protein; placebo; antimetabolite; gemcitabine; anti-PD-L1/TGF-beta_fusion_protein + antimetabolite + platinum-based_antineoplastic_agent	Bintrafusp Alfa + Cisplatin + Gemcitabine; Cisplatin + Gemcitabine; Bintrafusp Alfa + Cisplatin + Gemcitabine; Cisplatin + Gemcitabine; Placebo	anti-PD-L1/TGF-beta_fusion_protein + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; anti-PD-L1/TGF-beta_fusion_protein + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; gemcitabine; placebo	2019-001992-35  MS200647_0055	A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) as First-line Treatment of Biliary Tract Cancer	Biliary Tract Cancer; Cholangiocarcinoma; Gallbladder Cancer	- Clayton; - Blacktown; - Melbourne; - South Brisbane	https://clinicaltrials.gov/ct2/show/NCT04066491
NCT04068181	2019-001906-61--20180115	Phase 2		SA, QLD, NSW, VIC	28/08/2019	22/01/2020	Pembrolizumab; Pembrolizumab + Talimogene Laherparepvec; Talimogene Laherparepvec	anti-PD-1_monoclonal_antibody; oncolytic_HSV_virus; anti-PD-1_monoclonal_antibody + oncolytic_HSV_virus	Pembrolizumab + Talimogene Laherparepvec; Pembrolizumab + Talimogene Laherparepvec	anti-PD-1_monoclonal_antibody + oncolytic_HSV_virus; anti-PD-1_monoclonal_antibody + oncolytic_HSV_virus	2019-001906-61  20180115	Phase 2 Study of Talimogene Laherparepvec in Combination With Pembrolizumab in Subjects With Unresectable/Metastatic Stage IIIB-IVM1d Melanoma Who Have Progressed on Prior Anti PD-1 Based Therapy	Melanoma	3004 - Melbourne; 2060 - North Sydney; 5011 - Woodville South; 3000 - Melbourne; 4215 - Southport	https://clinicaltrials.gov/ct2/show/NCT04068181
NCT04068610	D910CC00001	Phase 1/Phase 2	NOT_RECRUITING	NSW, VIC	28/08/2019	13/09/2019	Bevacizumab; Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin; Durvalumab; Durvalumab + Fluorouracil + Leucovorin + Oleclumab + Oxaliplatin; Fluorouracil; Leucovorin; Oleclumab; Oxaliplatin	anti-CD73_monoclonal_antibody; platinum-based_antineoplastic_agent; anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; anti-CD73_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; Fluorouracil; folinic_acid; anti-PD-L1_monoclonal_antibody; anti-VEGF_monoclonal_antibody	Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin; Durvalumab + Fluorouracil + Leucovorin + Oleclumab + Oxaliplatin; Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin; Durvalumab + Fluorouracil + Leucovorin + Oleclumab + Oxaliplatin	anti-CD73_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; Fluorouracil; anti-CD73_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent	D910CC00001	A Phase 1b/2, Open-label, Multicenter Study of Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First-line Therapy in Metastatic Microsatellite-stable Colorectal Cancer (COLUMBIA-1)	Metastatic Microsatellite-stable Colorectal Cancer	3168 - Clayton; 3000 - Melbourne; 2298 - Waratah; 3084 - Heidelberg; 2148 - Blacktown	https://clinicaltrials.gov/ct2/show/NCT04068610
NCT04074759	FPT155-001	Phase 1		WA, VIC, NSW, QLD	30/08/2019	14/11/2018	FPT155; FPT155 + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody + soluble_CD80_fusion_protein; soluble_CD80_fusion_protein; anti-PD-1_monoclonal_antibody	FPT155; FPT155 + Pembrolizumab; FPT155 + Pembrolizumab	anti-PD-1_monoclonal_antibody + soluble_CD80_fusion_protein; soluble_CD80_fusion_protein; anti-PD-1_monoclonal_antibody + soluble_CD80_fusion_protein	FPT155-001	A Phase 1 Safety and Tolerability Study of FPT155 in Patients With Advanced Solid Tumors	Advanced Solid Tumors	2010 - Darlinghurst; 2050 - Camperdown; 3084 - Heidelberg; 6009 - Nedlands; 4066 - Auchenflower; 2031 - Randwick; 3144 - Malvern	https://clinicaltrials.gov/ct2/show/NCT04074759
NCT04077463	Chrysalis-2	Unknown			4/09/2019	4/09/2019	Amivantamab; Amivantamab + Carboplatin + Lazertinib + Pemetrexed; Amivantamab + Lazertinib; Amivantamab + Lazertinib + Osimertinib; Amivantamab + Osimertinib; Carboplatin; Lazertinib; Osimertinib; Pemetrexed	EGFR_inhibitor,third_generation; EGFR_inhibitor,third_generation + antimetabolite + bispecific_cMET/EGFR_monoclonal_antibody + platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent; antimetabolite; EGFR_inhibitor,third_generation + bispecific_cMET/EGFR_monoclonal_antibody; bispecific_cMET/EGFR_monoclonal_antibody	Amivantamab + Carboplatin + Lazertinib + Pemetrexed; Amivantamab + Lazertinib; Amivantamab + Lazertinib + Osimertinib; Amivantamab + Osimertinib; Lazertinib; Amivantamab + Carboplatin + Lazertinib + Pemetrexed; Amivantamab + Lazertinib; Amivantamab + Lazertinib + Osimertinib; Amivantamab + Osimertinib	EGFR_inhibitor,third_generation; EGFR_inhibitor,third_generation + antimetabolite + bispecific_cMET/EGFR_monoclonal_antibody + platinum-based_antineoplastic_agent; EGFR_inhibitor,third_generation + bispecific_cMET/EGFR_monoclonal_antibody; EGFR_inhibitor,third_generation + antimetabolite + bispecific_cMET/EGFR_monoclonal_antibody + platinum-based_antineoplastic_agent; EGFR_inhibitor,third_generation + bispecific_cMET/EGFR_monoclonal_antibody	73841937NSC1001  CR108656	An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ-73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non-Small Cell Lung Cancer	Carcinoma, Non-Small-Cell Lung		https://clinicaltrials.gov/ct2/show/NCT04077463
NCT04083235	NAPOLI-3	Phase 3		WA, SA, NSW, VIC	10/09/2019	19/02/2020	Fluorouracil; Fluorouracil + Irinotecan + Oxaliplatin; Gemcitabine; Gemcitabine + Nab-paclitaxel; Irinotecan; Leucovorin; Nab-paclitaxel; Oxaliplatin	platinum-based_antineoplastic_agent; antimetabolite; fluoropyrimidine + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; Fluorouracil; folinic_acid; gemcitabine; taxane; topoisomerase_inhibitor; fluoropyrimidine; antimetabolite + taxane	Fluorouracil + Irinotecan + Oxaliplatin; Gemcitabine + Nab-paclitaxel; Fluorouracil + Irinotecan + Oxaliplatin; Gemcitabine + Nab-paclitaxel; Leucovorin	antimetabolite + taxane; fluoropyrimidine + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; Fluorouracil; antimetabolite + taxane; fluoropyrimidine + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; folinic_acid; gemcitabine	2018-003585-14  D-US-60010-001	An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas	Metastatic Adenocarcinoma of the Pancreas	3168 - Clayton; 6008 - Subiaco; 2200 - Bankstown; 6009 - Nedlands; 2640 - Albury; 5011 - Woodville South; 6150 - Murdoch	https://clinicaltrials.gov/ct2/show/NCT04083235
NCT04083976	2019-002113-19--CR108661	Phase 2		WA, VIC, NSW, QLD, SA	10/09/2019	20/11/2019	Erdafitinib	pan-FGFR_inhibitor	Erdafitinib	pan-FGFR_inhibitor	2019-002113-19  CR108661	A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations	Advanced Solid Tumor	5042 - Adelaide; 3065 - Melbourne; 4101 - South Brisbane; 2010 - Darlinghurst; 6150 - Murdoch; 2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT04083976
NCT04093362	FOENIX-CCA3	Phase 3		NSW, VIC, SA	18/09/2019	1/03/2020	Cisplatin; Cisplatin + Gemcitabine; Futibatinib; Gemcitabine	platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; pan-FGFR_inhibitor,irreversible; gemcitabine; antimetabolite	Cisplatin + Gemcitabine; Futibatinib; Cisplatin + Gemcitabine	antimetabolite + platinum-based_antineoplastic_agent; pan-FGFR_inhibitor,irreversible; antimetabolite + platinum-based_antineoplastic_agent; gemcitabine	2019-004630-42  TAS-120-301	A Phase 3, Open-Label, Randomized Study of Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements FOENIX-CCA3	Advanced Cholangiocarcinoma; FGFR2 Gene Rearrangements	3002 - Melbourne; 2305 - Newcastle; 5042 - Bedford Park	https://clinicaltrials.gov/ct2/show/NCT04093362
NCT04097769	HX009-I-01	Phase 1		NSW	20/09/2019	12/06/2019	HX009	bispecific_PD-1/CD47_antibody	HX009	bispecific_PD-1/CD47_antibody	HX009-I-01	A Phase I, First-in-Human Study Evaluating the Safety, Tolerability, and Initial Efficacy of HX009 in Patients With Advanced Malignancies	Advanced Solid Tumor	2217 - Kogarah	https://clinicaltrials.gov/ct2/show/NCT04097769
NCT04100018	CheckMate-7DX	Phase 3		NZ, SA, NSW, VIC, QLD	23/09/2019	6/02/2020	Docetaxel; Docetaxel + Nivolumab + Prednisone; Docetaxel + Prednisone; Nivolumab; Placebo; Prednisone	anti-PD-1_monoclonal_antibody + glucocorticoid + taxane; glucocorticoid; anti-PD-1_monoclonal_antibody; placebo; glucocorticoid + taxane; taxane	Docetaxel + Nivolumab + Prednisone; Docetaxel + Prednisone; Docetaxel + Nivolumab + Prednisone; Docetaxel + Prednisone; Placebo	anti-PD-1_monoclonal_antibody + glucocorticoid + taxane; glucocorticoid + taxane; anti-PD-1_monoclonal_antibody + glucocorticoid + taxane; glucocorticoid + taxane; placebo	2019-002030-36  CA209-7DX	A Phase 3, Randomized, Double-Blind Study of Nivolumab or Placebo in Combination With Docetaxel, in Men With Metastatic Castration-resistant Prostate Cancer	Prostate Cancer	3199 - Frankston; 5006 - North Adelaide; Palmerston North; 3350 - Ballarat; 2250 - Gosford; 2145 - Westmead; Hamilton; 2480 - Lismore; 2076 - Wahroonga; 4102 - Woolloongabba; 3144 - Malvern; Tauranga; 4101 - South Brisbane	https://clinicaltrials.gov/ct2/show/NCT04100018
NCT04106219	J1O-MC-JZHD--17295	Phase 1		VIC, NSW, WA	26/09/2019	11/06/2020	Cyclophosphamide; Cyclophosphamide + LY3295668 + Topotecan; LY3295668; Topotecan	alkylating_agent; AURKA_inhibitor + alkylating_agent + topoisomerase_inhibitor; AURKA_inhibitor; topoisomerase_inhibitor	Cyclophosphamide + LY3295668 + Topotecan; LY3295668; Cyclophosphamide + LY3295668 + Topotecan	AURKA_inhibitor; AURKA_inhibitor + alkylating_agent + topoisomerase_inhibitor; AURKA_inhibitor + alkylating_agent + topoisomerase_inhibitor	J1O-MC-JZHD  17295	A Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 Erbumine as a Single Agent and in Combination in Patients With Relapsed/Refractory Neuroblastoma	Neuroblastoma	6009 - Perth; 3052 - Parkville; 2145 - Westmead	https://clinicaltrials.gov/ct2/show/NCT04106219
NCT04106492	2020-0185--SQ3370-001	Phase 1		SA, NSW	27/09/2019	1/08/2020	SQ3370	anthracycline	SQ3370	anthracycline	2020-0185  SQ3370-001	A Multicenter Phase 1, Open-Label Study of SQ3370 in Patients With Advanced Solid Tumors	Cancer	2050 - Camperdown; 5000 - Adelaide; 2065 - Sydney	https://clinicaltrials.gov/ct2/show/NCT04106492
NCT04109456	IN10018-004-01	Phase 1		WA, NSW, VIC	30/09/2019	16/03/2020	Atezolizumab; Atezolizumab + Cobimetinib; Cobimetinib	anti-PD-L1_monoclonal_antibody; MEK_inhibitor; MEK_inhibitor + anti-PD-L1_monoclonal_antibody	Atezolizumab + Cobimetinib; Cobimetinib; Atezolizumab + Cobimetinib	MEK_inhibitor; MEK_inhibitor + anti-PD-L1_monoclonal_antibody; MEK_inhibitor + anti-PD-L1_monoclonal_antibody	IN10018-004-01	A Phase Ib, Open-label Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of IN10018 as Monotherapy and Combination Therapy in Subjects With Metastatic Melanoma	Metastatic Melanoma	- Nedlands; - Melbourne; - Sydney	https://clinicaltrials.gov/ct2/show/NCT04109456
NCT04113616	KRT-232-104	Phase 1/Phase 2		WA, VIC, NSW	3/10/2019	25/09/2019	Cytarabine; Decitabine; Decitabine + Navtemadlin; Navtemadlin	MDM2_inhibitor; DNA_methyltransferase_inhibitor; DNA_methyltransferase_inhibitor + MDM2_inhibitor; antimetabolite	Decitabine + Navtemadlin; Navtemadlin; Cytarabine; Decitabine + Navtemadlin	DNA_methyltransferase_inhibitor + MDM2_inhibitor; MDM2_inhibitor; DNA_methyltransferase_inhibitor + MDM2_inhibitor; antimetabolite	KRT-232-104	An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)	Acute Myeloid Leukemia (AML), Secondary to Myeloproliferative Neoplasms (MPN); Relapsed or Refractory Acute Myeloid Leukemia (AML)	- Kogarah; 6005 - West Perth; - Clayton	https://clinicaltrials.gov/ct2/show/NCT04113616
NCT04122339	Maxinovel-10181-001	Phase 1		WA	10/10/2019	11/02/2020	MAX-10181	PD-L1_inhibitor,oral	MAX-10181	PD-L1_inhibitor,oral	Maxinovel-10181-001	A Phase I Study of MAX-10181 Given Orally to Patients With Advanced Solid Tumor	Solid Tumor	6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT04122339
NCT04123366	2019-001745-40--7339-007	Phase 2		WA, QLD, NSW, VIC	10/10/2019	18/11/2019	Olaparib; Olaparib + Pembrolizumab; Pembrolizumab	PARP_inhibitor; anti-PD-1_monoclonal_antibody; PARP_inhibitor + anti-PD-1_monoclonal_antibody	Olaparib + Pembrolizumab; Olaparib + Pembrolizumab	PARP_inhibitor + anti-PD-1_monoclonal_antibody; PARP_inhibitor + anti-PD-1_monoclonal_antibody	2019-001745-40  7339-007	A Phase 2 Study of Olaparib in Combination With Pembrolizumab in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer	Solid Tumors	4215 - Southport; 6009 - Nedlands; 2148 - Blacktown; 3168 - Clayton	https://clinicaltrials.gov/ct2/show/NCT04123366
NCT04128696	INDUCE-3	Phase 2/Phase 3		QLD, VIC, NSW, WA	16/10/2019	21/11/2019	GSK3359609; Pembrolizumab; Placebo	anti-PD-1_monoclonal_antibody; placebo; anti-ICOS_agonistic_antibody	Pembrolizumab; GSK3359609; Placebo	anti-PD-1_monoclonal_antibody; anti-ICOS_agonistic_antibody; placebo	209229	A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma	Neoplasms, Head and Neck	3084 - Heidelberg; 2148 - Blacktown; 4029 - Herston; 6009 - Nedlands; 2010 - Darlinghurst; 3000 - Melbourne; 2065 - St Leonards	https://clinicaltrials.gov/ct2/show/NCT04128696
NCT04129502	NL20191212--TAK-788-3001	Phase 3		QLD, NSW, SA, TAS	16/10/2019	6/01/2020	Carboplatin; Carboplatin + Cisplatin + Pemetrexed; Cisplatin; Mobocertinib; Pemetrexed	EGFR_inhibitor,exon_20_selective; platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; antimetabolite; ERBB2_inhibitor,exon_20_selective	Carboplatin + Cisplatin + Pemetrexed; Mobocertinib; Carboplatin + Cisplatin + Pemetrexed	EGFR_inhibitor,exon_20_selective; ERBB2_inhibitor,exon_20_selective; antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent	NL20191212  TAK-788-3001	A Randomized Phase 3 Multicenter Open-label Study to Compare the Efficacy of TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations	Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)	4102 - Woolloongabba; 2065 - St Leonards; 2137 - Kogarah; 5042 - Bedford Park; 7000 - Hobart	https://clinicaltrials.gov/ct2/show/NCT04129502
NCT04135261	4003.1	Phase 1		VIC, NSW	22/10/2019	24/09/2019	HBM4003	anti-CTLA-4_monoclonal_antibody	HBM4003	anti-CTLA-4_monoclonal_antibody	4003.1	A Phase 1 Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of HBM4003 in Subjects With Advanced Solid Tumors	Advanced Solid Tumor	2217 - Kogarah; 2109 - Macquarie; 3168 - Clayton; 3004 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04135261
NCT04139317	CINC280I12201	Phase 2	NOT_RECRUITING	SA, VIC, NSW	25/10/2019	22/01/2020	Capmatinib; Capmatinib + Pembrolizumab; Pembrolizumab	MET_inhibitor,type_1; anti-PD-1_monoclonal_antibody; MET_inhibitor,type_1 + anti-PD-1_monoclonal_antibody	Capmatinib + Pembrolizumab; Pembrolizumab; Capmatinib + Pembrolizumab	MET_inhibitor,type_1 + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; MET_inhibitor,type_1 + anti-PD-1_monoclonal_antibody	CINC280I12201	A Randomized, Open Label, Multicenter Phase II Study Evaluating the Efficacy and Safety of Capmatinib (INC280) Plus Pembrolizumab Versus Pembrolizumab Alone as First Line Treatment for Locally Advanced or Metastatic Non-small Cell Lung Cancer With PD-L1= 50%	Non-small Cell Lung Cancer (NSCLC)	3630 - Shepparton; 5006 - North Adelaide; 2500 - Wollongong	https://clinicaltrials.gov/ct2/show/NCT04139317
NCT04140526	PRESERVE-001	Phase 1/Phase 2		QLD, NSW, SA	28/10/2019	16/09/2020	ONC392; ONC392 + Pembrolizumab; Pembrolizumab	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	ONC392; ONC392 + Pembrolizumab; ONC392 + Pembrolizumab	anti-CTLA-4_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	4R44CA250824-02  ONC-392-001	Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001)	Urothelial Carcinoma; Metastatic Head and Neck Carcinoma; Gastroesophageal Junction Adenocarcinoma; Cervical Cancer; Salivary Gland Cancer; Metastatic Melanoma; Sarcomas; Ovarian Cancer; Metastatic Colorectal Cancer; Non Small Cell Lung Cancer; Pancreas Cancer; Adenoid Cystic Carcinoma; Esophageal Cancer; Metastatic Renal Cell Carcinoma; Metastatic Breast Cancer; Small Cell Lung Cancer; Gastric Cancer; Metastatic Prostate Cancer; Advanced Solid Tumor	5000 - Adelaide; 5042 - Bedford Park; 4120 - Southport; 2305 - New Lambton Heights	https://clinicaltrials.gov/ct2/show/NCT04140526
NCT04148937	J2I-MC-JZMA--17504	Phase 1	*NOT_RECRUITING	VIC	4/11/2019	16/01/2020	LY3475070; LY3475070 + Pembrolizumab; Pembrolizumab	CD73_inhibitor; anti-PD-1_monoclonal_antibody; CD73_inhibitor + anti-PD-1_monoclonal_antibody	LY3475070; LY3475070 + Pembrolizumab; LY3475070 + Pembrolizumab	CD73_inhibitor; CD73_inhibitor + anti-PD-1_monoclonal_antibody; CD73_inhibitor + anti-PD-1_monoclonal_antibody	J2I-MC-JZMA  17504	A Phase 1 Multicenter Global First in Human Study of the CD73 Inhibitor LY3475070 as Monotherapy or in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies	Advanced Cancer	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04148937
NCT04152018	2020-004009-29--C3891001	Phase 1		NSW	5/11/2019	13/11/2019	PF-06940434	alpha_V_beta_8_antagonist	PF-06940434	alpha_V_beta_8_antagonist	2020-004009-29  C3891001	A PHASE 1 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ESCALATING DOSES OF PF-06940434 IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS	Endometrial Cancer; Pancreatic Cancer; Ovarian Cancer; Melanoma Cancer; Squamous Cell Carcinoma of the Head and Neck; Esophageal Cancer; Lung Squamous Cell Carcinoma; Bile Duct Cancer; Renal Cell Carcinoma; Gastric Cancer; Urothelial Cancer	2500 - Wollongong; 2170 - Liverpool	https://clinicaltrials.gov/ct2/show/NCT04152018
NCT04154956	CARMEN-LC03	Phase 3		QLD, NSW	7/11/2019	6/02/2020	Docetaxel; Tusamitamab ravtansine	anti-CEACAM5_antibody-drug_conjugate; taxane	Docetaxel; Tusamitamab ravtansine	anti-CEACAM5_antibody-drug_conjugate; taxane	2019-001273-81  EFC15858	Randomized, Open Label Phase 3 Study of SAR408701 Versus Docetaxel in Previously Treated Metastatic Non- Squamous Non-Small Cell Lung Cancer Patients With CEACAM5 Positive Tumors	Non-small Cell Lung Cancer Metastatic	4102 - Woolloongabba; 2148 - Blacktown; 2298 - Waratah	https://clinicaltrials.gov/ct2/show/NCT04154956
NCT04157517	U1111-1238-9163--TAK-573-1001	Phase 1/Phase 2		SA	8/11/2019	12/12/2019	Pembrolizumab; Pembrolizumab + modakafusp alfa; modakafusp alfa	anti-PD-1_monoclonal_antibody; IFN_alpha2b-CD38_fusion_protein + anti-PD-1_monoclonal_antibody; IFN_alpha2b-CD38_fusion_protein	Pembrolizumab + modakafusp alfa; modakafusp alfa; Pembrolizumab + modakafusp alfa	IFN_alpha2b-CD38_fusion_protein; IFN_alpha2b-CD38_fusion_protein + anti-PD-1_monoclonal_antibody; IFN_alpha2b-CD38_fusion_protein + anti-PD-1_monoclonal_antibody	U1111-1238-9163  TAK-573-1001	An Open-Label, Dose-Escalation Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Modakafusp Alfa (TAK-573) as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors	Neoplasms; Melanoma	5011 - Woodville South	https://clinicaltrials.gov/ct2/show/NCT04157517
NCT04158583	2019-002830-35--WP41188	Phase 1		VIC	12/11/2019	9/12/2019	RO7296682	anti-CD25_monoclonal_antibody	RO7296682	anti-CD25_monoclonal_antibody	2019-002830-35  WP41188	An Open-label, Multicenter Phase 1 Study to Evaluate Safety, Tolerability, PK (Pharmacokinetics)/PD (Pharmacodynamics) of RO7296682, a T-regulatory Cell Depleting Antibody in Participants With Advanced and/or Metastatic Solid Tumors.	Solid Tumors	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04158583
NCT04161885	VIALE-T	Phase 3		NSW, VIC, SA	13/11/2019	26/02/2020	Azacitidine; Azacitidine + Venetoclax; Venetoclax	Bcl2_inhibitor + DNA_methyltransferase_inhibitor; Bcl2_inhibitor; DNA_methyltransferase_inhibitor; Bcl2_inhibitor + antimetabolite; antimetabolite	Azacitidine + Venetoclax; Azacitidine + Venetoclax	Bcl2_inhibitor + DNA_methyltransferase_inhibitor; Bcl2_inhibitor + antimetabolite; Bcl2_inhibitor + DNA_methyltransferase_inhibitor; Bcl2_inhibitor + antimetabolite	2019-002621-30  M19-063	A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine After Allogeneic Stem Cell Transplantation in Subjects With Acute Myeloid Leukemia (AML) (VIALE-T)	Acute Myeloid Leukemia (AML); Cancer	5000 - Adelaide; 2010 - Darlinghurst; 3000 - Melbourne; 3004 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04161885
NCT04162301	CS3002-101	Phase 1	NOT_RECRUITING	NSW, VIC	14/11/2019	30/12/2019	CS3002	CDK4/6_inhibitor	CS3002	CDK4/6_inhibitor	CS3002-101	A Phase I, Open-Label, Multiple-Dose, Dose Escalation and Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activities of CS3002, a CDK4/6 Inhibitor, in Subjects With Advanced Solid Tumors	Advanced Solid Tumor	3199 - Heidelberg; 2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT04162301
NCT04163900	2019-001025-28--NuTide	Phase 3		WA, QLD, VIC, NSW	15/11/2019	24/12/2019	Cisplatin; Cisplatin + Fosgemcitabine Palabenamide; Cisplatin + Gemcitabine; Fosgemcitabine Palabenamide; Gemcitabine	gemcitabine-phosphoramidate; platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; antimetabolite; gemcitabine-phosphoramidate + platinum-based_antineoplastic_agent; gemcitabine	Cisplatin + Fosgemcitabine Palabenamide; Cisplatin + Gemcitabine; Cisplatin + Fosgemcitabine Palabenamide; Cisplatin + Gemcitabine	antimetabolite + platinum-based_antineoplastic_agent; gemcitabine-phosphoramidate + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; gemcitabine-phosphoramidate + platinum-based_antineoplastic_agent	2019-001025-28  NuTide:121	A Phase III Open-Label, Multi-Centre, Randomized Study Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Previously Untreated Locally Advanced or Metastatic Biliary Tract Cancer	Biliary Tract Cancer	2145 - Westmead; 2305 - Newcastle; 3004 - Melbourne; 2217 - Kogarah; 3084 - Heidelberg; 2050 - Camperdown; 6150 - Murdoch; 6009 - Nedlands; 4814 - Townsville	https://clinicaltrials.gov/ct2/show/NCT04163900
NCT04164199	2019-002554-23--BGB-A317-290-LTE1	Phase 3		SA, NZ, QLD, VIC, NSW	15/11/2019	19/12/2019	Capecitabine; Capecitabine + Tislelizumab; Pamiparib; Pamiparib + Temozolomide; Pamiparib + Tislelizumab; Pemetrexed; Pemetrexed + Tislelizumab; Temozolomide; Tislelizumab	PARP_inhibitor; anti-PD-1_monoclonal_antibody; alkylating_agent; antimetabolite; PARP_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + fluoropyrimidine; PARP_inhibitor + alkylating_agent; anti-PD-1_monoclonal_antibody + antimetabolite; fluoropyrimidine	Capecitabine + Tislelizumab; Pamiparib; Pamiparib + Temozolomide; Pamiparib + Tislelizumab; Pemetrexed + Tislelizumab; Tislelizumab; Capecitabine + Tislelizumab; Pamiparib + Temozolomide; Pamiparib + Tislelizumab; Pemetrexed + Tislelizumab	PARP_inhibitor; PARP_inhibitor + alkylating_agent; PARP_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + antimetabolite; anti-PD-1_monoclonal_antibody + fluoropyrimidine; PARP_inhibitor + alkylating_agent; PARP_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + antimetabolite; anti-PD-1_monoclonal_antibody + fluoropyrimidine	2019-002554-23  BGB-A317-290-LTE1	An Open Label, Multicentre, Long-Term Extension Study of Tislelizumab- Containing Treatment and/or Pamiparib-Containing Treatment in Patients With Advanced Malignancies	Advanced Malignancies	2065 - Saint Leonards; 4101 - Brisbane; 2298 - Waratah; 5011 - Woodville; Auckland; - East Melbourne; 2031 - Randwick; 3168 - Clayton	https://clinicaltrials.gov/ct2/show/NCT04164199
NCT04170283	BGB-3111-LTE1	Phase 3		TAS, SA, QLD, NSW, VIC, WA	20/11/2019	21/01/2020	Tislelizumab; Tislelizumab + Zanubrutinib; Zanubrutinib	BTK_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; BTK_inhibitor	Tislelizumab + Zanubrutinib; Zanubrutinib; Tislelizumab + Zanubrutinib	BTK_inhibitor; BTK_inhibitor + anti-PD-1_monoclonal_antibody; BTK_inhibitor + anti-PD-1_monoclonal_antibody	BGB-3111-LTE1	An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies	B-cell Malignancies	- Kogarah; 5037 - Kurralta Park; 4120 - Greenslopes; - Sydney; - Concord; - Geelong; - Wodonga; - Westmead; - Malvern; - Melbourne; - Woolloongabba; - Perth; - Clayton; - Hobart; 3004 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04170283
NCT04171141	GUCY2C--C3861001	Phase 1		VIC	20/11/2019	19/11/2019	Bevacizumab; Bevacizumab + PF-07062119; PF-07062119	bispecific_T-cell_engager,GUCY2C-targeting; anti-VEGF_monoclonal_antibody + bispecific_T-cell_engager,GUCY2C-targeting; anti-VEGF_monoclonal_antibody	Bevacizumab + PF-07062119; PF-07062119; Bevacizumab + PF-07062119	anti-VEGF_monoclonal_antibody + bispecific_T-cell_engager,GUCY2C-targeting; bispecific_T-cell_engager,GUCY2C-targeting; anti-VEGF_monoclonal_antibody + bispecific_T-cell_engager,GUCY2C-targeting	GUCY2C  C3861001	A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF-07062119 IN PATIENTS WITH ADVANCED GASTROINTESTINAL TUMORS	Gastrointestinal Tumors; Colorectal Adenocarcinomas; Esophageal Adenocarcinomas; Gastric Adenocarcinomas	3000 - Melbourne; 3050 - Parkville	https://clinicaltrials.gov/ct2/show/NCT04171141
NCT04175171	GB221-001	Phase 1		WA	22/11/2019	7/11/2011	Coprelotamab; Trastuzumab	anti-ERBB2_monoclonal_antibody	Coprelotamab; Trastuzumab	anti-ERBB2_monoclonal_antibody	GB221-001	A Randomized, Double-blind, Parallel-group, Comparative Phase I Study to Evaluate the Safety and Pharmacokinetics of Single Intravenous (IV) Administration of GB221 Versus Herceptin® (Trastuzumab)	Metastatic Breast Cancer	6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT04175171
NCT04176757	ZN-c5-002	Phase 1		QLD, NSW, VIC	25/11/2019	3/01/2020	ZN-C5	selective_estrogen_receptor_degrader	ZN-C5	selective_estrogen_receptor_degrader	ZN-c5-002	A Phase 1 Open-Label, Multicenter Study to Evaluate Biomarkers for ZN-c5 in Subjects With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer	Breast Cancer	2109 - Sydney; 4870 - Cairns; 2170 - Liverpool; 3121 - Richmond	https://clinicaltrials.gov/ct2/show/NCT04176757
NCT04177108	2019-000810-12--CO41101	Phase 3	NOT_RECRUITING	WA, SA, NZ, QLD, VIC, NSW	26/11/2019	25/11/2019	Atezolizumab; Atezolizumab + Ipatasertib + Paclitaxel; Ipatasertib; Paclitaxel; Placebo	anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + pan-AKT_inhibitor + taxane; taxane; placebo; pan-AKT_inhibitor	Atezolizumab + Ipatasertib + Paclitaxel; Atezolizumab + Ipatasertib + Paclitaxel; Placebo	anti-PD-L1_monoclonal_antibody + pan-AKT_inhibitor + taxane; anti-PD-L1_monoclonal_antibody + pan-AKT_inhibitor + taxane; placebo	2019-000810-12  CO41101	A Phase III, Double-blind, Placebo-controlled, Randomized Study Of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer.	Triple-Negative Breast Cancer	4102 - Woolloongabba; 3168 - Clayton; 2065 - St Leonards; Auckland; 6008 - Subiaco; Tauranga; - St Albans; 5037 - Kurralta Park; 3000 - Melbourne; 2298 - Waratah; 2444 - Port Macquarie; 2109 - Macquarie Park; Wellington	https://clinicaltrials.gov/ct2/show/NCT04177108
NCT04178902	2018-003744-24--M19-025	Phase 1		WA, SA, VIC	26/11/2019	19/05/2020	ABBV-467	MCL1_inhibitor	ABBV-467	MCL1_inhibitor	2018-003744-24  M19-025	A First In Human Study of the MCL-1 Inhibitor, ABBV-467	Cancer; Multiple Myeloma (MM)	5000 - Adelaide; 6000 - Perth; 6009 - Nedlands; 3004 - Melbourne; 3065 - Fitzroy	https://clinicaltrials.gov/ct2/show/NCT04178902
NCT04180384	KX-ORAX-003	Phase 2		VIC, NZ	27/11/2019	23/09/2015	Oraxol; Oraxol + Paclitaxel; Paclitaxel	taxane	Oraxol + Paclitaxel; Oraxol + Paclitaxel	taxane	KX-ORAX-003	A Safety Study of Oraxol (HM30181 + Oral Paclitaxel) in Cancer Patients	Solid Tumor	Dunedin; Wellington; 3168 - Clayton; Auckland	https://clinicaltrials.gov/ct2/show/NCT04180384
NCT04185883	NCT04185883	Phase 1/Phase 2		QLD, SA, WA	4/12/2019	20/04/2021	AMG 404; AMG 404 + Sotorasib; Afatinib; Afatinib + Sotorasib; Atezolizumab; Atezolizumab + Sotorasib; Bevacizumab; Bevacizumab + Sotorasib; Carboplatin; Carboplatin + Docetaxel + Pembrolizumab + Pemetrexed + Sotorasib; Docetaxel; Everolimus; Everolimus + Sotorasib; Palbociclib; Palbociclib + Sotorasib; Panitumumab; Panitumumab + Sotorasib; Panitumumab + Sotorasib + Trametinib; Pembrolizumab; Pembrolizumab + Sotorasib; Pemetrexed; RMC-4630; RMC-4630 + Sotorasib; Sotorasib; Sotorasib + TNO155; Sotorasib + Trametinib; TNO155; Trametinib	KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + mTORC1_inhibitor; anti-PD-1_monoclonal_antibody; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-PD-L1_monoclonal_antibody; CDK4/6_inhibitor + KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; EGFR_inhibitor,second_generation; anti-EGFR_monoclonal_antibody; taxane; CDK4/6_inhibitor; EGFR_inhibitor,second_generation + KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + SHP2_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; anti-VEGF_monoclonal_antibody; SHP2_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + MEK_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor; platinum-based_antineoplastic_agent; antimetabolite; MEK_inhibitor; mTORC1_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + MEK_inhibitor + anti-EGFR_monoclonal_antibody	AMG 404 + Sotorasib; Afatinib + Sotorasib; Atezolizumab + Sotorasib; Bevacizumab + Sotorasib; Carboplatin + Docetaxel + Pembrolizumab + Pemetrexed + Sotorasib; Everolimus + Sotorasib; Palbociclib + Sotorasib; Panitumumab + Sotorasib; Panitumumab + Sotorasib + Trametinib; Pembrolizumab + Sotorasib; RMC-4630 + Sotorasib; Sotorasib; Sotorasib + TNO155; Sotorasib + Trametinib; AMG 404 + Sotorasib; Afatinib + Sotorasib; Atezolizumab + Sotorasib; Bevacizumab + Sotorasib; Carboplatin + Docetaxel + Pembrolizumab + Pemetrexed + Sotorasib; Everolimus + Sotorasib; Palbociclib + Sotorasib; Panitumumab + Sotorasib; Panitumumab + Sotorasib + Trametinib; Pembrolizumab + Sotorasib; RMC-4630 + Sotorasib; Sotorasib + TNO155; Sotorasib + Trametinib	CDK4/6_inhibitor + KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor; EGFR_inhibitor,second_generation + KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + MEK_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + MEK_inhibitor + anti-EGFR_monoclonal_antibody; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + SHP2_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-PD-L1_monoclonal_antibody; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-VEGF_monoclonal_antibody; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + mTORC1_inhibitor; CDK4/6_inhibitor + KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor; EGFR_inhibitor,second_generation + KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + MEK_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + MEK_inhibitor + anti-EGFR_monoclonal_antibody; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + SHP2_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-PD-L1_monoclonal_antibody; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-VEGF_monoclonal_antibody; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + mTORC1_inhibitor	20190135	A Phase 1b/2, Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib Monotherapy and in Combination With Other Anti-cancer Therapies in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)	Advanced Solid Tumors; Kirsten Rat Sarcoma (KRAS) pG12C Mutation	5011 - Woodville South; 4101 - South Brisbane; 6008 - Subiaco	https://clinicaltrials.gov/ct2/show/NCT04185883
NCT04186637	NEON-1	Phase 1		WA, NedlandsVIC, VIC	5/12/2019	2/06/2020	ALPN-202	dual_PD-L1/CTLA-4_inhibitor; CD28_agonist	ALPN-202	CD28_agonist; dual_PD-L1/CTLA-4_inhibitor	AIS-B01	An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies (NEON-1)	Lymphoma; Advanced Solid Tumor	6009 - Perth; 3004 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04186637
NCT04188548	EMBER	Phase 1		WA, NSW, PerthSA, SA	6/12/2019	10/12/2019	Abemaciclib; Abemaciclib + Anastrozole + Exemestane + Imlunestrant + Letrozole; Abemaciclib + Imlunestrant + Trastuzumab; Alpelisib; Alpelisib + Imlunestrant; Anastrozole; Everolimus; Everolimus + Imlunestrant; Exemestane; Imlunestrant; Imlunestrant + Pertuzumab + Trastuzumab; Letrozole; Pertuzumab; Trastuzumab	PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor + selective_estrogen_receptor_degrader; anti-ERBB2_monoclonal_antibody; selective_estrogen_receptor_degrader; CDK4/6_inhibitor; CDK4/6_inhibitor + aromatase_inhibitor + selective_estrogen_receptor_degrader; mTORC1_inhibitor + selective_estrogen_receptor_degrader; PI3K_alpha_inhibitor; CDK4/6_inhibitor + anti-ERBB2_monoclonal_antibody + selective_estrogen_receptor_degrader; aromatase_inhibitor; mTORC1_inhibitor; anti-ERBB2_monoclonal_antibody,dimerization_inhibitor	Abemaciclib + Anastrozole + Exemestane + Imlunestrant + Letrozole; Abemaciclib + Imlunestrant + Trastuzumab; Alpelisib + Imlunestrant; Everolimus + Imlunestrant; Imlunestrant; Imlunestrant + Pertuzumab + Trastuzumab; Abemaciclib + Anastrozole + Exemestane + Imlunestrant + Letrozole; Abemaciclib + Imlunestrant + Trastuzumab; Alpelisib + Imlunestrant; Everolimus + Imlunestrant; Imlunestrant + Pertuzumab + Trastuzumab	CDK4/6_inhibitor + anti-ERBB2_monoclonal_antibody + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + aromatase_inhibitor + selective_estrogen_receptor_degrader; PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor + selective_estrogen_receptor_degrader; mTORC1_inhibitor + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader; CDK4/6_inhibitor + anti-ERBB2_monoclonal_antibody + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + aromatase_inhibitor + selective_estrogen_receptor_degrader; PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor + selective_estrogen_receptor_degrader; mTORC1_inhibitor + selective_estrogen_receptor_degrader	J2J-MC-JZLA  17502	EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers	Breast Cancer; Advanced Breast Cancer; Endometrial Cancer; Metastatic Breast Cancer	2298 - Waratah; 2010 - Darlinghurst; 5037 - Kurralta Park; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT04188548
NCT04191096	KEYNOTE-991	Phase 3		QLD, NSW, VIC, NZ, WA	9/12/2019	12/02/2020	Enzalutamide; Enzalutamide + LHRH Agonist; Enzalutamide + Pembrolizumab; LHRH Agonist; Pembrolizumab; Placebo	anti-PD-1_monoclonal_antibody; placebo; LHRH_agonist + antiandrogen,nonsteroidal,second_generation; antiandrogen,nonsteroidal,second_generation; anti-PD-1_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation; LHRH_agonist	Enzalutamide + LHRH Agonist; Enzalutamide + Pembrolizumab; Enzalutamide + LHRH Agonist; Enzalutamide + Pembrolizumab; Placebo	LHRH_agonist + antiandrogen,nonsteroidal,second_generation; anti-PD-1_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation; LHRH_agonist + antiandrogen,nonsteroidal,second_generation; anti-PD-1_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation; placebo	2019-003633-41  3475-991	A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (KEYNOTE-991)	Metastatic Hormone-Sensitive Prostate Cancer	3000 - Melbourne; 3128 - Box Hill; 4120 - Greenslopes; 2444 - Port Macquarie; 2650 - Wagga Wagga; 6150 - Murdoch; 2050 - Camperdown; 3168 - Clayton; 4224 - Tugun; Auckland	https://clinicaltrials.gov/ct2/show/NCT04191096
NCT04191499	2019-002455-42--WO41554	Phase 2/Phase 3	NOT_RECRUITING	QLD, VIC, NSW, NZ	9/12/2019	29/01/2020	Fulvestrant; Fulvestrant + Inavolisib + Palbociclib; Fulvestrant + Palbociclib; Inavolisib; Palbociclib; Placebo	CDK4/6_inhibitor + selective_estrogen_receptor_degrader; placebo; CDK4/6_inhibitor; PI3K_alpha_inhibitor; selective_estrogen_receptor_degrader; CDK4/6_inhibitor + PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader	Fulvestrant + Inavolisib + Palbociclib; Fulvestrant + Palbociclib; Fulvestrant + Inavolisib + Palbociclib; Fulvestrant + Palbociclib; Placebo	CDK4/6_inhibitor + PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + selective_estrogen_receptor_degrader; placebo	2019-002455-42  WO41554	A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GDC-0077 Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer	Breast Cancer	Auckland; Christchurch; 4870 - Cairns; 4101 - South Brisbane; 3065 - Fitzroy; Hamilton; 4810 - Townsville; 4102 - Woolloongabba; 3084 - Heidelberg; 3199 - Frankston; 2500 - Wollongong; Palmerston North; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04191499
NCT04194944	LIBRETTO-431	Phase 3		QLD, VIC, NSW	11/12/2019	17/02/2020	Carboplatin; Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Cisplatin; Pembrolizumab; Pemetrexed; Selpercatinib	anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; RET_inhibitor; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite	Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Selpercatinib; Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed	RET_inhibitor; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent	J2G-MC-JZJC  17479	LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy With or Without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer	Non-Small Cell Lung Cancer	2050 - Camperdown; 2298 - Waratah; 3199 - Frankston; 3149 - Frankston; 3000 - Melbourne; 3065 - Melbourne; 3168 - Clayton; 2145 - Westmead; 4102 - Woolloongabba	https://clinicaltrials.gov/ct2/show/NCT04194944
NCT04195139	NUTMEG	Phase 2		TAS, SA, QLD, NSW, VIC, WA	11/12/2019	22/02/2018	Nivolumab; Nivolumab + Radiotherapy + Temozolomide; Radiotherapy; Radiotherapy + Temozolomide; Temozolomide	radiotherapy; anti-PD-1_monoclonal_antibody; alkylating_agent; alkylating_agent + anti-PD-1_monoclonal_antibody + radiotherapy; alkylating_agent + radiotherapy	Nivolumab + Radiotherapy + Temozolomide; Radiotherapy + Temozolomide; Nivolumab + Radiotherapy + Temozolomide; Radiotherapy + Temozolomide	alkylating_agent + anti-PD-1_monoclonal_antibody + radiotherapy; alkylating_agent + radiotherapy; alkylating_agent + anti-PD-1_monoclonal_antibody + radiotherapy; alkylating_agent + radiotherapy	ACTRN12617000267358  COGNO 16/01, CTC 0156	A Randomised Phase II Study of NivolUmab and TeMozolomide vs Temozolomide Alone in Newly Diagnosed Elderly Patients With Glioblastoma (NUTMEG)	Glioblastoma Multiforme	2305 - New Lambton Heights; 2250 - Gosford; 2031 - Randwick; 3168 - Clayton; 4102 - Woolloongabba; 4101 - South Brisbane; 3121 - Richmond; 2500 - Wollongong; 5000 - Adelaide; 2444 - Port Macquarie; 3000 - Melbourne; 5042 - Bedford Park; 7000 - Hobart; 2560 - Campbelltown; 6009 - Nedlands; 4029 - Herston; 3084 - Heidelberg; 2065 - Saint Leonards; 2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT04195139
NCT04199104	LEAP-10	Phase 3		NSW, SA	13/12/2019	5/02/2020	Lenvatinib; Lenvatinib + Pembrolizumab; Pembrolizumab; Placebo	anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; placebo; VEGF_inhibitor	Lenvatinib + Pembrolizumab; Lenvatinib + Pembrolizumab; Placebo	VEGF_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; placebo	MK-7902-010  7902-010	A Phase 3, Randomized, Placebo-controlled, Double-blind Clinical Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib as 1L Intervention in a PD-L1 Selected Population of Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (LEAP-010).	Head and Neck Squamous Cell Carcinoma	5000 - Adelaide; 2217 - Kogarah; 2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT04199104
NCT04205227	MK3475-951	Phase 1/Phase 2		NSW	19/12/2019	18/02/2020	ENB003; ENB003 + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; ETBR_inhibitor + anti-PD-1_monoclonal_antibody; ETBR_inhibitor	ENB003 + Pembrolizumab; ENB003 + Pembrolizumab	ETBR_inhibitor + anti-PD-1_monoclonal_antibody; ETBR_inhibitor + anti-PD-1_monoclonal_antibody	ENB-003-101 (MK3475-951)	A Phase 1/2A Trial of ENB 003 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors	Melanoma; Solid Tumor; Cancer; Ovary Cancer; Pancreatic Cancer	2148 - Blacktown; 2640 - Albury; 2010 - Darlinghurst	https://clinicaltrials.gov/ct2/show/NCT04205227
NCT04209855	MIRASOL	Phase 3		SA, NSW, VIC	24/12/2019	31/12/2019	Mirvetuximab Soravtansine; Paclitaxel; Pegylated liposomal doxorubicin; Topotecan	anthracycline; taxane; anti-FR-alpha_antibody-drug_conjugate; topoisomerase_inhibitor	Mirvetuximab Soravtansine; Paclitaxel; Pegylated liposomal doxorubicin; Topotecan	anti-FR-alpha_antibody-drug_conjugate; taxane; anthracycline; topoisomerase_inhibitor	2019-003509-80  IMGN853-0416	MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression	Epithelial Ovarian Cancer; Peritoneal Cancer; Fallopian Tube Cancer	2065 - Saint Leonards; 5065 - Toorak Gardens; 3144 - Malvern; 3168 - Clayton; 2031 - Randwick; 2305 - New Lambton Heights	https://clinicaltrials.gov/ct2/show/NCT04209855
NCT04210037	APG1252SU101	Phase 1/Phase 2		SA, NSW	24/12/2019	20/08/2020	Paclitaxel; Pelcitoclax	Bcl2_inhibitor; taxane	Pelcitoclax; Paclitaxel	Bcl2_inhibitor; taxane	APG1252SU101	A Multi-Center, Phase Ib/II Study of Combination Treatment of APG-1252 With Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer	Small Cell Lung Cancer	2148 - Westmead; 5042 - Bedford Park	https://clinicaltrials.gov/ct2/show/NCT04210037
NCT04211337	LIBRETTO-531	Phase 3		WA, VIC, NSW	26/12/2019	11/02/2020	Cabozantinib; Cabozantinib + Vandetanib; Selpercatinib; Vandetanib	EGFR_inhibitor,second_generation + VEGFR2_inhibitor; AXL_inhibitor + VEGFR2_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor; AXL_inhibitor + EGFR_inhibitor,second_generation; VEGFR2_inhibitor; EGFR_inhibitor,second_generation; KIT_inhibitor + RET_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + RET_inhibitor; KIT_inhibitor + VEGFR2_inhibitor; ROS1_inhibitor + VEGFR2_inhibitor; MET_inhibitor,type_2 + RET_inhibitor; RET_inhibitor + VEGFR2_inhibitor; MET_inhibitor,type_2 + VEGFR2_inhibitor; EGFR_inhibitor,second_generation + MET_inhibitor,type_2; EGFR_inhibitor,second_generation + RET_inhibitor; AXL_inhibitor; RET_inhibitor; RET_inhibitor + ROS1_inhibitor; AXL_inhibitor + RET_inhibitor; ROS1_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + VEGFR2_inhibitor; MET_inhibitor,type_2; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + EGFR_inhibitor,second_generation; EGFR_inhibitor,second_generation + KIT_inhibitor; EGFR_inhibitor,second_generation + ROS1_inhibitor; KIT_inhibitor	Cabozantinib + Vandetanib; Selpercatinib; Cabozantinib + Vandetanib	AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + EGFR_inhibitor,second_generation; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + RET_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + VEGFR2_inhibitor; AXL_inhibitor + EGFR_inhibitor,second_generation; AXL_inhibitor + RET_inhibitor; AXL_inhibitor + VEGFR2_inhibitor; EGFR_inhibitor,second_generation + KIT_inhibitor; EGFR_inhibitor,second_generation + MET_inhibitor,type_2; EGFR_inhibitor,second_generation + RET_inhibitor; EGFR_inhibitor,second_generation + ROS1_inhibitor; EGFR_inhibitor,second_generation + VEGFR2_inhibitor; KIT_inhibitor + RET_inhibitor; KIT_inhibitor + VEGFR2_inhibitor; MET_inhibitor,type_2 + RET_inhibitor; MET_inhibitor,type_2 + VEGFR2_inhibitor; RET_inhibitor; RET_inhibitor + ROS1_inhibitor; RET_inhibitor + VEGFR2_inhibitor; ROS1_inhibitor + VEGFR2_inhibitor; VEGFR2_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + EGFR_inhibitor,second_generation; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + RET_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + VEGFR2_inhibitor; AXL_inhibitor + EGFR_inhibitor,second_generation; AXL_inhibitor + RET_inhibitor; AXL_inhibitor + VEGFR2_inhibitor; EGFR_inhibitor,second_generation + KIT_inhibitor; EGFR_inhibitor,second_generation + MET_inhibitor,type_2; EGFR_inhibitor,second_generation + RET_inhibitor; EGFR_inhibitor,second_generation + ROS1_inhibitor; EGFR_inhibitor,second_generation + VEGFR2_inhibitor; KIT_inhibitor + RET_inhibitor; KIT_inhibitor + VEGFR2_inhibitor; MET_inhibitor,type_2 + RET_inhibitor; MET_inhibitor,type_2 + VEGFR2_inhibitor; RET_inhibitor + ROS1_inhibitor; RET_inhibitor + VEGFR2_inhibitor; ROS1_inhibitor + VEGFR2_inhibitor	J2G-MC-JZJB  17478	A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)	Medullary Thyroid Cancer	3004 - Melbourne; 6009 - Nedlands; 2065 - St. Leonards; 2050 - Camperdown; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04211337
NCT04215978	BGB-A317-A445-101	Phase 1		WA, NSW, VIC, NZ	2/01/2020	30/01/2020	BGB-A445; BGB-A445 + Tislelizumab; Tislelizumab	anti-PD-1_monoclonal_antibody; anti-OX40_agonistic_antibody; anti-OX40_agonistic_antibody + anti-PD-1_monoclonal_antibody	BGB-A445; BGB-A445 + Tislelizumab; BGB-A445 + Tislelizumab	anti-OX40_agonistic_antibody; anti-OX40_agonistic_antibody + anti-PD-1_monoclonal_antibody; anti-OX40_agonistic_antibody + anti-PD-1_monoclonal_antibody	BGB-A317-A445-101	Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of the Anti OX40 Agonist Monoclonal Antibody BGB-A445 in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors	Advanced Solid Tumor	6009 - Perth; 3004 - Melbourne; - Melbourne; 2146 - Blacktown	https://clinicaltrials.gov/ct2/show/NCT04215978
NCT04221035	HR-NBL2	Phase 3			6/01/2020	5/11/2019	Busulfan; Carboplatin; Cisplatin; Cyclophosphamide; Dacarbazine; Dinutuximab; Doxorubicin; Etoposide; Ifosfamide; Melphalan; Radiotherapy; Thiotepa; Vincristine	anti-GD2_monoclonal_antibody; alkylating_agent; doxorubicin; anthracycline; radiotherapy; platinum-based_antineoplastic_agent; vinca_alkaloid; topoisomerase_inhibitor	Radiotherapy; Thiotepa; Busulfan; Carboplatin; Cisplatin; Cyclophosphamide; Dacarbazine; Dinutuximab; Doxorubicin; Etoposide; Ifosfamide; Melphalan; Vincristine	alkylating_agent; radiotherapy; anthracycline; anti-GD2_monoclonal_antibody; doxorubicin; platinum-based_antineoplastic_agent; topoisomerase_inhibitor; vinca_alkaloid	2019/2894  2019-001068-31	High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)	High-Risk Neuroblastoma		https://clinicaltrials.gov/ct2/show/NCT04221035
NCT04221542	NCT04221542	Phase 1		VIC, NSW	9/01/2020	4/03/2020	Xaluritamig	bispecific_T-cell_engager,STEAP1-targeting	Xaluritamig	bispecific_T-cell_engager,STEAP1-targeting	20180146	A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer	Prostate Cancer	3168 - Clayton; 2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT04221542
NCT04222972	AcceleRET-Lung	Phase 3	NOT_RECRUITING	SA, NSW	10/01/2020	24/07/2020	Carboplatin; Cisplatin; Gemcitabine; Nab-paclitaxel; Paclitaxel; Pembrolizumab; Pemetrexed; Pralsetinib	anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; antimetabolite; RET_inhibitor; gemcitabine; taxane	Pembrolizumab; Pralsetinib; Carboplatin; Cisplatin; Gemcitabine; Nab-paclitaxel; Pemetrexed	RET_inhibitor; anti-PD-1_monoclonal_antibody; antimetabolite; gemcitabine; platinum-based_antineoplastic_agent; taxane	2019-002463-10  BO42864	A Phase III, Randomized, Open-Label Study of Pralsetinib Versus Standard of Care for First-Line Treatment of RET Fusion-Positive, Metastatic Non-Small Cell Lung Cancer	Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Respiratory Tract Disease; Bronchial Diseases; Carcinoma; Adenocarcinoma; Head and Neck Neoplasms; RET-fusion Non Small Cell Lung Cancer; Lung Neoplasm; Carcinoma, Non-Small-Cell Lung; Respiratory Tract Neoplasms; Neoplasms by Site; Thoracic Neoplasms; Neoplasms; Carcinoma, Bronchogenic; Lung Diseases; Neoplasms, Nerve Tissue	5042 - Bedford Park; 2065 - St Leonards	https://clinicaltrials.gov/ct2/show/NCT04222972
NCT04223856	EV-302	Phase 3	NOT_RECRUITING	SA, QLD, NSW, VIC	10/01/2020	30/03/2020	Carboplatin; Carboplatin + Cisplatin + Enfortumab Vedotin + Pembrolizumab; Carboplatin + Cisplatin + Gemcitabine; Cisplatin; Enfortumab Vedotin; Enfortumab Vedotin + Pembrolizumab; Gemcitabine; Pembrolizumab	anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; antimetabolite; anti-NECTIN4_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent; anti-NECTIN4_antibody-drug_conjugate; anti-NECTIN4_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody; gemcitabine	Carboplatin + Cisplatin + Enfortumab Vedotin + Pembrolizumab; Carboplatin + Cisplatin + Gemcitabine; Enfortumab Vedotin + Pembrolizumab; Carboplatin + Cisplatin + Enfortumab Vedotin + Pembrolizumab; Carboplatin + Cisplatin + Gemcitabine; Enfortumab Vedotin + Pembrolizumab	anti-NECTIN4_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody; anti-NECTIN4_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; anti-NECTIN4_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody; anti-NECTIN4_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; gemcitabine	2019-004542-15  SGN22E-003	An Open-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab Versus Chemotherapy Alone in Previously Untreated Locally Advanced or Metastatic Urothelial Cancer	Urothelial Cancer	3128 - Box Hill; 3084 - Heidelberg; 2109 - Macquarie Park; 5112 - South Australia; 4814 - Douglas; 4101 - South Brisbane	https://clinicaltrials.gov/ct2/show/NCT04223856
NCT04233060	CS3005-101	Phase 1		NSW	18/01/2020	10/01/2020	CS3005	adenosine_A2A_receptor_antagonist	CS3005	adenosine_A2A_receptor_antagonist	CS3005-101	A Phase I, Multi-center, Open-label, Dose Escalation Study of CS3005 in Subjects With Advanced Solid Tumors	Advanced Solid Tumor	2031 - Sydney	https://clinicaltrials.gov/ct2/show/NCT04233060
NCT04242199	INCB-99280-112	Phase 1		VIC, NSW, WA	27/01/2020	20/08/2020	INCB099280	PD-L1_inhibitor,oral	INCB099280	PD-L1_inhibitor,oral	INCB 99280-112	A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Select Advanced Solid Tumors	Advanced Solid Tumor; HepatoCellular Carcinoma; PD-L1 Amplified Tumor (9p24.1); Mesothelioma; Esophageal Squamous Cell Carcinoma; MSI-H/dMMR Tumors; Nasopharyngeal Carcinoma; Small-cell Lung Cancer; Merkel Cell Carcinoma; Cutaneous Squamous Cell Carcinoma; Cervical Cancer; Urothelial Carcinoma	03004 - Melbourne; 02050 - Camperdown; - Heidelberg; - Nedlands	https://clinicaltrials.gov/ct2/show/NCT04242199
NCT04246177	LEAP-012	Phase 3		WA, VIC, NSW, QLD, NZ	29/01/2020	22/05/2020	Lenvatinib; Lenvatinib + Pembrolizumab; Pembrolizumab; Placebo	anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; placebo; VEGF_inhibitor	Lenvatinib + Pembrolizumab; Lenvatinib + Pembrolizumab; Placebo	VEGF_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; placebo	2019-002345-37  7902-012	A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (LEAP-012)	Carcinoma, Hepatocellular	3084 - Heidelberg; 2217 - Kogarah; 6000 - Perth; 4102 - Brisbane; 3004 - Melbourne; Auckland	https://clinicaltrials.gov/ct2/show/NCT04246177
NCT04246489	2019-003583-40--MS200647-0017	Phase 2	NOT_RECRUITING	VIC, WA	29/01/2020	30/03/2020	Bintrafusp Alfa	anti-PD-L1/TGF-beta_fusion_protein	Bintrafusp Alfa	anti-PD-L1/TGF-beta_fusion_protein	2019-003583-40  MS200647_0017	A Phase II, Multicenter, Open Label Study of Bintrafusp Alfa (M7824) Monotherapy in Participants With Advanced, Unresectable Cervical Cancer With Disease Progression During or After Platinum-Containing Chemotherapy	Uterine Cervical Neoplasms	- Nedlands; - Melbourne; - Waratah	https://clinicaltrials.gov/ct2/show/NCT04246489
NCT04248829	YH25448-301	Phase 3		QLD	30/01/2020	13/02/2020	Gefitinib; Gefitinib + Lazertinib; Lazertinib; Placebo	EGFR_inhibitor,third_generation; EGFR_inhibitor,first_generation + EGFR_inhibitor,third_generation; EGFR_inhibitor,first_generation; placebo	Gefitinib + Lazertinib; Gefitinib + Lazertinib; Placebo	EGFR_inhibitor,first_generation + EGFR_inhibitor,third_generation; EGFR_inhibitor,first_generation + EGFR_inhibitor,third_generation; placebo	YH25448-301	A Phase III, Randomized, Double-blind Study to Assess the Efficacy and Safety of Lazertinib Versus Gefitinib as the First-line Treatment in Patients With Epidermal Growth Factor Receptor Sensitizing Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer	Non-Small Cell Lung Cancer	4102 - Woolloongabba	https://clinicaltrials.gov/ct2/show/NCT04248829
NCT04249843	BGB-3245-AU-001	Phase 1		NSW	31/01/2020	17/02/2020	BGB-3245	RAF_dimer_inhibitor	BGB-3245	RAF_dimer_inhibitor	BGB-3245-AU-001	A First-in-Human, Phase 1a/1b, Open Label, Dose-Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, and Antitumor Activity of the RAF Dimer Inhibitor BGB-3245 in Patients With Advanced or Refractory Tumors	B-Raf Mutation-Related Tumors; Solid Tumor	2010 - Sydney; 2010 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04249843
NCT04250155	GO41596	Phase 1		VIC	31/01/2020	9/03/2020	Atezolizumab; Atezolizumab + XmAb24306; XmAb24306	IL-15/IL-15R_Fc-fusion_protein; anti-PD-L1_monoclonal_antibody; IL-15/IL-15R_Fc-fusion_protein + anti-PD-L1_monoclonal_antibody	Atezolizumab + XmAb24306; XmAb24306; Atezolizumab + XmAb24306	IL-15/IL-15R_Fc-fusion_protein; IL-15/IL-15R_Fc-fusion_protein + anti-PD-L1_monoclonal_antibody; IL-15/IL-15R_Fc-fusion_protein + anti-PD-L1_monoclonal_antibody	GO41596	A Phase Ia/Ib, Open-Label, Multicenter, Global, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of XmAb24306 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors	Solid Tumors	3002 - East Melbourne	https://clinicaltrials.gov/ct2/show/NCT04250155
NCT04251117	GT-30	Phase 1/Phase 2	NOT_RECRUITING	NZ	31/01/2020		GNOS-PV02; GNOS-PV02 + INO-9012 + Pembrolizumab; INO-9012; Pembrolizumab	DNA_plasmid_encoding_IL-12; anti-PD-1_monoclonal_antibody; personalized_neoantigen_vaccine; DNA_plasmid_encoding_IL-12 + anti-PD-1_monoclonal_antibody + personalized_neoantigen_vaccine	GNOS-PV02 + INO-9012 + Pembrolizumab; GNOS-PV02 + INO-9012 + Pembrolizumab	DNA_plasmid_encoding_IL-12 + anti-PD-1_monoclonal_antibody + personalized_neoantigen_vaccine; DNA_plasmid_encoding_IL-12 + anti-PD-1_monoclonal_antibody + personalized_neoantigen_vaccine	GT-30	An Open-label, Multi-center, Phase I/IIa Study of a Personalized Neoantigen DNA Vaccine (GNOS-PV02) and Plasmid Encoded IL-12 (INO-9012) in Combination With Pembrolizumab (MK-3475) in Subjects With Advanced Hepatocellular Carcinoma	HCC	Auckland	https://clinicaltrials.gov/ct2/show/NCT04251117
NCT04251533	EPIK-B3	Phase 3		VIC, WA	5/02/2020	8/06/2020	Alpelisib; Alpelisib + Nab-paclitaxel; Nab-paclitaxel; Placebo	PI3K_alpha_inhibitor + taxane; taxane; placebo; PI3K_alpha_inhibitor	Alpelisib + Nab-paclitaxel; Nab-paclitaxel; Alpelisib + Nab-paclitaxel; Placebo	PI3K_alpha_inhibitor + taxane; taxane; PI3K_alpha_inhibitor + taxane; placebo	2019-002637-11  CBYL719H12301	A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositide-3-kinase Catalytic Subunit Alpha (PIK3CA) Mutation or Phosphatase and Tensin Homolog Protein (PTEN) Loss Without PIK3CA Mutation	Triple Negative Breast Neoplasms	3000 - Melbourne; 6150 - Murdoch; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT04251533
NCT04256421	SKYSCRAPER-02	Phase 3	NOT_RECRUITING	QLD, NSW, SA, NZ	5/02/2020	4/02/2020	Atezolizumab; Atezolizumab + Carboplatin + Etoposide; Atezolizumab + Carboplatin + Etoposide + Tiragolumab; Carboplatin; Etoposide; Placebo; Tiragolumab	anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; platinum-based_antineoplastic_agent; placebo; anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-PD-L1_monoclonal_antibody; topoisomerase_inhibitor	Atezolizumab + Carboplatin + Etoposide; Atezolizumab + Carboplatin + Etoposide + Tiragolumab; Atezolizumab + Carboplatin + Etoposide; Atezolizumab + Carboplatin + Etoposide + Tiragolumab; Placebo	anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; placebo	2019-003301-97  GO41767	A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab (Anti-Tigit Antibody) in Patients With Untreated Extensive-Stage Small Cell Lung Cancer	Small Cell Lung Cancer	4575 - Birtinya; Auckland; 5112 - Elizabeth Vale; 2050 - Camperdown; 2747 - Kingswood	https://clinicaltrials.gov/ct2/show/NCT04256421
NCT04262466	IMC-F106C-101	Unknown		NZ	10/02/2020	25/02/2020	Atezolizumab; IMC-F106C; Pembrolizumab; Tebentafusp	anti-PD-L1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; bispecific_T-cell_engager,PRAME-targeting; anti-CD3/scFv_fusion_protein,gp100-targeting	IMC-F106C; Atezolizumab; Pembrolizumab; Tebentafusp	bispecific_T-cell_engager,PRAME-targeting; anti-CD3/scFv_fusion_protein,gp100-targeting; anti-PD-1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody	IMC-F106C-101	Phase 1/2 Study of IMC-F106C in Advance PRAME-Positive Cancers	Select Advanced Solid Tumors	Auckland	https://clinicaltrials.gov/ct2/show/NCT04262466
NCT04262856	ARC-7	Phase 2		SA, NSW	10/02/2020	28/05/2020	Domvanalimab; Domvanalimab + Etrumadenant + Zimberelimab; Domvanalimab + Zimberelimab; Etrumadenant; Zimberelimab	adenosine_A2aR_and_A2bR_antagonist + anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; adenosine_A2aR_and_A2bR_antagonist; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-TIGIT_monoclonal_antibody	Domvanalimab + Etrumadenant + Zimberelimab; Domvanalimab + Zimberelimab; Zimberelimab; Domvanalimab + Etrumadenant + Zimberelimab; Domvanalimab + Zimberelimab	adenosine_A2aR_and_A2bR_antagonist + anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; adenosine_A2aR_and_A2bR_antagonist + anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody	AB154CSP0002	A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination With AB122, and AB154 in Combination With AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer	Lung Cancer; Nonsquamous Non Small Cell Lung Cancer; Non Small Cell Lung Cancer; Squamous Non Small Cell Lung Cancer	2640 - Albury; 2485 - Tweed Heads; 2450 - Coffs Harbour; 5112 - Elizabeth Vale; 2500 - Nowra	https://clinicaltrials.gov/ct2/show/NCT04262856
NCT04269200	DUO-E	Phase 3		NSW, VIC, SA, WA	13/02/2020	21/05/2020	Carboplatin; Durvalumab; Durvalumab + Olaparib; Olaparib; Paclitaxel; Placebo	PARP_inhibitor; PARP_inhibitor + anti-PD-L1_monoclonal_antibody; platinum-based_antineoplastic_agent; placebo; anti-PD-L1_monoclonal_antibody; taxane	Durvalumab + Olaparib; Carboplatin; Durvalumab + Olaparib; Paclitaxel; Placebo	PARP_inhibitor + anti-PD-L1_monoclonal_antibody; PARP_inhibitor + anti-PD-L1_monoclonal_antibody; placebo; platinum-based_antineoplastic_agent; taxane	2019-004112-60  D9311C00001	A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination With Durvalumab, Followed by Maintenance Durvalumab With or Without Olaparib in Patients With Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E)	Endometrial Neoplasms	3144 - Malvern; 3168 - Clayton; 2560 - Campbelltown; 6009 - Nedlands; 5042 - Bedford Park; NSW 2145 - Sydney; 3000 - Melbourne; 2444 - Port Macquarie; 2217 - Kogarah	https://clinicaltrials.gov/ct2/show/NCT04269200
NCT04277637	BGB-11417-101	Phase 1	NOT_RECRUITING	NZ, SA, VIC, NSW, QLD, WA	20/02/2020	24/03/2020	BGB-11417; BGB-11417 + Zanubrutinib; Zanubrutinib	BTK_inhibitor + Bcl2_inhibitor; BTK_inhibitor; Bcl2_inhibitor	BGB-11417; BGB-11417 + Zanubrutinib; BGB-11417 + Zanubrutinib	BTK_inhibitor + Bcl2_inhibitor; Bcl2_inhibitor; BTK_inhibitor + Bcl2_inhibitor	BGB-11417-101	A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients With Mature B-Cell Malignancies	Mature B-Cell Malignancies	3002 - East Melbourne; Auckland; 5042 - Adelaide; - Adelaide; 2139 - Concord; 4224 - Tugun; 3168 - Clayton; 4217 - Benowa; 2800 - Orange; 6009 - Nedlands; 3000 - Melbourne; 2010 - Darlinghurst	https://clinicaltrials.gov/ct2/show/NCT04277637
NCT04282018	BGB-A317-3111-10188-101	Phase 1/Phase 2		VIC, NSW, SA, WA	24/02/2020	25/05/2020	BGB-10188; BGB-10188 + Tislelizumab; BGB-10188 + Zanubrutinib; Tislelizumab; Zanubrutinib	PI3K_delta_inhibitor; anti-PD-1_monoclonal_antibody; PI3K_delta_inhibitor + anti-PD-1_monoclonal_antibody; BTK_inhibitor; BTK_inhibitor + PI3K_delta_inhibitor	BGB-10188; BGB-10188 + Tislelizumab; BGB-10188 + Zanubrutinib; BGB-10188 + Tislelizumab; BGB-10188 + Zanubrutinib	BTK_inhibitor + PI3K_delta_inhibitor; PI3K_delta_inhibitor; PI3K_delta_inhibitor + anti-PD-1_monoclonal_antibody; BTK_inhibitor + PI3K_delta_inhibitor; PI3K_delta_inhibitor + anti-PD-1_monoclonal_antibody	BGB-A317-3111-10188-101	A Phase 1/2, Dose Escalation and Expansion Study of BGB-10188, a Phosphatidylinositol 3-Kinase Delta (PI3Kd) Inhibitor, Combined With Zanubrutinib in Patients With Mature B-Cell Malignancies and Combined With Tislelizumab in Patients With Solid Tumors	Advanced Solid Tumor; Non-small Cell Lung Cancer; Chronic Lymphocytic Leukemia; Diffuse Large B Cell Lymphoma; Mantle Cell Lymphoma; Follicular Lymphoma; Marginal Zone Lymphoma; Metastatic Melanoma; Small Lymphocytic Lymphoma	5000 - Adelaide; 4029 - Herston; - West Perth; 2148 - Blacktown; - Clayton; - Darlinghurst; - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT04282018
NCT04284761	Biolen-PC	Phase 1		NSW, VIC, NZ	26/02/2020	11/10/2020	Bicalutamide	antiandrogen,nonsteroidal,first_generation	Bicalutamide	antiandrogen,nonsteroidal,first_generation	CP-001	A Study to Establish the Feasibility of Biolen for the Local Delivery of Bicalutamide in Patients With Prostate Cancer	Prostate Adenocarcinoma; Lower Urinary Tract Symptoms	2076 - Wahroonga; 2500 - Wollongong; 3144 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04284761
NCT04293094	NCT04293094	Phase 1		SA, VIC	3/03/2020	11/03/2020	AMG 650	KIF18A_inhibitor	AMG 650	KIF18A_inhibitor	20190131	A Phase 1, Multicenter, Open-label, Dose-Exploration and Dose-Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 650 in Subjects With Advanced Solid Tumors	Advanced Solid Tumors	3000 - Melbourne; 5011 - Woodville South	https://clinicaltrials.gov/ct2/show/NCT04293094
NCT04294160	CADPT01C12101	Phase 1		NSW	3/03/2020	22/07/2020	Dabrafenib; Dabrafenib + LTT462; Dabrafenib + LTT462 + Naporafenib; Dabrafenib + LTT462 + Spartalizumab; Dabrafenib + LTT462 + TNO155; Dabrafenib + LTT462 + Trametinib; Dabrafenib + TNO155 + Trametinib; LTT462; Naporafenib; Spartalizumab; TNO155; Trametinib	SHP2_inhibitor; anti-PD-1_monoclonal_antibody; BRAF_V600_inhibitor + ERK_inhibitor + RAF_dimer_inhibitor; BRAF_V600_inhibitor; ERK_inhibitor; BRAF_V600_inhibitor + MEK_inhibitor + SHP2_inhibitor; BRAF_V600_inhibitor + ERK_inhibitor + MEK_inhibitor; RAF_dimer_inhibitor; BRAF_V600_inhibitor + ERK_inhibitor; BRAF_V600_inhibitor + ERK_inhibitor + anti-PD-1_monoclonal_antibody; MEK_inhibitor; BRAF_V600_inhibitor + ERK_inhibitor + SHP2_inhibitor	Dabrafenib + LTT462; Dabrafenib + LTT462 + Naporafenib; Dabrafenib + LTT462 + Spartalizumab; Dabrafenib + LTT462 + TNO155; Dabrafenib + LTT462 + Trametinib; Dabrafenib + TNO155 + Trametinib; Dabrafenib + LTT462; Dabrafenib + LTT462 + Naporafenib; Dabrafenib + LTT462 + Spartalizumab; Dabrafenib + LTT462 + TNO155; Dabrafenib + LTT462 + Trametinib; Dabrafenib + TNO155 + Trametinib	BRAF_V600_inhibitor + ERK_inhibitor; BRAF_V600_inhibitor + ERK_inhibitor + MEK_inhibitor; BRAF_V600_inhibitor + ERK_inhibitor + RAF_dimer_inhibitor; BRAF_V600_inhibitor + ERK_inhibitor + SHP2_inhibitor; BRAF_V600_inhibitor + ERK_inhibitor + anti-PD-1_monoclonal_antibody; BRAF_V600_inhibitor + MEK_inhibitor + SHP2_inhibitor; BRAF_V600_inhibitor + ERK_inhibitor; BRAF_V600_inhibitor + ERK_inhibitor + MEK_inhibitor; BRAF_V600_inhibitor + ERK_inhibitor + RAF_dimer_inhibitor; BRAF_V600_inhibitor + ERK_inhibitor + SHP2_inhibitor; BRAF_V600_inhibitor + ERK_inhibitor + anti-PD-1_monoclonal_antibody; BRAF_V600_inhibitor + MEK_inhibitor + SHP2_inhibitor	CADPT01C12101	A Phase Ib, Multicenter, Open-label Dose Escalation and Expansion Platform Study of Select Drug Combinations in Adult Patients With Advanced or Metastatic BRAF V600 Colorectal Cancer	BRAF V600 Colorectal Cancer	2145 - Westmead	https://clinicaltrials.gov/ct2/show/NCT04294160
NCT04294810	SKYSCRAPER-01	Phase 3	NOT_RECRUITING	QLD, NSW, VIC	4/03/2020	4/03/2020	Atezolizumab; Atezolizumab + Tiragolumab; Placebo; Tiragolumab	anti-PD-L1_monoclonal_antibody; placebo; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-TIGIT_monoclonal_antibody	Atezolizumab; Atezolizumab + Tiragolumab; Atezolizumab + Tiragolumab; Placebo	anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; placebo	2019-002925-31  GO41717	A Phase III, Randomized, Double-Blinded, Placebo-Controlled Study of Tiragolumab, an Anti-Tigit Antibody, in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer	Non-Small Cell Lung Cancer	4102 - Woolloongabba; 3000 - Melbourne; 2010 - Darlinghurst; 3199 - Frankston; 3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT04294810
NCT04296890	SORAYA	Phase 3		VIC, NSW, QLD, WA	5/03/2020	23/07/2020	Mirvetuximab Soravtansine	anti-FR-alpha_antibody-drug_conjugate	Mirvetuximab Soravtansine	anti-FR-alpha_antibody-drug_conjugate	2020-000179-19  IMGN853-0417	SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression	Epithelial Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer	3199 - Frankston; 2065 - St. Leonards; 4066 - Auchenflower; 6008 - Subiaco	https://clinicaltrials.gov/ct2/show/NCT04296890
NCT04298918	2019-004200-35--CO41863	Phase 1/Phase 2		VIC	6/03/2020	23/09/2020	Placebo; Trastuzumab Emtansine; Trastuzumab Emtansine + Venetoclax; Venetoclax	Bcl2_inhibitor + anti-ERBB2_antibody-drug_conjugate; Bcl2_inhibitor; placebo; anti-ERBB2_antibody-drug_conjugate	Trastuzumab Emtansine; Trastuzumab Emtansine + Venetoclax; Placebo; Trastuzumab Emtansine + Venetoclax	Bcl2_inhibitor + anti-ERBB2_antibody-drug_conjugate; anti-ERBB2_antibody-drug_conjugate; Bcl2_inhibitor + anti-ERBB2_antibody-drug_conjugate; placebo	2019-004200-35  CO41863	A Phase lb/ll, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Venetoclax in Combination With Trastuzumab Emtansine in Patients With Previously Treated HER2-Positive Locally Advanced or Metastatic Breast Cancer	Breast Cancer	3002 - East Melbourne	https://clinicaltrials.gov/ct2/show/NCT04298918
NCT04300244	NIPU	Phase 2		WA	9/03/2020	4/05/2020	Ipilimumab; Ipilimumab + Nivolumab; Nivolumab; Sargramostim	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; Granulocyte-Macrophage_Colony_Stimulating_Factor	Ipilimumab + Nivolumab; Ipilimumab + Nivolumab; Sargramostim	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; Granulocyte-Macrophage_Colony_Stimulating_Factor; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	CA209-7H4 NIPU	Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma (the NIPU-study)	Cancer; Mesotheliomas Pleural; Mesothelioma; Cancer of Lung; Cancer, Lung; Lung; Pleura	- Perth	https://clinicaltrials.gov/ct2/show/NCT04300244
NCT04300647	SKYSCRAPER-04	Phase 2		QLD	9/03/2020	30/06/2020	Atezolizumab; Atezolizumab + Tiragolumab; Tiragolumab	anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-TIGIT_monoclonal_antibody	Atezolizumab; Atezolizumab + Tiragolumab; Atezolizumab + Tiragolumab	anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody	2019-004895-21  WO42017	A Phase II, Safety, and Efficacy Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Patients With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer	Cervical Cancer	4101 - South Brisbane	https://clinicaltrials.gov/ct2/show/NCT04300647
NCT04303780	2019-003582-18--20190009	Phase 3	NOT_RECRUITING	SA, VIC, NSW, QLD, WA	11/03/2020	4/06/2020	Docetaxel; Sotorasib	KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor; taxane	Docetaxel; Sotorasib	KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor; taxane	2019-003582-18  20190009	A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects With Mutated KRAS p.G12C	KRAS p, G12c Mutated /Advanced Metastatic NSCLC	6008 - Subiaco; 2170 - Liverpool; 3168 - Clayton; 4102 - Woolloongabba; 4032 - Chermside; 2148 - Blacktown; 2050 - Camperdown; 5011 - Woodville South; 2217 - Kogarah; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04303780
NCT04305041	2019-003956-35--3475-02A	Phase 1/Phase 2		QLD, NSW, WA	12/03/2020	26/06/2020	Lenvatinib; Lenvatinib + Pembrolizumab + Quavonlimab; Pembrolizumab; Pembrolizumab + Quavonlimab + Vibostolimab; Quavonlimab; Vibostolimab	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; VEGF_inhibitor; anti-TIGIT_monoclonal_antibody	Lenvatinib + Pembrolizumab + Quavonlimab; Pembrolizumab + Quavonlimab + Vibostolimab; Lenvatinib + Pembrolizumab + Quavonlimab; Pembrolizumab + Quavonlimab + Vibostolimab	VEGF_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; VEGF_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody	2019-003956-35  3475-02A	A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02A	Melanoma	6150 - Murdoch; 2065 - Wollstonecraft; 4215 - Southport; 2298 - Waratah	https://clinicaltrials.gov/ct2/show/NCT04305041
NCT04305054	2019-003977-24--3475-02B	Phase 1/Phase 2		QLD, NSW, WA	12/03/2020	1/07/2020	Lenvatinib; Lenvatinib + Pembrolizumab + Quavonlimab; Pembrolizumab; Pembrolizumab + Quavonlimab; Pembrolizumab + Vibostolimab; Quavonlimab; Vibostolimab	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; VEGF_inhibitor; anti-TIGIT_monoclonal_antibody; VEGF_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody	Lenvatinib + Pembrolizumab + Quavonlimab; Pembrolizumab; Pembrolizumab + Quavonlimab; Pembrolizumab + Vibostolimab; Lenvatinib + Pembrolizumab + Quavonlimab; Pembrolizumab + Quavonlimab; Pembrolizumab + Vibostolimab	VEGF_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; VEGF_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody	2019-003977-24  3475-02B	A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02B	Melanoma	2065 - Wollstonecraft; 6150 - Murdoch; 4120 - Southport; 2298 - Waratah	https://clinicaltrials.gov/ct2/show/NCT04305054
NCT04305249	ERASER	Phase 1		VIC, NSW	12/03/2020	15/08/2020	ATG-017	ERK_inhibitor	ATG-017	ERK_inhibitor	ATG-017-001	A Phase I, Open-Label, Multi-Center Dose Finding Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG-017 Monotherapy in Patients With Advanced Solid Tumors and Hematological Malignancies	Solid Tumor; Hematological Malignancy	3002 - East Melbourne; 3004 - Melbourne; 3084 - Heidelberg; - Sydney; - Randwick	https://clinicaltrials.gov/ct2/show/NCT04305249
NCT04305496	CAPItello-291	Phase 3		SA, NSW, VIC, QLD	12/03/2020	16/04/2020	Capivasertib; Capivasertib + Fulvestrant; Fulvestrant; Placebo	pan-AKT_inhibitor + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader; placebo; pan-AKT_inhibitor	Capivasertib + Fulvestrant; Fulvestrant; Capivasertib + Fulvestrant; Placebo	pan-AKT_inhibitor + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader; pan-AKT_inhibitor + selective_estrogen_receptor_degrader; placebo	D3615C00001	A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Fulvestrant Versus Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Breast Cancer Following Recurrence or Progression On or After Treatment With an Aromatase Inhibitor	Locally Advanced (Inoperable) or Metastatic Breast Cancer	4101 - South Brisbane; 3355 - Wendouree; 2640 - East Albury; 3135 - Ringwood East; 2060 - North Sydney; 4575 - Birtinya; 2139 - Concord; 2800 - Orange; 5000 - Adelaide; 2298 - Waratah; 5037 - Kurralta Park; 3350 - Ballarat; 3128 - Box Hill	https://clinicaltrials.gov/ct2/show/NCT04305496
NCT04311710	CheckMate-76U	Phase 1/Phase 2	NOT_RECRUITING	VIC, NZ	17/03/2020	22/06/2020	Ipilimumab; Nivolumab; rHuPH20	recombinant_human_hyaluronidase; anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody	Ipilimumab; Nivolumab; rHuPH20	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; recombinant_human_hyaluronidase	CA209-76U	A Phase 1/2 Pharmacokinetic Multi-tumor Study of Subcutaneous Formulation of Ipilimumab Monotherapy and in Combination With Subcutaneous Nivolumab	Tumor	3144 - Malvern; Auckland	https://clinicaltrials.gov/ct2/show/NCT04311710
NCT04322318	NCI-2020-01561--AREN1921	Phase 2		NZ, VIC, QLD, WA	26/03/2020	18/09/2020	Carboplatin; Carboplatin + Etoposide + Ifosfamide; Cyclophosphamide; Doxorubicin; Etoposide; Ifosfamide; Irinotecan; Topotecan; Vincristine	anthracycline; alkylating_agent; platinum-based_antineoplastic_agent; doxorubicin; alkylating_agent + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; vinca_alkaloid; topoisomerase_inhibitor	Carboplatin + Etoposide + Ifosfamide; Carboplatin + Etoposide + Ifosfamide; Cyclophosphamide; Doxorubicin; Irinotecan; Topotecan; Vincristine	alkylating_agent + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; alkylating_agent + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anthracycline; doxorubicin; vinca_alkaloid	NCI-2020-01561  AREN1921	Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)	Stage II Kidney Wilms Tumor; Stage IV Kidney Wilms Tumor; Stage III Kidney Wilms Tumor; Recurrent Kidney Wilms Tumor; Anaplastic Kidney Wilms Tumor	3052 - Parkville; Auckland; 6009 - Perth; 4101 - South Brisbane	https://clinicaltrials.gov/ct2/show/NCT04322318
NCT04322539	FRESCO-2	Phase 3	NOT_RECRUITING	SA, VIC, QLD, WA	26/03/2020	10/07/2020	Fruquintinib; Placebo	VEGFR1/2/3_inhibitor; placebo	Fruquintinib; Placebo	VEGFR1/2/3_inhibitor; placebo	2019-013-GLOB1	A Global Multicenter Randomized Placebo-Controlled Phase 3 Trial To Compare The Efficacy And Safety Of Fruquintinib Plus Best Supportive Care To Placebo Plus Best Supportive Care In Patients With Refractory Metastatic Colorectal Cancer	Metastatic Colorectal Cancer; Metastatic Colon Cancer	6009 - Perth; 5011 - Adelaide; 3168 - Melbourne; 4001 - Brisbane; 5042 - Adelaide; 3084 - Melbourne; 3021 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04322539
NCT04324814	SHR-1701-001AUS	Phase 1		WA, QLD, NSW	27/03/2020	31/03/2020	Retlirafusp alfa	PD-L1/TGF-beta_fusion_protein	Retlirafusp alfa	PD-L1/TGF-beta_fusion_protein	SHR-1701-001AUS	A Phase 1, Open-Label, Multi-Center, Non-Randomized, Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of SHR-1701 in Subjects With Advanced Solid Tumors	Advanced Solid Tumor	- Sydney; 4101 - South Brisbane; - Perth	https://clinicaltrials.gov/ct2/show/NCT04324814
NCT04334759	DREAM3R	Phase 3		NZ, SA, TAS, VIC, NSW, QLD, WA	6/04/2020	18/02/2021	Durvalumab	anti-PD-L1_monoclonal_antibody	Durvalumab	anti-PD-L1_monoclonal_antibody	PrE0506  DREAM3R	DREAM3R: DuRvalumab (MEDI4736) With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma - A Phase 3 Randomised Trial	Mesothelioma; Pleural Mesothelioma; Malignant Pleural Mesothelioma	2170 - Liverpool; 2450 - Coffs Harbour; 2259 - Hamlyn Terrace; Auckland; 4101 - South Brisbane; 7250 - Launceston; 3630 - Shepparton; 4102 - Woolloongabba; 4575 - Birtinya; 3168 - Clayton; 2250 - Gosford; 4066 - Auchenflower; 2145 - Westmead; 3021 - Saint Albans; 5011 - Woodville South; 2065 - Saint Leonards; 2148 - Blacktown; 2800 - Orange; 3084 - Heidelberg; 4032 - Chermside; 6009 - Nedlands; 2747 - Kingswood; 7000 - Hobart; 5042 - Bedford Park; 3000 - Melbourne; 3199 - Frankston; 2298 - Waratah; 3121 - Richmond	https://clinicaltrials.gov/ct2/show/NCT04334759
NCT04338269	CONTACT-03	Phase 3		QLD, NSW, VIC	8/04/2020	28/07/2020	Atezolizumab; Atezolizumab + Cabozantinib; Cabozantinib	VEGFR2_inhibitor + anti-PD-L1_monoclonal_antibody; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor; RET_inhibitor + anti-PD-L1_monoclonal_antibody; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + anti-PD-L1_monoclonal_antibody; VEGFR2_inhibitor; AXL_inhibitor + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; ROS1_inhibitor; MET_inhibitor,type_2; AXL_inhibitor; KIT_inhibitor + anti-PD-L1_monoclonal_antibody; RET_inhibitor; ROS1_inhibitor + anti-PD-L1_monoclonal_antibody; MET_inhibitor,type_2 + anti-PD-L1_monoclonal_antibody; KIT_inhibitor	Atezolizumab + Cabozantinib; Cabozantinib; Atezolizumab + Cabozantinib	AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + anti-PD-L1_monoclonal_antibody; AXL_inhibitor; AXL_inhibitor + anti-PD-L1_monoclonal_antibody; KIT_inhibitor; KIT_inhibitor + anti-PD-L1_monoclonal_antibody; MET_inhibitor,type_2; MET_inhibitor,type_2 + anti-PD-L1_monoclonal_antibody; RET_inhibitor; RET_inhibitor + anti-PD-L1_monoclonal_antibody; ROS1_inhibitor; ROS1_inhibitor + anti-PD-L1_monoclonal_antibody; VEGFR2_inhibitor; VEGFR2_inhibitor + anti-PD-L1_monoclonal_antibody; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + anti-PD-L1_monoclonal_antibody; AXL_inhibitor + anti-PD-L1_monoclonal_antibody; KIT_inhibitor + anti-PD-L1_monoclonal_antibody; MET_inhibitor,type_2 + anti-PD-L1_monoclonal_antibody; RET_inhibitor + anti-PD-L1_monoclonal_antibody; ROS1_inhibitor + anti-PD-L1_monoclonal_antibody; VEGFR2_inhibitor + anti-PD-L1_monoclonal_antibody	WO41994	A Phase III, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Atezolizumab Given in Combination With Cabozantinib Versus Cabozantinib Alone in Patients With Inoperable, Locally Advanced, or Metastatic Renal Cell Carcinoma Who Experienced Radiographic Tumor Progression During or After Immune Checkpoint Inhibitor Treatment	Carcinoma, Renal Cell	2109 - Macquarie Park; 2800 - Orange; 3550 - Bendigo; 3128 - Box Hill; 4101 - South Brisbane	https://clinicaltrials.gov/ct2/show/NCT04338269
NCT04338399	BURAN	Unknown		QLD	8/04/2020	12/12/2020	Buparlisib; Buparlisib + Paclitaxel; Paclitaxel	pan-PI3K_inhibitor; pan-PI3K_inhibitor + taxane; PI3K_alpha_inhibitor + taxane; taxane; PI3K_alpha_inhibitor	Buparlisib + Paclitaxel; Paclitaxel; Buparlisib + Paclitaxel	PI3K_alpha_inhibitor + taxane; pan-PI3K_inhibitor + taxane; taxane; PI3K_alpha_inhibitor + taxane; pan-PI3K_inhibitor + taxane	AN2025H0301	The BURAN Study of Buparlisib (AN2025) In Combination With Paclitaxel Compared to Paclitaxel Alone, in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma	Head and Neck Cancer	4102 - Brisbane	https://clinicaltrials.gov/ct2/show/NCT04338399
NCT04340193	CheckMate-74W	Phase 3		WA, SA, QLD, VIC, NSW	9/04/2020	15/09/2020	Ipilimumab; Ipilimumab + Nivolumab; Nivolumab; Placebo	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; placebo	Ipilimumab + Nivolumab; Ipilimumab + Nivolumab; Placebo	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; placebo	CA209-74W	A Randomized, Multi-center, Double-blinded, Placebo-controlled Phase 3 Study of Nivolumab and Ipilimumab, Nivolumab Monotherapy, or Placebo in Combination With Trans-arterial ChemoEmbolization (TACE) in Patients With Intermediate-stage Hepatocellular Carcinoma (HCC)	Liver Cancer	4560 - Birtinya; 3065 - Melbourne; 6150 - Murdoch; 2500 - Wollongong; 5000 - Adelaide	https://clinicaltrials.gov/ct2/show/NCT04340193
NCT04343885	UpFrontPSMA	Phase 2		VIC, NSW, QLD, SA	13/04/2020	21/04/2020	Docetaxel; Docetaxel + Lu-177 vipivotide tetraxetan; Lu-177 vipivotide tetraxetan	radioligand,PSMA-targeting + taxane; radioligand,PSMA-targeting; taxane	Docetaxel + Lu-177 vipivotide tetraxetan; Docetaxel + Lu-177 vipivotide tetraxetan	radioligand,PSMA-targeting + taxane; radioligand,PSMA-targeting + taxane	19/195	UpFrontPSMA : A Randomised Phase 2 Study of Sequential 177Lu-PSMA617 and Docetaxel Versus Docetaxel in Metastatic Hormone-Naive Prostate Cancer	Metastatic Hormone Naive Prostate Cancer	5000 - Adelaide; 2010 - Sydney; 4029 - Brisbane; 3084 - Melbourne; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04343885
NCT04349969	AK117-101	Phase 1		QLD, NSW, VIC, SA, WA	16/04/2020		AK117	anti-CD47_monoclonal_antibody	AK117	anti-CD47_monoclonal_antibody	AK117-101	A Phase 1, Multicenter, Open Label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK117 in Subjects With Relapsed/Refractory Advanced or Metastatic Solid Tumors or Lymphomas	Neoplasms Malignant	4101 - South Brisbane; 3084 - Heidelberg; 6009 - Nedlands; 5037 - Kurralta Park; - Sydney	https://clinicaltrials.gov/ct2/show/NCT04349969
NCT04353102	YH002002	Phase 1		NSW, VIC	20/04/2020	22/04/2020	YH002	anti-OX40_agonistic_antibody	YH002	anti-OX40_agonistic_antibody	YH002002	A First-in-Human (FIH), Multicenter, Open-Label, Phase 1 Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of YH002 in Subjects With Advanced Solid Malignancies	Advanced Solid Malignancies	2217 - Kogarah; 3199 - Frankston; 2162 - Macquarie	https://clinicaltrials.gov/ct2/show/NCT04353102
NCT04357756	YH001002	Phase 1		VIC, NSW	22/04/2020	21/04/2020	Toripalimab; Toripalimab + YH001; YH001	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Toripalimab + YH001; Toripalimab + YH001	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	YH001002	A First-in-human (FIH), Open-Label, Phase I Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of YH001 in Combination With Toripalimab Injection in Subjects With Advanced Solid Tumors	Advanced Solid Tumor	2148 - Blacktown; 2217 - Kogarah; 3199 - Frankston	https://clinicaltrials.gov/ct2/show/NCT04357756
NCT04362748	NCT04362748	Phase 1		NSW, VIC	27/04/2020	15/09/2020	Latikafusp	anti-PD-1_x_IL21_mutein	Latikafusp	anti-PD-1_x_IL21_mutein	20180144	A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 256 in Patients With Advanced Solid Tumors	Advanced Solid Tumors	2050 - Camperdown; 2010 - Darlinghurst; 3168 - Clayton	https://clinicaltrials.gov/ct2/show/NCT04362748
NCT04370704	INCAGN-2385-201	Phase 1/Phase 2		VIC	1/05/2020	27/07/2020	Retifanlimab	anti-PD-1_monoclonal_antibody	Retifanlimab	anti-PD-1_monoclonal_antibody	INCAGN 2385-201	A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies	Melanoma	03128 - Box Hill	https://clinicaltrials.gov/ct2/show/NCT04370704
NCT04380805	AK104-201-AU	Phase 2		NZ, SA, VIC, NSW, QLD, WA	8/05/2020	15/07/2020	AK104	bispecific_PD-1/CTLA-4_antibody	AK104	bispecific_PD-1/CTLA-4_antibody	AK104-201-AU	A Phase 2, Multicenter, Single Arm, Open Label Study to Evaluate the Efficacy and Safety of AK104 in Subjects With Recurrent or Metastatic Cervical Cancer	Metastatic Cervical Cancer; Recurrent Cervical Cancer	- Nedlands; - Brisbane; Auckland; - Adelaide; - Clayton; - Blacktown	https://clinicaltrials.gov/ct2/show/NCT04380805
NCT04383210	ELVCAP-001-01	Phase 2		VIC	12/05/2020	29/09/2020	Seribantumab	anti-ERBB3_monoclonal_antibody	Seribantumab	anti-ERBB3_monoclonal_antibody	ELVCAP-001-01	CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients With Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors	Lung Cancer; Gallbladder Cancer; Prostate Cancer; Uterine Cancer; Bladder Cancer; Esophageal Cancer; Bile Duct Cancer; Colorectal Cancer; Sarcoma; Metastatic Solid Tumor; Locally Advanced Solid Tumor; Breast Cancer; Pancreatic Cancer; Ovarian Cancer; Cholangiocarcinoma; Head and Neck Cancer; Kidney Cancer	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04383210
NCT04385277	NCI-2020-02950--ANBL19P1	Phase 2		QLD, VIC, NSW, NZ, WA	12/05/2020	30/11/2020	Dinutuximab; Dinutuximab + Irinotecan + Isotretinoin + Sargramostim + Temozolomide; Irinotecan; Isotretinoin; Sargramostim; Temozolomide	anti-GD2_monoclonal_antibody; alkylating_agent; Granulocyte-Macrophage_Colony_Stimulating_Factor; 13-cis-retinoic_acid + Granulocyte-Macrophage_Colony_Stimulating_Factor + alkylating_agent + anti-GD2_monoclonal_antibody + topoisomerase_inhibitor; 13-cis-retinoic_acid; topoisomerase_inhibitor	Dinutuximab + Irinotecan + Isotretinoin + Sargramostim + Temozolomide; Dinutuximab + Irinotecan + Isotretinoin + Sargramostim + Temozolomide	13-cis-retinoic_acid + Granulocyte-Macrophage_Colony_Stimulating_Factor + alkylating_agent + anti-GD2_monoclonal_antibody + topoisomerase_inhibitor; 13-cis-retinoic_acid + Granulocyte-Macrophage_Colony_Stimulating_Factor + alkylating_agent + anti-GD2_monoclonal_antibody + topoisomerase_inhibitor	NCI-2020-02950  ANBL19P1	A Pilot Study of Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide in the Post-Consolidation Setting for High-Risk Neuroblastoma	High Risk Neuroblastoma; Ganglioneuroblastoma, Nodular	2145 - Westmead; 3052 - Parkville; 6009 - Perth; Auckland; 4101 - South Brisbane	https://clinicaltrials.gov/ct2/show/NCT04385277
NCT04390763	daNIS-1	Phase 2	NOT_RECRUITING	VIC, NSW	18/05/2020	16/10/2020	Gemcitabine; Gemcitabine + NIS793 + Nab-paclitaxel; Gemcitabine + NIS793 + Nab-paclitaxel + Spartalizumab; Gemcitabine + Nab-paclitaxel; NIS793; Nab-paclitaxel; Spartalizumab	anti-TGF-beta_monoclonal_antibody + antimetabolite + taxane; anti-PD-1_monoclonal_antibody; antimetabolite; anti-TGF-beta_monoclonal_antibody; gemcitabine; anti-PD-1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody + antimetabolite + taxane; taxane; antimetabolite + taxane	Gemcitabine + NIS793 + Nab-paclitaxel; Gemcitabine + NIS793 + Nab-paclitaxel + Spartalizumab; Gemcitabine + Nab-paclitaxel; Gemcitabine + NIS793 + Nab-paclitaxel; Gemcitabine + NIS793 + Nab-paclitaxel + Spartalizumab; Gemcitabine + Nab-paclitaxel	anti-PD-1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody + antimetabolite + taxane; anti-TGF-beta_monoclonal_antibody + antimetabolite + taxane; antimetabolite + taxane; anti-PD-1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody + antimetabolite + taxane; anti-TGF-beta_monoclonal_antibody + antimetabolite + taxane; antimetabolite + taxane; gemcitabine	2020-000349-14  CNIS793B12201	A Phase II, Open Label, Randomized, Parallel Arm Study of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy Gemcitabine/Nab-paclitaxel, and Gemcitabine/Nab-paclitaxel Alone in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)	Metastatic Pancreatic Ductal Adenocarcinoma	3000 - Melbourne; 2145 - Westmead	https://clinicaltrials.gov/ct2/show/NCT04390763
NCT04402073	PersoMed-I	Phase 2			20/05/2020		Cisplatin; Lomustine; Radiotherapy; Sonidegib; Vincristine	radiotherapy; alkylating_agent; platinum-based_antineoplastic_agent; vinca_alkaloid; SMO_inhibitor,first_generation	Radiotherapy; Cisplatin; Lomustine; Sonidegib; Vincristine	radiotherapy; SMO_inhibitor,first_generation; alkylating_agent; platinum-based_antineoplastic_agent; vinca_alkaloid	1634	Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma (PersoMed-I)	Medulloblastoma		https://clinicaltrials.gov/ct2/show/NCT04402073
NCT04416516	ASN-002-003	Phase 2		QLD	4/06/2020	16/07/2020	Gusacitinib; Gusacitinib + Vismodegib; Vismodegib	SMO_inhibitor,first_generation + SYK/JAK_inhibitor; SYK/JAK_inhibitor; SMO_inhibitor,first_generation	Gusacitinib; Gusacitinib + Vismodegib; Gusacitinib + Vismodegib	SMO_inhibitor,first_generation + SYK/JAK_inhibitor; SYK/JAK_inhibitor; SMO_inhibitor,first_generation + SYK/JAK_inhibitor	ASN-002-003	A Phase 2A Study to Assess the Safety and Efficacy of ASN-002 Combined With a Hedgehog Pathway Inhibitor in the Treatment of Multiple Low Risk Basal Cell Carcinomas in Sporadic or Basal Cell Nevus Syndrome Patients	Basal Cell Nevus Syndrome; Basal Cell Carcinoma	4000 - Brisbane	https://clinicaltrials.gov/ct2/show/NCT04416516
NCT04417621	2020-000873-26--CLXH254C12201	Phase 2		NSW, QLD, WA	4/06/2020	30/10/2020	LTT462; LTT462 + Naporafenib; Naporafenib; Naporafenib + Ribociclib; Naporafenib + Trametinib; Ribociclib; Trametinib	CDK4/6_inhibitor; MEK_inhibitor + RAF_dimer_inhibitor; ERK_inhibitor; MEK_inhibitor; ERK_inhibitor + RAF_dimer_inhibitor; RAF_dimer_inhibitor; CDK4/6_inhibitor + RAF_dimer_inhibitor	LTT462 + Naporafenib; Naporafenib + Ribociclib; Naporafenib + Trametinib; LTT462 + Naporafenib; Naporafenib + Ribociclib; Naporafenib + Trametinib	CDK4/6_inhibitor + RAF_dimer_inhibitor; ERK_inhibitor + RAF_dimer_inhibitor; MEK_inhibitor + RAF_dimer_inhibitor; CDK4/6_inhibitor + RAF_dimer_inhibitor; ERK_inhibitor + RAF_dimer_inhibitor; MEK_inhibitor + RAF_dimer_inhibitor	2020-000873-26  CLXH254C12201	A Randomized, Open-label, Multi-arm, Two-part, Phase II Study to Assess Efficacy and Safety of Multiple LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic BRAFV600 or NRAS Mutant Melanoma	Melanoma	6008 - Subiaco; 2060 - North Sydney; 4102 - Wooloongabba	https://clinicaltrials.gov/ct2/show/NCT04417621
NCT04418661	U1111-1244-2555--TCD16210	Phase 1	*NOT_RECRUITING	QLD, VIC, NSW	5/06/2020	16/06/2020	Pembrolizumab; RMC-4630	SHP2_inhibitor; anti-PD-1_monoclonal_antibody	RMC-4630; Pembrolizumab	SHP2_inhibitor; anti-PD-1_monoclonal_antibody	U1111-1244-2555  TCD16210	A Phase 1/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of SAR442720 in Combination With Pembrolizumab in Patients With Advanced Malignancies	Metastatic Neoplasm	3081 - Heidelberg West; 4102 - Woolloongabba; 2031 - Randwick	https://clinicaltrials.gov/ct2/show/NCT04418661
NCT04419402	ENZA-p	Phase 2		QLD, NSW, VIC, SA, WA	5/06/2020	17/08/2020	Enzalutamide	antiandrogen,nonsteroidal,second_generation	Enzalutamide	antiandrogen,nonsteroidal,second_generation	ANZUP 1901	ENZA-p: A Randomised Phase II Trial Using PSMA as a Therapeutic Agent and Prognostic Indicator in Men With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide (ANZUP 1901)	Metastatic Castration-Resistant Prostate Cancer	3168 - Clayton; 3002 - Melbourne; 3004 - Melbourne; 2298 - Newcastle; 2170 - Liverpool; 5000 - Adelaide; 2065 - Sydney; 2010 - Darlinghurst; 4029 - Brisbane; 6009 - Nedlands; 3084 - Heidelberg; 6150 - Perth; 2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT04419402
NCT04423029	2021-000038-33--CA101-001	Phase 1/Phase 2		VIC	9/06/2020	10/07/2020	DF6002; Nivolumab	IL-12_Fc-fusion_protein; anti-PD-1_monoclonal_antibody	DF6002; Nivolumab	IL-12_Fc-fusion_protein; anti-PD-1_monoclonal_antibody	2021-000038-33  CA101-001	A Phase 1/2, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF6002 as a Monotherapy and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications	Solid Tumors	3084 - Heidelberg; 3128 - Box Hill	https://clinicaltrials.gov/ct2/show/NCT04423029
NCT04427072	GeoMETry-III	Phase 3	NOT_RECRUITING	VIC	11/06/2020	25/09/2020	Capmatinib; Docetaxel	MET_inhibitor,type_1; taxane	Capmatinib; Docetaxel	MET_inhibitor,type_1; taxane	CINC280A2301	A Phase III, Randomized, Controlled, Open-label, Multicenter, Global Study of Capmatinib Versus SoC Docetaxel Chemotherapy in Previously Treated Patients With EGFR wt, ALK Negative, Locally Advanced or Metastatic (Stage IIIB/IIIC or IV) NSCLC Harboring MET Exon 14 Skipping Mutation (MET?ex14).	Carcinoma, Non-Small-Cell Lung	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04427072
NCT04428151	LEAP-009	Phase 2		VIC, NSW, QLD	11/06/2020	6/08/2020	Capecitabine; Capecitabine + Cetuximab + Docetaxel + Paclitaxel; Cetuximab; Docetaxel; Lenvatinib; Lenvatinib + Pembrolizumab; Paclitaxel; Pembrolizumab	anti-PD-1_monoclonal_antibody; VEGF_inhibitor; anti-EGFR_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; taxane; anti-EGFR_monoclonal_antibody + fluoropyrimidine + taxane; fluoropyrimidine	Capecitabine + Cetuximab + Docetaxel + Paclitaxel; Lenvatinib; Lenvatinib + Pembrolizumab; Capecitabine + Cetuximab + Docetaxel + Paclitaxel; Lenvatinib + Pembrolizumab	VEGF_inhibitor; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; anti-EGFR_monoclonal_antibody + fluoropyrimidine + taxane; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; anti-EGFR_monoclonal_antibody + fluoropyrimidine + taxane	LEAP-009  7902-009	A Phase 2, Randomized, Open-label Three-arm Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) That Have Progressed After Platinum Therapy and Immunotherapy (PD-1/PD-L1 Inhibitors) (LEAP-009)	Squamous Cell Carcinoma of Head and Neck	4814 - Douglas; 3168 - Clayton; 2148 - Blacktown; 4120 - Brisbane; 2444 - Port Macquarie	https://clinicaltrials.gov/ct2/show/NCT04428151
NCT04428333	INDUCE-4	Phase 2/Phase 3		QLD, VIC, NSW	11/06/2020	13/08/2020	Fluorouracil; Fluorouracil + Pembrolizumab; GSK3359609; Pembrolizumab; Placebo	Fluorouracil; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + fluoropyrimidine; placebo; anti-ICOS_agonistic_antibody; fluoropyrimidine	Fluorouracil + Pembrolizumab; Fluorouracil + Pembrolizumab; GSK3359609; Placebo	anti-PD-1_monoclonal_antibody + fluoropyrimidine; Fluorouracil; anti-ICOS_agonistic_antibody; anti-PD-1_monoclonal_antibody + fluoropyrimidine; placebo	209227	A Randomized, Double-Blind, Adaptive, Phase II/III Study of GSK3359609 in Combination With Pembrolizumab and 5FU-Platinum Chemotherapy Versus Placebo in Combination With Pembrolizumab Plus 5FU-Platinum Chemotherapy for First-Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma	Neoplasms, Head and Neck	2148 - Blacktown; 3084 - Heidelberg; 3000 - Melbourne; 4102 - Woolloongabba	https://clinicaltrials.gov/ct2/show/NCT04428333
NCT04430842	QBS-72S-1001	Phase 1	NOT_RECRUITING	NSW	12/06/2020	20/07/2020	QBS10072S	amino_acid_analogue,LAT1-targeting	QBS10072S	amino_acid_analogue,LAT1-targeting	QBS-72S-1001	A Phase 1, Open Label, Multi-Center, Single and Multiple Dose, Dose Escalation and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S in Previously Treated Patients With Advanced or Metastatic Cancers With High LAT1 Signatures, and in Patients With Relapsed or Refractory Grade 4 Astrocytoma	Colorectal Cancer; Gastric Cancer; Astrocytoma; Sarcoma; Urinary Tract Cancer; Pleural Mesothelioma; Brain Cancer; Lung Cancer; Liver Cancer; Bladder Cancer; Prostate Cancer; Melanoma; Thymic Carcinoma; Pancreatic Cancer; Breast Cancer; Tongue Cancer; Cholangiocarcinoma; Ovarian Cancer; Kidney Cancer; Head and Neck Cancer; Brain Metastases; Cervical Cancer; Esophagus Cancer	2170 - Liverpool; 2217 - Kogarah	https://clinicaltrials.gov/ct2/show/NCT04430842
NCT04432207	IMU.201.101	Phase 1		NSW, VIC	16/06/2020	30/11/2020	IMU-201	B_cell_immunotherapy	IMU-201	B_cell_immunotherapy	IMU.201.101	An Open Label, Multi-Center, Dose Escalation/Expansion, Phase 1 Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer	Squamous Non-small-cell Lung Cancer; Adenocarcinoma Lung; Large Cell Carcinoma Lung; Non-small Cell Lung Cancer Stage IV; Non Small Cell Lung Cancer; Non Small Cell Lung Cancer Stage IIIB	2050 - Camperdown; 2109 - Macquarie; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04432207
NCT04434482	IMP4297-106	Phase 1		NSW, VIC	17/06/2020	7/08/2020	Senaparib; Senaparib + Temozolomide; Temozolomide	PARP_inhibitor; alkylating_agent; PARP_inhibitor + alkylating_agent	Senaparib + Temozolomide; Senaparib + Temozolomide	PARP_inhibitor + alkylating_agent; PARP_inhibitor + alkylating_agent	IMP4297-106	A Phase Ib/II, Open-Label, Multi-Center, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer	Advanced Solid Tumours; Small Cell Lung Cancer	3199 - Frankston; 2640 - Albury; 2148 - Blacktown; 2800 - Orange	https://clinicaltrials.gov/ct2/show/NCT04434482
NCT04438083	CRSP-ONC-003	Phase 1		VIC	18/06/2020	16/06/2020	CTX130	allogeneic_CAR-T-cell_therapy,CD70-targeting	CTX130	allogeneic_CAR-T-cell_therapy,CD70-targeting	CRSP-ONC-003	A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) in Subjects With Advanced, Relapsed or Refractory Renal Cell Carcinoma With Clear Cell Differentiation	Renal Cell Carcinoma	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04438083
NCT04446117	CONTACT-02	Phase 3		ACT, NSW, VIC, SA, TAS	24/06/2020	30/06/2020	Abiraterone; Abiraterone + Enzalutamide + Prednisone; Atezolizumab; Atezolizumab + Cabozantinib; Cabozantinib; Enzalutamide; Prednisone	VEGFR2_inhibitor + anti-PD-L1_monoclonal_antibody; glucocorticoid; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor; RET_inhibitor + anti-PD-L1_monoclonal_antibody; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + anti-PD-L1_monoclonal_antibody; VEGFR2_inhibitor; AXL_inhibitor + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; ROS1_inhibitor; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + glucocorticoid; CYP17A1_inhibitor; MET_inhibitor,type_2; antiandrogen,nonsteroidal,second_generation; AXL_inhibitor; KIT_inhibitor + anti-PD-L1_monoclonal_antibody; RET_inhibitor; ROS1_inhibitor + anti-PD-L1_monoclonal_antibody; MET_inhibitor,type_2 + anti-PD-L1_monoclonal_antibody; KIT_inhibitor	Abiraterone + Enzalutamide + Prednisone; Atezolizumab + Cabozantinib; Abiraterone + Enzalutamide + Prednisone; Atezolizumab + Cabozantinib	AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + anti-PD-L1_monoclonal_antibody; AXL_inhibitor + anti-PD-L1_monoclonal_antibody; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + glucocorticoid; KIT_inhibitor + anti-PD-L1_monoclonal_antibody; MET_inhibitor,type_2 + anti-PD-L1_monoclonal_antibody; RET_inhibitor + anti-PD-L1_monoclonal_antibody; ROS1_inhibitor + anti-PD-L1_monoclonal_antibody; VEGFR2_inhibitor + anti-PD-L1_monoclonal_antibody; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + anti-PD-L1_monoclonal_antibody; AXL_inhibitor + anti-PD-L1_monoclonal_antibody; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + glucocorticoid; KIT_inhibitor + anti-PD-L1_monoclonal_antibody; MET_inhibitor,type_2 + anti-PD-L1_monoclonal_antibody; RET_inhibitor + anti-PD-L1_monoclonal_antibody; ROS1_inhibitor + anti-PD-L1_monoclonal_antibody; VEGFR2_inhibitor + anti-PD-L1_monoclonal_antibody	XL184-315	A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination With Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects With Metastatic Castration-Resistant Prostate Cancer	Prostate Adenocarcinoma; Metastatic Prostate Cancer	3000 - Melbourne; 3128 - Box Hill; 3350 - Ballarat; 5000 - Adelaide; 3199 - Frankston; 2500 - Wollongong; 2065 - Saint Leonards; 2605 - Garran; 7250 - Launceston; 2109 - Sydney	https://clinicaltrials.gov/ct2/show/NCT04446117
NCT04446260	SHR-A1811-I-101	Phase 1		SA, NSW, VIC	24/06/2020	3/09/2020	SHR-A1811	anti-ERBB2_antibody-drug_conjugate	SHR-A1811	anti-ERBB2_antibody-drug_conjugate	SHR-A1811-I-101	A Phase 1 Multi-Country, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-A1811 in HER2 Expressing or Mutated Advanced Malignant Solid Tumor Subjects	Advanced Solid Tumors	2109 - Macquarie; 3199 - Frankston; 5042 - Bedford Park; 3004 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04446260
NCT04447118	PYRAMID-1	Phase 3		WA, NSW, Saint Leonard, SA	25/06/2020	11/09/2020	Docetaxel; Pyrotinib	EGFR_inhibitor,exon_20_selective; ERBB2_inhibitor,second_generation; taxane	Docetaxel; Pyrotinib	EGFR_inhibitor,exon_20_selective; ERBB2_inhibitor,second_generation; taxane	HR-BLTN-III-NSCLC	A Phase 3, Randomized, Open-label, Multicenter Study of the Efficacy and Safety of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) Harboring a HER2 Exon 20 Mutation Who Progressed on or After Treatment With Platinum Based Chemotherapy	HER2 Exon 20 Mutation; Non-squamous NSCLC	- Fitzroy; - North Adelaide; - St Leonards; - Nedlands; - Albury	https://clinicaltrials.gov/ct2/show/NCT04447118
NCT04449874	2020-000084-22--GO42144	Phase 1		VIC, NSW, NZ, WA	29/06/2020	29/07/2020	Atezolizumab; Atezolizumab + Divarasib; Bevacizumab; Bevacizumab + Divarasib; Cetuximab; Cetuximab + Divarasib; Divarasib; Divarasib + Erlotinib; Divarasib + RLY-1971; Erlotinib; RLY-1971	SHP2_inhibitor; KRAS_G12C_inhibitor + SHP2_inhibitor; KRAS_G12C_inhibitor + anti-PD-L1_monoclonal_antibody; KRAS_G12C_inhibitor; EGFR_inhibitor,first_generation; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; EGFR_inhibitor,first_generation + KRAS_G12C_inhibitor; anti-EGFR_monoclonal_antibody; KRAS_G12C_inhibitor + anti-VEGF_monoclonal_antibody; anti-VEGF_monoclonal_antibody	Atezolizumab + Divarasib; Bevacizumab + Divarasib; Cetuximab + Divarasib; Divarasib; Divarasib + Erlotinib; Divarasib + RLY-1971; Atezolizumab + Divarasib; Bevacizumab + Divarasib; Cetuximab + Divarasib; Divarasib + Erlotinib; Divarasib + RLY-1971	EGFR_inhibitor,first_generation + KRAS_G12C_inhibitor; KRAS_G12C_inhibitor; KRAS_G12C_inhibitor + SHP2_inhibitor; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-L1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-VEGF_monoclonal_antibody; EGFR_inhibitor,first_generation + KRAS_G12C_inhibitor; KRAS_G12C_inhibitor + SHP2_inhibitor; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-L1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-VEGF_monoclonal_antibody	2020-000084-22  GO42144	A Phase Ia/Ib Dose-Escalation and Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-6036 as a Single Agent and in Combination With Other Anti-cancer Therapies in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation	Non-Small Cell Lung Cancer; Advanced Solid Tumors; Colorectal Cancer	6009 - Nedlands; 2010 - Darlinghurst; Auckland; 3004 - Melbourne; Christchurch; 3002 - East Melbourne	https://clinicaltrials.gov/ct2/show/NCT04449874
NCT04450732	GQ1001X2101	Phase 1	NOT_RECRUITING	VIC, NSW	29/06/2020	7/07/2020	GQ1001	anti-ERBB2_antibody-drug_conjugate	GQ1001	anti-ERBB2_antibody-drug_conjugate	GQ1001X2101	A Phase 1, First-In-Human, Multicenter, Open-Label, Study of GQ1001, a HER2 Targeted Antibody-Drug Conjugate, Administered Intravenously, in Adult Patients With HER2-Positive Advanced Solid Tumors	Advanced Solid Tumor; HER2-positive Gastric Cancer; HER2-positive Breast Cancer	3050 - Melbourne; 2031 - Randwick	https://clinicaltrials.gov/ct2/show/NCT04450732
NCT04450901	YBL006C101	Phase 1		NSW	30/06/2020	1/07/2020	YBL006	anti-PD-1_monoclonal_antibody	YBL006	anti-PD-1_monoclonal_antibody	YBL006C101	A Phase 1, Open-Label, Multicenter, Single Arm, Dose Escalation/Dose Expansion Study of YBL-006 in Patients With Advanced Solid Tumors	Advanced Solid Tumors	2109 - Macquarie	https://clinicaltrials.gov/ct2/show/NCT04450901
NCT04455503	EVX-02-001	Phase 1/Phase 2		NSW, VIC, SA, WA	2/07/2020	13/07/2020	Nivolumab	anti-PD-1_monoclonal_antibody	Nivolumab	anti-PD-1_monoclonal_antibody	EVX-02-001	A Phase 1/2, Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1 After Complete Resection of Stage IIIB/IIIC/IIID or Stage IV Melanoma in Patients at High Risk for Recurrence	Melanoma Stage IV; Melanoma Stage III	6009 - Nedlands; 2170 - Goulburn; 3000 - Melbourne; 3350 - Drummond; 5042 - Adelaide; 3168 - Clayton	https://clinicaltrials.gov/ct2/show/NCT04455503
NCT04456699	MK-7339-003--7339-003	Phase 3		SA, VIC, NSW, QLD	2/07/2020	19/08/2020	Bevacizumab; Bevacizumab + Capecitabine; Bevacizumab + Fluorouracil + Leucovorin; Bevacizumab + Olaparib; Capecitabine; Fluorouracil; Leucovorin; Olaparib	PARP_inhibitor; anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid; PARP_inhibitor + anti-VEGF_monoclonal_antibody; Fluorouracil; folinic_acid; anti-VEGF_monoclonal_antibody + fluoropyrimidine; anti-VEGF_monoclonal_antibody; fluoropyrimidine	Bevacizumab + Capecitabine; Bevacizumab + Fluorouracil + Leucovorin; Bevacizumab + Olaparib; Olaparib; Bevacizumab + Capecitabine; Bevacizumab + Fluorouracil + Leucovorin; Bevacizumab + Olaparib	PARP_inhibitor; PARP_inhibitor + anti-VEGF_monoclonal_antibody; anti-VEGF_monoclonal_antibody + fluoropyrimidine; anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid; Fluorouracil; PARP_inhibitor + anti-VEGF_monoclonal_antibody; anti-VEGF_monoclonal_antibody + fluoropyrimidine; anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid	MK-7339-003  7339-003	A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer Who Have Not Progressed Following First-line Induction (LYNK-003)	Metastatic Colorectal Cancer	3168 - Clayton; 2170 - Liverpool; 3199 - Frankston; 2217 - Kogarah; 4029 - Herston; 5011 - Woodville South	https://clinicaltrials.gov/ct2/show/NCT04456699
NCT04458259	ARRAY-067-102--C4201002	Phase 1	NOT_RECRUITING	NSW	7/07/2020	24/09/2020	Axitinib; Axitinib + PF-07265807 + Sasanlimab; Methotrexate; Methotrexate + PF-07265807; PF-07265807; PF-07265807 + Sasanlimab; Sasanlimab	KIT_inhibitor,ATP-competitive; AXL/MER_inhibitor + antimetabolite; anti-PD-1_monoclonal_antibody; VEGFR/PDGFR_inhibitor; antimetabolite; AXL/MER_inhibitor; AXL/MER_inhibitor + antifolate; AXL/MER_inhibitor + VEGFR/PDGFR_inhibitor + anti-PD-1_monoclonal_antibody; AXL/MER_inhibitor + anti-PD-1_monoclonal_antibody; AXL/MER_inhibitor + KIT_inhibitor,ATP-competitive + anti-PD-1_monoclonal_antibody	Axitinib + PF-07265807 + Sasanlimab; Methotrexate + PF-07265807; PF-07265807; PF-07265807 + Sasanlimab; Axitinib + PF-07265807 + Sasanlimab; Methotrexate + PF-07265807; PF-07265807 + Sasanlimab	AXL/MER_inhibitor; AXL/MER_inhibitor + KIT_inhibitor,ATP-competitive + anti-PD-1_monoclonal_antibody; AXL/MER_inhibitor + VEGFR/PDGFR_inhibitor + anti-PD-1_monoclonal_antibody; AXL/MER_inhibitor + anti-PD-1_monoclonal_antibody; AXL/MER_inhibitor + antifolate; AXL/MER_inhibitor + antimetabolite; AXL/MER_inhibitor + KIT_inhibitor,ATP-competitive + anti-PD-1_monoclonal_antibody; AXL/MER_inhibitor + VEGFR/PDGFR_inhibitor + anti-PD-1_monoclonal_antibody; AXL/MER_inhibitor + anti-PD-1_monoclonal_antibody; AXL/MER_inhibitor + antifolate; AXL/MER_inhibitor + antimetabolite	ARRAY-067-102  C4201002	A PHASE 1, OPEN-LABEL, MULTI-CENTER, DOSE-FINDING, PHARMACOKINETIC, SAFETY AND TOLERABILITY STUDY OF PF 07265807 IN PARTICIPANTS WITH SELECTED ADVANCED OR METASTATIC SOLID TUMOR MALIGNANCIES	Neoplasm Metastasis	2109 - Macquarie University	https://clinicaltrials.gov/ct2/show/NCT04458259
NCT04460456	SBT6050-101	Phase 1		NSW, VIC, WA	7/07/2020	27/07/2020	Cemiplimab; Cemiplimab + SBT6050; Pembrolizumab; Pembrolizumab + SBT6050; SBT6050	anti-PD-1_monoclonal_antibody; anti-ERBB2_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody; anti-ERBB2_antibody-drug_conjugate	Cemiplimab + SBT6050; Pembrolizumab + SBT6050; SBT6050; Cemiplimab + SBT6050; Pembrolizumab + SBT6050	anti-ERBB2_antibody-drug_conjugate; anti-ERBB2_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody; anti-ERBB2_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody	SBT6050-101	A Phase 1/1B, Open-Label, Dose Escalation and Expansion Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced Solid Tumors Expressing HER2	HER2 Positive Solid Tumors	6009 - Nedlands; 3000 - Melbourne; 2109 - Sydney	https://clinicaltrials.gov/ct2/show/NCT04460456
NCT04464226	2019-003618-15--20321	Phase 3		SA	9/07/2020	20/10/2020	Darolutamide	antiandrogen,nonsteroidal,second_generation	Darolutamide	antiandrogen,nonsteroidal,second_generation	2019-003618-15  20321	An Open-label, Single Arm, Roll-over Study to Provide Continued Treatment With Darolutamide in Participants Who Were Enrolled in Previous Bayer Sponsored Studies	Cancer	5037 - Kurralta Park	https://clinicaltrials.gov/ct2/show/NCT04464226
NCT04468607	GO41751	Phase 1	NOT_RECRUITING	VIC	13/07/2020	31/08/2020	BLYG8824A	bispecific_T-cell_engager,LY6G6D-targeting	BLYG8824A	bispecific_T-cell_engager,LY6G6D-targeting	GO41751	A Phase I, Open-Label, Dose-Escalation Study Of The Safety And Pharmacokinetics Of BLYG8824A Administered Intravenously In Patients With Locally Advanced Or Metastatic Colorectal Cancer	Colorectal Cancer	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04468607
NCT04471428	CONTACT-01	Phase 3		WA, QLD, NSW, VIC, SA	15/07/2020	1/10/2020	Atezolizumab; Atezolizumab + Cabozantinib; Cabozantinib; Docetaxel	VEGFR2_inhibitor + anti-PD-L1_monoclonal_antibody; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor; RET_inhibitor + anti-PD-L1_monoclonal_antibody; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + anti-PD-L1_monoclonal_antibody; VEGFR2_inhibitor; AXL_inhibitor + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; ROS1_inhibitor; taxane; MET_inhibitor,type_2; AXL_inhibitor; KIT_inhibitor + anti-PD-L1_monoclonal_antibody; RET_inhibitor; ROS1_inhibitor + anti-PD-L1_monoclonal_antibody; MET_inhibitor,type_2 + anti-PD-L1_monoclonal_antibody; KIT_inhibitor	Atezolizumab + Cabozantinib; Docetaxel; Atezolizumab + Cabozantinib	AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + anti-PD-L1_monoclonal_antibody; AXL_inhibitor + anti-PD-L1_monoclonal_antibody; KIT_inhibitor + anti-PD-L1_monoclonal_antibody; MET_inhibitor,type_2 + anti-PD-L1_monoclonal_antibody; RET_inhibitor + anti-PD-L1_monoclonal_antibody; ROS1_inhibitor + anti-PD-L1_monoclonal_antibody; VEGFR2_inhibitor + anti-PD-L1_monoclonal_antibody; taxane; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + anti-PD-L1_monoclonal_antibody; AXL_inhibitor + anti-PD-L1_monoclonal_antibody; KIT_inhibitor + anti-PD-L1_monoclonal_antibody; MET_inhibitor,type_2 + anti-PD-L1_monoclonal_antibody; RET_inhibitor + anti-PD-L1_monoclonal_antibody; ROS1_inhibitor + anti-PD-L1_monoclonal_antibody; VEGFR2_inhibitor + anti-PD-L1_monoclonal_antibody	GO41892	A Phase III, Multicenter, Randomized, Open-Label, Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Atezolizumab Given in Combination With Cabozantinib Versus Docetaxel Monotherapy in Patients With Metastatic Non-Small Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy	Carcinoma, Non-Small-Cell Lung	4810 - Townsville; 5042 - Bedford Park; 6009 - Nedlands; 2065 - St. Leonards; 3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT04471428
NCT04472429	INCMGA-0012-303	Phase 3		SA, VIC, QLD	15/07/2020	9/11/2020	Carboplatin; Carboplatin + Paclitaxel; Carboplatin + Paclitaxel + Retifanlimab; Paclitaxel; Placebo; Retifanlimab	anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent + taxane; placebo; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; taxane	Carboplatin + Paclitaxel; Carboplatin + Paclitaxel + Retifanlimab; Carboplatin + Paclitaxel; Carboplatin + Paclitaxel + Retifanlimab; Placebo	anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; platinum-based_antineoplastic_agent + taxane; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; placebo; platinum-based_antineoplastic_agent + taxane	INCMGA 0012-303	A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2)	Squamous Cell Carcinoma of the Anal Canal	04102 - Woolloongabba; 03168 - Clayton; 5042 - Bedford Park	https://clinicaltrials.gov/ct2/show/NCT04472429
NCT04475523	CI-8993-101	Phase 1		VIC	17/07/2020	22/09/2020	CI-8993	anti-VISTA_monoclonal_antibody	CI-8993	anti-VISTA_monoclonal_antibody	CI-8993-101	Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies	Solid Tumor	3199 - Frankston	https://clinicaltrials.gov/ct2/show/NCT04475523
NCT04475939	ZEAL-1L	Phase 3		NSW, VIC, TAS	17/07/2020	26/10/2020	Niraparib; Niraparib + Pembrolizumab; Pembrolizumab; Placebo	PARP_inhibitor; anti-PD-1_monoclonal_antibody; PARP_inhibitor + anti-PD-1_monoclonal_antibody; placebo	Niraparib + Pembrolizumab; Pembrolizumab; Niraparib + Pembrolizumab; Placebo	PARP_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; PARP_inhibitor + anti-PD-1_monoclonal_antibody; placebo	213400	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease Has Remained Stable or Responded to First-Line Platinum Based Chemotherapy With Pembrolizumab for Stage IIIB/IIIC or IV Non-Small Cell Lung Cancer (ZEAL-1L)	Lung Cancer, Non-Small Cell	2148 - Blacktown; 3084 - Heidelberg; 7000 - Hobart; 3350 - Ballarat	https://clinicaltrials.gov/ct2/show/NCT04475939
NCT04478266	AMEERA-5	Phase 3		WA, VIC, NSW	20/07/2020	14/10/2020	Amcenestrant; Amcenestrant + Goserelin + Letrozole + Palbociclib; Goserelin; Letrozole; Palbociclib; Placebo	GnRH_analogue; placebo; CDK4/6_inhibitor + GnRH_analogue + aromatase_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor; CDK4/6_inhibitor + GnRH_agonist + aromatase_inhibitor + selective_estrogen_receptor_degrader; aromatase_inhibitor; selective_estrogen_receptor_degrader; GnRH_agonist	Amcenestrant + Goserelin + Letrozole + Palbociclib; Amcenestrant + Goserelin + Letrozole + Palbociclib; Placebo	CDK4/6_inhibitor + GnRH_agonist + aromatase_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + GnRH_analogue + aromatase_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + GnRH_agonist + aromatase_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + GnRH_analogue + aromatase_inhibitor + selective_estrogen_receptor_degrader; placebo	2020-001824-33  EFC15935	A Randomized, Multicenter, Double-blind Phase 3 Study of Amcenestrant (SAR439859) Plus Palbociclib Versus Letrozole Plus Palbociclib for the Treatment of Patients With ER (+), HER2 (-) Breast Cancer Who Have Not Received Prior Systemic Anti-cancer Treatment for Advanced Disease	Breast Cancer	3121 - Richmond; 6009 - Nedlands; 2109 - Macquarie Park; 2031 - Randwick; 2076 - Wahroonga	https://clinicaltrials.gov/ct2/show/NCT04478266
NCT04481009	YH003002	Phase 1/Phase 2		WA	22/07/2020	4/08/2020	Gemcitabine; Gemcitabine + Nab-paclitaxel + Toripalimab + YH003; Nab-paclitaxel; Toripalimab; Toripalimab + YH003; YH003	anti-PD-1_monoclonal_antibody; anti-OX40_agonistic_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + taxane; antimetabolite; anti-OX40_agonistic_antibody; gemcitabine; taxane; anti-OX40_agonistic_antibody + anti-PD-1_monoclonal_antibody	Gemcitabine + Nab-paclitaxel + Toripalimab + YH003; Toripalimab + YH003; Gemcitabine + Nab-paclitaxel + Toripalimab + YH003; Toripalimab + YH003	anti-OX40_agonistic_antibody + anti-PD-1_monoclonal_antibody; anti-OX40_agonistic_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + taxane; anti-OX40_agonistic_antibody + anti-PD-1_monoclonal_antibody; anti-OX40_agonistic_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + taxane; gemcitabine	YH003002	A Multicenter, Open-Label, Phase I/II Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of YH003 in Combination With Toripalimab (Anti-PD-1 mAb) in Subjects With Advanced Solid Tumors	Advanced Solid Tumors	6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT04481009
NCT04482309	DPT02	Phase 2		QLD, NSW, VIC, WA	22/07/2020	18/08/2020	Trastuzumab Deruxtecan	anti-ERBB2_antibody-drug_conjugate	Trastuzumab Deruxtecan	anti-ERBB2_antibody-drug_conjugate	D967VC00001	A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2 Expressing Tumors (DESTINY-PanTumor02)	Bladder Cancer, Biliary Tract Cancer, Cervical Cancer, Endometrial Cancer, Ovarian Cancer, Pancreatic Cancer, Rare Tumors	2031 - Randwick; 4066 - Auchenflower; 6009 - Nedlands; 3084 - Heidelberg; 2050 - Camperdown; NSW 2217 - Kogarah	https://clinicaltrials.gov/ct2/show/NCT04482309
NCT04487080	MARIPOSA	Phase 3	NOT_RECRUITING	VIC, NSW, QLD, SA, WA	27/07/2020	30/09/2020	Amivantamab; Amivantamab + Lazertinib; Lazertinib; Lazertinib + Osimertinib; Osimertinib; Placebo	EGFR_inhibitor,third_generation; bispecific_cMET/EGFR_monoclonal_antibody; placebo; EGFR_inhibitor,third_generation + bispecific_cMET/EGFR_monoclonal_antibody	Amivantamab + Lazertinib; Lazertinib + Osimertinib; Amivantamab + Lazertinib; Lazertinib + Osimertinib; Placebo	EGFR_inhibitor,third_generation; EGFR_inhibitor,third_generation + bispecific_cMET/EGFR_monoclonal_antibody; EGFR_inhibitor,third_generation + bispecific_cMET/EGFR_monoclonal_antibody; placebo	2020-000743-31  CR108856	A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer.	Carcinoma, Non-Small-Cell Lung	3144 - Malvern; 2145 - Westmead; 4102 - Woolloongabba; 6009 - Nedlands; 6150 - Murdoch; 3084 - Heidelberg; 2217 - Kogarah; 2500 - Wollongong; 5042 - Bedford Park	https://clinicaltrials.gov/ct2/show/NCT04487080
NCT04489771	2020-001907-18--6482-013	Phase 2		VIC, NSW	28/07/2020	13/09/2020	Belzutifan	HIF2a_inhibitor	Belzutifan	HIF2a_inhibitor	2020-001907-18  6482-013	Phase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma	Carcinoma, Renal Cell	3199 - Frankston; 3128 - Box Hill; 2109 - Macquarie University	https://clinicaltrials.gov/ct2/show/NCT04489771
NCT04493853	CAPItello-281	Phase 3		QLD, NSW	30/07/2020	13/07/2020	Abiraterone; Abiraterone + Capivasertib + Prednisolone + Prednisone; Abiraterone + Prednisolone + Prednisone; Capivasertib; Placebo; Prednisolone; Prednisone	glucocorticoid; CYP17A1_inhibitor + glucocorticoid + pan-AKT_inhibitor; placebo; CYP17A1_inhibitor; pan-AKT_inhibitor; CYP17A1_inhibitor + glucocorticoid	Abiraterone + Capivasertib + Prednisolone + Prednisone; Abiraterone + Prednisolone + Prednisone; Abiraterone + Capivasertib + Prednisolone + Prednisone; Abiraterone + Prednisolone + Prednisone; Placebo	CYP17A1_inhibitor + glucocorticoid; CYP17A1_inhibitor + glucocorticoid + pan-AKT_inhibitor; CYP17A1_inhibitor + glucocorticoid; CYP17A1_inhibitor + glucocorticoid + pan-AKT_inhibitor; placebo	D361BC00001	A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib+Abiraterone Versus Placebo+Abiraterone as Treatment for Patients With DeNovo Metastatic Hormone-Sensitive Prostate Cancer Characterised by PTEN Deficiency.	Hormone-Sensitive Prostate Cancer	2010 - Darlinghurst; 2747 - Kingswood; 2800 - Orange; 4575 - Birtinya; 4101 - South Brisbane	https://clinicaltrials.gov/ct2/show/NCT04493853
NCT04494425	DB-06	Phase 3	NOT_RECRUITING	TAS, VIC, NSW, QLD, WA	31/07/2020	24/07/2020	Capecitabine; Capecitabine + Nab-paclitaxel + Paclitaxel; Nab-paclitaxel; Paclitaxel; Trastuzumab Deruxtecan	fluoropyrimidine + taxane; taxane; fluoropyrimidine; anti-ERBB2_antibody-drug_conjugate	Capecitabine + Nab-paclitaxel + Paclitaxel; Trastuzumab Deruxtecan; Capecitabine + Nab-paclitaxel + Paclitaxel	anti-ERBB2_antibody-drug_conjugate; fluoropyrimidine + taxane; fluoropyrimidine + taxane	D9670C00001	A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Breast Cancer Patients Whose Disease Has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06)	Advanced or Metastatic Breast Cancer	6150 - Murdoch; 7000 - Hobart; 2010 - Darlinghurst; 2298 - Waratah; 3199 - Frankston; 2065 - St Leonards; 3065 - Fitzroy; 4101 - South Brisbane; 2139 - Concord; 4575 - Birtinya; 4066 - Auchenflower	https://clinicaltrials.gov/ct2/show/NCT04494425
NCT04497844	AMPLITUDE	Phase 3		SA, NZ, TAS, QLD, VIC, NSW, WA	4/08/2020	23/09/2020	Abiraterone; Abiraterone + Niraparib + Prednisone; Niraparib; Niraparib + Prednisone; Placebo; Prednisone	PARP_inhibitor; glucocorticoid; placebo; CYP17A1_inhibitor; CYP17A1_inhibitor + PARP_inhibitor + glucocorticoid; PARP_inhibitor + glucocorticoid	Abiraterone + Niraparib + Prednisone; Niraparib + Prednisone; Abiraterone + Niraparib + Prednisone; Niraparib + Prednisone; Placebo	CYP17A1_inhibitor + PARP_inhibitor + glucocorticoid; PARP_inhibitor + glucocorticoid; CYP17A1_inhibitor + PARP_inhibitor + glucocorticoid; PARP_inhibitor + glucocorticoid; placebo	2020-002209-25  CR108852	A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)	Metastatic Castrate Sensitive Prostate Cancer	4029 - Herston; 6150 - Murdoch; 2109 - North Ryde; 7000 - Hobart; 5037 - Kurralta Park; 2010 - Darlinghurst; 3000 - Melbourne; Auckland; 4101 - South Brisbane; 6008 - Subiaco; Christchurch; Tauranga; Dunedin Central; - Birtinya; 2170 - Liverpool	https://clinicaltrials.gov/ct2/show/NCT04497844
NCT04499924	MOUNTAINEER-02	Phase 2/Phase 3		Othe, NSW	5/08/2020	22/03/2021	Paclitaxel; Paclitaxel + Ramucirumab + Trastuzumab + Tucatinib; Placebo; Ramucirumab; Trastuzumab; Tucatinib	placebo; anti-VEGFR2_monoclonal_antibody; anti-ERBB2_monoclonal_antibody; ERBB2_inhibitor,third_generation + anti-ERBB2_monoclonal_antibody + anti-VEGFR2_monoclonal_antibody + taxane; ERBB2_inhibitor,third_generation; taxane	Paclitaxel + Ramucirumab + Trastuzumab + Tucatinib; Paclitaxel + Ramucirumab + Trastuzumab + Tucatinib; Placebo	ERBB2_inhibitor,third_generation + anti-ERBB2_monoclonal_antibody + anti-VEGFR2_monoclonal_antibody + taxane; ERBB2_inhibitor,third_generation + anti-ERBB2_monoclonal_antibody + anti-VEGFR2_monoclonal_antibody + taxane; placebo	SGNTUC-022	A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Subjects With Previously Treated, Locally-advanced Unresectable or Metastatic HER2+ Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)	Gastroesophageal Junction Adenocarcinoma; Gastric Adenocarcinoma; Esophageal Adenocarcinoma	2250 - Gosford	https://clinicaltrials.gov/ct2/show/NCT04499924
NCT04501276	ADG116-1003	Phase 1		SA	6/08/2020	23/09/2020	ADG116	anti-CTLA-4_monoclonal_antibody	ADG116	anti-CTLA-4_monoclonal_antibody	ADG116-1003	A Phase 1, Open-Label, Dose Escalation Study of ADG116 in Patients With Advanced/Metastatic Solid Tumors	Advanced/Metastatic Solid Tumors	5037 - Kurralta Park	https://clinicaltrials.gov/ct2/show/NCT04501276
NCT04505826	OP-1250-001	Phase 1/Phase 2		QLD, NSW, VIC, SA	10/08/2020	13/08/2020	Palazestrant	complete_estrogen_receptor_antagonist	Palazestrant	complete_estrogen_receptor_antagonist	OP-1250-001	A Phase I/II Open-label, First-in-Human, Multicenter, Dose Escalation and Dose Expansion Study of OP-1250 Monotherapy in Adult Subjects With Advanced and/or Metastatic Hormone Receptor (HR)-Positive, HER2-negative Breast Cancer	Hormone Receptor Positive Breast Carcinoma; HER2-negative Breast Cancer	2109 - Sydney; 2145 - Westmead; 4066 - Auchenflower; 3000 - Melbourne; 5000 - Adelaide	https://clinicaltrials.gov/ct2/show/NCT04505826
NCT04513925	SKYSCRAPER-03	Phase 3		NZ, SA, NSW, VIC, QLD, WA	14/08/2020	24/08/2020	Atezolizumab; Atezolizumab + Tiragolumab; Durvalumab; Tiragolumab	anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-TIGIT_monoclonal_antibody	Atezolizumab + Tiragolumab; Durvalumab; Atezolizumab + Tiragolumab	anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody	2019-004773-29  GO41854	A Phase III, Open-Label, Randomized Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Patients With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer Who Have Not Progressed After Concurrent Platinum-Based Chemoradiation	Non-small Cell Lung Cancer (NSCLC)	2560 - Campbelltown; 2148 - Blacktown; 2217 - Kogarah; 5042 - Bedford Park; Tauranga; 3168 - Victoria; 4102 - Woolloongabba; 6149 - Bull Creek	https://clinicaltrials.gov/ct2/show/NCT04513925
NCT04516447	ZN-c3-002	Phase 1		WA, QLD, VIC	18/08/2020	26/10/2020	Azenosertib; Azenosertib + Carboplatin; Azenosertib + Gemcitabine; Azenosertib + Paclitaxel; Carboplatin; Gemcitabine; Paclitaxel; Pegylated liposomal doxorubicin	WEE1_inhibitor; anthracycline; platinum-based_antineoplastic_agent; antimetabolite; WEE1_inhibitor + platinum-based_antineoplastic_agent; WEE1_inhibitor + taxane; WEE1_inhibitor + antimetabolite; gemcitabine; taxane	Azenosertib; Azenosertib + Carboplatin; Azenosertib + Gemcitabine; Azenosertib + Paclitaxel; Azenosertib + Carboplatin; Azenosertib + Gemcitabine; Azenosertib + Paclitaxel; Pegylated liposomal doxorubicin	WEE1_inhibitor; WEE1_inhibitor + antimetabolite; WEE1_inhibitor + platinum-based_antineoplastic_agent; WEE1_inhibitor + taxane; WEE1_inhibitor + antimetabolite; WEE1_inhibitor + platinum-based_antineoplastic_agent; WEE1_inhibitor + taxane; anthracycline; gemcitabine	ZN-c3-002	A Phase 1b Study of ZN-c3 in Combination With Chemotherapy in Patients With Platinum-Resistant Ovarian, Peritoneal or Fallopian Tube Cancer	Epithelial Ovarian Cancer; Solid Tumor; Peritoneal Cancer; Fallopian Tube Cancer	3144 - Melbourne; 4556 - Sunshine Coast; 6009 - Nedlands; 4101 - South Brisbane	https://clinicaltrials.gov/ct2/show/NCT04516447
NCT04521686	2020-002863-77--LOXO-IDH-20002	Phase 1		NSW	20/08/2020	16/10/2020	LY3410738	IDH1_R132_inhibitor,covalent	LY3410738	IDH1_R132_inhibitor,covalent	2020-002863-77  LOXO-IDH-20002	A Phase 1 Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations	Any Solid Tumor; Chondrosarcoma; Glioma; Cholangiocarcinoma	2010 - Darlinghurst	https://clinicaltrials.gov/ct2/show/NCT04521686
NCT04522323	D7980C00003	Phase 1		VIC, NSW	21/08/2020	5/08/2020	Axitinib; Axitinib + Lenvatinib + MEDI5752; Lenvatinib; Lenvatinib + MEDI5752; MEDI5752	KIT_inhibitor,ATP-competitive; VEGFR/PDGFR_inhibitor; VEGF_inhibitor; KIT_inhibitor,ATP-competitive + VEGF_inhibitor + bispecific_PD-L1/CTLA-4_antibody; VEGF_inhibitor + bispecific_PD-L1/CTLA-4_antibody; bispecific_PD-L1/CTLA-4_antibody; VEGFR/PDGFR_inhibitor + VEGF_inhibitor + bispecific_PD-L1/CTLA-4_antibody	Axitinib + Lenvatinib + MEDI5752; Lenvatinib + MEDI5752; Axitinib + Lenvatinib + MEDI5752; Lenvatinib + MEDI5752	KIT_inhibitor,ATP-competitive + VEGF_inhibitor + bispecific_PD-L1/CTLA-4_antibody; VEGFR/PDGFR_inhibitor + VEGF_inhibitor + bispecific_PD-L1/CTLA-4_antibody; VEGF_inhibitor + bispecific_PD-L1/CTLA-4_antibody; KIT_inhibitor,ATP-competitive + VEGF_inhibitor + bispecific_PD-L1/CTLA-4_antibody; VEGFR/PDGFR_inhibitor + VEGF_inhibitor + bispecific_PD-L1/CTLA-4_antibody; VEGF_inhibitor + bispecific_PD-L1/CTLA-4_antibody	D7980C00003	A Phase 1b, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI5752 in Combination With Axitinib in Subjects With Advanced Renal Cell Carcinoma	Advanced Renal Cell Carcinoma	3199 - Frankston; 2298 - Waratah; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04522323
NCT04524689	CARMEN-LC05	Phase 2		NSW, VIC	24/08/2020	26/10/2020	Carboplatin; Carboplatin + Pembrolizumab + Pemetrexed + Tusamitamab ravtansine; Carboplatin + Pembrolizumab + Tusamitamab ravtansine; Cisplatin; Cisplatin + Pembrolizumab + Pemetrexed + Tusamitamab ravtansine; Cisplatin + Pembrolizumab + Tusamitamab ravtansine; Pembrolizumab; Pembrolizumab + Tusamitamab ravtansine; Pemetrexed; Tusamitamab ravtansine	anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; anti-CEACAM5_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody; antimetabolite; anti-CEACAM5_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-CEACAM5_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent; anti-CEACAM5_antibody-drug_conjugate	Carboplatin + Pembrolizumab + Pemetrexed + Tusamitamab ravtansine; Carboplatin + Pembrolizumab + Tusamitamab ravtansine; Cisplatin + Pembrolizumab + Pemetrexed + Tusamitamab ravtansine; Cisplatin + Pembrolizumab + Tusamitamab ravtansine; Pembrolizumab + Tusamitamab ravtansine; Carboplatin + Pembrolizumab + Pemetrexed + Tusamitamab ravtansine; Carboplatin + Pembrolizumab + Tusamitamab ravtansine; Cisplatin + Pembrolizumab + Pemetrexed + Tusamitamab ravtansine; Cisplatin + Pembrolizumab + Tusamitamab ravtansine; Pembrolizumab + Tusamitamab ravtansine	anti-CEACAM5_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody; anti-CEACAM5_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-CEACAM5_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent; anti-CEACAM5_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody; anti-CEACAM5_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-CEACAM5_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent	U1111-1233-9798  ACT16146	Open-label, Phase 2 Study of Tusamitamab Ravtansine (SAR408701) Combined With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) Combined With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)	Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)	2109 - Macquarie Park; 3081 - Heidelberg West	https://clinicaltrials.gov/ct2/show/NCT04524689
NCT04524871	GO42216	Unknown		NZ	24/08/2020	2/11/2020	ADG126; ADG126 + Atezolizumab + Bevacizumab; Atezolizumab; Atezolizumab + Bevacizumab; Atezolizumab + Bevacizumab + TPST-1120; Atezolizumab + Bevacizumab + Tiragolumab; Atezolizumab + Bevacizumab + Tocilizumab; Bevacizumab; Bevacizumab + RO7247669; RO7247669; TPST-1120; Tiragolumab; Tocilizumab	anti-CTLA-4_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + anti-VEGF_monoclonal_antibody; PPAR-alpha_inhibitor; bispecific_PD-1/LAG3_antibody; anti-PD-L1_monoclonal_antibody; anti-IL-6_monoclonal_antibody; anti-TIGIT_monoclonal_antibody; anti-VEGF_monoclonal_antibody + bispecific_PD-1/LAG3_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-IL-6_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; PPAR-alpha_inhibitor + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody	ADG126 + Atezolizumab + Bevacizumab; Atezolizumab + Bevacizumab; Atezolizumab + Bevacizumab + TPST-1120; Atezolizumab + Bevacizumab + Tiragolumab; Atezolizumab + Bevacizumab + Tocilizumab; Bevacizumab + RO7247669; ADG126 + Atezolizumab + Bevacizumab; Atezolizumab + Bevacizumab; Atezolizumab + Bevacizumab + TPST-1120; Atezolizumab + Bevacizumab + Tiragolumab; Atezolizumab + Bevacizumab + Tocilizumab; Bevacizumab + RO7247669	PPAR-alpha_inhibitor + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-IL-6_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-VEGF_monoclonal_antibody + bispecific_PD-1/LAG3_antibody; PPAR-alpha_inhibitor + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-IL-6_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-VEGF_monoclonal_antibody + bispecific_PD-1/LAG3_antibody	GO42216	A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)	Advanced Liver Cancers	Auckland	https://clinicaltrials.gov/ct2/show/NCT04524871
NCT04526106	RLY-4008-101	Phase 1		WA, NSW, QLD	25/08/2020	2/09/2020	Lirafugratinib	FGFR2_inhibitor	Lirafugratinib	FGFR2_inhibitor	RLY-4008-101	A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With Intrahepatic Cholangiocarcinoma (ICC) and Other Advanced Solid Tumors	FGFR2 Gene Mutation; FGFR2 Amplification; FGFR2 Gene Rearrangement; Solid Tumor, Adult; Gastric Cancer; FGFR2 Gene Activation; Endometrial Cancer; Intrahepatic Cholangiocarcinoma; Breast Cancer; Cholangiocarcinoma; FGFR2 Gene Translocation	6009 - Nedlands; 2010 - Darlinghurst; 4101 - South Brisbane,	https://clinicaltrials.gov/ct2/show/NCT04526106
NCT04526509	NCT04526509	Phase 1		VIC	25/08/2020	21/12/2020	Cyclophosphamide; Fludarabine	alkylating_agent; antimetabolite	Cyclophosphamide; Fludarabine	alkylating_agent; antimetabolite	209012	Master Protocol to Assess the Safety and Recommended Phase 2 Dose of Next Generations of Autologous Enhanced NY-ESO-1/ LAGE-1a TCR Engineered T-cells, Alone or in Combination With Other Agents, in Participants With Advanced Tumors	Neoplasms	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04526509
NCT04526899	2020-002195-12--BNT111-01	Phase 2		NSW	26/08/2020	19/05/2021	BNT111; BNT111 + Cemiplimab; Cemiplimab	anti-PD-1_monoclonal_antibody + mRNA_personalised_cancer_vaccine; anti-PD-1_monoclonal_antibody; mRNA_personalised_cancer_vaccine	BNT111; BNT111 + Cemiplimab; Cemiplimab; BNT111 + Cemiplimab	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + mRNA_personalised_cancer_vaccine; mRNA_personalised_cancer_vaccine; anti-PD-1_monoclonal_antibody + mRNA_personalised_cancer_vaccine	2020-002195-12  BNT111-01	Open-label, Randomized Phase II Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD-1-refractory/Relapsed, Unresectable Stage III or IV Melanoma	Unresectable Melanoma; Melanoma Stage III; Melanoma Stage IV	2640 - East Albury	https://clinicaltrials.gov/ct2/show/NCT04526899
NCT04527991	TROPiCS-04	Phase 3		SA, NZ	27/08/2020	13/01/2021	Docetaxel; Docetaxel + Paclitaxel + Vinflunine; Paclitaxel; Sacituzumab Govitecan; Vinflunine	taxane + vinca_alkaloid; vinca_alkaloid; taxane; anti-Trop2_antibody-drug_conjugate	Docetaxel + Paclitaxel + Vinflunine; Sacituzumab Govitecan; Docetaxel + Paclitaxel + Vinflunine	anti-Trop2_antibody-drug_conjugate; taxane + vinca_alkaloid; taxane + vinca_alkaloid	2020-002964-29  IMMU-132-13	A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Subjects With Metastatic or Locally Advanced Unresectable Urothelial Cancer (TROPiCS-04)	Locally Advanced or Metastatic Unresectable Urothelial Cancer	5037 - Kurralta Park; Hamilton	https://clinicaltrials.gov/ct2/show/NCT04527991
NCT04534205	AHEAD-MERIT	Phase 2		QLD, NSW	1/09/2020	7/01/2021	EO1001; Pembrolizumab	anti-PD-1_monoclonal_antibody; ERBB2_inhibitor,second_generation; EGFR_inhibitor,second_generation	Pembrolizumab; EO1001	anti-PD-1_monoclonal_antibody; EGFR_inhibitor,second_generation; ERBB2_inhibitor,second_generation	2020-001400-41  BNT113-01	An Open Label Phase II Randomized Trial of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Monotherapy as a First Line Therapy in Patients With Unresectable Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Which is Positive for Human Papilloma Virus 16 (HPV16+) and Expresses PD-L1 (AHEAD-MERIT)	Recurrent Head and Neck Cancer; Unresectable Head and Neck Squamous Cell Carcinoma; Metastatic Head and Neck Cancer	2200 - Bankstown; 4224 - Tugun; 2500 - Wollongong	https://clinicaltrials.gov/ct2/show/NCT04534205
NCT04538664	PAPILLON	Phase 3		WA, NSW, VIC	4/09/2020	13/10/2020	Amivantamab; Amivantamab + Carboplatin + Pemetrexed; Carboplatin; Carboplatin + Pemetrexed; Pemetrexed	platinum-based_antineoplastic_agent; bispecific_cMET/EGFR_monoclonal_antibody; antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + bispecific_cMET/EGFR_monoclonal_antibody + platinum-based_antineoplastic_agent; antimetabolite	Amivantamab + Carboplatin + Pemetrexed; Carboplatin + Pemetrexed; Amivantamab + Carboplatin + Pemetrexed; Carboplatin + Pemetrexed	antimetabolite + bispecific_cMET/EGFR_monoclonal_antibody + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + bispecific_cMET/EGFR_monoclonal_antibody + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent	2020-000633-40  CR108850	A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Patients With EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer	Carcinoma, Non-Small-Cell Lung	3144 - Malvern; 3084 - Heidelberg; 2050 - Camperdown; 6009 - Nedlands; 2217 - Kogarah	https://clinicaltrials.gov/ct2/show/NCT04538664
NCT04538742	DB-07	Phase 1/Phase 2		VIC	4/09/2020	28/12/2020	Durvalumab; Durvalumab + Paclitaxel + Trastuzumab Deruxtecan; Durvalumab + Trastuzumab Deruxtecan; Paclitaxel; Paclitaxel + Trastuzumab Deruxtecan; Pertuzumab; Pertuzumab + Trastuzumab Deruxtecan; Trastuzumab Deruxtecan; Trastuzumab Deruxtecan + Tucatinib; Tucatinib	anti-ERBB2_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody + taxane; anti-ERBB2_antibody-drug_conjugate + taxane; anti-ERBB2_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody; ERBB2_inhibitor,third_generation + anti-ERBB2_antibody-drug_conjugate; anti-PD-L1_monoclonal_antibody; anti-ERBB2_antibody-drug_conjugate + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; ERBB2_inhibitor,third_generation; taxane; anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; anti-ERBB2_antibody-drug_conjugate	Durvalumab + Paclitaxel + Trastuzumab Deruxtecan; Durvalumab + Trastuzumab Deruxtecan; Paclitaxel + Trastuzumab Deruxtecan; Pertuzumab + Trastuzumab Deruxtecan; Trastuzumab Deruxtecan; Trastuzumab Deruxtecan + Tucatinib; Durvalumab + Paclitaxel + Trastuzumab Deruxtecan; Durvalumab + Trastuzumab Deruxtecan; Paclitaxel + Trastuzumab Deruxtecan; Pertuzumab + Trastuzumab Deruxtecan; Trastuzumab Deruxtecan + Tucatinib	ERBB2_inhibitor,third_generation + anti-ERBB2_antibody-drug_conjugate; anti-ERBB2_antibody-drug_conjugate; anti-ERBB2_antibody-drug_conjugate + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; anti-ERBB2_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody; anti-ERBB2_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody + taxane; anti-ERBB2_antibody-drug_conjugate + taxane; ERBB2_inhibitor,third_generation + anti-ERBB2_antibody-drug_conjugate; anti-ERBB2_antibody-drug_conjugate + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; anti-ERBB2_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody; anti-ERBB2_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody + taxane; anti-ERBB2_antibody-drug_conjugate + taxane	D967JC00001	A Phase 1b/2 Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination With Other Anti-cancer Agents in Patients With HER2-positive Metastatic Breast Cancer (DESTINY-Breast07)	Metastatic Breast Cancer	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04538742
NCT04543617	SKYSCRAPER-07	Phase 3		WA, NZ, QLD, VIC	10/09/2020	28/09/2020	Atezolizumab; Atezolizumab + Tiragolumab; Placebo; Radiotherapy; Tiragolumab	anti-PD-L1_monoclonal_antibody; radiotherapy; placebo; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-TIGIT_monoclonal_antibody	Atezolizumab + Tiragolumab; Atezolizumab + Tiragolumab; Placebo; Radiotherapy	anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; placebo; radiotherapy	2020-001178-31  YO42137	A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab With or Without Tiragolumab (Anti-TIGIT Antibody) in Patients With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy	Esophageal Squamous Cell Carcinoma	3084 - Heidelberg; 4102 - Woolloongabba; Tauranga; 6008 - Subiaco; Christchurch	https://clinicaltrials.gov/ct2/show/NCT04543617
NCT04546009	2020-000119-66--BO41843	Phase 3		SA, NZ, QLD, VIC, NSW, WA	11/09/2020	9/10/2020	Giredestrant; Giredestrant + Letrozole + Palbociclib; LHRH Agonist; Letrozole; Palbociclib; Placebo	placebo; CDK4/6_inhibitor; CDK4/6_inhibitor + aromatase_inhibitor + selective_estrogen_receptor_degrader; aromatase_inhibitor; selective_estrogen_receptor_degrader; LHRH_agonist	Giredestrant + Letrozole + Palbociclib; Giredestrant + Letrozole + Palbociclib; LHRH Agonist; Placebo	CDK4/6_inhibitor + aromatase_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + aromatase_inhibitor + selective_estrogen_receptor_degrader; LHRH_agonist; placebo	2020-000119-66  BO41843	A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of GDC-9545 Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Patients With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer	Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer	3084 - Heidelberg; 6150 - Murdoch; 2050 - Camperdown; 2010 - Darlinghurst; 3000 - Melbourne; 3021 - St Albans; 5042 - Bedford Park; 2298 - Waratah; 3199 - Frankston; 4101 - South Brisbane; Auckland; 4102 - Woolloongabba; Hamilton	https://clinicaltrials.gov/ct2/show/NCT04546009
NCT04551352	2020-000793-18--BP42169	Phase 1		VIC	16/09/2020	28/10/2020	Obinutuzumab; Tocilizumab	anti-IL-6_monoclonal_antibody; anti-CD20_monoclonal_antibody	Obinutuzumab; Tocilizumab	anti-CD20_monoclonal_antibody; anti-IL-6_monoclonal_antibody	2020-000793-18  BP42169	An Open-Label, Multicenter, Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7293583, A TYRP1-Targeting CD3 T-Cell Engager, in Participants With Metastatic Melanoma	Cutaneous Melanoma; Uveal Melanoma; Mucosal Melanoma	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04551352
NCT04551963	BGB-3111-113	Phase 1		SA, VIC, NSW, QLD, WA	16/09/2020	15/11/2020	Zanubrutinib	BTK_inhibitor	Zanubrutinib	BTK_inhibitor	BGB-3111-113	A Drug-Drug Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Patients With B-Cell Malignancies	B-cell Malignancies	2139 - Concord; 3168 - Clayton; 4224 - Tugun; 6009 - Nedlands; 5042 - Bedford Park; 3199 - Frankston; 5000 - Adelaide	https://clinicaltrials.gov/ct2/show/NCT04551963
NCT04556773	DB-08	Phase 1		VIC, NSW	21/09/2020	17/12/2020	Anastrozole; Anastrozole + Trastuzumab Deruxtecan; Capecitabine; Capecitabine + Trastuzumab Deruxtecan; Capivasertib; Capivasertib + Trastuzumab Deruxtecan; Durvalumab; Durvalumab + Paclitaxel + Trastuzumab Deruxtecan; Fulvestrant; Fulvestrant + Trastuzumab Deruxtecan; Paclitaxel; Trastuzumab Deruxtecan	anti-ERBB2_antibody-drug_conjugate + selective_estrogen_receptor_degrader; anti-ERBB2_antibody-drug_conjugate + aromatase_inhibitor; anti-PD-L1_monoclonal_antibody; taxane; selective_estrogen_receptor_degrader; fluoropyrimidine; anti-ERBB2_antibody-drug_conjugate; anti-ERBB2_antibody-drug_conjugate + fluoropyrimidine; anti-ERBB2_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody + taxane; pan-AKT_inhibitor; aromatase_inhibitor; anti-ERBB2_antibody-drug_conjugate + pan-AKT_inhibitor	Anastrozole + Trastuzumab Deruxtecan; Capecitabine + Trastuzumab Deruxtecan; Capivasertib + Trastuzumab Deruxtecan; Durvalumab + Paclitaxel + Trastuzumab Deruxtecan; Fulvestrant + Trastuzumab Deruxtecan; Anastrozole + Trastuzumab Deruxtecan; Capecitabine + Trastuzumab Deruxtecan; Capivasertib + Trastuzumab Deruxtecan; Durvalumab + Paclitaxel + Trastuzumab Deruxtecan; Fulvestrant + Trastuzumab Deruxtecan	anti-ERBB2_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody + taxane; anti-ERBB2_antibody-drug_conjugate + aromatase_inhibitor; anti-ERBB2_antibody-drug_conjugate + fluoropyrimidine; anti-ERBB2_antibody-drug_conjugate + pan-AKT_inhibitor; anti-ERBB2_antibody-drug_conjugate + selective_estrogen_receptor_degrader; anti-ERBB2_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody + taxane; anti-ERBB2_antibody-drug_conjugate + aromatase_inhibitor; anti-ERBB2_antibody-drug_conjugate + fluoropyrimidine; anti-ERBB2_antibody-drug_conjugate + pan-AKT_inhibitor; anti-ERBB2_antibody-drug_conjugate + selective_estrogen_receptor_degrader	D967JC00002	A Phase 1b Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination With Other Anti-cancer Agents in Patients With Metastatic HER2-low Breast Cancer (DESTINY-Breast08)	Metastatic Breast Cancer	3002 - East Melbourne; 2145 - Westmead	https://clinicaltrials.gov/ct2/show/NCT04556773
NCT04565275	ICP-CL-00303	Phase 1/Phase 2		NSW, VIC	25/09/2020	1/02/2021	Gunagratinib	pan-FGFR_inhibitor	Gunagratinib	pan-FGFR_inhibitor	ICP-CL-00303	A Multi-center Open-label, Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ICP-192 in Patients With Advanced Solid Tumors and FGFR Gene Alterations	Advanced Solid Tumors; Cholangiocarcinoma; Urothelial Carcinoma	3168 - Clayton; 3084 - Melbourne; 2109 - Macquarie Park	https://clinicaltrials.gov/ct2/show/NCT04565275
NCT04567615	2018-003151-38--CA224-073	Phase 2		NZ, NSW	28/09/2020	4/02/2021	Nivolumab; Nivolumab + Relatlimab; Relatlimab	anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Nivolumab; Nivolumab + Relatlimab; Nivolumab + Relatlimab	anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	2018-003151-38  CA224-073	A Phase 2, Randomized, Open-label Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Hepatocellular Carcinoma Who Are Naive to IO Therapy But Progressed on Tyrosine Kinase Inhibitors (RELATIVITY-073)	Liver Cell Carcinoma; Liver Cancer, Adult; Hepatoma; Hepatocellular Carcinoma; Liver Cell Carcinoma, Adult	Auckland; 2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT04567615
NCT04572152	AK119-102	Phase 1		VIC, NSW, QLD, SA	1/10/2020	18/01/2021	AK104; AK104 + AK119; AK119	anti-CD73_monoclonal_antibody; anti-CD73_monoclonal_antibody + bispecific_PD-1/CTLA-4_antibody; bispecific_PD-1/CTLA-4_antibody	AK104 + AK119; AK104 + AK119	anti-CD73_monoclonal_antibody + bispecific_PD-1/CTLA-4_antibody; anti-CD73_monoclonal_antibody + bispecific_PD-1/CTLA-4_antibody	AK119-102	A Phase 1a/1b, Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumor Activity of AK119 in Combination With AK104 in Subjects With Advanced or Metastatic Solid Tumors.	Advanced or Metastatic Solid Tumors	2148 - Blacktown; 3168 - Clayton; 5037 - Adelaide; 3004 - Melbourne; 4101 - South Brisbane	https://clinicaltrials.gov/ct2/show/NCT04572152
NCT04576455	2020-001984-10--WO42312	Phase 2		WA, NSW, VIC	6/10/2020	27/11/2020	Fulvestrant; Giredestrant; LHRH Agonist	selective_estrogen_receptor_degrader; LHRH_agonist	Fulvestrant; Giredestrant; LHRH Agonist	selective_estrogen_receptor_degrader; LHRH_agonist	2020-001984-10  WO42312	A Phase II, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of GDC-9545 Compared With Physician's Choice of Endocrine Monotherapy in Patients With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer	Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer	2010 - Darlinghurst; 3021 - St Albans; 2059 - North Sydney; 6150 - Murdoch	https://clinicaltrials.gov/ct2/show/NCT04576455
NCT04584112	2020-000531-47--CO42177	Phase 1		WA, QLD	12/10/2020	28/09/2020	Atezolizumab; Atezolizumab + Carboplatin + Cyclophosphamide + Doxorubicin + Filgrastim + Nab-paclitaxel + Pegfilgrastim + Tiragolumab; Atezolizumab + Cyclophosphamide + Doxorubicin + Filgrastim + Nab-paclitaxel + Pegfilgrastim + Tiragolumab; Atezolizumab + Nab-paclitaxel + Tiragolumab; Carboplatin; Cyclophosphamide; Doxorubicin; Filgrastim; Nab-paclitaxel; Pegfilgrastim; Tiragolumab	alkylating_agent + anthracycline + anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + granulocyte_colony_stimulating_factor + platinum-based_antineoplastic_agent + taxane; alkylating_agent; doxorubicin; alkylating_agent + anthracycline + anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + granulocyte_colony_stimulating_factor + taxane; granulocyte_colony_stimulating_factor; anti-PD-L1_monoclonal_antibody; taxane; anthracycline; platinum-based_antineoplastic_agent; anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + taxane	Atezolizumab + Carboplatin + Cyclophosphamide + Doxorubicin + Filgrastim + Nab-paclitaxel + Pegfilgrastim + Tiragolumab; Atezolizumab + Cyclophosphamide + Doxorubicin + Filgrastim + Nab-paclitaxel + Pegfilgrastim + Tiragolumab; Atezolizumab + Nab-paclitaxel + Tiragolumab; Atezolizumab + Carboplatin + Cyclophosphamide + Doxorubicin + Filgrastim + Nab-paclitaxel + Pegfilgrastim + Tiragolumab; Atezolizumab + Cyclophosphamide + Doxorubicin + Filgrastim + Nab-paclitaxel + Pegfilgrastim + Tiragolumab; Atezolizumab + Nab-paclitaxel + Tiragolumab	alkylating_agent + anthracycline + anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + granulocyte_colony_stimulating_factor + platinum-based_antineoplastic_agent + taxane; alkylating_agent + anthracycline + anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + granulocyte_colony_stimulating_factor + taxane; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + taxane; alkylating_agent + anthracycline + anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + granulocyte_colony_stimulating_factor + platinum-based_antineoplastic_agent + taxane; alkylating_agent + anthracycline + anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + granulocyte_colony_stimulating_factor + taxane; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + taxane; doxorubicin	2020-000531-47  CO42177	A Phase Ib, Open-Label, Multicohort Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Patients With Triple-Negative Breast Cancer	Triple-Negative Breast Cancer	6149 - Bull Creek; 4101 - South Brisbane	https://clinicaltrials.gov/ct2/show/NCT04584112
NCT04585035	KEYNOTE-C15--D1553-101	Phase 1/Phase 2		SA, NSW, VIC, WA	14/10/2020	2/10/2020	Garsorasib	KRAS_G12C_inhibitor	Garsorasib	KRAS_G12C_inhibitor	KEYNOTE-C15  D1553-101	A Phase 1/2, Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of D-1553 in Subjects With Advanced or Metastatic Solid Tumors With KRasG12C Mutation	NSCLC; CRC; Solid Tumor, Adult	3065 - Fitzroy; 3144 - Malvern; 2640 - East Albury; 5011 - Woodville South; 2148 - Blacktown; 6009 - Nedlands; 2298 - Waratah; 3199 - Frankston; 2217 - Kogarah	https://clinicaltrials.gov/ct2/show/NCT04585035
NCT04585750	KEYNOTE-D79--PMV-586-101	Unknown		WA, VIC, NSW	14/10/2020	29/10/2020	Pembrolizumab; Pembrolizumab + Rezatapopt; Rezatapopt	anti-PD-1_monoclonal_antibody + mutant_p53_reactivator,Y220C-selective; anti-PD-1_monoclonal_antibody; mutant_p53_reactivator,Y220C-selective	Pembrolizumab + Rezatapopt; Rezatapopt; Pembrolizumab + Rezatapopt	anti-PD-1_monoclonal_antibody + mutant_p53_reactivator,Y220C-selective; mutant_p53_reactivator,Y220C-selective; anti-PD-1_monoclonal_antibody + mutant_p53_reactivator,Y220C-selective	KEYNOTE-D79  PMV-586-101	A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)	Lung Cancer; Prostate Cancer; Colorectal Cancer; Metastatic Cancer; Advanced Solid Tumor; Metastatic Solid Tumor; Endometrial Cancer; Advanced Malignant Neoplasm; Other Cancer; Locally Advanced; Breast Cancer; Ovarian Cancer; Head and Neck Cancer	- Nedlands; - Clayton; - Camperdown	https://clinicaltrials.gov/ct2/show/NCT04585750
NCT04585815	2020-002829-28--B8011011	Phase 1/Phase 2		VIC, NSW	14/10/2020	10/11/2020	Axitinib; Axitinib + Sasanlimab; Binimetinib; Binimetinib + Encorafenib + Sasanlimab; Encorafenib; Sasanlimab	VEGFR/PDGFR_inhibitor + anti-PD-1_monoclonal_antibody; KIT_inhibitor,ATP-competitive; anti-PD-1_monoclonal_antibody; VEGFR/PDGFR_inhibitor; KIT_inhibitor,ATP-competitive + anti-PD-1_monoclonal_antibody; BRAF_V600_inhibitor; MEK_inhibitor; BRAF_V600_inhibitor + MEK_inhibitor + anti-PD-1_monoclonal_antibody	Axitinib + Sasanlimab; Binimetinib + Encorafenib + Sasanlimab; Axitinib + Sasanlimab; Binimetinib + Encorafenib + Sasanlimab	BRAF_V600_inhibitor + MEK_inhibitor + anti-PD-1_monoclonal_antibody; KIT_inhibitor,ATP-competitive + anti-PD-1_monoclonal_antibody; VEGFR/PDGFR_inhibitor + anti-PD-1_monoclonal_antibody; BRAF_V600_inhibitor + MEK_inhibitor + anti-PD-1_monoclonal_antibody; KIT_inhibitor,ATP-competitive + anti-PD-1_monoclonal_antibody; VEGFR/PDGFR_inhibitor + anti-PD-1_monoclonal_antibody	2020-002829-28  B8011011	A Phase 1b/2 Open Label Umbrella Study of Sasanlimab Combined With Anti-Cancer Therapies Targeting Multiple Molecular Mechanisms in Participants With Non-Small Cell Lung Cancer (NSCLC)	Carcinoma, Non-Small-Cell Lung	2065 - St Leonards; 2139 - Concord; 2050 - Camperdown; 3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT04585815
NCT04586231	2020-002075-35--6482-011	Phase 3		VIC, SA	14/10/2020	25/02/2021	Belzutifan; Belzutifan + Lenvatinib; Cabozantinib; Lenvatinib	HIF2a_inhibitor + VEGF_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor; VEGF_inhibitor; MET_inhibitor,type_2; VEGFR2_inhibitor; AXL_inhibitor; ROS1_inhibitor; RET_inhibitor; HIF2a_inhibitor; KIT_inhibitor	Belzutifan + Lenvatinib; Cabozantinib; Belzutifan + Lenvatinib	AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor; AXL_inhibitor; HIF2a_inhibitor + VEGF_inhibitor; KIT_inhibitor; MET_inhibitor,type_2; RET_inhibitor; ROS1_inhibitor; VEGFR2_inhibitor; HIF2a_inhibitor + VEGF_inhibitor	2020-002075-35  6482-011	An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination With Lenvatinib (MK-7902) vs Cabozantinib in Participants With Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy	Carcinoma, Renal Cell	3199 - Frankston; 3000 - Melbourne; 5112 - Elizabeth Vale	https://clinicaltrials.gov/ct2/show/NCT04586231
NCT04586335	CYH33-G102	Phase 1	NOT_RECRUITING	QLD	14/10/2020	28/09/2020	CYH33; CYH33 + Olaparib; Olaparib	PARP_inhibitor; PARP_inhibitor + PI3K_alpha_inhibitor; PI3K_alpha_inhibitor	CYH33 + Olaparib; CYH33 + Olaparib	PARP_inhibitor + PI3K_alpha_inhibitor; PARP_inhibitor + PI3K_alpha_inhibitor	CYH33-G102	Open Label, Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of CYH33, an Oral PI3K Inhibitor in Combination With Olaparib, an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.	Prostate Cancer; Solid Tumor; Endometrial Cancer; Ovarian Cancer; Breast Cancer	4101 - Brisbane	https://clinicaltrials.gov/ct2/show/NCT04586335
NCT04589845	2020-001847-16--BO41932	Phase 2		NZ, NSW, VIC, QLD	19/10/2020	18/01/2021	Alectinib; Atezolizumab; Belvarafenib; Entrectinib; Idasanutlin; Inavolisib; Ipatasertib; Pralsetinib; Trastuzumab Emtansine	MDM2_inhibitor; anti-PD-L1_monoclonal_antibody; ROS1_inhibitor; ALK_inhibitor,second_generation; anti-ERBB2_antibody-drug_conjugate; TRK_inhibitor,first_generation; pan-RAF_inhibitor; ALK_inhibitor,third_generation; ALK/RET_inhibitor; pan-AKT_inhibitor; PI3K_alpha_inhibitor; RET_inhibitor	Alectinib; Atezolizumab; Belvarafenib; Entrectinib; Idasanutlin; Inavolisib; Ipatasertib; Pralsetinib; Trastuzumab Emtansine	ALK/RET_inhibitor; ALK_inhibitor,second_generation; ALK_inhibitor,third_generation; MDM2_inhibitor; PI3K_alpha_inhibitor; RET_inhibitor; ROS1_inhibitor; TRK_inhibitor,first_generation; anti-ERBB2_antibody-drug_conjugate; anti-PD-L1_monoclonal_antibody; pan-AKT_inhibitor; pan-RAF_inhibitor	2020-001847-16  BO41932	Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial	Solid Tumors	2010 - Darlinghurst; 3000 - Melbourne; 3052 - Parkville; Auckland; Christchurch; 4102 - Woolloongabba; 2031 - Randwick	https://clinicaltrials.gov/ct2/show/NCT04589845
NCT04590963	INTERLINK-1	Phase 3		SA, VIC, NSW, QLD	19/10/2020	2/10/2020	Cetuximab; Cetuximab + Monalizumab; Monalizumab; Placebo	anti-EGFR_monoclonal_antibody + anti-NKG2A_monoclonal_antibody; anti-NKG2A_monoclonal_antibody; anti-EGFR_monoclonal_antibody; placebo	Cetuximab; Cetuximab + Monalizumab; Cetuximab + Monalizumab; Placebo	anti-EGFR_monoclonal_antibody; anti-EGFR_monoclonal_antibody + anti-NKG2A_monoclonal_antibody; anti-EGFR_monoclonal_antibody + anti-NKG2A_monoclonal_antibody; placebo	D7310C00001	A Phase 3 Randomized, Double-blind, Multicenter, Global Study of Monalizumab or Placebo in Combination With Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With an Immune Checkpoint Inhibitor	Squamous Cell Carcinoma of the Head and Neck	4102 - Woolloongabba; 5112 - Elizabeth Vale; 3000 - Melbourne; 2050 - Camperdown; 3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT04590963
NCT04597411	CAAA817A12101--PSMA-617-100	Phase 1		NSW	22/10/2020	1/04/2021	225Ac-PSMA-617; LHRH Agonist	radioligand,PSMA-targeting; LHRH_agonist	LHRH Agonist; 225Ac-PSMA-617	LHRH_agonist; radioligand,PSMA-targeting	CAAA817A12101  PSMA-617-100	AcTION: A Phase I Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer and Extensive Skeletal Metastases	Prostatic Neoplasms, Castration-Resistant	- Darlinghurst	https://clinicaltrials.gov/ct2/show/NCT04597411
NCT04603001	2020-002830-33--LOXO-IDH-20001	Phase 1	NOT_RECRUITING	VIC, WA	26/10/2020	1/12/2020	LY3410738	IDH1_R132_inhibitor,covalent	LY3410738	IDH1_R132_inhibitor,covalent	2020-002830-33  LOXO-IDH-20001	A Phase 1 Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations	Chronic Myelomonocytic Leukemia (CMML); Acute Myeloid Leukemia (AML); Myeloproliferative Neoplasms (MPNs); Myelodysplastic Syndrome (MDS)	6009 - Nedlands; 3000 - Melbourne; 3004 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04603001
NCT04604132	FIDES-03	Phase 1/Phase 2		VIC	27/10/2020	6/10/2020	Atezolizumab; Atezolizumab + Derazantinib; Derazantinib; Derazantinib + Paclitaxel + Ramucirumab; Paclitaxel; Paclitaxel + Ramucirumab; Ramucirumab	FGFR1/2/3_inhibitor + anti-VEGFR2_monoclonal_antibody + taxane; FGFR1/2/3_inhibitor; anti-VEGFR2_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; FGFR1/2/3_inhibitor + anti-PD-L1_monoclonal_antibody; taxane; anti-VEGFR2_monoclonal_antibody + taxane	Atezolizumab + Derazantinib; Derazantinib; Derazantinib + Paclitaxel + Ramucirumab; Paclitaxel + Ramucirumab; Atezolizumab + Derazantinib; Derazantinib + Paclitaxel + Ramucirumab; Paclitaxel + Ramucirumab	FGFR1/2/3_inhibitor; FGFR1/2/3_inhibitor + anti-PD-L1_monoclonal_antibody; FGFR1/2/3_inhibitor + anti-VEGFR2_monoclonal_antibody + taxane; anti-VEGFR2_monoclonal_antibody + taxane; FGFR1/2/3_inhibitor + anti-PD-L1_monoclonal_antibody; FGFR1/2/3_inhibitor + anti-VEGFR2_monoclonal_antibody + taxane; anti-VEGFR2_monoclonal_antibody + taxane	DZB-CS-202	A Phase 1b/2 Study of Derazantinib as Monotherapy and Combination Therapy With Paclitaxel, Ramucirumab or Atezolizumab in Patients With HER2-negative Gastric Adenocarcinoma Expressing FGFR2 Genetic Aberrations	Gastric Adenocarcinoma	3000 - Melbourne; 3168 - Clayton; 3181 - Prahran	https://clinicaltrials.gov/ct2/show/NCT04604132
NCT04606446	KAT6	Phase 1		WA, VIC, NSW	28/10/2020	16/11/2020	Fulvestrant; Fulvestrant + PF-07248144; Letrozole; Letrozole + PF-07248144 + Palbociclib; PF-07248144; Palbociclib	CDK4/6_inhibitor + KAT6_inhibitor + aromatase_inhibitor; CDK4/6_inhibitor; aromatase_inhibitor; KAT6_inhibitor; selective_estrogen_receptor_degrader; KAT6_inhibitor + selective_estrogen_receptor_degrader	Fulvestrant + PF-07248144; Letrozole + PF-07248144 + Palbociclib; PF-07248144; Fulvestrant + PF-07248144; Letrozole + PF-07248144 + Palbociclib	CDK4/6_inhibitor + KAT6_inhibitor + aromatase_inhibitor; KAT6_inhibitor; KAT6_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + KAT6_inhibitor + aromatase_inhibitor; KAT6_inhibitor + selective_estrogen_receptor_degrader	C4551001	A Phase 1 Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, and Anti-tumor Activity of PF-07248144 in Participants With Advanced or Metastatic Solid Tumors.	Locally Advanced or Metastatic Castration-resistant Prostate Cancer; Locally Advanced or Metastatic Non-small Cell Lung Cancer; Locally Advanced or Metastatic ER+ HER2- Breast Cancer	6008 - Subiaco; 3000 - Melbourne; 3021 - St Albans; 2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT04606446
NCT04607421	2020-001288-99--C4221015	Phase 3		NZ, SA, VIC, NSW, QLD	29/10/2020	21/12/2020	Bevacizumab; Bevacizumab + Capecitabine + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin; Capecitabine; Cetuximab; Cetuximab + Encorafenib; Cetuximab + Encorafenib + Fluorouracil + Irinotecan + Leucovorin; Cetuximab + Encorafenib + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin; Cetuximab + Encorafenib + Fluorouracil + Leucovorin + Oxaliplatin; Encorafenib; Fluorouracil; Irinotecan; Leucovorin; Oxaliplatin	BRAF_V600_inhibitor; anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; BRAF_V600_inhibitor + anti-EGFR_monoclonal_antibody; folinic_acid; anti-EGFR_monoclonal_antibody; fluoropyrimidine; BRAF_V600_inhibitor + anti-EGFR_monoclonal_antibody + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor; platinum-based_antineoplastic_agent; BRAF_V600_inhibitor + anti-EGFR_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; Fluorouracil; BRAF_V600_inhibitor + anti-EGFR_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-VEGF_monoclonal_antibody; topoisomerase_inhibitor	Bevacizumab + Capecitabine + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin; Cetuximab + Encorafenib; Cetuximab + Encorafenib + Fluorouracil + Irinotecan + Leucovorin; Cetuximab + Encorafenib + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin; Cetuximab + Encorafenib + Fluorouracil + Leucovorin + Oxaliplatin; Bevacizumab + Capecitabine + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin; Cetuximab + Encorafenib; Cetuximab + Encorafenib + Fluorouracil + Irinotecan + Leucovorin; Cetuximab + Encorafenib + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin; Cetuximab + Encorafenib + Fluorouracil + Leucovorin + Oxaliplatin	BRAF_V600_inhibitor + anti-EGFR_monoclonal_antibody; BRAF_V600_inhibitor + anti-EGFR_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; BRAF_V600_inhibitor + anti-EGFR_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; BRAF_V600_inhibitor + anti-EGFR_monoclonal_antibody + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor; anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; BRAF_V600_inhibitor + anti-EGFR_monoclonal_antibody; BRAF_V600_inhibitor + anti-EGFR_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; BRAF_V600_inhibitor + anti-EGFR_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; BRAF_V600_inhibitor + anti-EGFR_monoclonal_antibody + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor; Fluorouracil; anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent + topoisomerase_inhibitor	2020-001288-99  C4221015	AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE 3 STUDY OF FIRST-LINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEAD-IN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600E-MUTANT COLORECTAL CANCER	Neoplasms	4029 - Herston; 3000 - Melbourne; 2065 - St Leonards; 2170 - Liverpool; 2080 - Mount Kuring-Gai; 5011 - Adelaide; 3168 - Clayton	https://clinicaltrials.gov/ct2/show/NCT04607421
NCT04612751	2021-000274-28--DS1062-A-U104	Phase 1		NSW, SA	3/11/2020	6/11/2020	Carboplatin; Cisplatin; Datopotamab deruxtecan; Datopotamab deruxtecan + Durvalumab; Durvalumab	anti-PD-L1_monoclonal_antibody; platinum-based_antineoplastic_agent; anti-Trop2_antibody-drug_conjugate; anti-PD-L1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate	Datopotamab deruxtecan + Durvalumab; Carboplatin; Cisplatin; Datopotamab deruxtecan + Durvalumab	anti-PD-L1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-PD-L1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; platinum-based_antineoplastic_agent	2021-000274-28  DS1062-A-U104	A Phase 1b, Multicenter, 2-Part, Open-Label Study of Datopotamab Deruxtecan (Data-DXd) in Combination With Durvalumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung04)	Advanced or Metastatic NSCLC	2500 - Wollongong; 5042 - Bedford Park	https://clinicaltrials.gov/ct2/show/NCT04612751
NCT04613596	849-007	Phase 2		QLD	3/11/2020	2/12/2020	Adagrasib; Pembrolizumab	anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor	Adagrasib; Pembrolizumab	KRAS_G12C_inhibitor; anti-PD-1_monoclonal_antibody	849-007	A Phase 2 Trial of MRTX849 Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation	Metastatic Non-Small Cell Lung Cancer; Advanced Non-Small Cell Lung Cancer	4102 - Woolloongabba	https://clinicaltrials.gov/ct2/show/NCT04613596
NCT04618393	EMB02X101	Phase 1/Phase 2		VIC	5/11/2020	11/03/2021	EMB-02	bispecific_PD-1/LAG3_antibody	EMB-02	bispecific_PD-1/LAG3_antibody	EMB02X101	A Phase I/II Trial of EMB-02, a Bi-specific Antibody Against PD-1 and LAG-3, in Patients With Advanced Solid Tumors	Advanced Solid Tumors	3199 - Frankston	https://clinicaltrials.gov/ct2/show/NCT04618393
NCT04619004	2020-000730-17--U31402-A-U201	Phase 2		WA, NSW, VIC, QLD	6/11/2020	2/02/2021	Patritumab Deruxtecan	anti-ERBB3_antibody-drug_conjugate	Patritumab Deruxtecan	anti-ERBB3_antibody-drug_conjugate	2020-000730-17  U31402-A-U201	HERTHENA-Lung01: A Phase 2 Randomized Open-Label Study of Patritumab Deruxtecan (U3-1402) in Subjects With Previously Treated Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer (NSCLC)	Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor; Non-Small Cell Lung Cancer Metastatic	6008 - Subiaco; 4102 - Woolloongabba; 2148 - Blacktown; 2050 - Camperdown; 3000 - Melbourne; 2217 - Kogarah	https://clinicaltrials.gov/ct2/show/NCT04619004
NCT04619797	SKYSCRAPER-06	Unknown		NZ	6/11/2020	14/12/2020	Atezolizumab; Atezolizumab + Carboplatin + Cisplatin + Pemetrexed + Tiragolumab; Carboplatin; Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Cisplatin; Pembrolizumab; Pemetrexed; Placebo; Tiragolumab	anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; placebo; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite; anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody	Atezolizumab + Carboplatin + Cisplatin + Pemetrexed + Tiragolumab; Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Atezolizumab + Carboplatin + Cisplatin + Pemetrexed + Tiragolumab; Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Placebo	anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; placebo	2020-002851-39  BO42592	A Phase II/III, Randomized, Double-Blind, Placebo-Controlled Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Patients With Previously Untreated Advanced Non-Squamous Non-Small-Cell Lung Cancer	Non-small Cell Lung Cancer (NSCLC)	Palmerston North; Tauranga; Auckland; Hamilton	https://clinicaltrials.gov/ct2/show/NCT04619797
NCT04623775	2020-004026-31--CA224-104	Phase 2		VIC, NSW, QLD, NZ, WA	10/11/2020	17/02/2021	Carboplatin; Cisplatin; Nab-paclitaxel; Nivolumab; Nivolumab + Relatlimab; Paclitaxel; Pemetrexed; Relatlimab	anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody; platinum-based_antineoplastic_agent; antimetabolite; taxane; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Nivolumab; Nivolumab + Relatlimab; Carboplatin; Cisplatin; Nab-paclitaxel; Nivolumab + Relatlimab; Pemetrexed	anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; antimetabolite; platinum-based_antineoplastic_agent; taxane	2020-004026-31  CA224-104	A Phase 2 Randomized Double-blind Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)	Non-small Cell Lunch Cancer; Metastatic Non-small Cell Lung Cancer; Recurrent Non-small Cell Lung Cancer	6009 - Nedlands; 2050 - Camperdown; 6150 - Murdoch; 3199 - Frankston; 3550 - Bendigo; 3128 - Box Hill; 3350 - Ballarat; Christchurch; 4101 - South Brisbane; 2340 - Tamworth; 2250 - Gosford	https://clinicaltrials.gov/ct2/show/NCT04623775
NCT04624204	MK-7339-013--7339-013	Phase 3		VIC, NSW, QLD	10/11/2020	8/12/2020	Dexamethasone; Etoposide; Etoposide + Olaparib + Pembrolizumab + Radiotherapy; Olaparib; Pembrolizumab; Placebo; Radiotherapy	PARP_inhibitor; radiotherapy; glucocorticoid; anti-PD-1_monoclonal_antibody; placebo; PARP_inhibitor + anti-PD-1_monoclonal_antibody + radiotherapy + topoisomerase_inhibitor; topoisomerase_inhibitor	Etoposide + Olaparib + Pembrolizumab + Radiotherapy; Dexamethasone; Etoposide + Olaparib + Pembrolizumab + Radiotherapy; Placebo	PARP_inhibitor + anti-PD-1_monoclonal_antibody + radiotherapy + topoisomerase_inhibitor; PARP_inhibitor + anti-PD-1_monoclonal_antibody + radiotherapy + topoisomerase_inhibitor; glucocorticoid; placebo	MK-7339-013  7339-013	A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Pembrolizumab (MK-3475) in Combination With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib (MK-7339), Compared to Concurrent Chemoradiation Therapy Alone in Participants With Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC)	Small Cell Lung Cancer	3084 - Heidelberg; 2560 - Campbelltown; 2750 - Penrith; 3021 - St Albans; 4215 - Southport; 3199 - Frankston; 2298 - Waratah	https://clinicaltrials.gov/ct2/show/NCT04624204
NCT04626479	2019-003609-84--3475-03A	Phase 1/Phase 2		NSW, VIC, QLD, NZ	12/11/2020	16/12/2020	Belzutifan; Belzutifan + Lenvatinib + Pembrolizumab; Favezelimab; Favezelimab + Lenvatinib + Pembrolizumab; Lenvatinib; Lenvatinib + Pembrolizumab; Lenvatinib + Pembrolizumab + Quavonlimab; Pembrolizumab; Quavonlimab	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody; VEGF_inhibitor + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; HIF2a_inhibitor + VEGF_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; HIF2a_inhibitor	Belzutifan + Lenvatinib + Pembrolizumab; Favezelimab + Lenvatinib + Pembrolizumab; Lenvatinib + Pembrolizumab; Lenvatinib + Pembrolizumab + Quavonlimab; Belzutifan + Lenvatinib + Pembrolizumab; Favezelimab + Lenvatinib + Pembrolizumab; Lenvatinib + Pembrolizumab; Lenvatinib + Pembrolizumab + Quavonlimab	HIF2a_inhibitor + VEGF_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; HIF2a_inhibitor + VEGF_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody	2019-003609-84  3475-03A	A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants With RCC (U03): Substudy 03A	Carcinoma, Renal Cell	Auckland; 4029 - Herston; 2148 - Blacktown; 3084 - Heidelberg; 2217 - Kogarah	https://clinicaltrials.gov/ct2/show/NCT04626479
NCT04626518	2019-003610-13--3475-03B	Phase 1/Phase 2		QLD, VIC, NSW, NZ	12/11/2020	17/12/2020	Belzutifan; Belzutifan + Lenvatinib; Belzutifan + Pembrolizumab; Favezelimab; Favezelimab + Pembrolizumab; Lenvatinib; Lenvatinib + Pembrolizumab; MK-4830; MK-4830 + Pembrolizumab; Pembrolizumab; Pembrolizumab + Quavonlimab; Quavonlimab	anti-CTLA-4_monoclonal_antibody; HIF2a_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; HIF2a_inhibitor + VEGF_inhibitor; VEGF_inhibitor; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; HIF2a_inhibitor; anti-ILT4_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-ILT4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Belzutifan + Lenvatinib; Belzutifan + Pembrolizumab; Favezelimab + Pembrolizumab; Lenvatinib + Pembrolizumab; MK-4830 + Pembrolizumab; Pembrolizumab + Quavonlimab; Belzutifan + Lenvatinib; Belzutifan + Pembrolizumab; Favezelimab + Pembrolizumab; Lenvatinib + Pembrolizumab; MK-4830 + Pembrolizumab; Pembrolizumab + Quavonlimab	HIF2a_inhibitor + VEGF_inhibitor; HIF2a_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-ILT4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; HIF2a_inhibitor + VEGF_inhibitor; HIF2a_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-ILT4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	2019-003610-13  3475-03B	A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants With RCC (U03): Substudy 03B	Carcinoma, Renal Cell	Auckland; 3084 - Melbourne; 2217 - Kogarah; 2148 - Blacktown; 4029 - Herston	https://clinicaltrials.gov/ct2/show/NCT04626518
NCT04630756	D8230C00002	Phase 1/Phase 2		WA, VIC	16/11/2020	17/02/2021	AZD4573; AZD4573 + Acalabrutinib; Acalabrutinib	BTK_inhibitor + CDK9_inhibitor; CDK9_inhibitor; BTK_inhibitor	AZD4573 + Acalabrutinib; AZD4573 + Acalabrutinib	BTK_inhibitor + CDK9_inhibitor; BTK_inhibitor + CDK9_inhibitor	D8230C00002	A Modular Phase I/II, Open-label, Multicentre Study to Assess AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Haematological Malignancies	Advanced Haematological Malignancies	6009 - Nedlands; 3168 - Clayton	https://clinicaltrials.gov/ct2/show/NCT04630756
NCT04631601	2020-001305-23--20190505	Phase 1/Phase 2		NSW	17/11/2020	15/01/2021	AMG 404; Abiraterone; Enzalutamide	antiandrogen,nonsteroidal,second_generation; anti-PD-1_monoclonal_antibody; CYP17A1_inhibitor	AMG 404; Abiraterone; Enzalutamide	CYP17A1_inhibitor; anti-PD-1_monoclonal_antibody; antiandrogen,nonsteroidal,second_generation	2020-001305-23  20190505	A Master Protocol Evaluating the Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)	Metastatic Castration-resistant Prostate Cancer	2010 - Darlinghurst	https://clinicaltrials.gov/ct2/show/NCT04631601
NCT04634825	CP-MGA271-06	Phase 2		QLD, VIC, NSW	18/11/2020	17/03/2021	Enoblituzumab; Enoblituzumab + Retifanlimab; Enoblituzumab + Tebotelimab; Retifanlimab; Tebotelimab	humanized_PD-1xLAG-3_dual-affinity_re-targeting_protein; anti-CD276_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CD276_monoclonal_antibody + humanized_PD-1xLAG-3_dual-affinity_re-targeting_protein; anti-CD276_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Enoblituzumab + Retifanlimab; Enoblituzumab + Tebotelimab; Enoblituzumab + Retifanlimab; Enoblituzumab + Tebotelimab	anti-CD276_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CD276_monoclonal_antibody + humanized_PD-1xLAG-3_dual-affinity_re-targeting_protein; anti-CD276_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CD276_monoclonal_antibody + humanized_PD-1xLAG-3_dual-affinity_re-targeting_protein	CP-MGA271-06	A Phase 2 Open-Label Trial to Evaluate Enoblituzumab in Combination With Retifanlimab or Tebotelimab in the First-Line Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck	Head and Neck Cancer; Head and Neck Neoplasms; Head and Neck Squamous Cell Carcinoma	3168 - Ruse; 2298 - Waratah; 2065 - Sydney; 4215 - Southport; 3220 - Geelong; 2170 - Liverpool	https://clinicaltrials.gov/ct2/show/NCT04634825
NCT04642365	2020-003164-82--BP42595	Phase 1		VIC	24/11/2020	4/01/2021	Atezolizumab; Atezolizumab + RO7296682; RO7296682	anti-PD-L1_monoclonal_antibody; anti-CD25_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-CD25_monoclonal_antibody	Atezolizumab + RO7296682; Atezolizumab + RO7296682	anti-CD25_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-CD25_monoclonal_antibody + anti-PD-L1_monoclonal_antibody	2020-003164-82  BP42595	An Open-Label, Multicenter, Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Tumor Activity of RO7296682 in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors	Solid Tumors	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04642365
NCT04644068	PETRA	Phase 1/Phase 2		VIC	25/11/2020	12/11/2020	Carboplatin; Carboplatin + Paclitaxel + Saruparib; Paclitaxel; Paclitaxel + Saruparib; Saruparib	PARP_inhibitor; PARP1-selective_inhibitor; platinum-based_antineoplastic_agent; PARP1-selective_inhibitor + taxane; PARP1-selective_inhibitor + platinum-based_antineoplastic_agent + taxane; PARP_inhibitor + taxane; PARP_inhibitor + platinum-based_antineoplastic_agent + taxane; taxane	Carboplatin + Paclitaxel + Saruparib; Paclitaxel + Saruparib; Saruparib; Carboplatin + Paclitaxel + Saruparib; Paclitaxel + Saruparib	PARP1-selective_inhibitor; PARP1-selective_inhibitor + platinum-based_antineoplastic_agent + taxane; PARP1-selective_inhibitor + taxane; PARP_inhibitor; PARP_inhibitor + platinum-based_antineoplastic_agent + taxane; PARP_inhibitor + taxane; PARP1-selective_inhibitor + platinum-based_antineoplastic_agent + taxane; PARP1-selective_inhibitor + taxane; PARP_inhibitor + platinum-based_antineoplastic_agent + taxane; PARP_inhibitor + taxane	D9720C00001	A Modular Phase I/IIa, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies	Ovarian Cancer; Breast Cancer; Pancreatic Cancer; Prostate Cancer	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04644068
NCT04644237	DESTINY-LUNG02	Phase 2		WA, QLD	25/11/2020	19/03/2021	Trastuzumab Deruxtecan	anti-ERBB2_antibody-drug_conjugate	Trastuzumab Deruxtecan	anti-ERBB2_antibody-drug_conjugate	DS8201-A-U206	A Phase 2, Multicenter, Randomized Study of Trastuzumab Deruxtecan in Subjects With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) (DESTINY-LUNG02)	Non-Small Cell Lung Cancer	6008 - Subiaco; 4102 - Woolloongabba; 4814 - Townsville	https://clinicaltrials.gov/ct2/show/NCT04644237
NCT04645069	ADG126-1001	Phase 1		QLD, NSW, VIC	27/11/2020	15/03/2021	ADG126	anti-CTLA-4_monoclonal_antibody	ADG126	anti-CTLA-4_monoclonal_antibody	ADG126-1001	First-in-human (FIH), Open-Label, Phase I Dose Escalation Study of ADG126 in Patients With Advanced Malignancies	Advanced/Metastatic Tumors	3144 - Melbourne; 2228 - Sydney; 4575 - Sunshine Coast	https://clinicaltrials.gov/ct2/show/NCT04645069
NCT04649385	BGB-A317-15025-101	Phase 1		WA, SA, NZ, VIC	2/12/2020	4/03/2021	BGB-15025; BGB-15025 + Tislelizumab; Tislelizumab	HPK1_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; HPK1_inhibitor	BGB-15025; BGB-15025 + Tislelizumab; BGB-15025 + Tislelizumab	HPK1_inhibitor; HPK1_inhibitor + anti-PD-1_monoclonal_antibody; HPK1_inhibitor + anti-PD-1_monoclonal_antibody	BGB-A317-15025-101	A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors	Advanced Solid Tumor	3000 - Melbourne; 5037 - Windsor; 6009 - Nedlands; Auckland	https://clinicaltrials.gov/ct2/show/NCT04649385
NCT04650581	FINER	Phase 3		WA, QLD, VIC, NSW	2/12/2020	1/12/2020	Fulvestrant; Fulvestrant + Ipatasertib; Ipatasertib; Placebo	pan-AKT_inhibitor + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader; placebo; pan-AKT_inhibitor	Fulvestrant + Ipatasertib; Fulvestrant + Ipatasertib; Placebo	pan-AKT_inhibitor + selective_estrogen_receptor_degrader; pan-AKT_inhibitor + selective_estrogen_receptor_degrader; placebo	MA40	A Double-Blind Placebo-Controlled Randomized Phase III Trial of Fulvestrant and Ipatasertib as Treatment for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor	Breast Cancer	2541 - Nowra; 2109 - Macquarie University; 2324 - Gateshead; 3004 - Melbourne; 3021 - St. Albans; 3002 - East Melbourne; 4575 - Birtinya; 2576 - Bowral; 2031 - Randwick; 6150 - Murdoch; 6230 - Bunbury; 3199 - Frankston	https://clinicaltrials.gov/ct2/show/NCT04650581
NCT04655976	COSTAR-Lung	Phase 2/Phase 3		TAS, SA, QLD, NSW, VIC	7/12/2020	8/12/2020	Cobolimab; Cobolimab + Docetaxel + Dostarlimab; Docetaxel; Docetaxel + Dostarlimab; Dostarlimab	anti-TIM3_monoclonal_antibody; anti-PD-1_monoclonal_antibody + taxane; anti-PD-1_monoclonal_antibody + anti-TIM3_monoclonal_antibody + taxane; anti-PD-1_monoclonal_antibody; taxane	Cobolimab + Docetaxel + Dostarlimab; Docetaxel; Docetaxel + Dostarlimab; Cobolimab + Docetaxel + Dostarlimab; Docetaxel + Dostarlimab	anti-PD-1_monoclonal_antibody + anti-TIM3_monoclonal_antibody + taxane; anti-PD-1_monoclonal_antibody + taxane; taxane; anti-PD-1_monoclonal_antibody + anti-TIM3_monoclonal_antibody + taxane; anti-PD-1_monoclonal_antibody + taxane	2020-003433-37  213410	A Randomized, Open Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab + Docetaxel To Dostarlimab + Docetaxel To Docetaxel Alone In Participants With Advanced Nonsmall Cell Lung Cancer Who Have Progressed On Prior Anti-PD-(L)1 Therapy And Chemotherapy (COSTAR Lung)	Lung Cancer, Non-Small Cell	4101 - South Brisbane; 3004 - Melbourne; 3350 - Ballarat; 5037 - Kurralta Park; 7000 - Hobart; 2148 - Blacktown	https://clinicaltrials.gov/ct2/show/NCT04655976
NCT04656652	2020-004643-80--DS1062-A-U301	Phase 3		SA, NSW, VIC, QLD	7/12/2020	21/12/2020	DS-1062a; Docetaxel	taxane; anti-Trop2_antibody-drug_conjugate	DS-1062a; Docetaxel	anti-Trop2_antibody-drug_conjugate; taxane	2020-004643-80  DS1062-A-U301	Phase 3 Randomized Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-LUNG01)	Non-small Cell Lung Cancer	05042 - Bedford Park; 04101 - South Brisbane; 02109 - North Ryde; 02500 - Wollongong; 2145 - Sydney; 03084 - Heidelberg; 02148 - Blacktown; 2217 - Kogarah	https://clinicaltrials.gov/ct2/show/NCT04656652
NCT04657991	STARBOARD--C4221016	Unknown		NZ	8/12/2020	15/01/2021	Binimetinib; Binimetinib + Encorafenib + Pembrolizumab; Encorafenib; Pembrolizumab; Placebo	anti-PD-1_monoclonal_antibody; MEK_inhibitor; BRAF_V600_inhibitor + MEK_inhibitor + anti-PD-1_monoclonal_antibody; placebo; BRAF_V600_inhibitor	Binimetinib + Encorafenib + Pembrolizumab; Pembrolizumab; Binimetinib + Encorafenib + Pembrolizumab; Placebo	BRAF_V600_inhibitor + MEK_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; BRAF_V600_inhibitor + MEK_inhibitor + anti-PD-1_monoclonal_antibody; placebo	STARBOARD  C4221016	A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF ENCORAFENIB AND BINIMETINIB PLUS PEMBROLIZUMAB VERSUS PLACEBO PLUS PEMBROLIZUMAB IN PARTICIPANTS WITH BRAF V600E/K MUTATION-POSITIVE METASTATIC OR UNRESECTABLE LOCALLY ADVANCED MELANOMA	Melanoma	Canterbury; Manawatu; Auckland	https://clinicaltrials.gov/ct2/show/NCT04657991
NCT04659629	NL201-101	Phase 1		NSW, VIC	9/12/2020	26/04/2021	NL-201	IL-2/IL-15_receptor_agonist	NL-201	IL-2/IL-15_receptor_agonist	NL201-101	A First-in-Human Phase 1 Study of NL-201 in Patients With Relapsed or Refractory Cancer	Advanced Solid Tumor; Solid Tumor	- Heidelberg; - Sydney; 2065 - Sydney	https://clinicaltrials.gov/ct2/show/NCT04659629
NCT04662710	LEAP-015	Phase 3		WA, QLD, NSW	10/12/2020	30/12/2020	Capecitabine; Capecitabine + Fluorouracil + Lenvatinib + Leucovorin + Oxaliplatin + Pembrolizumab; Fluorouracil; Lenvatinib; Leucovorin; Oxaliplatin; Pembrolizumab	VEGF_inhibitor + anti-PD-1_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; VEGF_inhibitor; Fluorouracil; folinic_acid; fluoropyrimidine	Capecitabine + Fluorouracil + Lenvatinib + Leucovorin + Oxaliplatin + Pembrolizumab; Capecitabine + Fluorouracil + Lenvatinib + Leucovorin + Oxaliplatin + Pembrolizumab	VEGF_inhibitor + anti-PD-1_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; Fluorouracil; VEGF_inhibitor + anti-PD-1_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent	2020-001990-53  7902-015	Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy Compared With Standard of Care Therapy as First-line Intervention in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (LEAP-015)	Advanced/Metastatic Gastroesophageal Adenocarcinoma	2500 - Wollongong; 4029 - Herston; 2747 - Kingswood; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT04662710
NCT04665206	VT3989-001	Phase 1		VIC, WA	11/12/2020	24/03/2021	VT3989	TEAD_palmitoylation_inhibitor	VT3989	TEAD_palmitoylation_inhibitor	VT3989-001	Phase 1, Multi-Center, Open-Label, Study to Evaluate the Safety, Tolerability, and PK of VT3989 in Patients With Refractory Locally Advanced or Metastatic Solid Tumors Enriched for Tumors Harboring Mutations of the NF2 Gene	Solid Tumor, Adult; Mesothelioma	3168 - Clayton; 6009 - Nedlands; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04665206
NCT04665843	SKYSCRAPER-09	Unknown		NZ	14/12/2020	2/03/2021	Atezolizumab; Atezolizumab + Tiragolumab; Placebo; Tiragolumab	anti-PD-L1_monoclonal_antibody; placebo; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-TIGIT_monoclonal_antibody	Atezolizumab; Atezolizumab + Tiragolumab; Atezolizumab + Tiragolumab; Placebo	anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; placebo	2020-002852-19  BO42533	A Phase II, Randomized, Double Blind Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Patients With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck	Squamous Cell Carcinoma of Head and Neck	Wellington; Tauranga; Christchurch; Auckland	https://clinicaltrials.gov/ct2/show/NCT04665843
NCT04670679	FLAGSHP-1	Phase 1		VIC, WA	17/12/2020	15/12/2020	Cetuximab; Cetuximab + ERAS-601; ERAS-601	SHP2_inhibitor; SHP2_inhibitor + anti-EGFR_monoclonal_antibody; anti-EGFR_monoclonal_antibody	Cetuximab + ERAS-601; ERAS-601; Cetuximab + ERAS-601	SHP2_inhibitor; SHP2_inhibitor + anti-EGFR_monoclonal_antibody; SHP2_inhibitor + anti-EGFR_monoclonal_antibody	ERAS-601-01	An Open-Label, Multi-Center Phase 1/1b Dose Escalation and Expansion Study of ERAS-601 SHP2 Inhibitor as a Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced or Metastatic Solid Tumors	Advanced or Metastatic Solid Tumors	- Melbourne; - Perth	https://clinicaltrials.gov/ct2/show/NCT04670679
NCT04672460	2020-006101-35--C3441037	Phase 1	NOT_RECRUITING	VIC, NSW	17/12/2020	21/12/2020	Talazoparib	PARP_inhibitor	Talazoparib	PARP_inhibitor	2020-006101-35  C3441037	A PHASE 1, OPEN LABEL, CROSSOVER STUDY TO ESTABLISH BIOEQUIVALENCE BETWEEN THE PROPOSED SOFT GEL TALAZOPARIB CAPSULE FORMULATION AND THE CURRENT TALAZOPARIB COMMERCIAL FORMULATION AND TO ESTIMATE THE FOOD EFFECT ON PHARMACOKINETICS OF THE PROPOSED TALAZOPARIB SOFT GEL CAPSULE FORMULATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS	NSCLC; Solid Tumors; Pancreatic Cancer; Breast Cancer; Ovarian Cancer; Prostate Cancer; Colorectal Cancer; Advanced Solid Tumors	2305 - New Lambton Heights; 3168 - Clayton; 2170 - Liverpool; 3002 - East Melbourne; 3121 - Richmond	https://clinicaltrials.gov/ct2/show/NCT04672460
NCT04674683	HBI-8000-303	Phase 3		NSW, VIC, QLD, NZ, WA	19/12/2020	12/08/2021	Nivolumab; Placebo	anti-PD-1_monoclonal_antibody; placebo	Nivolumab; Placebo	anti-PD-1_monoclonal_antibody; placebo	HBI-8000-303	A Multicenter, Randomized, Double-Blind Phase 3 Study of HBI-8000 Combined With Nivolumab Versus Placebo With Nivolumab in Patients With Unresectable or Metastatic Melanoma Not Previously Treated With PD-1 or PD-L1 Inhibitors	Unresectable or Metastatic Melanoma; Progressive Brain Metastasis	- Shepparton; - Nedlands; - Brisbane; Hamilton; - Waratah; - Wahroonga; - Liverpool; 4556 - Buderim; - Ballarat; - Tweed Heads; - South Brisbane	https://clinicaltrials.gov/ct2/show/NCT04674683
NCT04675294	KEYNOTE-B87--AT148003	Phase 2		SA	19/12/2020	2/04/2021	Pembrolizumab	anti-PD-1_monoclonal_antibody	Pembrolizumab	anti-PD-1_monoclonal_antibody	KEYNOTE-B87  AT148003	A Phase 2 Study of Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)	Head and Neck Cancer; Head and Neck Squamous Cell Carcinoma	5037 - Adelaide	https://clinicaltrials.gov/ct2/show/NCT04675294
NCT04675333	KEYNOTE-B88--AT148004	Phase 2		SA	19/12/2020	10/05/2021	Carboplatin; Cisplatin; Fluorouracil; Pembrolizumab	anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; fluoropyrimidine	Pembrolizumab; Carboplatin; Cisplatin; Fluorouracil	anti-PD-1_monoclonal_antibody; fluoropyrimidine; platinum-based_antineoplastic_agent	KEYNOTE-B88  AT148004	A Phase 2 Study of Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)	Head and Neck Squamous Cell Carcinoma; Head and Neck Cancer	5037 - Adelaide	https://clinicaltrials.gov/ct2/show/NCT04675333
NCT04677855	PCUR101-003	Phase 1		NSW, SA	21/12/2020	30/03/2021	Abiraterone; Abiraterone + PCUR-101 + Prednisone; PCUR-101; Prednisone	glucocorticoid; CYP17A1_inhibitor + glucocorticoid + synthetic_plumbagin; synthetic_plumbagin; CYP17A1_inhibitor	Abiraterone + PCUR-101 + Prednisone; PCUR-101; Abiraterone + PCUR-101 + Prednisone	CYP17A1_inhibitor + glucocorticoid + synthetic_plumbagin; synthetic_plumbagin; CYP17A1_inhibitor + glucocorticoid + synthetic_plumbagin	PCUR101-003	A Phase I Study of PCUR-101 in Combination With Androgen Directed Therapy in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer	Prostate Cancer	2170 - Liverpool; 2217 - Kogarah; 5042 - Bedford Park	https://clinicaltrials.gov/ct2/show/NCT04677855
NCT04684108	SG301-001	Phase 1		QLD, VIC	24/12/2020		SG301	anti-CD38_monoclonal_antibody	SG301	anti-CD38_monoclonal_antibody	SG301-001	A First-in-human Phase 1 Study to Evaluate Safety, Tolerability, and Preliminary Efficacy of SG301 in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies	Hematological Malignancy; Relapsed or Refractory Multiple Myeloma	4558 - Maroochydore; 4224 - Tugun; 3199 - Frankston	https://clinicaltrials.gov/ct2/show/NCT04684108
NCT04685135	KRYSTAL-12	Phase 3		QLD, SA	28/12/2020	1/04/2021	Adagrasib; Docetaxel	KRAS_G12C_inhibitor; taxane	Adagrasib; Docetaxel	KRAS_G12C_inhibitor; taxane	849-012	A Randomized Phase 3 Study of MRTX849 Versus Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C Mutation	Metastatic Non Small Cell Lung Cancer; Advanced Non Small Cell Lung Cancer	- Saint Leonards; - Woolloongabba; - Bedford Park	https://clinicaltrials.gov/ct2/show/NCT04685135
NCT04686305	DL03	Phase 1		VIC	28/12/2020	9/03/2021	Carboplatin; Carboplatin + Durvalumab + Trastuzumab Deruxtecan; Cisplatin; Cisplatin + Durvalumab + Trastuzumab Deruxtecan; Durvalumab; Durvalumab + Pemetrexed + Trastuzumab Deruxtecan; Durvalumab + Trastuzumab Deruxtecan; Pemetrexed; Trastuzumab Deruxtecan	platinum-based_antineoplastic_agent; anti-ERBB2_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody; antimetabolite; anti-PD-L1_monoclonal_antibody; anti-ERBB2_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody + antimetabolite; anti-ERBB2_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent; anti-ERBB2_antibody-drug_conjugate	Carboplatin + Durvalumab + Trastuzumab Deruxtecan; Cisplatin + Durvalumab + Trastuzumab Deruxtecan; Durvalumab + Pemetrexed + Trastuzumab Deruxtecan; Durvalumab + Trastuzumab Deruxtecan; Trastuzumab Deruxtecan; Carboplatin + Durvalumab + Trastuzumab Deruxtecan; Cisplatin + Durvalumab + Trastuzumab Deruxtecan; Durvalumab + Pemetrexed + Trastuzumab Deruxtecan; Durvalumab + Trastuzumab Deruxtecan	anti-ERBB2_antibody-drug_conjugate; anti-ERBB2_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody; anti-ERBB2_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody + antimetabolite; anti-ERBB2_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent; anti-ERBB2_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody; anti-ERBB2_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody + antimetabolite; anti-ERBB2_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent	D967YC00001	A Phase Ib Multicenter, Open-label Dose-escalation Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Durvalumab in Combination With Cisplatin, Carboplatin or Pemetrexed in First-line Treatment of Patients With Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) and Human Epidermal Growth Factor Receptor 2 Overexpression (HER2+) (DESTINY-Lung03)	Locally Advanced or Metastatic Non-Small Cell Lung Cancer	3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT04686305
NCT04691804	SHR3162-III-305	Phase 3		VIC, NSW, SA	31/12/2020	18/03/2021	Abiraterone; Fuzuloparib; Placebo; Prednisone	PARP_inhibitor; glucocorticoid; placebo; CYP17A1_inhibitor	Fuzuloparib; Abiraterone; Placebo; Prednisone	PARP_inhibitor; CYP17A1_inhibitor; glucocorticoid; placebo	SHR3162-III-305	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer	Metastatic Castration-Resistant Prostate Cancer (mCRPC)	- Kurralta Park; - Wagga Wagga; - Bendigo; - Fitzroy; - Concord; - St Albans; - Sydney; - Gosford; - Wahroonga; - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04691804
NCT04699188	CJDQ443A12101	Phase 1/Phase 2		VIC	7/01/2021	24/02/2021	JDQ443; JDQ443 + Spartalizumab; JDQ443 + Spartalizumab + TNO155; JDQ443 + TNO155; Spartalizumab; TNO155	SHP2_inhibitor; KRAS_G12C_inhibitor + SHP2_inhibitor; anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + SHP2_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody	JDQ443; JDQ443 + Spartalizumab; JDQ443 + Spartalizumab + TNO155; JDQ443 + TNO155; JDQ443 + Spartalizumab; JDQ443 + Spartalizumab + TNO155; JDQ443 + TNO155	KRAS_G12C_inhibitor; KRAS_G12C_inhibitor + SHP2_inhibitor; KRAS_G12C_inhibitor + SHP2_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + SHP2_inhibitor; KRAS_G12C_inhibitor + SHP2_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody	CJDQ443A12101	A Phase Ib/II Open-label, Multi-center Dose Escalation Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation	Cancer of Lung; Neoplasms, Lung; Carcinoma, Colorectal; Lung Cancer; Pulmonary Neoplasms; Pulmonary Cancer; Carcinoma, Non-Small-Cell Lung; KRAS G12C Mutant Solid Tumors; Neoplasms, Pulmonary; Cancer of the Lung	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04699188
NCT04700072	2020-003742-36--3475-02D	Phase 1/Phase 2		NSW	7/01/2021	3/05/2021	Lenvatinib; Lenvatinib + Pembrolizumab; Lenvatinib + Pembrolizumab + Quavonlimab; Pembrolizumab; Quavonlimab	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; VEGF_inhibitor	Lenvatinib + Pembrolizumab; Lenvatinib + Pembrolizumab + Quavonlimab; Lenvatinib + Pembrolizumab; Lenvatinib + Pembrolizumab + Quavonlimab	VEGF_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody	2020-003742-36  3475-02D	A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02D	Melanoma	2298 - Waratah; 2065 - Wollstonecraft	https://clinicaltrials.gov/ct2/show/NCT04700072
NCT04702737	NCT04702737	Phase 1		NSW, VIC	11/01/2021	10/06/2021	Tarlatamab	bispecific_T-cell_engager,DLL3-targeting	Tarlatamab	bispecific_T-cell_engager,DLL3-targeting	20200040	A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of Delta-like Protein 3 Half-life Extended Bispecific T-cell Engager AMG 757 in Subjects With De Novo or Treatment Emergent Neuroendocrine Prostate Cancer	Neuroendocrine Prostate Cancer	3000 - Melbourne; 2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT04702737
NCT04702880	2020-001863-10--CA001-050	Phase 2		WA, QLD, VIC, NSW	11/01/2021	17/03/2021	BMS-986012; BMS-986012 + Carboplatin + Etoposide + Nivolumab; Carboplatin; Carboplatin + Etoposide + Nivolumab; Etoposide; Nivolumab	anti-fucosyl-GM1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + anti-fucosyl-GM1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; topoisomerase_inhibitor	BMS-986012 + Carboplatin + Etoposide + Nivolumab; Carboplatin + Etoposide + Nivolumab; BMS-986012 + Carboplatin + Etoposide + Nivolumab; Carboplatin + Etoposide + Nivolumab	anti-PD-1_monoclonal_antibody + anti-fucosyl-GM1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-PD-1_monoclonal_antibody + anti-fucosyl-GM1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor	2020-001863-10  CA001-050	A Randomized, Open-label Phase 2 Clinical Trial of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer	Extensive-stage Small Cell Lung Cancer	2145 - Westmead; 3004 - Melbourne; 4102 - Queensland; 6150 - Murdoch	https://clinicaltrials.gov/ct2/show/NCT04702880
NCT04704219	KEYNOTE-B61	Phase 2		WA, VIC, NSW, QLD, SA	11/01/2021	23/02/2021	Lenvatinib; Lenvatinib + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor	Lenvatinib + Pembrolizumab; Lenvatinib + Pembrolizumab	VEGF_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody	MK-3475-B61  3475-B61	A Phase 2, Single-arm, Open-label Clinical Trial of Pembrolizumab Plus Lenvatinib in Participants With First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (nccRCC) (KEYNOTE-B61)	Renal Cell Carcinoma	2109 - Macquarie Park; 6150 - Murdoch; 2298 - Waratah; 5037 - Kurralta Park; 4029 - Brisbane; 3168 - Clayton	https://clinicaltrials.gov/ct2/show/NCT04704219
NCT04713891	KFCS001	Phase 1		NSW	19/01/2021	9/03/2021	Atezolizumab; Atezolizumab + KF-0210; KF-0210	anti-PD-L1_monoclonal_antibody + prostaglandin_EP4_receptor_inhibitor; anti-PD-L1_monoclonal_antibody; prostaglandin_EP4_receptor_inhibitor	Atezolizumab + KF-0210; KF-0210; Atezolizumab + KF-0210	anti-PD-L1_monoclonal_antibody + prostaglandin_EP4_receptor_inhibitor; prostaglandin_EP4_receptor_inhibitor; anti-PD-L1_monoclonal_antibody + prostaglandin_EP4_receptor_inhibitor	KFCS001	A Phase I, Multi-Center, Open-Label Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of KF-0210 in Patients With Advanced Solid Tumors	Advanced Solid Tumor; Gastric Cancer; Colorectal Cancer; Squamous Cell Carcinoma of the Esophagus; Bladder Cancer; Lung Cancer	2031 - Randwick	https://clinicaltrials.gov/ct2/show/NCT04713891
NCT04720768	CELEBRATE	Phase 1/Phase 2		VIC	22/01/2021	4/06/2020	Binimetinib; Encorafenib; Palbociclib	MEK_inhibitor; CDK4/6_inhibitor; BRAF_V600_inhibitor	Encorafenib; Binimetinib; Palbociclib	BRAF_V600_inhibitor; CDK4/6_inhibitor; MEK_inhibitor	17/021	A Phase 1B Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of the Combination of Encorafenib, Binimetinib and Palbociclib in Patients With BRAF-mutant Metastatic Melanoma (The CELEBRATE Study)	Melanoma; Metastasis	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04720768
NCT04721015	2020-004953-57--M20-111	Phase 1		VIC, NSW	22/01/2021	18/02/2021	ABBV-637; ABBV-637 + Docetaxel; ABBV-637 + Osimertinib; Docetaxel; Osimertinib	EGFR_inhibitor,third_generation; EGFR_inhibitor,third_generation + anti-EGFR_antibody-drug_conjugate,Bcl-xL_payload; anti-EGFR_antibody-drug_conjugate,Bcl-xL_payload + taxane; anti-EGFR_antibody-drug_conjugate,Bcl-xL_payload; taxane	ABBV-637; ABBV-637 + Docetaxel; ABBV-637 + Osimertinib; ABBV-637 + Docetaxel; ABBV-637 + Osimertinib	EGFR_inhibitor,third_generation + anti-EGFR_antibody-drug_conjugate,Bcl-xL_payload; anti-EGFR_antibody-drug_conjugate,Bcl-xL_payload; anti-EGFR_antibody-drug_conjugate,Bcl-xL_payload + taxane; EGFR_inhibitor,third_generation + anti-EGFR_antibody-drug_conjugate,Bcl-xL_payload; anti-EGFR_antibody-drug_conjugate,Bcl-xL_payload + taxane	2020-004953-57  M20-111	A Phase 1 First In Human Study Evaluating Safety And Efficacy Of ABBV-637 As Either Monotherapy Or In Combination In Adult Subjects With Relapsed And Refractory Solid Tumors	Advanced Solid Tumors Cancer; Non Small Cell Lung Cancer (NSCLC)	2500 - Wollongong; 3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT04721015
NCT04725188	MK-7684A-002--7684A-002	Phase 2		ACT, WA, QLD	26/01/2021	20/04/2021	Docetaxel; Docetaxel + Pembrolizumab + Vibostolimab; Pembrolizumab; Pembrolizumab + Vibostolimab; Placebo; Vibostolimab	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + taxane; placebo; anti-TIGIT_monoclonal_antibody; taxane; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody	Docetaxel; Docetaxel + Pembrolizumab + Vibostolimab; Pembrolizumab + Vibostolimab; Docetaxel + Pembrolizumab + Vibostolimab; Pembrolizumab + Vibostolimab; Placebo	anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + taxane; taxane; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + taxane; placebo	MK-7684A-002  7684A-002	A Phase 2, Multicenter, Randomized Study to Compare the Efficacy and Safety of MK-7684A or MK-7684A Plus Docetaxel Versus Docetaxel Monotherapy in the Treatment of Participants With Metastatic Non-small Cell Lung Cancer With Progressive Disease After Treatment With a Platinum Doublet Chemotherapy and Immunotherapy	Metastatic Non Small Cell Lung Cancer	6150 - Murdoch; 2605 - Canberra; 4215 - Southport	https://clinicaltrials.gov/ct2/show/NCT04725188
NCT04726033	CUPID	Phase 0		WA	27/01/2021	4/08/2021	64Cu-TLX592	PSMA-targeting_antibody_radioimmunoconjugate	64Cu-TLX592	PSMA-targeting_antibody_radioimmunoconjugate	64Cu-TLX592-001	A Phase I, Single Centre, Open-label Study of TLX592 to Assess the Safety and Tolerability, Pharmacokinetics, Biodistribution and Radiation Dosimetry in Patients Diagnosed With Prostate Cancer	Metastatic Prostate Cancer	6014 - Perth	https://clinicaltrials.gov/ct2/show/NCT04726033
NCT04727554	NCT04727554	Phase 1		WA, VIC	27/01/2021	29/04/2021	AMG 404	anti-PD-1_monoclonal_antibody	AMG 404	anti-PD-1_monoclonal_antibody	20190136	A Phase 1, Multicenter, Open-label, Dose Exploration and Dose Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 994 Monotherapy and Combination of AMG 994 and AMG 404 in Subjects With Advanced Solid Tumors	Advanced Solid Tumors	6009 - Nedlands; 3168 - Clayton	https://clinicaltrials.gov/ct2/show/NCT04727554
NCT04728893	MK-1026-003--1026-003	Phase 2		VIC	28/01/2021	5/04/2021	Nemtabrutinib	BTK_inhibitor	Nemtabrutinib	BTK_inhibitor	MK-1026-003  1026-003	A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants With Hematologic Malignancies	Hematologic Malignancies	3128 - Box Hill	https://clinicaltrials.gov/ct2/show/NCT04728893
NCT04729387	CBYL719K12301	Phase 3	NOT_RECRUITING	VIC, SA	28/01/2021	2/07/2021	Alpelisib; Alpelisib + Olaparib; Olaparib; Paclitaxel; Paclitaxel + Pegylated liposomal doxorubicin; Pegylated liposomal doxorubicin	PARP_inhibitor; anthracycline; anthracycline + taxane; PI3K_alpha_inhibitor; taxane; PARP_inhibitor + PI3K_alpha_inhibitor	Alpelisib + Olaparib; Paclitaxel + Pegylated liposomal doxorubicin; Alpelisib + Olaparib; Paclitaxel + Pegylated liposomal doxorubicin	PARP_inhibitor + PI3K_alpha_inhibitor; anthracycline + taxane; PARP_inhibitor + PI3K_alpha_inhibitor; anthracycline + taxane	CBYL719K12301	EPIK-O: A Phase III, Multi-center, Randomized (1:1), Open-label, Active-controlled, Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Olaparib as Compared to Single Agent Cytotoxic Chemotherapy, in Participants With no Germline BRCA Mutation Detected, Platinum-resistant or Refractory, High-grade Serous Ovarian Cancer	Ovarian Cancer	3630 - Shepparton; 5041 - Bedford Park	https://clinicaltrials.gov/ct2/show/NCT04729387
NCT04736199	ARANOTE	Phase 3		SA, NZ, NSW, VIC	3/02/2021	23/02/2021	Darolutamide; Placebo	antiandrogen,nonsteroidal,second_generation; placebo	Darolutamide; Placebo	antiandrogen,nonsteroidal,second_generation; placebo	2020-003093-48  21140	A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Darolutamide in Addition to Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Men With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)	Prostatic Neoplasms	2109 - Macquarie University; Christchurch; Tauranga; - Heidelberg; 2065 - St Leonards; Hamilton; 5000 - South Terrace; 3199 - Frankston; 2751 - Sydney	https://clinicaltrials.gov/ct2/show/NCT04736199
NCT04736706	2020-002216-52--6482-012	Phase 3		WA, NSW, VIC, SA	3/02/2021	14/04/2021	Belzutifan; Belzutifan + Lenvatinib + Pembrolizumab; Lenvatinib; Lenvatinib + Pembrolizumab; Lenvatinib + Pembrolizumab + Quavonlimab; Pembrolizumab; Quavonlimab	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; HIF2a_inhibitor + VEGF_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; HIF2a_inhibitor	Belzutifan + Lenvatinib + Pembrolizumab; Lenvatinib + Pembrolizumab; Lenvatinib + Pembrolizumab + Quavonlimab; Belzutifan + Lenvatinib + Pembrolizumab; Lenvatinib + Pembrolizumab; Lenvatinib + Pembrolizumab + Quavonlimab	HIF2a_inhibitor + VEGF_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; HIF2a_inhibitor + VEGF_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody	2020-002216-52  6482-012	An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or MK-1308A in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, as First-Line Treatment in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)	Carcinoma, Renal Cell	3168 - Clayton; 5112 - Elizabeth Vale; 2170 - Liverpool; 2109 - Macquarie Park; 6150 - Murdoch	https://clinicaltrials.gov/ct2/show/NCT04736706
NCT04737122	LM061-01-102	Phase 1		NSW	3/02/2021	17/05/2021	LM-061	MET/VEGFR2/FLT3_inhibitor	LM-061	MET/VEGFR2/FLT3_inhibitor	LM061-01-102	A Phase I, First-in-Human, Open-Label, Dose Escalation Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-061 Tablet in Subjects With Advanced Tumors	Advanced Tumours	2217 - Kogarah	https://clinicaltrials.gov/ct2/show/NCT04737122
NCT04739670	BELLA	Phase 2		VIC	5/02/2021	1/03/2021	Atezolizumab; Atezolizumab + Bevacizumab + Carboplatin + Gemcitabine; Bevacizumab; Carboplatin; Gemcitabine	platinum-based_antineoplastic_agent; antimetabolite; anti-PD-L1_monoclonal_antibody; gemcitabine; anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent	Atezolizumab + Bevacizumab + Carboplatin + Gemcitabine; Atezolizumab + Bevacizumab + Carboplatin + Gemcitabine	anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; gemcitabine	19/002	A Single Arm Phase II Trial Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Early Relapsing Metastatic Triple Negative Breast Cancer	Metastatic Triple Negative Breast Cancer	- Melbourne	https://clinicaltrials.gov/ct2/show/NCT04739670
NCT04739761	DESTINY-B12	Phase 3		WA, VIC, NSW, QLD	5/02/2021	22/06/2021	Trastuzumab Deruxtecan	anti-ERBB2_antibody-drug_conjugate	Trastuzumab Deruxtecan	anti-ERBB2_antibody-drug_conjugate	D9673C00007	An Open-Label, Multinational, Multicenter, Phase 3b/4 Study of Trastuzumab Deruxtecan in Patients With or Without Baseline Brain Metastasis With Previously Treated Advanced/Metastatic HER2-Positive Breast Cancer (DESTINY-Breast12)	Breast Cancer	3084 - Heidelberg; 2065 - St Leonards; 6008 - Subiaco; 3168 - Clayton; 4066 - Auchenflower	https://clinicaltrials.gov/ct2/show/NCT04739761
NCT04740918	KATE3	Phase 3		QLD, VIC, NSW	5/02/2021	7/06/2021	Atezolizumab; Atezolizumab + Trastuzumab Emtansine; Pertuzumab; Placebo; Trastuzumab; Trastuzumab Emtansine	anti-ERBB2_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody; placebo; anti-PD-L1_monoclonal_antibody; anti-ERBB2_monoclonal_antibody; anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; anti-ERBB2_antibody-drug_conjugate	Atezolizumab + Trastuzumab Emtansine; Atezolizumab + Trastuzumab Emtansine; Pertuzumab; Placebo	anti-ERBB2_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody; anti-ERBB2_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody; anti-ERBB2_monoclonal_antibody; anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; placebo	2020-002818-41  MO42319	A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase III Study of the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo in Patients With HER2-Positive and PD-L1-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab- (+/- Pertuzumab) and Taxane-Based Therapy (KATE3)	Metastatic Breast Cancer	2065 - St. Leonards; 3021 - St Albans; 3002 - East Melbourne; 4102 - Woolloongabba; 2290 - Gateshead	https://clinicaltrials.gov/ct2/show/NCT04740918
NCT04744831	DESTINY-CRC02	Phase 2		QLD, VIC, NSW, SA	9/02/2021	5/03/2021	Trastuzumab Deruxtecan	anti-ERBB2_antibody-drug_conjugate	Trastuzumab Deruxtecan	anti-ERBB2_antibody-drug_conjugate	2020-004782-39  DS8201-A-U207	A Phase 2, Multicenter, Randomized, Study of Trastuzumab Deruxtecan in Participants With HER2-overexpressing Locally Advanced, Unresectable or Metastatic Colorectal Cancer (DESTINY-CRC02)	Advanced Colorectal Cancer	- Brisbane; - Clayton; - Blacktown; - Bedford Park; - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04744831
NCT04745689	TAZMAN	Phase 2		NSW	9/02/2021	23/02/2021	Barasertib; Barasertib + Durvalumab; Carboplatin; Cisplatin; Durvalumab; Etoposide	AURKB_inhibitor; platinum-based_antineoplastic_agent; AURKB_inhibitor + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; topoisomerase_inhibitor	Barasertib + Durvalumab; Barasertib + Durvalumab; Carboplatin; Cisplatin; Etoposide	AURKB_inhibitor + anti-PD-L1_monoclonal_antibody; AURKB_inhibitor + anti-PD-L1_monoclonal_antibody; platinum-based_antineoplastic_agent; topoisomerase_inhibitor	D6132C00001	A Phase II Multicenter, Open-Label, Single Arm Study to Determine the Efficacy, Safety and Tolerability of AZD2811 and Durvalumab Combination as Maintenance Therapy After Induction With Platinum-Based Chemotherapy Combined With Durvalumab, for the First-Line Treatment of Patients With Extensive Stage Small-Cell Lung Cancer	Small-Cell Lung Cancer	2500 - Wollongong; 2250 - North Gosford	https://clinicaltrials.gov/ct2/show/NCT04745689
NCT04746612	HH30134-G101	Phase 1		NSW	10/02/2021	8/04/2021	HH30134	AXL/FLT3/NTRK_inhibitor	HH30134	AXL/FLT3/NTRK_inhibitor	HH30134-G101	A Phase I, Multi-centre, Open-Label, First in Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HH30134 in Patients With Advanced Solid Tumours	Advanced Solid Tumors	- Randwick; - Blacktown	https://clinicaltrials.gov/ct2/show/NCT04746612
NCT04746924	BGB-A317-A1217-302--AdvanTIG-302	Phase 3		WA, SA, QLD, VIC, NSW	10/02/2021	8/06/2021	Ociperlimab; Ociperlimab + Tislelizumab; Pembrolizumab; Placebo; Tislelizumab	anti-PD-1_monoclonal_antibody; placebo; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-TIGIT_monoclonal_antibody	Ociperlimab + Tislelizumab; Pembrolizumab; Tislelizumab; Ociperlimab + Tislelizumab; Placebo	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; placebo	BGB-A317-A1217-302  AdvanTIG-302	A Phase 3, Randomized, Double-Blind Study of BGB-A1217, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, PD-L1-Selected, and Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer	NSCLC; Non-small Cell Lung Cancer	5112 - Elizabeth Vale; 4101 - South Brisbane; 3168 - Clayton; 4224 - Tugun; 2139 - Concord; 4032 - Chermside; 6150 - Murdoch; 2065 - Saint Leonards; 2298 - Waratah; 3350 - Ballarat; 3021 - St Albans	https://clinicaltrials.gov/ct2/show/NCT04746924
NCT04760288	AcceleRET-MTC	Phase 3		SA, NSW, VIC	18/02/2021		Cabozantinib; Cabozantinib + Vandetanib; Pralsetinib; Vandetanib	EGFR_inhibitor,second_generation + VEGFR2_inhibitor; AXL_inhibitor + VEGFR2_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor; AXL_inhibitor + EGFR_inhibitor,second_generation; VEGFR2_inhibitor; EGFR_inhibitor,second_generation; KIT_inhibitor + RET_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + RET_inhibitor; KIT_inhibitor + VEGFR2_inhibitor; ROS1_inhibitor + VEGFR2_inhibitor; MET_inhibitor,type_2 + RET_inhibitor; RET_inhibitor + VEGFR2_inhibitor; MET_inhibitor,type_2 + VEGFR2_inhibitor; EGFR_inhibitor,second_generation + MET_inhibitor,type_2; EGFR_inhibitor,second_generation + RET_inhibitor; AXL_inhibitor; RET_inhibitor; RET_inhibitor + ROS1_inhibitor; AXL_inhibitor + RET_inhibitor; ROS1_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + VEGFR2_inhibitor; MET_inhibitor,type_2; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + EGFR_inhibitor,second_generation; EGFR_inhibitor,second_generation + KIT_inhibitor; EGFR_inhibitor,second_generation + ROS1_inhibitor; KIT_inhibitor	Cabozantinib + Vandetanib; Pralsetinib; Cabozantinib + Vandetanib	AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + EGFR_inhibitor,second_generation; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + RET_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + VEGFR2_inhibitor; AXL_inhibitor + EGFR_inhibitor,second_generation; AXL_inhibitor + RET_inhibitor; AXL_inhibitor + VEGFR2_inhibitor; EGFR_inhibitor,second_generation + KIT_inhibitor; EGFR_inhibitor,second_generation + MET_inhibitor,type_2; EGFR_inhibitor,second_generation + RET_inhibitor; EGFR_inhibitor,second_generation + ROS1_inhibitor; EGFR_inhibitor,second_generation + VEGFR2_inhibitor; KIT_inhibitor + RET_inhibitor; KIT_inhibitor + VEGFR2_inhibitor; MET_inhibitor,type_2 + RET_inhibitor; MET_inhibitor,type_2 + VEGFR2_inhibitor; RET_inhibitor; RET_inhibitor + ROS1_inhibitor; RET_inhibitor + VEGFR2_inhibitor; ROS1_inhibitor + VEGFR2_inhibitor; VEGFR2_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + EGFR_inhibitor,second_generation; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + RET_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + VEGFR2_inhibitor; AXL_inhibitor + EGFR_inhibitor,second_generation; AXL_inhibitor + RET_inhibitor; AXL_inhibitor + VEGFR2_inhibitor; EGFR_inhibitor,second_generation + KIT_inhibitor; EGFR_inhibitor,second_generation + MET_inhibitor,type_2; EGFR_inhibitor,second_generation + RET_inhibitor; EGFR_inhibitor,second_generation + ROS1_inhibitor; EGFR_inhibitor,second_generation + VEGFR2_inhibitor; KIT_inhibitor + RET_inhibitor; KIT_inhibitor + VEGFR2_inhibitor; MET_inhibitor,type_2 + RET_inhibitor; MET_inhibitor,type_2 + VEGFR2_inhibitor; RET_inhibitor + ROS1_inhibitor; RET_inhibitor + VEGFR2_inhibitor; ROS1_inhibitor + VEGFR2_inhibitor	2020-005269-15  CO42865	A Phase III, Randomized, Open-Label Study of Pralsetinib Versus Standard of Care for Treatment of RET-Mutated Medullary Thyroid Cancer.	Thyroid Cancer	5037 - Kurralta Park; 2065 - St. Leonards; 2109 - Macquarie Park; 3004 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04760288
NCT04771130	BGB-11417-103	Phase 1/Phase 2		WA, QLD, VIC, NSW, NZ	25/02/2021	24/05/2021	Azacitidine; Azacitidine + BGB-11417; Azacitidine + BGB-11417 + Posaconazole; BGB-11417; Posaconazole	DNA_methyltransferase_inhibitor; Bcl2_inhibitor + antimetabolite; antimetabolite; azole_antifungal; Bcl2_inhibitor + antimetabolite + azole_antifungal; Bcl2_inhibitor + DNA_methyltransferase_inhibitor; Bcl2_inhibitor; Bcl2_inhibitor + DNA_methyltransferase_inhibitor + azole_antifungal	Azacitidine + BGB-11417; Azacitidine + BGB-11417 + Posaconazole; Azacitidine + BGB-11417; Azacitidine + BGB-11417 + Posaconazole	Bcl2_inhibitor + DNA_methyltransferase_inhibitor; Bcl2_inhibitor + DNA_methyltransferase_inhibitor + azole_antifungal; Bcl2_inhibitor + antimetabolite; Bcl2_inhibitor + antimetabolite + azole_antifungal; Bcl2_inhibitor + DNA_methyltransferase_inhibitor; Bcl2_inhibitor + DNA_methyltransferase_inhibitor + azole_antifungal; Bcl2_inhibitor + antimetabolite; Bcl2_inhibitor + antimetabolite + azole_antifungal	BGB-11417-103	A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid Malignancies	Myelodysplastic Syndromes; Acute Myeloid Leukemia; Myelodysplastic/Myeloproliferative Neoplasm	6150 - Murdoch; 4217 - Benowa; 2800 - Orange; 3084 - Heidelberg; Wellington; 6009 - Nedlands; 2217 - Sydney; 4224 - Tugun; 3065 - Melbourne; 3168 - Melbourne; 3004 - Melbourne; 6009 - Perth; 4215 - Gold Coast; Auckland; 2139 - Sydney	https://clinicaltrials.gov/ct2/show/NCT04771130
NCT04776148	2020-004289-20--7902-017	Phase 3		WA, SA, QLD, VIC	1/03/2021	29/03/2021	Lenvatinib; Lenvatinib + Pembrolizumab; Pembrolizumab; Regorafenib; Regorafenib + Trifluridine/Tipiracil; Trifluridine/Tipiracil	Tipiracil Hydrochloride; anti-PD-1_monoclonal_antibody; Trifluridine; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + antimetabolite; VEGF_inhibitor; thymidine_phosphorylase_inhibitor; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + Tipiracil Hydrochloride; antimetabolite; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + thymidine_phosphorylase_inhibitor; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + Trifluridine; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor	Lenvatinib + Pembrolizumab; Regorafenib + Trifluridine/Tipiracil; Lenvatinib + Pembrolizumab; Regorafenib + Trifluridine/Tipiracil	KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + Tipiracil Hydrochloride; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + Trifluridine; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + antimetabolite; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + thymidine_phosphorylase_inhibitor; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + Tipiracil Hydrochloride; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + Trifluridine; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + antimetabolite; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + thymidine_phosphorylase_inhibitor; VEGF_inhibitor + anti-PD-1_monoclonal_antibody	2020-004289-20  7902-017	A Phase 3 Randomized Study of Lenvatinib in Combination With Pembrolizumab Versus Standard of Care in Participants With Metastatic Colorectal Cancer Who Have Received and Progressed On or After or Became Intolerant to Prior Treatment	Colorectal Neoplasms	3021 - St Albans; 4120 - Greenslopes; 4029 - Brisbane; 5011 - Woodville; 6009 - Perth; 3002 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04776148
NCT04778410	GS-US-546-5920	Phase 2		WA	3/03/2021	28/06/2021	Azacitidine; Azacitidine + Magrolimab; Azacitidine + Magrolimab + Venetoclax; Cytarabine; Etoposide; Magrolimab; Mitoxantrone; Venetoclax	anti-CD47_monoclonal_antibody; DNA_methyltransferase_inhibitor; antimetabolite; antineoplastic_antibiotic; Bcl2_inhibitor; Bcl2_inhibitor + anti-CD47_monoclonal_antibody + antimetabolite; anti-CD47_monoclonal_antibody + antimetabolite; topoisomerase_inhibitor; DNA_methyltransferase_inhibitor + anti-CD47_monoclonal_antibody; Bcl2_inhibitor + DNA_methyltransferase_inhibitor + anti-CD47_monoclonal_antibody	Azacitidine + Magrolimab; Azacitidine + Magrolimab + Venetoclax; Magrolimab; Azacitidine + Magrolimab; Azacitidine + Magrolimab + Venetoclax; Cytarabine; Etoposide; Mitoxantrone	Bcl2_inhibitor + DNA_methyltransferase_inhibitor + anti-CD47_monoclonal_antibody; Bcl2_inhibitor + anti-CD47_monoclonal_antibody + antimetabolite; DNA_methyltransferase_inhibitor + anti-CD47_monoclonal_antibody; anti-CD47_monoclonal_antibody; anti-CD47_monoclonal_antibody + antimetabolite; Bcl2_inhibitor + DNA_methyltransferase_inhibitor + anti-CD47_monoclonal_antibody; Bcl2_inhibitor + anti-CD47_monoclonal_antibody + antimetabolite; DNA_methyltransferase_inhibitor + anti-CD47_monoclonal_antibody; anti-CD47_monoclonal_antibody + antimetabolite; antineoplastic_antibiotic; topoisomerase_inhibitor	GS-US-546-5920	A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Myeloid Malignancies	Myeloid Malignancies	6000 - Perth	https://clinicaltrials.gov/ct2/show/NCT04778410
NCT04784715	D967UC00001	Phase 3	NOT_RECRUITING	QLD, NSW	5/03/2021	26/04/2021	Pertuzumab; Pertuzumab + Trastuzumab Deruxtecan; Placebo; Trastuzumab; Trastuzumab Deruxtecan	anti-ERBB2_monoclonal_antibody; anti-ERBB2_antibody-drug_conjugate + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; placebo; anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; anti-ERBB2_antibody-drug_conjugate	Pertuzumab + Trastuzumab Deruxtecan; Pertuzumab + Trastuzumab Deruxtecan; Placebo	anti-ERBB2_antibody-drug_conjugate + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; anti-ERBB2_antibody-drug_conjugate + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; placebo	D967UC00001	Phase III Study of Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer (DESTINY-Breast09)	Metastatic; Breast Cancer; HER2-positive	4066 - Auchenflower; 2065 - St Leonards; 2109 - Macquarie University	https://clinicaltrials.gov/ct2/show/NCT04784715
NCT04786847	ProstACTSelect	Phase 1		WA	8/03/2021		177Lu-DOTA-rosopatamab	radioligand,PSMA-targeting	177Lu-DOTA-rosopatamab	radioligand,PSMA-targeting	177Lu-TLX591-001	A Phase 1 Safety, Tolerability, Biodistribution, Dosimetry and Efficacy Study of 177Lu-DOTA-TLX591 With Best Standard of Care in Patients With PSMA Expressing Metastatic Castration-resistant Prostate Cancer	Metastatic Prostate Cancer	6009 - Perth; 6150 - Perth	https://clinicaltrials.gov/ct2/show/NCT04786847
NCT04786964	CONTERNO	Unknown		NZ	8/03/2021	8/12/2021	Carboplatin; Carboplatin + Cisplatin + Cosibelimab + Pemetrexed; Carboplatin + Cisplatin + Pemetrexed; Cisplatin; Cosibelimab; Dexamethasone; Pemetrexed	glucocorticoid; platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; antimetabolite; anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent	Carboplatin + Cisplatin + Cosibelimab + Pemetrexed; Carboplatin + Cisplatin + Pemetrexed; Carboplatin + Cisplatin + Cosibelimab + Pemetrexed; Carboplatin + Cisplatin + Pemetrexed; Dexamethasone	anti-PD-L1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; glucocorticoid	CK-301-301	A Randomized, Open-Label, Phase 3 Study of Cosibelimab (CK-301) in Combination With Platinum+Pemetrexed Chemotherapy in Subjects With First-Line Metastatic Non-squamous Non-Small Cell Lung Cancer	Metastatic Non-squamous Non Small Cell Lung Cancer	Wellington	https://clinicaltrials.gov/ct2/show/NCT04786964
NCT04789096	TUGETHER	Phase 2		VIC	9/03/2021		Capecitabine; Pembrolizumab; Trastuzumab; Tucatinib	anti-ERBB2_monoclonal_antibody; anti-PD-1_monoclonal_antibody; ERBB2_inhibitor,third_generation; fluoropyrimidine	Capecitabine; Pembrolizumab; Trastuzumab; Tucatinib	ERBB2_inhibitor,third_generation; anti-ERBB2_monoclonal_antibody; anti-PD-1_monoclonal_antibody; fluoropyrimidine	BCT 2102	A Phase II, Two-arm, Non-comparative, Multicentre Study of Tucatinib (ONT-380), Pembrolizumab and Trastuzumab in Patients With Pre-treated Advanced HER2-positive Breast Cancer	Breast Cancer; HER2-positive Breast Cancer	3002 - Parkville	https://clinicaltrials.gov/ct2/show/NCT04789096
NCT04793958	KRYSTAL-10--849-010	Phase 3		SA, VIC, NSW	11/03/2021	15/03/2021	Adagrasib; Adagrasib + Cetuximab; Cetuximab	KRAS_G12C_inhibitor; anti-EGFR_monoclonal_antibody; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody	Adagrasib + Cetuximab; Adagrasib + Cetuximab	KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody	KRYSTAL-10  849-010	A Randomized Phase 3 Study of MRTX849 in Combination With Cetuximab Versus Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation With Disease Progression On or After Standard First-Line Therapy	Metastatic Colorectal Cancer; Advanced Colorectal Cancer	5042 - Bedford Park; 2298 - Waratah; 3004 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04793958
NCT04794699	IDE397-001	Unknown		NSW, SA	12/03/2021	14/04/2021	Docetaxel; Docetaxel + Paclitaxel; IDE397; Paclitaxel; Pemetrexed	MAT2A_inhibitor; taxane; antimetabolite	Docetaxel + Paclitaxel; Docetaxel + Paclitaxel; IDE397; Pemetrexed	taxane; MAT2A_inhibitor; antimetabolite	IDE397-001	An Open Label, Phase 1, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A Inhibitor) In Adult Participants With Advanced Solid Tumors	Solid Tumor	02010 - Darlinghurst; 05042 - Bedford Park	https://clinicaltrials.gov/ct2/show/NCT04794699
NCT04799054	transcendIT-101--TCTLR-101	Phase 1/Phase 2		NSW	16/03/2021	18/03/2021	Pembrolizumab; Pembrolizumab + TransCon TLR7/8 agonist; TransCon TLR7/8 agonist	anti-PD-1_monoclonal_antibody; TLR7/8_agonist; TLR7/8_agonist + anti-PD-1_monoclonal_antibody	Pembrolizumab + TransCon TLR7/8 agonist; TransCon TLR7/8 agonist; Pembrolizumab + TransCon TLR7/8 agonist	TLR7/8_agonist; TLR7/8_agonist + anti-PD-1_monoclonal_antibody; TLR7/8_agonist + anti-PD-1_monoclonal_antibody	transcendIT-101  TCTLR-101	Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study of TransCon TLR7/8 Agonist Alone or in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies	Metastatic Solid Tumor; Locally Advanced Solid Tumor; Advanced Solid Tumor	2500 - Wollongong	https://clinicaltrials.gov/ct2/show/NCT04799054
NCT04799249	PRESERVE-2	Phase 3		VIC, NSW, QLD	16/03/2021	15/04/2021	Carboplatin; Carboplatin + Gemcitabine + Trilaciclib; Gemcitabine; Placebo; Trilaciclib	platinum-based_antineoplastic_agent; placebo; CDK4/6_inhibitor + antimetabolite + platinum-based_antineoplastic_agent; CDK4/6_inhibitor; antimetabolite; gemcitabine	Carboplatin + Gemcitabine + Trilaciclib; Carboplatin + Gemcitabine + Trilaciclib; Placebo	CDK4/6_inhibitor + antimetabolite + platinum-based_antineoplastic_agent; CDK4/6_inhibitor + antimetabolite + platinum-based_antineoplastic_agent; gemcitabine; placebo	2020-004930-39  G1T28-208	A Phase 3, Randomized, Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE 2)	Breast Cancer; TNBC - Triple-Negative Breast Cancer	4575 - Birtinya; 3144 - Malvern; 08006 - East Melbourne; 2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT04799249
NCT04801095	WMS1030-101	Phase 1		VIC, WA	16/03/2021	14/07/2021	WM-S1-030	mutant_receptor_tyrosine_kinase_inhibitor	WM-S1-030	mutant_receptor_tyrosine_kinase_inhibitor	WMS1030-101	A Phase I, Open-label, Multicenter, Dose-escalation and Dose-expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of WM-S1-030 in Patients With Advanced Solid Tumors	Head and Neck Cancer; Cholangiocarcinoma; Pancreatic Cancer; Metastatic Solid Tumor; Advanced Solid Tumor; Colorectal Cancer; Lung Cancer	6009 - Nedlands; 3168 - Clayton	https://clinicaltrials.gov/ct2/show/NCT04801095
NCT04801966	TAILOR	Not Applicable		VIC	17/03/2021		Abemaciclib; Alpelisib; Atezolizumab; Binimetinib; Cobimetinib; Dabrafenib; Encorafenib; Nivolumab; Olaparib; Palbociclib; Pembrolizumab; Ribociclib; Talazoparib; Trametinib; Vemurafenib	PARP_inhibitor; anti-PD-1_monoclonal_antibody; BRAF_V600_inhibitor; anti-PD-L1_monoclonal_antibody; CDK4/6_inhibitor; PI3K_alpha_inhibitor; MEK_inhibitor	Abemaciclib; Alpelisib; Atezolizumab; Binimetinib; Cobimetinib; Dabrafenib; Encorafenib; Nivolumab; Olaparib; Palbociclib; Pembrolizumab; Ribociclib; Talazoparib; Trametinib; Vemurafenib	BRAF_V600_inhibitor; CDK4/6_inhibitor; MEK_inhibitor; PARP_inhibitor; PI3K_alpha_inhibitor; anti-PD-1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody	20/029	Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study	Cancer	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04801966
NCT04802759	2020-004889-19--CO42867	Phase 1/Phase 2		VIC, WA	17/03/2021	20/06/2021	Abemaciclib; Abemaciclib + Giredestrant; Everolimus; Everolimus + Giredestrant; Giredestrant; Giredestrant + Inavolisib; Giredestrant + Ipatasertib; Giredestrant + Palbociclib; Giredestrant + Ribociclib; Giredestrant + Samuraciclib; Inavolisib; Ipatasertib; Palbociclib; Ribociclib; Samuraciclib	PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader; CDK7_inhibitor + selective_estrogen_receptor_degrader; pan-AKT_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor; pan-AKT_inhibitor; mTORC1_inhibitor + selective_estrogen_receptor_degrader; PI3K_alpha_inhibitor; CDK7_inhibitor; mTORC1_inhibitor	Abemaciclib + Giredestrant; Everolimus + Giredestrant; Giredestrant; Giredestrant + Inavolisib; Giredestrant + Ipatasertib; Giredestrant + Palbociclib; Giredestrant + Ribociclib; Giredestrant + Samuraciclib; Abemaciclib + Giredestrant; Everolimus + Giredestrant; Giredestrant + Inavolisib; Giredestrant + Ipatasertib; Giredestrant + Palbociclib; Giredestrant + Ribociclib; Giredestrant + Samuraciclib	CDK4/6_inhibitor + selective_estrogen_receptor_degrader; CDK7_inhibitor + selective_estrogen_receptor_degrader; PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; mTORC1_inhibitor + selective_estrogen_receptor_degrader; pan-AKT_inhibitor + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader; CDK4/6_inhibitor + selective_estrogen_receptor_degrader; CDK7_inhibitor + selective_estrogen_receptor_degrader; PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; mTORC1_inhibitor + selective_estrogen_receptor_degrader; pan-AKT_inhibitor + selective_estrogen_receptor_degrader	2020-004889-19  CO42867	A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Breast Cancer (MORPHEUS- BREAST CANCER)	Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer	3000 - Melbourne; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT04802759
NCT04807972	2020-005767-31--M20-732	Phase 2		VIC	19/03/2021	28/05/2021	ABBV-927; ABBV-927 + Budigalimab; Budigalimab	anti-PD-1_monoclonal_antibody; anti-CD40_agonistic_antibody + anti-PD-1_monoclonal_antibody; anti-CD40_agonistic_antibody	ABBV-927; ABBV-927 + Budigalimab; Budigalimab; ABBV-927 + Budigalimab	anti-CD40_agonistic_antibody; anti-CD40_agonistic_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CD40_agonistic_antibody + anti-PD-1_monoclonal_antibody	2020-005767-31  M20-732	A Phase 1b/2, Randomized, Controlled, Open-Label Study Evaluating the Safety and Efficacy of ABBV-927 Administered in Combination With Modified FOLFIRINOX (mFFX) With or Without Budigalimab Compared to mFFX in Subjects With Untreated Metastatic Pancreatic Adenocarcinoma	Pancreatic Cancer	3168 - Clayton; 3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT04807972
NCT04810078	CheckMate-67T	Unknown		NZ	22/03/2021	24/05/2021	Nivolumab; rHuPH20	recombinant_human_hyaluronidase; anti-PD-1_monoclonal_antibody	Nivolumab; rHuPH20	anti-PD-1_monoclonal_antibody; recombinant_human_hyaluronidase	2020-003655-15  CA209-67T	A Phase 3, Open-label, Randomized, Noninferiority Trial of Subcutaneous Formulation of Nivolumab Versus Intravenous Nivolumab in Participants With Advanced or Metastatic Clear Cell Renal Cell Carcinoma Who Have Received Prior Systemic Therapy	Clear Cell Renal Cell Carcinoma	Hamilton; Auckland; Palmerston North	https://clinicaltrials.gov/ct2/show/NCT04810078
NCT04811027	TACTI-003	Phase 2		NSW	23/03/2021	27/08/2021	Eftilagimod Alpha; Pembrolizumab	anti-PD-1_monoclonal_antibody; T-cell_immunostimulatory_factor	Eftilagimod Alpha; Pembrolizumab	T-cell_immunostimulatory_factor; anti-PD-1_monoclonal_antibody	Keynote- PNC-34  TACTI-003	TACTI-003 (Two ACTive Immunotherapeutics): A Multicenter, Open Label, Randomized, Phase II Trial to Investigate a Soluble LAG-3 Fusion Protein, Eftilagimod Alpha (Efti; IMP321) in Combination With Pembrolizumab (PD-1 Antagonist) for First Line Treatment of Subjects With Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)	HNSCC	2109 - Macquarie Park; 2640 - East Albury	https://clinicaltrials.gov/ct2/show/NCT04811027
NCT04814108	ZN-c3-004	Phase 2		NSW, VIC	24/03/2021	1/06/2021	Azenosertib	WEE1_inhibitor	Azenosertib	WEE1_inhibitor	ZN-c3-004	A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women With Recurrent or Persistent Uterine Serous Carcinoma	Uterine Serous Carcinoma	3000 - Melbourne; 2065 - St Leonards; 3144 - Malvern	https://clinicaltrials.gov/ct2/show/NCT04814108
NCT04814875	AM-ATX101-03	Phase 1/Phase 2		WA, VIC, NSW	24/03/2021	1/09/2021	ATX-101; ATX-101 + Carboplatin + Pegylated liposomal doxorubicin; Carboplatin; Pegylated liposomal doxorubicin	anthracycline; platinum-based_antineoplastic_agent; anthracycline + cell_penetrating_peptide,PCNA-targeting + platinum-based_antineoplastic_agent; cell_penetrating_peptide,PCNA-targeting	ATX-101 + Carboplatin + Pegylated liposomal doxorubicin; ATX-101 + Carboplatin + Pegylated liposomal doxorubicin	anthracycline + cell_penetrating_peptide,PCNA-targeting + platinum-based_antineoplastic_agent; anthracycline + cell_penetrating_peptide,PCNA-targeting + platinum-based_antineoplastic_agent	AM ATX101-03	Phase 1b/2a Study Investigating ATX-101 in Combination With Platinum-based Chemotherapy in Platinum-sensitive, Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancer	High Grade Serious or Endometrioid Carcinoma of the Ovary, Fallopian Tube, or Primary Peritoneal Cancer; Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma	6008 - Subiaco; 3144 - Malvern; 3199 - Frankston; 6009 - Nedlands; 2148 - Blacktown	https://clinicaltrials.gov/ct2/show/NCT04814875
NCT04819100	LIBRETTO-432	Phase 3		QLD, VIC, NSW	26/03/2021	20/12/2021	Placebo; Selpercatinib	RET_inhibitor; placebo	Selpercatinib; Placebo	RET_inhibitor; placebo	J2G-MC-JZJX  18126	LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants With Stage IB-IIIA RET Fusion-Positive NSCLC	Carcinoma, Non-Small-Cell Lung	3550 - Bendigo; 3350 - Ballarat; 2640 - Albury; 4700 - Rockhampton; 3630 - Shepparton; 4814 - Douglas; 4575 - Birtinya; 3280 - Warrambool	https://clinicaltrials.gov/ct2/show/NCT04819100
NCT04821622	TALAPRO-3--C3441052	Phase 3		SA, QLD, NSW, VIC	29/03/2021	12/05/2021	Enzalutamide; Enzalutamide + Talazoparib; Placebo; Talazoparib	antiandrogen,nonsteroidal,second_generation; PARP_inhibitor; PARP_inhibitor + antiandrogen,nonsteroidal,second_generation; placebo	Enzalutamide; Enzalutamide + Talazoparib; Enzalutamide + Talazoparib; Placebo	PARP_inhibitor + antiandrogen,nonsteroidal,second_generation; antiandrogen,nonsteroidal,second_generation; PARP_inhibitor + antiandrogen,nonsteroidal,second_generation; placebo	TALAPRO-3  C3441052	TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER	Prostate Cancer	3144 - Malvern; 3002 - East Melbourne; 5011 - Woodville South; 4120 - Brisbane; 2050 - Camperdown; 4215 - Southport; 2500 - Wollongong; 3021 - St Albans	https://clinicaltrials.gov/ct2/show/NCT04821622
NCT04822298	NCT04822298	Phase 1		NSW	30/03/2021	31/08/2021	AMG 160	bispecific_T-cell_engager,PSMA-targeting	AMG 160	bispecific_T-cell_engager,PSMA-targeting	20180273	A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 160 in Subjects With Non-Small Cell Lung Cancer	Non-small Cell Lung Cancer; NSCLC	2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT04822298
NCT04822961	IMP4297-202	Phase 2		VIC, NSW, QLD	30/03/2021		Docetaxel; Placebo; Senaparib	PARP_inhibitor; taxane; placebo	Senaparib; Docetaxel; Placebo	PARP_inhibitor; placebo; taxane	IMP4297-202	A Randomized, Double-Blinded, Placebo-Controlled, Multicenter, Phase II Study to Evaluate Senaparib in mCRPC Patients With Homologous Recombination Repair Gene Alterations After Docetaxel Treatment	mCRPC 0 0	- Brisbane; - Tugun; - Sydney; - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04822961
NCT04829604	ACE-Breast03	Phase 2	NOT_RECRUITING	WA, QLD, VIC	2/04/2021	5/04/2021	ARX788; ARX788 + Trastuzumab Deruxtecan + Trastuzumab Emtansine + Tucatinib; Trastuzumab Deruxtecan; Trastuzumab Emtansine; Tucatinib	ERBB2_inhibitor,third_generation + anti-ERBB2_antibody-drug_conjugate; ERBB2_inhibitor,third_generation; anti-ERBB2_antibody-drug_conjugate	ARX788 + Trastuzumab Deruxtecan + Trastuzumab Emtansine + Tucatinib; ARX788 + Trastuzumab Deruxtecan + Trastuzumab Emtansine + Tucatinib	ERBB2_inhibitor,third_generation + anti-ERBB2_antibody-drug_conjugate; ERBB2_inhibitor,third_generation + anti-ERBB2_antibody-drug_conjugate	ACE-Breast-03	A Global, Phase 2 Study of ARX788 in HER2-positive, Metastatic Breast Cancer Patients Whose Disease is Resistant or Refractory to T-DM-1 or T-DXd, and/or Tucatinib-containing Regimens	HER2 Positive Metastatic Breast Cancer	3199 - Frankston; 6009 - Nedlands; 3168 - Clayton; 4102 - Woolloongabba	https://clinicaltrials.gov/ct2/show/NCT04829604
NCT04830124	ARTISTRY-6	Phase 2		NSW	2/04/2021	27/05/2021	Nemvaleukin alfa	IL-2_fusion_protein	Nemvaleukin alfa	IL-2_fusion_protein	ALKS 4230-006	A Phase 2, Open-label, Multicenter, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy Administered Subcutaneously in Patients With Advanced Cutaneous Melanoma or Intravenously in Patients With Advanced Mucosal Melanoma Who Have Previously Received Anti-PD-[L]-1 Therapy - ARTISTRY-6	Mucosal Melanoma; Cutaneous Melanoma	2298 - Waratah	https://clinicaltrials.gov/ct2/show/NCT04830124
NCT04830202	C20-503			WA	5/04/2021		Telisotuzumab Vedotin	anti-cMET_antibody-drug_conjugate	Telisotuzumab Vedotin	anti-cMET_antibody-drug_conjugate	C20-503	Expanded Access to Telisotuzumab Vedotin	Non-Small Cell Lung Cancer (NSCLC)	6005 - West Perth	https://clinicaltrials.gov/ct2/show/NCT04830202
NCT04834973	KN-B16--QB46C-H06	Phase 1/Phase 2		NSW	8/04/2021	7/05/2021	Pembrolizumab; Pembrolizumab + Tigilanol Tiglate; Tigilanol Tiglate	protein_kinase_C_regulator; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + protein_kinase_C_regulator	Pembrolizumab + Tigilanol Tiglate; Pembrolizumab + Tigilanol Tiglate	anti-PD-1_monoclonal_antibody + protein_kinase_C_regulator; anti-PD-1_monoclonal_antibody + protein_kinase_C_regulator	KN-B16  QB46C-H06	A Phase Ib/IIa, Dose-escalation Study to Evaluate the Safety, Tolerability, and Preliminary Effectiveness of Intratumoural Tigilanol Tiglate in Combination With Intravenous Pembrolizumab in Adults With Stage IIIb to IV M1c-melanoma	Melanoma	2065 - Wollstonecraft	https://clinicaltrials.gov/ct2/show/NCT04834973
NCT04835805	2020-003674-41--GO42273	Phase 1		WA, NSW, VIC	8/04/2021	13/05/2021	Atezolizumab; Atezolizumab + Belvarafenib + Cobimetinib; Belvarafenib; Belvarafenib + Cobimetinib; Cobimetinib	anti-PD-L1_monoclonal_antibody; MEK_inhibitor + pan-RAF_inhibitor; MEK_inhibitor; pan-RAF_inhibitor; MEK_inhibitor + anti-PD-L1_monoclonal_antibody + pan-RAF_inhibitor	Atezolizumab + Belvarafenib + Cobimetinib; Belvarafenib; Belvarafenib + Cobimetinib; Atezolizumab + Belvarafenib + Cobimetinib; Belvarafenib + Cobimetinib	MEK_inhibitor + anti-PD-L1_monoclonal_antibody + pan-RAF_inhibitor; MEK_inhibitor + pan-RAF_inhibitor; pan-RAF_inhibitor; MEK_inhibitor + anti-PD-L1_monoclonal_antibody + pan-RAF_inhibitor; MEK_inhibitor + pan-RAF_inhibitor	2020-003674-41  GO42273	A Phase Ib, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Atezolizumab in Patients With NRAS-Mutant Advanced Melanoma Who Have Received Anti-PD-1/PD-L1 Therapy	Melanoma	6009 - Nedlands; 2298 - Waratah; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04835805
NCT04844073	CP-MVC-101-01	Phase 1/Phase 2		NSW, VIC, SA	14/04/2021	8/03/2021	MVC-101	bispecific_T-cell_engager,EGFR-targeting	MVC-101	bispecific_T-cell_engager,EGFR-targeting	CP-MVC-101-01	A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study of MVC-101, An EGFR x CD3 COnditional Bispecific Redirected Activation (COBRA™) Protein in Patients With Unresectable Locally Advanced or Metastatic Cancer	Carcinoma, Non-Small-Cell Lung; Squamous Cell Carcinoma of the Head and Neck; Colorectal Neoplasms	2031 - Randwick; 3168 - Clayton; 3084 - Heidelberg; 3052 - Melbourne; 5042 - Bedford Park	https://clinicaltrials.gov/ct2/show/NCT04844073
NCT04849273	TPX-0131-01	Phase 1/Phase 2		WA, VIC, NSW	19/04/2021	2/08/2021	Zotizalkib	ALK_inhibitor,fourth_generation	Zotizalkib	ALK_inhibitor,fourth_generation	TPX-0131-01	A Phase 1/2 Study of TPX-0131, A Novel Oral ALK Tyrosine Kinase Inhibitor in Subjects With ALK+ Advanced or Metastatic NSCLC	Non Small Cell Lung Cancer; Non-Small Cell Lung Cancer; Metastatic Solid Tumor; NSCLC; Advanced Solid Tumor; ALK Gene Mutation	3000 - Melbourne; 3084 - Heidelberg; 2148 - Blacktown; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT04849273
NCT04851834	XNTR-20-02	Phase 1/Phase 2		SA	20/04/2021		NTX-301; NTX-301 + Temozolomide; Temozolomide	alkylating_agent; DNMT1_inhibitor; DNMT1_inhibitor + alkylating_agent	NTX-301; NTX-301 + Temozolomide; NTX-301 + Temozolomide	DNMT1_inhibitor; DNMT1_inhibitor + alkylating_agent; DNMT1_inhibitor + alkylating_agent	XNTR-20-02	A Phase 1/2, Open-label, Dose-exploration and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NTX-301 Monotherapy in Advanced Solid Tumours, and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer, and in Combination With Temozolomide as Adjuvant (Maintenance) Therapy in High-grade Glioma (Optional Arm)	High-grade Glioma; Advanced Solid Tumor; Platinum-Resistant Urothelial Carcinoma; Platinum-Resistant Ovarian Cancer	- Bedford Park	https://clinicaltrials.gov/ct2/show/NCT04851834
NCT04854499	2020-005708-20--GS-US-548-5916	Phase 2		NSW	22/04/2021	7/09/2021	Carboplatin; Carboplatin + Cisplatin + Fluorouracil + Magrolimab + Pembrolizumab; Carboplatin + Cisplatin + Fluorouracil + Pembrolizumab; Cisplatin; Docetaxel; Docetaxel + Magrolimab; Fluorouracil; Fluorouracil + Magrolimab + Pembrolizumab; Magrolimab; Magrolimab + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; anti-CD47_monoclonal_antibody + taxane; anti-CD47_monoclonal_antibody + anti-PD-1_monoclonal_antibody + fluoropyrimidine; taxane; fluoropyrimidine; anti-CD47_monoclonal_antibody + anti-PD-1_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; anti-CD47_monoclonal_antibody + anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; anti-CD47_monoclonal_antibody; anti-PD-1_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; Fluorouracil	Carboplatin + Cisplatin + Fluorouracil + Magrolimab + Pembrolizumab; Carboplatin + Cisplatin + Fluorouracil + Pembrolizumab; Docetaxel + Magrolimab; Fluorouracil + Magrolimab + Pembrolizumab; Magrolimab + Pembrolizumab; Carboplatin + Cisplatin + Fluorouracil + Magrolimab + Pembrolizumab; Carboplatin + Cisplatin + Fluorouracil + Pembrolizumab; Docetaxel + Magrolimab; Fluorouracil + Magrolimab + Pembrolizumab; Magrolimab + Pembrolizumab	anti-CD47_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CD47_monoclonal_antibody + anti-PD-1_monoclonal_antibody + fluoropyrimidine; anti-CD47_monoclonal_antibody + anti-PD-1_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; anti-CD47_monoclonal_antibody + taxane; anti-PD-1_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; Fluorouracil; anti-CD47_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CD47_monoclonal_antibody + anti-PD-1_monoclonal_antibody + fluoropyrimidine; anti-CD47_monoclonal_antibody + anti-PD-1_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; anti-CD47_monoclonal_antibody + taxane; anti-PD-1_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent	2020-005708-20  GS-US-548-5916	A Phase 2 Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma	Head and Neck Squamous Cell Carcinoma	2109 - Macquarie University	https://clinicaltrials.gov/ct2/show/NCT04854499
NCT04857372	CIAG933A12101	Phase 1		VIC	23/04/2021	21/10/2021	IAG933	YAP-TEAD_inhibitor	IAG933	YAP-TEAD_inhibitor	CIAG933A12101	An Open-label, Multi-center, Phase I Study of Oral IAG933 in Adult Patients With Advanced Mesothelioma and Other Solid Tumors	Mesothelioma	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04857372
NCT04861779	HSK29116-101	Phase 1		WA, NSW	27/04/2021		HSK29116	PROTAC_antineoplastic_drug	HSK29116	PROTAC_antineoplastic_drug	HSK29116-101	A Phase Ia/b Clinical Study on Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of BTK Protein Degradation Agent HSK29116 in Subjects With Relapsed or Refractory B-Cell Malignancy	Relapsed/Refractory B-Cell Malignancies	- Phillip; - Perth	https://clinicaltrials.gov/ct2/show/NCT04861779
NCT04862663	CAPItello-292	Phase 3		NSW, WA	28/04/2021	10/05/2021	Capivasertib; Capivasertib + Fulvestrant + Palbociclib; Fulvestrant; Fulvestrant + Palbociclib; Palbociclib; Placebo	CDK4/6_inhibitor + selective_estrogen_receptor_degrader; placebo; CDK4/6_inhibitor + pan-AKT_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor; pan-AKT_inhibitor; selective_estrogen_receptor_degrader	Capivasertib + Fulvestrant + Palbociclib; Fulvestrant + Palbociclib; Capivasertib + Fulvestrant + Palbociclib; Fulvestrant + Palbociclib; Placebo	CDK4/6_inhibitor + pan-AKT_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + pan-AKT_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + selective_estrogen_receptor_degrader; placebo	D361DC00001	A Phase Ib/III Randomised Study of Capivasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer	Locally Advanced (Inoperable) or Metastatic Breast Cancer	6009 - Nedlands; 2010 - Darlinghurst; 2228 - Miranda	https://clinicaltrials.gov/ct2/show/NCT04862663
NCT04865419	D8241C00001	Phase 1/Phase 2		VIC	29/04/2021	11/06/2021	AZD0466	dual_Bcl2/BclxL_inhibitor	AZD0466	dual_Bcl2/BclxL_inhibitor	D8241C00001	A Modular Phase I/II, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD0466 Monotherapy or in Combination in Patients With Advanced Haematological Malignancies	Haematological Malignancies	3004 - Melbourne; 3050 - Parkville	https://clinicaltrials.gov/ct2/show/NCT04865419
NCT04870112	SCope-D1	Unknown		NZ	3/05/2021	28/06/2021	Carboplatin; Cisplatin; Durvalumab; Etoposide	anti-PD-L1_monoclonal_antibody; platinum-based_antineoplastic_agent; topoisomerase_inhibitor	Carboplatin; Cisplatin; Durvalumab; Etoposide	anti-PD-L1_monoclonal_antibody; platinum-based_antineoplastic_agent; topoisomerase_inhibitor	2020-006041-18  D9072C00001	A Phase 1/2a, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of Subcutaneous Durvalumab in Patients With Non-Small Cell and Small Cell Lung Cancer - SCope-D1	Non-Small Cell Lung Cancer; Small Cell Lung Cancer	Christchurch	https://clinicaltrials.gov/ct2/show/NCT04870112
NCT04871282	RINGSIDE	Phase 2/Phase 3		SA, QLD, VIC	4/05/2021	30/03/2021	AL102; Placebo	gamma_secretase_inhibitor; placebo	AL102; Placebo	gamma_secretase_inhibitor; placebo	AL-DES-01	RINGSIDE: A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients With Progressing Desmoid Tumors	Desmoid Tumor; Desmoid	4102 - Woolloongabba; 5037 - Kurralta Park; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04871282
NCT04876651	PROSTACT	Phase 3		WA	6/05/2021		177Lu-DOTA-rosopatamab	radioligand,PSMA-targeting	177Lu-DOTA-rosopatamab	radioligand,PSMA-targeting	177Lu-TLX591-002	A Multinational, Multicenter, Prospective, Randomized, Controlled, Open Label Phase 3 Study With Best Standard of Care With and Without 177Lu-DOTA-rosopatamab for Patients With PSMA Expressing Metastatic Castration-resistant Prostate Cancer Progressing Despite Prior Treatment With a Novel Androgen Axis Drug	Metastatic Prostate Cancer	6150 - Perth; 6009 - Perth	https://clinicaltrials.gov/ct2/show/NCT04876651
NCT04879329	KEYNOTE-D78--RC48G001	Phase 2		VIC, Othe	10/05/2021	3/05/2022	Disitamab vedotin; Disitamab vedotin + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; anti-ERBB2_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody; anti-ERBB2_antibody-drug_conjugate	Disitamab vedotin; Disitamab vedotin + Pembrolizumab; Disitamab vedotin + Pembrolizumab	anti-ERBB2_antibody-drug_conjugate; anti-ERBB2_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody; anti-ERBB2_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody	KEYNOTE-D78  RC48G001	A Phase 2 Multi-Cohort, Open-Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48-ADC) Alone and in Combination With Pembrolizumab in Subjects With Locally-Advanced Unresectable or Metastatic Urothelial Carcinoma That Expresses HER2	Urothelial Carcinoma	3199 - Frankston	https://clinicaltrials.gov/ct2/show/NCT04879329
NCT04879368	INTEGRATEIIb	Phase 3		QLD, VIC, NSW, TAS, SA, NZ, ACT, NT, WA	10/05/2021	1/06/2021	Docetaxel; Irinotecan; Nivolumab; Paclitaxel; Regorafenib	anti-PD-1_monoclonal_antibody; taxane; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor; topoisomerase_inhibitor	Docetaxel; Irinotecan; Nivolumab; Paclitaxel; Regorafenib	KIT/PDGFR/RET/VEGFR/FGFR_inhibitor; anti-PD-1_monoclonal_antibody; taxane; topoisomerase_inhibitor	2020-004617-12  AG0315OG/CTC0140	A Randomised Phase III Open Label Study of Regorafenib + Nivolumab vs Standard Chemotherapy in Refractory Advanced Gastro-Oesophageal Cancer (AGOC)	Gastro-Oesophageal Cancer	2145 - Westmead; 4560 - Sunshine Coast; 3168 - Clayton; 2250 - Gosford; 2031 - Randwick; - Tamworth; - Adelaide; 700 - Hobart; - Perth; 2139 - Concord; 4814 - Douglas; 6008 - Subiaco; - Newcastle; Christchurch; Auckland; 3355 - Wendouree; 3931 - Mornington; 2450 - Coffs Harbour; 2065 - St Leonards; - Box Hill; 2217 - Kogarah; 2444 - Port Macquarie; 5035 - Ashford; - Ballarat; - Sydney; - Canberra; 2010 - Darlinghurst; 0810 - Tiwi; 5042 - Bedford Park; 2035 - New Lambton Heights; 6009 - Nedlands; - Melbourne; 4029 - Herston; 2640 - Albury; 2485 - Tweed Heads; 3084 - Heidelberg; 5011 - Woodville South	https://clinicaltrials.gov/ct2/show/NCT04879368
NCT04880564	CN1-201	Phase 1/Phase 2		VIC	10/05/2021	28/07/2021	CN1; CN1 + Tenalisib; Tenalisib	PI3K_delta_inhibitor + anti-OX40_agonistic_antibody; PI3K-delta/gamma/SIK3_inhibitor; PI3K_delta_inhibitor; PI3K-delta/gamma/SIK3_inhibitor + anti-OX40_agonistic_antibody; anti-OX40_agonistic_antibody; PI3K-delta/gamma_inhibitor + anti-OX40_agonistic_antibody; PI3K-delta/gamma_inhibitor	CN1 + Tenalisib; CN1 + Tenalisib	PI3K-delta/gamma/SIK3_inhibitor + anti-OX40_agonistic_antibody; PI3K-delta/gamma_inhibitor + anti-OX40_agonistic_antibody; PI3K_delta_inhibitor + anti-OX40_agonistic_antibody; PI3K-delta/gamma/SIK3_inhibitor + anti-OX40_agonistic_antibody; PI3K-delta/gamma_inhibitor + anti-OX40_agonistic_antibody; PI3K_delta_inhibitor + anti-OX40_agonistic_antibody	CN1-201	An Open-label, Multi-centre, Phase I/II Study to Investigate the Safety, Tolerability, and Preliminary Efficacy of CN1 in Combination With CN401 in Adult Patients With Relapsed/Refractory Lymphoid Malignancies	Relapsed Lymphoid Malignancies; Refractory Lymphoid Malignancies	3168 - Bentleigh	https://clinicaltrials.gov/ct2/show/NCT04880564
NCT04886804	2020-004563-47--1479-0001	Phase 1		VIC	14/05/2021	22/06/2021	Zongertinib	ERBB2_inhibitor,second_generation	Zongertinib	ERBB2_inhibitor,second_generation	2020-004563-47  1479-0001	An Open Label, Phase I Dose Escalation Trial, With Dose Confirmation and Expansion, of BI 1810631 as Monotherapy in Patients With Advanced or Metastatic Solid Tumors With HER2 Aberrations	Non-Small Cell Lung Cancer; Neoplasm Metastasis	3144 - Malvern	https://clinicaltrials.gov/ct2/show/NCT04886804
NCT04891718	PBI-MST-02	Phase 0		SA, NSW	18/05/2021		MVC-101; MVC-101 + Nivolumab; Nivolumab	bispecific_T-cell_engager,EGFR-targeting; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + bispecific_T-cell_engager,EGFR-targeting	MVC-101 + Nivolumab; MVC-101 + Nivolumab	anti-PD-1_monoclonal_antibody + bispecific_T-cell_engager,EGFR-targeting; anti-PD-1_monoclonal_antibody + bispecific_T-cell_engager,EGFR-targeting	PBI-MST-02	A Phase 0 Master Protocol Using the CIVO® Platform to Evaluate Intratumoural Microdoses of Anti-Cancer Therapies in Patients With Solid Tumours	Solid Tumour	2050 - Camperdown; 2500 - Wollongong; 5042 - Bedford Park	https://clinicaltrials.gov/ct2/show/NCT04891718
NCT04895358	2020-005407-38--3475-B49	Phase 3		NSW, VIC, WA	20/05/2021	18/06/2021	Capecitabine; Capecitabine + Nab-paclitaxel + Paclitaxel + Pegylated liposomal doxorubicin; Capecitabine + Nab-paclitaxel + Paclitaxel + Pegylated liposomal doxorubicin + Pembrolizumab; Dexamethasone; Nab-paclitaxel; Paclitaxel; Pegylated liposomal doxorubicin; Pembrolizumab; Placebo	anthracycline; glucocorticoid; anti-PD-1_monoclonal_antibody; placebo; anthracycline + fluoropyrimidine + taxane; taxane; fluoropyrimidine; anthracycline + anti-PD-1_monoclonal_antibody + fluoropyrimidine + taxane	Capecitabine + Nab-paclitaxel + Paclitaxel + Pegylated liposomal doxorubicin; Capecitabine + Nab-paclitaxel + Paclitaxel + Pegylated liposomal doxorubicin + Pembrolizumab; Capecitabine + Nab-paclitaxel + Paclitaxel + Pegylated liposomal doxorubicin; Capecitabine + Nab-paclitaxel + Paclitaxel + Pegylated liposomal doxorubicin + Pembrolizumab; Dexamethasone; Placebo	anthracycline + anti-PD-1_monoclonal_antibody + fluoropyrimidine + taxane; anthracycline + fluoropyrimidine + taxane; anthracycline + anti-PD-1_monoclonal_antibody + fluoropyrimidine + taxane; anthracycline + fluoropyrimidine + taxane; glucocorticoid; placebo	2020-005407-38  3475-B49	A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the Treatment of Chemotherapy-Candidate Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Locally Recurrent Inoperable or Metastatic Breast Cancer (KEYNOTE-B49)	Breast Neoplasms	2109 - Macquarie Park; 6009 - Nedlands; 3199 - Frankston; 2145 - Westmead	https://clinicaltrials.gov/ct2/show/NCT04895358
NCT04895709	2021-001188-26--CA052-002	Phase 1/Phase 2		WA, QLD, VIC, NSW	20/05/2021	27/05/2021	BMS-986340; BMS-986340 + Docetaxel; BMS-986340 + Nivolumab; Docetaxel; Nivolumab	anti-PD-1_monoclonal_antibody; anti-CCR8_monoclonal_antibody + taxane; anti-CCR8_monoclonal_antibody + anti-PD-1_monoclonal_antibody; taxane; anti-CCR8_monoclonal_antibody	BMS-986340; BMS-986340 + Docetaxel; BMS-986340 + Nivolumab; BMS-986340 + Docetaxel; BMS-986340 + Nivolumab	anti-CCR8_monoclonal_antibody; anti-CCR8_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CCR8_monoclonal_antibody + taxane; anti-CCR8_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CCR8_monoclonal_antibody + taxane	2021-001188-26  CA052-002	A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors	Pancreatic Adenocarcinoma; Non-Small-Cell Lung Cancer; Ovarian Neoplasms; Urothelial Carcinoma; Cervical Cancer; Triple Negative Breast Neoplasms; Microsatellite Stable Colorectal Cancer; Gastric/Gastroesophageal Junction Adenocarcinoma; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Melanoma	2170 - Liverpool; 4102 - Brisbane; 3065 - Melbourne; 3144 - Malvern; 2148 - Blacktown; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT04895709
NCT04901806	PBI-200-101	Phase 1/Phase 2		VIC	26/05/2021	20/07/2021	PBI-200	TRK_inhibitor,second_generation	PBI-200	TRK_inhibitor,second_generation	PBI-200-101	A Phase 1/2 Study of PBI-200 in Subjects With NTRK-Fusion-Positive Advanced or Metastatic Solid Tumors	Desmoplastic Small Round Cell Tumor; Brain Tumor, Primary; Solid Tumor, Adult	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04901806
NCT04907851	RXC004-0003	Phase 2	*NOT_RECRUITING	NSW	1/06/2021		Denosumab; RXC004	anti-RANK_L_monoclonal_antibody; PORCN_inhibitor	RXC004; Denosumab	PORCN_inhibitor; anti-RANK_L_monoclonal_antibody	RXC004/0003	A Modular, Phase II, Open-Label, Multicentre Study to Assess the Preliminary Efficacy and Safety of RXC004, in Patients With Advanced Solid Tumours That Have Progressed Following Therapy With Current Standard of Care	Advanced Solid Tumours	2500 - Wollongong	https://clinicaltrials.gov/ct2/show/NCT04907851
NCT04909125	SVIFT-Nodal-Trial	Not Applicable		NSW	1/06/2021	1/06/2021	Radiotherapy	radiotherapy	Radiotherapy	radiotherapy	SVIFT Nodal Trial	Standard Versus Investigatioinal Fractionation Trial - Nodal Radiation	Breast Cancer; Post Mastectomy	2065 - St Leonards	https://clinicaltrials.gov/ct2/show/NCT04909125
NCT04913220	U1111-1254-0189--ACT16845	Phase 1/Phase 2		NSW, VIC	4/06/2021	15/07/2021	Cemiplimab; THOR-707	anti-PD-1_monoclonal_antibody; IL-2_variant	Cemiplimab; THOR-707	anti-PD-1_monoclonal_antibody; IL-2_variant	U1111-1254-0189  ACT16845	A Phase 1/2 Non-randomized, Open-label, Multi-cohort, Multi-center Study Assessing the Clinical Benefit of SAR444245 (THOR- 707) Combined With Cemiplimab for the Treatment of Participants With Advanced Unresectable or Metastatic Skin Cancers	Squamous Cell Carcinoma of Skin; Malignant Melanoma	3081 - Heidelberg West; 2109 - Macquarie Park	https://clinicaltrials.gov/ct2/show/NCT04913220
NCT04913285	KN-8701	Phase 1	NOT_RECRUITING	WA	4/06/2021	4/08/2021	Binimetinib; Binimetinib + Exarafenib; Exarafenib	MEK_inhibitor + pan-RAF_inhibitor; MEK_inhibitor; pan-RAF_inhibitor	Binimetinib + Exarafenib; Exarafenib; Binimetinib + Exarafenib	MEK_inhibitor + pan-RAF_inhibitor; pan-RAF_inhibitor; MEK_inhibitor + pan-RAF_inhibitor	KN-8701	A Phase 1/1b Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of KIN-2787 in Participants With BRAF and/or NRAS Mutation-positive Solid Tumors.	Non-small Cell Lung Cancer; Solid Tumor, Adult; Melanoma	6009 - Perth	https://clinicaltrials.gov/ct2/show/NCT04913285
NCT04914117	RC118G001	Phase 1		VIC, NSW, SA	4/06/2021		RC118	anti-CLDN18.2_antibody-drug_conjugate	RC118	anti-CLDN18.2_antibody-drug_conjugate	RC118G001	Phase 1, First-in-Human, Multicentre, Open-label Study of RC118 for Injection in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours	Metastatic Solid Tumor; Unresectable Solid Tumor; Locally Advanced Solid Tumor	2109 - Macquarie Park; 3199 - Frankston; 5042 - Bedford Park; 3144 - Malvern	https://clinicaltrials.gov/ct2/show/NCT04914117
NCT04914286	GFH018X0201	Phase 1/Phase 2		WA	4/06/2021	20/10/2021	GFH018; GFH018 + Toripalimab; Toripalimab	anti-PD-1_monoclonal_antibody; TGFBR1_inhibitor + anti-PD-1_monoclonal_antibody; TGFBR1_inhibitor	GFH018 + Toripalimab; GFH018 + Toripalimab	TGFBR1_inhibitor + anti-PD-1_monoclonal_antibody; TGFBR1_inhibitor + anti-PD-1_monoclonal_antibody	GFH018X0201	A Multi-center, Single-arm, and Open-label Phase Ib/II Study Exploring the Safety/Tolerability, Pharmacokinetics, and Efficacy of GFH018 in Combination With Toripalimab in the Treatment of Patients With Advanced Solid Tumors	Advanced Solid Tumor	- Perth	https://clinicaltrials.gov/ct2/show/NCT04914286
NCT04914897	U1111-1254-0107--ACT16849	Phase 2		VIC, NSW	7/06/2021	23/09/2021	Carboplatin; Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Cisplatin; Nab-paclitaxel; Nab-paclitaxel + Paclitaxel + Pembrolizumab; Paclitaxel; Pembrolizumab; Pemetrexed; THOR-707	anti-PD-1_monoclonal_antibody + taxane; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; IL-2_variant; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite; taxane	Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Nab-paclitaxel + Paclitaxel + Pembrolizumab; Pembrolizumab; Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Nab-paclitaxel + Paclitaxel + Pembrolizumab; THOR-707	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + taxane; IL-2_variant; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + taxane	U1111-1254-0107  ACT16849	A Phase 2 Non-randomized, Open-label, Multi-cohort, Multi-center Study Assessing the Clinical Benefit of SAR444245 (THOR-707) Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Pleural Mesothelioma	Non-small Cell Lung Cancer; Pleural Mesothelioma	2109 - Macquarie Park; 3121 - Richmond	https://clinicaltrials.gov/ct2/show/NCT04914897
NCT04918810	GUIDE	Phase 2		NSW, VIC	9/06/2021		Docetaxel	taxane	Docetaxel	taxane	ANZUP 1903	A Randomised Non-comparative Phase II Trial of Biomarker-driven Intermittent Docetaxel Versus Standard-of-care (SOC) Docetaxel in Metastatic Castration-resistant Prostate Cancer (mCRPC)	Castration Resistant Prostatic Cancer	3630 - Shepparton; 2460 - Albury; 2050 - Camperdown; 2830 - Dubbo; - Sydney	https://clinicaltrials.gov/ct2/show/NCT04918810
NCT04921358	BGB-A317-Sitravatinib-301	Phase 3		QLD, VIC, NSW, SA	10/06/2021	27/07/2021	Docetaxel; Sitravatinib; Sitravatinib + Tislelizumab; Tislelizumab	anti-PD-1_monoclonal_antibody; KIT/PDGFR/RET/VEGFR_inhibitor; KIT/PDGFR/RET/VEGFR_inhibitor + anti-PD-1_monoclonal_antibody; taxane; KIT_inhibitor + anti-PD-1_monoclonal_antibody; RET_inhibitor + anti-PD-1_monoclonal_antibody; VEGFR_inhibitor; VEGFR_inhibitor + anti-PD-1_monoclonal_antibody; PDGFR_inhibitor; PDGFR_inhibitor + anti-PD-1_monoclonal_antibody; RET_inhibitor; KIT_inhibitor	Docetaxel; Sitravatinib + Tislelizumab; Sitravatinib + Tislelizumab	KIT/PDGFR/RET/VEGFR_inhibitor + anti-PD-1_monoclonal_antibody; KIT_inhibitor + anti-PD-1_monoclonal_antibody; PDGFR_inhibitor + anti-PD-1_monoclonal_antibody; RET_inhibitor + anti-PD-1_monoclonal_antibody; VEGFR_inhibitor + anti-PD-1_monoclonal_antibody; taxane; KIT/PDGFR/RET/VEGFR_inhibitor + anti-PD-1_monoclonal_antibody; KIT_inhibitor + anti-PD-1_monoclonal_antibody; PDGFR_inhibitor + anti-PD-1_monoclonal_antibody; RET_inhibitor + anti-PD-1_monoclonal_antibody; VEGFR_inhibitor + anti-PD-1_monoclonal_antibody	BGB-A317-Sitravatinib 301	A Randomized Phase 3 Study of Tislelizumab in Combination With Sitravatinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer That Progressed on or After Platinum-Based Chemotherapy and Anti-PD-(L)1 Antibody	Non-Small Cell Lung Cancer (NSCLC)	4120 - Greenslopes; 2217 - Kogarah; - Tweed Heads; 5000 - Adelaide; 2148 - Blacktown; 2560 - Campbelltown; 4556 - Sippy Downs; 3021 - Saint Albans; 3076 - Epping; - Clayton; 3002 - East Melbourne	https://clinicaltrials.gov/ct2/show/NCT04921358
NCT04924075	MK-6482-015--6482-015	Phase 2		VIC, NSW	11/06/2021	12/08/2021	Belzutifan	HIF2a_inhibitor	Belzutifan	HIF2a_inhibitor	MK-6482-015  6482-015	A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, Formerly PT2977) Monotherapy in Participants With Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors With HIF-2a Related Genetic Alterations	HIF-2a Mutated Cancers; Advanced Gastrointestinal Stromal Tumor; Pancreatic Neuroendocrine Tumor; Von Hippel-Lindau Disease; Pheochromocytoma/Paraganglioma	2031 - Randwick; 3050 - Parkville	https://clinicaltrials.gov/ct2/show/NCT04924075
NCT04925284	XB002-101	Unknown		NSW	14/06/2021	7/06/2021	Bevacizumab; Bevacizumab + XB002; Nivolumab; Nivolumab + XB002; XB002	anti-PD-1_monoclonal_antibody + anti-TF_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody; anti-TF_antibody-drug_conjugate + anti-VEGF_monoclonal_antibody; anti-VEGF_monoclonal_antibody; anti-TF_antibody-drug_conjugate	Bevacizumab + XB002; Nivolumab + XB002; XB002; Bevacizumab + XB002; Nivolumab + XB002	anti-PD-1_monoclonal_antibody + anti-TF_antibody-drug_conjugate; anti-TF_antibody-drug_conjugate; anti-TF_antibody-drug_conjugate + anti-VEGF_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TF_antibody-drug_conjugate; anti-TF_antibody-drug_conjugate + anti-VEGF_monoclonal_antibody	XB002-101	A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 as Single-Agent and Combination Therapy in Subjects With Inoperable Locally Advanced or Metastatic Solid Tumors	Hormone Receptor-positive Breast Cancer; Metastatic Castration-resistant Prostate Cancer; SCCHN; Triple Negative Breast Cancer; Epithelial Ovarian Cancer; Pancreatic Cancer; Tissue Factor-Expressing Solid Tumors; Non Small Cell Lung Cancer; Cervical Cancer; Esophageal SCC; Endometrial Cancer	2010 - Darlinghurst; 2065 - Saint Leonards	https://clinicaltrials.gov/ct2/show/NCT04925284
NCT04925648	PICASSO	Phase 2		NSW, VIC	14/06/2021	18/10/2021	Darolutamide; Dasatinib	PDGFRA_inhibitor; SRC_inhibitor; YES1_inhibitor; antiandrogen,nonsteroidal,second_generation; BCR-ABL1_inhibitor,second_generation; KIT_inhibitor	Dasatinib; Darolutamide	BCR-ABL1_inhibitor,second_generation; KIT_inhibitor; PDGFRA_inhibitor; SRC_inhibitor; YES1_inhibitor; antiandrogen,nonsteroidal,second_generation	PICASSO	PICAASO / CA180-722: Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction	Metastatic Prostate Cancer	3000 - Melbourne; 2010 - Sydney	https://clinicaltrials.gov/ct2/show/NCT04925648
NCT04928846	2021-001811-94--M18-868	Phase 3		VIC	16/06/2021	25/03/2022	Docetaxel; Telisotuzumab Vedotin	taxane; anti-cMET_antibody-drug_conjugate	Docetaxel; Telisotuzumab Vedotin	anti-cMET_antibody-drug_conjugate; taxane	2021-001811-94  M18-868	A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer	Non Small Cell Lung Cancer	3220 - Geelong	https://clinicaltrials.gov/ct2/show/NCT04928846
NCT04929223	WO42758	Unknown		VIC	18/06/2021	22/10/2021	Atezolizumab; Atezolizumab + Bevacizumab + Tiragolumab; Atezolizumab + SY-5609; Atezolizumab + Tiragolumab; Bevacizumab; Bevacizumab + Inavolisib; Cetuximab; Cetuximab + Divarasib; Cetuximab + Inavolisib; Divarasib; Inavolisib; SY-5609; Tiragolumab	PI3K_alpha_inhibitor + anti-EGFR_monoclonal_antibody; KRAS_G12C_inhibitor; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + anti-VEGF_monoclonal_antibody; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; anti-EGFR_monoclonal_antibody; PI3K_alpha_inhibitor + anti-VEGF_monoclonal_antibody; anti-TIGIT_monoclonal_antibody; PI3K_alpha_inhibitor; CDK7_inhibitor; anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; CDK7_inhibitor + anti-PD-L1_monoclonal_antibody	Atezolizumab + Bevacizumab + Tiragolumab; Atezolizumab + SY-5609; Atezolizumab + Tiragolumab; Bevacizumab + Inavolisib; Cetuximab + Divarasib; Cetuximab + Inavolisib; Atezolizumab + Bevacizumab + Tiragolumab; Atezolizumab + SY-5609; Atezolizumab + Tiragolumab; Bevacizumab + Inavolisib; Cetuximab + Divarasib; Cetuximab + Inavolisib	CDK7_inhibitor + anti-PD-L1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; PI3K_alpha_inhibitor + anti-EGFR_monoclonal_antibody; PI3K_alpha_inhibitor + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + anti-VEGF_monoclonal_antibody; CDK7_inhibitor + anti-PD-L1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; PI3K_alpha_inhibitor + anti-EGFR_monoclonal_antibody; PI3K_alpha_inhibitor + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + anti-VEGF_monoclonal_antibody	WO42758	A Phase I/Ib Global, Multicenter, Open-label Umbrella Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)	Metastatic Colorectal Cancer	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04929223
NCT04931342	GOG-3051--WO42178	Phase 2	NOT_RECRUITING	VIC	18/06/2021	7/10/2021	Atezolizumab; Atezolizumab + Bevacizumab; Bevacizumab; Cobimetinib; Ipatasertib; Ipatasertib + Paclitaxel; Paclitaxel; Trastuzumab Emtansine	pan-AKT_inhibitor; anti-PD-L1_monoclonal_antibody; MEK_inhibitor; anti-VEGF_monoclonal_antibody; taxane; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; pan-AKT_inhibitor + taxane; anti-ERBB2_antibody-drug_conjugate	Atezolizumab + Bevacizumab; Cobimetinib; Ipatasertib + Paclitaxel; Trastuzumab Emtansine; Atezolizumab + Bevacizumab; Ipatasertib + Paclitaxel	MEK_inhibitor; anti-ERBB2_antibody-drug_conjugate; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; pan-AKT_inhibitor + taxane; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; pan-AKT_inhibitor + taxane	GOG-3051  WO42178	A Phase II, Open-Label, Multicenter, Platform Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors	Ovarian Cancer	3144 - Malvern	https://clinicaltrials.gov/ct2/show/NCT04931342
NCT04935359	CNIS793B12301	Phase 3		WA	23/06/2021	30/09/2021	Gemcitabine; Gemcitabine + NIS793 + Nab-paclitaxel; Gemcitabine + Nab-paclitaxel; NIS793; Nab-paclitaxel; Placebo	anti-TGF-beta_monoclonal_antibody + antimetabolite + taxane; placebo; antimetabolite; anti-TGF-beta_monoclonal_antibody; gemcitabine; taxane; antimetabolite + taxane	Gemcitabine + NIS793 + Nab-paclitaxel; Gemcitabine + Nab-paclitaxel; Gemcitabine + NIS793 + Nab-paclitaxel; Gemcitabine + Nab-paclitaxel; Placebo	anti-TGF-beta_monoclonal_antibody + antimetabolite + taxane; antimetabolite + taxane; anti-TGF-beta_monoclonal_antibody + antimetabolite + taxane; antimetabolite + taxane; gemcitabine; placebo	CNIS793B12301	A Randomized, Double-blind, Phase III Study, Comparing NIS793 in Combination With Gemcitabine and Nab-paclitaxel Versus (vs.) Placebo Combined With Gemcitabine and Nab-paclitaxel for First Line Treatment of Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)	Metastatic Pancreatic Ductal Adenocarcinoma	- Perth	https://clinicaltrials.gov/ct2/show/NCT04935359
NCT04938817	MK-3475-B98--3475-B98	Phase 1/Phase 2		WA, NSW, QLD	24/06/2021	19/08/2021	Favezelimab; Favezelimab + Pembrolizumab; Lenvatinib; Lenvatinib + Pembrolizumab + Quavonlimab; MK-4830; MK-4830 + Pembrolizumab + Quavonlimab; Pembrolizumab; Pembrolizumab + Quavonlimab; Quavonlimab	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; VEGF_inhibitor; anti-CTLA-4_monoclonal_antibody + anti-ILT4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-ILT4_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Favezelimab + Pembrolizumab; Lenvatinib + Pembrolizumab + Quavonlimab; MK-4830 + Pembrolizumab + Quavonlimab; Pembrolizumab + Quavonlimab; Favezelimab + Pembrolizumab; Lenvatinib + Pembrolizumab + Quavonlimab; MK-4830 + Pembrolizumab + Quavonlimab; Pembrolizumab + Quavonlimab	VEGF_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-ILT4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-ILT4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	MK-3475-B98  3475-B98	A Phase 1b/2 Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Investigational Agents for the Treatment of Participants With PD-1/L1-refractory Extensive-Stage Small Cell Lung Cancer in Need of Second-Line Therapy (KEYNOTE-B98)	Small Cell Lung Carcinoma	2145 - Westmead; 6009 - Perth; 4032 - Brisbane	https://clinicaltrials.gov/ct2/show/NCT04938817
NCT04947189	4CAST	Unknown		NSW	1/07/2021	1/11/2022	Dexamethasone; Dexamethasone + Docetaxel + Seviteronel; Docetaxel; Seviteronel	glucocorticoid; CYP17A1_inhibitor + glucocorticoid + taxane; taxane; CYP17A1_inhibitor	Dexamethasone + Docetaxel + Seviteronel; Dexamethasone + Docetaxel + Seviteronel	CYP17A1_inhibitor + glucocorticoid + taxane; CYP17A1_inhibitor + glucocorticoid + taxane	4CAST	4CAST: A Phase 1b Dose Exploration and Dose Expansion, Open-label, Single-centre Study Evaluating the Safety and Efficacy of INO-464 in Combination With Chemotherapy in Patients With metASTatic Breast Cancer	Triple Negative Breast Cancer	2010 - Darlinghurst	https://clinicaltrials.gov/ct2/show/NCT04947189
NCT04952753	daNIS-3	Phase 2		WA	7/07/2021	15/11/2021	Bevacizumab; Bevacizumab + NIS793; Bevacizumab + NIS793 + Tislelizumab; NIS793; Tislelizumab	anti-TGF-beta_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-VEGF_monoclonal_antibody; anti-TGF-beta_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody + anti-VEGF_monoclonal_antibody	Bevacizumab; Bevacizumab + NIS793; Bevacizumab + NIS793 + Tislelizumab; Bevacizumab + NIS793; Bevacizumab + NIS793 + Tislelizumab	anti-PD-1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-TGF-beta_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-VEGF_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-TGF-beta_monoclonal_antibody + anti-VEGF_monoclonal_antibody	2021-000553-40  CNIS793E12201	An Open-label, Multi-center, ph II Platform Study Evaluating the Efficacy and Safety of NIS793 and Other New Investigational Drug Combinations With SOC Anti-cancer Therapy for the 2L Treatment of Metastatic Colorectal Cancer (mCRC)	Metastatic Colorectal Cancer	- Perth	https://clinicaltrials.gov/ct2/show/NCT04952753
NCT04956640	2021-000595-12--LOXO-RAS-20001	Phase 1		NSW	9/07/2021	19/07/2021	Abemaciclib; Cetuximab; Erlotinib; LY3295668; Olomorasib; Pembrolizumab; TNO155	SHP2_inhibitor; anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor; EGFR_inhibitor,first_generation; AURKA_inhibitor; CDK4/6_inhibitor; anti-EGFR_monoclonal_antibody	Olomorasib; Abemaciclib; Cetuximab; Erlotinib; LY3295668; Pembrolizumab; TNO155	KRAS_G12C_inhibitor; AURKA_inhibitor; CDK4/6_inhibitor; EGFR_inhibitor,first_generation; SHP2_inhibitor; anti-EGFR_monoclonal_antibody; anti-PD-1_monoclonal_antibody	2021-000595-12  LOXO-RAS-20001	A Phase 1a/1b Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors	Ovarian Neoplasms; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Pancreatic Neoplasms; Colorectal Neoplams	2010 - Darlinghurst	https://clinicaltrials.gov/ct2/show/NCT04956640
NCT04958785	2021-001074-27--GS-US-586-6144	Phase 2		QLD, VIC	12/07/2021		Magrolimab; Magrolimab + Nab-paclitaxel + Paclitaxel; Nab-paclitaxel; Nab-paclitaxel + Paclitaxel; Paclitaxel	anti-CD47_monoclonal_antibody; taxane; anti-CD47_monoclonal_antibody + taxane	Magrolimab + Nab-paclitaxel + Paclitaxel; Nab-paclitaxel + Paclitaxel; Magrolimab + Nab-paclitaxel + Paclitaxel; Nab-paclitaxel + Paclitaxel	anti-CD47_monoclonal_antibody + taxane; taxane; anti-CD47_monoclonal_antibody + taxane	2021-001074-27  GS-US-586-6144	A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Nab-Paclitaxel or Paclitaxel Versus Nab-Paclitaxel or Paclitaxel in Previously Untreated Patients With Metastatic Triple-Negative Breast Cancer	Triple-Negative Breast Cancer	3135 - Ringwood East; 4556 - Sippy Downs	https://clinicaltrials.gov/ct2/show/NCT04958785
NCT04964375	ABSK043-101	Phase 1		NSW, VIC, QLD	16/07/2021		ABSK-043	PD-L1_inhibitor,oral	ABSK-043	PD-L1_inhibitor,oral	ABSK043-101	A Phase 1, Open-Label Study of ABSK043 to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced Solid Tumor	Neoplasms	- Frankston; 4101 - Brisbane; - Liverpool	https://clinicaltrials.gov/ct2/show/NCT04964375
NCT04964934	SERENA-6	Phase 3		NSW, QLD, WA	16/07/2021	30/06/2021	Abemaciclib; Abemaciclib + Anastrozole + Camizestrant + Letrozole + Palbociclib; Anastrozole; Camizestrant; Letrozole; Palbociclib; Placebo	placebo; CDK4/6_inhibitor; CDK4/6_inhibitor + aromatase_inhibitor + selective_estrogen_receptor_degrader; aromatase_inhibitor; selective_estrogen_receptor_degrader	Abemaciclib + Anastrozole + Camizestrant + Letrozole + Palbociclib; Abemaciclib + Anastrozole + Camizestrant + Letrozole + Palbociclib; Placebo	CDK4/6_inhibitor + aromatase_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + aromatase_inhibitor + selective_estrogen_receptor_degrader; placebo	D8534C00001	A Phase III, Double-blind, Randomised Study to Assess Switching to AZD9833 (a Next Generation, Oral SERD) + CDK4/6 Inhibitor (Palbociclib or Abemaciclib) vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole)+ CDK4/6 Inhibitor in HR+/HER2-MBC Patients With Detectable ESR1Mutation Without Disease Progression During 1L Treatment With Aromatase Inhibitor+ CDK4/6 Inhibitor- A ctDNA Guided Early Switch Study	ER-Positive HER2-Negative Breast Cancer	6008 - Subiaco; 4575 - Birtinya; 2010 - Darlinghurst	https://clinicaltrials.gov/ct2/show/NCT04964934
NCT04969861	20-214-36	Phase 2/Phase 3		NSW	21/07/2021	9/03/2022	Bempegaldesleukin; Bempegaldesleukin + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; IL-2_variant; IL-2_variant + anti-PD-1_monoclonal_antibody	Bempegaldesleukin + Pembrolizumab; Pembrolizumab; Bempegaldesleukin + Pembrolizumab	IL-2_variant + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; IL-2_variant + anti-PD-1_monoclonal_antibody	20-214-36	A Phase 2/3, Randomized, Open-label Study to Compare Bempegaldesleukin (NKTR-214) Combined With Pembrolizumab vs. Pembrolizumab Alone in First-Line Treatment of Patients With Metastatic or Recurrent HNSCC With PD-L1 Expressing Tumors	Metastatic Head and Neck Cancer; Recurrent Head and Neck Cancer	- Camperdown	https://clinicaltrials.gov/ct2/show/NCT04969861
NCT04969887	MOST-CIRCUIT	Phase 2	*NOT_RECRUITING	NSW, VIC	21/07/2021	3/08/2021	Ipilimumab; Ipilimumab + Nivolumab; Nivolumab	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Ipilimumab + Nivolumab; Ipilimumab + Nivolumab	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	CA209-6D6  ONJ2021-002	Ipilimumab and Nivolumab Combination Therapy in Patients With Selected Immunotherapy Sensitive Advanced Rare Cancers	Neuroendocrine Tumors; MSI-H Solid Malignant Tumor; Female Reproductive System Neoplasm; Advanced Biliary Tract Cancer	- Bendigo; 2640 - Albury; 2145 - Sydney; 3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT04969887
NCT04974398	AK105-304	Phase 3		NSW	23/07/2021	16/08/2021	Cisplatin; Cisplatin + Gemcitabine; Cisplatin + Gemcitabine + Penpulimab; Gemcitabine; Penpulimab; Placebo	anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; placebo; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; gemcitabine	Cisplatin + Gemcitabine; Cisplatin + Gemcitabine + Penpulimab; Cisplatin + Gemcitabine; Cisplatin + Gemcitabine + Penpulimab; Placebo	anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; gemcitabine; placebo	AK105-304	A Randomized, Double-blind, Multi-center Phase III Study of Penpulimab (AK105) Combined With Chemotherapy Versus Placebo Combined With Chemotherapy in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma	Nasopharyngeal Carcinoma	2010 - Darlinghurst; 2065 - St Leonards	https://clinicaltrials.gov/ct2/show/NCT04974398
NCT04975308	EMBER-3	Phase 3		SA, NSW, VIC, QLD	23/07/2021	4/10/2021	Exemestane; Exemestane + Fulvestrant; Fulvestrant; Imlunestrant	aromatase_inhibitor; selective_estrogen_receptor_degrader; aromatase_inhibitor + selective_estrogen_receptor_degrader	Exemestane + Fulvestrant; Imlunestrant; Exemestane + Fulvestrant	aromatase_inhibitor + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader; aromatase_inhibitor + selective_estrogen_receptor_degrader	J2J-OX-JZLC  18175	EMBER-3: A Randomized, Open-Label, Phase 3 Study of LY3484356 vs Investigator's Choice of Endocrine Therapy, in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy	Neoplasm Metastasis; Breast Neoplasms	2010 - Darlinghurst; 3128 - Box Hill; 5000 - Adelaide; 4102 - Woolloongabba	https://clinicaltrials.gov/ct2/show/NCT04975308
NCT04976634	MK-6482-016--6482-016	Phase 2		NSW, VIC	26/07/2021	18/08/2021	Belzutifan; Belzutifan + Lenvatinib + Pembrolizumab; Lenvatinib; Lenvatinib + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; HIF2a_inhibitor; HIF2a_inhibitor + VEGF_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor	Belzutifan + Lenvatinib + Pembrolizumab; Lenvatinib + Pembrolizumab; Belzutifan + Lenvatinib + Pembrolizumab; Lenvatinib + Pembrolizumab	HIF2a_inhibitor + VEGF_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; HIF2a_inhibitor + VEGF_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody	MK-6482-016  6482-016	An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Multiple Solid Tumors	Colorectal Neoplasms; Biliary Tract Neoplasms; Esophageal Neoplasms; Pancreatic Ductal Adenocarcinoma; Endometrial Neoplasms; Carcinoma, Hepatocellular	2145 - Westmead; 2250 - Gosford; 3144 - Malvern	https://clinicaltrials.gov/ct2/show/NCT04976634
NCT04985604	DAY101-102	Phase 1/Phase 2		VIC	2/08/2021	15/07/2021	Pimasertib; Pimasertib + Tovorafenib; Tovorafenib	MEK_inhibitor + RAF_inhibitor,type_2; RAF_inhibitor,type_2; MEK_inhibitor	Pimasertib + Tovorafenib; Tovorafenib; Pimasertib + Tovorafenib	MEK_inhibitor + RAF_inhibitor,type_2; RAF_inhibitor,type_2; MEK_inhibitor + RAF_inhibitor,type_2	DAY101-102	A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination With Other Therapies for Patients With Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations	Solid Tumor; Melanoma	- Clayton	https://clinicaltrials.gov/ct2/show/NCT04985604
NCT04985721	IMPARP-HRD	Phase 2		VIC	2/08/2021		Pamiparib; Pamiparib + Tislelizumab; Tislelizumab	PARP_inhibitor; anti-PD-1_monoclonal_antibody; PARP_inhibitor + anti-PD-1_monoclonal_antibody	Pamiparib + Tislelizumab; Pamiparib + Tislelizumab	PARP_inhibitor + anti-PD-1_monoclonal_antibody; PARP_inhibitor + anti-PD-1_monoclonal_antibody	20/044	An Open Label, Signal Seeking, Translational, Phase II Trial of Pamiparib in Combination With Tislelizumab in Patients With Advanced Tumours With Homologous Recombination Repair Defects	Cancer	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04985721
NCT04985825	I-PACE	Phase 2		WA, NSW, VIC	2/08/2021	16/12/2021	Imgatuzumab	anti-EGFR_monoclonal_antibody	Imgatuzumab	anti-EGFR_monoclonal_antibody	2021-003262-12  PO-001	Phase 2 Study of Imgatuzumab in Patients With Advanced Cutaneous Squamous Cell Carcinoma (I-PACE)	Cutaneous Squamous Cell Carcinoma	6009 - Nedlands; 3000 - Melbourne; 2298 - Waratah	https://clinicaltrials.gov/ct2/show/NCT04985825
NCT04986852	KEYNOTE-C14	Phase 2		WA	3/08/2021	30/09/2021	Olinvacimab; Olinvacimab + Pembrolizumab; Pembrolizumab	anti-VEGFR2_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-VEGFR2_monoclonal_antibody	Olinvacimab + Pembrolizumab; Olinvacimab + Pembrolizumab	anti-PD-1_monoclonal_antibody + anti-VEGFR2_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-VEGFR2_monoclonal_antibody	PMC_TTAC-0001_06 / KEYNOTE-C14	A Phase II, Open-Label, Multicenter Study of Olinvacimab in Combination With Pembrolizumab in Patients With Metastatic Triple-Negative Breast Cancer	Metastatic Triple-Negative Breast Cancer	6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT04986852
NCT04986865	PROBE	Phase 1		VIC, NSW	3/08/2021		ATG-101	bispecific_PD-L1/4-1BB_antibody	ATG-101	bispecific_PD-L1/4-1BB_antibody	ATG-101-001	A First-in-Human Phase I Trial of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas	Advanced Solid Tumor; Mature B-cell Non-Hodgkin Lymphoma; Metastatic Solid Tumor	2031 - Randwick; 3004 - Melbourne; 8006 - East Melbourne; 3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT04986865
NCT04987203	AV-951-20-304	Phase 3		VIC	3/08/2021	9/09/2021	Nivolumab; Nivolumab + Tivozanib; Tivozanib	anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor	Nivolumab + Tivozanib; Tivozanib; Nivolumab + Tivozanib	VEGF_inhibitor; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody	AV-951-20-304	TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor	Renal Cell Carcinoma	8006 - East Melbourne	https://clinicaltrials.gov/ct2/show/NCT04987203
NCT04994132	NCI-2021-06711--ARST2031	Phase 3		NSW, VIC, WA	6/08/2021	13/09/2021	Cyclophosphamide; Cyclophosphamide + Dactinomycin + Radiotherapy + Vincristine; Cyclophosphamide + Dactinomycin + Radiotherapy + Vincristine + Vinorelbine; Dactinomycin; Radiotherapy; Vincristine; Vinorelbine	radiotherapy; alkylating_agent; alkylating_agent + antineoplastic_antibiotic + radiotherapy + vinca_alkaloid; vinca_alkaloid; antineoplastic_antibiotic	Cyclophosphamide + Dactinomycin + Radiotherapy + Vincristine; Cyclophosphamide + Dactinomycin + Radiotherapy + Vincristine + Vinorelbine; Cyclophosphamide + Dactinomycin + Radiotherapy + Vincristine; Cyclophosphamide + Dactinomycin + Radiotherapy + Vincristine + Vinorelbine	alkylating_agent + antineoplastic_antibiotic + radiotherapy + vinca_alkaloid; alkylating_agent + antineoplastic_antibiotic + radiotherapy + vinca_alkaloid	NCI-2021-06711  ARST2031	A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy With Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) Plus VINO-CPO Maintenance in Patients With High Risk Rhabdomyosarcoma (HR-RMS)	Embryonal Rhabdomyosarcoma; Spindle Cell/Sclerosing Rhabdomyosarcoma; Solid Alveolar Rhabdomyosarcoma; Spindle Cell Rhabdomyosarcoma; Alveolar Rhabdomyosarcoma; Metastatic Embryonal Rhabdomyosarcoma; Metastatic Rhabdomyosarcoma; Botryoid-Type Embryonal Rhabdomyosarcoma	2310 - Hunter Regional Mail Centre; 2145 - Westmead; 3052 - Parkville; 6009 - Perth	https://clinicaltrials.gov/ct2/show/NCT04994132
NCT04995523	ARTEMIDE-01	Phase 1/Phase 2		VIC	9/08/2021	14/09/2021	AZD2936	bispecific_PD-1/TIGIT_antibody	AZD2936	bispecific_PD-1/TIGIT_antibody	2021-000857-23  D7020C00001	A Phase I/II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic Non-small Cell Lung Cancer	Non-Small-Cell Lung Carcinoma	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04995523
NCT04996875	2021-001010-10--CGT9486-20-201	Phase 2		VIC	9/08/2021	9/11/2021	CGT9486	KIT_inhibitor	CGT9486	KIT_inhibitor	2021-001010-10  CGT9486-20-201	A Phase 2 Open-Label, Multicenter Clinical Study of the Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Profiles of CGT9486 as a Single Agent in Patients With Advanced Systemic Mastocytosis	Aggressive Systemic Mastocytosis (ASM); SM With an Associated Hematologic Neoplasm (SM-AHN); Advanced Systemic Mastocytosis (AdvSM); Mast Cell Leukemia (MCL)	3051 - Melbourne N.	https://clinicaltrials.gov/ct2/show/NCT04996875
NCT05005273	2021-000039-29--CA020-016	Phase 2		NSW, VIC, QLD	13/08/2021		BMS-986207; Ipilimumab; Nivolumab; Placebo	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; placebo; anti-TIGIT_monoclonal_antibody	BMS-986207; Ipilimumab; Nivolumab; Placebo	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-TIGIT_monoclonal_antibody; placebo	2021-000039-29  CA020-016	A Phase 2 Randomized Double-blind Study of BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer	Non-Small Cell Lung Cancer	- Wahroonga; 2800 - Orange; 4814 - Douglas; 3280 - Warrnambool	https://clinicaltrials.gov/ct2/show/NCT05005273
NCT05006716	BGB-16673-101	Phase 1		VIC, WA	16/08/2021		BGB-16673	BTK-PROTAC	BGB-16673	BTK-PROTAC	BGB-16673-101	A Phase 1, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Patients With B-Cell Malignancies	Waldenström Macroglobulinemia; Non-hodgkin Lymphoma; B-cell Malignancy; Marginal Zone Lymphoma; Follicular Lymphoma	3000 - Melbourne; 6005 - West Perth	https://clinicaltrials.gov/ct2/show/NCT05006716
NCT05014815	2021-001075-17--AdvanTIG-205	Phase 2		TAS, VIC, QLD	20/08/2021	16/11/2021	Ociperlimab; Ociperlimab + Tislelizumab; Placebo; Tislelizumab	anti-PD-1_monoclonal_antibody; placebo; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-TIGIT_monoclonal_antibody	Ociperlimab + Tislelizumab; Tislelizumab; Ociperlimab + Tislelizumab; Placebo	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; placebo	2021-001075-17  AdvanTIG-205	A Phase 2, Randomized, Double-blind Study of Ociperlimab (BGB A1217) and Tislelizumab With Chemotherapy in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) Without Sensitizing EGFR or ALK Mutations Who Have Received No Previous Treatment for Metastatic Disease	Non Small Cell Lung Cancer	4814 - Douglas; 7250 - Launceston; - Wodonga; 3199 - Frankston	https://clinicaltrials.gov/ct2/show/NCT05014815
NCT05021120	AK127-101	Phase 0		VIC, NSW, SA	25/08/2021		AK104; AK127	bispecific_PD-1/CTLA-4_antibody; anti-TIGIT_monoclonal_antibody	AK104; AK127	anti-TIGIT_monoclonal_antibody; bispecific_PD-1/CTLA-4_antibody	AK127-101	A Phase 1a/1b, Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumour Activity of AK127 in Combination With AK104 in Subjects With Advanced or Metastatic Solid Tumours	Advanced or Metastatic Solid Tumours	- Melbourne; - Sydney; - Adelaide	https://clinicaltrials.gov/ct2/show/NCT05021120
NCT05029882	2023-509335-60-00--M21-404	Unknown		QLD, VIC	1/09/2021	13/10/2021	ABBV-400; ABBV-400 + Bevacizumab; Bevacizumab; Bevacizumab + Trifluridine/Tipiracil; Trifluridine/Tipiracil	anti-VEGF_monoclonal_antibody + antimetabolite; Tipiracil Hydrochloride + anti-VEGF_monoclonal_antibody; Tipiracil Hydrochloride; anti-VEGF_monoclonal_antibody + anti-cMET_antibody-drug_conjugate; Trifluridine; antimetabolite; anti-cMET_antibody-drug_conjugate; Trifluridine + anti-VEGF_monoclonal_antibody; thymidine_phosphorylase_inhibitor; anti-VEGF_monoclonal_antibody + thymidine_phosphorylase_inhibitor; anti-VEGF_monoclonal_antibody	ABBV-400; ABBV-400 + Bevacizumab; Bevacizumab + Trifluridine/Tipiracil; ABBV-400 + Bevacizumab; Bevacizumab + Trifluridine/Tipiracil	Tipiracil Hydrochloride + anti-VEGF_monoclonal_antibody; Trifluridine + anti-VEGF_monoclonal_antibody; anti-VEGF_monoclonal_antibody + anti-cMET_antibody-drug_conjugate; anti-VEGF_monoclonal_antibody + antimetabolite; anti-VEGF_monoclonal_antibody + thymidine_phosphorylase_inhibitor; anti-cMET_antibody-drug_conjugate; Tipiracil Hydrochloride + anti-VEGF_monoclonal_antibody; Trifluridine + anti-VEGF_monoclonal_antibody; anti-VEGF_monoclonal_antibody + anti-cMET_antibody-drug_conjugate; anti-VEGF_monoclonal_antibody + antimetabolite; anti-VEGF_monoclonal_antibody + thymidine_phosphorylase_inhibitor	2023-509335-60-00  M21-404	A Phase 1 First in Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-400 as Monotherapy and in Combination With Bevacizumab in Adult Subjects With Advanced Solid Tumors	Gastroesophageal Adenocarcinoma; Advanced Solid Tumors; Colorectal Cancer; Non-Small Cell Lung Cancer	3084 - Heidelberg; 4101 - South Brisbane	https://clinicaltrials.gov/ct2/show/NCT05029882
NCT05031494	YH003004	Phase 2		VIC	2/09/2021	8/12/2021	Gemcitabine; Gemcitabine + Nab-paclitaxel + Toripalimab + YH003; Nab-paclitaxel; Toripalimab; Toripalimab + YH003; YH003	anti-PD-1_monoclonal_antibody; anti-OX40_agonistic_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + taxane; antimetabolite; anti-OX40_agonistic_antibody; gemcitabine; taxane; anti-OX40_agonistic_antibody + anti-PD-1_monoclonal_antibody	Gemcitabine + Nab-paclitaxel + Toripalimab + YH003; Toripalimab + YH003; Gemcitabine + Nab-paclitaxel + Toripalimab + YH003; Toripalimab + YH003	anti-OX40_agonistic_antibody + anti-PD-1_monoclonal_antibody; anti-OX40_agonistic_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + taxane; anti-OX40_agonistic_antibody + anti-PD-1_monoclonal_antibody; anti-OX40_agonistic_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + taxane; gemcitabine	YH003004	A Multi-center, Open-label Phase II Study to Evaluate the Safety and Efficacy of YH003 in Combination With Toripalimab (Anti-PD-1 mAb) in Patients With Unresectable/Metastatic Melanoma and Pancreatic Ductal Adenocarcinoma (PDAC)	Pancreatic Ductal Adenocarcinoma; Melanoma	3121 - Richmond	https://clinicaltrials.gov/ct2/show/NCT05031494
NCT05040932	YH004002	Phase 1		VIC, NSW	10/09/2021	7/12/2021	Toripalimab; YH004	anti-PD-1_monoclonal_antibody; anti-4-1BB_agonistic_antibody	YH004; Toripalimab	anti-4-1BB_agonistic_antibody; anti-PD-1_monoclonal_antibody	YH004002	A First-In-Human, Multicenter, Open-Label, Phase I Dose Escalation Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of YH004 As A Single Agent And Combination With Toripalimab In Subjects With Advanced Solid Tumors And Relapsed Or Refractory Non-Hodgkin Lymphoma	Cancer	3144 - Malvern East; 2145 - Sydney; 2217 - Wollongong	https://clinicaltrials.gov/ct2/show/NCT05040932
NCT05041257	IMGN853419	Phase 2		VIC, NSW	13/09/2021	31/08/2021	Mirvetuximab Soravtansine	anti-FR-alpha_antibody-drug_conjugate	Mirvetuximab Soravtansine	anti-FR-alpha_antibody-drug_conjugate	IMGN853419	A Phase 2, Single Arm Study of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (PICCOLO)	Ovarian Cancer; Peritoneal Cancer; Fallopian Tube Cancer	3165 - Clayton; 2305 - New Lambton Heights; 3144 - Malvern	https://clinicaltrials.gov/ct2/show/NCT05041257
NCT05042128	ASCEND	Phase 2		SA, WA	13/09/2021		CEND-1; CEND-1 + Gemcitabine + Nab-paclitaxel; Gemcitabine; Gemcitabine + Nab-paclitaxel; Nab-paclitaxel; Paclitaxel; Placebo	tumor-homing_peptide_iRGD; placebo; antimetabolite; antimetabolite + taxane + tumor-homing_peptide_iRGD; gemcitabine; taxane; antimetabolite + taxane	CEND-1 + Gemcitabine + Nab-paclitaxel; Gemcitabine + Nab-paclitaxel; CEND-1 + Gemcitabine + Nab-paclitaxel; Gemcitabine + Nab-paclitaxel; Placebo	antimetabolite + taxane; antimetabolite + taxane + tumor-homing_peptide_iRGD; antimetabolite + taxane; antimetabolite + taxane + tumor-homing_peptide_iRGD; gemcitabine; placebo	CTC0304	A Randomised, Double-blinded Phase II Study of Gemcitabine and Nab-Paclitaxel With CEND-1 or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma	Pancreatic Ductal Adenocarcinoma; Metastatic Pancreatic Cancer	5011 - Woodville South; 6008 - Subiaco	https://clinicaltrials.gov/ct2/show/NCT05042128
NCT05043090	SAMETA	Phase 3		NSW, VIC	13/09/2021	28/10/2021	Durvalumab; Durvalumab + Savolitinib; Savolitinib; Sunitinib	MET_inhibitor,type_1 + anti-PD-L1_monoclonal_antibody; KIT_inhibitor,first_generation; VEGFR_inhibitor; anti-PD-L1_monoclonal_antibody; MET_inhibitor,type_1; PDGFR_inhibitor	Durvalumab; Durvalumab + Savolitinib; Sunitinib; Durvalumab + Savolitinib	KIT_inhibitor,first_generation; MET_inhibitor,type_1 + anti-PD-L1_monoclonal_antibody; PDGFR_inhibitor; VEGFR_inhibitor; anti-PD-L1_monoclonal_antibody; MET_inhibitor,type_1 + anti-PD-L1_monoclonal_antibody	2021-000336-55  D5086C00001	A Phase III, Open Label, Randomised, 3-Arm, Multi-Centre Study of Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic Papillary Renal Cell Carcinoma (SAMETA)	Papillary Renal Cell Carcinoma	3144 - Malvern; 2065 - St Leonards; 2145 - Westmead; 3128 - Box Hill	https://clinicaltrials.gov/ct2/show/NCT05043090
NCT05052801	FORTITUDE-101	Phase 3		WA, NSW	22/09/2021	7/03/2022	Bemarituzumab; Placebo	anti-FGFR2_monoclonal_antibody; placebo	Bemarituzumab; Placebo	anti-FGFR2_monoclonal_antibody; placebo	20210096	A Randomized, Multi-center, Double-blind, Placebo-controlled Phase 3 Study of Bemarituzumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer With FGFR2b Overexpression	Gastric Cancer; Gastroesophageal Junction Adenocarcinoma	2170 - Liverpool; 6150 - Murdoch	https://clinicaltrials.gov/ct2/show/NCT05052801
NCT05053854	PARLuNET	Phase 1		VIC	23/09/2021		Octreotate; Octreotate + Talazoparib; Talazoparib	PARP_inhibitor; PARP_inhibitor + radionuclide_therapy; radionuclide_therapy	Octreotate + Talazoparib; Octreotate + Talazoparib	PARP_inhibitor + radionuclide_therapy; PARP_inhibitor + radionuclide_therapy	PMC67199	Phase 1 Trial of PARP Inhibitor Combined With 177Lu-DOTA-Octreotate Peptide Receptor Radionuclide Therapy (PRRT) in Patients With Metastatic NeuroEndocrine Tumor	Neuroendocrine Tumors	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT05053854
NCT05054725	RMC-4630-03	Phase 2		NSW, VIC	23/09/2021	30/12/2021	RMC-4630; RMC-4630 + Sotorasib; Sotorasib	SHP2_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + SHP2_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor	RMC-4630 + Sotorasib; RMC-4630 + Sotorasib	KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + SHP2_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + SHP2_inhibitor	RMC-4630-03	A Phase 2, Open-Label, Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies	Non-Small Cell Lung Cancer	3630 - Shepparton; 2148 - Blacktown	https://clinicaltrials.gov/ct2/show/NCT05054725
NCT05059262	MOTION	Phase 3		NSW	28/09/2021	14/10/2021	Placebo; Vimseltinib	CSF1R_inhibitor; placebo	Vimseltinib; Placebo	CSF1R_inhibitor; placebo	DCC-3014-03-001	A Phase 3, Randomized, Placebo-controlled, Double-blind Study of Vimseltinib to Assess the Efficacy and Safety in Patients With Tenosynovial Giant Cell Tumor (MOTION)	Tenosynovial Giant Cell Tumor, Localized; Tenosynovial Giant Cell Tumor; Pigmented Villonodular Synovitis; Giant Cell Tumor of Tendon Sheath; Tenosynovial Giant Cell Tumor, Diffuse	- Camperdown	https://clinicaltrials.gov/ct2/show/NCT05059262
NCT05059522	2021-002457-29--B9991046	Phase 3		QLD	28/09/2021	29/09/2021	Avelumab; Avelumab + Axitinib; Avelumab + PF-04518600 + Utomilumab; Avelumab + Pemetrexed; Avelumab + Talazoparib; Axitinib; PF-04518600; Pemetrexed; Talazoparib; Utomilumab	PARP_inhibitor; PARP_inhibitor + anti-PD-L1_monoclonal_antibody; VEGFR/PDGFR_inhibitor; anti-PD-L1_monoclonal_antibody; KIT_inhibitor,ATP-competitive; anti-4-1BB_agonistic_antibody + anti-OX40_agonistic_antibody + anti-PD-L1_monoclonal_antibody; antimetabolite; KIT_inhibitor,ATP-competitive + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + antimetabolite; anti-OX40_agonistic_antibody; anti-4-1BB_agonistic_antibody; VEGFR/PDGFR_inhibitor + anti-PD-L1_monoclonal_antibody	Avelumab; Avelumab + Axitinib; Avelumab + PF-04518600 + Utomilumab; Avelumab + Pemetrexed; Avelumab + Talazoparib; Avelumab + Axitinib; Avelumab + PF-04518600 + Utomilumab; Avelumab + Pemetrexed; Avelumab + Talazoparib	KIT_inhibitor,ATP-competitive + anti-PD-L1_monoclonal_antibody; PARP_inhibitor + anti-PD-L1_monoclonal_antibody; VEGFR/PDGFR_inhibitor + anti-PD-L1_monoclonal_antibody; anti-4-1BB_agonistic_antibody + anti-OX40_agonistic_antibody + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + antimetabolite; KIT_inhibitor,ATP-competitive + anti-PD-L1_monoclonal_antibody; PARP_inhibitor + anti-PD-L1_monoclonal_antibody; VEGFR/PDGFR_inhibitor + anti-PD-L1_monoclonal_antibody; anti-4-1BB_agonistic_antibody + anti-OX40_agonistic_antibody + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + antimetabolite	2021-002457-29  B9991046	Avelumab Master Protocol: An Open-label Continuation Study for Participants Continuing From Pfizer-sponsored Avelumab Clinical Studies.	Ovarian Cancer; Solid Tumors; NSCLC; Urothelial Cancer; Advanced Malignancies	4032 - Chermside	https://clinicaltrials.gov/ct2/show/NCT05059522
NCT05061134	MONETTE	Phase 2		VIC	29/09/2021		Ceralasertib; Ceralasertib + Durvalumab; Durvalumab	ATR_inhibitor + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; ATR_inhibitor	Ceralasertib; Ceralasertib + Durvalumab; Ceralasertib + Durvalumab	ATR_inhibitor; ATR_inhibitor + anti-PD-L1_monoclonal_antibody; ATR_inhibitor + anti-PD-L1_monoclonal_antibody	D533AC00001	A Randomised, Open-Label, Phase 2 Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Unresectable or Advanced Melanoma and Primary or Secondary Resistance to PD-(L)1 Inhibition	Melanoma	3002 - East Melbourne; 4029 - Herston	https://clinicaltrials.gov/ct2/show/NCT05061134
NCT05061823	2021-000179-36--MS200647-0054	Unknown			30/09/2021	1/12/2021	Bintrafusp Alfa	anti-PD-L1/TGF-beta_fusion_protein	Bintrafusp Alfa	anti-PD-L1/TGF-beta_fusion_protein	2021-000179-36  MS200647_0054	An Open-label, Multicenter Follow-up Study to Collect Long-term Data on Participants From Multiple Bintrafusp Alfa (M7824) Clinical Studies	Cancer; Lung Cancer		https://clinicaltrials.gov/ct2/show/NCT05061823
NCT05064059	2021-001309-60--4280A-007	Phase 3		NSW, VIC, QLD	1/10/2021	10/11/2021	Favezelimab; Favezelimab + Pembrolizumab; Pembrolizumab; Regorafenib; Regorafenib + Trifluridine/Tipiracil; Trifluridine/Tipiracil	KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + Tipiracil Hydrochloride; Tipiracil Hydrochloride; anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody; Trifluridine; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + antimetabolite; antimetabolite; thymidine_phosphorylase_inhibitor; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + thymidine_phosphorylase_inhibitor; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + Trifluridine; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Favezelimab + Pembrolizumab; Regorafenib + Trifluridine/Tipiracil; Favezelimab + Pembrolizumab; Regorafenib + Trifluridine/Tipiracil	KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + Tipiracil Hydrochloride; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + Trifluridine; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + antimetabolite; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + thymidine_phosphorylase_inhibitor; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + Tipiracil Hydrochloride; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + Trifluridine; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + antimetabolite; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + thymidine_phosphorylase_inhibitor; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	2021-001309-60  4280A-007	A Phase 3 Study of MK-4280A (Coformulated Favezelimab [MK-4280] Plus Pembrolizumab [MK-3475]) Versus Standard of Care in Previously Treated Metastatic PD-L1 Positive Colorectal Cancer	Colorectal Cancer	4029 - Herston; 3199 - Frankston; 2145 - Westmead	https://clinicaltrials.gov/ct2/show/NCT05064059
NCT05067283	MK-1084-001--1084-001	Phase 1		NSW, VIC, NZ	5/10/2021	17/12/2021	MK-1084; MK-1084 + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody	MK-1084; MK-1084 + Pembrolizumab; MK-1084 + Pembrolizumab	KRAS_G12C_inhibitor; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody	MK-1084-001  1084-001	A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and in Combination With Pembrolizumab in Subjects With KRASG12C Mutant Advanced Solid Tumors	Advanced Solid Tumors	Canterbury; 3168 - Clayton; 2170 - Liverpool	https://clinicaltrials.gov/ct2/show/NCT05067283
NCT05073484	BAT-6021-002-CR	Phase 1		NSW	11/10/2021	29/10/2021	BAT6021	anti-TIGIT_monoclonal_antibody	BAT6021	anti-TIGIT_monoclonal_antibody	BAT-6021-002-CR	A Phase 1, Multi-Center, Open-Label Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BAT6021 as Mono Therapy or in Combination With BAT1308 in Patients With Advanced Solid Tumors	Advanced Solid Tumor	2170 - Liverpool	https://clinicaltrials.gov/ct2/show/NCT05073484
NCT05075577	EPI-7386-CS-010	Unknown		NSW, VIC	13/10/2021	21/12/2021	EPI-7386; EPI-7386 + Enzalutamide; Enzalutamide	antiandrogen,nonsteroidal,second_generation; antiandrogen,AR_NTD_inhibitor; antiandrogen,AR_NTD_inhibitor + antiandrogen,nonsteroidal,second_generation	EPI-7386 + Enzalutamide; Enzalutamide; EPI-7386 + Enzalutamide	antiandrogen,AR_NTD_inhibitor + antiandrogen,nonsteroidal,second_generation; antiandrogen,nonsteroidal,second_generation; antiandrogen,AR_NTD_inhibitor + antiandrogen,nonsteroidal,second_generation	EPI-7386-CS-010	A Phase 1/2 Study of EPI-7386 in Combination With Enzalutamide Compared With Enzalutamide Alone in Subjects With Metastatic Castration-Resistant Prostate Cancer	Prostate Cancer	2010 - Darlinghurst; 3128 - Box Hill	https://clinicaltrials.gov/ct2/show/NCT05075577
NCT05081609	IL-Believe	Phase 1/Phase 2		QLD	18/10/2021	11/01/2022	Pembrolizumab	anti-PD-1_monoclonal_antibody	Pembrolizumab	anti-PD-1_monoclonal_antibody	ASND0029	Phase 1/2, Open-label, Dose Escalation and Dose Expansion of TransCon IL-2 ß/? Alone or in Combination With Pembrolizumab or Standard of Care Chemotherapy in Participants Aged 18 Years or Older With Locally Advanced or Metastatic Solid Tumor Malignancies	Metastatic Solid Tumor; Locally Advanced Solid Tumor; Advanced Solid Tumor	4215 - Southport	https://clinicaltrials.gov/ct2/show/NCT05081609
NCT05082545	SHR-2002-I-102--SHR-2002-102	Phase 1		WA, NSW, QLD	19/10/2021	23/11/2021	SHR-1316; SHR-1316 + SHR-2002; SHR-2002	bispecific_CD112R/TIGIT_antibody; anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + bispecific_CD112R/TIGIT_antibody	SHR-1316 + SHR-2002; SHR-1316 + SHR-2002	anti-PD-L1_monoclonal_antibody + bispecific_CD112R/TIGIT_antibody; anti-PD-L1_monoclonal_antibody + bispecific_CD112R/TIGIT_antibody	SHR-2002-I-102  SHR-2002-102	A Phase I Clinical Study on the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SHR-2002 Injection in Combination With SHR-1316 in Patients With Advanced Malignant Tumors	Advanced Malignant Tumors	4101 - Brisbane; 2031 - Sydney; 6009 - Perth; 2170 - Sydney	https://clinicaltrials.gov/ct2/show/NCT05082545
NCT05084859	SM08502-ONC-03	Phase 1		QLD, NSW, SA	20/10/2021	3/11/2021	Abiraterone; Abiraterone + Prednisone + SM08502; Docetaxel; Docetaxel + SM08502; Panitumumab; Panitumumab + SM08502; Prednisone; SM08502	CLK_inhibitor + taxane; glucocorticoid; CLK_inhibitor + anti-EGFR_monoclonal_antibody; CLK_inhibitor; CYP17A1_inhibitor; anti-EGFR_monoclonal_antibody; taxane; CLK_inhibitor + CYP17A1_inhibitor + glucocorticoid	Abiraterone + Prednisone + SM08502; Docetaxel + SM08502; Panitumumab + SM08502; Abiraterone + Prednisone + SM08502; Docetaxel + SM08502; Panitumumab + SM08502	CLK_inhibitor + CYP17A1_inhibitor + glucocorticoid; CLK_inhibitor + anti-EGFR_monoclonal_antibody; CLK_inhibitor + taxane; CLK_inhibitor + CYP17A1_inhibitor + glucocorticoid; CLK_inhibitor + anti-EGFR_monoclonal_antibody; CLK_inhibitor + taxane	SM08502-ONC-03	A Phase 1b, Open-Label, Dose-Escalation, Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors	Non-small Cell Lung Cancer; Colorectal Cancer; Castration-resistant Prostate Cancer	5011 - Woodville South; 2050 - Camperdown; 2010 - Darlinghurst; 4215 - South Brisbane	https://clinicaltrials.gov/ct2/show/NCT05084859
NCT05086692	MDNA11-01	Phase 1/Phase 2		QLD, VIC, NSW	21/10/2021	27/08/2021	MDNA11	IL-2_superkine	MDNA11	IL-2_superkine	MDNA11-01	A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors	Cervical Cancer; Merkel Cell Carcinoma; Cutaneous Squamous Cell Carcinoma; Non-Small Cell Lung Cancer Squamous; Non-Small Cell Lung Cancer Non-squamous; Unresectable Solid Tumor; Biliary Tract Cancer; Cholangiocarcinoma; Ovarian Cancer; Triple Negative Breast Cancer; Gallbladder Cancer; Uterine Cancer; Bladder Cancer; Squamous Cell Carcinoma of Head and Neck; Melanoma; Basal Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Colorectal Cancer; Gastric Cancer; Renal Cell Carcinoma; Advanced Solid Tumor; Sarcoma	2031 - Randwick; 3144 - Malvern; 4101 - South Brisbane; 4120 - Greenslopes; 2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT05086692
NCT05089734	EVOKE-01	Phase 3		TAS, VIC, QLD	22/10/2021	17/11/2021	Docetaxel; Sacituzumab Govitecan	taxane; anti-Trop2_antibody-drug_conjugate	Docetaxel; Sacituzumab Govitecan	anti-Trop2_antibody-drug_conjugate; taxane	2021-003578-30  GS-US-577-6153	Open-Label, Global, Multicenter, Randomized, Phase 3 Study of Sacituzumab Govitecan Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy	Non-Small Cell Lung Cancer	7000 - Hobart; 4120 - Greenslopes; 3168 - Clayton	https://clinicaltrials.gov/ct2/show/NCT05089734
NCT05092360	ARTISTRY-7	Phase 3		QLD, SA	25/10/2021	10/01/2022	Gemcitabine; Gemcitabine + Paclitaxel + Pegylated liposomal doxorubicin + Topotecan; Nemvaleukin alfa; Paclitaxel; Pegylated liposomal doxorubicin; Pembrolizumab; Topotecan	anthracycline; anti-PD-1_monoclonal_antibody; antimetabolite; gemcitabine; taxane; topoisomerase_inhibitor; anthracycline + antimetabolite + taxane + topoisomerase_inhibitor; IL-2_fusion_protein	Gemcitabine + Paclitaxel + Pegylated liposomal doxorubicin + Topotecan; Pembrolizumab; Gemcitabine + Paclitaxel + Pegylated liposomal doxorubicin + Topotecan; Nemvaleukin alfa	anthracycline + antimetabolite + taxane + topoisomerase_inhibitor; anti-PD-1_monoclonal_antibody; IL-2_fusion_protein; anthracycline + antimetabolite + taxane + topoisomerase_inhibitor; gemcitabine	GOG-3063  ALKS 4230-007	A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARTISTRY-7)	Fallopian Tube Cancer; Platinum-resistant Ovarian Cancer; Primary Peritoneal Cancer	5000 - Adelaide; 4066 - South Brisbane	https://clinicaltrials.gov/ct2/show/NCT05092360
NCT05094336	MTAP	Phase 1/Phase 2		NSW	26/10/2021	1/02/2022	AMG 193; AMG 193 + Docetaxel + Pemetrexed; AMG 193 + Pemetrexed; Docetaxel; Pemetrexed	PRMT5_inhibitor + antimetabolite; PRMT5_inhibitor; taxane; antimetabolite; PRMT5_inhibitor + antimetabolite + taxane	AMG 193; AMG 193 + Docetaxel + Pemetrexed; AMG 193 + Pemetrexed; AMG 193 + Docetaxel + Pemetrexed; AMG 193 + Pemetrexed	PRMT5_inhibitor; PRMT5_inhibitor + antimetabolite; PRMT5_inhibitor + antimetabolite + taxane; PRMT5_inhibitor + antimetabolite; PRMT5_inhibitor + antimetabolite + taxane	20210023	A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 Alone and in Combination With Docetaxel in Subjects With Advanced MTAP-null Solid Tumors	Advanced MTAP-null Solid Tumors	2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT05094336
NCT05102214	HLX301-001	Phase 1/Phase 2		NSW, VIC, QLD, SA	1/11/2021		HLX301	bispecific_PD-L1/TIGIT_antibody	HLX301	bispecific_PD-L1/TIGIT_antibody	HLX301-001	A Phase 1/2 Study of HLX301, A Recombinant Humanized Anti-PDL1 and Anti-TIGIT Bispecific Antibody, in Patients With Locally Advanced or Metastatic Solid Tumors	Non-small Cell Lung Cancer; Locally Advanced or Metastatic Solid Tumors	- Adelaide; 4575 - Birtinya; - Camperdown; - Blacktown; - Brighton	https://clinicaltrials.gov/ct2/show/NCT05102214
NCT05109650	BAT-6026-002-CR	Phase 1		NSW	5/11/2021	15/11/2021	BAT6026	anti-OX40_agonistic_antibody	BAT6026	anti-OX40_agonistic_antibody	BAT-6026-002-CR	A Phase 1, Multi-Center, Open-Label Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BAT6026 as Monotherapy and in Combination With BAT1308 in Patients With Advanced Solid Tumours	Advanced Solid Tumour	- Sydney; - Kogarah	https://clinicaltrials.gov/ct2/show/NCT05109650
NCT05111626	FORTITUDE-102	Phase 3		SA	8/11/2021	14/03/2022	Bemarituzumab; Bemarituzumab + Nivolumab; Nivolumab; Placebo	anti-PD-1_monoclonal_antibody; anti-FGFR2_monoclonal_antibody; anti-FGFR2_monoclonal_antibody + anti-PD-1_monoclonal_antibody; placebo	Bemarituzumab + Nivolumab; Nivolumab; Bemarituzumab + Nivolumab; Placebo	anti-FGFR2_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-FGFR2_monoclonal_antibody + anti-PD-1_monoclonal_antibody; placebo	20210098	A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression	Gastric Cancer; Gastroesophageal Junction Adenocarcinoma	5011 - Woodville South	https://clinicaltrials.gov/ct2/show/NCT05111626
NCT05116189	MK-3475-B96--3475-B96	Phase 3		VIC, NSW, QLD	10/11/2021	13/12/2021	Bevacizumab; Bevacizumab + Docetaxel + Paclitaxel; Bevacizumab + Docetaxel + Paclitaxel + Pembrolizumab; Docetaxel; Paclitaxel; Pembrolizumab; Placebo	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + taxane; placebo; anti-VEGF_monoclonal_antibody + taxane; anti-VEGF_monoclonal_antibody; taxane	Bevacizumab + Docetaxel + Paclitaxel; Bevacizumab + Docetaxel + Paclitaxel + Pembrolizumab; Bevacizumab + Docetaxel + Paclitaxel; Bevacizumab + Docetaxel + Paclitaxel + Pembrolizumab; Placebo	anti-PD-1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + taxane; anti-VEGF_monoclonal_antibody + taxane; anti-PD-1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + taxane; anti-VEGF_monoclonal_antibody + taxane; placebo	MK-3475-B96  3475-B96	A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Versus Placebo in Combination With Paclitaxel With or Without Bevacizumab for the Treatment of Platinum-resistant Recurrent Ovarian Cancer (KEYNOTE-B96/ENGOT-ov65)	Fallopian Tube Neoplasms; Carcinoma, Ovarian Epithelial; Ovarian Cancer	2145 - Westmead; 3002 - Melbourne; 4120 - Brisbane	https://clinicaltrials.gov/ct2/show/NCT05116189
NCT05116202	BO43328	Phase 1/Phase 2	*PAUSED	WA, NSW	10/11/2021		Atezolizumab; Atezolizumab + Tiragolumab; Ipilimumab; Ipilimumab + Nivolumab; Nivolumab; RO7247669; RO7247669 + Tiragolumab; Tiragolumab	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-TIGIT_monoclonal_antibody; bispecific_PD-1/LAG3_antibody; anti-TIGIT_monoclonal_antibody + bispecific_PD-1/LAG3_antibody; anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody	Atezolizumab + Tiragolumab; Ipilimumab + Nivolumab; RO7247669; RO7247669 + Tiragolumab; Atezolizumab + Tiragolumab; Ipilimumab + Nivolumab; RO7247669 + Tiragolumab	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-TIGIT_monoclonal_antibody + bispecific_PD-1/LAG3_antibody; bispecific_PD-1/LAG3_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-TIGIT_monoclonal_antibody + bispecific_PD-1/LAG3_antibody	BO43328	A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)	Melanoma	2060 - North Sydney; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT05116202
NCT05117476	CLN-619-001	Phase 1		WA	11/11/2021	29/10/2021	CLN-619; CLN-619 + Pembrolizumab; Pembrolizumab	anti-MICA/MICB_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-MICA/MICB_monoclonal_antibody	CLN-619; CLN-619 + Pembrolizumab; CLN-619 + Pembrolizumab	anti-MICA/MICB_monoclonal_antibody; anti-MICA/MICB_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-MICA/MICB_monoclonal_antibody + anti-PD-1_monoclonal_antibody	CLN-619-001	A Phase 1 Dose-Escalation Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamic Activity of CLN-619 (Anti-MICA/MICB Antibody) Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors	Advanced Solid Tumor	6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT05117476
NCT05118789	NVL-520-01	Phase 1/Phase 2		VIC	12/11/2021	4/01/2022	NVL-520; Tegafur-gimeracil-oteracil pPotassium	ROS1_inhibitor; DPD_inhibitor; antimetabolite; orotate_phosphoribosyltransferase_inhibitor	NVL-520; Tegafur-gimeracil-oteracil pPotassium	ROS1_inhibitor; DPD_inhibitor; antimetabolite; orotate_phosphoribosyltransferase_inhibitor	NVL-520-01	A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors (ARROS-1)	Locally Advanced Solid Tumor; Metastatic Solid Tumor	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT05118789
NCT05123482	D6900C00001	Phase 1/Phase 2		VIC	17/11/2021	18/10/2021	AZD8205	anti-B7H4_antibody-drug_conjugate	AZD8205	anti-B7H4_antibody-drug_conjugate	D6900C00001	A Phase I/IIa Multi-center, Open-label Master Protocol to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Antitumor Activity of AZD8205 in Participants With Advanced or Metastatic Solid Malignancies	Endometrial Cancer; Cholangiocarcinoma; Ovarian Cancer; Breast Cancer	VIC 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT05123482
NCT05128825	ZN-c3-005	Unknown		SA, QLD	22/11/2021	17/02/2022	Azenosertib	WEE1_inhibitor	Azenosertib	WEE1_inhibitor	ZN-c3-005	A Phase 2 Open-Label, Multicenter Study To Evaluate Efficacy And Safety Of ZN-c3 In Subjects With High-Grade Serous Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer (ZN-c3-005/GOG-3066/DENALI)	High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer	5065 - Toorak Gardens; 4032 - Brisbane; 5037 - Adelaide; 4101 - South Brisbane	https://clinicaltrials.gov/ct2/show/NCT05128825
NCT05129280	2021-000624-35--BE43244	Phase 1		VIC	22/11/2021	25/01/2022	RO7444973; Tocilizumab	bispecific_T-cell_engager,MAGE-A4-targeting; anti-IL-6_monoclonal_antibody	RO7444973; Tocilizumab	bispecific_T-cell_engager,MAGE-A4-targeting; anti-IL-6_monoclonal_antibody	2021-000624-35  BE43244	An Open-label, Multicenter, Phase I Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid Tumors	Solid Tumors	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT05129280
NCT05132075	KontRASt-02	Unknown		QLD	24/11/2021	15/06/2022	Docetaxel; JDQ443	KRAS_G12C_inhibitor; taxane	Docetaxel; JDQ443	KRAS_G12C_inhibitor; taxane	2021-002605-10  CJDQ443B12301	A Randomized, Controlled, Open Label, Phase III Study Evaluating the Efficacy and Safety of JDQ443 Versus Docetaxel in Previously Treated Subjects With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer	Non-Small Cell Lung Cancer	4215 - Southport; 4812 - Hyde Park; 4066 - Auchenflower; 4101 - South Brisbane	https://clinicaltrials.gov/ct2/show/NCT05132075
NCT05132582	HER2CLIMB-05	Phase 3		Othe, VIC	24/11/2021	7/03/2022	Pertuzumab; Pertuzumab + Trastuzumab; Pertuzumab + Trastuzumab + Tucatinib; Placebo; Trastuzumab; Tucatinib	ERBB2_inhibitor,third_generation + anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; placebo; anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; anti-ERBB2_monoclonal_antibody; ERBB2_inhibitor,third_generation; anti-ERBB2_monoclonal_antibody,dimerization_inhibitor	Pertuzumab + Trastuzumab; Pertuzumab + Trastuzumab + Tucatinib; Pertuzumab + Trastuzumab; Pertuzumab + Trastuzumab + Tucatinib; Placebo	ERBB2_inhibitor,third_generation + anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; ERBB2_inhibitor,third_generation + anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; placebo	SGNTUC-028	A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05)	HER2 Positive Breast Cancer	3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT05132582
NCT05150236	EVOLUTION	Phase 2		WA, SA, NSW, VIC, QLD	9/12/2021		Ipilimumab; Ipilimumab + Lu-177 vipivotide tetraxetan + Nivolumab; Lu-177 vipivotide tetraxetan; Nivolumab	anti-CTLA-4_monoclonal_antibody; radioligand,PSMA-targeting; anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + radioligand,PSMA-targeting	Ipilimumab + Lu-177 vipivotide tetraxetan + Nivolumab; Lu-177 vipivotide tetraxetan; Ipilimumab + Lu-177 vipivotide tetraxetan + Nivolumab	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + radioligand,PSMA-targeting; radioligand,PSMA-targeting; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + radioligand,PSMA-targeting	ANZUP 2001	Phase II Study of Radionuclide 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With MetastaticCastration Resistant Prostate Cancer (mCRPC)	Genital Neoplasms, Male; Neoplasms by Site; Neoplasms; Prostatic Disease; Prostate Cancer; Urogenital Neoplasms; Prostatic Neoplasms	4029 - Herston; 6009 - Nedlands; 6150 - Perth; 3084 - Heidelberg; 5000 - Adelaide; 3000 - Melbourne; 2010 - Darlinghurst; 3004 - Melbourne; 2298 - Newcastle; 2076 - Wahroonga	https://clinicaltrials.gov/ct2/show/NCT05150236
NCT05150457	BNA035-101	Phase 1		NSW	9/12/2021		BNA35	bispecific_EGFR/4-1BB_antibody	BNA35	bispecific_EGFR/4-1BB_antibody	BNA035-101	A Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BNA035 in Patients With Advanced Solid Tumors	Refractory Solid Tumors	2217 - Kogarah	https://clinicaltrials.gov/ct2/show/NCT05150457
NCT05150691	DB-1303-O-1001	Phase 1/Phase 2		QLD	9/12/2021	31/01/2022	DB-1303	anti-ERBB2_antibody-drug_conjugate	DB-1303	anti-ERBB2_antibody-drug_conjugate	DB-1303-O-1001	A Phase 1/2a, Multicenter, Open-Label, Non-Randomized First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1303 in Patients With Advanced/Metastatic Solid Tumors	HER2-positive Advanced Solid Tumor	4101 - South Brisbane	https://clinicaltrials.gov/ct2/show/NCT05150691
NCT05152147	HERIZON-GEA-01	Phase 3		SA, VIC, NSW, WA	9/12/2021	2/12/2021	Capecitabine; Capecitabine + Cisplatin + Fluorouracil + Oxaliplatin + Trastuzumab; Cisplatin; Fluorouracil; Oxaliplatin; Tislelizumab; Tislelizumab + Zanidatamab; Trastuzumab; Zanidatamab	anti-PD-1_monoclonal_antibody + bispecific_ERBB2/ERBB2_antibody; anti-ERBB2_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; Fluorouracil; anti-ERBB2_monoclonal_antibody; bispecific_ERBB2/ERBB2_antibody; fluoropyrimidine	Capecitabine + Cisplatin + Fluorouracil + Oxaliplatin + Trastuzumab; Tislelizumab + Zanidatamab; Zanidatamab; Capecitabine + Cisplatin + Fluorouracil + Oxaliplatin + Trastuzumab; Tislelizumab + Zanidatamab	anti-ERBB2_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + bispecific_ERBB2/ERBB2_antibody; bispecific_ERBB2/ERBB2_antibody; Fluorouracil; anti-ERBB2_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + bispecific_ERBB2/ERBB2_antibody	2021-000296-36  ZWI-ZW25-301	A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination With Chemotherapy With or Without Tislelizumab in Subjects With HER2-positive Unresectable Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GEA)	Gastroesophageal Adenocarcinoma; Esophageal Adenocarcinoma; Gastric Neoplasms	- Bedford Park; 2640 - Albury; 3084 - Heidelberg; 6150 - Murdoch; - Liverpool	https://clinicaltrials.gov/ct2/show/NCT05152147
NCT05153239	PM1183-C-008-21	Phase 3		VIC, NSW	10/12/2021	22/07/2022	Irinotecan; Irinotecan + Lurbinectedin; Lurbinectedin; Topotecan	DNA_minor_groove-binding_agent; DNA_minor_groove-binding_agent + topoisomerase_inhibitor; topoisomerase_inhibitor	Irinotecan + Lurbinectedin; Lurbinectedin; Irinotecan + Lurbinectedin; Topotecan	DNA_minor_groove-binding_agent; DNA_minor_groove-binding_agent + topoisomerase_inhibitor; DNA_minor_groove-binding_agent + topoisomerase_inhibitor	PM1183-C-008-21	A Randomized, Multicenter, Open-label, Phase III Study of Lurbinectedin Single-Agent or Lurbinectedin in Combination With Irinotecan Versus Investigator's Choice (Topotecan or Irinotecan) in Relapsed Small Cell Lung Cancer Patients (LAGOON Trial)	Relapsed Small Cell Lung Cancer	3128 - Box Hill; 3350 - Ballarat Central; 2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT05153239
NCT05155254	KEYNOTE-D18	Phase 3		NSW	13/12/2021	21/12/2021	IO102-IO103; IO102-IO103 + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; immune-modulatory_vaccine,IDO/PD-L1-targeting; anti-PD-1_monoclonal_antibody + immune-modulatory_vaccine,IDO/PD-L1-targeting	IO102-IO103 + Pembrolizumab; Pembrolizumab; IO102-IO103 + Pembrolizumab	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + immune-modulatory_vaccine,IDO/PD-L1-targeting; anti-PD-1_monoclonal_antibody + immune-modulatory_vaccine,IDO/PD-L1-targeting	2021-004594-32  IO102-IO103-013 / KEYNOTE-D18	An Open-label, Randomized, Phase 3 Clinical Trial of IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Patients With Previously Untreated, Unresectable, or Metastatic (Advanced) Melanoma (IO102-IO103-013 / MK3475-D18)	Metastatic Melanoma; Unresectable Melanoma	2500 - Wollongong	https://clinicaltrials.gov/ct2/show/NCT05155254
NCT05156892	TICTOC	Phase 1		NSW	14/12/2021		Itraconazole; Itraconazole + Tamoxifen; Tamoxifen	selective_estrogen_receptor_modulator; SMO_inhibitor + selective_estrogen_receptor_modulator; SMO_inhibitor	Itraconazole + Tamoxifen; Itraconazole + Tamoxifen	SMO_inhibitor + selective_estrogen_receptor_modulator; SMO_inhibitor + selective_estrogen_receptor_modulator	TICTOC	A Phase I/II Trial Investigating the Tolerability, Toxicity and Efficacy of Tamoxifen and SUBA-Itraconazole in Patients With Platinum Resistant Recurrent Epithelial Ovarian Cancer	Ovarian Cancer	2010 - Sydney	https://clinicaltrials.gov/ct2/show/NCT05156892
NCT05159388	2019-003456-36--CL1-95012-001	Phase 1/Phase 2		NSW, SA	16/12/2021	8/09/2021	Dexamethasone; PRS-344	bispecific_PD-L1/4-1BB_antibody; glucocorticoid	PRS-344; Dexamethasone	bispecific_PD-L1/4-1BB_antibody; glucocorticoid	2019-003456-36  CL1-95012-001	A First in Human Phase 1-2 Open-Label, Multicenter, Dose Escalation and Expansion Study of PRS-344/S095012 in Patients With Solid Tumors	Solid Tumor	- Woodville South; - Camperdown	https://clinicaltrials.gov/ct2/show/NCT05159388
NCT05166577	VT3996-301	Phase 1/Phase 2		NSW	22/12/2021	7/10/2021	Nanatinostat; Nanatinostat + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; HDAC_inhibitor,class_1_selective; HDAC_inhibitor,class_1_selective + anti-PD-1_monoclonal_antibody	Nanatinostat; Nanatinostat + Pembrolizumab; Nanatinostat + Pembrolizumab	HDAC_inhibitor,class_1_selective; HDAC_inhibitor,class_1_selective + anti-PD-1_monoclonal_antibody; HDAC_inhibitor,class_1_selective + anti-PD-1_monoclonal_antibody	VT3996-301	An Open-Label, Multicenter Phase 1b/2 Study of Nanatinostat and Valganciclovir in Patients With Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors and in Combination With Pembrolizumab in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma	EBV Related Carcinoma; EBV-Related Gastric Carcinoma; EBV-Related Sarcoma; Nasopharyngeal Carcinoma; EBV-Related Leiomyosarcoma	2148 - Blacktown	https://clinicaltrials.gov/ct2/show/NCT05166577
NCT05169684	2021-003990-74--CA022-009	Phase 2		SA, NSW, VIC	27/12/2021	14/02/2022	BMS-986218; BMS-986218 + Docetaxel; BMS-986218 + Docetaxel + Nivolumab; BMS-986218 + Nivolumab; Docetaxel; Nivolumab	anti-CTLA-4_monoclonal_antibody + taxane; anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + taxane; taxane	BMS-986218 + Docetaxel; BMS-986218 + Docetaxel + Nivolumab; BMS-986218 + Nivolumab; Docetaxel; BMS-986218 + Docetaxel; BMS-986218 + Docetaxel + Nivolumab; BMS-986218 + Nivolumab	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + taxane; anti-CTLA-4_monoclonal_antibody + taxane; taxane; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + taxane; anti-CTLA-4_monoclonal_antibody + taxane	2021-003990-74  CA022-009	A Phase 2, Open-label, Randomized Controlled Trial of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer	Prostatic Neoplasms, Castration-Resistant	5112 - Elizabeth Vale; 2010 - Darlinghurst; 3084 - Heidleberg	https://clinicaltrials.gov/ct2/show/NCT05169684
NCT05169697	YH002004	Phase 1		NSW, VIC	27/12/2021	21/02/2022	YH001; YH001 + YH002; YH002	anti-CTLA-4_monoclonal_antibody; anti-OX40_agonistic_antibody; anti-CTLA-4_monoclonal_antibody + anti-OX40_agonistic_antibody	YH001 + YH002; YH001 + YH002	anti-CTLA-4_monoclonal_antibody + anti-OX40_agonistic_antibody; anti-CTLA-4_monoclonal_antibody + anti-OX40_agonistic_antibody	YH002004	A Multicenter, Open-label, Phase I Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of YH002 in Combination With YH001 in Subjects With Advanced Solid Tumors	Advanced Solid Tumor	2109 - Sydney; 3144 - Malvern; 3199 - Frankston; 2800 - Orange	https://clinicaltrials.gov/ct2/show/NCT05169697
NCT05173987	MK-3475-C93--3475-C93	Phase 3		NSW, VIC	30/12/2021	3/02/2022	Carboplatin; Carboplatin + Cisplatin + Docetaxel + Paclitaxel; Cisplatin; Docetaxel; Paclitaxel; Pembrolizumab	anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; taxane; platinum-based_antineoplastic_agent + taxane	Carboplatin + Cisplatin + Docetaxel + Paclitaxel; Pembrolizumab; Carboplatin + Cisplatin + Docetaxel + Paclitaxel	anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent + taxane; platinum-based_antineoplastic_agent + taxane	MK-3475-C93  3475-C93	A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab Versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting (KEYNOTE-C93/GOG-3064/ENGOT-en15)	Endometrial Neoplasms	2065 - St Leonards; 3168 - Clayton; 2145 - Westmead; 3002 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT05173987
NCT05176483	STELLAR-002	Phase 1		QLD	4/01/2022	14/12/2021	Ipilimumab; Ipilimumab + Nivolumab + Zanzalintinib; Nivolumab; Nivolumab + Relatlimab + Zanzalintinib; Nivolumab + Zanzalintinib; Relatlimab; Zanzalintinib	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody; MET/VEGFR2/AXL/MER_inhibitor; MET/VEGFR2/AXL/MER_inhibitor + anti-PD-1_monoclonal_antibody; MET/VEGFR2/AXL/MER_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; MET/VEGFR2/AXL/MER_inhibitor + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Ipilimumab + Nivolumab + Zanzalintinib; Nivolumab + Relatlimab + Zanzalintinib; Nivolumab + Zanzalintinib; Zanzalintinib; Ipilimumab + Nivolumab + Zanzalintinib; Nivolumab + Relatlimab + Zanzalintinib; Nivolumab + Zanzalintinib	MET/VEGFR2/AXL/MER_inhibitor; MET/VEGFR2/AXL/MER_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; MET/VEGFR2/AXL/MER_inhibitor + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; MET/VEGFR2/AXL/MER_inhibitor + anti-PD-1_monoclonal_antibody; MET/VEGFR2/AXL/MER_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; MET/VEGFR2/AXL/MER_inhibitor + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; MET/VEGFR2/AXL/MER_inhibitor + anti-PD-1_monoclonal_antibody	XL092-002	A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination With Immuno-Oncology Agents in Subjects With Unresectable Advanced or Metastatic Solid Tumors	Non-small Cell Lung Cancer; Renal Cell Carcinoma; Colorectal Cancer; Solid Tumor; Head and Neck Squamous Cell Carcinoma; Hepatocellular Carcinoma; Metastatic Castration-resistant Prostate Cancer; Urothelial Carcinoma	4102 - Brisbane	https://clinicaltrials.gov/ct2/show/NCT05176483
NCT05176509	YH003005	Phase 1		VIC, NSW	4/01/2022	5/04/2022	Pembrolizumab; YH001; YH003	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-OX40_agonistic_antibody	Pembrolizumab; YH001; YH003	anti-CTLA-4_monoclonal_antibody; anti-OX40_agonistic_antibody; anti-PD-1_monoclonal_antibody	YH003005	A Multicenter, Open-Label, Phase I Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of the Combination of YH003, YH001 and Pembrolizumab in Subjects With Advanced Solid Tumors	Solid Tumor	2148 - Blacktown; - Melbourne; 2217 - Kogarah; - Prahran	https://clinicaltrials.gov/ct2/show/NCT05176509
NCT05180799	BA3071-001	Phase 1/Phase 2		SA, NSW	6/01/2022	3/08/2022	BA3071; Nivolumab	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody	BA3071; Nivolumab	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody	BA3071-001	A Phase 1/2 Study of BA3071 in Combination With Nivolumab in Patients With Advanced Solid Tumors	Small Cell Lung Cancer; Solid Tumor, Adult; Renal Cell Carcinoma; Gastric Cancer; Melanoma; Hepatocellular Carcinoma; Cervical Carcinoma; NSCLC; Urothelial Carcinoma	5000 - Adelaide; 2228 - Miranda	https://clinicaltrials.gov/ct2/show/NCT05180799
NCT05182931	I-FIRST	Phase 2		WA, VIC, NSW, QLD	10/01/2022		Dabrafenib; Trametinib	MEK_inhibitor; BRAF_V600_inhibitor	Dabrafenib; Trametinib	BRAF_V600_inhibitor; MEK_inhibitor	ONJ2021-006	A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study)	Thyroid Cancer	3168 - Clayton; - Perth; - Melbourne; 3084 - Heidelberg; - Prahran; 4029 - Brisbane; - Sydney; 3128 - Box Hill	https://clinicaltrials.gov/ct2/show/NCT05182931
NCT05186974	EVOKE-02	Phase 2		SA, NSW	11/01/2022	30/05/2022	Carboplatin; Carboplatin + Cisplatin + Pembrolizumab; Carboplatin + Pembrolizumab; Cisplatin; Cisplatin + Pembrolizumab; Pembrolizumab; Pembrolizumab + Sacituzumab Govitecan; Sacituzumab Govitecan	anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent; anti-Trop2_antibody-drug_conjugate	Carboplatin + Cisplatin + Pembrolizumab; Carboplatin + Pembrolizumab; Cisplatin + Pembrolizumab; Pembrolizumab; Pembrolizumab + Sacituzumab Govitecan; Carboplatin + Cisplatin + Pembrolizumab; Carboplatin + Pembrolizumab; Cisplatin + Pembrolizumab; Pembrolizumab + Sacituzumab Govitecan	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent	2021-004280-27  GS-US-576-6220	An Open-label, Multicenter, Phase 2 Study of Sacituzumab Govitecan Combinations in First-line Treatment of Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) Without Actionable Genomic Alterations	Non-small Cell Lung Cancer	5087 - Windsor Gardens; 2576 - Bowral	https://clinicaltrials.gov/ct2/show/NCT05186974
NCT05187624	2021-001197-37--BP42573	Phase 1	NOT_RECRUITING	VIC	12/01/2022	5/04/2022	RO7428731	bispecific_T-cell_engager,EGFRvIII-targeting	RO7428731	bispecific_T-cell_engager,EGFRvIII-targeting	2021-001197-37  BP42573	An Open-label, Multicenter, Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of RO7428731 in Participants With Glioblastoma Expressing Mutant Epidermal Growth Factor Receptor Variant III	Glioblastoma	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT05187624
NCT05188664	LM302-01-201	Phase 1/Phase 2		NSW	12/01/2022	10/05/2022	LM-302; LM-302 + Toripalimab; Toripalimab	anti-PD-1_monoclonal_antibody; anti-CDLN18.2_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody; anti-CDLN18.2_antibody-drug_conjugate	LM-302; LM-302 + Toripalimab; LM-302 + Toripalimab	anti-CDLN18.2_antibody-drug_conjugate; anti-CDLN18.2_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody; anti-CDLN18.2_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody	LM302-01-201	A Phase I/II, Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM- 302 in Combination With Toripalimab in Patients With Advanced Solid Tumors	Advanced Solid Tumor	- Sydney	https://clinicaltrials.gov/ct2/show/NCT05188664
NCT05198752	SWP1001-06	Phase 1		VIC, QLD	20/01/2022	18/03/2022	SW1115C3	mRNA_personalised_cancer_vaccine	SW1115C3	mRNA_personalised_cancer_vaccine	SWP1001-06	A Phase 1 Clinical Study to Evaluate the Tolerability, Safety,Immunogenicity and Efficacy of the Neoantigen mRNA Personalised Cancer Vaccine SW1115C3 in Patients With Advanced Malignant Solid Tumours	Solid Tumor	- Benowa; - Frankston	https://clinicaltrials.gov/ct2/show/NCT05198752
NCT05198934	CodeBreak-300	Phase 3		NSW	20/01/2022	19/04/2022	Panitumumab; Panitumumab + Sotorasib; Regorafenib; Sotorasib	KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor; anti-EGFR_monoclonal_antibody; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody	Panitumumab + Sotorasib; Regorafenib; Panitumumab + Sotorasib	KIT/PDGFR/RET/VEGFR/FGFR_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody	20190172	A Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib and Panitumumab Versus Investigator's Choice (Trifluridine and Tipiracil, or Regorafenib) for the Treatment of Previously Treated Metastatic Colorectal Cancer Subjects With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation	Colorectal Cancer (CRC)	2065 - St Leonards	https://clinicaltrials.gov/ct2/show/NCT05198934
NCT05199753	LM108-01-101	Phase 1/Phase 2		WA, SA, QLD, NSW, VIC	20/01/2022		LM-108	anti-CCR8_monoclonal_antibody	LM-108	anti-CCR8_monoclonal_antibody	LM108-01-101	A Phase I/II, First-in-Human (FIH), Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-108 as a Single Agent or in Combination With Anti-PD-1 Antibody in Subjects With Advanced Solid Tumours	Advanced Solid Tumor	QLD 4101 - South Brisbane; VIC 3004 - Melbourne; NSW 2148 - Sydney; SA 5042 - Bedford Park; WA 6009 - Nedlands; VIC 3144 - Malvern	https://clinicaltrials.gov/ct2/show/NCT05199753
NCT05200013	BAT-7104-002-CR	Phase 1		NSW	20/01/2022		BAT7104	bispecific_PD-L1/CD47_antibody	BAT7104	bispecific_PD-L1/CD47_antibody	BAT-7104-002-CR	A Phase 1, Multi-Center, Open-Label Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BAT7104 in Patients With Advanced Solid Tumours	Patients With Advanced Solid Tumors	2109 - Sydney	https://clinicaltrials.gov/ct2/show/NCT05200013
NCT05200273	AK114-102	Phase 1		SA	20/01/2022		AK114	anti-IL-1beta_monoclonal_antibody	AK114	anti-IL-1beta_monoclonal_antibody	AK114-102	A Phase 1a, Multicenter, Open-label, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK114 in Subjects With Advanced or Metastatic Solid Tumors	Malignancy; Metastasis; Advanced or Metastatic Solid Tumors	- Kurralta Park	https://clinicaltrials.gov/ct2/show/NCT05200273
NCT05201547	DOMENICA	Unknown		ACT, NSW	21/01/2022	15/04/2022	Carboplatin; Carboplatin + Paclitaxel; Dostarlimab; Paclitaxel	anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; taxane; platinum-based_antineoplastic_agent + taxane	Carboplatin + Paclitaxel; Dostarlimab; Carboplatin + Paclitaxel	anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent + taxane; platinum-based_antineoplastic_agent + taxane	GINECO-EN105b	Randomized Phase III Trial in MMR Deficient Endometrial Cancer Patients Comparing Chemotherapy Alone Versus Dostarlimab in First Line Advanced/Metastatic Setting	Endometrial Cancer	2298 - Waratah; 2605 - Garran	https://clinicaltrials.gov/ct2/show/NCT05201547
NCT05205109	ATG-037-001	Phase 1		WA, SA, VIC, QLD	24/01/2022		ATG 037; Pembrolizumab	CD73_inhibitor; anti-PD-1_monoclonal_antibody	ATG 037; Pembrolizumab	CD73_inhibitor; anti-PD-1_monoclonal_antibody	ATG-037-001	A Phase I, Multi-center, Open-label, and Dose-finding Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG 037 Monotherapy and Combination Therapy With Pembrolizumab in Patients With Locally Advanced or Metastatic Solid Tumors	Locally Advanced or Metastatic Solid Tumors	4217 - Benowa; WA6153 - Mount Pleasant; 3199 - Frankston; 5042 - Bedford Park	https://clinicaltrials.gov/ct2/show/NCT05205109
NCT05208944	THIO-101	Phase 2		SA, QLD	26/01/2022	8/06/2022	Cemiplimab	anti-PD-1_monoclonal_antibody	Cemiplimab	anti-PD-1_monoclonal_antibody	THIO-101	A Multicenter, Open-Label, Dose-Finding, Phase 2 Study Evaluating THIO Sequenced With Cemiplimab (LIBTAYO®) in Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC)	Carcinoma, Non-Small-Cell Lung	4556 - Buderim; 5000 - Adelaide	https://clinicaltrials.gov/ct2/show/NCT05208944
NCT05212922	YH001	Phase 2		NSW, VIC	28/01/2022		Toripalimab; Toripalimab + YH001; YH001	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Toripalimab + YH001; Toripalimab + YH001	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	YH001004	An Open-Label, Non-Randomized, Multi-center Phase 2 Study of YH001 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC) and Hepatocellular Carcinoma (HCC)	HCC; NSCLC Stage IIIB; NSCLC Stage IV	2170 - Liverpool; 3220 - Geelong	https://clinicaltrials.gov/ct2/show/NCT05212922
NCT05215340	TROPION-Lung08	Phase 3		VIC	31/01/2022	4/03/2022	Datopotamab deruxtecan; Datopotamab deruxtecan + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody; anti-Trop2_antibody-drug_conjugate	Datopotamab deruxtecan + Pembrolizumab; Pembrolizumab; Datopotamab deruxtecan + Pembrolizumab	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate	2021-002555-10  DS1062-A-U304	A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects With Advanced or Metastatic PD-L1 High (TPS =50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)	Metastatic Non Small Cell Lung Cancer	3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT05215340
NCT05217446	SEAMARK	Phase 2		QLD	1/02/2022		Cetuximab; Cetuximab + Encorafenib + Pembrolizumab; Encorafenib; Pembrolizumab	BRAF_V600_inhibitor + anti-EGFR_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-EGFR_monoclonal_antibody; BRAF_V600_inhibitor	Cetuximab + Encorafenib + Pembrolizumab; Pembrolizumab; Cetuximab + Encorafenib + Pembrolizumab	BRAF_V600_inhibitor + anti-EGFR_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; BRAF_V600_inhibitor + anti-EGFR_monoclonal_antibody + anti-PD-1_monoclonal_antibody	2021-003715-26  C4221022	A PHASE 2, RANDOMIZED, OPEN-LABEL STUDY OF ENCORAFENIB AND CETUXIMAB PLUS PEMBROLIZUMAB VERSUS PEMBROLIZUMAB ALONE IN PARTICIPANTS WITH PREVIOUSLY UNTREATED BRAF V600E-MUTANT, MSI H/DMMR METASTATIC COLORECTAL CANCER	Metastatic Colorectal Cancer	4120 - Brisbane	https://clinicaltrials.gov/ct2/show/NCT05217446
NCT05218499	2021-002392-20--1403-0008	Phase 2/Phase 3		SA, NSW, VIC, QLD	1/02/2022	25/03/2022	Brigimadlin; Doxorubicin	anthracycline; MDM2_inhibitor; doxorubicin	Brigimadlin; Doxorubicin	MDM2_inhibitor; anthracycline; doxorubicin	2021-002392-20  1403-0008	Brightline-1: A Phase II/III, Randomized, Open-label, Multi-center Study of BI 907828 Compared to Doxorubicin as First Line Treatment of Patients With Advanced Dedifferentiated Liposarcoma	Liposarcoma, Dedifferentiated	12345 - Melbourne; 12345 - Woolloongabba; 12345 - Kurralta Park; 12345 - Randwick	https://clinicaltrials.gov/ct2/show/NCT05218499
NCT05220098	TAK-280-1501	Phase 1/Phase 2		VIC	2/02/2022	22/04/2022	TAK-280	bispecific_T-cell_engager,B7H3-targeting	TAK-280	bispecific_T-cell_engager,B7H3-targeting	TAK-280-1501	A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-280 in Patients With Unresectable Locally Advanced or Metastatic Cancer	Unresectable Locally Advanced or Metastatic Cancer	3168 - Clayton	https://clinicaltrials.gov/ct2/show/NCT05220098
NCT05221840	PACIFIC-9	Phase 3		VIC, NSW, SA	3/02/2022	7/02/2022	Durvalumab; Durvalumab + Monalizumab; Durvalumab + Oleclumab; Monalizumab; Oleclumab; Placebo; Radiotherapy	anti-CD73_monoclonal_antibody; radiotherapy; placebo; anti-NKG2A_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; anti-NKG2A_monoclonal_antibody; anti-CD73_monoclonal_antibody + anti-PD-L1_monoclonal_antibody	Durvalumab; Durvalumab + Monalizumab; Durvalumab + Oleclumab; Durvalumab + Monalizumab; Durvalumab + Oleclumab; Placebo; Radiotherapy	anti-CD73_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-NKG2A_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; anti-CD73_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-NKG2A_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; placebo; radiotherapy	2021-004346-37  D9078C00001	A Phase III, Double-blind, Placebo-controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy	Non-Small Cell Lung Cancer	3128 - Box Hill; 3021 - St Albans; 2250 - Gosford; 3002 - East Melbourne; 5112 - Elizabeth Vale	https://clinicaltrials.gov/ct2/show/NCT05221840
NCT05224141	MK-7684A-008--7684A-008	Phase 3		NSW, VIC	4/02/2022	24/03/2022	Atezolizumab; Atezolizumab + Carboplatin + Cisplatin + Etoposide; Carboplatin; Carboplatin + Cisplatin + Etoposide + Pembrolizumab + Vibostolimab; Cisplatin; Dexamethasone; Etoposide; Pembrolizumab; Placebo; Vibostolimab	glucocorticoid; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; placebo; anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-PD-L1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; topoisomerase_inhibitor	Atezolizumab + Carboplatin + Cisplatin + Etoposide; Carboplatin + Cisplatin + Etoposide + Pembrolizumab + Vibostolimab; Atezolizumab + Carboplatin + Cisplatin + Etoposide; Carboplatin + Cisplatin + Etoposide + Pembrolizumab + Vibostolimab; Dexamethasone; Placebo	anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; glucocorticoid; placebo	MK-7684A-008  7684A-008	A Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination With Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination With Etoposide and Platinum Followed by Atezolizumab for the First-Line Treatment of Participants With Extensive-Stage Small Cell Lung Cancer	Small Cell Lung Carcinoma	2298 - Waratah; 3199 - Frankston	https://clinicaltrials.gov/ct2/show/NCT05224141
NCT05234437	U1111-1258-4085--QB46C-H04	Phase 2		QLD, NSW	10/02/2022	9/03/2022	Tigilanol Tiglate	protein_kinase_C_regulator	Tigilanol Tiglate	protein_kinase_C_regulator	U1111-1258-4085  QB46C-H04	A Phase IIb, Multicentre, Open Label Study to Evaluate the Effectiveness, Safety and Tolerability of Intratumoural Tigilanol Tiglate in Adult Participants With Stage IIIB to IV M1c Melanoma	Melanoma	2065 - Wollstonecraft; 4870 - Cairns	https://clinicaltrials.gov/ct2/show/NCT05234437
NCT05237206	SUPLEXA-101	Phase 1		SA	14/02/2022	28/04/2022	SUPLEXA	autologous_adoptive_cell-based_immunotherapy	SUPLEXA	autologous_adoptive_cell-based_immunotherapy	SUPLEXA-101	A Phase 1, First-in-Human, Open-label Single Agent Study of SUPLEXA Therapeutic Cells in Patients With Metastatic Solid Tumours and Haematologic Malignancies	Oncology	5000 - Adelaide	https://clinicaltrials.gov/ct2/show/NCT05237206
NCT05245968	NCT05245968	Phase 1		VIC, SA	18/02/2022	1/12/2021	Imatinib; Imatinib + Pimitespib; Pimitespib; Sunitinib	PDGFRA_inhibitor; HSP90_inhibitor + PDGFRA_inhibitor; KIT_inhibitor,first_generation; BCR-ABL1_inhibitor,first_generation; VEGFR_inhibitor; PDGFR_inhibitor; HSP90_inhibitor; KIT_inhibitor; HSP90_inhibitor + KIT_inhibitor; BCR-ABL1_inhibitor,first_generation + HSP90_inhibitor	Imatinib + Pimitespib; Sunitinib; Imatinib + Pimitespib	BCR-ABL1_inhibitor,first_generation + HSP90_inhibitor; HSP90_inhibitor + KIT_inhibitor; HSP90_inhibitor + PDGFRA_inhibitor; KIT_inhibitor,first_generation; PDGFR_inhibitor; VEGFR_inhibitor; BCR-ABL1_inhibitor,first_generation + HSP90_inhibitor; HSP90_inhibitor + KIT_inhibitor; HSP90_inhibitor + PDGFRA_inhibitor	10058060	A Phase 1 Study of TAS-116 (Pimitespib) in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumor	Gastrointestinal Stromal Tumors	- Melbourne; - Adelaide	https://clinicaltrials.gov/ct2/show/NCT05245968
NCT05252364	HP518-CS-001	Phase 1		VIC, NSW	23/02/2022	14/12/2021	HP518	antiandrogen,oral_PROTAC	HP518	antiandrogen,oral_PROTAC	HP518-CS-001	A Phase 1 Open-Label Study to Assess the Safety, Pharmacokinetics, and Anti-tumor Activity of Oral HP518 in Patients With Metastatic Castration-Resistant Prostate Cancer	Metastatic Castration-resistant Prostate Cancer	2050 - Camperdown; 3181 - Melbourne; 2640 - Albury; 3000 - Melbourne; 2113 - Macquarie Park	https://clinicaltrials.gov/ct2/show/NCT05252364
NCT05252390	NUV-868-01	Unknown		VIC, NSW, WA	23/02/2022	29/03/2022	Enzalutamide; Enzalutamide + NUV-868; NUV-868; NUV-868 + Olaparib; Olaparib	antiandrogen,nonsteroidal,second_generation; PARP_inhibitor; BET_inhibitor; BET_inhibitor + antiandrogen,nonsteroidal,second_generation; BET_inhibitor + PARP_inhibitor	Enzalutamide + NUV-868; NUV-868; NUV-868 + Olaparib; Enzalutamide + NUV-868; NUV-868 + Olaparib	BET_inhibitor; BET_inhibitor + PARP_inhibitor; BET_inhibitor + antiandrogen,nonsteroidal,second_generation; BET_inhibitor + PARP_inhibitor; BET_inhibitor + antiandrogen,nonsteroidal,second_generation	NUV-868-01	Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors	Cancer of Pancreas; Breast Cancer; Pancreatic Cancer; Triple-negative Breast Cancer; Castrate Resistant Prostate Cancer; Prostatic Cancer; Ovarian Cancer; Breast Carcinoma; Cancer of Ovary; Castration Resistant Prostatic Neoplasms; Cancer of the Ovary; Triple Negative Breast Neoplasms; Pancreas Neoplasm; Ovary Neoplasm; Cancer of the Breast; Ovary Cancer; Cancer of Prostate; Prostate Neoplasm; Cancer of the Prostate; Cancer of the Pancreas; Advanced Solid Tumor; Cancer of Breast; Castration Resistant Prostatic Cancer; Pancreas Cancer; Triple Negative Breast Cancer; Breast Tumor; Prostate Cancer	3144 - Malvern; 6009 - Nedlands; 2298 - Waratah; 3000 - Melbourne; 2109 - North Ryde	https://clinicaltrials.gov/ct2/show/NCT05252390
NCT05253651	MOUNTAINEER-03	Phase 3		Othe, VIC	24/02/2022	24/10/2022	Bevacizumab; Bevacizumab + Cetuximab; Cetuximab; Fluorouracil; Leucovorin; Oxaliplatin; Trastuzumab; Trastuzumab + Tucatinib; Tucatinib	anti-EGFR_monoclonal_antibody + anti-VEGF_monoclonal_antibody; platinum-based_antineoplastic_agent; Fluorouracil; folinic_acid; anti-ERBB2_monoclonal_antibody; anti-VEGF_monoclonal_antibody; anti-EGFR_monoclonal_antibody; ERBB2_inhibitor,third_generation; fluoropyrimidine; ERBB2_inhibitor,third_generation + anti-ERBB2_monoclonal_antibody	Bevacizumab + Cetuximab; Trastuzumab + Tucatinib; Bevacizumab + Cetuximab; Fluorouracil; Leucovorin; Oxaliplatin; Trastuzumab + Tucatinib	ERBB2_inhibitor,third_generation + anti-ERBB2_monoclonal_antibody; anti-EGFR_monoclonal_antibody + anti-VEGF_monoclonal_antibody; ERBB2_inhibitor,third_generation + anti-ERBB2_monoclonal_antibody; Fluorouracil; anti-EGFR_monoclonal_antibody + anti-VEGF_monoclonal_antibody; fluoropyrimidine; folinic_acid; platinum-based_antineoplastic_agent	SGNTUC-029	An Open-label Randomized Phase 3 Study of Tucatinib in Combination With Trastuzumab and mFOLFOX6 Versus mFOLFOX6 Given With or Without Either Cetuximab or Bevacizumab as First-line Treatment for Subjects With HER2+ Metastatic Colorectal Cancer	Colorectal Neoplasms	3065 - Fitzroy	https://clinicaltrials.gov/ct2/show/NCT05253651
NCT05254171	ASPIRE	Phase 2/Phase 3		NSW	24/02/2022	8/08/2022	Gemcitabine; Gemcitabine + Ivospemin + Nab-paclitaxel; Gemcitabine + Nab-paclitaxel; Ivospemin; Nab-paclitaxel; Placebo	polyamine_analogue; antimetabolite + polyamine_analogue + taxane; placebo; antimetabolite; gemcitabine; taxane; antimetabolite + taxane	Gemcitabine + Ivospemin + Nab-paclitaxel; Gemcitabine + Nab-paclitaxel; Gemcitabine + Ivospemin + Nab-paclitaxel; Gemcitabine + Nab-paclitaxel; Placebo	antimetabolite + polyamine_analogue + taxane; antimetabolite + taxane; antimetabolite + polyamine_analogue + taxane; antimetabolite + taxane; gemcitabine; placebo	CL-SBP-101-04	A Randomized, Double-Blind, Placebo-Controlled Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma	Pancreatic Ductal Adenocarcinoma; Pancreatic Cancer Stage IV; Pancreatic Cancer Metastatic	2485 - Tweed Heads	https://clinicaltrials.gov/ct2/show/NCT05254171
NCT05257408	GOG-3073--CORT125134-556	Unknown		VIC	25/02/2022	29/06/2022	Nab-paclitaxel	taxane	Nab-paclitaxel	taxane	GOG-3073  CORT125134-556	A Phase 3 Study of Relacorilant in Combination With Nab-Paclitaxel Versus Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (ROSELLA)	Peritoneal Neoplasms; Fallopian Tube Neoplasms; Ovarian Neoplasm	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT05257408
NCT05261399	SAFFRON	Phase 3		NSW, WA	2/03/2022		Carboplatin; Carboplatin + Cisplatin + Pemetrexed; Cisplatin; Osimertinib; Osimertinib + Savolitinib; Pemetrexed; Savolitinib	EGFR_inhibitor,third_generation; platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; antimetabolite; EGFR_inhibitor,third_generation + MET_inhibitor,type_1; MET_inhibitor,type_1	Carboplatin + Cisplatin + Pemetrexed; Osimertinib + Savolitinib; Carboplatin + Cisplatin + Pemetrexed; Osimertinib + Savolitinib	EGFR_inhibitor,third_generation + MET_inhibitor,type_1; antimetabolite + platinum-based_antineoplastic_agent; EGFR_inhibitor,third_generation + MET_inhibitor,type_1; antimetabolite + platinum-based_antineoplastic_agent	2021-006374-24  D5087C00001	A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated, MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (SAFFRON).	Non-Small-Cell Lung; Carcinoma	2298 - Waratah NSW; 6160 - Fremantle; 2170 - Liverpool	https://clinicaltrials.gov/ct2/show/NCT05261399
NCT05263180	EMB09X101	Unknown		NSW, VIC	2/03/2022	25/07/2022	EMB-09	bispecific_PD-L1/OX40_antibody	EMB-09	bispecific_PD-L1/OX40_antibody	EMB09X101	A First-in-human, Phase I Trial of EMB-09, a Bispecific Antibody Targeting PD-L1 and OX-40 in Patients With Advanced or Metastatic Solid Tumors	Advanced Solid Tumor	- Sydney; - Frankston; - Leonards Hill	https://clinicaltrials.gov/ct2/show/NCT05263180
NCT05266105	OP-1250-002	Phase 1		QLD, NSW, VIC, WA	4/03/2022	10/12/2021	Palazestrant; Palazestrant + Palbociclib; Palbociclib	CDK4/6_inhibitor + complete_estrogen_receptor_antagonist; complete_estrogen_receptor_antagonist; CDK4/6_inhibitor	Palazestrant + Palbociclib; Palazestrant + Palbociclib	CDK4/6_inhibitor + complete_estrogen_receptor_antagonist; CDK4/6_inhibitor + complete_estrogen_receptor_antagonist	OP-1250-002	A Phase 1 Dose Escalation and Expansion Open-label, Multicenter, Study of OP-1250 in Combination With the CDK4/6 Inhibitor Palbociclib in Adult Subjects With Advanced or Metastatic HR-positive, HER2-negative Breast Cancer	Breast Cancer	3220 - Geelong; 3168 - Clayton; 2145 - Westmead; 4101 - South Brisbane; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT05266105
NCT05267626	CP-AU-007-01	Phase 1/Phase 2		SA, NSW, VIC	4/03/2022		AU-007; AU-007 + Aldesleukin; Aldesleukin	anti-IL-2_monoclonal_antibody; IL-2_variant + anti-IL-2_monoclonal_antibody; IL-2_variant	AU-007; AU-007 + Aldesleukin; AU-007 + Aldesleukin	IL-2_variant + anti-IL-2_monoclonal_antibody; anti-IL-2_monoclonal_antibody; IL-2_variant + anti-IL-2_monoclonal_antibody	CP-AU-007-01	A Phase 1/2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Ra Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer	Advanced Solid Tumor; Metastatic Cancer	2228 - Miranda; 3168 - Clayton; 3084 - Heidelberg; 5042 - Bedford Park	https://clinicaltrials.gov/ct2/show/NCT05267626
NCT05269316	IMP9064-101	Phase 1		WA, NSW	7/03/2022	11/02/2022	IMP9064; Senaparib	PARP_inhibitor; ATR_inhibitor	IMP9064; Senaparib	ATR_inhibitor; PARP_inhibitor	IMP9064-101	A First-in-human, Phase 1/2, Open-label, Multi-center, Dose-escalation and Dose-expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of the ATR Inhibitor IMP9064 Monotherapy and in Combination With PARP Inhibitor Senaparib in Patients With Advanced Solid Tumors	Advanced Solid Tumor; Solid Tumor	6009 - Nedlands; 2148 - Blacktown	https://clinicaltrials.gov/ct2/show/NCT05269316
NCT05269355	SUNRISELMS	Phase 2/Phase 3		NSW, VIC	8/03/2022	23/05/2022	Dacarbazine; Dacarbazine + Unesbulin; Placebo; Unesbulin	alkylating_agent; BMI-1_inhibitor + alkylating_agent; BMI-1_inhibitor; placebo	Dacarbazine + Unesbulin; Dacarbazine + Unesbulin; Placebo	BMI-1_inhibitor + alkylating_agent; BMI-1_inhibitor + alkylating_agent; placebo	PTC596-ONC-008-LMS	A Phase 2/3 Study to Evaluate the Efficacy and Safety of Unesbulin in Unresectable or Metastatic, Relapsed or Refractory Leiomyosarcoma	Leiomyosarcoma	2031 - Randwick; 3000 - East Melbourne	https://clinicaltrials.gov/ct2/show/NCT05269355
NCT05277168	SHR-A1904-I-104	Phase 1/Phase 2		NSW	14/03/2022		SHR-A1904	anti-CLDN18.2_antibody-drug_conjugate	SHR-A1904	anti-CLDN18.2_antibody-drug_conjugate	SHR-A1904-I-104	AN OPEN-LABEL, SINGLE-ARM, MULTI-CENTER PHASE I/IIA CLINICAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS	Advanced Solid Tumors	2031 - Randwick	https://clinicaltrials.gov/ct2/show/NCT05277168
NCT05279300	CS5001-101	Phase 1		NSW	15/03/2022	28/03/2022	CS5001	anti-ROR1_antibody-drug_conjugate	CS5001	anti-ROR1_antibody-drug_conjugate	CS5001-101	A Phase I, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CS5001, an Anti-ROR1 Antibody Drug Conjugate, in Patients With Advanced Solid Tumors and Lymphomas	Advanced Solid Tumor; Advanced Lymphoma	2031 - Randwick	https://clinicaltrials.gov/ct2/show/NCT05279300
NCT05286801	NCI-2022-01992--NCI-2022-01992	Phase 1/Phase 2		QLD	18/03/2022	9/09/2022	Atezolizumab; Atezolizumab + Tiragolumab; Tiragolumab	anti-PD-L1_monoclonal_antibody; anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody	Atezolizumab + Tiragolumab; Atezolizumab + Tiragolumab	anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody	NCI-2022-01992  NCI-2022-01992	A Phase 1/2 Study of Tiragolumab (NSC# 827799) and Atezolizumab (NSC# 783608) in Patients With Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors	Recurrent Malignant Solid Neoplasm; Epithelioid Sarcoma; Rhabdoid Tumor; Kidney Medullary Carcinoma; Refractory Atypical Teratoid/Rhabdoid Tumor; Recurrent Chordoma; Recurrent Kidney Medullary Carcinoma; Refractory Kidney Medullary Carcinoma; Poorly Differentiated Chordoma; Refractory Rhabdoid Tumor; Refractory Epithelioid Sarcoma; Recurrent Epithelioid Sarcoma; Recurrent Rhabdoid Tumor; Refractory Malignant Solid Neoplasm; Refractory Chordoma; Atypical Teratoid/Rhabdoid Tumor; Recurrent Atypical Teratoid/Rhabdoid Tumor; Malignant Solid Neoplasm	4101 - South Brisbane	https://clinicaltrials.gov/ct2/show/NCT05286801
NCT05288166	CYCLONE-3	Phase 3		South AustTAS, WA, TAS, SA, QLD, NSW, VIC	21/03/2022	14/04/2022	Abemaciclib; Abemaciclib + Abiraterone + Prednisolone + Prednisone; Abiraterone; Abiraterone + Prednisolone + Prednisone; Placebo; Prednisolone; Prednisone	glucocorticoid; placebo; CYP17A1_inhibitor; CDK4/6_inhibitor; CYP17A1_inhibitor + glucocorticoid; CDK4/6_inhibitor + CYP17A1_inhibitor + glucocorticoid	Abemaciclib + Abiraterone + Prednisolone + Prednisone; Abiraterone + Prednisolone + Prednisone; Abemaciclib + Abiraterone + Prednisolone + Prednisone; Abiraterone + Prednisolone + Prednisone; Placebo	CDK4/6_inhibitor + CYP17A1_inhibitor + glucocorticoid; CYP17A1_inhibitor + glucocorticoid; CDK4/6_inhibitor + CYP17A1_inhibitor + glucocorticoid; CYP17A1_inhibitor + glucocorticoid; placebo	I3Y-MC-JPEG  18448	CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer	Steroid Synthesis Inhibitors; Prednisone; Cyclin-Dependent Kinase 4; Physiological Effects of Drugs; Abiraterone Acetate; Neoplasm Metastasis; Cytochrome P-450; Hormones; Enzyme Inhibitors; Antineoplastic Agents, Hormonal; Androgens; Antineoplastic Agents; Hormones, Hormone Substitutes, and Hormone Antagonists; Cyclin-Dependent Kinase 6; Urogenital Neoplasms; Prednisolone; Prostatic Neoplasms	3084 - Heidelberg; 2050 - Camperdown; 6150 - Murdoch; 4215 - Southport; 3128 - Box Hill; 2010 - Darlinghurst; 5037 - Kurralta Park; 7000 - Hobart; 3002 - East Melbourne; 4101 - South Brisbane; 5112 - Elizabeth Vale; 2109 - Macquarie University; 2170 - Liverpool; 2450 - Coffs Harbour; 3065 - Melbourne; 3168 - Clayton; 4102 - Woolloongabba; 3220 - Geelong	https://clinicaltrials.gov/ct2/show/NCT05288166
NCT05290597	CIBI363A101	Phase 1		NSW	22/03/2022		IBI363	anti-PD-1_IL-2-immunocytokine_conjugate	IBI363	anti-PD-1_IL-2-immunocytokine_conjugate	CIBI363A101	A Phase 1, Open-label, Multicenter, Dose Escalation Study of IBI363 (PD1-IL2m) in Subjects With Advanced Solid Malignancies or Lymphomas	Solid Malignancies or Lymphomas	2500 - Wollongong	https://clinicaltrials.gov/ct2/show/NCT05290597
NCT05304585	NCI-2022-01012--ARST2032	Phase 3		NSW, WA	31/03/2022	22/06/2022	Cyclophosphamide; Cyclophosphamide + Dactinomycin + Radiotherapy + Vincristine; Dactinomycin; Dactinomycin + Vincristine; Radiotherapy; Vincristine	radiotherapy; alkylating_agent; alkylating_agent + antineoplastic_antibiotic + radiotherapy + vinca_alkaloid; vinca_alkaloid; antineoplastic_antibiotic + vinca_alkaloid; antineoplastic_antibiotic	Cyclophosphamide + Dactinomycin + Radiotherapy + Vincristine; Dactinomycin + Vincristine; Cyclophosphamide + Dactinomycin + Radiotherapy + Vincristine; Dactinomycin + Vincristine	alkylating_agent + antineoplastic_antibiotic + radiotherapy + vinca_alkaloid; antineoplastic_antibiotic + vinca_alkaloid; alkylating_agent + antineoplastic_antibiotic + radiotherapy + vinca_alkaloid; antineoplastic_antibiotic + vinca_alkaloid	NCI-2022-01012  ARST2032	A Prospective Phase 3 Study of Patients With Newly Diagnosed Very Low-Risk and Low-Risk Fusion Negative Rhabdomyosarcoma	Spindle Cell/Sclerosing Rhabdomyosarcoma; Fusion-Negative Alveolar Rhabdomyosarcoma; Embryonal Rhabdomyosarcoma	2145 - Westmead; 6009 - Perth	https://clinicaltrials.gov/ct2/show/NCT05304585
NCT05306444	HBM-7008.1	Phase 1		NSW	1/04/2022		CLN-418	bispecific_B7H4/4-1BB_antibody	CLN-418	bispecific_B7H4/4-1BB_antibody	HBM 7008.1	A Phase 1 Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of HBM7008 in Subjects With Advanced Solid Tumors	Advanced Solid Tumor	2217 - Kogarah	https://clinicaltrials.gov/ct2/show/NCT05306444
NCT05307705	PIKASSO-01	Phase 1		NSW	1/04/2022	11/05/2022	Abemaciclib; Abemaciclib + Fulvestrant + Imlunestrant + LOXO-783; Anastrozole; Exemestane; Fulvestrant; Fulvestrant + Imlunestrant + LOXO-783; Fulvestrant + LOXO-783; Imlunestrant; LOXO-783; LOXO-783 + Paclitaxel; Letrozole; Paclitaxel	PI3Kalpha_H1047R_inhibitor; PI3Kalpha_H1047R_inhibitor + taxane; PI3Kalpha_H1047R_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + PI3Kalpha_H1047R_inhibitor + selective_estrogen_receptor_degrader; taxane; selective_estrogen_receptor_degrader; CDK4/6_inhibitor; aromatase_inhibitor	Abemaciclib + Fulvestrant + Imlunestrant + LOXO-783; Fulvestrant + Imlunestrant + LOXO-783; Fulvestrant + LOXO-783; LOXO-783; LOXO-783 + Paclitaxel; Abemaciclib + Fulvestrant + Imlunestrant + LOXO-783; Anastrozole; Exemestane; Fulvestrant + Imlunestrant + LOXO-783; Fulvestrant + LOXO-783; LOXO-783 + Paclitaxel; Letrozole	CDK4/6_inhibitor + PI3Kalpha_H1047R_inhibitor + selective_estrogen_receptor_degrader; PI3Kalpha_H1047R_inhibitor; PI3Kalpha_H1047R_inhibitor + selective_estrogen_receptor_degrader; PI3Kalpha_H1047R_inhibitor + taxane; CDK4/6_inhibitor + PI3Kalpha_H1047R_inhibitor + selective_estrogen_receptor_degrader; PI3Kalpha_H1047R_inhibitor + selective_estrogen_receptor_degrader; PI3Kalpha_H1047R_inhibitor + taxane; aromatase_inhibitor	J4C-OX-JZUA  LOXO-PIK-21001	A Study of LOXO-783 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With Advanced Breast Cancer and Other Solid Tumors With a PIK3CA H1047R Mutation	Breast Cancer; Solid Tumour	2010 - Sydney	https://clinicaltrials.gov/ct2/show/NCT05307705
NCT05309421	KEYNOTE-KN-D36--EVX-01-001	Phase 2		NSW, WA	4/04/2022		EVX-01; EVX-01 + Pembrolizumab; Pembrolizumab	autologous_anticancer_vaccine; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + autologous_anticancer_vaccine	EVX-01 + Pembrolizumab; EVX-01 + Pembrolizumab	anti-PD-1_monoclonal_antibody + autologous_anticancer_vaccine; anti-PD-1_monoclonal_antibody + autologous_anticancer_vaccine	KEYNOTE KN-D36  EVX-01-001	An Open Label, Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Checkpoint Inhibitor Treatment naïve Adults With Unresectable or Metastatic Melanoma	Melanoma Stage III; Melanoma Stage IV	2065 - Wollstonecraft; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT05309421
NCT05311176	nextHERIZON	Phase 2		SA	5/04/2022		IMU-131; IMU-131 + Irinotecan + Paclitaxel; IMU-131 + Pembrolizumab + Trastuzumab; Irinotecan; Paclitaxel; Pembrolizumab; Trastuzumab	anti-PD-1_monoclonal_antibody; ERBB2_B-cell_antigen + anti-ERBB2_monoclonal_antibody + anti-PD-1_monoclonal_antibody; ERBB2_B-cell_antigen + taxane + topoisomerase_inhibitor; anti-ERBB2_monoclonal_antibody; ERBB2_B-cell_antigen; taxane; topoisomerase_inhibitor	IMU-131 + Irinotecan + Paclitaxel; IMU-131 + Pembrolizumab + Trastuzumab; IMU-131 + Irinotecan + Paclitaxel; IMU-131 + Pembrolizumab + Trastuzumab	ERBB2_B-cell_antigen + anti-ERBB2_monoclonal_antibody + anti-PD-1_monoclonal_antibody; ERBB2_B-cell_antigen + taxane + topoisomerase_inhibitor; ERBB2_B-cell_antigen + anti-ERBB2_monoclonal_antibody + anti-PD-1_monoclonal_antibody; ERBB2_B-cell_antigen + taxane + topoisomerase_inhibitor	IMU.131.203	nextHERIZON: An Open-Label, Signal Generating, Phase 2 Study of HER-Vaxx in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric or Gastroesophageal Junction (GEJ) Adenocarcinomas Who Have Previously Received Trastuzumab and Progressed on This Treatment	Gastroesophageal Junction Adenocarcinoma; Cancer of Stomach; Gastric Adenocarcinoma; Stomach Cancer; Stomach Adenocarcinoma; Gastric Cancer	5011 - Woodville South	https://clinicaltrials.gov/ct2/show/NCT05311176
NCT05315700	ORIC-114-01	Phase 1		NSW, WA	7/04/2022	10/03/2022	ORIC-114	EGFR_inhibitor,exon_20_selective; ERBB2_inhibitor,exon_20_selective	ORIC-114	EGFR_inhibitor,exon_20_selective; ERBB2_inhibitor,exon_20_selective	ORIC-114-01	An Open-Label, Phase 1/1b, Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration	Solid Tumor	- Camperdown; - Nedlands	https://clinicaltrials.gov/ct2/show/NCT05315700
NCT05317078	NCT05317078	Unknown		VIC	7/04/2022	28/02/2023	AMG-794	bispecific_T-cell_engager,CLDN6-targeting	AMG-794	bispecific_T-cell_engager,CLDN6-targeting	20210007	Phase 1 First-In-Human Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 794 in Participants With Claudin 6-positive Advanced/Metastatic Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications	Non-squamous Non-small Cell Lung Cancer; Epithelial Ovarian Cancer; Claudin 6-positive Advanced/Metastatic Malignant Solid Tumors	3144 - Malvern	https://clinicaltrials.gov/ct2/show/NCT05317078
NCT05325866	FORTITUDE-301	Phase 1		WA	13/04/2022	23/09/2022	Bemarituzumab	anti-FGFR2_monoclonal_antibody	Bemarituzumab	anti-FGFR2_monoclonal_antibody	20210104	A Phase 1b/2, Multicenter, Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors With FGFR2b Overexpression (FORTITUDE-301)	Solid Tumors	6150 - Murdoch	https://clinicaltrials.gov/ct2/show/NCT05325866
NCT05327530	2021-003669-36--MS100070-0119	Phase 2		QLD, NT	14/04/2022	17/08/2022	Avelumab; Avelumab + Sacituzumab Govitecan; Sacituzumab Govitecan	anti-PD-L1_monoclonal_antibody; anti-Trop2_antibody-drug_conjugate; anti-PD-L1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate	Avelumab; Avelumab + Sacituzumab Govitecan; Avelumab + Sacituzumab Govitecan	anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-PD-L1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate	2021-003669-36  MS100070_0119	A Phase II, Multicenter, Randomized, Open Label, Parallel-Arm, Umbrella Study of Avelumab (MSB0010718C) in Combination With Other AntiTumor Agents as a Maintenance Treatment in Participants With Locally Advanced or Metastatic Urothelial Carcinoma Whose Disease Did Not Progress With First Line Platinum-Containing Chemotherapy (JAVELIN Bladder Medley)	Locally Advanced or Metastatic Urothelial Carcinoma	- Southport; - Newcastle	https://clinicaltrials.gov/ct2/show/NCT05327530
NCT05328908	RELATIVITY-123	Phase 3		SA, QLD, VIC, NSW, WA	14/04/2022	28/04/2022	Nivolumab; Nivolumab + Relatlimab; Regorafenib; Regorafenib + Trifluridine/Tipiracil; Relatlimab; Trifluridine/Tipiracil	KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + Tipiracil Hydrochloride; Tipiracil Hydrochloride; anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody; Trifluridine; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + antimetabolite; antimetabolite; thymidine_phosphorylase_inhibitor; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + thymidine_phosphorylase_inhibitor; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + Trifluridine; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Nivolumab + Relatlimab; Regorafenib + Trifluridine/Tipiracil; Nivolumab + Relatlimab; Regorafenib + Trifluridine/Tipiracil	KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + Tipiracil Hydrochloride; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + Trifluridine; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + antimetabolite; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + thymidine_phosphorylase_inhibitor; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + Tipiracil Hydrochloride; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + Trifluridine; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + antimetabolite; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor + thymidine_phosphorylase_inhibitor; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	2021-004285-35  CA224-123	A Phase 3, Randomized, Open-label (Sponsor Blinded) Study of Relatlimab-nivolumab Fixed-dose Combination Versus Regorafenib or Trifluridine + Tipiracil (TAS-102) for Participants With Later-lines of Metastatic Colorectal Cancer	Colorectal Neoplasms	4102 - Greenslopes Qld; 3168 - Clayton; 2145 - Westmead; - Woodville South; 6009 - Perth; 3084 - Melbourne; 2650 - Wagga Wagga	https://clinicaltrials.gov/ct2/show/NCT05328908
NCT05329545	UP-NEXT	Phase 3		VIC	15/04/2022	23/06/2022	Placebo; Upifitamab Rilsodotin	placebo; anti-NaPi2b_antibody-drug_conjugate	Upifitamab Rilsodotin; Placebo	anti-NaPi2b_antibody-drug_conjugate; placebo	XMT-1536-3	A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants With Recurrent, Platinum-Sensitive, Ovarian Cancer (UP-NEXT)	Primary Peritoneal Cancer; High Grade Serous Ovarian Cancer; Fallopian Tube Cancer	3121 - Richmond	https://clinicaltrials.gov/ct2/show/NCT05329545
NCT05330429	2022-500177-13-00--GS-US-587-6156	Phase 2		NSW	15/04/2022	8/07/2022	Bevacizumab; Bevacizumab + Fluorouracil + Irinotecan + Leucovorin; Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Magrolimab; Fluorouracil; Irinotecan; Leucovorin; Magrolimab	anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor; anti-CD47_monoclonal_antibody; Fluorouracil; folinic_acid; anti-CD47_monoclonal_antibody + anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor; anti-VEGF_monoclonal_antibody; topoisomerase_inhibitor; fluoropyrimidine	Bevacizumab + Fluorouracil + Irinotecan + Leucovorin; Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Magrolimab; Bevacizumab + Fluorouracil + Irinotecan + Leucovorin; Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Magrolimab	anti-CD47_monoclonal_antibody + anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor; anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor; Fluorouracil; anti-CD47_monoclonal_antibody + anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor; anti-VEGF_monoclonal_antibody + fluoropyrimidine + folinic_acid + topoisomerase_inhibitor	2022-500177-13-00  GS-US-587-6156	A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Bevacizumab and FOLFIRI Versus Bevacizumab and FOLFIRI in Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)	Metastatic Colorectal Cancer	2065 - St Leonards	https://clinicaltrials.gov/ct2/show/NCT05330429
NCT05332574	GB263T-FIH001	Phase 1/Phase 2			12/04/2022		GB263T	trispecific_EGFR/cMET/cMET_antibody	GB263T	trispecific_EGFR/cMET/cMET_antibody	GB263T-FIH001	A Phase I/II, First-in-Human, Open-Label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of a Trispecific EGFR/cMET/cMET Antibody GB263T in Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors	NSCLC; Other Solid Tumors		https://clinicaltrials.gov/ct2/show/NCT05332574
NCT05337137	RELATIVITY-106	Phase 1/Phase 2		WA, VIC, NSW	20/04/2022	5/05/2022	Bevacizumab; Bevacizumab + Nivolumab; Bevacizumab + Nivolumab + Relatlimab; Nivolumab; Placebo; Relatlimab	anti-PD-1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody; placebo; anti-VEGF_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-VEGF_monoclonal_antibody	Bevacizumab + Nivolumab; Bevacizumab + Nivolumab + Relatlimab; Bevacizumab + Nivolumab; Bevacizumab + Nivolumab + Relatlimab; Placebo	anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; placebo	2021-003606-53  CA224-106	A Phase 1/2, Safety Confirmation and Double-blind, Placebo-controlled, Randomized Study of Relatlimab in Combination With Nivolumab and Bevacizumab in Treatment-naive Advanced/Metastatic Hepatocellular Carcinoma	Carcinoma, Hepatocellular	2050 - Camperdown; 3084 - Heidelberg; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT05337137
NCT05338346	ATRIUM	Phase 1	NOT_RECRUITING	QLD, NSW, VIC	21/04/2022	8/07/2022	ATG-018	ATR_inhibitor	ATG-018	ATR_inhibitor	ATG-018-001	A Phase I, Open-Label, Multi-Center, Dose Finding Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG-018 (ATR Inhibitor) Treatment in Patients With Advanced Solid Tumors and Hematological Malignancies	Hematological Malignancies; Advanced Solid Tumors	- Sydney; - Melbourne; - Camperdown; - Heidelberg; - Brisbane	https://clinicaltrials.gov/ct2/show/NCT05338346
NCT05338970	2021-005879-40--U31402-A-U301	Phase 3		NSW, VIC, QLD	21/04/2022	13/04/2022	Carboplatin; Carboplatin + Cisplatin + Pemetrexed; Cisplatin; Patritumab Deruxtecan; Pemetrexed	anti-ERBB3_antibody-drug_conjugate; platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; antimetabolite	Carboplatin + Cisplatin + Pemetrexed; Patritumab Deruxtecan; Carboplatin + Cisplatin + Pemetrexed	anti-ERBB3_antibody-drug_conjugate; antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent	2021-005879-40  U31402-A-U301	A Phase 3, Randomized, Open-label Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced Epidermal Growth Factor Receptor-mutated (EGFRm) Non-small Cell Lung Cancer (NSCLC) After Failure of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy (HERTHENA-Lung02)	EGFR L858R; Nonsquamous Non-small Cell Lung Cancer	3084 - Melbourne; 2050 - Camperdown; 4102 - Woolloongabba	https://clinicaltrials.gov/ct2/show/NCT05338970
NCT05340374	LuCAB	Phase 1/Phase 2		VIC	22/04/2022		Cabazitaxel; Cabazitaxel + Lu-177 vipivotide tetraxetan; Lu-177 vipivotide tetraxetan	radioligand,PSMA-targeting + taxane; radioligand,PSMA-targeting; taxane	Cabazitaxel + Lu-177 vipivotide tetraxetan; Cabazitaxel + Lu-177 vipivotide tetraxetan	radioligand,PSMA-targeting + taxane; radioligand,PSMA-targeting + taxane	21/018	Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer	mCRPC 0 0; Metastatic Castration-resistant Prostate Cancer	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT05340374
NCT05348577	CAPItello-280	Phase 3		SA, QLD, NSW	27/04/2022	25/03/2022	Capivasertib; Capivasertib + Docetaxel; Docetaxel; Placebo	taxane; placebo; pan-AKT_inhibitor + taxane; pan-AKT_inhibitor	Capivasertib + Docetaxel; Docetaxel; Capivasertib + Docetaxel; Placebo	pan-AKT_inhibitor + taxane; taxane; pan-AKT_inhibitor + taxane; placebo	2021-005201-27  D361EC00001	A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)	Prostate Cancer	4102 - Woolloongabba; 4575 - Birtinya; 2076 - Wahroonga; 5000 - North Adelaide; 2228 - Miranda; 4020 - Redcliffe; 2800 - Orange	https://clinicaltrials.gov/ct2/show/NCT05348577
NCT05349643	AMB-051-07	Phase 2		NSW	27/04/2022	26/01/2023	AMB-05X	anti-CSF1R_monoclonal_antibody	AMB-05X	anti-CSF1R_monoclonal_antibody	AMB-051-07	A Phase 2, Open-Label, Adaptive, Dose-Ranging Study With Long-Term Extension to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Intra Articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor	TGCT; Pigmented Villonodular Synovitis; Tenosynovial Giant Cell Tumor	- Camperdown	https://clinicaltrials.gov/ct2/show/NCT05349643
NCT05352672	2021-004453-23--R3767-ONC-2011	Phase 3		TAS	29/04/2022	14/07/2022	Cemiplimab; Cemiplimab + Fianlimab; Fianlimab; Pembrolizumab; Placebo	anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody; placebo; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Cemiplimab; Cemiplimab + Fianlimab; Pembrolizumab; Cemiplimab + Fianlimab; Placebo	anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; placebo	2021-004453-23  R3767-ONC-2011	A Phase 3 Trial of Fianlimab (REGN3767, Anti-LAG-3) + Cemiplimab Versus Pembrolizumab in Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma	Melanoma	7000 - Hobart	https://clinicaltrials.gov/ct2/show/NCT05352672
NCT05355298	AMP945-PC-201	Phase 1/Phase 2		NSW, VIC	2/05/2022	31/05/2022	AMP945; Gemcitabine; Nab-paclitaxel	FAK_inhibitor; taxane; antimetabolite	AMP945; Gemcitabine; Nab-paclitaxel	FAK_inhibitor; antimetabolite; taxane	AMP945-PC-201	A Phase 1b/2a, Multicentre, Open Label Study of the Pharmacokinetics, Safety and Efficacy of AMP945 in Combination With Nab-paclitaxel and Gemcitabine in Pancreatic Cancer Patients	PDAC; Pancreatic Ductal Adenocarcinoma; Pancreatic Cancer	2145 - Westmead; 3168 - Clayton; 2065 - St Leonards; 3021 - St Albans	https://clinicaltrials.gov/ct2/show/NCT05355298
NCT05356741	2021-004731-91--AMX-818-001	Phase 1		VIC	2/05/2022	27/04/2022	AMX-818; AMX-818 + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody + bispecific_T-cell_engager,ERBB2-targeting; anti-PD-1_monoclonal_antibody; bispecific_T-cell_engager,ERBB2-targeting	AMX-818; AMX-818 + Pembrolizumab; AMX-818 + Pembrolizumab	anti-PD-1_monoclonal_antibody + bispecific_T-cell_engager,ERBB2-targeting; bispecific_T-cell_engager,ERBB2-targeting; anti-PD-1_monoclonal_antibody + bispecific_T-cell_engager,ERBB2-targeting	2021-004731-91  AMX 818-001	A Phase 1, Multicenter, Open-Label, First-in-Human Study of the Safety and Pharmacokinetics of AMX 818 Alone and in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers	Locally Advanced or Metastatic HER2-Expressing Cancers	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT05356741
NCT05359861	SRF388-201	Phase 2		VIC	4/05/2022	12/04/2022	Atezolizumab; Atezolizumab + Bevacizumab; Atezolizumab + Bevacizumab + SRF388; Bevacizumab; Placebo; SRF388	placebo; anti-PD-L1_monoclonal_antibody; anti-VEGF_monoclonal_antibody; anti-IL27_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-IL27_monoclonal_antibody	Atezolizumab + Bevacizumab; Atezolizumab + Bevacizumab + SRF388; Atezolizumab + Bevacizumab; Atezolizumab + Bevacizumab + SRF388; Placebo	anti-IL27_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-IL27_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; placebo	SRF388-201	A Randomized Phase 2 Trial of Atezolizumab and Bevacizumab in Combination With SRF388 or Placebo in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma	Hepatocellular Carcinoma	3004 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT05359861
NCT05361395	2021-005462-17--20200469	Phase 1		NSW	4/05/2022	24/08/2022	Atezolizumab; Atezolizumab + Carboplatin + Etoposide + Tarlatamab; Atezolizumab + Tarlatamab; Carboplatin; Etoposide; Tarlatamab	anti-PD-L1_monoclonal_antibody + bispecific_T-cell_engager,DLL3-targeting; platinum-based_antineoplastic_agent; bispecific_T-cell_engager,DLL3-targeting; anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + bispecific_T-cell_engager,DLL3-targeting + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; topoisomerase_inhibitor	Atezolizumab + Carboplatin + Etoposide + Tarlatamab; Atezolizumab + Tarlatamab; Atezolizumab + Carboplatin + Etoposide + Tarlatamab; Atezolizumab + Tarlatamab	anti-PD-L1_monoclonal_antibody + bispecific_T-cell_engager,DLL3-targeting; anti-PD-L1_monoclonal_antibody + bispecific_T-cell_engager,DLL3-targeting + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-PD-L1_monoclonal_antibody + bispecific_T-cell_engager,DLL3-targeting; anti-PD-L1_monoclonal_antibody + bispecific_T-cell_engager,DLL3-targeting + platinum-based_antineoplastic_agent + topoisomerase_inhibitor	2021-005462-17  20200469	A Phase 1b Study Evaluating the Safety and Efficacy of First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer	Extensive Stage Small Cell Lung Cancer	2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT05361395
NCT05363605	FPI-1966-101	Phase 1/Phase 2		WA	6/05/2022	20/04/2022					FPI-1966-101	A Phase 1/2 Study of [225Ac]-FPI-1966, [111In]-FPI-1967, and Vofatamab in Participants With FGFR3-expressing Advanced, Inoperable, Metastatic and/or Recurrent Solid Tumours	Colorectal Cancer; Advanced Solid Tumor; Gastric Cancer; Lung Cancer; Bladder Carcinoma; FGFR3 Receptor; FGFR3; Head and Neck Squamous Cell Carcinoma; Liver Cancer; Breast Cancer; Ovarian Cancer; Susceptible FGFR3 Genetic Alterations; FGFR3 Protein Overexpression; FGFR3 Overexpression	6150 - Murdoch	https://clinicaltrials.gov/ct2/show/NCT05363605
NCT05364073	FURMO-002	Phase 1		NSW, VIC	6/05/2022		Furmonertinib	EGFR_inhibitor,third_generation; EGFR_inhibitor,exon_20_selective; ERBB2_inhibitor,exon_20_selective	Furmonertinib	EGFR_inhibitor,exon_20_selective; EGFR_inhibitor,third_generation; ERBB2_inhibitor,exon_20_selective	FURMO-002	A Phase 1b Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Antitumor Activity of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer With Activating EGFR or HER2 Mutations, Including Exon 20 Insertion Mutations	Carcinoma, Non-Small-Cell Lung; Respiratory Tract Diseases; Respiratory Tract Neoplasms; Neoplasms by Site; Non-Small Cell Lung Cancer; Thoracic Neoplasms; Neoplasms; Carcinoma, Bronchogenic; Lung Diseases; Molecular Mechanisms of Pharmacological Action; Protein Kinase Inhibitors; Lung Neoplasms; Enzyme Inhibitors; Bronchial Neoplasms; Antineoplastic Agents	3084 - Heidelberg; 2148 - Blacktown	https://clinicaltrials.gov/ct2/show/NCT05364073
NCT05367440	PETRANHA	Phase 1/Phase 2		NSW, VIC	10/05/2022		Abiraterone; Abiraterone + Saruparib; Darolutamide; Darolutamide + Saruparib; Enzalutamide; Enzalutamide + Saruparib; Saruparib	PARP_inhibitor; PARP1-selective_inhibitor; CYP17A1_inhibitor + PARP1-selective_inhibitor; PARP_inhibitor + antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor; antiandrogen,nonsteroidal,second_generation; PARP1-selective_inhibitor + antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor + PARP_inhibitor	Abiraterone + Saruparib; Darolutamide + Saruparib; Enzalutamide + Saruparib; Abiraterone + Saruparib; Darolutamide + Saruparib; Enzalutamide + Saruparib	CYP17A1_inhibitor + PARP1-selective_inhibitor; CYP17A1_inhibitor + PARP_inhibitor; PARP1-selective_inhibitor + antiandrogen,nonsteroidal,second_generation; PARP_inhibitor + antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor + PARP1-selective_inhibitor; CYP17A1_inhibitor + PARP_inhibitor; PARP1-selective_inhibitor + antiandrogen,nonsteroidal,second_generation; PARP_inhibitor + antiandrogen,nonsteroidal,second_generation	2021-006289-19  D9720C00003	A Multi-arm, Open-label Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD5305 in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer (PETRANHA)	Metastatic Prostate Cancer	3002 - East Melbourne; 2065 - St. Leonards; 3000 - Melbourne; 2010 - Darlinghurst	https://clinicaltrials.gov/ct2/show/NCT05367440
NCT05381909	BGB-24714-101	Phase 1		NZ, VIC, QLD	19/05/2022		BGB-24714; Paclitaxel	IAP_inhibitor; taxane; SMAC_mimetic	BGB-24714; Paclitaxel	IAP_inhibitor; SMAC_mimetic; taxane	BGB-24714-101	A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of Second Mitochondrial-derived Activator of Caspases Mimetic BGB-24714 as Monotherapy and in Combination With Chemotherapy in Patients With Advanced or Metastatic Solid Tumors	Solid Tumor, Adult	3000 - Melbourne; 4101 - Queensland; Auckland	https://clinicaltrials.gov/ct2/show/NCT05381909
NCT05382286	ASCENT-04	Phase 3		WA, TAS, VIC, NSW	19/05/2022	25/07/2022	Carboplatin; Gemcitabine; Nab-paclitaxel; Paclitaxel; Pembrolizumab; Pembrolizumab + Sacituzumab Govitecan; Sacituzumab Govitecan	anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; antimetabolite; gemcitabine; taxane; anti-Trop2_antibody-drug_conjugate	Pembrolizumab; Pembrolizumab + Sacituzumab Govitecan; Carboplatin; Gemcitabine; Nab-paclitaxel; Pembrolizumab + Sacituzumab Govitecan	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; antimetabolite; gemcitabine; platinum-based_antineoplastic_agent; taxane	2021-005742-14  GS-US-592-6173	A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1	PD-L1 Positive; Triple Negative Breast Cancer	7000 - Hobart; 3084 - Melbourne; 2640 - Albury; 6009 - Nedlands; 2060 - North Sydney; 3168 - Clayton; 2065 - St Leonards	https://clinicaltrials.gov/ct2/show/NCT05382286
NCT05382299	ASCENT-03	Phase 3		WA, TAS, NSW, VIC	19/05/2022	20/07/2022	Carboplatin; Gemcitabine; Nab-paclitaxel; Paclitaxel; Sacituzumab Govitecan	platinum-based_antineoplastic_agent; gemcitabine; taxane; antimetabolite; anti-Trop2_antibody-drug_conjugate	Sacituzumab Govitecan; Carboplatin; Gemcitabine; Nab-paclitaxel	anti-Trop2_antibody-drug_conjugate; antimetabolite; gemcitabine; platinum-based_antineoplastic_agent; taxane	2021-005743-79  GS-US-592-6238	A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors Do Express PD-L1	PD-L1 Negative; Triple Negative Breast Cancer	7000 - Hobart; 3084 - Melbourne; 2640 - Albury; 6009 - Nedlands; 2060 - North Sydney; 3168 - Clayton; 2065 - St Leonards	https://clinicaltrials.gov/ct2/show/NCT05382299
NCT05383079	AlphaBet	Phase 1/Phase 2		VIC	19/05/2022		Lu-177 vipivotide tetraxetan; Lu-177 vipivotide tetraxetan + Radium-223; Radium-223	radioligand,PSMA-targeting; radium_223_radionuclide; radioligand,PSMA-targeting + radium_223_radionuclide	Lu-177 vipivotide tetraxetan + Radium-223; Lu-177 vipivotide tetraxetan + Radium-223	radioligand,PSMA-targeting + radium_223_radionuclide; radioligand,PSMA-targeting + radium_223_radionuclide	21/029	Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men With Metastatic Castration-Resistant Prostate Cancer: Phase I/II Study	mCRPC 0 0; Prostate Cancer; Metastatic Castration-resistant Prostate Cancer	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT05383079
NCT05383352	SIRACUSA	Phase 1		SA, VIC	20/05/2022	30/05/2022	Fluorouracil; Fluorouracil + Liposomal Irinotecan; Irinotecan; Leucovorin; Liposomal Irinotecan	fluoropyrimidine + topoisomerase_inhibitor; Fluorouracil; folinic_acid; topoisomerase_inhibitor; fluoropyrimidine	Fluorouracil + Liposomal Irinotecan; Fluorouracil + Liposomal Irinotecan; Leucovorin	fluoropyrimidine + topoisomerase_inhibitor; Fluorouracil; fluoropyrimidine + topoisomerase_inhibitor; folinic_acid	2021-003264-26  D-FR-60010-015	A Phase I, Randomised, Open-Label, Single-Dose, Two-Treatment, Two-Way Crossover, Two-Stage Study to Evaluate the Bioequivalence of Onivyde (Irinotecan Liposome Injection) Manufactured at Two Different Sites Administered in Combination With Anti-Cancer Agents in Adult Participants With Metastatic Pancreatic Adenocarcinoma	Metastatic Pancreatic Adenocarcinoma	- Frankston; - Bedford Park	https://clinicaltrials.gov/ct2/show/NCT05383352
NCT05384626	NVL-655-01	Phase 1/Phase 2		VIC	20/05/2022	9/06/2022	Lorlatinib; NVL-655	ROS1_inhibitor; ALK_inhibitor,third_generation; ALK_inhibitor,fourth_generation	Lorlatinib; NVL-655	ALK_inhibitor,fourth_generation; ALK_inhibitor,third_generation; ROS1_inhibitor	NVL-655-01	A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors (ALKOVE-1)	Locally Advanced Solid Tumor; Metastatic Solid Tumor	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT05384626
NCT05388669	PALOMA-3	Phase 3		SA, NSW, VIC, WA	24/05/2022	5/08/2022	Amivantamab; Amivantamab + Lazertinib; Amivantamab + Lazertinib + rHuPH20; Lazertinib; Osimertinib; rHuPH20	recombinant_human_hyaluronidase; EGFR_inhibitor,third_generation + bispecific_cMET/EGFR_monoclonal_antibody + recombinant_human_hyaluronidase; EGFR_inhibitor,third_generation; bispecific_cMET/EGFR_monoclonal_antibody; EGFR_inhibitor,third_generation + bispecific_cMET/EGFR_monoclonal_antibody	Amivantamab + Lazertinib; Amivantamab + Lazertinib + rHuPH20; Amivantamab + Lazertinib; Amivantamab + Lazertinib + rHuPH20; Osimertinib	EGFR_inhibitor,third_generation + bispecific_cMET/EGFR_monoclonal_antibody; EGFR_inhibitor,third_generation + bispecific_cMET/EGFR_monoclonal_antibody + recombinant_human_hyaluronidase; EGFR_inhibitor,third_generation + bispecific_cMET/EGFR_monoclonal_antibody; EGFR_inhibitor,third_generation + bispecific_cMET/EGFR_monoclonal_antibody + recombinant_human_hyaluronidase	2022-000525-25  CR109211	A Phase 3, Open-label, Randomized Study of Lazertinib With Subcutaneous Amivantamab Administered Via Manual Injection Compared With Intravenous Amivantamab or Amivantamab Subcutaneous On Body Delivery System in Patients With EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer After Progression on Osimertinib and Chemotherapy	Advanced or Metastatic Non-small Cell Lung Cancer	2145 - Westmead; 2050 - Camperdown; 6150 - Murdoch; 3000 - Melbourne; 5000 - Adelaide	https://clinicaltrials.gov/ct2/show/NCT05388669
NCT05393791	ANZadapt	Phase 2		QLD, NSW, WA	26/05/2022	10/11/2022	Abiraterone; Abiraterone + Enzalutamide; Enzalutamide	antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor	Abiraterone + Enzalutamide; Abiraterone + Enzalutamide	CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation	ANZUP 2101  79835	ANZadapt: Phase II Randomised Controlled Trial of Patient-specific Adaptive Versus Continuous Abiraterone or eNZalutamide in Metastatic Castration-resistant Prostate Cancer	Prostatic Neoplasms, Castration-Resistant	2298 - Newcastle; 4101 - South Brisbane; 2065 - St Leonards; 2076 - Wahroonga; 6150 - Murdoch; 2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT05393791
NCT05399654	INCLINE-101	Phase 1/Phase 2		WA	1/06/2022	28/06/2022	TAC-001	TLR9_agonistic_antibody_conjugate	TAC-001	TLR9_agonistic_antibody_conjugate	INCLINE-101	A Phase 1/2, Open Label, Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors	Advanced or Metastatic Solid Tumors	6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT05399654
NCT05410145	D3S-001-100	Phase 1		NSW, VIC	8/06/2022		D3S-001	KRAS_G12C_inhibitor	D3S-001	KRAS_G12C_inhibitor	D3S-001-100	A Phase 1, Open-label, Dose-escalation and Dose-expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3S-001 Monotherapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation	KRAS P.G12C	3144 - Malvern; 2109 - Sydney	https://clinicaltrials.gov/ct2/show/NCT05410145
NCT05411133	A001	Phase 1		NSW	9/06/2022	30/05/2022	ARB202	bispecific_T-cell_engager,CDH17-targeting	ARB202	bispecific_T-cell_engager,CDH17-targeting	A001	A Phase 1, First-in-human Study of ARB202, Bispecific Antibody to CDH17 and CD3 in Advanced Gastrointestinal Malignancies	Colorectal Adenocarcinoma; Pancreatic Cancer; Cholangiocarcinoma; Liver Cancer; Gastrointestinal Cancer; Gastric Cancer	- Sydney	https://clinicaltrials.gov/ct2/show/NCT05411133
NCT05415072	2021-003380-95--CDYP688A12101	Phase 1/Phase 2		NSW	10/06/2022	4/07/2022	DYP688; Tebentafusp	GNAQ/GNA11_inhibitor; anti-CD3/scFv_fusion_protein,gp100-targeting	Tebentafusp; DYP688	anti-CD3/scFv_fusion_protein,gp100-targeting; GNAQ/GNA11_inhibitor	2021-003380-95  CDYP688A12101	A Phase I/II, Multi-center, Open Label Study of DYP688 in Patients With Metastatic Uveal Melanoma (MUM) and Other GNAQ/11 Mutant Melanomas	Metastatic Uveal Melanoma	2145 - Westmead	https://clinicaltrials.gov/ct2/show/NCT05415072
NCT05417594	CERTIS1	Phase 1/Phase 2		NSW, VIC	14/06/2022		AZD9574; AZD9574 + Temozolomide; Temozolomide	alkylating_agent; PARP1-selective_inhibitor; PARP1-selective_inhibitor + alkylating_agent	AZD9574; AZD9574 + Temozolomide; AZD9574 + Temozolomide	PARP1-selective_inhibitor; PARP1-selective_inhibitor + alkylating_agent; PARP1-selective_inhibitor + alkylating_agent	2021-006227-17  D8410C00001	A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (CERTIS1)	Advanced Solid Malignancies	2050 - Camperdown; 3000 - Melbourne; 2010 - Darlinghurst	https://clinicaltrials.gov/ct2/show/NCT05417594
NCT05419375	BX43361	Phase 2		WA, VIC	15/06/2022	22/07/2022					BX43361	Master Screening Study to Determine Biomarker Status and Potential Trial Eligibility for Patients With Malignant Tumors	Solid Tumors	6009 - Nedlands; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT05419375
NCT05419388	BP43963	Phase 2	NOT_RECRUITING	NSW, QLD, NZ	15/06/2022	15/08/2022	RO7247669	bispecific_PD-1/LAG3_antibody	RO7247669	bispecific_PD-1/LAG3_antibody	BP43963	A Randomized, Open-Label, Multicenter, Phase II Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic Melanoma	Melanoma	Wellington; 2060 - North Sydney; 4102 - Woolloongabba	https://clinicaltrials.gov/ct2/show/NCT05419388
NCT05425862	REPAIR	Phase 1		VIC	21/06/2022	21/10/2022	Pidnarulex; Pidnarulex + Talazoparib; Talazoparib	RNA_polymerase_I_transcription_inhibitor; PARP_inhibitor + RNA_polymerase_I_transcription_inhibitor; PARP_inhibitor	Pidnarulex + Talazoparib; Pidnarulex + Talazoparib	PARP_inhibitor + RNA_polymerase_I_transcription_inhibitor; PARP_inhibitor + RNA_polymerase_I_transcription_inhibitor	20/019	Phase 1 Trial of Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate Cancer	Metastatic Castration Resistant Prostate Cancer (mCRPC)	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT05425862
NCT05425940	STELLAR-303	Phase 3		NSW, VIC	21/06/2022	7/09/2022	Atezolizumab; Atezolizumab + Zanzalintinib; Regorafenib; Zanzalintinib	anti-PD-L1_monoclonal_antibody; MET/VEGFR2/AXL/MER_inhibitor; MET/VEGFR2/AXL/MER_inhibitor + anti-PD-L1_monoclonal_antibody; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor	Atezolizumab + Zanzalintinib; Regorafenib; Atezolizumab + Zanzalintinib	KIT/PDGFR/RET/VEGFR/FGFR_inhibitor; MET/VEGFR2/AXL/MER_inhibitor + anti-PD-L1_monoclonal_antibody; MET/VEGFR2/AXL/MER_inhibitor + anti-PD-L1_monoclonal_antibody	2021-003243-21  XL092-303	A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer	Colorectal Cancer	2444 - Port Macquarie; 3021 - Melbourne; 3002 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT05425940
NCT05440786	J1S-MC-JP04--18434	Phase 2		VIC, NSW	1/07/2022		Abemaciclib; Abemaciclib + Irinotecan + Temozolomide; Irinotecan; Irinotecan + Temozolomide; Temozolomide	alkylating_agent; alkylating_agent + topoisomerase_inhibitor; CDK4/6_inhibitor; topoisomerase_inhibitor; CDK4/6_inhibitor + alkylating_agent + topoisomerase_inhibitor	Abemaciclib + Irinotecan + Temozolomide; Irinotecan + Temozolomide; Abemaciclib + Irinotecan + Temozolomide; Irinotecan + Temozolomide	CDK4/6_inhibitor + alkylating_agent + topoisomerase_inhibitor; alkylating_agent + topoisomerase_inhibitor; CDK4/6_inhibitor + alkylating_agent + topoisomerase_inhibitor; alkylating_agent + topoisomerase_inhibitor	J1S-MC-JP04  18434	A Randomized, Open-Label, Phase 2 Study Evaluating Abemaciclib in Combination With Irinotecan and Temozolomide in Participants With Relapsed or Refractory Ewing's Sarcoma	Neoplasm Metastasis; Sarcoma, Ewing	2145 - Westmead; 3000 - Melbourne; 2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT05440786
NCT05440864	NEOTOMA	Unknown			1/07/2022		Durvalumab; Durvalumab + Tremelimumab; Tremelimumab	anti-PD-L1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody	Durvalumab + Tremelimumab; Durvalumab + Tremelimumab	anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody	22-5353	Perioperative Therapy With Durvalumab Plus Tremelimumab for Patients With Resectable Hepatocellular Carcinoma (HCC) - A Phase II Trial (NEOTOMA)	Hepatocellular Carcinoma		https://clinicaltrials.gov/ct2/show/NCT05440864
NCT05450692	LATIFY	Phase 3		VIC, NSW, QLD, SA	11/07/2022	15/09/2022	Ceralasertib; Ceralasertib + Durvalumab; Docetaxel; Durvalumab	ATR_inhibitor + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; ATR_inhibitor; taxane	Ceralasertib + Durvalumab; Docetaxel; Ceralasertib + Durvalumab	ATR_inhibitor + anti-PD-L1_monoclonal_antibody; taxane; ATR_inhibitor + anti-PD-L1_monoclonal_antibody	2022-000493-26  D533BC00001	A Phase III, Open-label, Randomised, Multicentre Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations, and Whose Disease Has Progressed On or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy: LATIFY	Advanced or Metastatic Non-Small Cell Lung Cancer	5112 - Elizabeth Vale; 4101 - South Brisbane; 3355 - Wendouree; 2500 - Wollongong	https://clinicaltrials.gov/ct2/show/NCT05450692
NCT05450744	IPAX-2	Phase 1		SA, NZ, QLD, VIC	11/07/2022	1/04/2023	131I-IPA; 131I-TLX-101	radioligand,LAT1/2-targeting; radioiodine_conjugate	131I-IPA; 131I-TLX-101	radioiodine_conjugate; radioligand,LAT1/2-targeting	131I-TLX-101-002 (IPAX-2)	A Phase 1 Safety and Dose Finding Study of 131I -TLX101 Plus Standard of Care in Patients With Newly Diagnosed Glioblastoma	Neoplastic Disease; Glioblastoma; Glioblastoma Multiforme	Auckland; - Gold Coast; - Adelaide; - Melbourne	https://clinicaltrials.gov/ct2/show/NCT05450744
NCT05458219	CIBI343A101	Phase 1		QLD	14/07/2022		IBI343	anti-CLDN18.2_antibody-drug_conjugate	IBI343	anti-CLDN18.2_antibody-drug_conjugate	CIBI343A101	A Phase 1a/b, Multicenter, Open-label, First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors	Locally Advanced Unresectable or Metastatic Solid Tumors	4217 - Benowa	https://clinicaltrials.gov/ct2/show/NCT05458219
NCT05459129	CO43613	Unknown		SA, WA	14/07/2022	13/04/2023	Atezolizumab; Atezolizumab + Carboplatin + Paclitaxel + Tiragolumab; Atezolizumab + Tiragolumab; Carboplatin; Paclitaxel; Tiragolumab	anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; anti-PD-L1_monoclonal_antibody; platinum-based_antineoplastic_agent; taxane; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-TIGIT_monoclonal_antibody	Atezolizumab + Carboplatin + Paclitaxel + Tiragolumab; Atezolizumab + Tiragolumab; Atezolizumab + Carboplatin + Paclitaxel + Tiragolumab; Atezolizumab + Tiragolumab	anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane	CO43613	A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)	Squamous Cell Carcinoma of the Head and Neck	5000 - Adelaide; 6009 - Perth	https://clinicaltrials.gov/ct2/show/NCT05459129
NCT05462236	AUM001-2001-MK3475-D65	Phase 2		QLD	18/07/2022	14/04/2023	AUM001; AUM001 + Irinotecan + Pembrolizumab; Irinotecan; Pembrolizumab	MNK_inhibitor; anti-PD-1_monoclonal_antibody; MNK_inhibitor + anti-PD-1_monoclonal_antibody + topoisomerase_inhibitor; topoisomerase_inhibitor	AUM001 + Irinotecan + Pembrolizumab; AUM001 + Irinotecan + Pembrolizumab	MNK_inhibitor + anti-PD-1_monoclonal_antibody + topoisomerase_inhibitor; MNK_inhibitor + anti-PD-1_monoclonal_antibody + topoisomerase_inhibitor	AUM001-2001-MK3475-D65	A Phase II Open Label, Dose-finding run-in and Cohort Expansion Study to Evaluate the Safety, Tolerability and Effectiveness of AUM001 in Combination With Pembrolizumab or Irinotecan in Metastatic Colorectal Cancer	Metastatic Colorectal Cancer	4217 - Benowa	https://clinicaltrials.gov/ct2/show/NCT05462236
NCT05462717	RMC-6291-001	Phase 1		VIC	18/07/2022	19/09/2022	RMC-6291	KRAS_G12C_inhibitor	RMC-6291	KRAS_G12C_inhibitor	RMC-6291-001	Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors	Pancreatic Ductal Adenocarcinoma; Advanced Solid Tumor; Colorectal Cancer (CRC); Non-Small Cell Lung Cancer (NSCLC)	3199 - Frankston	https://clinicaltrials.gov/ct2/show/NCT05462717
NCT05466799	TRIPP-FFX	Unknown		VIC, QLD, SA	20/07/2022	26/04/2023	OncoSil	brachytherapy	OncoSil	brachytherapy	ONCO01P04	An Open-label, Multi-centre, Randomized Study of TaRgeted Intratumoural Placement of P-32 (OncoSil™) in Addition to FOLFIRINOX Chemotherapy vs FOLFIRINOX Alone in Patients With Unresectable Locally Advanced Pancreatic Adenocarcinoma.	Locally Advanced Pancreatic Cancer	- Richmond; - Adelaide	https://clinicaltrials.gov/ct2/show/NCT05466799
NCT05468697	MK-6482-024--6482-024	Phase 1/Phase 2		NSW	21/07/2022		Belzutifan; Palbociclib	HIF2a_inhibitor; CDK4/6_inhibitor	Palbociclib; Belzutifan	CDK4/6_inhibitor; HIF2a_inhibitor	MK-6482-024  6482-024	A Multicenter, Open-label, Randomized, Phase 1/2 Study of Belzutifan in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma	Renal Cell Carcinoma	2109 - Macquarie University	https://clinicaltrials.gov/ct2/show/NCT05468697
NCT05480865	Argonaut	Phase 1		SA	29/07/2022		BBP-398; BBP-398 + Sotorasib; Sotorasib	SHP2_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + SHP2_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor	BBP-398 + Sotorasib; BBP-398 + Sotorasib	KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + SHP2_inhibitor; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + SHP2_inhibitor	NAV-1003	A Phase 1 Study of the SHP2 Inhibitor BBP-398 (Formerly Known as IACS-15509) in Combination With the KRAS-G12C Inhibitor Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation	Metastatic Solid Tumor; Metastatic NSCLC; Non Small Cell Lung Cancer; Solid Tumor, Adult	5000 - Adelaide	https://clinicaltrials.gov/ct2/show/NCT05480865
NCT05487235	2021-006479-40--GO43712	Phase 1		WA	4/08/2022	17/08/2022	Atezolizumab; Atezolizumab + RLY-1971; RLY-1971	SHP2_inhibitor; anti-PD-L1_monoclonal_antibody; SHP2_inhibitor + anti-PD-L1_monoclonal_antibody	Atezolizumab + RLY-1971; Atezolizumab + RLY-1971	SHP2_inhibitor + anti-PD-L1_monoclonal_antibody; SHP2_inhibitor + anti-PD-L1_monoclonal_antibody	2021-006479-40  GO43712	A Phase Ib, Open-Label Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors	Advanced Solid Tumors; Metastatic Solid Tumors	6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT05487235
NCT05494762	BGB-A317-B167-101	Phase 1		VIC, NSW, SA	10/08/2022		BGB-B167; BGB-B167 + Tislelizumab; Tislelizumab	bispecific_CEACAM5/4-1BB_antibody; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + bispecific_CEACAM5/4-1BB_antibody	BGB-B167 + Tislelizumab; BGB-B167 + Tislelizumab	anti-PD-1_monoclonal_antibody + bispecific_CEACAM5/4-1BB_antibody; anti-PD-1_monoclonal_antibody + bispecific_CEACAM5/4-1BB_antibody	BGB-A317-B167-101	A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B167, Alone and in Combination With Tislelizumab in Patients With Selected Advanced or Metastatic Solid Tumors	Solid Tumor	3004 - Melbourne; 3168 - Clayton; 2148 - Blacktown; 5125 - Kurralta Park; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT05494762
NCT05494918	JSKN003-101	Phase 1		WA	10/08/2022	2/09/2022	JSKN003	anti-ERBB2_antibody-drug_conjugate	JSKN003	anti-ERBB2_antibody-drug_conjugate	JSKN003-101	A Phase I, Multi-center, Open-label, Dose Escalation, First-In-Human Study to Assess the Safety, Tolerability and Pharmacokinetics of JSKN003 in Subjects With Advanced or Metastatic Solid Malignant Tumors	Advanced Solid Tumors; Metastatic Solid Tumors	6009 - Perth	https://clinicaltrials.gov/ct2/show/NCT05494918
NCT05498428	PALOMA-2	Phase 2		WA, VIC	12/08/2022	11/11/2022	Amivantamab; Amivantamab + Carboplatin + Lazertinib + Osimertinib + Pemetrexed; Amivantamab + Carboplatin + Pemetrexed; Amivantamab + Lazertinib; Carboplatin; Lazertinib; Osimertinib; Pemetrexed	EGFR_inhibitor,third_generation; EGFR_inhibitor,third_generation + antimetabolite + bispecific_cMET/EGFR_monoclonal_antibody + platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent; antimetabolite + bispecific_cMET/EGFR_monoclonal_antibody + platinum-based_antineoplastic_agent; antimetabolite; EGFR_inhibitor,third_generation + bispecific_cMET/EGFR_monoclonal_antibody; bispecific_cMET/EGFR_monoclonal_antibody	Amivantamab + Carboplatin + Lazertinib + Osimertinib + Pemetrexed; Amivantamab + Carboplatin + Pemetrexed; Amivantamab + Lazertinib; Amivantamab + Carboplatin + Lazertinib + Osimertinib + Pemetrexed; Amivantamab + Carboplatin + Pemetrexed; Amivantamab + Lazertinib	EGFR_inhibitor,third_generation + antimetabolite + bispecific_cMET/EGFR_monoclonal_antibody + platinum-based_antineoplastic_agent; EGFR_inhibitor,third_generation + bispecific_cMET/EGFR_monoclonal_antibody; antimetabolite + bispecific_cMET/EGFR_monoclonal_antibody + platinum-based_antineoplastic_agent; EGFR_inhibitor,third_generation + antimetabolite + bispecific_cMET/EGFR_monoclonal_antibody + platinum-based_antineoplastic_agent; EGFR_inhibitor,third_generation + bispecific_cMET/EGFR_monoclonal_antibody; antimetabolite + bispecific_cMET/EGFR_monoclonal_antibody + platinum-based_antineoplastic_agent	2022-000526-21  CR109264	A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients With Advanced or Metastatic Solid Tumors Including EGFR-mutated Non-Small Cell Lung Cancer	Carcinoma, Non-small-Cell Lung	6009 - Nedlands; VIC 3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT05498428
NCT05498597	AMT-151-01	Phase 1		NSW, VIC, QLD, SA, WA	12/08/2022		AMT-151	anti-FR-alpha_antibody-drug_conjugate	AMT-151	anti-FR-alpha_antibody-drug_conjugate	AMT-151-01	First-in-Human, Phase 1 Study of AMT-151, an Anti-Folate Receptor Alpha Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours	Ovarian Clear Cell Carcinoma; Ovarian Carcinoma; Ovarian Cancer; Advanced Cancer; Malignant Pleural Mesothelioma; Ovarian Endometrioid Adenocarcinoma; Endometrial Cancer; Ovarian Epithelial Cancer; Ovarian Mucinous Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Ovarian Clear Cell Adenocarcinoma; Pancreatic Ductal Adenocarcinoma; Endometrial Serous Adenocarcinoma; Advanced Solid Tumor; Triple Negative Breast Cancer; Endometrial Adenocarcinoma; Endometrial Endometrioid Adenocarcinoma; Lung Adenocarcinoma; Advanced Carcinoma	- Adelaide; - Perth; - Brisbane; - South Brisbane; - Sydney; - Malvern	https://clinicaltrials.gov/ct2/show/NCT05498597
NCT05501886	VIKTORIA-1	Phase 3		WA, VIC, NSW, QLD, SA	16/08/2022	30/09/2022	Alpelisib; Alpelisib + Fulvestrant; Fulvestrant; Fulvestrant + Gedatolisib; Fulvestrant + Gedatolisib + Palbociclib; Gedatolisib; Palbociclib	PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + pan-PI3K/mTORC1/mTORC2_inhibitor + selective_estrogen_receptor_degrader; pan-PI3K/mTORC1/mTORC2_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor; pan-PI3K/mTORC1/mTORC2_inhibitor; PI3K_alpha_inhibitor; selective_estrogen_receptor_degrader	Alpelisib + Fulvestrant; Fulvestrant; Fulvestrant + Gedatolisib; Fulvestrant + Gedatolisib + Palbociclib; Alpelisib + Fulvestrant; Fulvestrant + Gedatolisib; Fulvestrant + Gedatolisib + Palbociclib	CDK4/6_inhibitor + pan-PI3K/mTORC1/mTORC2_inhibitor + selective_estrogen_receptor_degrader; PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; pan-PI3K/mTORC1/mTORC2_inhibitor + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader; CDK4/6_inhibitor + pan-PI3K/mTORC1/mTORC2_inhibitor + selective_estrogen_receptor_degrader; PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; pan-PI3K/mTORC1/mTORC2_inhibitor + selective_estrogen_receptor_degrader	2021-005235-24  CELC-G-301	Phase 3, Open-Label, Randomized, Study Comparing Gedatolisib Combined With Fulvestrant & With or Without Palbociclib to Standard-of-Care Therapies in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination w/Non-Steroidal Aromatase Inhibitor Therapy	Breast Cancer	- Fitzroy; - South Brisbane; - Wahroonga; - Frankston; - Adelaide; - Southport; - Nedlands; - Woodville	https://clinicaltrials.gov/ct2/show/NCT05501886
NCT05508906	OP-1250-003	Phase 1		WA	19/08/2022	31/08/2022	Alpelisib; Alpelisib + Palazestrant; Palazestrant; Palazestrant + Ribociclib; Ribociclib	CDK4/6_inhibitor + complete_estrogen_receptor_antagonist; complete_estrogen_receptor_antagonist; CDK4/6_inhibitor; PI3K_alpha_inhibitor + complete_estrogen_receptor_antagonist; PI3K_alpha_inhibitor	Alpelisib + Palazestrant; Palazestrant + Ribociclib; Alpelisib + Palazestrant; Palazestrant + Ribociclib	CDK4/6_inhibitor + complete_estrogen_receptor_antagonist; PI3K_alpha_inhibitor + complete_estrogen_receptor_antagonist; CDK4/6_inhibitor + complete_estrogen_receptor_antagonist; PI3K_alpha_inhibitor + complete_estrogen_receptor_antagonist	OP-1250-003	A Phase 1b Open-Label Multicenter Study of OP-1250 in Combination With the CDK4/6 Inhibitor Ribociclib or With the PI3K Inhibitor Alpelisib in Adult Subjects With Advanced and/or Metastatic HR Positive, HER2 Negative Breast Cancer	Metastatic Breast Cancer; Advanced Breast Cancer; HR-positive Breast Cancer; HER2-negative Breast Cancer	6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT05508906
NCT05512377	2022-001500-18--1403-0011	Phase 2		QLD	23/08/2022	25/11/2022	Brigimadlin	MDM2_inhibitor	Brigimadlin	MDM2_inhibitor	2022-001500-18  1403-0011	Brightline-2: A Phase IIa/IIb, Open-label, Single-arm, Multi-centre Trial of BI 907828 for Treatment of Patients With Locally Advanced / Metastatic, MDM2 Amplified, TP53 Wild-type Biliary Tract Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, or Other Selected Solid Tumours	Biliary Tract Cancer; Solid Tumors; Pancreatic Neoplasms; Lung Neoplasms; Bladder Cancer	4101 - South Brisbane	https://clinicaltrials.gov/ct2/show/NCT05512377
NCT05513703	2022-500608-23-00--M22-137	Phase 2		VIC	24/08/2022		Telisotuzumab Vedotin	anti-cMET_antibody-drug_conjugate	Telisotuzumab Vedotin	anti-cMET_antibody-drug_conjugate	2022-500608-23-00  M22-137	Phase 2, Open-Label Study in Subjects With Previously Untreated MET Amplified Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)	Non Small Cell Lung Cancer	3168 - Clayton	https://clinicaltrials.gov/ct2/show/NCT05513703
NCT05519449	ENGAGER-PSMA-01--PSMA-007-001	Phase 1		WA	29/08/2022	15/09/2022	JANX007	PSMA-tumor-activated_T-cell_engager	JANX007	PSMA-tumor-activated_T-cell_engager	ENGAGER-PSMA-01  PSMA-007-001	A Phase 1, Open-Label, Multicenter Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer	Metastatic Castration-resistant Prostate Cancer; Castration Resistant Prostatic Cancer; Prostate Cancer	6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT05519449
NCT05521412	VIOLET	Phase 1/Phase 2		VIC	30/08/2022	29/09/2022					21/028	EValuation of radIOLigand Treatment in mEn With Metastatic Castration-resistant Prostate Cancer With [161Tb]Tb-PSMA-I&T: Phase I/II Study	Metastatic Castration-resistant Prostate Cancer; Prostate Cancer	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT05521412
NCT05523947	YH32367-101	Phase 1/Phase 2		SA	1/09/2022	26/08/2022	YH32367	bispecific_ERBB2/4-1BB_antibody	YH32367	bispecific_ERBB2/4-1BB_antibody	YH32367-101	A Phase 1/2, Non-randomized, Open-label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of YH32367 in Patients With HER2-Positive Locally Advanced or Metastatic Solid Tumors	HER2-Positive Solid Tumor	- Adelaide	https://clinicaltrials.gov/ct2/show/NCT05523947
NCT05525247	SLC-3010-001	Phase 1/Phase 2		Pert, WA, NSW	1/09/2022	19/01/2023	Gemcitabine	gemcitabine; antimetabolite	Gemcitabine	antimetabolite; gemcitabine	SLC-3010-001	A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of SLC-3010 Monotherapy and in Combination With Various Anticancer Therapies in Patients With Advanced Solid Tumors	Advanced Solid Tumor	2298 - Waratah; 6153 - Brentwood	https://clinicaltrials.gov/ct2/show/NCT05525247
NCT05533697	2022-000925-26--mRNA-4359-P101	Phase 1/Phase 2		WA	9/09/2022	18/08/2022	Pembrolizumab; Pembrolizumab + mRNA-4359; mRNA-4359	anti-PD-1_monoclonal_antibody + mRNA_personalised_cancer_vaccine,IDO/PD-L1-targeting; anti-PD-1_monoclonal_antibody; mRNA_personalised_cancer_vaccine,IDO/PD-L1-targeting	Pembrolizumab + mRNA-4359; mRNA-4359; Pembrolizumab + mRNA-4359	anti-PD-1_monoclonal_antibody + mRNA_personalised_cancer_vaccine,IDO/PD-L1-targeting; mRNA_personalised_cancer_vaccine,IDO/PD-L1-targeting; anti-PD-1_monoclonal_antibody + mRNA_personalised_cancer_vaccine,IDO/PD-L1-targeting	2022-000925-26  mRNA-4359-P101	Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors	Advanced Solid Tumors	6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT05533697
NCT05543629	CA115-001	Phase 1/Phase 2		VIC	16/09/2022	4/10/2022	Carboplatin; Carboplatin + Nivolumab + Paclitaxel; Carboplatin + Nivolumab + Pemetrexed; Docetaxel; Docetaxel + Nivolumab; Nivolumab; Paclitaxel; Pemetrexed	anti-PD-1_monoclonal_antibody + taxane; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite; taxane	Carboplatin + Nivolumab + Paclitaxel; Carboplatin + Nivolumab + Pemetrexed; Docetaxel + Nivolumab; Nivolumab; Carboplatin + Nivolumab + Paclitaxel; Carboplatin + Nivolumab + Pemetrexed; Docetaxel + Nivolumab	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; anti-PD-1_monoclonal_antibody + taxane; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; anti-PD-1_monoclonal_antibody + taxane	CA115-001	A Phase 1b/2 Study of BMS-986442 in Combination With Nivolumab or Nivolumab and Chemotherapies in Participants With Advanced Solid Tumors and Non-small Cell Lung Cancer	Non-small Cell Lung Cancer; Advanced Solid Tumors	3168 - Clayton	https://clinicaltrials.gov/ct2/show/NCT05543629
NCT05544552	SURF301	Phase 1/Phase 2		SA, QLD, VIC, NSW, WA	16/09/2022		TYRA-300	FGFR3_inhibitor	TYRA-300	FGFR3_inhibitor	TYR300-101	A Multicenter, Open-label Phase 1/2 Study of TYRA300 in Advanced Urothelial Carcinoma and Other Solid Tumors With Activating FGFR3 Gene Alterations (SURF301)	Urothelial Carcinoma; Metastatic Urothelial Carcinoma; Solid Tumor; Locally Advanced Urothelial Carcinoma	3084 - Heidelberg; 2109 - Macquarie Park; 6009 - Nedlands; 3000 - Melbourne; 5042 - Bedford Park; 4215 - Southport; 4102 - Woolloongabba	https://clinicaltrials.gov/ct2/show/NCT05544552
NCT05546476	PROACC-1	Phase 2		VIC	19/09/2022	21/11/2022	Placebo; Ponsegromab	anti-GDF15_monoclonal_antibody; placebo	Ponsegromab; Placebo	anti-GDF15_monoclonal_antibody; placebo	2022-003016-87  C3651003	A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF PONSEGROMAB IN PATIENTS WITH CANCER, CACHEXIA, AND ELEVATED CONCENTRATIONS OF GDF-15, FOLLOWED BY AN OPTIONAL OPEN-LABEL TREATMENT PERIOD	Pancreatic Cancer; Fatigue; Colorectal Cancer; Loss of Appetite; Cachexia; Non-small Cell Lung Cancer	3000 - Melbourne; 3021 - St Albans	https://clinicaltrials.gov/ct2/show/NCT05546476
NCT05549297	IMCgp100-203	Unknown		NSW, VIC, QLD	22/09/2022	19/12/2022	Pembrolizumab; Pembrolizumab + Tebentafusp; Tebentafusp	anti-PD-1_monoclonal_antibody; anti-CD3/scFv_fusion_protein,gp100-targeting + anti-PD-1_monoclonal_antibody; anti-CD3/scFv_fusion_protein,gp100-targeting	Pembrolizumab + Tebentafusp; Tebentafusp; Pembrolizumab + Tebentafusp	anti-CD3/scFv_fusion_protein,gp100-targeting; anti-CD3/scFv_fusion_protein,gp100-targeting + anti-PD-1_monoclonal_antibody; anti-CD3/scFv_fusion_protein,gp100-targeting + anti-PD-1_monoclonal_antibody	IMCgp100-203	Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination With Pembrolizumab Versus Investigator's Choice in HLA-A*02:01-positive Participants With Previously Treated Advanced Melanoma (TEBE-AM)	Advanced Melanoma	4102 - Woolloongabba; 3004 - Melbourne; 4120 - Greenslopes; 2065 - Wollstonecraft	https://clinicaltrials.gov/ct2/show/NCT05549297
NCT05551117	Tamarack	Phase 2		VIC	22/09/2022		Vobramitamab duocarmazine	anti-B7H3_antibody-drug_conjugate	Vobramitamab duocarmazine	anti-B7H3_antibody-drug_conjugate	CP-MGC018-03	A Phase 2, Randomized, Open-label, Study of Two Dose Levels of Obramitamab Duocarmazine in Participants With Metastatic Castration-resistant Prostate Cancer	Androgen-Independent Prostatic Cancer; Hormone Refractory Prostatic Cancer; Androgen-Resistant Prostatic Cancer; Castration-Resistant Prostatic Cancer; Androgen-Insensitive Prostatic Cancer	3144 - Malvern; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT05551117
NCT05555732	2022-500802-16--DS1062-A-U303	Phase 3		NSW, VIC	27/09/2022	11/01/2023	Carboplatin; Carboplatin + Cisplatin + Pembrolizumab; Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Cisplatin; Datopotamab deruxtecan; Pembrolizumab; Pemetrexed	anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite; anti-Trop2_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent	Carboplatin + Cisplatin + Pembrolizumab; Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Pembrolizumab; Carboplatin + Cisplatin + Pembrolizumab; Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Datopotamab deruxtecan	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent; anti-Trop2_antibody-drug_conjugate	2022-500802-16  DS1062-A-U303	A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in Subjects With No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07)	Metastatic Non Small Cell Lung Cancer	2500 - Wollongong; 3199 - Frankston	https://clinicaltrials.gov/ct2/show/NCT05555732
NCT05562830	MK-3475-04A--3475-04A	Phase 1/Phase 2		QLD	3/10/2022	16/11/2022	Pembrolizumab; Zilovertamab vedotin	anti-PD-1_monoclonal_antibody; anti-ROR1_antibody-drug_conjugate	Zilovertamab vedotin; Pembrolizumab	anti-ROR1_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody	MK-3475-04A  3475-04A	A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Study of Investigational Agents With or Without Pembrolizumab in Participants With PD-1/L1 Refractory Locally Advanced or Metastatic Urothelial Carcinoma (KEYMAKER-U04): Substudy 04A	Urothelial Carcinoma	4029 - Brisbane	https://clinicaltrials.gov/ct2/show/NCT05562830
NCT05572463	PLATFORM201	Phase 1/Phase 2		QLD	7/10/2022		IBI110; IBI110 + Sintilimab; Sintilimab	anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	IBI110 + Sintilimab; IBI110 + Sintilimab	anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	PLATFORM201	A Randomized, Open-label, Multicenter, Multi-arm, Phase 1b/2 Platform Study to Evaluate Safety and Efficacy of Investigational Immunotherapies in Participants With Previously Treated Unresectable or Metastatic Melanoma	Metastatic Cutaneous Melanoma; Unresectable Cutaneous Melanoma	4102 - Woolloongabba	https://clinicaltrials.gov/ct2/show/NCT05572463
NCT05577416	AB-218-IIT-201	Phase 0		VIC	13/10/2022	11/10/2022	Safusidenib	IDH1_R132_inhibitor	Safusidenib	IDH1_R132_inhibitor	2022.003	A Phase 0/2 Study of AB-218 in Patients With IDH1 Mutated Low Grade Glioma	Glioma	- Melbourne	https://clinicaltrials.gov/ct2/show/NCT05577416
NCT05577715	2022-000131-23--CA116-003	Phase 2		NSW	13/10/2022		Farletuzumab Ecteribulin	anti-FR-alpha_antibody-drug_conjugate	Farletuzumab Ecteribulin	anti-FR-alpha_antibody-drug_conjugate	2022-000131-23  CA116-003	A Phase 2, Open-label, Randomized Study of MORAb-202 (Farletuzumab Ecteribulin), a Folate Receptor Alpha-targeting Antibody-Drug Conjugate, in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) After Progression on Prior Therapies	Carcinoma, Non-Small-Cell Lung	2500 - Wollongong; 1871 - Liverpool	https://clinicaltrials.gov/ct2/show/NCT05577715
NCT05580770	MEKRAF-AST-101	Phase 1/Phase 2		VIC	14/10/2022		BGB-3245; Mirdametinib	MEK_inhibitor; RAF_dimer_inhibitor	BGB-3245; Mirdametinib	MEK_inhibitor; RAF_dimer_inhibitor	MEKRAF-AST-101	A Phase 1/2a Open-Label, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Mirdametinib in Combination With BGB-3245 in Patients With Advanced Solid Tumors	Advanced Solid Tumor	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT05580770
NCT05581004	2021-006708-34--GO43860	Phase 1		WA	14/10/2022	20/10/2022	Atezolizumab; Atezolizumab + RO7502175; RO7502175	anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + unknown_drug_class; unknown_drug_class	Atezolizumab + RO7502175; RO7502175; Atezolizumab + RO7502175	anti-PD-L1_monoclonal_antibody + unknown_drug_class; unknown_drug_class; anti-PD-L1_monoclonal_antibody + unknown_drug_class	2021-006708-34  GO43860	A Phase Ia/Ib, Open Label, Multicenter, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors	Gastric Cancer; Clear Cell RCC; Melanoma; TNBC; Esophageal Cancer; HCC; Locally Advanced or Metastatic Solid Tumors; HNSCC; NSCLC; Urothelial Carcinoma; Cervical Cancer	6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT05581004
NCT05594875	SHR-A1921-I-102-AUS	Phase 1		NSW, QLD	26/10/2022		SHR-A1921	antibody-drug_conjugate,unknown_target	SHR-A1921	antibody-drug_conjugate,unknown_target	SHR-A1921-I-102-AUS	An Open-Label, Multi-Center Phase I Clinical Study on the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of SHR-A1921 for Injection in Subjects With Advanced Solid Tumors	Advanced Solid Tumor	4101 - Brisbane; 2170 - Sydney; 2031 - Sydney; 2109 - Sydney	https://clinicaltrials.gov/ct2/show/NCT05594875
NCT05598151	HM-EZHI-101	Phase 1		VIC, SA	28/10/2022		HM97662	EZH1/2_inhibitor	HM97662	EZH1/2_inhibitor	HM-EZHI-101	A Phase I, Open-Label, Multicenter, Dose Escalation and Expansion Study of HM97662 as a Single Agent in Patients With Advanced or Metastatic Solid Tumors	Advanced or Metastatic Solid Tumors	- Adelaide; - Clayton; - Ballarat; - Frankston	https://clinicaltrials.gov/ct2/show/NCT05598151
NCT05599984	M23-385	Unknown		VIC	31/10/2022	5/12/2022	Budigalimab; Carboplatin; Carboplatin + Cisplatin; Cisplatin	anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent	Budigalimab; Carboplatin + Cisplatin; Carboplatin + Cisplatin	anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent	M23-385	A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-706 as Monotherapy and in Combination With Budigalimab (ABBV-181), Carboplatin, or Cisplatin in Adult Subjects With Advanced Solid Tumors	Advanced Solid Tumors	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT05599984
NCT05607498	EMB07X101	Phase 1		WA, VIC	7/11/2022		EMB-07	bispecific_PD-L1/OX40_antibody; bispecific_T-cell_engager,ROR1-targeting	EMB-07	bispecific_PD-L1/OX40_antibody; bispecific_T-cell_engager,ROR1-targeting	EMB07X101	A First-in-human, Phase I, Open-Label Study of EMB-07, a Bi-specific Antibody Anti-CD3 and Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) in Patients With Locally Advanced/Metastatic Solid Tumors	Advanced/Metastatic Solid Tumors	- Frankston; - Nedlands	https://clinicaltrials.gov/ct2/show/NCT05607498
NCT05607550	FURMO-004	Unknown		QLD, NSW	7/11/2022	1/06/2023	Carboplatin; Carboplatin + Cisplatin + Pemetrexed; Cisplatin; Furmonertinib; Pemetrexed	EGFR_inhibitor,third_generation; EGFR_inhibitor,exon_20_selective; platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; antimetabolite; ERBB2_inhibitor,exon_20_selective	Carboplatin + Cisplatin + Pemetrexed; Furmonertinib; Carboplatin + Cisplatin + Pemetrexed	EGFR_inhibitor,exon_20_selective; EGFR_inhibitor,third_generation; ERBB2_inhibitor,exon_20_selective; antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent	FURMO-004	A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)	Metastatic Non-Small Cell Lung Cancer; EGFR Exon 20 Mutations; Advanced Non-Small Cell Lung Cancer	NSW 2065 - St Leonards; 2148 - Blacktown; 4102 - Woolloongabba	https://clinicaltrials.gov/ct2/show/NCT05607550
NCT05609370	BGB-A317-LBL-007-201	Phase 1/Phase 2		WA, VIC, QLD	8/11/2022		Bevacizumab; Bevacizumab + Capecitabine; Bevacizumab + Capecitabine + LBL-007; Bevacizumab + Capecitabine + LBL-007 + Tislelizumab; Capecitabine; LBL-007; Tislelizumab	anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + fluoropyrimidine; anti-VEGF_monoclonal_antibody + fluoropyrimidine; anti-LAG3_monoclonal_antibody + anti-VEGF_monoclonal_antibody + fluoropyrimidine; anti-VEGF_monoclonal_antibody; fluoropyrimidine	Bevacizumab + Capecitabine; Bevacizumab + Capecitabine + LBL-007; Bevacizumab + Capecitabine + LBL-007 + Tislelizumab; Bevacizumab + Capecitabine; Bevacizumab + Capecitabine + LBL-007; Bevacizumab + Capecitabine + LBL-007 + Tislelizumab	anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + fluoropyrimidine; anti-LAG3_monoclonal_antibody + anti-VEGF_monoclonal_antibody + fluoropyrimidine; anti-VEGF_monoclonal_antibody + fluoropyrimidine; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + fluoropyrimidine; anti-LAG3_monoclonal_antibody + anti-VEGF_monoclonal_antibody + fluoropyrimidine; anti-VEGF_monoclonal_antibody + fluoropyrimidine	BGB-A317-LBL-007-201	A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Capecitabine Versus Bevacizumab Plus Capecitabine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer	Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer	4101 - South Brisbane; 3004 - Melbourne; 3168 - Clayton; 4217 - Benowa; 6150 - Murdoch	https://clinicaltrials.gov/ct2/show/NCT05609370
NCT05609968	MK-3475-D46--3475-D46	Phase 3		VIC	8/11/2022		Pembrolizumab; Pembrolizumab + Sacituzumab Govitecan; Sacituzumab Govitecan	anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody; anti-Trop2_antibody-drug_conjugate	Pembrolizumab; Pembrolizumab + Sacituzumab Govitecan; Pembrolizumab + Sacituzumab Govitecan	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate	MK-3475-D46  3475-D46	An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab (MK-3475) in Combination With Sacituzumab Govitecan Versus MK-3475 Monotherapy as First-line Treatment in Participants With PD L1 TPS Greater Than or Equal to 50% Metastatic Non-small Cell Lung Cancer (KEYNOTE D46/EVOKE-03)	Carcinoma, Non-Small-Cell Lung	3199 - Frankston	https://clinicaltrials.gov/ct2/show/NCT05609968
NCT05611931	XPORT-EC-042	Phase 3			3/11/2022	1/11/2022	Placebo; Selinexor	selective_inhibitor_of_nuclear_export; placebo	Selinexor; Placebo	selective_inhibitor_of_nuclear_export; placebo	GOG-3083  XPORT-EC-042	A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma	Endometrial Cancer		https://clinicaltrials.gov/ct2/show/NCT05611931
NCT05613088	2021-004807-42--CA116-001	Phase 2		VIC, QLD	14/11/2022		Farletuzumab Ecteribulin; Paclitaxel; Pegylated liposomal doxorubicin; Topotecan	anthracycline; taxane; anti-FR-alpha_antibody-drug_conjugate; topoisomerase_inhibitor	Farletuzumab Ecteribulin; Paclitaxel; Pegylated liposomal doxorubicin; Topotecan	anti-FR-alpha_antibody-drug_conjugate; anthracycline; taxane; topoisomerase_inhibitor	2021-004807-42  CA116-001	A Phase 2 Open-label Randomized Study of Farletuzumab Ecteribulin (MORAb-202), a Folate Receptor Alpha-targeting Antibody-drug Conjugate, Versus Investigator's Choice Chemotherapy in Women With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	Neoplasms, Ovarian	4032 - Chermside; 3144 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT05613088
NCT05613842	BOP	Phase 2		NSW	14/11/2022	9/08/2022	Lu-177 vipivotide tetraxetan	radioligand,PSMA-targeting	Lu-177 vipivotide tetraxetan	radioligand,PSMA-targeting	062022-01	Assessment of the Diagnostic Value of 64Cu-SAR-BBN PET Imaging for Men With Negative PSMA PET in Prostate Cancer	Prostate Cancer	2010 - Sydney	https://clinicaltrials.gov/ct2/show/NCT05613842
NCT05614258	ADG206-1001	Phase 1		SA, VIC	14/11/2022		ADG206	anti-4-1BB_agonistic_antibody	ADG206	anti-4-1BB_agonistic_antibody	ADG206-1001	A First-in-Human (FIH), Open-Label, Phase 1 Study of ADG206, a CD137 Agonist Antibody, in Subjects With Advanced/Metastatic Solid Tumors	Advanced/Metastatic Solid Tumors	3168 - Clayton; 5037 - Kurralta Park	https://clinicaltrials.gov/ct2/show/NCT05614258
NCT05614739	J4G-OX-JZVA--LOXO-FG3-22001	Phase 1		NSW	14/11/2022	19/01/2023	LOXO-435; LOXO-435 + Pembrolizumab; Pembrolizumab	FGFR3_inhibitor; anti-PD-1_monoclonal_antibody; FGFR3_inhibitor + anti-PD-1_monoclonal_antibody	LOXO-435; LOXO-435 + Pembrolizumab; LOXO-435 + Pembrolizumab	FGFR3_inhibitor; FGFR3_inhibitor + anti-PD-1_monoclonal_antibody; FGFR3_inhibitor + anti-PD-1_monoclonal_antibody	J4G-OX-JZVA  LOXO-FG3-22001	An Open-Label, Multicenter Study of LOXO-435 (LY3866288) In Advanced Solid Tumor Malignancies With FGFR3 Alterations	Urinary Bladder Neoplasms; Ureteral Neoplasms; Neoplasm Metastasis	NSW 2010 - Darlinghurst	https://clinicaltrials.gov/ct2/show/NCT05614739
NCT05618028	M23-324	Phase 1		VIC	16/11/2022		ABBV-525	MALT1_inhibitor	ABBV-525	MALT1_inhibitor	M23-324	A First-in-Human Study of ABBV-525 (MALT1 Inhibitor) in B-Cell Malignancies	B Cell Malignancies; Chronic Lymphocytic Leukemia; Diffuse Large B-Cell Lymphoma; Non-Hodgkin's Lymphoma	3004 - Melbourne; 3168 - Clayton	https://clinicaltrials.gov/ct2/show/NCT05618028
NCT05619913	EPOCH	Phase 2		QLD, VIC, NSW	17/11/2022		Eribulin; Eribulin + Pembrolizumab; Pembrolizumab	macrocyclic_ketone_analogue; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + macrocyclic_ketone_analogue	Eribulin; Eribulin + Pembrolizumab; Eribulin + Pembrolizumab	anti-PD-1_monoclonal_antibody + macrocyclic_ketone_analogue; macrocyclic_ketone_analogue; anti-PD-1_monoclonal_antibody + macrocyclic_ketone_analogue	ANZGOG 1828/2021	The EPOCH Study: Phase II Open Labelled Study Investigating the Use of Single Agent Eribulin and Eribulin in Combination With Pembrolizumab in Relapsed Tubo-ovarian or Uterine Carcinosarcoma	Ovarian Carcinosarcoma; Uterine Carcinosarcoma	- Randwick; - Clayton; - Herston	https://clinicaltrials.gov/ct2/show/NCT05619913
NCT05625399	RELATIVITY-127	Phase 3		VIC, NSW	22/11/2022		Nivolumab; Nivolumab + Relatlimab; Relatlimab	anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Nivolumab + Relatlimab; Nivolumab + Relatlimab	anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	2022-000575-39  CA224-127	A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination Versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants With Previously Untreated Metastatic or Unresectable Melanoma	Melanoma	2145 - Westmead; 2650 - Wagga Wagga; 3004 - Prahran	https://clinicaltrials.gov/ct2/show/NCT05625399
NCT05625412	2022-500930-27--IM043-004	Phase 1		QLD, NSW	22/11/2022		BMS-986360; BMS-986360 + Capecitabine; BMS-986360 + Docetaxel; BMS-986360 + Nivolumab; Capecitabine; Docetaxel; Nivolumab	anti-PD-1_monoclonal_antibody; JNK_inhibitor + taxane; JNK_inhibitor; JNK_inhibitor + fluoropyrimidine; JNK_inhibitor + anti-PD-1_monoclonal_antibody; taxane; fluoropyrimidine	BMS-986360; BMS-986360 + Capecitabine; BMS-986360 + Docetaxel; BMS-986360 + Nivolumab; BMS-986360 + Capecitabine; BMS-986360 + Docetaxel; BMS-986360 + Nivolumab	JNK_inhibitor; JNK_inhibitor + anti-PD-1_monoclonal_antibody; JNK_inhibitor + fluoropyrimidine; JNK_inhibitor + taxane; JNK_inhibitor + anti-PD-1_monoclonal_antibody; JNK_inhibitor + fluoropyrimidine; JNK_inhibitor + taxane	2022-500930-27  IM043-004	A Phase 1, Open-label, Multicenter Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors	Advanced Solid Tumors	2010 - Darlinghurst; 4120 - Brisbane	https://clinicaltrials.gov/ct2/show/NCT05625412
NCT05635708	BGB-LC-201	Phase 2		NSW	2/12/2022	7/03/2023	BGB-A445; BGB-A445 + Tislelizumab; Carboplatin; Cisplatin; LBL-007; LBL-007 + Tislelizumab; Paclitaxel; Pemetrexed; Tislelizumab	anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody; platinum-based_antineoplastic_agent; antimetabolite; anti-OX40_agonistic_antibody; taxane; anti-OX40_agonistic_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	BGB-A445 + Tislelizumab; LBL-007 + Tislelizumab; Tislelizumab; BGB-A445 + Tislelizumab; Carboplatin; Cisplatin; LBL-007 + Tislelizumab; Paclitaxel; Pemetrexed	anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-OX40_agonistic_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-OX40_agonistic_antibody + anti-PD-1_monoclonal_antibody; antimetabolite; platinum-based_antineoplastic_agent; taxane	BGB-LC-201	Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer	Non-small Cell Lung Cancer; Metastatic Non-small Cell Lung Cancer	2086 - Frenchs Forest; 2444 - Port Macquarie,	https://clinicaltrials.gov/ct2/show/NCT05635708
NCT05636215	CIBI354A101	Phase 1/Phase 2		NSW	5/12/2022		IBI354	anti-ERBB2_antibody-drug_conjugate	IBI354	anti-ERBB2_antibody-drug_conjugate	CIBI354A101	A Phase 1/2, Multicenter, Open-label Study of IBI354 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors	Locally Advanced Unresectable or Metastatic Solid Tumors	2031 - Randwick	https://clinicaltrials.gov/ct2/show/NCT05636215
NCT05642949	MHB036C-CP001EN	Phase 1/Phase 2		SA, VIC, QLD	8/12/2022		MHB036C	anti-Trop2_antibody-drug_conjugate	MHB036C	anti-Trop2_antibody-drug_conjugate	MHB036C-CP001EN	Phase 1/2, Multi-center, Open-label, Dose Escalation and Cohort Expansion Study to Evaluate the Safety/Tolerability, Pharmacokinetics and Efficacy of MHB036C in Participants With Advanced or Metastatic Solid Tumors	Advanced Solid Tumor	5042 - Adelaide; 4217 - Gold Coast; 3144 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT05642949
NCT05645692	BO44157	Phase 2		NSW	9/12/2022	13/04/2023	Atezolizumab; RO7247669; RO7247669 + Tiragolumab; Tiragolumab	bispecific_PD-1/LAG3_antibody; anti-TIGIT_monoclonal_antibody + bispecific_PD-1/LAG3_antibody; anti-PD-L1_monoclonal_antibody; anti-TIGIT_monoclonal_antibody	Atezolizumab; RO7247669; RO7247669 + Tiragolumab; RO7247669 + Tiragolumab	anti-PD-L1_monoclonal_antibody; anti-TIGIT_monoclonal_antibody + bispecific_PD-1/LAG3_antibody; bispecific_PD-1/LAG3_antibody; anti-TIGIT_monoclonal_antibody + bispecific_PD-1/LAG3_antibody	BO44157	A Phase II, Randomized, Multicenter, Open-Label, Controlled Study of RO7247669 Alone or in Combination With Tiragolumab Versus Atezolizumab in Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer Who Are Ineligible for Platinum-Containing Chemotherapy	Urothelial Cancer	2109 - Macquarie Park	https://clinicaltrials.gov/ct2/show/NCT05645692
NCT05647122	EGRET	Phase 1		VIC	12/12/2022		AZD9592; AZD9592 + Osimertinib; Osimertinib	EGFR_inhibitor,third_generation; bispecific_cMET/EGFR_antibody; EGFR_inhibitor,third_generation + bispecific_cMET/EGFR_antibody	AZD9592; AZD9592 + Osimertinib; AZD9592 + Osimertinib	EGFR_inhibitor,third_generation + bispecific_cMET/EGFR_antibody; bispecific_cMET/EGFR_antibody; EGFR_inhibitor,third_generation + bispecific_cMET/EGFR_antibody	D9350C00001	A Phase I, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumors	Head and Neck Neoplasms; Carcinoma Non-small Cell Lung; Advanced Solid Tumours	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT05647122
NCT05650203	JS009-002-I	Phase 1		NSW, QLD, WA	14/12/2022		JS-006; JS-006 + JS-009 + Toripalimab; JS-009; Toripalimab	anti-PD-1_monoclonal_antibody; anti-CD112R_monoclonal_antibody; anti-TIGIT_monoclonal_antibody; anti-CD112R_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody	JS-006 + JS-009 + Toripalimab; JS-006 + JS-009 + Toripalimab	anti-CD112R_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-CD112R_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody	JS009-002-I	A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of JS009 Monotherapy and JS009 as a Triple Combination Therapy in Combination With Toripalimab and JS006 in Patients With Advanced Malignancies	Primary Condition: Advanced Tumors	2148 - Blacktown; 4101 - South Brisbane; 6009 - Perth	https://clinicaltrials.gov/ct2/show/NCT05650203
NCT05650879	HER2	Phase 1		WA	14/12/2022	20/03/2023	ELVN-002; ELVN-002 + Trastuzumab Deruxtecan; ELVN-002 + Trastuzumab Emtansine; Trastuzumab Deruxtecan; Trastuzumab Emtansine	ERBB2_inhibitor,exon_20_selective + anti-ERBB2_antibody-drug_conjugate; ERBB2_inhibitor,exon_20_selective; anti-ERBB2_antibody-drug_conjugate	ELVN-002; ELVN-002 + Trastuzumab Deruxtecan; ELVN-002 + Trastuzumab Emtansine; ELVN-002 + Trastuzumab Deruxtecan; ELVN-002 + Trastuzumab Emtansine	ERBB2_inhibitor,exon_20_selective; ERBB2_inhibitor,exon_20_selective + anti-ERBB2_antibody-drug_conjugate; ERBB2_inhibitor,exon_20_selective + anti-ERBB2_antibody-drug_conjugate	ELVN-002-001	A Phase 1a/1b Study of ELVN-002 for the Treatment of Patients With HER2 Mutant Non-Small Cell Lung Cancer	HER2 Amplification; HER2 Gene Mutation; HER2 Mutant Non-small Cell Lung Cancer; HER2-positive Metastatic Breast Cancer	6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT05650879
NCT05652855	MHB088C-CP001EN	Phase 1/Phase 2		SA, VIC, QLD	15/12/2022		MHB088C	anti-B7H3_antibody-drug_conjugate	MHB088C	anti-B7H3_antibody-drug_conjugate	MHB088C-CP001EN	Phase 1/2, Two-Part, Multi-center, Open-label, Dose Escalation and Dose Expansion First-In-Human Study to Evaluate the Safety/Tolerability, Pharmacokinetics and Efficacy of MHB088C in Participants With Advanced or Metastatic Solid Tumors	Advanced or Metastatic Solid Tumors	5042 - Adelaide; 3144 - Melbourne; 4217 - Gold Coast	https://clinicaltrials.gov/ct2/show/NCT05652855
NCT05652868	KisMET-01--MYTX-011-01	Unknown		NSW	15/12/2022	23/03/2023	MYTX-011	anti-cMET_antibody-drug_conjugate	MYTX-011	anti-cMET_antibody-drug_conjugate	KisMET-01  MYTX-011-01	A Phase 1 Multicenter Dose Escalation and Dose Expansion Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer - KisMET-01	NSCLC Stage IV; Advanced Non-Small Cell Squamous Lung Cancer; Advanced Non-Small Cell Lung Cancer; Non-Small Cell Lung Cancer; Advanced Non-Small Cell Non-Squamous Lung Cancer; NSCLC Stage IIIB; NSCLC	2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT05652868
NCT05654623	VERITAC-2	Phase 3		TAS, QLD	16/12/2022	3/03/2023	ARV-471; Fulvestrant	selective_estrogen_receptor_degrader; ER_PROTAC_degrader	ARV-471; Fulvestrant	ER_PROTAC_degrader; selective_estrogen_receptor_degrader	2022-500544-38-00  C4891001	A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER TRIAL OF ARV-471 (PF-07850327) VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE (VERITAC-2)	Advanced Breast Cancer	7000 - Hobart; 4575 - Birtinya	https://clinicaltrials.gov/ct2/show/NCT05654623
NCT05694936	VADER	Phase 2		VIC, NSW, SA	23/01/2023		Cetuximab; Cetuximab + Panitumumab; Cetuximab + Panitumumab + Sodium Valproate; Panitumumab; Sodium Valproate	anti-EGFR_monoclonal_antibody; HDAC_inhibitor + anti-EGFR_monoclonal_antibody; HDAC_inhibitor	Cetuximab + Panitumumab; Cetuximab + Panitumumab + Sodium Valproate; Cetuximab + Panitumumab; Cetuximab + Panitumumab + Sodium Valproate	HDAC_inhibitor + anti-EGFR_monoclonal_antibody; anti-EGFR_monoclonal_antibody; HDAC_inhibitor + anti-EGFR_monoclonal_antibody	VADER	A Phase II Randomised Controlled Trial to Determine the Efficacy of Combining the HDAC Inhibitor Sodium Valproate With EGFR Monoclonal Antibody (Panitumumab or Cetuximab) Maintenance in the First-line Treatment of Patients With RAS Wild Type Metastatic Colorectal Cancer (CRC)	Metastatic Colorectal Cancer	3350 - Ballarat Central; 2065 - Saint Leonards; 5000 - Adelaide; 3199 - Frankston; 5042 - Bedford Park; 3000 - Melbourne; 3084 - Melbourne; 3128 - Box Hill; 3280 - Warrnambool	https://clinicaltrials.gov/ct2/show/NCT05694936
NCT05712356	BOLSTER	Unknown		SA	3/02/2023	24/08/2023	Cisplatin; Durvalumab; Gemcitabine; Paclitaxel; Placebo	platinum-based_antineoplastic_agent; placebo; antimetabolite; anti-PD-L1_monoclonal_antibody; gemcitabine; taxane	Cisplatin; Durvalumab; Gemcitabine; Paclitaxel; Placebo	anti-PD-L1_monoclonal_antibody; antimetabolite; gemcitabine; placebo; platinum-based_antineoplastic_agent; taxane	2023-503740-14  LSTA1-P02	A Phase 2a, Double-blind, Placebo-controlled, Multi-center, Randomized Study Evaluating LSTA1 When Added to Standard of Care (SoC) Versus Standard of Care Alone in Subjects With Advanced Solid Tumors	Intrahepatic Cholangiocarcinoma; HNSCC; Hypopharynx Squamous Cell Carcinoma; Larynx Squamous Cell Carcinoma; Head and Neck Cancer; Gall Bladder Cancer; Cholangiocarcinoma; Squamous Cell Carcinoma of the Larynx; Squamous Cell Carcinoma of the Oropharynx; Oral Cavity Cancer; Hypopharynx Cancer; Oropharynx Cancer; Advanced Head and Neck Squamous Cell Carcinoma; Bile Duct Cancer; Cancer of the Head and Neck; Oral Cavity Squamous Cell Carcinoma; Larynx Cancer; Gall Bladder Carcinoma; Gallbladder Cancer; Squamous Cell Carcinoma of the Hypopharynx; Gallbladder Carcinoma; Squamous Cell Carcinoma of the Head and Neck; Oropharynx Squamous Cell Carcinoma; Head and Neck Squamous Cell Carcinoma; Squamous Cell Carcinoma of Head and Neck; Squamous Cell Carcinoma of the Oral Cavity; Extrahepatic Cholangiocarcinoma	5011 - Woodville South	https://clinicaltrials.gov/ct2/show/NCT05712356
NCT05718895	CLINCH	Phase 1		QLD, SA	8/02/2023		ATG 022	anti-CLDN18.2_antibody-drug_conjugate	ATG 022	anti-CLDN18.2_antibody-drug_conjugate	ATG-022-ST-001	An Open, Multi-center, Phase I Clinical Study of ATG 022 in Patients With Advanced/Metastatic Solid Tumors	Advanced/Metastatic Solid Tumors	- Malvern; - South Brisbane; - Adelaide	https://clinicaltrials.gov/ct2/show/NCT05718895
NCT05720130	TheraPb-ADVC001	Phase 1/Phase 2		QLD	9/02/2023		212Pb-ADVC001; Abiraterone; Abiraterone + Enzalutamide; Enzalutamide	antiandrogen,nonsteroidal,second_generation; radioligand,PSMA-targeting; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor	Abiraterone + Enzalutamide; 212Pb-ADVC001; Abiraterone + Enzalutamide	CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation; radioligand,PSMA-targeting	TheraPb-ADVC001	TheraPb: Phase I/II Dose Escalation and Toxicity Study of [212Pb]Pb-ADVC001 in Metastatic Prostate Adenocarcinoma	Castration-Resistant; Prostatic Neoplasms	4029 - Brisbane	https://clinicaltrials.gov/ct2/show/NCT05720130
NCT05725291	AMT-116-01	Phase 1		QLD	13/02/2023		AMT-116	anti-CD44v9_antibody-drug_conjugate	AMT-116	anti-CD44v9_antibody-drug_conjugate	AMT-116-01	First-in-Human, Phase 1 Study of AMT-116 in Patients With Advanced Solid Tumors	Advanced Solid Tumor	- Brisbane	https://clinicaltrials.gov/ct2/show/NCT05725291
NCT05727176	FOENIX-CCA4	Unknown		NSW, VIC	14/02/2023	12/05/2023	Futibatinib	pan-FGFR_inhibitor,irreversible	Futibatinib	pan-FGFR_inhibitor,irreversible	2023-503665-39  TAS-120-205	Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements	Advanced Cholangiocarcinoma; FGFR2 Fusions; Gene Rearrangement	2010 - Sydney; 3004 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT05727176
NCT05727904	TILVANCE-301--IOV-MEL-301	Unknown		QLD	14/02/2023	30/03/2023	Pembrolizumab	anti-PD-1_monoclonal_antibody	Pembrolizumab	anti-PD-1_monoclonal_antibody	TILVANCE-301  IOV-MEL-301	A Phase 3, Multicenter, Randomized, Open-label, Parallel Group, Treatment Study to Assess the Efficacy and Safety of the Lifileucel (LN-144, Autologous Tumor Infiltrating Lymphocytes [TIL]) Regimen in Combination With Pembrolizumab Compared With Pembrolizumab Monotherapy in Participants With Untreated, Unresectable or Metastatic Melanoma	Metastatic Melanoma; Unresectable Melanoma; Melanoma	4120 - Greenslopes	https://clinicaltrials.gov/ct2/show/NCT05727904
NCT05735080	INX-315-01	Phase 1/Phase 2		VIC	21/02/2023	28/03/2023	INX-315	CDK2_inhibitor	INX-315	CDK2_inhibitor	INX-315-01	A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of INX-315 in Patients With Advanced Cancer	Metastatic Cancer; Breast Cancer Metastatic; Solid Tumor; Breast Cancer; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast; CCNE1 Amplification; Hormone Receptor Positive Tumor; Ovarian Cancer; Advanced Cancer	3052 - Parkville	https://clinicaltrials.gov/ct2/show/NCT05735080
NCT05759728	CNA3103-001	Phase 1/Phase 2		SA	8/03/2023		CNA3103	autologous_CAR-T-cell_therapy,LGR5-targeting	CNA3103	autologous_CAR-T-cell_therapy,LGR5-targeting	CNA3103-001	A Phase 1/2a, Multicenter, Open-Label, Dose Escalation and Expansion Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Adult Subjects With Metastatic Colorectal Cancer	Colorectal Cancer Metastatic	5000 - Adelaide	https://clinicaltrials.gov/ct2/show/NCT05759728
NCT05763004	IOS-1002-201	Phase 1		VIC, WA	10/03/2023		Tegafur-gimeracil-oteracil pPotassium	DPD_inhibitor; antimetabolite; orotate_phosphoribosyltransferase_inhibitor	Tegafur-gimeracil-oteracil pPotassium	DPD_inhibitor; antimetabolite; orotate_phosphoribosyltransferase_inhibitor	IOS-1002-201	A Phase 1a/1b, First-in-human, Open-label, Non-randomized, Multicenter, Dose-escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Efficacy, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of IOS-1002 Administered Alone and in Combination With a PD-1 Monoclonal Antibody in Advanced Solid Tumors	Solid Tumor, Adult	- Melbourne; - Heidelberg; - Clayton; - Perth	https://clinicaltrials.gov/ct2/show/NCT05763004
NCT05774873	CIBI334A101	Phase 1		NSW	20/03/2023		IBI334	bispecific_EGFR/B7H3_antibody	IBI334	bispecific_EGFR/B7H3_antibody	CIBI334A101	A Phase 1 Study of IBI334 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors	Solid Tumors	2145 - Waratah	https://clinicaltrials.gov/ct2/show/NCT05774873
NCT05775289	BO44178	Phase 2		QLD, VIC, SA	20/03/2023	15/03/2023	Carboplatin; Carboplatin + Pembrolizumab + Pemetrexed; Carboplatin + Pemetrexed + RO7247669; Paclitaxel; Pembrolizumab; Pemetrexed; RO7247669	anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; antimetabolite + bispecific_PD-1/LAG3_antibody + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite; bispecific_PD-1/LAG3_antibody; taxane	Carboplatin + Pembrolizumab + Pemetrexed; Carboplatin + Pemetrexed + RO7247669; Carboplatin + Pembrolizumab + Pemetrexed; Carboplatin + Pemetrexed + RO7247669; Paclitaxel	anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + bispecific_PD-1/LAG3_antibody + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + bispecific_PD-1/LAG3_antibody + platinum-based_antineoplastic_agent; taxane	BO44178	A Phase II, Randomized, Multicenter, Double-Blind, Controlled Study of RO7247669 Plus Platinum-Based Chemotherapy Versus Pembrolizumab Plus Platinum-Based Chemotherapy in Patients With Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer	Non-small Cell Lung Cancer	4217 - Benowa; 3168 - Clayton; 3220 - Geelong; 5112 - Adelaide	https://clinicaltrials.gov/ct2/show/NCT05775289
NCT05789082	2022-003048-28--BO44426	Phase 1/Phase 2		NSW	29/03/2023		Divarasib; Divarasib + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody	Divarasib + Pembrolizumab; Divarasib + Pembrolizumab	KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody	2022-003048-28  BO44426	A Phase Ib/II, Open-Label, Multicenter Study Evaluating the Safety, Activity, and Pharmacokinetics of GDC-6036 in Combination With Other Anti-Cancer Therapies in Patients With Previously Untreated Advanced Or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation	Non-Small Cell Lung Cancer	2139 - Concord	https://clinicaltrials.gov/ct2/show/NCT05789082
NCT05800665	GO44537	Phase 1		VIC	5/04/2023	2/05/2023	RO-7656594	unknown_drug_class	RO-7656594	unknown_drug_class	GO44537	A Phase 1, Open-Label, Multicenter, Dose-Escalation and Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 in Patients With Advanced or Metastatic Prostate Cancer	Advanced Prostate Cancer; Metastatic Prostate Cancer	3065 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT05800665
NCT05805501	BO43936	Phase 2		SA, QLD	10/04/2023	21/04/2023	Axitinib; Axitinib + Pembrolizumab; Axitinib + RO7247669; Axitinib + RO7247669 + Tiragolumab; Pembrolizumab; RO7247669; Tiragolumab	VEGFR/PDGFR_inhibitor + anti-TIGIT_monoclonal_antibody + bispecific_PD-1/LAG3_antibody; VEGFR/PDGFR_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; VEGFR/PDGFR_inhibitor; KIT_inhibitor,ATP-competitive + anti-PD-1_monoclonal_antibody; bispecific_PD-1/LAG3_antibody; KIT_inhibitor,ATP-competitive + anti-TIGIT_monoclonal_antibody + bispecific_PD-1/LAG3_antibody; VEGFR/PDGFR_inhibitor + bispecific_PD-1/LAG3_antibody; KIT_inhibitor,ATP-competitive; KIT_inhibitor,ATP-competitive + bispecific_PD-1/LAG3_antibody; anti-TIGIT_monoclonal_antibody	Axitinib + Pembrolizumab; Axitinib + RO7247669; Axitinib + RO7247669 + Tiragolumab; Axitinib + Pembrolizumab; Axitinib + RO7247669; Axitinib + RO7247669 + Tiragolumab	KIT_inhibitor,ATP-competitive + anti-PD-1_monoclonal_antibody; KIT_inhibitor,ATP-competitive + anti-TIGIT_monoclonal_antibody + bispecific_PD-1/LAG3_antibody; KIT_inhibitor,ATP-competitive + bispecific_PD-1/LAG3_antibody; VEGFR/PDGFR_inhibitor + anti-PD-1_monoclonal_antibody; VEGFR/PDGFR_inhibitor + anti-TIGIT_monoclonal_antibody + bispecific_PD-1/LAG3_antibody; VEGFR/PDGFR_inhibitor + bispecific_PD-1/LAG3_antibody; KIT_inhibitor,ATP-competitive + anti-PD-1_monoclonal_antibody; KIT_inhibitor,ATP-competitive + anti-TIGIT_monoclonal_antibody + bispecific_PD-1/LAG3_antibody; KIT_inhibitor,ATP-competitive + bispecific_PD-1/LAG3_antibody; VEGFR/PDGFR_inhibitor + anti-PD-1_monoclonal_antibody; VEGFR/PDGFR_inhibitor + anti-TIGIT_monoclonal_antibody + bispecific_PD-1/LAG3_antibody; VEGFR/PDGFR_inhibitor + bispecific_PD-1/LAG3_antibody	BO43936	A Randomized Open Label Phase II Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma	Renal Cell Carcinoma	4575 - Birtinya; 5037 - Kurralta Park	https://clinicaltrials.gov/ct2/show/NCT05805501
NCT05807035	CAN001	Phase 1		SA	10/04/2023	10/02/2023	Radvax	autologous_anticancer_vaccine	Radvax	autologous_anticancer_vaccine	CAN001	A Phase I Trial of Autologous Tumour Vaccine for Advanced Solid Cancers	Solid Tumor	5046 - Adelaide	https://clinicaltrials.gov/ct2/show/NCT05807035
NCT05818683	2022-503132-14--CR109321	Phase 1		QLD, VIC, NSW	19/04/2023		Cetrelimab; Cetrelimab + JNJ-78278343; JNJ-78278343	anti-PD-1_monoclonal_antibody; bispecific_T-cell_engager,KLK2-targeting; anti-PD-1_monoclonal_antibody + bispecific_T-cell_engager,KLK2-targeting	Cetrelimab + JNJ-78278343; Cetrelimab + JNJ-78278343	anti-PD-1_monoclonal_antibody + bispecific_T-cell_engager,KLK2-targeting; anti-PD-1_monoclonal_antibody + bispecific_T-cell_engager,KLK2-targeting	2022-503132-14  CR109321	A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination With JNJ-63723283 (Cetrelimab) for Metastatic Castration-Resistant Prostate Cancer	Metastatic Castration-resistant Prostate Neoplasms	4102 - Woolloongabba; 2109 - Macquarie University; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT05818683
NCT05830084	REGO-EWING	Unknown			13/04/2023	27/03/2023	Radiotherapy; Regorafenib	radiotherapy; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor	Radiotherapy; Regorafenib	radiotherapy; KIT/PDGFR/RET/VEGFR/FGFR_inhibitor	2022/3545  2022-002874-10	Phase Ib Study of the Combination of Regorafenib With Conventional Chemotherapy for the Treatment of Newly Diagnosed Patients With Multimetastatic Ewing Sarcoma	Bone Cancer		https://clinicaltrials.gov/ct2/show/NCT05830084
NCT05848011	CP-MGD019-02	Unknown		VIC	8/05/2023	28/09/2023	Docetaxel; Docetaxel + Lorigerlimab + Prednisone; Lorigerlimab; Prednisone	bispecific_PD-1×CTLA-4_dual-affinity_responsive_target_molecule + glucocorticoid + taxane; glucocorticoid; bispecific_PD-1×CTLA-4_dual-affinity_responsive_target_molecule; taxane	Docetaxel + Lorigerlimab + Prednisone; Docetaxel + Lorigerlimab + Prednisone	bispecific_PD-1×CTLA-4_dual-affinity_responsive_target_molecule + glucocorticoid + taxane; bispecific_PD-1×CTLA-4_dual-affinity_responsive_target_molecule + glucocorticoid + taxane	CP-MGD019-02	A Phase 2, Randomized, Open-Label, Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer	Hormone Refractory Prostatic Cancer; Androgen-Independent Prostatic Neoplasms; Androgen-Resistant Prostatic Cancer; Androgen-Independent Prostatic Cancer; Immune Checkpoint Inhibitor; Prostate Cancer Recurrent; Inhibitory Checkpoint Molecule; Androgen-Insensitive Prostatic Cance; Immunotherapy	- North Melbourne	https://clinicaltrials.gov/ct2/show/NCT05848011
NCT05858164	NCT05858164	Unknown		QLD	15/05/2023	7/08/2023	BAY2862789	DGK-alpha_inhibitor	BAY2862789	DGK-alpha_inhibitor	22231	An Open-label, Phase 1, First-in-human, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Maximum Tolerated or Administered Dose, Pharmacokinetics, Pharmacodynamics, and Tumor Response Profile of the Diacylglycerol Kinase Alpha Inhibitor (DGKai) BAY 2862789 in Participants With Advanced Solid Tumors	Advanced Solid Tumors; Non-small Cell Lung Cancer	4102 - Woolloongabba	https://clinicaltrials.gov/ct2/show/NCT05858164
NCT05858736	PRESERVE-009	Phase 1		SA, NSW, QLD	15/05/2023		AI-025; ONC392	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody	AI-025; ONC392	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody	AI-061-AU-01	Safety, Pharmacokinetics (PK) and Efficacy of AI-061, A 1:1 Co-formulation of AI-025 (Anti-PD-1) and ONC-392 (Anti-CTLA-4) Antibodies in Advanced Solid Tumors: An Open-Label Phase 1 Study	Endometrial Cancer; Anal Cancer; Cervical Cancer; Non Small Cell Lung Cancer; Fallopian Tube Cancer; Gastroesophageal-junction Cancer; Bladder Cancer; Hepatocellular Carcinoma; Melanoma; Esophageal Cancer; Head and Neck Squamous Cell Carcinoma; High Grade Serous Adenocarcinoma of Ovary; Gastric Cancer; Renal Cell Carcinoma; Primary Peritoneal Carcinoma; Bile Duct Cancer; Colorectal Cancer	5042 - Bedford Park; 2010 - Darlinghurst; 5000 - Adelaide; 4120 - Southport	https://clinicaltrials.gov/ct2/show/NCT05858736
NCT05867121	2022-502615-11-00--GO44010	Unknown		NSW	19/05/2023	2/10/2023	Atezolizumab; Atezolizumab + Gemcitabine + Nab-paclitaxel + RO7496353; Atezolizumab + RO7496353; Capecitabine; Capecitabine + Nivolumab + Oxaliplatin + RO7496353 + Tegafur-gimeracil-oteracil pPotassium; Gemcitabine; Nab-paclitaxel; Nivolumab; Oxaliplatin; RO7496353; Tegafur-gimeracil-oteracil pPotassium	anti-PD-1_monoclonal_antibody; DPD_inhibitor + anti-PD-1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody + antimetabolite + fluoropyrimidine + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody + fluoropyrimidine + orotate_phosphoribosyltransferase_inhibitor + platinum-based_antineoplastic_agent; gemcitabine; taxane; fluoropyrimidine; anti-PD-L1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody + antimetabolite + taxane; platinum-based_antineoplastic_agent; antimetabolite; orotate_phosphoribosyltransferase_inhibitor; anti-TGF-beta_monoclonal_antibody; DPD_inhibitor	Atezolizumab + Gemcitabine + Nab-paclitaxel + RO7496353; Atezolizumab + RO7496353; Capecitabine + Nivolumab + Oxaliplatin + RO7496353 + Tegafur-gimeracil-oteracil pPotassium; Atezolizumab + Gemcitabine + Nab-paclitaxel + RO7496353; Atezolizumab + RO7496353; Capecitabine + Nivolumab + Oxaliplatin + RO7496353 + Tegafur-gimeracil-oteracil pPotassium	DPD_inhibitor + anti-PD-1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody + antimetabolite + fluoropyrimidine + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody + fluoropyrimidine + orotate_phosphoribosyltransferase_inhibitor + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody + antimetabolite + taxane; DPD_inhibitor + anti-PD-1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody + fluoropyrimidine + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody + antimetabolite + fluoropyrimidine + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody + fluoropyrimidine + orotate_phosphoribosyltransferase_inhibitor + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody + antimetabolite + taxane; gemcitabine	2022-502615-11-00  GO44010	A Phase Ib, Open-Label, Multicenter Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-Care Chemotherapy in Patients With Locally Advanced or Metastatic Solid Tumors	Metastatic Solid Tumor; Gastric Cancer; Non-small Cell Lung Cancer; Pancreatic Ductal Adenocarcinoma	2010 - Darlinghurst	https://clinicaltrials.gov/ct2/show/NCT05867121
NCT05867303	RC198-G001	Phase 1		QLD	19/05/2023		RC198	undisclosed_fusion_protein	RC198	undisclosed_fusion_protein	RC198-G001	A Phase 1, First-in-Human, Multicenter, Open-Label Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors	Renal Cell Carcinoma; Non-small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma; Melanoma; Urothelial Carcinoma; Colorectal Carcinoma	4066 - Auchenflower	https://clinicaltrials.gov/ct2/show/NCT05867303
NCT05868174	177Lu-TLX250-001	Phase 1		WA, SA, QLD, VIC, NSW	22/05/2023	23/05/2023	177Lu-TLX250; 177Lu-TLX250 + Peposertib; Peposertib	DNA-dependent_protein_kinase_inhibitor; 177Lu-anti-CA9-radioconjugate; 177Lu-anti-CA9-radioconjugate + DNA-dependent_protein_kinase_inhibitor	177Lu-TLX250 + Peposertib; 177Lu-TLX250 + Peposertib	177Lu-anti-CA9-radioconjugate + DNA-dependent_protein_kinase_inhibitor; 177Lu-anti-CA9-radioconjugate + DNA-dependent_protein_kinase_inhibitor	177Lu-TLX250-001	A Phase 1b Dose Escalation/Expansion Study of the Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX (CAIX)-Expressing Solid Tumors	Advanced Solid Tumor; Solid Tumor, Adult; Advanced Renal Cell Carcinoma	- Brisbane; - Adelaide; - Perth; - Melbourne; - North Ryde	https://clinicaltrials.gov/ct2/show/NCT05868174
NCT05870748	STRO-002-GM3	Phase 2		NSW	23/05/2023		Pegfilgrastim	granulocyte_colony_stimulating_factor	Pegfilgrastim	granulocyte_colony_stimulating_factor	STRO-002-GM3	REFRaME-O1: A Phase 2 Open-label Study Evaluating the Efficacy and Safety of Luveltamab Tazevibulin (STRO-002) in Women With Relapsed Platinum-resistant Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing Folate Receptor Alpha (FOLR1)	Ovarian Cancer; Fallopian Tube Cancer; Platinum-resistant Ovarian Cancer; Epithelial Ovarian Cancer; Primary Peritoneal Cancer	2145 - Sydney	https://clinicaltrials.gov/ct2/show/NCT05870748
NCT05872295	IKS014-01	Phase 1		VIC, NSW, WA	24/05/2023		IKS014	anti-ERBB2_antibody-drug_conjugate	IKS014	anti-ERBB2_antibody-drug_conjugate	IKS014-01	A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS014, a HER2-Targeting Antibody Drug Conjugate (ADC), in Participants With Advanced HER2+ Solid Tumors	Gastroesophageal-junction Cancer; Breast Cancer; Gastric Cancer	- Frankston; - Melbourne; - Sydney; 6009 - Perth	https://clinicaltrials.gov/ct2/show/NCT05872295
NCT05876754	ProvIDHe	Phase 3			17/05/2023	8/05/2023	Ivosidenib	IDH1_R132_inhibitor	Ivosidenib	IDH1_R132_inhibitor	2022-501463-40  DIM-95031-002	An Open-Label Early Access Phase 3b Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma	Cholangiocarcinoma		https://clinicaltrials.gov/ct2/show/NCT05876754
NCT05878288	DISCERN	Phase 2		VIC	26/05/2023		Cemiplimab	anti-PD-1_monoclonal_antibody	Cemiplimab	anti-PD-1_monoclonal_antibody	HREC/88736/PMCC-2022-326880	Comprehensive and Deep Profiling in Cutaneous Squamous Cell Carcinomas to Unravel Treatment Efficacy in Immunotherapy Treated Patients	Non-melanoma Skin Cancer; Cutaneous Squamous Cell Carcinoma of the Head and Neck; Neoplasms; Cutaneous Squamous Cell Carcinoma	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT05878288
NCT05879822	2022-502716-37-00--INCB-99280-211	Unknown		NZ	30/05/2023		INCB099280	PD-L1_inhibitor,oral	INCB099280	PD-L1_inhibitor,oral	2022-502716-37-00  INCB 99280-211	A Phase 2 Study Evaluating INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive	Advanced Solid Tumor	Dunedin	https://clinicaltrials.gov/ct2/show/NCT05879822
NCT05884398	LIBERTAS	Unknown		VIC, NSW, QLD	1/06/2023	31/08/2023	Apalutamide	antiandrogen,nonsteroidal,second_generation	Apalutamide	antiandrogen,nonsteroidal,second_generation	56021927PCR3020  CR109327	A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide With Continued Versus Intermittent Androgen-Deprivation Therapy (ADT) Following PSA Response in Participants With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)	Metastatic Castrate-sensitive Prostate Cancer	4101 - South Brisbane; 2109 - Macquarie University; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT05884398
NCT05886868	BL0020-101	Unknown		QLD, NSW	2/06/2023		BL0020	unknown_drug_class	BL0020	unknown_drug_class	BL0020-101	A Phase I, International, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of BL0020 as A Single Agent in Patients With Advanced Solid Tumors	Advanced Solid Tumor	- Sydney; - Birtinya	https://clinicaltrials.gov/ct2/show/NCT05886868
NCT05886920	D3S-002-100	Phase 1		WA	2/06/2023		D3S-002	ERK_inhibitor	D3S-002	ERK_inhibitor	D3S-002-100	A Phase 1, Open-label, Dose-escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose of D3S-002 Monotherapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations	Advanced Solid Tumors With MAPK Pathway Mutations	6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT05886920
NCT05891171	ARC-25	Unknown		SA	6/06/2023	13/10/2023	Carboplatin; Carboplatin + Pemetrexed + Zimberelimab; Fluorouracil; Fluorouracil + Leucovorin + Oxaliplatin + Zimberelimab; Leucovorin; Oxaliplatin; Pemetrexed; Zimberelimab	anti-PD-1_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite; Fluorouracil; folinic_acid; fluoropyrimidine	Carboplatin + Pemetrexed + Zimberelimab; Fluorouracil + Leucovorin + Oxaliplatin + Zimberelimab; Carboplatin + Pemetrexed + Zimberelimab; Fluorouracil + Leucovorin + Oxaliplatin + Zimberelimab	anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent; Fluorouracil; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + fluoropyrimidine + folinic_acid + platinum-based_antineoplastic_agent	ARC-25	A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB598 Monotherapy and Combination Therapy in Participants With Advanced Malignancies	Gastric Cancer; Gastroesophageal-junction Cancer (GEJ); Bladder Cancer; Esophageal Cancer; Advanced Malignancies; Ovarian Cancer; Head and Neck Squamous Cell Carcinoma (HNSCC); Triple Negative Breast Cancer (TNBC); Non-Small Cell Lung Cancer (NSCLC); Renal Cell Carcinoma (RCC); Advanced Cancer; Cervical Cancer	- Adelaide	https://clinicaltrials.gov/ct2/show/NCT05891171
NCT05894239	2022-502046-28-00--WO44263	Unknown		WA, NSW, QLD	8/06/2023	28/07/2023	Inavolisib; Placebo	placebo; PI3K_alpha_inhibitor	Inavolisib; Placebo	PI3K_alpha_inhibitor; placebo	2022-502046-28-00  WO44263	A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo As Maintenance Therapy After First Line Induction Therapy in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer	Metastatic Breast Cancer	2010 - Darlinghurst; 4556 - Sippy Downs; 6009 - Perth	https://clinicaltrials.gov/ct2/show/NCT05894239
NCT05904496	U1111-1290-6118--BGB-A317-30813-101	Phase 1		WA, VIC	14/06/2023		BGB-30813; BGB-30813 + Tislelizumab; Tislelizumab	anti-PD-1_monoclonal_antibody; DGK-zeta_inhibitor + anti-PD-1_monoclonal_antibody; DGK-zeta_inhibitor	BGB-30813; BGB-30813 + Tislelizumab; BGB-30813 + Tislelizumab	DGK-zeta_inhibitor; DGK-zeta_inhibitor + anti-PD-1_monoclonal_antibody; DGK-zeta_inhibitor + anti-PD-1_monoclonal_antibody	U1111-1290-6118  BGB-A317-30813-101	A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGK? Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Solid Tumors	Advanced Solid Tumors	3000 - Melbourne; 6009 - Nedlands; 3168 - Clayton	https://clinicaltrials.gov/ct2/show/NCT05904496
NCT05904886	SKYSCRAPER-14	Unknown		NZ	15/06/2023	14/09/2023	Atezolizumab; Atezolizumab + Bevacizumab; Atezolizumab + Bevacizumab + Tiragolumab; Bevacizumab; Placebo; Tiragolumab	placebo; anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody	Atezolizumab + Bevacizumab; Atezolizumab + Bevacizumab + Tiragolumab; Atezolizumab + Bevacizumab; Atezolizumab + Bevacizumab + Tiragolumab; Placebo	anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; placebo	2023-503422-39-00  CO44668	A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma	Carcinoma, Hepatocellular	Auckland; Wellington	https://clinicaltrials.gov/ct2/show/NCT05904886
NCT05907304	SEACRAFT-1	Unknown		WA	18/06/2023	17/08/2023	Naporafenib; Naporafenib + Trametinib; Trametinib	MEK_inhibitor; RAF_dimer_inhibitor; MEK_inhibitor + RAF_dimer_inhibitor	Naporafenib + Trametinib; Naporafenib + Trametinib	MEK_inhibitor + RAF_dimer_inhibitor; MEK_inhibitor + RAF_dimer_inhibitor	ERAS-254-01	An Open-label Study to Assess the Safety and Efficacy of Naporafenib (ERAS-254) Administered With Trametinib in Previously Treated Patients With Locally Advanced Unresectable or Metastatic Solid Tumor Malignancies With RAS Q61X Mutations	Advanced or Metastatic Solid Tumors	- Perth	https://clinicaltrials.gov/ct2/show/NCT05907304
NCT05907954	IDE196-009	Unknown		NSW	18/06/2023	3/07/2023	Darovasertib	PKC_inhibitor	Darovasertib	PKC_inhibitor	IDE196-009	(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma	Uveal Melanoma	2010 - Sydney	https://clinicaltrials.gov/ct2/show/NCT05907954
NCT05909397	VERITAC-3	Unknown		VIC, SA	18/06/2023	9/08/2023	ARV-471; Letrozole; Palbociclib	aromatase_inhibitor; CDK4/6_inhibitor; ER_PROTAC_degrader	ARV-471; Letrozole; Palbociclib	CDK4/6_inhibitor; ER_PROTAC_degrader; aromatase_inhibitor	2022-500545-24-00  C4891002	A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY OF ARV-471(PF-07850327) PLUS PALBOCICLIB VERSUS LETROZOLE PLUS PALBOCICLIB FOR THE TREATMENT OF PARTICIPANTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI-CANCER TREATMENT FOR ADVANCED DISEASE (VERITAC-3)	Breast Cancer	5000 - Adelaide; 3186 - Brighton; 3144 - Malvern; 3220 - Geelong	https://clinicaltrials.gov/ct2/show/NCT05909397
NCT05911295	KEYNOTE-D74--SGNDV-001	Unknown		NSW, Othe	22/06/2023	22/09/2023	Carboplatin; Carboplatin + Cisplatin + Gemcitabine; Cisplatin; Disitamab vedotin; Disitamab vedotin + Pembrolizumab; Gemcitabine; Pembrolizumab	anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; antimetabolite; anti-ERBB2_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody; gemcitabine; anti-ERBB2_antibody-drug_conjugate	Carboplatin + Cisplatin + Gemcitabine; Disitamab vedotin + Pembrolizumab; Carboplatin + Cisplatin + Gemcitabine; Disitamab vedotin + Pembrolizumab	anti-ERBB2_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody; antimetabolite + platinum-based_antineoplastic_agent; anti-ERBB2_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody; antimetabolite + platinum-based_antineoplastic_agent; gemcitabine	KEYNOTE-D74  SGNDV-001	An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination With Pembrolizumab Versus Chemotherapy in Subjects With Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma That Expresses HER2 (IHC 1+ and Greater)	Urothelial Carcinoma	2109 - Brisbane	https://clinicaltrials.gov/ct2/show/NCT05911295
NCT05920356	2022-501863-41--20190341	Unknown		SA, NSW, VIC	27/06/2023		Carboplatin; Carboplatin + Pembrolizumab + Pemetrexed; Carboplatin + Pemetrexed + Sotorasib; Pembrolizumab; Pemetrexed; Sotorasib	KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor; anti-PD-1_monoclonal_antibody; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + antimetabolite + platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite	Carboplatin + Pembrolizumab + Pemetrexed; Carboplatin + Pemetrexed + Sotorasib; Carboplatin + Pembrolizumab + Pemetrexed; Carboplatin + Pemetrexed + Sotorasib	KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; KRAS_G12C/NRAS_G12C/HRAS_G12C_inhibitor + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent	2022-501863-41  20190341	A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers, Negative for PD-L1, and Positive for KRAS p.G12C (CodeBreaK 202)	Non-Small Cell Lung Cancer (NSCLC)	3000 - Melbourne; 5000 - Adelaide; 2065 - St Leonards; 3004 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT05920356
NCT05954871	2022-502530-10-00--GO44272	Unknown		VIC	20/07/2023		Cetuximab; Cetuximab + RLY-1971; Osimertinib; Osimertinib + RLY-1971; RLY-1971	SHP2_inhibitor; EGFR_inhibitor,third_generation; EGFR_inhibitor,third_generation + SHP2_inhibitor; SHP2_inhibitor + anti-EGFR_monoclonal_antibody; anti-EGFR_monoclonal_antibody	Cetuximab + RLY-1971; Osimertinib + RLY-1971; Cetuximab + RLY-1971; Osimertinib + RLY-1971	EGFR_inhibitor,third_generation + SHP2_inhibitor; SHP2_inhibitor + anti-EGFR_monoclonal_antibody; EGFR_inhibitor,third_generation + SHP2_inhibitor; SHP2_inhibitor + anti-EGFR_monoclonal_antibody	2022-502530-10-00  GO44272	A Phase Ib Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Patients With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Patients With Metastatic Colorectal Cancer	Non-Small Cell Lung Cancer; Colorectal Cancer	3065 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT05954871
NCT05957081	MarkV-01	Unknown		QLD, VIC	24/07/2023		Pembrolizumab	anti-PD-1_monoclonal_antibody	Pembrolizumab	anti-PD-1_monoclonal_antibody	KEYNOTE-E80  MarkV-01	A Phase 1a/1b, First-in-Human, Open Label Study to Assess the Safety, Tolerability, and Pharmacokinetics of PMC-309 (Anti-VISTA), as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced or Metastatic Solid Tumors	Advanced or Metastatic Solid Tumors	3350 - Ballarat; 4217 - Benowa; 3004 - Melbourne; 3144 - Malvern	https://clinicaltrials.gov/ct2/show/NCT05957081
NCT05957536	D3L-001-100	Unknown		VIC	24/07/2023	19/09/2023					D3L-001-100	A Phase 1, Open-label Dose Escalation and Dose-Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3L-001 Monotherapy in Subjects With HER2-Positive Advanced Solid Tumors.	HER-2 Positive Advanced Solid Tumors	3144 - Malvern	https://clinicaltrials.gov/ct2/show/NCT05957536
NCT05967689	REZILIENT2	Unknown		VIC, NSW	1/08/2023	27/07/2023	TAS6417	EGFR_inhibitor,exon_20_selective	TAS6417	EGFR_inhibitor,exon_20_selective	2023-503865-48  TAS6417-201	An Open-Label, Phase 2b, Global Multicenter Cohort Trial to Assess the Safety and Efficacy of Zipalertinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Exon 20 Insertion and Uncommon/Single or Compound Epidermal Growth Factor Receptor Mutations.	Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations	2200 - Bankstown; 2065 - Saint Leonards; - Melbourne	https://clinicaltrials.gov/ct2/show/NCT05967689
NCT05975073	NCT05975073	Unknown		SA	3/08/2023	27/07/2023	AMG 193; AMG 193 + IDE397; IDE397; Pemetrexed	MAT2A_inhibitor + PRMT5_inhibitor; PRMT5_inhibitor; MAT2A_inhibitor; antimetabolite	AMG 193 + IDE397; AMG 193 + IDE397; Pemetrexed	MAT2A_inhibitor + PRMT5_inhibitor; MAT2A_inhibitor + PRMT5_inhibitor; antimetabolite	20220127	A Phase 1/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 in Combination With IDE397 in Subjects With Advanced MTAP-null Solid Tumors	MTAP-null Non-Small-Cell Lung Cancer; MTAP-null Solid Tumors	5011 - Woodville South	https://clinicaltrials.gov/ct2/show/NCT05975073
NCT05984277	eVOLVE-Lung02	Unknown		QLD, NSW, VIC	9/08/2023	24/10/2023	Carboplatin; Carboplatin + Paclitaxel + Pembrolizumab + Pemetrexed; Carboplatin + Paclitaxel + Pemetrexed; MEDI5752; Paclitaxel; Pembrolizumab; Pemetrexed	anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; antimetabolite; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; bispecific_PD-L1/CTLA-4_antibody; antimetabolite + platinum-based_antineoplastic_agent + taxane; taxane	Carboplatin + Paclitaxel + Pembrolizumab + Pemetrexed; Carboplatin + Paclitaxel + Pemetrexed; Carboplatin + Paclitaxel + Pembrolizumab + Pemetrexed; Carboplatin + Paclitaxel + Pemetrexed; MEDI5752	anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; antimetabolite + platinum-based_antineoplastic_agent + taxane; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; antimetabolite + platinum-based_antineoplastic_agent + taxane; bispecific_PD-L1/CTLA-4_antibody	2023-000056-38  D798AC00001	A Phase III, Two-Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer (mNSCLC).	Metastatic Non-small Cell Lung Cancer	3168 - Clayton; 4101 - South Brisbane; 3065 - Fitzroy; NSW 2145 - Sydney; 3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT05984277
NCT05987332	IDE196-002	Unknown		VIC, NSW, QLD	14/08/2023		Crizotinib; Crizotinib + Darovasertib; Dacarbazine; Dacarbazine + Ipilimumab + Nivolumab + Pembrolizumab; Darovasertib; Ipilimumab; Nivolumab; Pembrolizumab	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; alkylating_agent; alkylating_agent + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; MET_inhibitor,type_1; ROS1_inhibitor; ALK_inhibitor,first_generation; PKC_inhibitor + ROS1_inhibitor; PKC_inhibitor; ALK_inhibitor,first_generation + PKC_inhibitor; MET_inhibitor,type_1 + PKC_inhibitor	Crizotinib + Darovasertib; Dacarbazine + Ipilimumab + Nivolumab + Pembrolizumab; Crizotinib + Darovasertib; Dacarbazine + Ipilimumab + Nivolumab + Pembrolizumab	ALK_inhibitor,first_generation + PKC_inhibitor; MET_inhibitor,type_1 + PKC_inhibitor; PKC_inhibitor + ROS1_inhibitor; alkylating_agent + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; ALK_inhibitor,first_generation + PKC_inhibitor; MET_inhibitor,type_1 + PKC_inhibitor; PKC_inhibitor + ROS1_inhibitor; alkylating_agent + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	IDE196-002	IDE196 (Darovasertib) in Combination With Crizotinib Versus Investigator's Choice of Treatment as First-line Therapy in HLA-A2 Negative Metastatic Uveal Melanoma (DAR-UM-2)	Metastatic Uveal Melanoma	3168 - Melbourne; 4102 - Brisbane; 2145 - Sydney	https://clinicaltrials.gov/ct2/show/NCT05987332
NCT05991349	CIBI129A101	Unknown		NSW	14/08/2023		IBI129	anti-B7H3_antibody-drug_conjugate	IBI129	anti-B7H3_antibody-drug_conjugate	CIBI129A101	A Phase 1/2 Study of IBI129 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors	Solid Tumor	2217 - Sydney	https://clinicaltrials.gov/ct2/show/NCT05991349
NCT05997615	U1111-1287-6968--TCD17896	Unknown		VIC	18/08/2023	10/08/2023	AMX-500	unknown_drug_class	AMX-500	unknown_drug_class	U1111-1287-6968  TCD17896	A Phase 1, First-in-human Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of AMX-500 in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC)	Hormone-refractory Prostate Cancer	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT05997615
NCT06003231	SGNDV-005	Unknown		Othe, VIC	21/08/2023	14/11/2023	Disitamab vedotin	anti-ERBB2_antibody-drug_conjugate	Disitamab vedotin	anti-ERBB2_antibody-drug_conjugate	SGNDV-005	A Phase 2 Basket Study of Disitamab Vedotin in Adult Subjects With Previously Treated, Locally-Advanced Unresectable or Metastatic Solid Tumors That Express HER2	Carcinoma, Squamous Cell of Head and Neck; Endometrial Neoplasms; Ovarian Neoplasms; Carcinoma, Non-Small-Cell Lung	3199 - Frankston	https://clinicaltrials.gov/ct2/show/NCT06003231
NCT06007690	CoMpass	Unknown		QLD, VIC	23/08/2023	6/12/2023					AU-011-301	A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma	Uveal Melanoma; Choroidal Melanoma; Ocular Melanoma; Indeterminate Lesions	3002 - East Melbourne; 4000 - Brisbane	https://clinicaltrials.gov/ct2/show/NCT06007690
NCT06016738	OPERA-01	Unknown		VIC, SA	30/08/2023	10/10/2023	Anastrozole; Anastrozole + Exemestane + Fulvestrant + Letrozole; Exemestane; Fulvestrant; Letrozole; Palazestrant	complete_estrogen_receptor_antagonist; aromatase_inhibitor + selective_estrogen_receptor_degrader; aromatase_inhibitor; selective_estrogen_receptor_degrader	Anastrozole + Exemestane + Fulvestrant + Letrozole; Palazestrant; Anastrozole + Exemestane + Fulvestrant + Letrozole	aromatase_inhibitor + selective_estrogen_receptor_degrader; complete_estrogen_receptor_antagonist; aromatase_inhibitor + selective_estrogen_receptor_degrader	OPERA-01  OP-1250-301	A Phase 3 Randomized, Open-Label Study Of OP-1250 Monotherapy vs Standard of Care for the Treatment of ER+, HER2- Advanced or Metastatic Breast Cancer Following Endocrine and CDK 4/6 Inhibitor Therapy (OPERA-01)	Advanced Breast Cancer; HER2 Negative Breast Carcinoma; Breast Cancer; ER Positive Breast Cancer; Metastatic Breast Cancer	3168 - Clayton; 5000 - Adelaide; 3355 - Ballarat Central	https://clinicaltrials.gov/ct2/show/NCT06016738
NCT06018337	CTR20233708--DB-1303-O-3002	Unknown		QLD	30/08/2023	18/01/2024	Capecitabine; Capecitabine + Nab-paclitaxel + Paclitaxel; DB-1303; Nab-paclitaxel; Paclitaxel	fluoropyrimidine + taxane; taxane; fluoropyrimidine; anti-ERBB2_antibody-drug_conjugate	Capecitabine + Nab-paclitaxel + Paclitaxel; DB-1303; Capecitabine + Nab-paclitaxel + Paclitaxel	anti-ERBB2_antibody-drug_conjugate; fluoropyrimidine + taxane; fluoropyrimidine + taxane	CTR20233708  DB-1303-O-3002	A Phase 3, Randomized, Multi-center, Open-Label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-Low, Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients Whose Disease Has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02)	Metastatic Breast Cancer	- South Brisbane	https://clinicaltrials.gov/ct2/show/NCT06018337
NCT06031441	GO44431	Unknown		VIC	11/09/2023		Atezolizumab; Atezolizumab + RO7566802; RO7566802	anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + unknown_drug_class; unknown_drug_class	Atezolizumab + RO7566802; Atezolizumab + RO7566802	anti-PD-L1_monoclonal_antibody + unknown_drug_class; anti-PD-L1_monoclonal_antibody + unknown_drug_class	GO44431	A Phase I, Open-Label, Multicenter, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors	Metastatic Solid Tumors; Recurrent Solid Tumors; Locally Advanced Solid Tumors	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT06031441
NCT06036836	MK-4280A-010--4280A-010	Unknown		NSW	14/09/2023	29/09/2023	Favezelimab; Favezelimab + Lenvatinib + Pembrolizumab; Favezelimab + Pembrolizumab; Lenvatinib; Lenvatinib + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody; VEGF_inhibitor + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; VEGF_inhibitor; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Favezelimab + Lenvatinib + Pembrolizumab; Favezelimab + Pembrolizumab; Lenvatinib + Pembrolizumab; Pembrolizumab; Favezelimab + Lenvatinib + Pembrolizumab; Favezelimab + Pembrolizumab; Lenvatinib + Pembrolizumab	VEGF_inhibitor + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	MK-4280A-010  4280A-010	A Multicenter, Randomized, Double-Blind, Phase 2, Basket Study of MK-4280A, a Coformulation of Favezelimab (MK-4280) With Pembrolizumab (MK-3475) in Selected Solid Tumors	Endometrial Cancer; Cutaneous Squamous Cell Carcinoma; Solid Tumor	2148 - Blacktown	https://clinicaltrials.gov/ct2/show/NCT06036836
NCT06058793	2023-504522-19-00--1403-0019	Unknown		VIC	28/09/2023	12/12/2023	Brigimadlin	MDM2_inhibitor	Brigimadlin	MDM2_inhibitor	2023-504522-19-00  1403-0019	Brightline-4: A Phase III Open-label, Single-arm, Multi-center Study to Assess the Safety and Efficacy of Brigimadlin (BI 907828) Treatment in Patients With Treatment-naïve or Pre-treated Advanced Dedifferentiated Liposarcoma	Liposarcoma, Dedifferentiated	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT06058793
NCT06063681	StingrayTx	Unknown		NSW, VIC	2/10/2023	12/10/2023	SR-8541A	ENPP1_inhibitor	SR-8541A	ENPP1_inhibitor	StingrayTx	Phase 1, Dose Escalation, Safety, Tolerability, and Pharmacokinetic Study of SR-8541A (ENPP1 Inhibitor) Administered Orally as Monotherapy in Subjects With Advanced/Metastatic Solid Tumors	Advanced / Metastatic Solid Tumor	2031 - Randwick; 3168 - Clayton; 3199 - Frankston	https://clinicaltrials.gov/ct2/show/NCT06063681
NCT06064877	FIERCE-HN	Unknown		NSW	3/10/2023	11/01/2024	Cetuximab; Cetuximab + Ficlatuzumab; Ficlatuzumab; Placebo	anti-EGFR_monoclonal_antibody; placebo; anti-EGFR_monoclonal_antibody + anti-HGF_monoclonal_antibody; anti-HGF_monoclonal_antibody	Cetuximab + Ficlatuzumab; Cetuximab + Ficlatuzumab; Placebo	anti-EGFR_monoclonal_antibody + anti-HGF_monoclonal_antibody; anti-EGFR_monoclonal_antibody + anti-HGF_monoclonal_antibody; placebo	AV-299-23-301	A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN)	Recurrent Head and Neck Squamous Cell Carcinoma; Metastatic Head-and-neck Squamous-cell Carcinoma	- Sydney	https://clinicaltrials.gov/ct2/show/NCT06064877
NCT06065748	2022-502980-39-00--CO44657	Unknown		QLD, VIC	4/10/2023		Abemaciclib; Abemaciclib + Fulvestrant + Palbociclib + Ribociclib; Abemaciclib + Giredestrant + Palbociclib + Ribociclib; Fulvestrant; Giredestrant; LHRH Agonist; Palbociclib; Ribociclib	CDK4/6_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor; selective_estrogen_receptor_degrader; LHRH_agonist	Abemaciclib + Fulvestrant + Palbociclib + Ribociclib; Abemaciclib + Giredestrant + Palbociclib + Ribociclib; Abemaciclib + Fulvestrant + Palbociclib + Ribociclib; Abemaciclib + Giredestrant + Palbociclib + Ribociclib; LHRH Agonist	CDK4/6_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + selective_estrogen_receptor_degrader; LHRH_agonist	2022-502980-39-00  CO44657	A Phase III Randomized, Open-Label Study Evaluating Efficacy and Safety of Giredestrant Compared With Fulvestrant, Both Combined With a CDK4/6 Inhibitor, in Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer With Resistance to Prior Adjuvant Endocrine Therapy	Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer	4556 - Sippy Downs; 3021 - St Albans	https://clinicaltrials.gov/ct2/show/NCT06065748
NCT06072781	RAMP-301	Unknown		QLD	10/10/2023		Anastrozole; Avutometinib; Avutometinib + Defactinib; Defactinib; Letrozole; Paclitaxel; Pegylated liposomal doxorubicin; Topotecan	anthracycline; FAK_inhibitor; RAF/MEK_clamp; FAK_inhibitor + RAF/MEK_clamp; aromatase_inhibitor; taxane; topoisomerase_inhibitor	Avutometinib + Defactinib; Anastrozole; Avutometinib + Defactinib; Letrozole; Paclitaxel; Pegylated liposomal doxorubicin; Topotecan	FAK_inhibitor + RAF/MEK_clamp; FAK_inhibitor + RAF/MEK_clamp; anthracycline; aromatase_inhibitor; taxane; topoisomerase_inhibitor	GOG-3097  VS-6766-301	A Phase 3, Randomized, Open-Label Study of Combination Therapy With Avutometinib Plus Defactinib Versus Investigator's Choice of Treatment in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP 301)	Low Grade Serous Ovarian Cancer	4066 - Auchenflower	https://clinicaltrials.gov/ct2/show/NCT06072781
NCT06074497	KGX101ST101	Unknown		VIC, QLD	10/10/2023		KGX101	IL-12_Fc-fusion_protein	KGX101	IL-12_Fc-fusion_protein	KGX101ST101	A Phase 1, First-in-Human, Multicenter, Open-Label, Dose Escalation Trial of KGX101 Administered as a Monotherapy to Patients With Advanced or Metastatic Solid Tumors	Advanced or Metastatic Solid Tumors	3199 - Frankston; 4575 - Birtinya	https://clinicaltrials.gov/ct2/show/NCT06074497
NCT06074588	2023-503539-16--2870-004	Unknown		NSW	10/10/2023	12/11/2023	Dexamethasone; Dexamethasone + Sacituzumab tirumotecan; Docetaxel; Docetaxel + Pemetrexed; Pemetrexed; Sacituzumab tirumotecan	glucocorticoid; anti-Trop2_antibody-drug_conjugate + glucocorticoid; antimetabolite; taxane; anti-Trop2_antibody-drug_conjugate; antimetabolite + taxane	Dexamethasone + Sacituzumab tirumotecan; Docetaxel + Pemetrexed; Dexamethasone + Sacituzumab tirumotecan; Docetaxel + Pemetrexed	anti-Trop2_antibody-drug_conjugate + glucocorticoid; antimetabolite + taxane; anti-Trop2_antibody-drug_conjugate + glucocorticoid; antimetabolite + taxane	2023-503539-16  2870-004	A Randomized, Open-label, Phase 3 Study of MK-2870 vs Chemotherapy (Docetaxel or Pemetrexed) in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations	Non-small Cell Lung Cancer (NSCLC)	2145 - Westmead	https://clinicaltrials.gov/ct2/show/NCT06074588
NCT06082960	GS-US-521-6317	Unknown		VIC	13/10/2023	9/10/2023	GS-9911; GS-9911 + Zimberelimab; Zimberelimab	anti-PD-1_monoclonal_antibody; DGK-alpha_inhibitor + anti-PD-1_monoclonal_antibody; DGK-alpha_inhibitor	GS-9911; GS-9911 + Zimberelimab; GS-9911 + Zimberelimab	DGK-alpha_inhibitor; DGK-alpha_inhibitor + anti-PD-1_monoclonal_antibody; DGK-alpha_inhibitor + anti-PD-1_monoclonal_antibody	GS-US-521-6317	A Phase 1 Study to Evaluate the Safety and Tolerability of GS-9911 as Monotherapy and in Combination With an Anti-PD-1 Monoclonal Antibody in Adults With Advanced Solid Tumors	Solid Tumors	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT06082960
NCT06092580	AWT020-001	Unknown		QLD, VIC, SA	23/10/2023	15/09/2023	AWT020	anti-PD1-IL2_fusion_protein	AWT020	anti-PD1-IL2_fusion_protein	AWT020-001	A Phase 1/2, First-in-human, Open-label Study of Single-agent AWT020 in Patients With Progressive Locally Advanced or Metastatic Cancer	Advanced Cancer	5042 - Bedford Park; - Melbourne; 4101 - South Brisbane	https://clinicaltrials.gov/ct2/show/NCT06092580
NCT06097728	eVOLVE-Meso	Unknown		WA, VIC	24/10/2023		Carboplatin; Carboplatin + Pemetrexed; Cisplatin; Ipilimumab; Ipilimumab + Nivolumab + Pemetrexed; MEDI5752; Nivolumab; Pemetrexed	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent; antimetabolite; bispecific_PD-L1/CTLA-4_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite	Carboplatin + Pemetrexed; Ipilimumab + Nivolumab + Pemetrexed; Carboplatin + Pemetrexed; Cisplatin; Ipilimumab + Nivolumab + Pemetrexed; MEDI5752	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite; antimetabolite + platinum-based_antineoplastic_agent; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite; antimetabolite + platinum-based_antineoplastic_agent; bispecific_PD-L1/CTLA-4_antibody	2023-000067-32  D7988C00001	A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (MEDI5752) in Combination With Carboplatin Plus Pemetrexed Versus Platinum Plus Pemetrexed or Nivolumab Plus Ipilimumab in Participants With Unresectable Pleural Mesothelioma (eVOLVE-Meso)	Unresectable Pleural Mesothelioma	3168 - Clayton; 6009 - Nedlands	https://clinicaltrials.gov/ct2/show/NCT06097728
NCT06099782	2023-506017-22--3475A-F11	Unknown		NSW, VIC	25/10/2023	26/12/2023	Pembrolizumab	anti-PD-1_monoclonal_antibody	Pembrolizumab	anti-PD-1_monoclonal_antibody	2023-506017-22  3475A-F11	A Phase 2 Study to Evaluate Patient Reported Preference for Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Over Intravenous Pembrolizumab Formulation in Participants With Multiple Tumor Types (MK-3475A-F11)	Melanoma; Renal Cell Carcinoma; Non-Small Cell Lung Cancer	2444 - Port Macquarie; 3199 - Frankston	https://clinicaltrials.gov/ct2/show/NCT06099782
NCT06103864	D7630C00001	Unknown		NSW, VIC, WA	27/10/2023		Carboplatin; Carboplatin + Gemcitabine + Nab-paclitaxel + Paclitaxel + Pembrolizumab; Datopotamab deruxtecan; Durvalumab; Gemcitabine; Nab-paclitaxel; Paclitaxel; Pembrolizumab	anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; antimetabolite; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; anti-PD-L1_monoclonal_antibody; gemcitabine; taxane; anti-Trop2_antibody-drug_conjugate	Carboplatin + Gemcitabine + Nab-paclitaxel + Paclitaxel + Pembrolizumab; Durvalumab; Carboplatin + Gemcitabine + Nab-paclitaxel + Paclitaxel + Pembrolizumab; Datopotamab deruxtecan	anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; anti-PD-L1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; anti-Trop2_antibody-drug_conjugate; gemcitabine	D7630C00001	A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)	Breast Cancer	2298 - Waratah; 3000 - Melbourne; 6009 - Perth; 3065 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT06103864
NCT06105632	2023-506487-13-00--C4391022	Unknown		QLD	27/10/2023		Everolimus; Exemestane; Fulvestrant; Fulvestrant + PF-07220060; PF-07220060	aromatase_inhibitor; mTORC1_inhibitor; CDK4_selective_inhibitor + selective_estrogen_receptor_degrader; CDK4_selective_inhibitor; selective_estrogen_receptor_degrader	Fulvestrant + PF-07220060; Everolimus; Exemestane; Fulvestrant + PF-07220060	CDK4_selective_inhibitor + selective_estrogen_receptor_degrader; CDK4_selective_inhibitor + selective_estrogen_receptor_degrader; aromatase_inhibitor; mTORC1_inhibitor	2023-506487-13-00  C4391022	AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER PHASE 3 STUDY OF PF-07220060 PLUS FULVESTRANT COMPARED TO INVESTIGATOR'S CHOICE OF THERAPY IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED/METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR CDK 4/6 INHIBITOR BASED THERAPY	Advanced or Metastatic Breast Cancer	4812 - Townsville	https://clinicaltrials.gov/ct2/show/NCT06105632
NCT06108479	DF6215-001	Unknown		VIC	31/10/2023	28/11/2023					DF6215-001	A Phase 1/1b, First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of DF6215 in Patients With Advanced (Unresectable, Recurrent, or Metastatic) Solid Tumors	Solid Tumor, Adult	3199 - Frankston	https://clinicaltrials.gov/ct2/show/NCT06108479
NCT06112314	PRISM-MEL-301	Unknown		QLD, NSW	1/11/2023		IMC-F106C; IMC-F106C + Nivolumab; Nivolumab; Nivolumab + Relatlimab; Relatlimab	anti-PD-1_monoclonal_antibody + bispecific_T-cell_engager,PRAME-targeting; anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody; bispecific_T-cell_engager,PRAME-targeting; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	IMC-F106C + Nivolumab; Nivolumab + Relatlimab; IMC-F106C + Nivolumab; Nivolumab + Relatlimab	anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + bispecific_T-cell_engager,PRAME-targeting; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + bispecific_T-cell_engager,PRAME-targeting	2023-505306-42-00  IMC-F106C-301	A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (PRISM-MEL-301	Advanced Melanoma	- Wollstonecraft; - Woolloongabba	https://clinicaltrials.gov/ct2/show/NCT06112314
NCT06117774	DeLLphi-306	Unknown		VIC, NSW, WA	7/11/2023		Placebo; Radiotherapy; Tarlatamab	radiotherapy; placebo; bispecific_T-cell_engager,DLL3-targeting	Tarlatamab; Placebo; Radiotherapy	bispecific_T-cell_engager,DLL3-targeting; placebo; radiotherapy	2023-506235-15  20230016	A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Who Have Not Progressed Following Concurrent Chemoradiation Therapy	Limited Stage Small Cell Lung Cancer; Small Cell Lung Cancer	6150 - Murdoch; 2050 - Camperdown; 2444 - Port Macquarie; 2145 - Westmead; 3168 - Clayton	https://clinicaltrials.gov/ct2/show/NCT06117774
NCT06119581	SUNRAY-01	Unknown		QLD, VIC	7/11/2023		Carboplatin; Carboplatin + Cisplatin + Olomorasib + Pembrolizumab + Pemetrexed; Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Cisplatin; Olomorasib; Olomorasib + Pembrolizumab; Pembrolizumab; Pemetrexed; Placebo	KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor; platinum-based_antineoplastic_agent; placebo; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody	Carboplatin + Cisplatin + Olomorasib + Pembrolizumab + Pemetrexed; Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Olomorasib + Pembrolizumab; Pembrolizumab; Carboplatin + Cisplatin + Olomorasib + Pembrolizumab + Pemetrexed; Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Olomorasib + Pembrolizumab; Placebo	KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; placebo	J3M-MC-JZQB  18612	SUNRAY-01, A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those With PD-L1 Expression =50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum Regardless of PD-L1 Expression	Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung	3630 - Shepparton; 4066 - Auchenflower	https://clinicaltrials.gov/ct2/show/NCT06119581
NCT06120283	2023-506888-34-00--BGB-43395-101	Unknown		NSW, VIC	7/11/2023	1/12/2023	BGB-43395; BGB-43395 + Fulvestrant; BGB-43395 + Fulvestrant + Letrozole; Fulvestrant; Letrozole	CDK4_selective_inhibitor + aromatase_inhibitor + selective_estrogen_receptor_degrader; aromatase_inhibitor; CDK4_selective_inhibitor + selective_estrogen_receptor_degrader; CDK4_selective_inhibitor; selective_estrogen_receptor_degrader	BGB-43395 + Fulvestrant; BGB-43395 + Fulvestrant + Letrozole; BGB-43395 + Fulvestrant; BGB-43395 + Fulvestrant + Letrozole	CDK4_selective_inhibitor + aromatase_inhibitor + selective_estrogen_receptor_degrader; CDK4_selective_inhibitor + selective_estrogen_receptor_degrader; CDK4_selective_inhibitor + aromatase_inhibitor + selective_estrogen_receptor_degrader; CDK4_selective_inhibitor + selective_estrogen_receptor_degrader	2023-506888-34-00  BGB-43395-101	A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the CDK4 Inhibitor BGB-43395, Alone or as Part of Combination Therapies in Patients With Metastatic HR+/HER2- Breast Cancer and Other Advanced Solid Tumors	Hormone Receptor Positive HER-2 Negative Breast Cancer; Advanced Solid Tumor; Non-small Cell Lung Cancer; Metastatic Breast Cancer; Hormone-receptor-positive Breast Cancer; HER2-negative Breast Cancer; Hormone Receptor Positive Breast Carcinoma; Hormone Receptor Positive Malignant Neoplasm of Breast; Advanced Breast Cancer	3000 - Melbourne; 2148 - Blacktown	https://clinicaltrials.gov/ct2/show/NCT06120283
NCT06120491	EvoPAR-PR01	Unknown		QLD, VIC, NSW, SA	7/11/2023		Abiraterone; Abiraterone + Darolutamide + Enzalutamide; Abiraterone + Darolutamide + Enzalutamide + Saruparib; Darolutamide; Enzalutamide; Placebo; Saruparib	PARP_inhibitor; PARP1-selective_inhibitor; placebo; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor; antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor + PARP_inhibitor + antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor + PARP1-selective_inhibitor + antiandrogen,nonsteroidal,second_generation	Abiraterone + Darolutamide + Enzalutamide; Abiraterone + Darolutamide + Enzalutamide + Saruparib; Abiraterone + Darolutamide + Enzalutamide; Abiraterone + Darolutamide + Enzalutamide + Saruparib; Placebo	CYP17A1_inhibitor + PARP1-selective_inhibitor + antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor + PARP_inhibitor + antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor + PARP1-selective_inhibitor + antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor + PARP_inhibitor + antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation; placebo	2023-504214-30-00  D9723C00001	A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of AZD5305 in Combination With Physician's Choice New Hormonal Agents in Patients With HRRm and Non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01)	Metastatic Castration-Sensitive Prostate Cancer	5037 - Kurralta Park; 2010 - Darlinghurst; 3000 - Melbourne; 4032 - Chermside; 4812 - Hyde Park; 2031 - Randwick; 4101 - South Brisbane	https://clinicaltrials.gov/ct2/show/NCT06120491
NCT06130553	PRIMROSE	Unknown		VIC	14/11/2023	19/01/2024	AZD3470; Pemetrexed	PRMT5_inhibitor; antimetabolite	AZD3470; Pemetrexed	PRMT5_inhibitor; antimetabolite	165618  D9970C00001	PRIMROSE: A Modular Phase I/IIa, Multi-centre, Dose Escalation, and Expansion Study of AZD3470, a MTA Cooperative PRMT5 Inhibitor, as Monotherapy and in Combination With Anticancer Agents in Patients With Advanced/Metastatic Solid Tumours That Are MTAP Deficient	Advanced Solid Tumours That Are MTAP Deficient	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT06130553
NCT06131398	NCT06131398	Unknown		SA	14/11/2023	7/03/2024	Pembrolizumab	anti-PD-1_monoclonal_antibody	Pembrolizumab	anti-PD-1_monoclonal_antibody	20220028	A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 355 as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors	Advanced Solid Tumors	5011 - Woodville South	https://clinicaltrials.gov/ct2/show/NCT06131398
NCT06132958	2023-504816-14--2870-005	Unknown		VIC	15/11/2023	6/12/2023	Dexamethasone; Dexamethasone + Sacituzumab tirumotecan; Doxorubicin; Doxorubicin + Paclitaxel; Paclitaxel; Sacituzumab tirumotecan	anthracycline; glucocorticoid; doxorubicin; anthracycline + taxane; anti-Trop2_antibody-drug_conjugate + glucocorticoid; taxane; anti-Trop2_antibody-drug_conjugate	Dexamethasone + Sacituzumab tirumotecan; Doxorubicin + Paclitaxel; Dexamethasone + Sacituzumab tirumotecan; Doxorubicin + Paclitaxel	anthracycline + taxane; anti-Trop2_antibody-drug_conjugate + glucocorticoid; anthracycline + taxane; anti-Trop2_antibody-drug_conjugate + glucocorticoid; doxorubicin	2023-504816-14  2870-005	A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy (MK-2870-005/ENGOT-en23/GOG-3095)	Endometrial Cancer	3199 - Frankston; 3002 - East Melbourne	https://clinicaltrials.gov/ct2/show/NCT06132958
NCT06136624	2023-504899-25--5684-003	Unknown		NSW	18/11/2023	31/12/2023	Abiraterone; Abiraterone + Enzalutamide + Prednisone; Dexamethasone; Enzalutamide; Prednisone	CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + glucocorticoid; glucocorticoid; CYP17A1_inhibitor; antiandrogen,nonsteroidal,second_generation	Abiraterone + Enzalutamide + Prednisone; Dexamethasone; Abiraterone + Enzalutamide + Prednisone	CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + glucocorticoid; glucocorticoid; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + glucocorticoid	2023-504899-25  5684-003	A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy	Prostate Cancer Metastatic	2109 - Macquarie University	https://clinicaltrials.gov/ct2/show/NCT06136624
NCT06136650	MK-5684-004--5684-004	Unknown		NSW	18/11/2023	18/12/2023	Abiraterone; Abiraterone + Enzalutamide + Prednisone; Dexamethasone; Enzalutamide; Prednisone	antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + glucocorticoid; glucocorticoid; CYP17A1_inhibitor	Abiraterone + Enzalutamide + Prednisone; Dexamethasone; Abiraterone + Enzalutamide + Prednisone	CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + glucocorticoid; glucocorticoid; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + glucocorticoid	MK-5684-004  5684-004	A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment With One Next-generation Hormonal Agent (NHA)	Metastatic Castration-resistant Prostate Cancer (mCRPC); Prostatic Neoplasms	2109 - Macquarie University	https://clinicaltrials.gov/ct2/show/NCT06136650
NCT06151574	2023-504308-27-00--1479-0008	Unknown		NSW	30/11/2023	15/01/2024	Carboplatin; Cisplatin; Pembrolizumab; Pembrolizumab + Pemetrexed; Pemetrexed; Zongertinib	anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; ERBB2_inhibitor,second_generation; antimetabolite; anti-PD-1_monoclonal_antibody + antimetabolite	Pembrolizumab + Pemetrexed; Zongertinib; Carboplatin; Cisplatin; Pembrolizumab + Pemetrexed	ERBB2_inhibitor,second_generation; anti-PD-1_monoclonal_antibody + antimetabolite; anti-PD-1_monoclonal_antibody + antimetabolite; platinum-based_antineoplastic_agent	2023-504308-27-00  1479-0008	Beamion LUNG-2: A Phase III, Open-label, Randomized, Active-controlled, Multi-centre Trial Evaluating Orally Administered BI 1810631 Compared With Standard of Care as First-line Treatment in Patients With Unresectable, Locally Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer Harbouring HER2 Tyrosine Kinase Domain Mutations	Lung Cancer, Non-squamous, Non-small Cell	2065 - St Leonards	https://clinicaltrials.gov/ct2/show/NCT06151574
NCT06157541	TCaP	Unknown		QLD, VIC	6/12/2023		Ifosfamide; Pembrolizumab	anti-PD-1_monoclonal_antibody; alkylating_agent	Ifosfamide; Pembrolizumab	alkylating_agent; anti-PD-1_monoclonal_antibody	P3894 / MSD-MK3475-E78	Phase I/II Clinical Trial of Allogeneic Cytomegalovirus-specific T Cells in Combination With Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma Multiforme	Astrocytoma, Grade IV; Glioblastoma Multiforme	4006 - Herston; 3084 - Heidelberg; 4006 - Bowen Hills; 4102 - Woolloongabba	https://clinicaltrials.gov/ct2/show/NCT06157541
NCT06162572	SPLFIO-174	Unknown		VIC, NSW, SA	8/12/2023		Cemiplimab	anti-PD-1_monoclonal_antibody	Cemiplimab	anti-PD-1_monoclonal_antibody	SPLFIO-174	A Phase 1b/2, Multicenter, Open-label Platform Study of Select Immunotherapy Combinations in Adult Participants With Previously Untreated Advanced Non-small Cell Lung Cancer (NSCLC) With High PD-L1 Expression	Non-small Cell Lung Cancer (NSCLC)	5042 - Bedford Park; 3021 - St Albans; 2640 - Albury	https://clinicaltrials.gov/ct2/show/NCT06162572
NCT06170190	CIBI133A101	Unknown		NSW	14/12/2023		IBI133	anti-ERBB3_monoclonal_antibody	IBI133	anti-ERBB3_monoclonal_antibody	CIBI133A101	A Multicentre, Open-label, Phase 1/2 Study of IBI133 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumours	Locally Advanced Unresectable or Metastatic Solid Tumors	2170 - Liverpool	https://clinicaltrials.gov/ct2/show/NCT06170190
NCT06170788	MK-2870-007--2870-007	Unknown		NSW	14/12/2023	15/12/2023	Dexamethasone; Dexamethasone + Pembrolizumab + Sacituzumab tirumotecan; Pembrolizumab; Sacituzumab tirumotecan	glucocorticoid; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate + glucocorticoid; anti-Trop2_antibody-drug_conjugate	Dexamethasone + Pembrolizumab + Sacituzumab tirumotecan; Pembrolizumab; Dexamethasone + Pembrolizumab + Sacituzumab tirumotecan	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate + glucocorticoid; anti-PD-1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate + glucocorticoid	MK-2870-007  2870-007	A Randomized, Open-label, Phase 3 Study of MK-2870 in Combination With Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS Greater Than or Equal to 50%	Non-small Cell Lung Cancer (NSCLC)	2145 - Westmead	https://clinicaltrials.gov/ct2/show/NCT06170788
NCT06174987	2023-506330-73-00--ROMast-001	Unknown		SA, VIC	18/12/2023		Trastuzumab Deruxtecan	anti-ERBB2_antibody-drug_conjugate	Trastuzumab Deruxtecan	anti-ERBB2_antibody-drug_conjugate	2023-506330-73-00  ROMast-001	A Master Rollover Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)	Metastatic Cancer; Advanced Cancer	3168 - Clayton VIC; 5042 - Bedford Park SA	https://clinicaltrials.gov/ct2/show/NCT06174987
NCT06179160	2023-507091-47-00--INCB161734-101	Unknown		WA, NSW, VIC	21/12/2023	4/01/2024	Cetuximab; INCB161734; Retifanlimab	anti-PD-1_monoclonal_antibody; KRAS_G12D_inhibitor; anti-EGFR_monoclonal_antibody	INCB161734; Cetuximab; Retifanlimab	KRAS_G12D_inhibitor; anti-EGFR_monoclonal_antibody; anti-PD-1_monoclonal_antibody	2023-507091-47-00  INCB161734-101	A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation	Solid Tumors	06009 - Nedlands; 02010 - Darlinghurst; 02050 - Camperdown; 3051 - North Melbourne; 03004 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT06179160
NCT06179511	D9470C00001	Unknown		VIC	22/12/2023		AZD9829	anti-CD123_antibody-drug_conjugate	AZD9829	anti-CD123_antibody-drug_conjugate	D9470C00001	A Modular Phase I/II, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of AZD9829 as Monotherapy or in Combination in Patients With CD123-Positive Hematological Malignancies	Hematological Malignancies	VIC 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT06179511
NCT06184035	Tumorad	Unknown		SA, VIC	28/12/2023	30/11/2023					2023-505224-64  Tumorad-01	A Phase I/IIa, Dose Escalation and Dose Expansion, First-in-human, Open-label, Multicenter, Single-arm Study Evaluating the Safety, Tolerability, Dosimetry, and Early Efficacy of [177Lu]Lu-SN201 in Participants With Progressive or Treatment-refractory Locally Advanced Unresectable, Metastatic or Recurrent Solid Tumors	Recurrent Solid Tumor; Metastatic Cancer; Solid Tumor; Refractory Cancer; Unresectable Solid Tumor; Locally Advanced Solid Tumor	5000 - Adelaide; 3065 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT06184035
NCT06188208	2023-508386-32-00--VVD-130850-01	Unknown		QLD, SA	3/01/2024	5/01/2024	Pembrolizumab	anti-PD-1_monoclonal_antibody	Pembrolizumab	anti-PD-1_monoclonal_antibody	2023-508386-32-00  VVD-130850-01	A Phase 1, Open-Label, 2-Part, Multicenter, First-in-Human Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Tumor Activity of the STAT3 Inhibitor VVD-130850 as Single Agent and in Combination With Checkpoint Inhibition in Participants With Advanced Solid and Hematologic Tumors	Advanced Hematologic Tumors; Advanced Solid Tumors	- South Brisbane; - Adelaide	https://clinicaltrials.gov/ct2/show/NCT06188208
NCT06188520	CYCAD-1	Unknown		VIC	3/01/2024	5/12/2023	AZD8421; AZD8421 + Abemaciclib + Camizestrant; AZD8421 + Camizestrant + Palbociclib; AZD8421 + Camizestrant + Ribociclib; Abemaciclib; Camizestrant; Palbociclib; Ribociclib	CDK4/6_inhibitor; selective_estrogen_receptor_degrader; CDK2_inhibitor + CDK4/6_inhibitor + selective_estrogen_receptor_degrader; CDK2_inhibitor	AZD8421; AZD8421 + Abemaciclib + Camizestrant; AZD8421 + Camizestrant + Palbociclib; AZD8421 + Camizestrant + Ribociclib; AZD8421 + Abemaciclib + Camizestrant; AZD8421 + Camizestrant + Palbociclib; AZD8421 + Camizestrant + Ribociclib	CDK2_inhibitor; CDK2_inhibitor + CDK4/6_inhibitor + selective_estrogen_receptor_degrader; CDK2_inhibitor + CDK4/6_inhibitor + selective_estrogen_receptor_degrader	D8470C00001	A Phase I/IIa, First-in-human, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors	High-grade Serous Ovarian Cancer (HGSOC); ER+ HER2- Advanced Breast Cancer	3002 - East Melbourne	https://clinicaltrials.gov/ct2/show/NCT06188520
NCT06188702	CL1-95035-001	Unknown		VIC, NSW	3/01/2024	29/04/2024	Pemetrexed	antimetabolite	Pemetrexed	antimetabolite	CL1-95035-001	A Phase 1, Open-label, Multicenter Clinical Trial of S095035 (MAT2A Inhibitor) in Adult Participants With Advanced or Metastatic Solid Tumors With Homozygous Deletion of MTAP	MTAP-deleted Solid Tumors	2031 - Randwick; 3004 - Prahran	https://clinicaltrials.gov/ct2/show/NCT06188702
NCT06198426	CIBI3004A101	Unknown		NSW	10/01/2024		IBI3004	unknown_drug_class	IBI3004	unknown_drug_class	CIBI3004A101	A Phase 1/2, Multicenter, Open-label Study of IBI3004 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors	Solid Tumor	2770 - Randwick	https://clinicaltrials.gov/ct2/show/NCT06198426
NCT06199908	AMT-562-01	Unknown		VIC, NSW, SA	10/01/2024		AMT-562	anti-ERBB3_antibody-drug_conjugate	AMT-562	anti-ERBB3_antibody-drug_conjugate	AMT-562-01	First-in-Human, Phase 1 Study of AMT-562 in Patients With Advanced Solid Tumors	Advanced Solid Tumors	- Malvern; - North Ryde	https://clinicaltrials.gov/ct2/show/NCT06199908
NCT06203210	IDeate-Lung02	Unknown		VIC, NSW, QLD, WA	12/01/2024		Amrubicin; Amrubicin + Lurbinectedin + Topotecan; Lurbinectedin; Topotecan	DNA_minor_groove-binding_agent; anthracycline; DNA_minor_groove-binding_agent + anthracycline + topoisomerase_inhibitor; topoisomerase_inhibitor	Amrubicin + Lurbinectedin + Topotecan; Amrubicin + Lurbinectedin + Topotecan	DNA_minor_groove-binding_agent + anthracycline + topoisomerase_inhibitor; DNA_minor_groove-binding_agent + anthracycline + topoisomerase_inhibitor	2023-509628-16  DS7300-188	A Phase 3, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody Drug Conjugate (ADC), Versus Treatment of Physician's Choice (TPC) in Subjects With Relapsed Small Cell Lung Cancer (SCLC) (IDeate-Lung02)	Small Cell Lung Cancer	3021 - St Albans; 4102 - Woolloongabba; 3350 - Ballarat; 4814 - Townsville; 6008 - Subiaco; 2050 - Camperdown	https://clinicaltrials.gov/ct2/show/NCT06203210
NCT06208657	OPTIMISE	Unknown		VIC, NSW, QLD, SA, WA, NT	17/01/2024		Irinotecan; Irinotecan + Paxalisib + Temozolomide; Paxalisib; Pimasertib; Temozolomide	dual_PI3K/mTOR_inhibitor; alkylating_agent + dual_PI3K/mTOR_inhibitor + topoisomerase_inhibitor; alkylating_agent; MEK_inhibitor; topoisomerase_inhibitor	Irinotecan + Paxalisib + Temozolomide; Pimasertib; Irinotecan + Paxalisib + Temozolomide	MEK_inhibitor; alkylating_agent + dual_PI3K/mTOR_inhibitor + topoisomerase_inhibitor; alkylating_agent + dual_PI3K/mTOR_inhibitor + topoisomerase_inhibitor	OPTIMISE	Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer	Childhood Brain Tumor; Childhood Cancer; Refractory Cancer; Childhood Solid Tumor; Recurrent Cancer	- Brisbane; - Melbourne; - Newcastle; - Perth; - Adelaide; - Sydney	https://clinicaltrials.gov/ct2/show/NCT06208657
NCT06219941	D9800C00001	Unknown		NSW, VIC	23/01/2024	13/12/2023	AZD0901; Fluorouracil; Gemcitabine; Irinotecan; Leucovorin; Liposomal Irinotecan	antimetabolite; anti-CLDN18.2_antibody-drug_conjugate; Fluorouracil; folinic_acid; gemcitabine; topoisomerase_inhibitor; fluoropyrimidine	AZD0901; Fluorouracil; Gemcitabine; Irinotecan; Leucovorin; Liposomal Irinotecan	anti-CLDN18.2_antibody-drug_conjugate; Fluorouracil; antimetabolite; fluoropyrimidine; folinic_acid; gemcitabine; topoisomerase_inhibitor	D9800C00001	A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Tumours Expressing Claudin 18.2.	Gastroesophageal Junction Cancer; Pancreatic Adenocarcinoma; Gastric Cancer	3000 - Melbourne; 2031 - Randwick	https://clinicaltrials.gov/ct2/show/NCT06219941
NCT06220864	SNV1521-101	Unknown		NSW	24/01/2024	23/02/2024					SNV1521-101	A Phase 1, Open-Label Dose Escalation and Expansion Study of SNV1521 in Participants With Advanced Solid Tumors	Advanced Solid Tumor	2031 - Randwick	https://clinicaltrials.gov/ct2/show/NCT06220864
NCT06226766	JSKN033-101	Unknown		NSW	26/01/2024		Envafolimab; JSKN003	anti-PD-L1_monoclonal_antibody; anti-ERBB2_antibody-drug_conjugate	Envafolimab; JSKN003	anti-ERBB2_antibody-drug_conjugate; anti-PD-L1_monoclonal_antibody	JSKN033-101	Phase I/II Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of JSKN033 in Patients With Advanced or Metastatic Solid Malignant Tumors	Advanced Solid Tumor	2031 - Randwick	https://clinicaltrials.gov/ct2/show/NCT06226766
NCT06233942	2023-509958-65-00--BG-C9074-101	Unknown		WA, NSW	31/01/2024	12/04/2024	Tislelizumab	anti-PD-1_monoclonal_antibody	Tislelizumab	anti-PD-1_monoclonal_antibody	2023-509958-65-00  BG-C9074-101	Phase 1a/1b Study of BG-C9074, an Antibody Drug Conjugate Targeting B7H4, as Monotherapy and in Combination With Tislelizumab in Participants With Advanced Solid Tumors	Advanced Solid Tumor	6009 - Nedlands; 2500 - Wollongong	https://clinicaltrials.gov/ct2/show/NCT06233942
NCT06242691	2023-508684-68--1200-002	Unknown		VIC	5/02/2024	29/02/2024	Dexamethasone	glucocorticoid	Dexamethasone	glucocorticoid	2023-508684-68  1200-002	A Phase 1/2 Open-label Study to Evaluate the Safety and Efficacy of MK-1200 in Participants With Advanced Solid Tumors	Advanced Solid Tumors	3004 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT06242691
NCT06253130	IMP1734-101	Unknown		NSW, VIC, QLD	12/02/2024	11/12/2023	IMP1734	PARP1-selective_inhibitor	IMP1734	PARP1-selective_inhibitor	2023-509230-19  EIK1003-001 (IMP1734-101)	A First-in-human, Phase 1/2, Open-label, Multi-center, Dose-escalation, Dose-optimization, and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of PARP1 Selective Inhibitor, IMP1734, as Monotherapy in Patients With Advanced Solid Tumors	Advanced Solid Tumor	4102 - Woolloongabba; 2031 - Randwick; 3199 - Frankston; 2109 - Sydney; 4101 - South Brisbane; 4125 - Southport	https://clinicaltrials.gov/ct2/show/NCT06253130
NCT06256588	JADE	Unknown		QLD, NSW, VIC	13/02/2024		Dostarlimab; Placebo	anti-PD-1_monoclonal_antibody; placebo	Dostarlimab; Placebo	anti-PD-1_monoclonal_antibody; placebo	2023-508613-17-00  221530	A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate Dostarlimab as Sequential Therapy After Chemoradiation in Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma	Neoplasms, Head and Neck	3004 - Melbourne; 4029 - Herston; 2148 - Blacktown; 3220 - Geelong; 3350 - Ballarat; 4814 - Douglas	https://clinicaltrials.gov/ct2/show/NCT06256588
NCT06257264	BG-68501-101	Unknown		NSW	13/02/2024	28/02/2024	BG-68501; BG-68501 + Fulvestrant; Fulvestrant	selective_estrogen_receptor_degrader; CDK2_inhibitor + selective_estrogen_receptor_degrader; CDK2_inhibitor	BG-68501 + Fulvestrant; BG-68501 + Fulvestrant	CDK2_inhibitor + selective_estrogen_receptor_degrader; CDK2_inhibitor + selective_estrogen_receptor_degrader	BG-68501-101	A Phase 1a/1b Study of BG-68501, a Selective CDK2 Inhibitor, in Participants With Advanced Solid Tumors	Ovarian Cancer; Hormone Receptor Positive HER-2 Negative Breast Cancer; Gastric Cancer; Advanced Solid Tumor; Small Cell Lung Cancer; Breast Cancer; Hormone-receptor-positive Breast Cancer; Endometrial Cancer; Prostate Cancer	2148 - Blacktown; 2065 - St Leonards	https://clinicaltrials.gov/ct2/show/NCT06257264
NCT06267729	APOLLO	Unknown		VIC	20/02/2024		AZD0754	allogeneic_CAR-T-cell_therapy,STEAP2-targeting	AZD0754	allogeneic_CAR-T-cell_therapy,STEAP2-targeting	D9660C00001	A Phase I/II Open Label Study to Evaluate the Safety, Cellular Kinetics, and Efficacy of AZD0754, a Chimeric Antigen Receptor (CAR) T-cell Therapy Directed Against STEAP2, in Adult Participants With Metastatic Prostate Cancer: APOLLO	Metastatic Prostate Cancer	3002 - East Melbourne	https://clinicaltrials.gov/ct2/show/NCT06267729
NCT06302426	INI-4001-101	Unknown		NSW, VIC	8/03/2024		INI-4001	TLR7/8_agonist	INI-4001	TLR7/8_agonist	INI-4001-101	An Open-label, Multiple-Ascending Dose, Two-Part Dose Ranging and Cohort Expansion Study of INI-4001 in Patients With Advanced Solid Tumours	Advanced Solid Tumor	2640 - Albury; 3144 - Malvern	https://clinicaltrials.gov/ct2/show/NCT06302426
NCT06305962	177Lu-RAD204.2023.0001	Unknown		QLD	12/03/2024		177Lu-RAD204	177Lu-anti-PD-L1_radioconjugate	177Lu-RAD204	177Lu-anti-PD-L1_radioconjugate	177Lu-RAD204.2023.0001	Phase 0/1 Study of the Safety and Tolerability of 177Lu-RAD204, a Lutetium-177 Radiolabelled Single Domain Antibody Against Programmed Cell Death-Ligand 1 in Patients With Metastatic Non-small Cell Lung Cancer	Non Small Cell Lung Cancer; PDL1 Gene Mutation	4102 - Woolloongabba	https://clinicaltrials.gov/ct2/show/NCT06305962
NCT06307015	DE-RADIATE	Unknown		NSW	12/03/2024		Radiotherapy	radiotherapy	Radiotherapy	radiotherapy	2023/ETH02441	De-escalation of Radiation Dose in HPV-associated Oropharyngeal Squamous Cell Carcinoma Utilising FMISO PET and Magnetic Resonance Imaging as Non-Invasive Biomarkers of Hypoxia (DE-RADIATE)	HPV Positive Oropharyngeal Squamous Cell Carcinoma	2065 - Saint Leonards	https://clinicaltrials.gov/ct2/show/NCT06307015
NCT06325748	SENTI-202-101	Unknown		NSW, VIC	22/03/2024		Cytarabine; Fludarabine	antimetabolite	Cytarabine; Fludarabine	antimetabolite	SENTI-202-101	SENTI-202-101: A Phase 1, Multicenter, Open-Label Study of SENTI-202, a Selective Off-the-Shelf Logic Gated CAR NK Cell Therapy, in Subjects With CD33 and/or FLT3 Expressing Hematological Malignancies	CD33 Expressing Hematological Malignancies; AML/MDS; FLT3 Expressing Hematological Malignancies	2050 - Camperdown; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT06325748
NCT06326411	NST-628	Unknown		SA, NSW	22/03/2024		NST-628	pan-RAF/MEK_glue	NST-628	pan-RAF/MEK_glue	NST-628-001	A Phase I, Open Label Single-arm Two-part Study to Investigate Safety, Pharmacokinetics, and Preliminary Efficacy of Pan-RAF/MEK Glue NST-628 Oral Tablets in Subject With Solid Tumors Harboring Genetic Alterations in the MAPK Pathway and With Other Solid Tumors	Ras (KRAS or NRAS) Gene Mutation; Melanoma; MEK Mutation; NSCLC; MAPK Pathway Gene Mutation; Oncology; Solid Tumor, Adult; RAF Gene Mutation; Glioma	5042 - Adelaide; 2031 - Rand	https://clinicaltrials.gov/ct2/show/NCT06326411
NCT06336148	ACTM-838-01	Unknown		NSW, VIC, SA	28/03/2024		ACTM-838	IL-15/STING_variant,S.Typhimurium-attenuated_bacterial_cancer_therapy	ACTM-838	IL-15/STING_variant,S.Typhimurium-attenuated_bacterial_cancer_therapy	ACTM-838-01	A Phase 1a/1b Open-label, Dose-Escalation and Expansion Study of ACTM-838 as a Single Agent in Patients With Advanced Solid Tumors	Solid Tumor	5042 - Bedford Park; 3004 - Melbourne; 2145 - Westmead	https://clinicaltrials.gov/ct2/show/NCT06336148
NCT06337084	MNPR-101-D001	Unknown		VIC	29/03/2024						MNPR-101-D001	Open Label Pilot Study Evaluating Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors	Gastric Cancer; Ovarian Cancer; Bladder Cancer; Triple-negative Breast Cancer; Pancreatic Cancer; Colorectal Cancer; Lung Cancer; Urothelial Carcinoma; Solid Tumor, Adult	3051 - North Melbourne	https://clinicaltrials.gov/ct2/show/NCT06337084
NCT06341647	HREC-233-23	Unknown		VIC	2/04/2024		AB-201; Cyclophosphamide; Fludarabine	alkylating_agent; antimetabolite; allogeneic_CAR-NK-cell_therapy,ERBB2-targeting	AB-201; Cyclophosphamide; Fludarabine	allogeneic_CAR-NK-cell_therapy,ERBB2-targeting; alkylating_agent; antimetabolite	103300 (HREC 233/23)  AB-201-01	A Multicenter, Open-label, Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced Human Epidermal Growth Factor Receptor 2 Positive(HER2+) Solid Tumors	Gastroesophageal Junction Adenocarcinoma; Breast Cancer; Gastric Cancer	3004 - Melbourne; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT06341647
NCT06343402	ONKORAS-101--TBBO8520-101	Unknown		VIC	2/04/2024		Pembrolizumab; Tegafur-gimeracil-oteracil pPotassium	anti-PD-1_monoclonal_antibody; DPD_inhibitor; antimetabolite; orotate_phosphoribosyltransferase_inhibitor	Pembrolizumab; Tegafur-gimeracil-oteracil pPotassium	anti-PD-1_monoclonal_antibody; DPD_inhibitor; antimetabolite; orotate_phosphoribosyltransferase_inhibitor	ONKORAS-101  TBBO8520-101	A Phase 1a/1b Open-Label Study of BBO-8520 Monotherapy and BBO-8520 in Combination With Pembrolizumab in Subjects With Advanced KRASG12C Mutant Non-Small Cell Lung Cancer - the ONKORAS-101 Study	Advanced Lung Carcinoma; Metastatic Lung Cancer; NSCLC; KRAS G12C; Metastatic Non-Small Cell Lung Cancer; Non-small Cell Lung Cancer	3051 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT06343402
NCT06345079	STOPNET	Unknown		QLD	3/04/2024		Octreotide	somatostatin_analog	Octreotide	somatostatin_analog	AG0219NET	A Randomised Study of Cessation of Somatostatin Analogues After Peptide Receptor Radionuclide Therapy in Mid-Gut Neuroendocrine Tumours (STOPNET)	Neuroendocrine Tumors	4006 - Brisbane	https://clinicaltrials.gov/ct2/show/NCT06345079
NCT06349408	CIBI3001A101	Unknown		NSW	5/04/2024		IBI3001	anti-EGFR/B7H3_antibody-drug_conjugate	IBI3001	anti-EGFR/B7H3_antibody-drug_conjugate	CIBI3001A101	A Phase 1/2 Study of IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors	Locally Advanced Solid Tumor	2500 - Wollongong	https://clinicaltrials.gov/ct2/show/NCT06349408
NCT06350097	TROPION-Lung14	Unknown		NSW, VIC	5/04/2024		Datopotamab deruxtecan; Datopotamab deruxtecan + Osimertinib; Osimertinib	EGFR_inhibitor,third_generation; EGFR_inhibitor,third_generation + anti-Trop2_antibody-drug_conjugate; anti-Trop2_antibody-drug_conjugate	Datopotamab deruxtecan + Osimertinib; Osimertinib; Datopotamab deruxtecan + Osimertinib	EGFR_inhibitor,third_generation; EGFR_inhibitor,third_generation + anti-Trop2_antibody-drug_conjugate; EGFR_inhibitor,third_generation + anti-Trop2_antibody-drug_conjugate	D516NC00001	A Phase III, Open-label, Randomised Study of Osimertinib With or Without Datopotamab Deruxtecan (Dato-DXd), as First-line Treatment in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation-positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer	Non-small Cell Lung Cancer	2217 - Kogarah; 3168 - Clayton	https://clinicaltrials.gov/ct2/show/NCT06350097
NCT06351904	RAG-01-01	Unknown		NSW	8/04/2024	3/04/2024	Bacillus Calmette-Guérin	BCG_vaccine	Bacillus Calmette-Guérin	BCG_vaccine	RAG-01-01	A Phase ?, Open Label, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) Therapy	Non-Muscle-Invasive Bladder Cancer (NMIBC)	2065 - St Leonards	https://clinicaltrials.gov/ct2/show/NCT06351904
NCT06357533	TROPION-Lung10	Unknown		QLD, VIC	10/04/2024		Datopotamab deruxtecan; Pembrolizumab; Rilvegostomig	anti-PD-1_monoclonal_antibody; anti-Trop2_antibody-drug_conjugate; bispecific_PD-1/TIGIT_antibody	Pembrolizumab; Rilvegostomig; Datopotamab deruxtecan	anti-PD-1_monoclonal_antibody; bispecific_PD-1/TIGIT_antibody; anti-Trop2_antibody-drug_conjugate	D7632C00001	A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for the First-line Treatment of Participants With Locally-advanced or Metastatic Non-squamous NSCLC With High PD-L1 Expression (TC = 50%) and Without Actionable Genomic Alterations (TROPION-Lung10)	Non-Small Cell Lung Cancer	3168 - Clayton; 3000 - Melbourne; QL 4101 - South Brisbane	https://clinicaltrials.gov/ct2/show/NCT06357533
NCT06365853	2023-505617-24-00--IMGN853-0424	Unknown		VIC	15/04/2024		Leucovorin; Mirvetuximab Soravtansine; Prednisolone	folinic_acid; glucocorticoid; anti-FR-alpha_antibody-drug_conjugate	Prednisolone; Leucovorin; Mirvetuximab Soravtansine	glucocorticoid; anti-FR-alpha_antibody-drug_conjugate; folinic_acid	2023-505617-24-00  IMGN853-0424	A Randomized Phase 2 Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Patients With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression	Folate Receptor-Alpha Positive; Recurrent Ovarian Cancer	- Clayton	https://clinicaltrials.gov/ct2/show/NCT06365853
NCT06372574	GO44669	Unknown		VIC	18/04/2024		RO7617991; Tocilizumab	anti-IL-6_monoclonal_antibody; unknown_drug_class	RO7617991; Tocilizumab	unknown_drug_class; anti-IL-6_monoclonal_antibody	GO44669	A Phase I, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Anti-Tumor Activity of RO7617991 in HLA-A*02-Positive Patients With Locally Advanced and/or Metastatic MAGE-A4-Positive Solid Tumors	Refractory Cancer; Solid Tumor, Adult; Recurrent Cancer	3002 - East Melbourne	https://clinicaltrials.gov/ct2/show/NCT06372574
NCT06400485	AMT-676-01	Unknown		WA, New South wWalesQLD, VIC, NSW, QLD	6/05/2024		AMT-676	anti-CDH17_antibody-drug_conjugate	AMT-676	anti-CDH17_antibody-drug_conjugate	AMT-676-01	First-in-Human, Phase 1 Study of AMT-676 in Patients With Advanced Solid Tumors	Advanced Solid Tumors	- Randwick; - Greenslopes; - Macquarie; - Nedlands; - Melbourne	https://clinicaltrials.gov/ct2/show/NCT06400485
